,tweet_author,tweet_text
0,hematopoiesis news,   scientists conducted a phase ii study of acalabrutinib in patients with relapsed refractory  cll who were ibrutinib intolerant  and found an overall response rate of       https   t co ej m qpc p https   t co kuzz zo  r
1,michael wang  md,this phase   acalabrutinib venetoclax  av  trial that is still in recruitment phase will study how well venetoclax and acalabrutinib works in mcl patients who either relapsed or non respondent to the initial therapy   https   t co gg g at  n
2, stoncology, nice backs  astrazenecas  calquence for  cll https   t co vb lpdogra
3,toby eyre, acalabrutinib is a valuable option in pts intolerant to  ibrutinib  further valuable data to help decision making in  cll   early view   haematologica https   t co z kclzax d
4,lymphoma hub,nice has recommended the use of acalabrutinib for patients with treatment na ve chronic lymphocytic leukemia  find out more here https   t co  oujptlcin  lymsm  lymphoma
5,david ledger,nice backs astrazeneca s calquence for cll https   t co jopnlnid r https   t co  pwy nkp s
6,n wales cancer forum,this is england for now   these decisions usually come to wales too   more info   https   t co sr tu zshh https   t co ofdwedlav 
7,european pharmaceutical review,astrazeneca s calquence  acalabrutinib   a chemotherapy free monotherapy  will be offered to patients with chronic lymphocytic  leukaemia   oncology  drugapprovals  pharma  healthnews find out more here  https   t co qyuft cn b https   t co sxve nggx 
8,graham collins,superstar  tobyeyre   responding to the excellent news of nice approval of acalabrutinib in frontline cll for fcr   br unsuitable patients  https   t co lacvpotrwx
9,cll ireland,cll patients all know the drug ibrutinib and yesterday in the uk acalabrutinib was approved and now a new drug pirtobrutinib is making a big impact for relapsed patients in recent  clinicaltrials  cancertrials ie  cllsociety  lal ni  bloodcancerirl https   t co murr kphsz
10,mice ideas,optimal management of high risk cll with acalabrutinib    march             pm        pm  speaker     dr p g subramanian  mumbai  speaker     group captain  dr  harshit khurana  pune  chair  dr s h advani  mumbai moderator  dr m b agarwal  mumbai  link  https   t co ou demfice https   t co nvaedomrll
11,farooq a wandroo,acalabrutinib for all forms of cll  nice today get ready   swbhpharmacy  stevenshanu  hojansenya  swbh randd  oncology at az https   t co pg gautz j
12,leukaemia care,it has been announced today  thursday   th march  that the national institute for health and care excellence  nice  have made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia  cll  patients in england 
13,helen oram,nice has recommended the use of acalabrutinib  as a monotherapy option for adults with   a   p deletion or tp   mutation  or  no   p deletion or tp   mutation  and fludarabine plus cyclophosphamide and rituximab  fcr   or bendamustine plus rituximab  br  is unsuitable  https   t co ntyg vlkyz
14,healthwatch,a brand new oral treatment  acalabrutinib  taken as a twice daily tablet  for untreated  blood cancer  chronic lymphocytic leukaemia  has today  thursday    march       been recommended for nhs use by nice  https   t co nloyybepra
15,pharmabox in,nice backs astrazeneca s calquence for cll https   t co p fy o mti
16,pharma trader,nice backs astrazeneca s calquence for cll https   t co v wjokqqtm
17,everything pharma,nice backs astrazeneca s calquence for cll https   t co  raq sljis
18,ijpsonline,nice backs astrazeneca s calquence for cll https   t co hkpfa iw n
19,iceberg vision,nice backs astrazeneca s calquence for cll https   t co  b ryahrxx
20,pharmatimes,nice backs astrazeneca s calquence for cll https   t co fteaemfsw   pharma  lifesciences
21,paperbirds hematology,new article  phase   study of acalabrutinib in ibrutinib intolerant patients with relapsed refractory chronic lymphocytic leukemia https   t co osjpzyceze  cll  leusm  hematology
22,pharma news,targeted oral monotherapy calquence  acalabrutinib  recommended by nice for patients with chronic lymphocytic leukaemia  cll  https   t co tj w zckd   pharmanews  clinicalresearchnews  biotechnews  lifesciencesnews  medicalnews  healthcarenews  pharmiwebnews https   t co wya uuojqo
23,cll ireland,as the uk approve new treatments for  cll with acalabrutinib now available  ireland falls far behind  patients need better options    janrynne  donnellystephen  hselive  davidcullinane  hsenccp  paulreiddublin  ipposi  paulmcauliffe  roisinshortall https   t co tw zainolp
24,pharmaphorum,  nicecomms backs nhs use for  astrazeneca s calquence for new leukaemia indication  and  daiichisankyo s cholesterol lowering drugs nilemdo and nustendi  heor https   t co pqfk n pci
25,toby eyre, acalabrutinib  nicecomms approved for  l  cll in uk   all pts considered unfit for fcr or br   all pts tp   mut del   all relapsed cll  enjoyed talking about this with  cllsupport chair of trustees marc auckland on sky news this am    great news for our  cll pts   bloodcancer uk https   t co sh iidgkel
26,lymphoma papers,safety and antitumor activity of acalabrutinib for relapsed refractory b cell malignancies  a japanese phase i study  lymphoma  lymsm https   t co nrxd yk zm
27,paperbirds hematology,new article  safety and antitumor activity of acalabrutinib for relapsed refractory b cell malignancies  a japanese phase i study https   t co ivdjs l z   cll  leusm  hematology
28,lymphoma hub,congress   ebmt      michaelwangmd   mdandersonnews  discussed results of the zuma   study in r r mantel cell lymphoma by morphology and prior btki exposure to ibrutinib and or acalabrutinib  he concluded that all subgroups drew clinical benefit from kte x   treatment   lymsm https   t co vufxrfrbgd
29,trip database,new trip  acalabrutinib  calquence  for treatment of chronic lymphocytic leukaemia  cll  https   t co mr qszwczx
30,osgood,calquence commercial had a really pretty lady in it  chanel  twittersupport a nurse i think
31,paperbirds hematology,new clinical trial  acalabrutinib  umbralisib  and ublituximab for the treatment of previously untreated mantle cell lymphoma https   t co i  benjlrg  mcl  lymsm  hematology
32,thiago carvalho, solidarity negotiated with astra zeneca to test its cancer drug acalabrutinib  which dampens the immune system  investigators changed treatment protocols to include the medicine  but then the company decided not to give the green light    https   t co x  mjlnv  
33,kartos therapeutics,icymi  please view our  ash   tip poster presentation about a new study that will explore the combination of krt      mdm i    acalabrutinib in patients with r r b cell malignancies  https   t co g uoottdlo  find out more at https   t co sgbnxj znx  lymsm  cll  dlbcl
34,apoli naria,iqvia rds argentina s r l  representa en argentina a     janssen vaccines  amp  prevention b v     pharma b v     astrazeneca ab    amgen inc   acalabrutinib apremilast lanadelumab abatacept remdesivir infliximab mesilato de cenicriviroc  https   t co kuruk rkiy  cc    spitta    
35,michael wang  md,maria  we appreciate you  our group has passed   fda inspections  in       we led ibrutinib fda approval  in       we led acalabrutinib fda approval and in       we led brexucarbatagene autoleucel fda approval  without your leadership and our wonderful team  not possible  https   t co fpumj qaq 
36,cardio targets,the role of acalabrutinib in adults with chronic lymphocytic leukemia https   t co xv  it zeo
37,lymphoma papers,the role of acalabrutinib in adults with chronic lymphocytic leukemia  lymphoma  lymsm https   t co lvp uro so
38,paperbirds hematology,new article  the role of acalabrutinib in adults with chronic lymphocytic leukemia https   t co xrlun evpu  cll  leusm  hematology
39,cardio targets,the role of acalabrutinib in adults with chronic lymphocytic leukemia  https   t co apru  bg r
40,paperbirds hematology,new article  the role of acalabrutinib in adults with chronic lymphocytic leukemia  https   t co yanuxmbr    cll  leusm  hematology
41,jeff sharman,the role of cd   in addition to btk inhibitors is not a closed story   we previously published obinutuzumab benefit with acalabrutinib  https   t co klsjuwwfdm      now we show  ublituximab to ibrutinib has benefit in   p  tgtherapeutics  anthonymatomd   https   t co l qrcv uds
42,paperbirds hematology,new clinical trial  acalabrutinib and rituximab for the treatment of previously untreated mantle cell lymphoma https   t co kpdyk kvoo  mcl  lymsm  hematology
43,im m dico,acalabrutinib alcanza el objetivo primario de eficacia en comparaci n con ibrutinib en llc  astrazenecaes         https   t co  vtn bsx o
44,firstword pharma,physician views preview  digging into the impressive us launch of astrazeneca s calquence  azn https   t co mv lvmuuqb
45,cancernetwork   home of the journal oncology , icymi  overall  the phase   elevate rr trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program  https   t co m  j  lbfc
46,tom henry  mba  rph  cph,cll research  acalabrutinib   an analysis of cardiovascular events https   t co spouz fdnp
47,medivizor,comparing acalabrutinib to standard treatments in patients with chronic lymphocytic l    https   t co tlxiunst a via  medivizor  leukemia
48,mednetnews,mcl survival likely affected by reason for acalabrutinib discontinuation https   t co hsjczh kq 
49,ajmc,mantle cell lymphoma survival likely affected by reason for acalabrutinib discontinuation  https   t co cbfjm ghpy https   t co plfzmtrpzo
50,patient worthy,calquence beneficial for cll  study shows https   t co zlyxexhka   calquence  cll  chroniclymphocyticleukemia  rarecancer  treatment  llsusa
51,paperbirds hematology,new clinical trial  alicia  acalabrutinib in cll therapy  https   t co xuhpwiu mo  cll  leusm  hematology
52,cat,https   t co ndvz ayo k
53,hemalatha rangarajan md, tctm    gvhdsm  chronicgvhd  stephanieleemd number of registered studies for cgvhd  drugs in these studies  a newer  itinib    oral acalabrutinib https   t co cxlx uwecv
54,mednetnews,mantle cell lymphoma treatment market by product type  acalabrutinib  jcar      and by end users application  hospital  clinic  market share  forecast data  in depth analysis  and detailed overview  and forecast              https   t co h s og g n
55,bita fakhri,in this review  we tried to situate  acalabrutinib among the treatment options for patients with treatment naive and rel ref cll   https   t co ajnffcevep
56,ncpe,acalabrutinib  calquence     hta id          national centre for pharmacoeconomics   https   t co hvplp ze b https   t co wi dvbzxzt
57,journal onkologie,news von https   t co y rvlbthwz   lesen sie jetzt den vollst ndigen beitrag unter  https   t co c mrjsbxlu   arzt  schmerz  cll immunchemotherapie  leuk mie  immuntherapie  neutropenie  mutation  acalabrutinib  patient  therapie  unvertr glichkeiten  zulassung  studie
58,oncology learning network,in this video  dr danilov   ohsunews  discusses the use of  acalabrutinib    calquencehcp  as a treatment option for  patients with cll  sll  and mcl   watch here  https   t co uulj g   s   meded  medtwitter  healthcare https   t co  fhgk h v 
59,oncology learning network,in this video interview  dr graff   mercyonedsm  discusses the evolving treatment landscape for  cll in recent years  especially with the introduction of  acalabrutinib  calquence  astrazeneca    watch here  https   t co tdq yoivv  https   t co  zw geap w
60,onclive com,for the phase   trial  investigators set out to evaluate pfs benefit with acalabrutinib versus ibrutinib in previously treated patients with high risk cll   leusm https   t co rfp zfi ua
61,medivizor,comparing acalabrutinib to standard treatments in patients with chronic lymphocytic    from  medivizor  https   t co tlxiunst a  leukemia
62,trialsite news,astrazeneca s calquence meets primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia  https   t co k ggko  lz   hematology  oncology  acalabrutinib  cll  pfs  n      astrazeneca https   t co rm   oxva 
63,trip database,new trip  acalabrutinib https   t co xn yfvxe z
64,lyfebulb,calquence approved in japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https   t co qc wdwwccp  chronicillness  digitalhealth  lyfebulb
65,onclive com,acalabrutinib showed noninferior progression free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high risk chronic lymphocytic leukemia   leusm https   t co oyihndet i
66,the medical ed cons ,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica   https   t co hg z bvktk
67,cancernetwork   home of the journal oncology ,overall  the phase   elevate rr trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program     astrazeneca  https   t co m  j  lbfc
68,carnivoreshealth,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co lvzyqyfrza https   t co ek ttoltu 
69,portfolio penny,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co aaqf btz m https   t co  oki gxpjp
70,fancyfinancy,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co h uhkfdvpk https   t co ysanwczglk
71,robo schmobo,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co bfn cravg  https   t co qc sl xbce
72,financial carnivores,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co showno jih https   t co fxx gkb ww
73,lymphoma hub,news  acalabrutinib has met the primary endpoint of non inferior pfs vs ibrutinib in the phase iii elevate rr trial for r r cll  find out more here https   t co qarwkgmnje  lymsm https   t co piptt tbg 
74,netcancer,  ammh mato  l acalabrutinib un nouveau traitement chez les patients adultes atteints d une  leuc mie lympho de chronique   retrouvez tous les d tails de cette mol cule sur notre findrugs   https   t co tvrzx nlcp   cancer  innovation  informationpatient  h matologie  traitement https   t co mlpo wmwbk
75,dmgaz,a head to head study of two  leukemia drugs showed one may be safer relative to side effects associated with cardiac issues   cardiology  cancer  stroke https   t co zqsvegsayv
76,amit patel  ,impact of  cart therapy in those patients with  mantle cell  lymphoma that remain alive in this cohort after  acalabrutinib failure https   t co ces lsuoio
77,blood advances,acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib https   t co rmicwsmc z  cll https   t co vaarexgtfh
78,the medical ed cons ,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica   https   t co hg z bvktk
79,silas inman,acalabrutinib shows noninferior pfs  less atrial fibrillation versus ibrutinib in high risk cll https   t co hknmf nr m
80,onclive com,acalabrutinib shows noninferior pfs versus ibrutinib in high risk cll  leusm https   t co ikwuezsi i
81,targeted oncology,in adults with previously treated  high risk chronic lymphocytic leukemia  treatment with acalabrutinib was found to be non inferior to treatment with ibrutinib in terms of progression free survival   leusm https   t co zah khpfkv
82,analysource  premier drug pricing services,five things for pharma marketers to know  tuesday  january            roundup   mm amp m   medical marketing and media https   t co dpi rn plu   covid    boostershot  calquence   merck  statnews  mmmnews  nytimes  endpts  politico  cnbc  moderna tx  astrazenecaus  pfizer https   t co pvcoprgyc 
83,helix biopharma,astrazeneca said its calquence had lower rate of atrial fibrillation cases compared with johnson  amp  johnson and abbvie s rival btk inhibitor imbruvica in a head to head phase   chronic lymphocytic leukemia trial   azn  jnj  abbv  leukemia  pharma  https   t co  n kv mhza
84,alphabronze,astrazeneca said its calquence had lower rate of atrial fibrillation cases compared with johnson  amp  johnson and abbvie s rival btk inhibitor imbruvica in a head to head phase   chronic lymphocytic leukemia trial   azn  jnj  abbv  leukemia  pharma  https   t co pbhwvartai
85,trialsite news,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia  https   t co ivzqptqgyj   astrazeneca  calquence  lymphoma  mantle  cell  lymphoma  pfs  cll  acalabrutinib https   t co hsryadwja 
86,plexus ventures, az says  calquence is a safer drug than  imbruvica https   t co e rz zoogo via  pharmaphorum  astrazeneca
87,toby eyre,outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib https   t co hosyreaeo 
88,paperbirds hematology,new article  the european medicines agency review of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia  https   t co n i my hqy  cll  leusm  hematology
89,biopharmaasia,calquence approved for the treatment of relapsed or refractory chronic lymphocytic leukaemia in japan   https   t co nmsyygkfsm
90, stoncology, astrazeneca reported that  calquence met primary efficacy endpoint in head to head trial against  ibrutinib in  chroniclymphocyticleukemia https   t co  pjxyijgxy
91, stoncology, astrazeneca reported that  calquence approved in japan for the treatment of   relapsed or  refractory  chroniclymphocyticleukaemia https   t co alf oezq j
92,bio talent,calquence tops imbruvica in chronic lymphocytic leukaemia study  https   t co ecfqjzcqho  find us at https   t co  ddltqr h  https   t co  d dyockdw
93, stoncology, astrazeneca reported that  calquence met primary efficacy endpoint in head to head trial against  ibrutinib in  chroniclymphocyticleukaemia https   t co  hi lswq e
94,roberto bonin,calquence ha raggiunto l endpoint primario di efficacia nello studio testa a testa contro ibrutinib nella leucemia linfocitica cronica https   t co  xcbbettfm
95,taro shiga,                                                https   t co nbxvw yna   prtimes jp      acalabrutinib  calquence    cll   cardioonc                                    https   t co pq zeoaltz
96,susan,astrazeneca touts calquence safety win against imbruvica in leukemia trial showdown https   t co hdbf xjqmy
97,biocentury,monday s quick takes include comirnaty s provisional approval in australia and authorization in hong kong  plus priority reviews for albireo and iterum  and calquence meets in phase iii cll trial https   t co nvyd cgqyp
98,endpoints news,three years after first launching calquence as a second generation btk inhibitor  astrazeneca continues to tout new data to compete with j amp j and abbvie s first generation blockbuster imbruvica    https   t co tlgdxmdx o
99,pharma top news,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica   biopharma dive  pharmatopnews  oncologytopnews  oncology  https   t co re damfx x
100,onclive com,acalabrutinib approved in japan for relapsed refractory cll  leusm https   t co  klyhko dq
101,fiercepharma,astrazeneca touts calquence safety win against imbruvica in leukemia trial showdown https   t co kbg dcffmb
102,benlazar s m amin ,outcomes of relapsed mantle cell  lymphoma patients after discontinuing acalabrutinib   jain     american journal of hematology   wiley online library https   t co o qbbgml r https   t co bat qqnckg
103,webwire,calquence approved in japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https   t co pmcbcuocgs
104,tecnomedicina,calquence ha raggiunto l endpoint primario di efficacia nello studio testa a testa contro ibrutinib nella leucemia linfocitica cronica https   t co bsv lyniyl
105,hemonc today,   topline results of randomized phase   elevate rr trial show that acalabrutinib exhibits comparable efficacy and superior safety when compared with ibrutinib for chronic lymphocytic leukemia https   t co kuiibqsloz  cll  astrazeneca https   t co r  qeefl o
106,brainsights ios app,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia   neuro central via brainsights for ios https   t co sqar eaiyz
107,dr timos papagatsias,astrazeneca touts calquence safety win against imbruvica in leukemia trial showdown https   t co  kgb wpfov  strategy  competitiveintelligence  marketing  pharma  productmarketing  pharmaceutical  healthcare  biotech
108,newexpressnews,astrazeneca touts calquence safety win against imbruvica in leukemia trial showdown https   t co shghmeihre
109,biopharma dive,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co xoboklteux by  byjongardner  azn  abbv  jnj
110,market intelligence  healthcare,astrazeneca s calquence was as effective as johnson  amp  johnson s imbruvica in delaying the progression of a type of blood cancer in a late stage study https   t co m ykcm n a   azn  jnj https   t co lbwf   mrk
111,ben fidler,astrazeneca  with new data  claims its leukemia drug is safer than imbruvica https   t co hlhoijmqzy  byjongardner  azn  abbv  jnj  mrk  lly
112,                   insights  pharma   ,astrazeneca touts calquence safety win against imbruvica in leukemia trial showdown https   t co rmkhedopxj
113,pharmabox in,astrazeneca touts calquence safety win against imbruvica in leukemia trial showdown https   t co anpvugeyzs
114,cafepharma,az says calquence is a safer drug than imbruvica https   t co rp bdquhoe
115,calgary herald,astrazeneca says calquence approved in japan for cll https   t co vvdwaqwqay
116,endpoints news,three years after first launching calquence as a second generation btk inhibitor  astrazeneca continues to tout new data to compete with j amp j and abbvie s first generation blockbuster imbruvica  by   jasonmmast  https   t co tlgdxmv so
117,david ledger,calquence tops imbruvica in chronic lymphocytic leukaemia study https   t co  owwcmewbc https   t co fzp ss egh
118,biotech   tech stock focus, azn astrazeneca reports positive phase   results of calquence against ibrutinib in cll https   t co bc gdtrxbd
119,dr timos papagatsias,astrazeneca s calquence nabs another win against imbruvica  but eli lilly is on its heels https   t co crih rtttv  strategy  competitiveintelligence  marketing  productmarketing  pharma  biotech  pharmaceutical  healthcare https   t co fephag  jz
120,corporate news, azn calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia https   t co y h eimryd
121,                   insights  pharma   ,astrazeneca s calquence nabs another win against imbruvica  but eli lilly is on its heels https   t co rr rh xzyz
122,paperbirds hematology,new clinical trial  a study on limiting treatment time with acalabrutinib combined with obinutuzumab in people with cll or sll https   t co pcxrdx rys  cll  leusm  hematology
123,investorsobserver, azn        reports calquence met primary efficacy endpoint in a head to head trial against ibrutinib  receives approval in japan for treatment of relapsed or refractory chronic lymphocytic leukemia    https   t co mdjbolle y
124,devdiscourse,brief astrazeneca says calquence approved in japan for cll https   t co fbgch txu 
125,company news hq,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukaemia https   t co ny qwdup o
126,chitraders, azn astrazeneca s calquence successful in lymphocytic leukaemia study https   t co  yoennjgjv
127,    ,awesomecapital  astrazeneca  calquence safer than imbruvica https   t co cxedylnqvy
128,briefing com, azn  astrazeneca reports calquence met primary efficacy endpoint in head to head trial against ibrutinib  recieves    https   t co fvib  nojy
129,quant data,astrazeneca s calquence met its primary efficacy endpoint  related tickers   azn read more at  https   t co  zmd  eky 
130,pharmatimes,calquence tops imbruvica in chronic lymphocytic leukaemia study https   t co rym dexyju  pharmanews  pharma
131,otc dynamics  inc , azn calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia https   t co wx bckcevx
132,latest news from business wire,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia https   t co fbgmw  yxz https   t co  ruxrwogie
133,impharma news,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia  https   t co ww syfqmgi
134,crwe world,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia https   t co z lm bskso
135,astrazenecaus,today we announced high level results from the head to head elevate rr phase iii trial in adults with previously treated  high risk chronic lymphocytic  leukemia  learn more  https   t co kucufov mt https   t co bjlnjyzube
136,stock titan, azn calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukemia https   t co pcj mo  hg
137,gordon gekko,astrazeneca s calquence successful in lymphocytic leukaemia study https   t co e lkfbw zg
138,investor news,astrazeneca s calquence successful in lymphocytic leukaemia study  azn https   t co mikeqaidx 
139,stocks tweets,astrazeneca s calquence successful in lymphocytic leukaemia study https   t co tvircguaeg
140,breaking news, azn   astrazeneca s calquence successful in lymphocytic leukaemia study https   t co tupuq e jw
141,soumyajyoti biswas, azn astrazeneca s calquence met primary endpoint in head to head trial vs  ibrutinib the company states    positive high level results from the elevate rr phase iii trial showed astrazeneca s calquence  or acalabrutinib  met th    https   t co  sexne wox
142,pharmaphorum,  astrazeneca says calquence is less likely to cause atrial fibrillation than j amp j and abbvie s market leading btk inhibitor imbruvica  also gets green light for the drug in japan for relapsed chronic lymphocytic  leukaemia  pharma  oncology https   t co ckiwpoqqi  https   t co oajbym tew
143,shifting wealth,astrazeneca s calquence approved in japan for cll treatment  azn
144,dough, azn calquence head to head study vs imbruvica in  l cll non inferior pfs with significant reduction in atrial fibrillation 
145,shifting wealth,astrazeneca s calquence met primary endpoint in head to head trial vs  ibrutinib  azn
146,finanzlinksratings,  goldman bel sst astrazeneca auf  sell    ziel      pence  new york  dpa afx analyser    die us investmentbank goldman sachs hat die einstufung f r astrazeneca angesichts positiver studiendaten mit dem medikament calquence zur behandlung  https   t co ll o n  fn aktiencheck
147,finanzlinksratings,  dpa afx  goldman bel sst astrazeneca auf  sell    ziel      pence  new york  dpa afx analyser    die us investmentbank goldman sachs hat die einstufung f r astrazeneca angesichts positiver studiendaten mit dem medikament calquence zur  https   t co s lcqal  i finanztreff
148,pharmabox in,calquence tops imbruvica in chronic lymphocytic leukaemia study https   t co ced  rpvq 
149,lifepronow pharma research and news,calquence approved in japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia  https   t co    f eyyw  https   t co qjihtirewu
150,josekun,brief astraxeneca says calquence approved in japan for cll https   t co   s wnhmwz
151,josekun,astrazeneca s leukaemia treatment wins approval in japan  calquence meets primary goal https   t co qizmgrqdqg
152,jan ehses, azn https   t co  qbjq d  e
153,jan ehses, azn https   t co xievirvgut
154,kevin jacobs            , azn calquence approved in japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia
155,golden casino news,calquence met primary endpoint against ibrutinib   https   t co  dnw je hx
156,golden casino news,calquence approved in japan for cll   https   t co ay  hrr mf
157,kevin jacobs            , azn calquence met primary endpoint against ibrutinib   met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukaemia   superior safety on key secondary endpoint of atrial fibrillation
158,sharecast com,astrazeneca reports positive test results  new approval for  calquence  https   t co mkjcgptvio
159,ein presswire  pharmaceutical newswire,astrazeneca s leukaemia treatment wins approval in japan  calquence meets primary goal https   t co itc  p  kp
160,value s vector,livesquawk   azn   astrazeneca plc   calquence met primary endpoint against ibrutinib calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukaemia
161,devdiscourse,brief astraxeneca says calquence approved in japan for cll https   t co jjwbaalbwl
162,devdiscourse,brief astrazeneca says calquence met primary endpoint against ibrutinib https   t co pudcymtl  
163,mathan, azn   astrazeneca plc   calquence met primary endpoint against ibrutinib calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukaemia
164,cision news,calquence approved in japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https   t co vxtrombric
165,cision news,calquence approved in japan for cll https   t co livcdcnsxj
166,company news hq,calquence approved in japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia https   t co  brx cbnuq
167,cision news,calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukaemia https   t co e z jbbjch
168,cision news,calquence met primary endpoint against ibrutinib https   t co nb inloyke
169,livesquawk, azn   astrazeneca plc   calquence met primary endpoint against ibrutinib calquence met primary efficacy endpoint in head to head trial against ibrutinib in chronic lymphocytic leukaemia
170,tyr kinase papers,the european medicines agency review of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia https   t co zdbyiv ngy
171,paperbirds hematology,new clinical trial  acalabrutinib in cll and mcl patients subjected to allogeneic hematopoietic stem cell transplantation  allosct  https   t co s yrtwe ly  mcl  lymsm  hematology
172,paperbirds hematology,new clinical trial  acalabrutinib in cll and mcl patients subjected to allogeneic hematopoietic stem cell transplantation  allosct  https   t co bvsrwzhwbx  cll  leusm  hematology
173,health radio online,astrazeneca s new calquence  data in mantle cell lymphoma  mcl  read more  https   t co aahaiq  rn  calquence  ash      mantlecelllymphoma
174,medivizor,check out  comparing acalabrutinib to standard treatments in patients with chronic ly    https   t co tlxiunst a via  medivizor  leukemia
175,aaron goodman    papa heme ,this is what happens when you let oncologists design trials for a viral infection   the following therapies are were being tested in covid   trials  ruxolitinib etoposide ibrutinib selinexor lenalidomide acalabrutinib baricitinib zanabrutinib chest radiation
176,cadth,cadth has issued a final recommendation that  acalabrutinib   calquence  be reimbursed with clinical criteria and or conditions for the treatment of chronic lymphocytic  leukemia  previously untreated     read the full recommendation here  https   t co dab gavddc https   t co z zfvd  nw
177,toby eyre,great to continue to recruit into the first ever randomised  l trial in  richters transformation  rchop vs rchop acalabrutinib  we are a quarter of the way there   lymsm  cll  ouh research  annaschuh  https   t co dvl pno oy
178,lymphoma papers,acalabrutinib  a highly selective  potent bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia   lymphoma  lymsm https   t co vntojxbal 
179,paperbirds hematology,new article  acalabrutinib  a highly selective  potent bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia  https   t co aa xlpsm    cll  leusm  hematology
180,medivizor,learn more  comparing acalabrutinib to standard treatments in patients with chroni    https   t co tlxiunst a  leukemia  via  medivizor 
181,top news corner,new post  acalabrutinib market report  size  key players and global forecast to       has been published on https   t co fdzrb krvd   https   t co  tixxqsj c https   t co firppydhi 
182,pharmazeutische zeitung,mit acalabrutinib kam im dezember ein neuer bruton tyrosinkinase btk  hemmer auf den markt  der neuling wird wie das seit      verf gbare ibrutinib peroral bei patienten mit chronisch lymphatischer  leuk mie eingesetzt https   t co jjqy xcuam
183,rs ,https   t co xtwa bz nb
184,amar bhandari,global acalabrutinib market in depth analysis report      https   t co nx nfukgfb
185,industry news engine,acalabrutinib market report till        global manufacturers analysis https   t co t    apid 
186,targeted oncology, the pfs for patients in the acalabrutinib arms  of the elevate cll tn trial  outperformed the control  which was obinutuzumab chlorambucil  by a significant difference   dr  seymour said during this live virtual meeting  https   t co ozz ovjcle  leukemia
187,medicina e informazione,leucemia linfatica cronica  acalabrutinib   approvato in europa  ha dimostrato un beneficio significativo in termini di efficacia e tollerabilit  a lungo termine tanto nel trattamento in prima linea quanto nella malattia recidivante o refrattaria https   t co r cpilgrth https   t co tqkhouaiup
188,calquence   acalabrutinib ,https   t co w  aqqbux  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
189,calquence   acalabrutinib ,https   t co w  aqqbux  see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
190,calquence   acalabrutinib ,https   t co w  aqqbux  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
191,calquence   acalabrutinib ,https   t co w  aqqbux  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
192,calquence   acalabrutinib ,https   t co w  aqqbux  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
193,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
194,calquence   acalabrutinib ,https   t co w  aqqbux  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
195,calquence   acalabrutinib ,https   t co w  aqqbux  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
196,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
197,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
198,calquence   acalabrutinib ,https   t co w  aqqbux  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
199,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
200,joseph cioccio  do,why might a person with cll be anemic     bm involved  rai iii   dx   bm bx tx   venetoclax obinutuzumab or acalabrutinib     obinu fcr      aiha  dx  dat     t bili    ldh    hapto     retic tx roids if fail then as above     prca     retics   tx   ist   cioc edu   
201,curehuntr, clinicaltrial rituximab  acalabrutinib  and durvalumab  rad  in primary cns lymphoma  https   t co l wzhd npv
202,vjhemonc, zanubrutinib for ibrutinib acalabrutinib intolerant r r b cell malignancies w  ian flinn of  sarahcannondocs  https   t co jvphvqolus   ash    ash hematology  hemonc  leusm  leukemia  cllsm  ctsm
203,trialbulletin,rituximab  acalabrutinib  and durvalumab  rad  in primary cns lymphoma   status  not yet recruiting   condition summary  primary central nervous system lymphoma  pcnsl  https   t co sfbdbbit n
204,onclive soss,  seemaalibhat  of  osuccc james discusses the rationale to evaluate  acalabrutinib in chronic lymphocytic leukemia  cll https   t co rtgycoo dq https   t co ltnbss  zi
205,targeted oncology, the pfs for patients in the acalabrutinib arms  of the elevate cll tn trial  outperformed the control  which was obinutuzumab chlorambucil  by a significant difference   dr  seymour  of  karmanoscancer  said in this live virtual meeting  https   t co ozz ovjcle  cll  leusm
206,medivizor,new  comparing acalabrutinib to standard treatments in patients with chronic lymphocy    https   t co tlxiunst a via  medivizor  leukemia
207,drugdocs, calquence product monograph  prescribing info  health technology assessments and more    access drug documents  
208,oncology nursing news,in case you missed it  patients with cll who received treatment with single agent acalabrutinib experienced a low incidence of cardiac toxicities  according to data from a pooled analysis across   clinical trials  https   t co cx xgouih 
209,ematoinfo, ash     nuove importanti conferme sull utilizzo di  acalabrutinib in combinazione nel trattamento della leucemia linfatica cronica  con risultati significativi in termini di risposta completa e mrd negativit   le parole di francesca romana mauro  https   t co srgfxxx ts
210,oncology nursing news,patients with cll who received treatment with single agent acalabrutinib experienced a low incidence of cardiac toxicities  according to data from a pooled analysis across   clinical trials  https   t co cx xgouih 
211,medivizor,check out comparing acalabrutinib to standard treatments in patients with chronic lym    https   t co tlxiunst a via  medivizor  leukemia
212,onclive com,results showed that     of     patients with cll who received treatment with the  nd generation btk inhibitor as a monotherapy experienced cardiac toxicity of any grade at a median follow up of      months   ash hematology  ash   https   t co pyx ezazc 
213,pharmanewsintel,astrazeneca s phase    clinicaltrial found that multiple cell lymphoma patients treated with astrazeneca s  cancerdrug  calquence  remained progression free for an average of    months    https   t co c xxpxjt n
214,jpubb              ,                 calquence                                                           https   t co isvqylmtwe
215,pr times    ,                 calquence                                     https   t co uaxtcybcan
216,pr times    ,                 calquence                                     https   t co  bz nyuwon
217,wmr tokyo          ,                 calquence r                                               https   t co rwagdqt  p
218,ashleigh walls,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co bufoyox iy  bloodcancerawareness  ad https   t co tjcmlppbwn https   t co xsjy  zzgo
219,bargainbriana,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co olblat iul  bloodcancerawareness  ad https   t co in kmidsin https   t co   brod   j
220,april golightly,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co uzjsifxtb   bloodcancerawareness  ad https   t co    omf  rh https   t co m fmvhot h
221,dough, azn lr op multiple best in class oncology portfolio deserves premium oncology portfolio includes multiple potentially best in class assets  including tagrisso  lynparza  calquence  enhertu  and imfinzi https   t co kfigbg jvi
222,jorge,cancer drug as covid    treatment scrapped from who solidarity trials https   t co iso vje js
223,isanidad, investigaci n     los datos de  acalabrutinib de   ensayos cl nicos refuerzan su perfil de seguridad cardiovascular en pacientes con  leucemia linfoc tica cr nica  astrazenecaes   https   t co c  komibjt
224,isanidad,  los datos de  acalabrutinib de   ensayos cl nicos refuerzan su perfil de seguridad cardiovascular en pacientes con  leucemia linfoc tica cr nica  astrazenecaes   https   t co c  komibjt
225,onclive com,patients with cll who received treatment with single agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation   ash hematology  ash   https   t co  bpqyna km
226,trip database,new trip  acalabrutinib  calquence    chronic lymphocytic leukaemia  cll  https   t co u lryivdfk
227,radyo la verdad     ,kinumpirma ng department of health na hindi na gagamitin sa world health organization solidarity trial ng therapeutics o mga gamot ang acalabrutinib  https   t co fwv nc tzt
228,cure magazine,at a median follow up of      months      of the patient population who received calquence monotherapy experienced a cardiac toxicity of any severity  which led to treatment discontinuation in only seven patients  https   t co w nlttqfjf
229,radyo la verdad     ,acalabrutinib  hindi na gagamitin sa who solidarity trial ng therapeutic    https   t co fwv nc tzt via  youtube
230,ronald m  chavin,            in a decision announced today by the who  bad news for astrazeneca s blood cancer drug  calquence  acalabrutinib   for treating covid     astrazeneca had already announced the failure of calquence https   t co  jwlijshtd https   t co aspnyotalf https   t co hfq fonqgc
231,untv news and rescue,acalabrutinib  hindi na gagamitin sa who solidarity trial ng therapeutics   doh  https   t co rwkcivpg p
232,dzbb super radyo,  pasyente  nakumpleto na ang clinical trial ng avigan bilang gamot sa covid    sa pilipinas  clinical trial ng cancer drug na acalabrutinib sa paghanap ng gamot kontra covid     hindi na itinuloy ng  who   superbalitasahapon https   t co jl zdrja g
233,radyo agila dzec      khz,cancer drug na acalabrutinib inalis na sa mga gamot na kasama sa who solidarity trial https   t co pxanq ooia
234,cnn philippines, nagbigay na ng recommendation ang who  it s not going to be part of the solidarity trial anymore   doh spokesperson maria rosario vergeire says  https   t co bogahkfymh
235,dzbb super radyo,paggamit ng cancer drug na acalabrutinib bilang bahagi ng solidarity trial sa paghanap ng gamot para sa covid     hindi na itinuloy ng world health organization o  who    via  isa umali
236,medivizor,new  comparing acalabrutinib to standard treatments in patients with chronic lymphocy    https   t co tlxiunst a via  medivizor  leukemia
237,this messy season family blog,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co vriquhrkff   bloodcancerawareness  ad https   t co y lmrkor k https   t co ktadjk puw
238,        ,                             mantlecell lymphoma                    calquence                                             btk                    https   t co b  z puj x
239,cook eat go, ad consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co pkc  tf kq   bloodcancerawareness https   t co  v  qkmds  https   t co p jizk jo 
240,im m dico,los datos de calquence de   ensayos cl nicos refuerzan su perfil de seguridad cardiovascular en pacientes con llc  https   t co sz v trm k
241,william v  sweeney,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co  q vwzswbs  bloodcancerawareness  ad https   t co ffjjehskg  https   t co iya qtcd f
242,caryn bailey,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co frgjjnx v   bloodcancerawareness  ad https   t co ufyqjrbgzt https   t co syejqjn a 
243,christi b,with  calquence  feel supported all day and night with patient and caregiver resources  calquence is an oral   x a day prescription medication to treat adult patients with cll or sll  learn more at  https   t co ay qxbphkk    bloodcancerawareness  ad https   t co o g s xemh https   t co  aigr uzif
244,trip database,new trip    p deletion testing for access to acalabrutinib in patients w  relapsed or refractory chronic lymphocytic leukaemia https   t co  vvu ifbfi
245,kami allen,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co  aavbcjudc  bloodcancerawareness  ad https   t co qui rhta   https   t co     na gz 
246,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
247,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
248,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual conference 
249,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
250,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual conference 
251,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence 
252,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual conference 
253,calquence   acalabrutinib ,https   t co w  aqpuk a this year s all virtual ash      conference featured clinical data about calquence a treatment option for adults with cll 
254,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence 
255,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
256,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
257,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence 
258,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence 
259,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence 
260,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual conference 
261,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence 
262,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual conference 
263,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
264,calquence   acalabrutinib ,https   t co w  aqqbux  don t miss dr michael wang present astrazeneca s clinical data from calquence at this year s virtual conference 
265,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual conference 
266,calquence   acalabrutinib ,https   t co w  aqqbux  learn more about the demonstrated safety and tolerability profile of calquence 
267,coralie seright  lovebugs and postcards ,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co t  tzi gec  bloodcancerawareness  ad https   t co koo  igjvp https   t co vkf  hrjuh
268,elizabeth hurt,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co bcu eb  ym  bloodcancerawareness  ad https   t co cmwmutldvy https   t co fiz xlq fg
269,ematoinfo, ash     leucemia linfatica cronica  il trattamento con acalabrutinib in monoterapia si caratterizza per l ottimo profilo di safety  elemento assolutamente decisivo nell ambito di questa patologia  l intervista a paolo ghia   sanraffaelemi    https   t co dtzv l  cp
270,benlazar s m amin ,acalabrutinib r chop in nd  dlbcl  ash   https   t co hrek ingxx
271,benlazar s m amin ,acalabrutinib in r r mcl  ash   https   t co jwz tliwxs
272,benlazar s m amin ,acalabrutinib cost effectiveness  ash   https   t co if eyva in
273,benlazar s m amin ,acalabrutinib cardiovascular events  ash   https   t co ilbghugwz 
274,benlazar s m amin ,avo  acalabrutinib  venettoclax   r o in r r  cll  ash   https   t co mgeta ugg 
275,paperbirds hematology,new clinical trial  early intervention with acalabrutinib in patients with high risk cll https   t co nh vpenafs  cll  leusm  hematology
276,pepvax inc,acalabrutinib demonstrates low cardiac risk in chronic lymphocytic leukemia   targeted oncology https   t co icvz  sp f https   t co s eod ivwm
277,pharmaphorum,nhs england is to grant immediate access to cancer drug calquence from  astrazeneca for certain patients with chronic lymphocytic leukaemia  cll  after nice backed it in first draft recommendations https   t co tdeyedncwj  cancer  pharma
278,nice,nice has recommended the use of acalabrutinib for certain adults with untreated and treated chronic lymphocytic leukaemia  read the draft guidance and take part in the consultation until monday    january       at  https   t co qrgsgacudd https   t co idztwq bhk
279,mednetnews,acalabrutinib demonstrates low cardiac risk in chronic lymphocytic leukemia   targeted oncology https   t co xwpswp ij 
280,bionest partners,astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice  after demonstrating positive long term efficacy and tolerability in  mcl  does this open the door for calquence in  cll  https   t co txiwpyegnp https   t co  gvcmtxmrb
281,lisa o driscoll,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co v  unah p   bloodcancerawareness  ad https   t co dljdcktd e https   t co aqd ulx ac
282,tamara bowman,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co ejeihp kp    bloodcancerawareness  ad https   t co dyu rg   a https   t co yr   q fyx
283,david ledger,nice backs az  calquence for chronic lymphocytic leukaemia https   t co lmxjbu jhb https   t co   cpbuyhr 
284,benlazar s m amin ,management of waldenstr m macroglobulinemia in       acalabrutinib and zanubrutinib  ash   https   t co aplkp w tt
285,plexus ventures,nice backs  astrazeneca  calquence for chronic lymphocytic  leukaemia https   t co js rsgnnsg  pharmatimes  astrazeneca  cll
286,pharmafocus,nice recommendation for astrazeneca s calquence in chronic lymphocytic leukaemia populations https   t co n hbz  fjn https   t co g  vaz hq 
287,cpl life sciences,  nicecomms backs  astrazeneca calquence for chronic lymphocytic  leukaemia https   t co  ex ktion   regulatory
288,targeted oncology,dr  brown discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next generation btk inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia  https   t co   pvookpdi  leusm  ash  
289,pharma news,eligible patients in england with chronic lymphocytic leukaemia  cll  granted immediate access to calquence   acalabrutinib  following positive nice recommendation https   t co zzjpwgs in  news  pharma  clinicalresearch  biotech  lifesciences  medical  healthcare  pharmiweb https   t co ucovldyehl
290,pharma news,calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia https   t co girqo u  g  news  pharma  clinicalresearch  biotech  lifesciences  medical  healthcare  pharmiweb https   t co glztdptda 
291,jon angelo,nice recommendation for astrazeneca s calquence in chronic lymphocytic leukaemia populations   https   t co bjq uj hw   pharmaceutical
292,nwokeagulu,pooled analysis of   clinical trials reflects low cardiac risk with acalabrutinib in cll https   t co vpfsnr hv 
293,prescient healthcare group,prescient coverage of  ash      day    chronic lymphocytic leukemia   cll     ror inhibitor  mdm inhibitor  ibrutinib  acalabrutinib  zanubritinib  ublituximab  loxo    https   t co la dlpmhmq https   t co ukc q evmi
294,onclive com,pooled analysis of   clinical trials reflects low cardiac risk with acalabrutinib in cll  danafarber  ash hematology  ash    leusm https   t co qiuwm drlb
295,paperbirds hematology,new clinical trial  acalabrutinib for the treatment of relapsed or refractory autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia https   t co  ecceez  l  cll  leusm  hematology
296,smart clinical pharmacology,aprobaci n de acalabrutinib contra leucemia linfoc tica cr nica en la uni n europea https   t co mmuj l xgj via  medscape
297,pharmabox in,nice backs az  calquence for chronic lymphocytic leukaemia https   t co dmm  g osj
298,pharmatimes,nice backs az  calquence for chronic lymphocytic leukaemia https   t co qserojzmbw  pharmanews  pharma
299, stoncology, astrazeneca reported that  calquence data across four trials reinforces  cardiovascular safety profile in patients with  chroniclymphocyticleukaemia https   t co  hc   om m
300, stoncology, astrazeneca reported that  calquence data across four trials reinforces  cardiovascular safety profile in patients with  chroniclymphocyticleukaemia https   t co  hc   om m
301,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data were released at ash 
302,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data were released at ash 
303,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data were released at ash 
304,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data were released at ash 
305,calquence   acalabrutinib ,https   t co w  aqpuk a this year s all virtual ash      conference featured clinical data about calquence a treatment option for adults with cll   ash  
306,vshariharakrishnan,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co zwg vq riu
307,joseph cioccio  do,the only pts to still benefit from chemo in  cll are young with unmutated ighv and no tp   or   pdel otherwise front line tx is chemo free    preferred tx either venetoclax obinatuzumab or acalabrutinib w  or w o cd   moab  ash     https   t co zpspqny y 
308,pharmabox in,astrazeneca reports long term efficacy and tolerability of calquence  acalabrutinib  in p ll ace ly     study for mcl https   t co jodduon uf
309,toby eyre,pleased to be leading uk  ncri partners caramel pilot trial in older pts with  l  acalabrutinib  rituximab in elderly pts unfit for standard immunochemotherapy in  mcl   hopefully opening q          how will it compare to  ibrutinib r phase ii data  https   t co  lmhoxgk y
310,    ,awesomecapital  ash  astrazeneca s calquence  beigene s brukinsa t    https   t co  ro scdvhe
311,investor news,calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukemia  azn https   t co ogzpjrnaof
312,brainsights ios app,correcting and replacing calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma   neuro central via brainsights for ios https   t co sz in majt
313,targeted oncology,dr  brown discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next generation btk inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia  https   t co   pvooc bs  ash    leusm
314,pharma top news,ash       astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice   fiercepharma  pharmatopnews  oncology  oncologytopnews https   t co gbb x ttk 
315,david ledger,calquence shows long term efficacy and tolerability in mcl https   t co xuh besmtw https   t co oggl  ukl 
316,seattlecancercarealliance,today at  ash    poster session with  mshadman  md  mph         phase   study of zanubrutinib in patients with relapsed refractory b cell malignancies intolerant to ibrutinib acalabrutinib  https   t co d httqeuko  hematology https   t co gzja gkcqz
317,impharma news,calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukemia  https   t co of  lnxw k
318,biotech   tech stock focus, azn calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukemia    business wire https   t co lipcf dfs 
319,crwe world,correcting and replacing amp nbsp calquence shows long term efficacy and tolerability at three years for patients with r https   t co cj p wttrc
320,company news hq,calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic https   t co  nveud  ja
321,anne sweden,consider  calquence for any adult you may know living with chronic lymphocytic leukemia  cll   small lymphocytic lymphoma  sll  or mantle cell lymphoma  mcl   it s a convenient oral  x a day capsule  learn more   bloodcancerawareness https   t co  umq   vmi  ad https   t co kpqsmvmglq
322,lifepronow pharma research and news,az s calquence shows long term efficacy and tolerability in mcl https   t co hauiz uwds https   t co xaryjen k 
323,pharmacutical daily,correcting and replacing calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co tlyhapsvh 
324,the british journal of cardiology,pooled analysis  ash hematology of cardiovascular safety data in     patients treated with calquence  acalabrutinib  monotherapy for chronic lymphocytic leukaemia  cll   the most common adult leukaemia  showed a low incidence of cardiac adverse events   astrazeneca  bcoscardioonc
325,devdiscourse,brief astrazeneca says less than    of patients treated with calquence discontinued treatment due to cardiac adverse events in pooled analysis https   t co gf pgelqwf
326,otc dynamics  inc , azn correcting and replacing calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co  bobpbyxpl
327,stock titan, azn correcting and replacing calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co bdmczawjho
328,investor news,correcting and replacing calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle     azn https   t co mdcwshoapb
329,keeping life sane,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co houclnvd x  bloodcancerawareness  ad https   t co ozejghghae https   t co  mgh iukcd
330,otc dynamics  inc , azn calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukemia https   t co ci lkinfd 
331,shifting wealth,astrazeneca says data from four calquence trials reinforces cv safety in cll  azn
332,cision news,calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukaemia https   t co fpte  udsd
333,astrazenecaus,cardiovascular  cv  adverse events may be a key consideration in chronic lymphocytic  leukemia  cll  treatment decisions  today at  ash   we re presenting results of an analysis of pooled cv safety data across four trials in cll  learn more  https   t co  gi xwevvo https   t co jyv ngflmc
334,stock titan, azn calquence data across four trials reinforces cardiovascular safety profile in patients with chronic lymphocytic leukemia https   t co s amanuu z
335,biotech   tech stock focus, azn  bgne ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co  jrhkdtonr
336,dr  carsten wenzel,calquence shows long term efficacy and tolerability in mcl https   t co jvhjwiyvfe https   t co ksgnbyhnkb
337,biopharmaasia,ace ly     phase ii trial results substantiate established efficacy and safety profile of calquence   https   t co b jiezlf s
338,prescient healthcare group,prescient coverage of  ash      day    chronic lymphocytic leukemia   cll     acalabrutinib  venetoclax  obinutuzumab https   t co mrbdl adeq https   t co wly gaoftm
339,chitraders, azn astrazeneca s calquence shows long term efficacy and tolerability in patients with blood cancer https   t co zbfxehq au
340,wic      p i  ,   astrazeneca s calquence shows long term efficacy and tolerability in patients with blood cancer https   t co fol  mrfbo vi  wic      p i   fin nci l re ds
341,gordon gekko,astrazeneca s calquence shows long term efficacy and tolerability in patients with blood cancer https   t co a ifrxmogz
342,investor news,astrazeneca s calquence shows long term efficacy and tolerability in patients with blood cancer  azn https   t co  ywmcnr vs
343,breaking news, azn   astrazeneca s calquence shows long term efficacy and tolerability in patients with blood cancer https   t co ibdbch oel
344,pharmatimes,calquence shows long term efficacy and tolerability in mcl https   t co  f l e svk  pharmanews  pharma
345,pharmabox in,calquence shows long term efficacy and tolerability in mcl https   t co  ddznkc to
346,pharmashots   incisive news in   shots,astrazeneca reports long term efficacy and tolerability of calquence  acalabrutinib  in p ll ace ly     study for mcl  pharmashot  astrazeneca  https   t co ssi xzmusr https   t co y  kfuqk d
347,medicircle in,long term follow up results from the positive ace ly     phase ii trial showed patients with relapsed or refractory mantle cell lymphoma  mcl  treated with calquence  acalabrutinib  remained   latestpharmanewsdec   latestastrazenecanewsdec   https   t co gqhzzuj bw
348, stoncology, astrazeneca reported that  calquence shows long term efficacy and tolerability at three years  for patients with  relapsed or  refractory  mantlecelllymphoma  azn https   t co ijgskqcdkz
349,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
350,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
351,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
352,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
353,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
354,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
355,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
356,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
357,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
358,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
359,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about the demonstrated safety and tolerability profile of calquence  join the virtual conversation to learn more   ash  
360,cafepharma,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co  dd cdj d 
361,shifting wealth,calquence shows long term efficacy  tolerability at   years in r r mcl   azn
362,analyst land news,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co  nqwprmrmn https   t co  fsa r  co
363,enosi life sciences,these  cytokine storms  are created when there are high levels of pro inflammatory tnf       some covid    patients suffer from  cytokine storms   in which immune systems end up attacking the body after getting revving up to fight off the coronavirus    https   t co tsbsvaarx 
364,exbulletin,ash  astrazeneca s calquence and beigene s brukinsa are turning heads with new data  putting imbruvica on high alert https   t co mp bbwr e 
365,dr timos papagatsias,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co nb tyqwit   strategy  competitiveintelligence  marketing  pharma  pharmaceutical  productmarketing  healthcare  biotech https   t co  cn  fmgtb
366,wall st  justin bieber think trade ,  news alert  astrazeneca announced calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma in presentation at ash        time date            t                       think trade
367,pharmacrowd,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co   gy npuli https   t co yz ef oah 
368,fintechzoom,new article   johnson  amp  johnson   ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice  has been published on fintech zoom   https   t co adpnj rbbf  fintechzoom  fintech  blockchain  crypto  cryptocurrency  ico
369,continental clinical,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co s  iu vet 
370,newexpressnews,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co w z zsgppo
371,pharmabox in,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co xginjqbg s
372,                   insights  pharma   ,ash  astrazeneca s calquence  beigene s brukinsa turn heads with new data  putting imbruvica on notice https   t co  oyzzhkila
373,company news hq,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle https   t co gq bdnvfbd
374,brainsights ios app,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma   neuro central via brainsights for ios https   t co ni xttqufd
375,anthony mato,very thoughtful answer  thanks for taking my question  clive zent discussing which may be best the anti cd antibody to pair with the btk inhibitor acalabrutinib  https   t co dnhmdywrce
376,pharmacutical daily,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co lypjvlt pj
377,stock market news,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co ejoacuqoxi  stockmarket
378,hottest stocks now, azn reveals findings from mid stage trial evaluating calquence in patients with relapsed or refractory mantle cell lymphoma       astrazeneca        mcl        mantlecelllymphoma      lymphoma      https   t co mnw szidyn
379,otc dynamics  inc , azn calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co py vcpqgfd
380,corporate news, azn calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co lnacbngpha
381,impharma news,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma  https   t co rfvqm ityj
382,investor news,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma  azn https   t co ervmjfkqll
383,crwe world,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle c https   t co y fjzibpqg
384,latest news from business wire,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co vf   vobyt https   t co th  uhyuxl
385,astrazenecaus,today we announced long term follow up results of the ace ly     trial in relapsed or refractory mantle cell  lymphoma  mcl  at  ash    learn more about this latest development for people living with mcl  https   t co elpwoku  y https   t co qjrsitwfna
386,cision news,calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co rmh  fkmxg
387,stock titan, azn calquence shows long term efficacy and tolerability at three years for patients with relapsed or refractory mantle cell lymphoma https   t co bbujycz kq
388,trip database,new trip  acalabrutinib  calquence    chronic lymphocytic leukaemia  cll  https   t co u lryivdfk
389,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss dr michael wang present astrazeneca s clinical data from calquence at this year s virtual  ash   conference 
390,ingrid glimelius,loxo     in mantle cell  lymphoma  very beneficial toxicity profile and orr of     in previously treated   ash   will it kill ibrutinib and acalabrutinib https   t co khtxbdyhlt
391,maria badillo  msn rn ocn ccrp,not able to join  ash     this year as i let my other team member register for this year s conference  excited to hear the results of our trials we run for  mcl such as loxo     vls    ibrutinib  acalabrutinib zuma   car t   michaelwangmd  mdandersonnews  ashfromhome
392,toby eyre,thorough overview on safety data with btkis by nicola lamanna    https   t co fneyyotxw   rct of  acalabrutinib vs  ibrutinib monotherapy in high risk r r  cll awaited with great interest  cll  ash   https   t co fznkil taz
393,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data will be released at  ash   that oncologists hematologists won t want to miss 
394,          bouter ll m ,selective inhibition of thromboinflammation in covid    by btk inhibitors  inc  the off label administration of acalabrutinib    https   t co aci  psadx
395,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data will be released at  ash   that oncologists hematologists won t want to miss 
396,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data will be released at  ash   that oncologists hematologists won t want to miss 
397,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data will be released at  ash   that oncologists hematologists won t want to miss 
398,calquence   acalabrutinib ,https   t co w  aqpuk a new calquence clinical data will be released at  ash   that oncologists hematologists won t want to miss 
399,mostly harmless,omg now i am getting ads for super specialized cancer immunotherapy drugs  like they were new cars or something  just in time for christmas  it s calquence 
400,biociencia,aprobaci n de acalabrutinib contra leucemia linfoc tica cr nica en la uni n europea https   t co yzwtqpojk  a trav s de  medscape
401,medscape es,la agencia europea de medicamentos  ema  acaba de aprobar acalabrutinib para el tratamiento de leucemia linfoc tica cr nica  una de las leucemias m s comunes en adultos  la terapia deber  ser aplicada por un especialista en f rmacos neopl sicos  https   t co  v y maete
402,brand institute  inc,congratulations to astrazeneca on the ema approval of calquence   bibrands  calquence is a prescription medicine used to treat adults with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll     emaapproval  drugnaming  cll  sll https   t co qgnderdrkt
403,dr pablo marcelo lombardo,aprobaci n de acalabrutinib contra leucemia linfoc tica cr nica en la uni n europea https   t co nmrvbg nmi via  medscape
404,rebecca miller,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co pux hd vqp  bloodcancerawareness  ad https   t co  rbcwl esz https   t co vziq g ih 
405,lavonne cladoosby long,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co obedjid i   bloodcancerawareness  ad https   t co urxc  dmbn https   t co ryxzgbiqmp
406,kelly tomlinson,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co bdfy cjrvs  bloodcancerawareness  ad https   t co cbq wfcicj https   t co yjrlec  oo
407,calquence   acalabrutinib ,https   t co w  aqpuk a this year s all virtual ash      conference will feature clinical data about calquence a treatment option for adults with cll   ash  
408,calquence   acalabrutinib ,https   t co w  aqpuk a this year s all virtual ash      conference will feature clinical data about calquence a treatment option for adults with cll   ash  
409,calquence   acalabrutinib ,https   t co w  aqpuk a attention  ash   attendees  tune in on dec   to watch dr paolo ghia present on the final analysis of the pivotal calquence trial in patients with relapsed refractory cll 
410,calquence   acalabrutinib ,https   t co w  aqpuk a this year s all virtual ash      conference will feature clinical data about calquence a treatment option for adults with cll   ash  
411,calquence   acalabrutinib ,https   t co w  aqpuk a attention  ash   attendees  tune in on dec   to watch dr paolo ghia present on the final analysis of the pivotal calquence trial in patients with relapsed refractory cll 
412,calquence   acalabrutinib ,https   t co w  aqpuk a attention  ash   attendees  tune in on dec   to watch dr paolo ghia present on the final analysis of the pivotal calquence trial in patients with relapsed refractory cll 
413,calquence   acalabrutinib ,https   t co w  aqpuk a attention  ash   attendees  tune in on dec   to watch dr paolo ghia present on the final analysis of the pivotal calquence trial in patients with relapsed refractory cll 
414,calquence   acalabrutinib ,https   t co w  aqpuk a this year s all virtual ash      conference will feature clinical data about calquence a treatment option for adults with cll   ash  
415,mommy s playbook,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co muuscdsy z  bloodcancerawareness  ad https   t co jpqihptq   https   t co pk   nekco
416,knowmedge,q   acalabrutinib is used to manage what condition   abim  meded
417,icecreamstickyfinger,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co xbm mdi nb  bloodcancerawareness  ad https   t co cjhlogykp  https   t co q tbjwrh z
418,brittany,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co b ijdbrmxt  bloodcancerawareness  ad https   t co rksdwqr cj https   t co x kyjoqzla
419,carrie,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co lajjr sdop  bloodcancerawareness  ad https   t co owkwowjo v https   t co   s rwleha
420,christian yosores,doh said the  acalabrutinib  arm of who s solidarity trial will no longer push through because evidence from astrazeneca s trial showed that there was  no significant improvement  in the treatment outcomes of patients     bomboradyonews
421,inquirer,doh said the acalabrutinib arm of the who led solidarity therapeutics trial will no longer push through after astrazeneca s study showed the anticancer drug did not help reduce deaths and the need for assisted ventilation among hospitalized covid    patients     jovicyeeinq
422,jovic yee,doh said the acalabrutinib arm of the who led solidarity therapeutics trial will no longer push through after astrazeneca s study showed the anticancer drug did not help reduce deaths and the need for assisted ventilation among hospitalized covid    patients  inquirerdotnet
423,maria,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll   https   t co ltugbbuilm  bloodcancerawareness  ad https   t co miqqpzwy d
424,heidi bee,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription  calquencehcp  for adult patients  https   t co ogel fmzup  bloodcancerawareness  ad https   t co wzvwaoc pz https   t co  lnar r ix
425,catherine lewis,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co wevhibxqfi  bloodcancerawareness  ad https   t co  yuqycolcl https   t co eqpzomqe p
426, covid evidence,https   t co k gfhg  vk   who covid    solidarity trial for covid    treatments  condition    covid   interventions    drug  remdesivir    drug  acalabrutinib    drug  interferon beta  a    other  standard of care sponsor   https   t co svbnahlq h  covid    sarscov   coronavirus
427,medivizor,new by  medivizor  comparing acalabrutinib to standard treatments in patients with chronic lymphocyt    https   t co tlxiunst a  leukemia
428,medivizor,comparing acalabrutinib to standard treatments in patients with chronic lymphocytic     via  medivizor  https   t co tlxiunst a  leukemia
429,kathy hodson,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co bn qvszi w  bloodcancerawareness  ad https   t co  qz ggn vh https   t co fjeaolmtmz
430,home jobs by mom,with calquence  feel supported all day and night with patient and caregiver resources  calquence is an oral   x a day prescription medication to treat adult patients with cll or sll  learn more at https   t co ph cfydjbt  bloodcancerawareness  ad https   t co lnzxmpdung https   t co  g xh drp 
431,angie agerter,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co  vet   saj  bloodcancerawareness  ad https   t co pcdnz rbwv https   t co glvehvrjgk
432,ana,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co q  d tjxsi  bloodcancerawareness  ad https   t co sccbjkei i https   t co a  abmwqi 
433,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual  ash   conference 
434,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual  ash   conference 
435,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual  ash   conference 
436,calquence   acalabrutinib ,https   t co w  aqpuk a don t miss astrazeneca s big reveal of calquence patient data at this year s virtual  ash   conference 
437,lindsey g ,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co qqefubedeb  bloodcancerawareness  ad https   t co kaw gaaicw https   t co cbv ek wia
438,gelbe liste,zum    dezember      kommt das arzneimittel  calquence  acalabrutinib  auf den deutschen markt  es handelt sich um eine neue behandlungsoption bei chronisch lymphatischer  leuk mie  cll   https   t co iyuxxile f https   t co tmmuy  pt 
439,icefairy,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co hoei qx x   bloodcancerawareness  ad https   t co  pc rehyop https   t co zhmhd ibbx
440,imperfect women,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients with cll  https   t co   tinmmkc   bloodcancerawareness  ad https   t co  dvkefatdr https   t co loqjpg  c 
441,candy washington,with calquence  feel supported all day and night with patient and caregiver resources  calquence is an oral   x a day prescription medication to treat adult patients with cll or sll  learn more at https   t co unujqqxdgf  bloodcancerawareness  ad https   t co en t idtxo https   t co b rqzgn  v
442,lauren beth,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription  calquence for adult patients  https   t co eyswyazd y  bloodcancerawareness  ad https   t co el  pgno a https   t co tvwxabpcpv
443,lynne mac lean,top story  acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia   medivizor https   t co gwx rorgd   see more https   t co jwix tg ze
444,paul wright,top story  acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia   medivizor https   t co upzrftns u  see more https   t co vxnuh zy l
445,medivizor,acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia https   t co gl tkhwkic via  medivizor  leukemia
446,tf  , azn    astrazeneca has revealed that early stage data concerning the efficacy of its acquired drug acalabrutinib in the treatment of blood cancers and solid tumours was invented and falsified   now covid vaccine   https   t co cntfh d  s
447,leave the cannoli,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co xdway czsg  bloodcancerawareness  ad https   t co  tkqmxdmwr https   t co llexbmheia
448,mafiusa,headline news   steals  amp  deals  emilyreviewscom   with calquence  feel supported all day and night with patient and caregiver resources  calquence is an oral   x a day prescription medication to treat adult patients wit  https   t co fprp xavpm  see more https   t co fupedpbsxb
449,emily reviews,with calquence  feel supported all day and night with patient and caregiver resources  calquence is an oral   x a day prescription medication to treat adult patients with cll or sll  learn more at https   t co wkoeyhumed  bloodcancerawareness  ad https   t co  db qfx bf https   t co   rnxfjsnr
450,kelly   alex,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co txh hadz e  bloodcancerawareness  ad https   t co yi xxgkaj 
451,deliciously savvy,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients    https   t co zl uxxvp o     bloodcancerawareness  ad https   t co xkhd ia up https   t co  y   bu uo
452,deliciously savvy,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients    https   t co  rkhq kkb      bloodcancerawareness  ad https   t co xkhd ia up https   t co s sme pygl
453,    ,          calavi                                                             calquence               calavi                                   https   t co iz ybcr yt
454,haute autorit  de sant , contribuez   nous  valuons le nouveau  m dicament calquence  acalabrutinib  dans le traitement des patients atteints de  leuc mie lympho de chronique  llc  non pr c demment trait e   https   t co wtnjnrgz r
455,cleverly changing  she her ,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co uriujonuss  bloodcancerawareness  ad https   t co dehy fk py https   t co jxsuseqcdf
456,elmens,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co ak c fltfh    bloodcancerawareness  ad https   t co untvkfioca https   t co fftigajqbz
457,alexandria,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co oej xpplui  bloodcancerawareness  ad https   t co n pmogg yd https   t co rymmowarrc
458,jaclyn,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co cph dlgt z  bloodcancerawareness  ad https   t co ktikltoycd https   t co  bueqior j
459,stephanie beautybrite  ,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co tbytawea q  bloodcancerawareness  ad https   t co odxrud vnt https   t co gzh  orrub
460,stephanie beautybrite  ,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co tbytawea q  bloodcancerawareness  ad https   t co odxrud vnt https   t co neek pstsx
461,jennifer soltys,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co wksexhuduz  bloodcancerawareness  ad https   t co qx efpn cp https   t co xnvrekv eg
462,vanessa diaz,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co plswjtj wf  bloodcancerawareness  ad https   t co mnumx b da https   t co b fcazp xq
463,colleen padilla,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co leqnl ojxb  bloodcancerawareness  ad https   t co iwox aatey https   t co dvvkndaqwn
464,jenn p,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co lhc iinxyc  bloodcancerawareness  ad https   t co ikakhztspp https   t co z   ljrid 
465,jays sweetnsour life,taking cll medication should be as convenient as an oral  twice a day capsule  if you or someone you love has cll  you may have options with prescription calquence for adult patients  https   t co pnkgq  acr  bloodcancerawareness  ad https   t co g fg ponie https   t co  cfdzrgjf 
466,fancyfinancy,astrazeneca cancer drug found ineffective for treating covid    https   t co dhkynnrzmg
467,fancyfinancy,astrazeneca s calquence fails pair of phase ii covid    trials https   t co  ddvzef hc https   t co  gunjqcsvx
468,zazoom social news,leucemia linfocitica  acalabrutinib approvato in ue     leucemia  linfocitica   acalabrutinib  https   t co z l ov wl 
469,kimberly kong,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co dfxwwkx oz   bloodcancerawareness  ad https   t co lyfgo  dcu https   t co liwdtfqo  
470,a watcher,                                                                calquence  calavi                                                          https   t co x pede spp
471,toby eyre,v comprehensive rw by danilov  amp   drdanpersky  acalabrutinib in  mcl  cll  amp   wm  recommended reading   lymsm   incorporating acalabrutinib  a selective next generation btk inhibitor  into clinical practice for the treatment of haematological malignancies https   t co wrngl z jl
472,amber koehler  pa c,great news for patients with  cll in the eu  https   t co zfrmfv caw
473,mariah moon,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co cav wt  fb  bloodcancerawareness  ad https   t co k oknkqgo  https   t co  qbnlkibus
474,onclive com,results showed that the majority of patients who received a     to    day course of acalabrutinib experienced improvement in oxygenation that was found to occur within   to   days of treatment   covid    https   t co nssvaz vet
475,erica valentin,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co  spf  oa a  bloodcancerawareness  ad https   t co sb xa ayep https   t co mupucji bg
476,lymphoma papers,incorporating acalabrutinib  a selective next generation bruton tyrosine kinase inhibitor  into clinical practice for the treatment of haematological malignancies   lymphoma  lymsm https   t co p if dqkzn
477,trip database,new trip  acalabrutinib  calquence    chronic lymphocytic leukaemia  cll  https   t co u lryivdfk
478,onclive com,the approvals of ibrutinib and acalabrutinib have been transformative to the cll treatment paradigm  but could have even more power in combination   askarbnik  novanthealth  leusm https   t co sinvk s sw
479,practiceupdate,pembrolizumab plus acalabrutinib for platinum resistant metastatic  urothelial carcinoma       esmo   interview with  sonpavde     blcsm  myesmo  https   t co z  gbayma 
480,onclive com,the addition of acalabrutinib to best supportive care in patients with respiratory symptoms from  covid    failed to increase the proportion of patients who remained alive and free of respiratory failure  https   t co muscsbq xr
481,amy smith,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co ai fkmguan  bloodcancerawareness  ad https   t co  bmcbv qbe https   t co euebm vlqc
482,paperbirds hematology,new article  incorporating acalabrutinib  a selective next generation bruton tyrosine kinase inhibitor  into clinical practice for the treatment of haematological malignancies  https   t co opcvzamkg   mcl  lymsm  hematology https   t co auitt he m
483,momglenz,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co uthofgllbr  bloodcancerawareness  ad https   t co erxhermwx  https   t co aytlnpbbpz
484,da vinci   also follow  outdoorsybw,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want   calquencehc is a prescription treatment option for adult patients with cll  https   t co uuqc svym   bloodcancerawareness  ad https   t co mnljx r ze https   t co hx lvkywy 
485,gelbe liste,die europ ische kommission hat  calquence mit dem wirkstoff  acalabrutinib die zulassung f r die behandlung von chronisch lymphatischer  leuk mie  cll  erteilt  https   t co opbrvsmvbf https   t co sfv  fdpr 
486,jpubb              ,                                         calquence  calavi                           https   t co osfvr ezrl
487,newsrelea se,                                                    calquence calavi           https   t co w qitdmj m
488,pr times    ,                                        calquence calavi         https   t co untxvmf  k
489,    vs  ai                    ,                                          calquence calavi                   ai  ai                 coronavirus https   t co h ojfyzp g
490,pr times    ,                                        calquence calavi         https   t co ow fo u g 
491,wmr tokyo          ,                                        calquence calavi ii         https   t co rbkwkopkxv
492,colin cesvette,top story  treatment for cll sll and mcl   calquence   acalabrutinib  https   t co btawyjmr f  see more https   t co  krqoklmtg
493,what s up dearie ,with calquence  feel supported day and night with their patient and caregiver resources  calquence is an oral   x a day prescription medication used to treat adult patients with cll  learn more at https   t co r x hv lu    bloodcancerawareness  ad https   t co u rpybdixu https   t co lijfv mulj
494,biotechbiopharma,astrazeneca cancer drug found ineffective for treating covid    https   t co o  khfbzc 
495,cadth,cadth has issued a recommendation for  acalabrutinib   calquence  to be reimbursed with clinical criteria and or conditions for the treatment of chronic lymphocytic  leukemia   see the full recommendation   https   t co guoozzsthw https   t co  ahcvlyvmr
496,biotechbiopharma,astrazeneca s calquence fails pair of phase ii covid    trials https   t co jxqcmsyl w https   t co knflrjddzm
497,melissa weintraub,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co r dnlk  vf   bloodcancerawareness  ad https   t co kmzvq  uzc https   t co va aziqr u
498,heather   pink ninja blogger,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co oxsb lnyt    bloodcancerawareness  ad https   t co nzbonf seu https   t co vw xohqcmk
499,garf,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co   v  io du   bloodcancerawareness  ad https   t co rwxmoq  a  https   t co kqycp  fqs
500,your helpful wendy,if you or someone you love has blood cancer  cll  sll or mcl   you have treatment options with  calquence it s a convenient oral   x a day capsule  so you can focus on the lifestyle you want   bloodcancerawareness https   t co   ykw xnci  ad https   t co xce dys  t
501,financial carnivores,astrazeneca cancer drug found ineffective for treating covid    https   t co umzllpdq e
502,financial carnivores,astrazeneca s calquence fails pair of phase ii covid    trials https   t co ezxaeuk ym https   t co xlx olp yu
503,my life is a journey   ,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co krn kp qki  bloodcancerawareness  ad https   t co zk pqedzaw https   t co qsg f rec 
504,quant data,astrazeneca says presentations support calquence efficacy and tolerability with long term follow up in mantle cell lymphoma and pooled safety data in chronic lymphocytic leukaemia  related tickers   azn read more at  https   t co kofetli vu
505,swedish biotech,astrazeneca cancer drug found ineffective for treating covid    https   t co qzswlwdd w
506,        ,                                       update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    https   t co zf pslc x  https   t co tpwsvtwgc 
507,swedish biotech,astrazeneca s calquence fails pair of phase ii covid    trials https   t co  g xhxdxb  https   t co nn kjnetvf
508,cure magazine,cure  amp  astrazeneca are proud to present the first calquence connections on november    at  pm et  join us as a doctor  patient  and care team discusses their experiences with chronic lymphocytic leukemia and answers audience questions  learn more  https   t co qpxnz ovii https   t co fuuowhri c
509,wrapped up n u,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co  thbetrrxi  bloodcancerawareness  ad https   t co qhd kft  l https   t co s  tcxxd n
510,pamelamaynard,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co avt iqnvp   bloodcancerawareness  ad https   t co pktv   ka  https   t co oiiaxqdj a
511,sensiblysara,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co xstvkyn sq  bloodcancerawareness  ad https   t co cwbf taupw https   t co ovbuuhcakb
512,the frugal navy wife,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want   calquencehcp is a prescription treatment option for adult patients with cll  https   t co  matlnpacn  bloodcancerawareness  ad https   t co awwpf p uw https   t co  bsvjuahpp
513,christine   the growing creatives,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co luqkyckbps  bloodcancerawareness  ad https   t co d p  hxvt  https   t co crtzqedwyy
514,onclive com,acalabrutinib misses the mark in patients hospitalized with  covid    related respiratory symptoms https   t co ylodsq t y
515,dcapdepon,https   t co z ot mndtf https   t co d  dnzh n 
516,medical tribune    ,btk   acalabrutinib              eu      https   t co hcshfs pgh
517,the zamp camp,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co vygvwsvgsb  bloodcancerawareness  ad https   t co vkysadnznj https   t co  e xmie un
518,lori felix,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co z v lbsqza  bloodcancerawareness  ad https   t co ed bfsuath https   t co awok w xcs
519,michele nadeem baker,cll treatment research  final ascend study data  acalabrutinib beat standard of care for r r cll https   t co iljkwhcbdk   cll  chroniclymphocyticleukemia  ascendstudy  acalabrutinib  btkinhibitor  mdedgehemonc  michelenadeemb
520,niecyisms by clc studios,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co fowtbgo i   bloodcancerawareness  ad https   t co f kkf gjc  https   t co  uslbuwuyl
521,liz cleland,consider  calquencehcp for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co bdmdw az       bloodcancerawareness  ad  https   t co mhoyuvp  s https   t co kknsh   pk
522,theyumyumfoodie,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co cprveo bre  bloodcancerawareness  ad https   t co wmjaves c  https   t co pff wchufg
523,susie s reviews,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co fuj  ejwm    bloodcancerawareness  ad https   t co  timaq  rw https   t co ee bhd bwe
524,amanda taylor,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co fchujzmann  bloodcancerawareness  ad https   t co  xmle  n k https   t co htydq zwiz
525,anne marie   this mama cooks  on a diet,with calquence  feel supported day and night with their patient and caregiver resources  calquence is an oral   x a day prescription medication used to treat adult patients with cll  learn more at https   t co fdhqnumcqa   bloodcancerawareness  ad https   t co dotcyuzt m https   t co n  fijkpfx
526,shelly belly,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co agncci ppz  bloodcancerawareness  ad https   t co yeepwji zo https   t co qeitteobzc
527,missinglynxx,with calquence  feel supported day and night with their patient and caregiver resources  calquence is an oral   x a day prescription medication used to treat adult patients with cll  learn more at https   t co qpx ahm jw   bloodcancerawareness  ad https   t co faexnryeho https   t co  gtq zk co
528,cismef quoi de neuf,calquence   acalabrutinib https   t co meuhtzquhl
529,krystal     ,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co adjbsj xr   bloodcancerawareness  ad https   t co qmsgjjyjxw https   t co c fs  op b
530,biopharmaasia,updated calavi phase ii trials results for calquence in patients hospitalised with symptoms of covid      https   t co wdmtr u e 
531,           ,                 calquence r  eu                            pr times https   t co xttymfnt t
532,oncology news australia,oncology news update   acalabrutinib demonstrated superior progression free survival for r r chronic lymphocytic leukaemia patients  has been published on oncology news australia   https   t co fnawjkbpk   oncnews https   t co lfworuazfn
533,newsrelea se,                             calquence  eu                          https   t co  y hzmf cp
534,jpubb              ,                 calquence   eu                                         https   t co  cgrkhwot 
535,a watcher,                                calquence   eu                                                                                             https   t co  yonzetwqt
536,pr times    ,                 calquence  eu                          https   t co vh mjj zbr
537,kaila yu,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co ey f fvmhm  bloodcancerawareness  ad https   t co  mvkmmpjj  https   t co btq ehvmho
538,pr times    ,                 calquence  eu                          https   t co fqxikga lg
539,wmr tokyo          ,                 calquence r  eu                          https   t co ucdmguqyxu
540,olivia douglass,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co  nphq krvi  bloodcancerawareness  ad https   t co  cwa  k  q https   t co ttu  cfcir
541,susie s reviews,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co fuj  ejwm    bloodcancerawareness  ad https   t co  timaq  rw https   t co uoyyrbmnmp
542,trendy cyndie reviewz   newz,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co ugojpw  rp   bloodcancerawareness  ad https   t co wpblwdjus  https   t co ffwukoueqm
543,momma lew   food and fun by reesa lewandowski,taking cll medication should be as convenient as an oral   x a day capsule  allowing you to focus on the lifestyle you want  calquence is a prescription treatment option for adult patients with cll  https   t co  a p ihcfo  bloodcancerawareness  ad https   t co gebizrbvsc https   t co sqlorm cyj
544,jessica,with  calquencehcp  feel supported day and night with their patient and caregiver resources  calquence is an oral   x a day prescription medication used to treat adult patients with cll  learn more at https   t co xotvzgtjek   bloodcancerawareness  ad https   t co chby ro    https   t co hv uxgckgt
545,tara pittman,consider calquence for any adult you may know living with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   it s a prescription oral  x a day capsule  learn more  https   t co pzi z mxgy   bloodcancerawareness  ad https   t co  f m tftck https   t co  femfscdit
546,trip database,new trip    p deletion testing for access to acalabrutinib in patients w  relapsed or refractory chronic lymphocytic leukaemia https   t co  vvu ifbfi
547,vikesh gudka,astrazeneca s calquence fails pair of phase ii covid    trials   biospace https   t co q  su gnoc  jobs
548,evaluate japan,az btk   calquence                                      btk                 il            eli lilly  regeneron  az                      https   t co enkelagsec           covid  
549,carnivoreshealth,astrazeneca cancer drug found ineffective for treating covid    https   t co ailwvnmoru
550,carnivoreshealth,astrazeneca s calquence fails pair of phase ii covid    trials https   t co vqxsotahda https   t co tnjshnr  l
551,onclive com,the regulatory decision was based on data from two phase   clinical chronic lymphocytic leukemia trials  elevate tn and ascend  myunisr  ema news  leusc https   t co c qkcbuhoz
552,ecam norway,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short https   t co mix uz  xv
553,carlo franzini,novita  nel trattamento della leucemia linfatica cronica   approvato  calquence    acalabrutinib   di  astrazeneca  iscrizione gratuita alle newsletter xagena di medicina  https   t co abt a psfd   ematologia  medicina  oncoematologia  xagena  farmacia https   t co bqib  jvtk
554,cure magazine,join cure  amp  astrazeneca on november    at  pm et for calquence connections  dr  jeff sharman joins jim  a patient with chronic lymphocytic leukemia  jim s wife  becky  and a nurse  to discuss their experiences with this disease  learn more  amp  register  https   t co qpxnz ovii https   t co utbtfkflu 
555,kaushik a sejpal,https   t co zbytmwm  l
556,official page of monkeyviral com, calquence fails to prevent respiratory failure in covid    patients   medlancr is now trending on https   t co faru cltsb    https   t co rsypfzotyu
557,pilotforpulmonary,in calavi phase ii trials  calquence  acalabrutinib  fails to reduce mortality or respiratory failure in patients hospitalized with covid    https   t co kcd cteejo
558,el global,tras la recomendaci n de la ema  la comisi n europea ha aprobado tambi n este tratamiento  un inhibidor selectivo de la tirosina kinasa de bruton  astrazenecaes  https   t co ahdx   ypl
559,kari tikkinen,astrazeneca press release on  acalabrutinib phase   trials  unfortunately no help  more  covid research from high quality trials needed  press release  https   t co kqfzqis xu  registrations  https   t co hse  huqpq https   t co vnjm pbzzo   erictopol  martinlandray  germhuntermd https   t co tldcwnpiyq
560,pharma top news,astrazeneca cancer drug found ineffective for covid      biopharma dive  pharmatopnews  https   t co vmgnbyau a
561,fintechzoom,new article   costco   astrazeneca s  azn  calquence fails in coronavirus study  has been published on fintech zoom   https   t co  vh i s uf  fintechzoom  fintech  blockchain  crypto  cryptocurrency  ico https   t co xbjefywqzs
562,ester hern ndez,no solo hay avances con la vacuna de la covid       aprobado el tratamiento contra la leucemia linfoc tica cr nica  la leucemia m s com n en pacientes adultos https   t co  vwjmdoo c
563,ecancer en espa ol, acalabrutinib demostr  una  supervivencia sin progresi n superior para los pacientes con leucemia linfoc tica cr nica r r  astrazeneca   ecancer  oncoreporte https   t co qlfq n xht
564,journal of the  nccn,comparing front line treatments in  cll with a focus on  acalabrutinib  https   t co wwayd f  a  leusm  jnccn    https   t co zwcohj kfg
565,european pharmaceutical review,astrazenaca reveals  calquence  acalabrutinib  did not increase the proportion of hospitalised  covid   patients who remained alive and free of respiratory failure   clinicaltrials  pharma  therapeutics  drugrepurposing read the news  https   t co   dmejighv https   t co oyykqz cza
566,carlo centemeri,astrazeneca s calquence fails to help patients hospitalised with covid    respiratory symptoms https   t co oatqnmeiom via  fwpharma
567,paperbirds hematology,new clinical trial  modified vr cap and acalabrutinib as first line therapy for the treatment of transplant eligible patients with mantle cell lymphoma https   t co wmkvrluz t  mcl  lymsm  hematology
568,salvador s,la ue aprueba calquence  astrazeneca  para leucemia linfoc tica cr nica https   t co eeoovga uh
569,sortiraparis,covid      le calquence  un traitement efficace contre les chocs cytokiniques   https   t co deatqirrjm
570,laurent pradal,covid      le calquence  un traitement efficace contre les chocs cytokiniques   https   t co jgri pbzdh
571,cafepharma,astrazeneca cancer drug found ineffective for covid    https   t co tr hczw p 
572,pharmaceutical,astrazeneca s calquence fails pair of phase ii covid    trials https   t co o  qdwbtvh https   t co wdkhm q tc
573,serena tinari,one more  covid    promising drug  down   this time is  astrazeneca calquence  acalabrutinib   cc  recheckhealth   https   t co ry vdlyvkw
574,pharma prime time, astrazeneca cancer drug found ineffective for  covid    pharmanews  elonmusk   healthcare https   t co  uvuaahx l
575,miguel angel grullon c ,astrazeneca s calquence fails to help patients hospitalised with covid    respiratory symptoms   acalabrutinib est  aprobado para el tratamiento de adultos con leucemia linfoc tica cr nica y adultos con linfoma de c lulas del manto  https   t co  kmebv xnk
576,sosyal medya,astrazeneca n n umut olan ilac  koronavir s tedavisinde etkisiz kald   reuters  n haberine g re koronavir s hastalar n n ba    kl k sisteminde olu an sorunlar  bask lamas  ama lanan kan kanseri ilac  calquence in sonu lar  ba ar s z oldu   https   t co r r odanse
577, investigando,la adici n del inhibidor btk acalabrutinib al tratamiento en pacientes hospitalizados con s ntomas respiratorios de la covid no aumentar a la proporci n de pacientes vivos sin insuficiencia respiratoria https   t co rtqfo g s 
578,onclive soss,  seemaalibhat   of  osuccc james  discusses the rationale to evaluate  acalabrutinib in chronic lymphocytic leukemia  cll https   t co rtgycoo dq https   t co wet geb dn
579,biocalifornia,astrazeneca s calquence fails pair of phase ii covid    trials https   t co ihfebobtnz https   t co x xohusvtb
580,helen ong, azn  s  calquence fails  covid    study  joining the list of  repurposed meds that have fallen short    agnpf  s repurposed  ifenprodil for  ard in  covid patients remains highly promising  company expected to report ph b   interim results shortly  np https   t co zoc fhnixa
581,lyke lyfe,update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid      https   t co aslygswgl  mednews https   t co  rkjlnkcs 
582,takehiko yoshino,astrazeneca s  azn  calquence fails in coronavirus study https   t co qb uah  wo via  yahoo
583,brainstormer     ,https   t co suaksavil 
584,brainstormer     ,https   t co k meaqvyqs  een nieuw goed door eu gekeurd medicijn calquence  astrazenica  voor bloedkankersoorten is een trial geweest ook onder ziekenhuis opname pati nten covid  zowel opname c   zonder beademing en ic ventilatie pati nten    hoe dan   https   t co y qnmom pd
585,onclive com,the european union has approved the next generation btk inhibitor acalabrutinib for use in adult patients with chronic lymphocytic leukemia   myunisr  ema news https   t co bdkvq albn
586,pharmaceutical market europe,az s btk inhibitor calquence fails in covid    study https   t co hb ldmmpal
587,pharmabox in,astrazenca s calquence  acalabrutinib  fails to meet its primary endpoint in p ii studies for covid    https   t co gluexnp bx
588,christina h,https   t co  rltuixf f
589,fiercepharma,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short  https   t co  swjzesdoe
590,nikita,astrazeneca s  azn  calquence fails in coronavirus study https   t co yr  fkrg u via  yahoo
591,biotech   tech stock focus, azn astrazeneca s calquence fails pair of phase ii covid    trials   biospace https   t co rgjt vmcwu  jobs
592,maisa, azn saying its mid stage trial of calquence  acalabrutinib  as an addition to the best supportive care for patients hospitalized with respiratory symptoms of covid    didn t meet the primary endpoint 
593,r mandy alcuria,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short   fiercepharma https   t co axvdewyjlq
594,ronald m  chavin,             in a clinical trial just released today by astrazeneca  bad news for their anti leukemia  amp  anti lymphoma drug  calquence  acalabrutinib   for treating covid     there was no benefit from the drug https   t co  jwlijshtd https   t co ktfr wsqkf https   t co hpp ma xfg
595,continental clinical,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short https   t co hslehpjkus
596,endpoints news,in today s  covid   roundup  though the presidential election has come and gone  tensions between the white house and government health officials remain   https   t co vgnlrngxd 
597,webwire,update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    https   t co kmncb pkpq
598,infectotuits,otro anticuerpo monoclonal que no funciona en evitar empeoramiento en pacientes con  covid    ac  el posicionamiento de  astrazeneca sobre  acalabrutinib https   t co ma hsabnyr
599,zdravmedinfo,acalabrutinib                                                                 covid    https   t co pdp iecxs 
600,koronavir s haber   , ngiltere  sve  ortakl    olan  nl  ila   irketi astrazeneca taraf ndan kan kanseri tedavisi i in kullan lan calquence ilac n n korona vir s tedavisinde ba ar s z oldu u a  kland  
601,maybeawriter,astrazeneca says its blood cancer medicine calquence failed to help patients hospitalized with respiratory symptoms of covid    https   t co wnl oitzvl via  business
602,siber gazete,astrazeneca n n umut olan ilac  koronavir s tedavisinde etkisiz kald   reuters  n haberine g re koronavir s hastalar n n ba    kl k sisteminde olu an sorunlar  bask lamas  ama lanan kan kanseri ilac  calquence in sonu lar  ba ar s z oldu    covid  haber  sondakika https   t co oedrtjvlmh
603,kevin paul oge,astrazeneca s calquence fails pair of phase ii covid    trials   biospace https   t co q  xyvy wd  jobs
604,dr timos papagatsias,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short https   t co mhciedu  j   gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  biotech  healthcare  productmarketing  pharma  pharmaceutical https   t co xjcjaceodl
605,newexpressnews,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short https   t co frvb iwhvy
606,briefing com, azn  astrazeneca reports calavi phase ii trials for calquence in patients hospitalized with respiratory symptoms of    https   t co srcsom ldb
607,synergy healthcare  llc,covid    tracker  moderna hits phase   case count for vaccine review  astrazeneca s calquence misses in covid trial   fiercepharma https   t co gbtiba wby
608,fuerza fuerza,la ue aprueba calquence  astrazeneca  para leucemia linfoc tica cr nica https   t co wfmiathx w
609,redacci n m dica, industria  la ue aprueba calquence   astrazeneca  para la leucemia linfoc tica cr nica  https   t co lsnumf   l
610,ben fidler,astrazeneca cancer drug found ineffective for treating  covid   https   t co jcpwbagcnj by kristin jensen  azn  rhhby  nvs  sny  regn
611,lu chen  nobias,https   t co uifz zegup acalabrutinib did not meet the primary endpoint to keep patient alive or free of ventilator  cytokine storm hypothesis is almost dead 
612,pharmabox in,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short https   t co z f c bbtg
613,                   insights  pharma   ,astrazeneca s calquence fails covid    study  joining the list of repurposed meds that have fallen short https   t co  qjwe fuuq
614,nathan vardi,calquence misses in trial of later stage covid    patients  disappointing result for those who thought a selective btk inhibitor could make a difference in the pandemic  https   t co  wchkrmf s
615,haber  com   , nl  ila   reticisi astrazeneca n n kan kanseri ilac  calquence  n koronavir s tedavisinde etkisiz oldu u belirlendi  https   t co  ggczlhbnp https   t co  jqbxnk ct
616,endpoints news,covid    roundup  political pressures at fda continue post election  medicago takes gsk adjuvant into its first phii iii https   t co vgnlrmywlz
617,    ,awesomecapital  astrazeneca s calquence flunks mid stage covid        https   t co qfi j  ivg
618,abc gazetesi,kanser ilac  calquence  n koronavir s tedavisinde etkisiz oldu u ortaya   kt  https   t co vllirsrpen  kovid  
619,dr timos papagatsias,covid    roundup  political pressures at fda continue post election  astrazeneca s attempt to repurpose calquence  https   t co  ef p y  l   gt  gt  gt  https   t co hta isgiv   strategy  competitiveintelligence  marketing  pharma  productmarketing  biotech  pharmaceutical  healthcare https   t co hqbapkkgfz
620,leonid schneider,  astrazeneca s repurposed leukaemia drug  calquence surprisingly does not work at all against  covid     tagesschau https   t co z nqrvwyse
621,mr  rama vs  comics,yo  this ads are staring to scare the shit out of me  what do to know calquence https   t co m ers jyhj
622,imran iftikhar,no one can match my faith  i am truly the most beloved man of the lord      news   astrazeneca s blood cancer treatment  calquence  failed to improve survival rates and prevent lung failure in patients hospitalised with symptoms of  covid    https   t co  jszcml hj
623,anand c  patel,these failures  anti il    now btki  make me think patients need to be objectively identified as having crs before entry into studies of immunomodulators for covid  rather than a  everyone who s really sick  approach  https   t co vas bwoepi
624,allison gatlin, biotech and  pharmaceuticals news   fprx is up again    roughly     right    on preclinical data in cancer treatment   azn sank after calquence missed its key goal in phase   study of hospitalized  covid   patients 
625,bioinvest io,        astrazeneca                                            calquence                                                                calquence                                           https   t co j  djcwice
626,mednetnews,update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid      small molecules https   t co mrdhwd ori
627,jon angelo,astrazeneca s calquence fails to improve survival rates in coronavirus patients   https   t co oxda k e e  pharmaceutical
628,briefing com, azn         reports calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of  covid   did not meet primary endpoint
629,        gmp,acalabrutinib                                                                 covid      https   t co qalaudcamk https   t co  v uqnpue 
630,cde news, astrazeneca s cancer drug  calquence fails to meet main goal in  covid    trials https   t co nd  lweqk 
631,company news hq,update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    https   t co aidqp ynup
632,pharmashots   incisive news in   shots,astrazenca s calquence  acalabrutinib  fails to meet its primary endpoint in p ii studies for covid     pharmashot  astrazeneca  https   t co  khxxjinht https   t co eqiiafhmiw
633,terra, coronav rus  medicamento contra o c ncer da astrazeneca tem resultado  decepcionante  no tratamento da covid    https   t co cwr  fqacw
634,briefing com, azn  astrazeneca reports calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of    https   t co srcsom ldb
635,the medical ed cons ,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials  after it showed benefit for patients in intensive care   https   t co ojmqtdfcz 
636,soumyajyoti biswas, azn astrazeneca  nasdaq azn  reports phase ii results from the calavi trials investigating btk inhibitor calquence  acalabrutinib  plus best supportive care  bsc  versus bsc alone in hospitalised patients with covid    disease     https   t co duaogusx  
637,san francisco biotechnology network,sfbn feed  covid    roundup  astrazeneca s attempt to repurpose calquence flops  it may be time to cross off another repurposed drug from the list of potential covid    treatments  astrazeneca s      bayarea  biotech https   t co zq exzsfi 
638,daniel j drucker,no role for targeting btk  covid   update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    https   t co e hk oo uh
639,                   insights  pharma   ,covid    roundup  astrazeneca s attempt to repurpose calquence flops https   t co  o gacy ra
640,endpoints news,covid    roundup  astrazeneca s attempt to repurpose calquence flops https   t co vgnlrmywlz
641,chitraders, azn astrazeneca s calquence flunks mid stage covid    study https   t co bb v  s  i
642,pressreleasepoint,https   t co md alh   h update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid   
643,gordon gekko,astrazeneca s calquence flunks mid stage covid    study https   t co dc zf   br
644,breaking news, azn   astrazeneca s calquence flunks mid stage covid    study https   t co  ag vdmrqf
645,market intelligence  healthcare,astrazeneca s  cancer drug  calquence disappoints in mid stage covid    trials  azn  covid    clinicaltrials https   t co qnhszuidur https   t co rv f qcyim
646,nicolas viudez,apr s novartis et son canakinumab  la semaine derni re  c est d sormais acalabrutinib d astrazeneca qui  choue sur les formes s v res du  covid    https   t co p yr jadak
647,chitraders, azn announced calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    did not meet primary endpoint https   t co lf zh r ng
648,quant data,astrazeneca announced calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    did not meet primary endpoint  related tickers   azn
649,firstword pharma,astrazeneca s calquence fails to help patients hospitalised with  covid   respiratory symptoms https   t co cjxcevftwe  azn
650,al arabiya english, astrazeneca s blood cancer treatment  calquence  fails to improve survival rates and prevent lung failure in patients hospitalized with symptoms of  covid    the drugmaker says  citing results from mid stage trials   https   t co lwm b  qgk
651,bloomberg australia,astrazeneca says its blood cancer medicine calquence failed to help patients hospitalized with respiratory symptoms of covid    https   t co  d unggvsq
652,econom a digital,el f rmaco contra la leucemia calquence  desarrollado por astrazeneca  ha fracasado en los ensayos que estudiaban su eficacia en pacientes con coronavirus https   t co atfcav tcm
653,bloomberg,astrazeneca says its blood cancer medicine calquence failed to help patients hospitalized with respiratory symptoms of covid    https   t co zemwr ugta
654,nel sestayo,calavi did not meet the primary endpoint of increasing the proportion of patients who remained alive and free of respiratory failure https   t co hsia ga     azn
655,healthcare, biotoday      astrazeneca btk   calquence covid           https   t co y mnlyxxdu
656, easy branches  guestpostingservices,astrazeneca s cancer drug fails to meet main goal in covid    trials  astrazeneca plc said on thursday its blood cancer treatment  calquence  failed to meet the main goal of mid stage trials  testing it in patients hospitalized with  https   t co gsr  b dcg  financialpersonal
657,m, azn acalabrutinib fails its covid trial https   t co wbzjc xoji
658,                   insights  pharma   ,     astrazeneca btk   calquence covid           https   t co trxn wrvtx
659,cision news,update on calavi phase ii trials for calquence in patients hospitalised with respiratory symptoms of covid    https   t co ojihiikdfs
660,ritrattodellasalute, leucemia linfatica cronica   acalabrutinib approvato in eu  ha dimostrato un beneficio significativo in termini di efficacia e tollerabilit  a lungo termine  https   t co tuukhxiboj https   t co usmo mbsgp
661,larvol,the european commission has approved  astrazeneca s  calquence  acalabrutinib for the treatment of adult patients with chronic lymphocytic leukaemia  cll   for full article visit  https   t co wegfgeehwu  cancernews  cancerdata
662,i malati invisibili,tumori rari   leucemia linfatica cronica  llc   la commissione europea ha approvato acalabrutinib  https   t co tpmvnlxcjj  comitatoimalatiinvisibili  imalatiinvisibili  comitatoimi  comitatoimionlus  malattierare https   t co freckmurcm
663, stoncology, calquence approved in the eu for the treatment of  chroniclymphocyticleukaemia  azn https   t co b jejr vud
664,chris manfuso,eu ok for az s calquence in cll https   t co lsxgvjv  e https   t co dcrxsiem i
665, investigando,la ce aprob  el inhibidor selectivo btk acalabrutinib para la leucemia linfoc tica cr nica  as  como el linfoma linfoc tico peque o  combinado con obinutuzumab y en monoterapia reducir a el riesgo de progresi n de enfermedad o muerte https   t co rb fycixd 
666,benlazar s m amin ,acalabrutinib receives approval in europe for the treatment of  cll  leusm https   t co gegxg etdy
667,david ledger,eu ok for az s calquence in cll https   t co tgf ldqabv https   t co st rlugiot
668,onclive com,acalabrutinib approved in europe for chronic lymphocytic leukemia  myunisr  leusm  https   t co graudkjhgz
669,samir sheth  ,one tweet about pharma and already getting ads to join an event on btk inhibitors  a treatment for cll  courtesy of calquence acalabrutinib   https   t co tcegcdsn t
670,plexus ventures, astrazeneca  eu approves  calquence to treat chronic lymphocytic  leukaemia https   t co ymlse hexx  nasdaq  astrazeneca
671,bls d com,leucemia linfatica cronica  acalabrutinib ottiene l approvazione in europa https   t co crbftxg es
672,jos  viurquis,el medicamento acalabrutinib ha mejorado a pacientes en situaci n grave de covid     publicado en la secci n  salud de  notimex  https   t co   sijtws x
673,urotoday com,a randomized phase   trial of pembrolizumab vs pembrolizumab  amp  acalabrutinib in patients with platinum resistant  muc   beyondtheabstract on urotoday  gt  https   t co lp h gcqrl  americancancer  tiansterzhang  mrharrisonmd  alvaajjai  sonpavde  daniel j george  lenappleman https   t co pinvzp k  
674,blood cancer uncensored,venetoclax and obinutuzumab funded in england by nice  acalabrutinib licensed  the end of fcr chemotherapy for cll  https   t co wpivzeffdg
675,sporo ila za javnost o sta,zdravilo calquence je v eu odobreno za zdravljenje kroni ne limfocitne levkemije https   t co mtvdqauajm  astrazenecauk
676,grttwit,calquence approved in the eu for the treatment of patients with chronic lymphocytic leukaemia https   t co  zeuvejti 
677,repubblica salute,leucemia linfatica cronica  approvata in europa una nuova terapia mirata  via libera dalla commissione europea per acalabrutinib  un farmaco target di nuova generazione  per il trattamento dei pazienti adulti  sia in prima linea sia dopo ricaduta  o per  https   t co qtffrwy jl
678,biopharmaasia,calquence approved in the eu for the treatment of patients with chronic lymphocytic leukaemia   https   t co atb wmed f
679,pharmabox in,eu ok for az s calquence in cll https   t co kxxpfdvwh 
680,pharma trader,eu ok for az s calquence in cll https   t co bdtcvecciq
681,iceberg vision,eu ok for az s calquence in cll https   t co pz ccphlxf
682,everything pharma,eu ok for az s calquence in cll https   t co by jj bqug
683,theriaque officiel, amm europ enne pour  calquence   acalabrutinib dans la leuc mie lympho de chronique  llc https   t co rhdgyikwrq
684,pharmacrowd,eu ok for az s calquence in cll https   t co xd v kxshm https   t co dhtjonbc  
685,salutedomani,terapia leucemia linfatica cronica  acalabrutinib approvato in europa https   t co dq rtksexo
686,saluteh   com,terapia leucemia linfatica cronica  acalabrutinib approvato in europa https   t co b kqjv  f 
687,antonio caperna,terapia leucemia linfatica cronica  acalabrutinib approvato in europa https   t co trqsguerum
688,derma news ok,terapia leucemia linfatica cronica  acalabrutinib approvato in europa https   t co iowm    zk
689,medinews, leucemia linfatica cronica   acalabrutinib approvato in europa per  beneficio significativo in termini di efficacia e tollerabilit  a lungo termine nel trattamento in prima linea e nella malattia recidivante o refrattaria   https   t co kiojg le   https   t co jewfs raph
690,lymphoma hub,next generation btki  acalabrutinib  has been approved in europe for the treatment of adult patients with cll  acalabrutinib demonstrated promising clinical efficacy and was well tolerated across the two clinical studies which led to its approval    https   t co mm j fnhdx https   t co  oofqtrfbh
691,pharmabox in,astrazeneca s calquence  acalabrutinib  receives eu s approval for chronic lymphocytic leukaemia https   t co uyqyvyj iv
692,pharmashots   incisive news in   shots,astrazeneca s calquence  acalabrutinib  receives eu s approval for chronic lymphocytic leukaemia  pharmashot  astrazeneca  https   t co f aagsbudx https   t co o bcfz xyp
693,prashant mehta,acalabrutinib launched at a whopping     l  month with pap support with the ibrutinib generic available i am not sure how much this will help   i wish for a lower cost and better access
694,medicircle in,calquence is approved for the treatment of cll and small lymphocytic lymphoma in the us and is approved for cll in several other countries worldwide   latestpharmanewsnov   latestastrazenecanewsnov   treatmentforchroniclymphocyticleukaemia  treatmentforcll https   t co wtcz igmdo
695,webwire,calquence approved in the eu for the treatment of chronic lymphocytic leukaemia https   t co aviaqf wqr
696,himani chandna, learnings from who s solidarity trial  covaxin by when   why acalabrutinib arm should be added   why remdesivir needs more testing before being junked    icmr nari chief dr samiran panda tells  theprintindia in a detailed interview    https   t co  h srlb ej
697,healthcareprwire,astrazeneca s calquence  acalabrutinib  has been approved in the european union  eu  for the treatment of adult patients with chronic lymphocytic leukaemia  healthcare    leukaemia  bloodcancer  cancer  https   t co v bvnx wye
698,industryprwire,calquence approved in the eu for the treatment of chronic lymphocytic leukaemia https   t co gffgz bdvw
699,larvol, calquence approved in the eu for the treatment of chronic lymphocytic leukaemia  explore more predictive biomarker data and news for free at  https   t co vjfqpnsgak for full news article visit  https   t co lxht  qlsp  cancernews  cancerdata https   t co tmiquuhzvp
700,briefing com, azn  astrazeneca receives eu approval for calquence https   t co gghpz jtzu
701,stocks tweets,astrazeneca s calquence ok d in europe for cll https   t co chppeks wr
702,firstword pharma,astrazeneca s btk inhibitor calquence approved in europe for cll https   t co gfzw xrazl  azn
703,company news hq,calquence approved in the eu for the treatment of chronic lymphocytic leukaemia https   t co ojyst  oly
704,the pharma letter,european approval for  calquence in cll  astrazeneca https   t co bhuqbu gjg https   t co jznx hhofn
705,nonsell com,astrazeneca  eu approves calquence to treat chronic lymphocytic leukaemia    us market news   source  nasdaq news   https   t co fwudbvkdvl
706,quant data,astrazeneca announced calquence approved in the eu for the treatment of chronic lymphocytic leukaemia  related tickers   azn
707,inara bright,astrazeneca announced calquence approved in the eu for the treatment of chronic lymphocytic leukaemia  azn
708,mehrdad yousefi,astrazeneca s said its drug calquence had received european union approval for the treatment of adult patients with chronic lymphocytic leukaemia  ccl  adding to approvals already received in the us and several other countries worldwide 
709,wheeliedealer, azn calquence approved in eu for treating chronic lymphocytic leukaemia 
710,graniteshares europe, astrazeneca s  calquence   acalabrutinib  has been approved in the eu for the treatment of adult patients with chronic lymphocytic  leukaemia   cll   the most common type of leukaemia in adults   oncology  haematology  pharma  azn  singlestocketps https   t co   gsmttizu
711,ein presswire  eu politics newswire,brief astrazeneca says calquence approved in the eu for cll https   t co  xfrlo bfh
712,golden casino news,calquence approved in the eu for the treatment of chronic lymphocytic leukaemia   https   t co hdbtnczdxf
713,urology,pembrolizumab vs pembrolizumab and acalabrutinib in patients with platinum resistant metastatic urothelial cancer https   t co l mgr zqzr  bladdercancer  blcsm
714,oncology,pembrolizumab plus acalabrutinib for platinum resistant metastatic urothelial carcinoma https   t co secpevmd e  oncology
715,wcm englander institute for precision medicine,interested in chronic lymphocytic  leukemia research    if so  don t miss  safety study supports acalabrutinib alone or in combination for cll   in  oncologytimes with  engipm member richard furman  m d   richardfurmanmd     precisionmedicine   https   t co bjymrcfvgu
716,aloysius pendergast,one to rule them all   economic evaluation of ibrutinib versus acalabrutinib versus zanubrutinib for patients with relapsed or refractory mantle cell lymphoma   blood   american society of hematology https   t co twnhgdfz c https   t co pfxw  m h 
717,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
718,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
719,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
720,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
721,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
722,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
723,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
724,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
725,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
726,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
727,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
728,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
729,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
730,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
731,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
732,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
733,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
734,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
735,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
736,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
737,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
738,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
739,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy 
740,toby eyre,long term fup for  acalabrutinib in r r  mantle cell  lymphoma  median   prior lines d c     due to pd      aes  mdor     m mpfs     m  ki    or prior lines            interestingly not predictive of pfs estim     progression free at   m  lymsm  ash     https   t co xsiblszkjj
741,medwave,sakigake designated hae med berotralstat  az s acalabrutinib clear pafsc review orphanpacific s sakigake designated hereditary angioedema  hae  treatment berotralstat  which was de    https   t co   svdclr q
742,onclive soss,  seemaalibhat   of  osuccc james  discusses the rationale to evaluate  acalabrutinib in chronic lymphocytic leukemia  cll https   t co rtgycoo dq https   t co pmolthoc o
743,michele nadeem baker,many cll patients are now placed on btk inhibitors  learn what they are   and how they work with dr  richard furman   cll  ibrutinib  acalabrutinib  btkinhibitor  weillcornell  richardfurmanmd https   t co agokuhal w
744,oncology,pembrolizumab vs pembrolizumab and acalabrutinib in patients with platinum resistant metastatic urothelial cancer https   t co pj lshrspj  oncology
745,urology,pembrolizumab plus acalabrutinib for platinum resistant metastatic urothelial carcinoma https   t co weawnzjqpl  bladdercancer  blcsm
746,kate cwynarski,excited to open remodl a  ci andy davies  trial design allowing hd mtx prophylaxis if indicated  r chop    acalabrutinib  also likely to provide additional cns prophylaxis  data from phase i ii accept trial promising  ash       also correlative translational work   lymsm  dlbcl https   t co gyfudrotfq
747,david henry,acalabrutinib  a next gen btk inhibitor  provides prolonged progression free survival and better tolerability  compared w  standard of care regimens for relapsed or refractory cll  according to final results from the phase   ascend study https   t co lx  hdgckn https   t co cw gebebpq
748,wcm lymphoma,dr  richard furman explains how bruton s tyrosine kinase  btk  inhibitors like ibrutinib  acalabrutinib and zanubrutinib can work to treat people w   chroniclymphocyticleukemia   cll   via  patientpower  https   t co  p bsdjqb   leusm  lymsm
749,     obsoleted,science  global trial eliminates drugs  pivots to new ones  https   t co erz bkzihe  remdesivir                         btk inhibitor   acalabrutinib https   t co ywghva  x                               
750,lymphoma papers,accept   combining acalabrutinib with rituximab  cyclophosphamide  doxorubicin  vincristine and prednisolone  r chop  for diffuse large b cell lymphoma  dlbcl   study protocol for a phase ib ii open label non randomised clinical trial   lymphoma  lymsm https   t co  gzq qrnzc
751,theprint science,icmr recommends dropping interferon  adding cancer drug acalabrutinib to who solidarity trial   chandnahimani reports   theprinthealth  https   t co kgpl rj  a
752,theprint science,icmr recommends dropping interferon  adding cancer drug acalabrutinib to who solidarity trial   chandnahimani reports   theprinthealth  https   t co kgpl rj  a
753,shekhar gupta,icmr recommends dropping interferon  adding cancer drug acalabrutinib to who solidarity trial   chandnahimani reports   theprinthealth  https   t co ndvt ta tw
754,theprintindia,icmr recommends dropping interferon  adding cancer drug acalabrutinib to who solidarity trial   chandnahimani reports   theprinthealth  https   t co n grqkefrh
755,univadis,acalabrutinib allein oder in kombination mit obinutuzumab zeigt im vergleich zu anderen frontline behandlungen bei patienten mit chronisch lymphatischer leuk mie  cll   die f r fludarabin nicht geeignet sind  ein g nstiges pfs und os  https   t co hadqcrhobl https   t co ed xjqg sy
756,univadis,acalabrutinib in monoterapia o in combinazione con obinutuzumab ottiene una sopravvivenza libera da progressione  progression free survival  pfs  e una sopravvivenza complessiva  overall survival  os  favorevoli rispetto ad altri trattamenti di prima    https   t co ea p   l w https   t co  yayafse f
757,onclive soss,  seemaalibhat   of  osuccc james  discusses the approval of acalabrutinib in chronic lymphocytic leukemia based on data from the phase   elevate tn trial  leusm  cll https   t co siwprkyngi https   t co emb ikuthu
758,marty fecarotta,try calquence it worked for me  went from     white cells to normal in   months 
759,medelis  oncologycro,world health organization eyes cancer drug in treating covid    https   t co dh jb  iik via  abscbnnews
760,medical dialogues,inclusion of cancer drug in who covid solidarity trial  cdsco panel asks icmr to submit more clarification  icmr  who  covid    acalabrutinib  cdsco  astrazeneca  nari  cancer  remdesivir  dexamethasone  calquence https   t co aoqm shpsd
761,medwave,sakigake designated hae med berotralstat  az s acalabrutinib up for pafsc review on oct     a key health ministry panel will review whether to recommend approval for orphanpacific s sakigake d    https   t co y   rns vd
762,lymphoma hub,  how does acalabrutinib compare with current standard of care treatments for r r cll  https   t co q jr ajfz   lymsm  lymphoma https   t co kuejkqcgmd
763,sunstar cebu,the anti cancer drug acalabrutinib has been included in the ongoing solidarity trial of the world health organization  who  to find a treatment for the coronavirus disease       covid      https   t co   dbllqrsp
764,     ,interferon withdrawn from solidarity  new agent coming   acalabrutinib   
765,mike thompson  md  phd  fasco,mt  hemonctoday  oct           llsusa  amp   astrazeneca partner on clinical trial of acalabrutinib for patients with blood cancer  amp   covid      read our interview w  burd  llsusa  amp  byrd  osuccc james https   t co vmi  kqlmu  cllsm  leusm  covid    covid  ncancer  ccc    covid  nccc
766,covid    and cancer consortium  ccc    registry,n    acalabrutinib  covid  ncancer https   t co yyleehnued
767,entire market information,astrazeneca pharma india will launch calquence in india on oct     stock trades flat https   t co  zov tsddw
768,        ,                 btk                                                                                      https   t co cforyw mkp
769,antibiotic steward  bassam ghanem,new drugs will be soon added to solidarity trial   acalabrutinib  capsule   btk  inhibitor  lymphoma drug   potential candidates medi     iv inj  anti il    monoclonal antibody bemcentinib capsule   axl inhibitor all these drugs are currently part of uk accord mega trial  covid   https   t co vvov v nhx
770,exppharma,  astrazeneca to launch  oncology drug  calquence in india https   t co in frsyjyr    pharma  pharmanews
771,thiago carvalho,acalabrutinib is a btk inhibitor  used in mantle cell lymphoma  have to look up the rationale behind this one  as an ex b cell person  i think of btk as primarily being important for b  and natural abs https   t co mt   j nja
772,julien potet,two major findings in  kakape s piece on the solidarity trial     gilead knew about these negative results two weeks before signing a us  bn deal with eu for  remdesivir       who will now test acalabrutinib  i e  cancer drug  for  covid   https   t co bikimdltjs
773,zavingsin,astrazeneca pharma india will launch calquence in india on oct     stock trades flat https   t co l hjde bdy
774,cnn philippines,health experts are looking into testing a drug used to treat cancer patients as a possible cure to coronavirus after several drugs tested were found to have no effect on covid    patients  https   t co j ly h uz 
775,iiflmarkets,astrazeneca pharma india will launch calquence in india on oct     stock trades flat https   t co wqjcksh bx
776,theuemployed,astrazeneca pharma india will launch calquence in india on oct     stock trades flat https   t co  uudrd  u 
777,doktor net ph,health undersecretary maria rosario vergeire said friday that the world health organization  who  has included acalabrutinib in its clinical trial for covid    treatments   doktornews https   t co ehvdrqzsys
778,sun star pampanga,the anti cancer drug acalabrutinib has been included in the ongoing solidarity trial of the world health organization  who  to find a treatment for the coronavirus disease       covid       read   https   t co nh ydo nyk https   t co eanej t hu
779,abs cbn news,world health organization eyes cancer drug in treating  covid   https   t co hkeonklouv
780,abs cbn news channel,world health organization eyes cancer drug in treating  covid   https   t co  ice pkzgo
781,dayco india,astrazeneca pharma india to launch calquence  in india news  https   t co fipjmskl j  follow us  website  https   t co v yqpzh  g  facebook  https   t co tltvz lpgc  youtube https   t co  beykx tis  instagram https   t co  p zay yih  india  astrazenecapharma  daycosecurities https   t co vmb ueasl 
782,medical dialogues,astrazeneca to launch cancer drug acalabrutinib under brand name calquence  astrazeneca  astrazenecain  astrazeneca  astrazenecanews  acalabrutinibcapsules  bloodcancer  calquence https   t co gggl j pfv
783,vikas kumar sharma,hero moto             pleasure                                                       astrazeneca                       mantle cell lymphoma        calquence              persistent systems                       capiot                              
784,finreach,astrazeneca pharma will launch calquence in india on october       stockmarket  stockmarketnews  finance  financenewsdaily  finreach  india
785,madurai trading academy, astrazeneca pharma   company will launch calquence in india on october     https   t co eeflp vqjo
786, enritchansrajpandey, good morning all      exclusive morning market news  amp  update    astrazeneca pharma  to launch calquence in india on october     company had received import and market permission from drugs controller general of india on march     the     frontpag
787,k karthik raja,astrazeneca pharma   company will launch calquence in india on october   
788,the hans india,astrazeneca pharma india to launch cancer drug with brand name   calquence  on october     cancerdrug  calquence https   t co xscn z gjq
789,markets today,astrazeneca pharma  drug firm astrazeneca pharma india said it will launch its acalabrutinib     mg capsules  used for treatment of various types of blood cancers  under the brand name  calquence  in the country on october    
790,ancient stock analysis,here are a few  stockstowatch out for ahead of today s trade  also watch out for persistent which is to acquire us based capiot software for       m  amp  astrazeneca which is to launch calquence in india  used for lymphoma treatment       frontpage app https   t co zwrzzx djd
791,cnbc tv  ,here are a few  stockstowatch out for ahead of today s trade   also watch out for persistent which is to acquire us based capiot software for       m  amp  astrazeneca which is to launch calquence in india  used for lymphoma treatment https   t co hplxr dz r
792,markets today,astrazeneca pharma will launch calquence in india on october     kpmg has resigned as the auditor with effect from october   for upl s material arm in mauritius   upl corporation 
793,medscape pharmacists,acalabrutinib  alone or in combo with obinutuzumab  showed favorable pfs and os in cll  https   t co rstkm verd  cllsm https   t co myabmndmy 
794,markets today,astrazeneca pharma will launch calquence in india on october   
795,neeraj bajpai,astrazeneca astrazeneca pharma india to launch calquence in india on october          alert  calquence medicine is used to treat adults with mantle cell lymphoma  cnbc awaaz
796,bloombergquint,astrazeneca pharma to launch its acalabrutinib     milligram capsules  used for treatment of various types of blood cancers  https   t co edpj ugqly
797,redbox india,astrazeneca pharma  co to launch calquence in india on oct       calquence is used to treat adults with mantle cell lymphoma
798,cnbc tv  ,astrazeneca pharma india to launch calquence in india on october           calquence is used to treat adults with mantle cell lymphoma   pharmaceutical  pharmanews https   t co iwbfacxehp
799,trip database,new trip  acalabrutinib  calquence  for treatment of chronic lymphocytic leukaemia  cll  https   t co mr qszwczx
800,bse corporate news,astrazen   launch of acalabrutinib    mg capsules  calquence   https   t co irmnufnykx
801,myupchar, covid     cancer                          coronavirus                               icmrdelhi                                      coronaupdates  letsbeatcorona  indiafightscorona  mohfw india  coronavirusindia https   t co rkoqzwyv j
802,itsm   industrial,etindustrynews  icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment  etindustrynews https   t co  ujsqrmtsf  yosoyjabali
803,teena thacker,the   icmrdelhi  has sought approval from the govt s panel of experts for testing cancer drug  acalabrutinib as part of the    whosearo   solidarity  trial  which seeks to find an effective treatment for  covid    https   t co  ffdszxi  
804,onclive soss,  seemaalibhat   of  osuccc james  on the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia  leusm  cll https   t co ie lhznlyd https   t co  sffixztxt
805,pinsider news,icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment https   t co i   asvu m
806,ej,acalabrutinib https   t co w nrjqp  l
807,       ,btk   acalabrutinib           cll sll mcl                          https   t co oj yd np w         
808,guwahati news,icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment https   t co p ye ddzzx https   t co gcwxootyrh
809,economic times,india s health research body indian council of medical research   icmr  has approached government s panel of experts to approve testing of acalabrutinib  a cancer drug as part of the world heath organization s global  solidarity  trial   https   t co klyepcss u
810,      ,btk   acalabrutinib           cll sll mcl                                                      cll  sll  mcl  https   t co rwnwksamdd
811,mango news,icmr has approached govt s panel of experts to approve testing of acalabrutinib  a cancer drug as testing drugs to find an effective treatment for covid        icmr   astrazeneca  acalabrutinib  nari    worldheathorganization  who  coronavirus  covid    mangonews https   t co u gyr ia u
812,maj dr b p singh sg medallist  siachen glacier  ,icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment https   t co ustquorhuk   shared via  ethealthworld app 
813,        ,btk   acalabrutinib           cll sll mcl                          https   t co po  zfscrv
814,                   insights  pharma   ,btk   acalabrutinib           cll sll mcl                          https   t co pw  sw lew
815,jinu james,icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment https   t co  ostrcb jj via  ethealthworld
816,et industry news,icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment  etindustrynews https   t co lgsxxma as
817,ethealthworld,ethealthworld   icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment  icmr  dexamethasone  clinicaltrial  covid  thewho  solidarity  remdesivir  acalabrutinib https   t co tudmfd xmy
818,freddy pizart  r n ,medscape  acalabrutinib  alone or in combo with obinutuzumab  showed favorable pfs and os in cll  https   t co dt  c w sq  cllsm https   t co gin esjpyz https   t co soshsm ag 
819,aaj ka samachar,icmr approaches experts panel to approve testing of cancer drug acalabrutinib for covid treatment https   t co g adawpoee
820,ketan,icmr approaches experts panel to approve testing of cancer drug  acalabrutinib  for covid treatment  https   t co   znuycdbz https   t co r  tpk pl 
821,       yindu   ,                      mantlecell lymphoma                    calquence                      https   t co fwc pvoxxi
822,urotoday com,a randomized phase   trial of pembrolizumab vs pembrolizumab  amp  acalabrutinib in patients with platinum resistant  muc   beyondtheabstract on urotoday  gt  https   t co lp h gcqrl  americancancer  tiansterzhang  mrharrisonmd  alvaajjai  sonpavde  daniel j george  lenappleman https   t co omhhghhvfd
823,v v  ganesha,    icmr seeks govt panel approval to test cancer drug acalabrutinib in who s solidarity trial      https   t co nvhqinp kd via  theprintindia
824,theprint science,icmr seeks govt panel approval to test cancer drug acalabrutinib in who s solidarity trial  theprint s  chandnahimani reports  https   t co  fvkgq oio
825,medscape,acalabrutinib  alone or in combo with obinutuzumab  showed favorable pfs and os in cll  https   t co kxxbva  s   cllsm https   t co si vixzgxg
826,himani chandna,breaking   icmr seeks govt panel approval to test cancer drug acalabrutinib in who s solidarity trial    panel has asked for more clarification  amp  said that  results on remdesivir from the solidarity trial may be available in a few weeks    https   t co nkxzugzi     theprintindia
827,theprintindia,icmr seeks govt panel approval to test cancer drug acalabrutinib in who s solidarity trial  theprint s  chandnahimani reports  https   t co vyihnlme c
828,               ,            acalabrutinib                                    btk           btk               https   t co p mejetkyq
829,           ,            acalabrutinib                                    btk           btk               https   t co hnjfvuzojo
830,           ,            acalabrutinib                                    btk           btk               https   t co wfycvmuuc 
831,mdedge,acalabrutinib use alone or with obinutuzumab shows positive results for cll  https   t co mpacafp ac  lymphomahub https   t co elkx bm dl
832,www zdravezpravy cz,naj t   innou l  bu medikamenty pro onemocn n  covid    pomohou i  e t  odborn ci     solidaritytrial  who  who europe  muni cz  czecrin  lecbacovidu  sukl  remdesivir  acalabrutinib  interferon   https   t co  kgnvrzcxe
833,agd biomedicals,from medscape hematology oncology headlines gt  gt https   t co sqxkinih x  acalabrutinib bests other frontline cll therapies
834,medscape oncology,acalabrutinib  alone or in combo with obinutuzumab  showed favorable pfs and os in cll  https   t co c pmekl  f  cllsm https   t co mmi lhpge 
835,mdedge hematology   oncology,acalabrutinib use alone or with obinutuzumab shows positive results for cll  https   t co lxodjkxfop  lymphomahub https   t co x  m  qiyn
836,paperbirds hematology,new article  comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia  a systematic review and network meta analysis  https   t co qslki tk g  cll  leusm  hematology
837,edna, nccnhem   cll sequencing   phase iii rcts  st line  only resonate    amp  e     show os benefit  elevate tn  does obinutuzumab add much to acalabrutinib   acalabrutinib vs ibrutinib  bleeding     maybe    fatigue  rash  venetoclax  consolidation    u mrd    bcl    btk   cd    
838,clinicaltrialsdata, azn phase   acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with covid     nct          estimated primary completion date           
839,clinicaltrialsdata, azn phase   acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with covid     nct          estimated primary completion date           
840,clinicaltrialsdata, azn phase   a study to evaluate relative bioavailability  proton pump inhibitor  ppi   rabeprazole  effect  food effect and particle size effect of new acalabrutinib tablet in healthy subjects nct          estimated primary completion date           
841,medwave,btk   acalabrutinib cll sll        btk   acalabrutinib                                        cll sll                                               https   t co ai n  e  s
842,      ,btk   acalabrutinib cll sll                             cll  https   t co dmfvzymlph
843,       ,btk   acalabrutinib cll sll       https   t co ntwqm  ogw         
844,abe dental,              up btk   acalabrutinib cll sll       https   t co hquqdcwo s                             https   t co mv i cmpzy
845,taan pacheco,el instituto nacional del c ncer analiz  que tratamiento con acalabrutinib  puede ser efectivo para ayudar a combatir el covid      covid    salud   informaci n sobre el estudio en  notimex    https   t co kpu vylrqu
846,hemonc today,  llsusa  amp   astrazeneca partner on clinical trial of acalabrutinib for patients with blood cancer and  covid      read our interview with amy burd  phd  llsusa  amp  john c  byrd  md  osuccc james https   t co tfryvg ttj https   t co vtmztfac s
847,cancer review,trial to test acalabrutinib for patients with blood cancer  covid      healio https   t co  yiagabyis
848,cancer update,trial to test acalabrutinib for patients with blood cancer  covid      healio https   t co  ohiaow bj
849,cancer research news,trial to test acalabrutinib for patients with blood cancer  covid    https   t co t vxyndzvw
850,        ,btk   acalabrutinib cll sll       https   t co xcgzedw bp
851,                   insights  pharma   ,btk   acalabrutinib cll sll       https   t co dchq ieprz
852,drugpatentwatch,calquence drug profile       https   t co  yrgchvchs
853,indoximity   ,comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia  a systematic review and network meta analysis https   t co  vomknfuwa  clinicaltherapeutics  physicians
854,clinicaltherapeutics,comparative efficacy of acalabrutinib in frontline treatment of chronic lymphocytic leukemia  a systematic review and network meta analysis https   t co  n ykicec 
855,vasanthi ilangovan,acalabrutinib drug is blocking btk  briton tyrosine kinase  protein  this helps to control cytokines and improve oxygenation in severe cases  this is cancer drug  p
856,sherry,can anyone get this info to   realdonaldtrump  flotus  erictrump  donaldjtrumpjr  ivankatrump   welovetrump  acalabrutinib  calquence for  covid       https   t co modq lhn f via  oncnursingnews
857,sid murlidhar,hydroxychloroquine  remdesivir  calquence  jakafi  olumiant  kineret  ilaris  mavrilimumab   why do all these possible covid    treatments sound like definite decepticon school dropouts 
858,urotoday com,a randomized phase   trial of pembrolizumab vs pembrolizumab  amp  acalabrutinib in patients with platinum resistant  muc   beyondtheabstract on urotoday  gt  https   t co lp h gcqrl  americancancer  tiansterzhang  mrharrisonmd  alvaajjai  sonpavde  daniel j george  lenappleman https   t co jfnkir h t
859,medivizor,check out acalabrutinib in patients with relapsed or refractory chronic lymphocytic l    https   t co gl tkhwkic via  medivizor  leukemia
860,oncology tube,phase iii ascend  randomized trial of acalabrutinib   paolo ghia  md  ph d   myunisr  rrcll  cll   link to full video  https   t co bbc    xcs https   t co  afsuky jg
861,dtw research  inc,during q   astrazeneca highlighted caluquence s  keep inspiring  campaign       astrazeneca  calwuence  acalabrutinib  keepinspiring  newcampagintheme  calendar  oncology  leukemia  antineoplastics  interestingmarketing  q   q       leukemiamarket  dtwmarkethighlight https   t co rx  b  xog
862,cancer discovery,september is  leukemia and  lymphoma awarenessmonth   icymi  acalabrutinib plus obinutuzumab in treatment na ve and relapsed refractory chronic lymphocytic  leukemia    ohiostate  cll  clinicaltrial  https   t co  yesjaxhvu https   t co uax lg xqr
863,paperbirds hematology,new clinical trial  acalabrutinib with r chop in previously untreated mantle cell lymphoma https   t co a iqxo ior  mcl  lymsm  hematology
864,trip database,new trip  acalabrutinib  calquence  for treatment of chronic lymphocytic leukaemia  cll  https   t co mr qszwczx
865,tian zhang  md  mhs,pembrolizumab vs pembrolizumab acalabrutinib for metastatic  bladddercancer is fully published   journalcancer  dukegucancer  sonpavde  alvaajjai  peterodonnell  daniel j george  mrharrisonmd  mattmilowsky https   t co  ytsmfpav 
866,onclive soss,  erleneseymour  of  karmanoscancer  on the progression free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia  leusm https   t co chhtusi xb https   t co mdaq wvyr 
867,paperbirds hematology,new clinical trial  a study in healthy subjects to assess bioavailability  proportion of a drug which enters the circulation to have an active effect  of acalabrutinib tablet and protonpump inhibitor effect  members of a class of  https   t co yj obiqhxw  mcl  lymsm  hematology
868,occupandi temporis,this hypothesis is already in clinical trial with oral oncolytic agents such  acalabrutinib https   t co qef wffahy
869,oncology tube,paolo ghia  md  ph d   myunisr  rrcll  cll ascend  phase iii  randomized trial of acalabrutinib https   t co kijnp umsx https   t co vwrqfy hcn
870,australianprescriber,https   t co r dzg rzr 
871,tap clinical trial network, stellar update welcome to  kingscollegenhs  amp   uhsft who recently opened to this study of  acalabrutinib  in combination with chop r  in patients with newly diagnosed  richterssyndrome        planned sites are now open to recruitment    annaschuh   tobyeyre    crctu  cch bham
872,filippo masini,phase i ii clinical trial based early economic evaluation of acalabrutinib for relapsed chronic lymphocytic leukaemia     https   t co nvthdy sej
873,filippo masini,acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia  a short review on     https   t co f ksnrflue
874,oncology tube,michael wang  md  michaelwangmd  mdandersonnews durable response with single agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma https   t co lkytgypkko https   t co jyjozlds h
875,trip database,new trip  acalabrutinib  calquence  for treatment of chronic lymphocytic leukaemia  cll  https   t co mr qszwczx
876,tap clinical trial network, stellar update congratulations  cruk bi on registering your  st patient    patients are now part of this study of  acalabrutinib  in combination with chop r  in patients with newly diagnosed  richterssyndrome  thank you anna  nicole  dr rafferty and the team  crctu  annaschuh 
877,biomassspec,simultaneous measurement of acalabrutinib  ibrutinib  and their metabolites in beagle dog plasma by uplc ms ms and its application to a pharmacokinetic study  jpba  https   t co xftxi xax 
878,calquence   acalabrutinib ,https   t co w  aqpuk a learn more about calquence for adult patients with chronic lymphocytic leukemia  cll    bloodcancerawarenessmonth
879,onclive com,watch  jennifer woyach  md  of  osuccc james  discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia   leusm https   t co l cjqxftae
880,kolkata ravi specialities pharma pvt ltd  ,calquence is a prescription medicine used to treat adults with mantle cell lymphoma  mcl  who have received at least one prior treatment for their cancer  https   t co v pu xu wz
881,delhi ravi worldwide medicines,calquence is a prescription medicine used to treat adults with mantle cell lymphoma  mcl  who have received at least one prior treatment for their cancer  https   t co lqnpqdjcld
882,targeted oncology,acalabrutinib sustained superiority in terms of extended progression free survival with a tolerable safety profile in patients with relapsed refractory chronic lymphocytic leukemia  which was inclusive of patients with high risk features    https   t co lh ei x cs  leusm
883,curehuntr, clinicaltrial lccc      a phase   trial of acalabrutinib in relapsed refractory primary and secondary cns lymphomas https   t co dayd bwvco
884,trialbulletin,lccc      a phase   trial of acalabrutinib in relapsed refractory primary and secondary cns lymphomas  status  not yet recruiting   condition summary  lymphoma https   t co eiyyrlg tz
885,paperbirds hematology,new clinical trial  acalabrutinib in combination with r chop for previously untreated diffuse large b cell lymphoma  dlbcl  https   t co mdkb bpfyj  dlbcl  lymsm  hematology
886,onclive com,acalabrutinib continued to show prolonged progression free survival with a favorable safety profile in patients with relapsed refractory chronic lymphocytic leukemia   myunisr  leusm https   t co dhtw bqxav
887,helen ong,once a highly promising  btk inhibitor in pre clinical studies  acalabrutinib lacks os benefit in  cll trial   relevant to  and wondering about   apto  gc     currently under a similar study https   t co kawebgns  
888,onclive com,watch  paolo ghia  md  phd  of  myunisr  discusses overall survival data with acalabrutinib in patients with relapsed refractory chronic lymphocytic leukemia in the phase   ascend trial   leusm https   t co nlnyc mznt
889,onclive com,paolo ghia  md  phd  of  myunisr  highlights the safety profile of acalabrutinib in cll   leusm https   t co iqwhdujulf
890,stem cells in the news,acalabrutinib demonstrates superior pfs over standard  f care in relapsed refractory cll https   t co   uys zwut
891,chadi nabhan md  mba  facp,nice quick editorial on btki in  cll too many of them but will be interesting to see the  rd generation  also  await the results of the trial comparing acalabrutinib to ibrutinib  sometime in        asco pubs https   t co hestcjw  q
892,stem cell watch,acalabrutinib demonstrates superior pfs over standard  f care in relapsed refractory cll   targeted oncology https   t co u  hu dhye
893,stem cells in the news,acalabrutinib shows sustained superiority over standard of care regimens in relapsed   https   t co hhuh  vklr
894,oncology news update,dr  woyach on the role of acalabrutinib in cll https   t co uq qtyn ql
895,gabriel chinchilla,soho       calquence prescribing information https   t co jvs  prqt 
896,onclive com,watch  jennifer woyach  md  of  osuccc james  discusses the role of acalabrutinib in chronic lymphocytic leukemia   leusm https   t co fl   iqocz
897,onclive com,acalabrutinib shows sustained superiority over standard of care regimens in relapsed refractory cll  myunisr  leusm https   t co wbr vsrdee
898,lymphoma hub,congress    soho        moriegertz from  mayoclinic discussed therapy options for  wm  bortezomib and carfilzomib has demonstrated fast and deep responses  acalabrutinib showed high response rates with low risk of bleeding   lymsm https   t co a  y jbndr
899,hemonc today,news from  societyofhemonc  soho       patients treated with acalabrutinib   astrazeneca  had longer progression free survival than with standard regimens https   t co uox mryqjt data presented by paolo ghia  md  phd  sanraffaelemi https   t co a sbgzyv r
900,seema ali bhat,this debate  cll will cll   answer it  wish the single agent btki could be acalabrutinib in the cll   study https   t co ypqecnvhjj
901,teamhaem,our patient with tp   undisrupted cll has been commenced in acalabrutinib  he has some concerns as his wcc has increased  from    to     and he is getting recurrent headaches  what would you advise   teamhaem
902,lymphoma hub,the ascend trial presented again at  soho     by p ghia of  myunisr      acalabrutinib received recently the chmp positive opinion to be approved for patients with cll  https   t co itpxmpovyt https   t co    hzvrhcq
903,ronald m  chavin,            trials in china have been carried out on il   blocker tocilizumab  trials in italy for il   blocker anakinra  and trials in the u s  for il   blocker acalabrutinib  all with positive outcomes   https   t co rknhjglloe https   t co dqynnz qh  https   t co  jwlijb  f
904,dr  luis villela,mantle cell lymphoma   m    y o bulky mediastinum      x cm   amp  abdomen     x  cm   spectacular response with rchop rdhap  pet ct negative  deauville   residual   pathology  p   positive and fish p    ve      next step asct vs allo  maintenance rituximab vs  acalabrutinib  off la 
905,targeted oncology,dr  woyach discusses the rationale and efficacy for the phase     trial of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co  pwmedrn q  leukemia  leusm
906,steven artandi  md  phd,sci member steve coutre and colleagues found that acalabrutinib with or without obinutuzumab significantly improved progression free survival in a  clinicaltrial for treatment naive chronic lymphocytic  leukemia  https   t co  kjaesitfp  cll
907,mahmoud aljurf,phase iii  randomized trial of acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory cll  acalabrutinib significantly improved pfs compared with i r or b r  amp  has an acceptable safety profile in pts with r r cll https   t co lbretukmwd
908,targeted oncology,dr  woyach discusses the rationale and efficacy for the phase     trial of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co  pwmedrn q  cllsm  leusm
909,md anderson leukemia,new  clinicaltrial            acalabrutinib   obinutuzumab in tx naive  cll   pi  jan burger  m d   ph d  of  mdandersonnews  leukemia   nct           https   t co wsjdld  fp   endcancer  leusm
910,the asco post,acalabrutinib improves progression free survival vs idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory cll https   t co  kjx zgock  leusm  hematology
911,targeted oncology,dr  woyach discusses the rationale and efficacy for the phase     trial of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co  pwmedrn q  leusm  leukemia
912,the asco post,drs seema bhat  amp  jennifer woyach  final ascend results confirm acalabrutinib as a standard for relapsed cll https   t co x uoif o l  leusm  hematology  osuccc james https   t co nzo hydla 
913, news sydney,     australians battling blood cancer will get some financial relief with today s pbs listing of a drug called calquence  used against a form of chronic leukaemia  https   t co twh kqycs    news https   t co mwfagm l m
914, news sydney,more than       cancer patients could benefit from a new drug treatment being listed on the pharmaceutical benefits scheme  calquence is now available for patients with a form of chronic leukaemia  https   t co twh kqycs    news https   t co jpkiyldw i
915,lymphoma australia,federal health minister  greghuntmp announced that from september   keytruda is now reimbursed on pbs for relapsed refractory pmbcl  amp  calquence  acalabrutinib  is approved for cll  amp  sll  great news for lymphoma patients  lime lymphoma  lymphomaawarenessmonth  msd aus  astrazeneca https   t co  ggubmapjs
916,rozalina sarkezians,to mark world lymphoma awareness month   astrazeneca calquence is now reimbursed for certain australian patients with chronic lymphocytic leukaemia  cll    small lymphocytic lymphoma  sll    bloodcancerawarenessmonth  lymphoma  leukemia   lymphomaoz  https   t co lmoxmenisy
917,haemdoc,acalabrutinib pbs listing  p y   inhibitors in australian comparitive study  pre operative anaemia screening pays off https   t co kbt f  tz 
918,specialty pharmacy continuum,cancer drugs may dampen  cytokinestorm that occurs in patients with severe  covid    https   t co sed  kmi a  calquence  btkinhibitors
919,tom henry  mba  rph  cph,acalabrutinib a second generation btki https   t co trvc a lcr
920,leukaemia foundation,brilliant news for people living w   bloodcancer    healthgovau added  calquence to the  pbs ensuring more people are able to access better treatments  amp  improve outcomes  https   t co r ldo h xe
921,narinder grewal  md,btk inhibitors might combat the  cytokinestorm that occurs in patients with severe  covid    https   t co npoghwrygo  idse online llsusa sloan kettering danafarber leedshospitals  calquence  btkinhibitors
922,anesthesiology news,btk inhibitors might combat the  cytokinestorm that occurs in patients with severe  covid    https   t co qbrob  zvm   idse online  llsusa  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
923,mw gunter,early data from a clinical study suggest that blocking the bruton tyrosine kinase  btk  protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe covid     https   t co n sbrukda  https   t co bs clmh yb
924,medivizor,check out  acalabrutinib in patients with relapsed or refractory chronic lymphocytic     https   t co gl tkhwkic via  medivizor  leukemia
925,greg hunt,on september    calquence will be listed on the pbs for the first time for the treatment of chronic lymphocytic leukaemia and small lymphocytic lymphoma    video     newsfirst https   t co  olafu yyv
926,filippo masini,ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia https   t co lnnojhofj 
927,narinder grewal  md,btk inhibitors might combat the  cytokinestorm that occurs in patients with severe  covid    https   t co npoghwrygo  idse online llsusa sloan kettering danafarber leedshospitals  calquence  btkinhibitors
928,anesthesiology news,btk inhibitors might combat the  cytokinestorm that occurs in patients with severe  covid    https   t co qbrob  zvm   idse online  llsusa  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
929,paperbirds hematology,new clinical trial  a combination of acalabrutinib with r chop in subjects with previously untreated non gcb subtype dlbcl  ace ly      https   t co u   pwg zl  dlbcl  lymsm  hematology
930,cancernetwork   home of the journal oncology , icymi  both the phase   ace cl     trial and the pivotal phase   ascend trial showed the long term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co pdysrg  zc
931,jasdeep sandhu,i know my phone is listening to me and targeting ads to me  but if it could save the calquence and brukinsa ads during office hours i d appreciate it    thank you 
932,specialty pharmacy continuum,cancer drugs may dampen  cytokinestorm that occurs in patients with severe  covid    https   t co sed  kmi a  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
933,dr  iv n r  gonz lez,a randomized  phase trial of  pembrolizumab vs pembrolizumab and  acalabrutinib in patients with platinum resistant metastatic  urothelialcancer https   t co gkbdbubfno  oncoalert  katsuakimaehara  pgrivasmdphd  crisbergerot  viveksubbiah  dryukselurun https   t co x jnjpukbd https   t co xrwqccszgi
934,ignacio duran,a randomized phase   trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum resist  https   t co t nns  fwc
935,acs journal cancer,us fda approval of the btk inhibitor acalabrutinib for chronic lymphocytic leukemia  cll  and small lymphocytic lymphoma  sll  represents several concerning patterns in trial design and drug approvals in btk inhibitors  https   t co hc fikstq   vprasadmdmph https   t co lqy lne qr
936,medicine matters oncology,news  adding acalabrutinib to pembrolizumab in patients with metastatic  urothelialcancer does not improve outcomes  report  tiansterzhang  daniel j george et al in  journalcancer w  accompanying editorial by  pgrivasmdphd  uroupdate  wileynews  dukecancer https   t co w vclscn l
937,medivizor,acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia from  medivizor  https   t co gl tkhwkic  leukemia
938,cancernetwork   home of the journal oncology , icymi  both the phase   ace cl     trial and the pivotal phase   ascend trial showed the long term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co rzpyiwgyyh
939,curehuntr, clinicaltrial retreatment with venetoclax and acalabrutinib after venetoclax limited duration  reveal  https   t co og   s kob
940,trialbulletin,retreatment with venetoclax and acalabrutinib after venetoclax limited duration  reveal   status  not yet recruiting   condition summary  cll sll https   t co  nyrrenc  
941,oncologynurseadvisor,the addition of acalabrutinib to pembrolizumab failed to improve objective response rate  progression free survival  and overall survival  os  among patients with platinum resistant metastatic urothelial cancer  according to the results of a phase   study  https   t co ppkhetw eb
942,fondation arc,suivi   long terme d une th rapie cibl e pour les patients atteints de leuc mie lympho de chronique  pr s de      de r ponse apr s   ans de traitement   acalabrutinib  llc  https   t co svbxwvqjkv
943,paperbirds hematology,new clinical trial  retreatment with venetoclax and acalabrutinib after venetoclax limited duration  reveal  https   t co vqtrqckabw  cll  leusm  hematology
944,renal   urology news,acalabrutinib plus pembrolizumab failed to improve outcomes in relapsed muc https   t co  qofgtt nq
945,hematology advisor,nurse led approaches for facilitating patient adherence to treatment with acalabrutinib for relapsed refractory  mcl were described in the clinical journal of  oncology nursing  which center on educating patients and monitoring treatment adherence and aes  https   t co tw wcsbopt
946,cancertherapyadvisor,nurse led approaches for facilitating patient adherence to treatment with acalabrutinib for relapsed refractory mantle cell  lymphoma  mcl  described in a new report published in the clinical journal of oncology nursing  https   t co  mbt sjyqt
947,conquer the patient voice,the treatment of patients with  cll has changed dramatically with the introduction of drugs that target the b cell antigen receptor pathway  learn more about the first line treatment with calquence  and its long term responses  https   t co vfrnemacbz
948,amer  urol  assn ,acalabrutinib plus pembrolizumab failed to improve outcomes in relapsed muc https   t co dtc nuiyq 
949,oncologynurseadvisor,a new report presents a review of strategies that facilitate ae management and medication adherence among patients receiving acalabrutinib to treat mantle cell lymphoma  https   t co ihqfe xeof  lymphoma
950,oncologynurseadvisor,a new report presents a review of strategies that facilitate ae management and medication adherence among patients receiving acalabrutinib to treat mcl  https   t co ihqfe xeof  lymphoma
951,univadis,   patienten mit platinrefrakt rem metastasiertem urothelkarzinom wurden randomisiert pembrolizumab mit oder ohne acalabrutinib zugeteilt  https   t co z aivsl tg https   t co p  r yjv s
952,onclive com,watch  ian flinn  md  of  sarahcannondocs  tycel jovelle phillips  md  of  umich  bijal shah  md  of  moffittnews  and javier munoz  md  facp  of  mayoclinic  discuss the use of acalabrutinib in r r mantle cell lymphoma   lymsm https   t co jkii  iuxl https   t co huyh ghjjv
953,cancertherapyadvisor,acalabrutinib plus pembrolizumab failed to improve outcomes in relapsed metastatic urothelial cancer   https   t co efbljbji m  cancer
954,tekcrispy,estudio revela que el medicamento acalabrutinib  aprobado por la fda  puede calmar la tormenta de citoquinas en pacientes con coronavirus  https   t co  v ycwc so https   t co vdje pliop
955,trip database,new trip  ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia https   t co fz hyfhto 
956,cure magazine,follow up data further support the use of calquence in patients with relapsed or refractory chronic lymphocytic leukemia  https   t co keoj c dhr
957,garvs,they re just rolling in now    this is an ad for acalabrutinib  which is a cancer drug of unknown effectiveness that  astrazeneca charges over         month for   in       az paid half a billion dollars for using paid shills to sell a drug to patients it wasn t meant for https   t co ok  flyykp
958,alejandro de bary,hay    ensayos cl nicos en per  relacionados al covid  los tratamientos en prueba son  plasma     ivermectina mavrilimumab ruxolitinib acalabrutinib hidroxicloroquina tocilzumab solidaridad  oms     f rmacos   resultados habr  reci n en unos meses
959,paperbirds hematology,new clinical trial  acalabrutinib and obinutuzumab for the treatment of chronic lymphocytic leukemia https   t co idy uepkfc  cll  leusm  hematology
960,specialty pharmacy continuum,cancer drugs may dampen  cytokinestorm that occurs in patients with severe  covid    https   t co sed  kmi a  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
961,cancernetwork   home of the journal oncology , icymi  both the phase   ace cl     trial and the pivotal phase   ascend trial showed the long term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co pdysrg  zc
962,pharmacyphunquiz,this is your name game real or fake edition  here are four  bruton tyrosine kinase  btk  inhibitors   only three are real  can you id the fake   a  ibrutinib b  zanubrutinib c  oceabrutinib d  acalabrutinib  the answer is in the thread
963,medivizor,learn more  acalabrutinib in patients with relapsed or refractory chronic lymphocy    https   t co gl tkhwkic  leukemia  via  medivizor 
964,immunotherapypapers,a randomized phase   trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum resistant metastatic urothelial cancer  https   t co   ww rq mt
965,maria badillo  msn rn ocn ccrp,our article is finally published  oncologynursing  onscjon from our colleagues  mdandersonnews with  michaelwangmd  so happy to share how we manage our  mcl patients taking  acalabrutinib   astrazeneca  astrazenecaus  carolporterdnp https   t co  n fomgo q
966,cure magazine,follow up data further support the use of calquence versus standard of care regimens in patients with relapsed or refractory chronic lymphocytic leukemia  https   t co ocrwbq hxy
967,immuno oncology,a randomized phase   trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum resistant metastatic urothelial cancer  https   t co dad koreug https   t co  lskc  bqj
968,    ,                   calquence                                             https   t co jqgookzpuu
969,guru sonpavde  md,acalabrutinib  btk inhibitors deplete mdscs    pembro did not improve outcomes vs  pembro in a randomized phase ii trial of unselected post platinum metastatic  urothelialcarcinoma  need greater role for better patient selection informed by preclinical   early clinical data  https   t co poff  nz p
970,trip database,new trip  ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia https   t co fz hyfhto 
971,nash peters,https   t co  zsazxbeas phase i  acalabrutinib  calquence  by  astrazeneca  suspension via nasogastric co administered with a ppi  in the treatment of  covid   calquence is a selective btk inhibitor currently approved in the us for treatment of certain haematological malignancies
972,ali khaki,just published in  journalcancer an editorial  neerajaiims  montypal  pgrivasmdphd and i wrote reviewing rapid check phase   trial of acalabrutinib and pembrolizumab led by  tiansterzhang   we review the trial and the broader io trial landscape for auc  https   t co pvkagmnwlz
973,acs journal cancer,available via  openaccess   a randomized phase   trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum resistant metastatic urothelial cancer https   t co  orqiihy m  accompanying editorial   https   t co   efssgxzd https   t co   elqdzbht
974,infectiousdiseaseadv,in this study   emergency  unregistered use of acalabrutinib was available to patients hospitalized with advanced  covid    in accordance with the  who meuri guidelines   idatwitter https   t co om lk wic 
975,lymphomaaction,the european medicines agency has approved a new drug called acalabrutinib for people with chronic lymphocytic leukaemia  cll   read more here  gt  https   t co khiapcvoyx  ema news  lymphoma  lymphomamatters https   t co  fcyhwpr s
976,h matologie,acalabrutinib   une v ritable avanc e pour la prise en charge de la leuc mie lympho de chronique en rechute ou r fractaire   https   t co vdhzyzomcx  actushemato par laly nsiala et c cile tomowiak https   t co iod jlqkpv
977,       ,                 calquence                                      https   t co hutiogi     prtimes jp  
978,    ,                 calquence                                      https   t co mv  g ahbr  prtimes jp  
979,md anderson leukemia,new  clinicaltrial            phase ii study of acalabrutinib  aca    venetoclax  ven      early obinutuzumab  obin  for pts w  chronic lymphocytic  leukemia   cll    pi   wwierda of  mdandersonnews  leukemia   nct           https   t co steip cuwp    endcancer  leusm
980,    aqours           ,                 calquence                                           https   t co hnmj rvib   prtimes jp  
981,    aqours           ,                 calquence                                      https   t co dnn x krfo  prtimes jp                                                
982,newsrelea se,                             calquence                                      https   t co va dbnbhmx
983,jpubb              ,                 calquence                                                       https   t co omgt ytdvy
984,pr times    ,                 calquence                                    https   t co b yznhktsv
985,           ,                 calquence                                        pr times https   t co u ccpbrcoi
986,pr times    ,                 calquence                                    https   t co mf  c fusv
987,wmr tokyo          ,                 calquence                                      https   t co brxyufm vz
988,specialty pharmacy continuum,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co ihzza hhcz  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
989,infectiousdiseasese,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co ukpnfj ogy  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
990,clinicaloncologynews,myriad trials are testing immunomodulating blood cancer agents to combat cytokine storm in patients with severe covid     https   t co  dradatvfz   astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  covid    calquence  btkinhibitors
991,pharmacy practice news,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co viemld zkl  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
992,cota  inc ,researchers are exploring  btk inhibitors  amp  other blood  cancer drugs for covid     a study found the btk inhibitor acalabrutinib showed benefit in a small uncontrolled case series of hospitalized patients with severe  covid     learn more  https   t co fbkhoxqgim  pharmpracnews
993,pete afrasiabi, cnntownhall  acalabrutinib showing    percent improvement in patients on oxygen and    percent improvement for those on ventilators  all being discharged in a small off label study  can fda do an eua for small studies similar to this one 
994,pharmacy practice news,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co viemlcqytd  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
995,esmo   eur  oncology,ema recommends marketing authorisation for acalabrutinib  a bruton  tyrosinekinaseinhibitor  intended for the treatment of chronic lymphocytic  leukaemia https   t co  csrnveqrh  leusm https   t co emjmtex oy
996, rzte zeitung,acalabrutinib zur zulassung als cll arznei empfohlen ein wesentlicher treiber der chronisch lymphatischen leuk mie ist der b zell rezeptor signalweg  in dem die bruton tyrosinkinase  btk  eine zentrale position einnimmt  acalabrutinib hemmt die btk  https   t co kbuuknkmd  https   t co gdm  xsgck
997,medivizor,new by  medivizor  acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia https   t co gl tkhwkic  leukemia
998,agd biomedicals,from medscape hematology oncology headlines gt  gt https   t co hl ujxcsvu green light for avapritinib for gist  acalabrutinib for cll
999,ronald m  chavin,            both astrazeneca s acalabrutinib and janssen pharmacyclic s ibrutinib are btk inhibiting cancer drugs being tested against mid stage covid    in separate clinical trials  https   t co f vuinapks https   t co uu e jxxwj https   t co  jwlijshtd https   t co b maro  lv
1000,clinicaloncologynews,myriad trials are testing immunomodulating blood cancer agents to combat cytokine storm in patients with severe covid     https   t co  dradatvfz   astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  covid    calquence  btkinhibitors
1001,lymphoma hub,news  chmp adopts positive opinion for acalabrutinib for the treatment of patients with  cll    https   t co nmzb  x lj  lymsm https   t co plk vr zgz
1002,meedo,according to a new small study   acalabrutinib may counter the hyperinflammatory  cytokinestorm in severe  covid   patients with greater efficacy seen in patients receiving supplemental oxygen  no serious acalabrutinib associated toxicity was observed  https   t co aicsf pvhl
1003,agd biomedicals,from medscape hematology oncology headlines gt  gt https   t co hl ujxcsvu green light for avapritinib for gist  acalabrutinib for cll
1004,biopharmaasia,calquence recommended for eu approval by chmp for chronic lymphocytic leukaemia   https   t co dqxedot ti
1005,trialbulletin,a study to evaluate effects of proton pump inhibitor on acalabrutinib capsule when administered orally with coca cola in healthy participants  status  recruiting   condition summary  infectious disease https   t co edw zybsg 
1006,curehuntr, clinicaltrial a study to evaluate effects of proton pump inhibitor on acalabrutinib capsule when administered orally with coca cola in healthy participants https   t co   hojadgqg
1007,specialty pharmacy continuum,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co ihzza hhcz  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
1008,pete afrasiabi,acalabrutinib showing    percent improvement in patients on oxygen and    percent improvement for those on ventilators  all being discharged in a small off label study  fda needs an eua for small studies across the country    us fda    cdcgov  https   t co lj zjpr us
1009, stoncology, calquence recommended for approval in the eu by  chmp for  chroniclymphocyticleukaemia  azn https   t co hhswrnajvd
1010,apotheke adhoc, astrazeneca kann sich hoffnung auf die zulassung von zwei krebsmedikamenten in der europ ischen union machen  die europ ische  arzneimittelagentur habe die zulassung von  calquence   acalabrutinib  sowie von  imfinzi   durvalumab  empfohlen   pharmazie https   t co ipmam b zq https   t co  dwmrfwkff
1011,      ,btk   acalabrutinib cll                             cll  https   t co scrqhclqdh
1012,       ,btk   acalabrutinib cll            https   t co b  ybqrtdk         
1013,trialbulletin,a study to evaluate relative bioavailability  proton pump inhibitor  ppi   rabeprazole  effect  food effect and particle size effect of new acalabrutinib tablet in healthy subjects  status  recruiting   condition summary  bioavailability  b cell lymphoid  https   t co d w ta  dh
1014,curehuntr, clinicaltrial a study to evaluate relative bioavailability  proton pump inhibitor  ppi   rabeprazole  effect  food effect and particle size effect of new acalabrutinib tablet in healthy subjects https   t co l kzyt cyq
1015,infectiousdiseasese,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co ukpnfipdpq  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
1016,abe dental,              up btk   acalabrutinib cll            https   t co zephn                                  https   t co mv i cmpzy
1017,tweets,acalabrutinib           cll                     elevate tn         cll                    https   t co knnnqkx  z        
1018,specialty pharmacy continuum,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co ihzza hhcz  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
1019,andy vermaut,ema green light for avapritinib for gist  acalabrutinib for cll https   t co dkf tiujs  https   t co cqpapcmmfm
1020,pharmacy practice news,cancer drugs tapped for  covid   to dampen  cytokinestorm that occurs in patients with severe covid     https   t co viemlcqytd  astrazeneca  llsusa  drdonaldharvey  thenci  sloan kettering  danafarber  leedshospitals  calquence  btkinhibitors
1021,        ,     btk   acalabrutinib cll               ascend              cll    acalabrutinib                     idelalisib               https   t co  rufdaonnh
1022,        ,btk   acalabrutinib cll            https   t co cn s xjg  
1023,                   insights  pharma   ,btk   acalabrutinib cll            https   t co y hgygavjm
1024,jon angelo,two chmp recommendations for astrazeneca  imfinzi in first line lung cancer  calquence in chronic lymphocytic leukaemia   https   t co zbaxum  hd  pharmaceutical
1025,pharmafocus,two chmp recommendations for astrazeneca  imfinzi in first line lung cancer  calquence in chronic lymphocytic leukaemia https   t co mvyedgvfja  pharma https   t co yxn vqhotk
1026,company news hq,calquence recommended for approval in the eu by chmp for chronic lymphocytic leukaemia https   t co sjekz qq z
1027,finwire news,astra zenecas calquence f r godk nnanderekommendation i eu https   t co iu  nalmep
1028,contentoflifer,astrazeneca s calquence receives positive chmp opinion for chronic blood cancer https   t co dumk kuxgy
1029,graniteshares europe, azn calquence   acalabrutinib  has been recommended for marketing authorisation in the eu for the treatment of adult patients with chronic lymphocytic  leukaemia   cll  haematology  pharma  stocks  astrazeneca  singlestocketps https   t co t kvqk qry
1030,directorstalk,astrazeneca calquence recommended for approval in the eu   https   t co fs kisz xs  azn
1031,francis alexander,astrazeneca calquence recommended for approval in the eu   https   t co dky d ow m    azn  trading  shares  stocks  ratings https   t co yhdwc edoi
1032,cision news,calquence recommended for approval in the eu by chmp for chronic lymphocytic leukaemia https   t co  ykvqtkbmg
1033,daniel macdonald, azn   astrazeneca plc calquence receives positive chmp opinion for cll https   t co gdwzuapse 
1034,cancernetwork   home of the journal oncology , icymi  both the phase   ace cl     trial and the pivotal phase   ascend trial showed the long term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co pdysrg  zc
1035,latika,acalabrutinib  a selective btk inhibitor  was administered off label to    patients hospitalized with severe  covid    https   t co bnmmxvnaz 
1036,i malati invisibili,malattie rare   leucemia linfocitica cronica  parere positivo del chmp dell ema per acalabrutinib  https   t co  uivwlaly   comitatoimalatiinvisibili  imalatiinvisibili  comitatoimi  comitatoimionlus  malattierare https   t co   ijgqm   
1037,australianprescriber,https   t co r dzg rzr 
1038,emergency live, covid     aifa  aifa ufficiale autorizza tre nuovi studi su  acalabrutinib   ifn  a e la molecola  abx    https   t co ekwngaokp 
1039,investor news,european advisory group backs astrazeneca s calquence for leukemia treatment  azn https   t co cfkz zxhii
1040,investor news,european advisory group back s astrazeneca s calquence for cll  azn https   t co yyqdleeotm
1041,benigno pi era,european advisory group back s astrazeneca s calquence for cll https   t co iuyuf hmrv
1042,breaking news, azn   european advisory group back s astrazeneca s calquence for cll https   t co mternmkawy
1043,md anderson cancer center,a study led by our  michaelwangmd shows the viability of acalabrutinib in treating relapsed mantle cell lymphoma  https   t co ccjdjmx sa  targetedonc  lymphoma  endcancer
1044,maria badillo  msn rn ocn ccrp,so excited on our new article about acalabrutinib  managing adverse events amp  improving adherence in pts with mantle cell lymphoma   michaelwangmd    mdandersonnews    astrazeneca    oncologynursing   cjon   texasnursesassn   https   t co ngadwmbp d
1045,paperbirds hematology,new clinical trial  modified immune cells  cd   car t cells  and acalabrutinib for the treatment of relapsed or refractory mantle cell lymphoma https   t co zespr jz u  mcl  lymsm  hematology
1046,paperbirds hematology,new clinical trial  modified immune cells  cd   car t cells  and acalabrutinib for the treatment of relapsed or refractory mantle cell lymphoma https   t co y jpgrhicp  tcl  lymsm  hematology
1047,i malati invisibili,neoplasie delle cellule b   profilo di sicurezza favorevole per l inibitore di btk di nuova generazione acalabrutinib  https   t co lvdt w xko  comitatoimalatiinvisibili  imalatiinvisibili  comitatoimi  comitatoimionlus  malattierare https   t co l k i gnzb
1048,wcm lymphoma,dr  richard furman notes differences among btk inhibitors ibrutinib   st generation   acalabrutinib  amp  zanubrutinib   nd generation  in patients w  b cell malignancies  via  onclive  https   t co pb pwo  co
1049,emilio mordini,study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe covid    infection    scoopit https   t co i x uoxqfi
1050,karrie esther moen,the drug acalabrutinib may help treat severe covid    infection https   t co jo jzgw oq
1051,jill feldman, rapid improvement of symptoms  amp  oxygenation  for patients with  covid   correlated with reduced inflammatory markers and no serious toxicity with short course of acalabrutinib  sounds promising   aacrcovid https   t co   to  dm h
1052,sayub mazher,off label use of acalabrutinib to treat severe covid     infection https   t co iinpayk yx
1053,liz highleyman,louis staudt   thenci   more support for idea that different types of therapies work at different stages of  covid     lymphoma btk inhibitor acalabrutinib may work at  trunk  of tree to prevent cytokine storm   aacrcovid https   t co mydrtddkhc
1054,liz highleyman,louis staudt   thenci   acalabrutinib  calquence  blocked inflammation  amp  reversed severe  covid   in small study  clinical improvement appeared related to improvement in inflammatory markers  suggesting activation of monocytes  amp  macrophages is key to hyperinflammation   aacrcovid https   t co maumujyw n
1055,a n n ,research from  nih   researchers observed that the off label use of the cancer drug acalabrutinib  a btk inhibitor     was associated with reduced respiratory distress  amp   a reduction in the overactive immune response       https   t co rj m  jbjz  aacrcovid  louis m  staudt
1056,liz highleyman,louis staudt of  thenci    surprised to be presenting on an infectious disease    discusses study of  lymphoma drug acalabrutinib  calquence  for  covid     aacrcovid https   t co hvc pfuqzt
1057,dubai globalnews,                       calquence                                  https   t co yjmsmekukz
1058,onclive com,paolo ghia  md  phd  of  myunisr  discusses the final results from the phase   ascend trial with acalabrutinib monotherapy in patients with relapsed refractory cll   asco  asco    leusm https   t co dinfpdyzgk https   t co dymbej  ox
1059,onclive com,btk inhibitors have become an important drug class in many b cell malignancies  and the next generation inhibitor zanubrutinib could be an alternative option for those intolerant of ibrutinib or acalabrutinib   sarahcannondocs  asco  asco    lymsm https   t co wbc plaojz
1060,onclive com,final results from the phase   ascend trial confirm earlier data that support the favorable safety and efficacy of acalabrutinib compared with standard of care regimens in patients with relapsed refractory cll   myunisr  asco  asco    leusm https   t co bikj w vgd
1061,lymphoma papers,acalabrutinib  managing adverse events and improving adherence in patients with mantle cell lymphoma   lymphoma  lymsm https   t co blnwg   ly
1062,lymphoma papers,acalabrutinib for mantle cell lymphoma  chronic lymphocytic leukaemia   lymphoma  lymsm https   t co jmcqcjzood
1063,health radio online,eha   virtual congress   calquence  trial results for chronic lymphocytic leukemia read more  https   t co vtun  iibi  eha    calquence  chroniclymphocyticleukemia https   t co  guqesdepa
1064,talha badar,clinical and biological implications of target occupancy in cll treated with the btk inhibitor acalabrutinib  bid dosing maintained higher btk occupancy and  more potent pathway inhibition compared with qd dosing  https   t co  xmqy  g b  leusm  bloodjournal
1065,pacientesconidp,el medicamento acalabrutinib inhibe la la prote na tirosina quinasa de bruton  btk  y se asocio con una reducci n de las dificultades respiratorias y de la respuesta inmune hiperactiva que causa la muerte de los enfermos criticos por el covid  fuente  infoabe https   t co wu  eqdkvh
1066,paperbirds hematology,new article  acalabrutinib  managing adverse events and improving adherence in patients with mantle cell lymphoma  https   t co hqkubowxqf  mcl  lymsm  hematology https   t co hxlp gnd x
1067,paperbirds hematology,new article  acalabrutinib for mantle cell lymphoma  chronic lymphocytic leukaemia  https   t co edrirfc ow  mcl  lymsm  hematology https   t co zfs veb tm
1068,onclive com,  jeff sharman  of  theusonetwork  discusses the rationale for examining acalabrutinib in this patients with acute respiratory distress syndrome caused by  covid     https   t co  klhgyzlma https   t co xusvyakgio
1069,onclive com,final ascend data confirm safety  efficacy of acalabrutinib in r r cll  myunisr  asco  asco    leusm https   t co yfubveh  y
1070,adry pm,hematologylife llc acalabrutinib itk       hospitalespa oldebuenosaires https   t co  vi mh okw
1071,om prakash sharma,india to give    of     patients for clinical trial of cancer drug acalabrutinib for covid https   t co tdcuz wpma
1072,theprint science,india to give    of     patients for clinical trial of cancer drug acalabrutinib for covid   chandnahimani reports   theprintexclusive  https   t co hiijv hono
1073,ak,https   t co mavtwbj kr
1074,theprinthindi,                                                                                                                                   chandnahimani               https   t co  dgsdbj f 
1075,mohd wamique,india to give    of     patients for clinical trial of cancer drug acalabrutinib for covid
1076,onclive com,treatment with the btk inhibitor acalabrutinib resulted in decreased inflammation and improve outcomes in patients with severe  covid      jeff sharman  theusonetwork https   t co lvbpld kdo https   t co oh seyzyuc
1077,ronald m  chavin,            although the price of         per month and the slowness of setting up the clinical trial are negatives  india has agreed to become the guinea pigs for a phase   clinical trial of calquence  acalabrutinib  for covid     https   t co kfrrsugnqm https   t co  jwlijshtd
1078,prof archie d souza,the drug  branded as calquence by astrazeneca  has improved clinical outcomes of patients with severe covid     according to a peer reviewed study  https   t co l x e    x
1079,dr  divyesh b mundra   ,astrazeneca is set to start phase   of clinical trial of anti cancer drug  btk inhibitor  acalabrutinib  calquence  for treating severe  covid   patients with respiratory failure in    as a part of its global trial of     patients   cspramesh  spkalantri https   t co  yjieznlgf
1080,himani chandna,india joins global trial of astrazeneca s blood cancer drug  acalabrutinib  for treating severe covid   patients    out of total     patients     to join from india   more than    per cent of the total sample size   https   t co izp xyfewy via  theprintindia
1081,gk, acalabrutinib an anti cancer drug reduced markers of inflammation  amp  improved clinical outcomes of patients with severe covid       astrazenica  india to give    of     patients for clinical trial of cancer drug acalabrutinib for covid https   t co vcb rktrzv via  theprintindia
1082,seshutatikola,india to give    of     patients for clinical trial of cancer drug acalabrutinib for covid https   t co wxoqrtg lp via  theprintindia
1083,theprintindia,india to give    of     patients for clinical trial of cancer drug acalabrutinib for covid   chandnahimani reports   theprintexclusive  https   t co vgdb utoax
1084,oncology nursing news,treatment with the btk inhibitor acalabrutinib resulted in decreased inflammation and improved outcomes in patients with severe covid     according to new research  https   t co  l mduxnyo
1085,                                         ,                                                                 calquence                                                                 cll                                                                                                                  mcl 
1086,whitecoats,a group of researchers made the recent observation that the lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe covid    infection  to know more  visit https   t co cqciwhihr    whitecoats  bedreffective  covid    covid  corona  coronavirus https   t co  hbxixqw m
1087,          ,                    calquence                                                    amwalalghadar https   t co  kfkqrqvu 
1088,       ,                        calquence                                    https   t co bt ls nvyy
1089,oncology board,acalabrutinib may be beneficial for patients with advanced covid     early data says   https   t co  yrob zt d  acalabrutinib may be beneficial for patients with advanced covid     early data says  https   t co  yrob zt d https   t co btydakpdpv https   t co ib tdct  y
1090,air medical today,study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe covid    infection   news wise https   t co niuhbrfaka
1091, oo  ,calquence con k de queso dijo mi jefe
1092,afex capital,    azn                  astrazeneca           acalabrutinib                                                           
1093,stocktrend,astrazeneca  lymphoma drug acalabrutinib a potential therapy for severe covid      azn can be trusted over scam  mrna who have only interest in insider trading  sec let this scam run on daily basis with no action   spy
1094,joe ele, azn plc astrazeneca  lymphoma drug acalabrutinib a potential therapy for severe covid    https   t co aq  s l  k
1095,jeremy,astrazeneca  lymphoma drug acalabrutinib a potential therapy for severe covid   
1096,breaking market news,astrazeneca  lymphoma drug acalabrutinib a potential therapy for severe covid   
1097,first squawk,astrazeneca  lymphoma drug acalabrutinib a potential therapy for severe covid   
1098,onclive com,early data suggest acalabrutinib may benefit patients with advanced  covid     jeff sharman  theusonetwork  oncology https   t co qxxrwoi  t https   t co  mcbruoks 
1099,mark sparta,new study in  covid   patients suggests lymphoma drug might offer a potential therapeutic approach for severe infection of the virus  hackensackumc https   t co mgv wmfxot
1100,raman pathak  quant trader ,lymphoma drug acalabrutinib a potential therapy for severe covid    https   t co fionmpe  r
1101,medical dialogues,lymphoma drug acalabrutinib a potential therapy for severe covid     lymphomadrug  acalabrutinib  covid    covid    https   t co k qwd barf
1102,middle east   pakistan times of news,study suggests lymphoma drug acalabrutinib might offer a potential therapeutic approach for severe covid    infection https   t co phrlpunj x
1103,dtw research  inc,astrazeneca announced the approval of calquence for cll sll during the first quarter of          calquence  astrazeneca  acalabrutinib  leukemia  chroniclympoidleukemia  cll  lymphoma  smalllymphocyticlymphoma  sll  oncology  q   q       lymphomamarket  dtwmarkethighlights https   t co f yj jx yp
1104,mike thompson  md  phd  fasco,inhibition of bruton tyrosine kinase in patients with severe covid     jun           roschewskimd et al   sciimmunology https   t co zsunnrragk  covid    ccc    covid  ncancer acalabrutinib administered off label to    patients hospitalized with severe covid   
1105,dough,baml  azn top pick for best in class growth          e sales cagr  driving c    ebit cagr   impressive launch portfolio include calquence in cll enhertu  in post kadcyla breast cancer   roxadustat  china ongoing  us from end   e  farxiga heart failure  from mid   e   key product
1106,australianprescriber,https   t co r dzg rzr 
1107,vinay prasad md mph,new paper out with sunny kim  ohsunews heme onc fellow in cancer journal on acalabrutinib in cll  cancer regulatory trials deprive control arm pts of current standard of care  among other problems    marketing  gt  evidence   gt  clinical use  https   t co uvrorrriwu https   t co lv  gk gud
1108,mike thompson  md  phd  fasco,   astrazeneca announces calavi trial  ace id      to examine acalabrutinib for patients with covid     april           matthew fowler  cancernetwrk https   t co xkg af pnc  caxtx  ccc        ncov  covid  clinicaltrials  nct         az press release  https   t co p mymhjyba
1109,mike thompson  md  phd  fasco,inhibition of bruton tyrosine kinase in patients with severe covid     jun           roschewskimd et al   sciimmunology  https   t co zsunnrragk  covid    ccc    covid  ncancer acalabrutinib administered off label to    patients hospitalized with severe  covid   https   t co ywye wqx i
1110,i malati invisibili,malattie rare   leucemia linfatica cronica ricaduta refrattaria  acalabrutinib conferma la sua alta efficienza a lungo termine  https   t co   r cwhba   comitatoimalatiinvisibili  imalatiinvisibili  comitatoimi  comitatoimionlus  malattierare https   t co i  fwx ubn
1111,javed khan,cancer research in the time of two pandemics https   t co ec cf pdfe   highlights an insightful use of treating hyperinflamation of  covid    with acalabrutinib targeting bruton s tyrosine kinase  btk  as well as discussing racial injustices magnified by  covid  
1112,the asco post,john c  byrd  md  on cll sll  acalabrutinib in treatment naive patients https   t co u h sfsnwt  eha  virtual  eha    leusm  lymsm  osuccc james https   t co hwcav qx  
1113,ellen kendall,excited to share our work about cll treated with acalabrutinib  lucky to have worked with such incredible coworkers  amp  mentors  nih nhlbi https   t co bcl vivxxb
1114,blood journal,clinical and biological implications of target occupancy in  cll treated with the btk inhibitor acalabrutinib https   t co kocrwcjkqc https   t co xi pvvmdwp
1115,farmaciahuap,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial https   t co   hx pdmun
1116,drugpatentwatch,calquence drug profile       https   t co kpfdsfmbya
1117,ecancer, eha    prof paolo ghia of  myunisr outlines the final results of the ascend trial  evaluating acalabrutinib vs idelalisib   rituximab or bendamustine   rituximab in r r  chronic lymphocytic leukaemia  watch here  https   t co zmpsslrvna  oncology  eha  virtual  eha      cll https   t co  n  iwrkbf
1118,wcm lymphoma,dr  richard furman speaks to  onclive about the safety of acalabrutinib monotherapy in patients w  chronic lymphocytic  leukemia   myeloma and aggressive  lymphoma  according to a pooled analysis from   different  clinicaltrials  https   t co a xfdctwp 
1119,australianprescriber,https   t co r dzg rzr 
1120,jon,   acalabrutinib and ibrutinib  which are fda approved to treat different kinds of leukemia  are being studied to see if they can help patients with inflammation caused by the virus    coronavirusdrug
1121,benlazar s m amin ,occupy btk  the key to controlling cll   gt  gt  gt clinical and biological implications of target occupancy in cll treated with the btk inhibitor acalabrutinib   blood   american society of hematology https   t co zkpivww  e
1122,eduardo flavio oliveira ribeiro,what a remarkable paper   too many important findings on btk resynthesis and occupancy  amazing  clinical and biological implications of target occupancy in cll treated with the btk inhibitor acalabrutinib   blood   american society of hematology https   t co qqtjvyi cr
1123,cure magazine, collectively  these results support acalabrutinib use in upfront cll   said dr  john c  byrd  https   t co gmdxrw w y
1124,tap clinical trial network, stellar update recruitment continues with   patients now randomised to this investigation of   acalabrutinib  in combination with chop r  in patients with newly diagnosed  richterssyndrome   ouhospitals  churchillhospital  annaschuh   crctu
1125,raul cordoba  md  phd, oncoalert clinical and biological implications of target occupancy in  cll treated with the btk inhibitor  acalabrutinib     bloodjournal    american society of hematology  leusm  cllsm  lymsm  https   t co xwbchtysm 
1126,calquence   acalabrutinib ,https   t co w  aqpuk a  see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
1127,calquence   acalabrutinib ,https   t co w  aqpuk a  see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
1128,calquence   acalabrutinib ,https   t co w  aqpuk a  see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
1129,calquence   acalabrutinib ,https   t co w  aqpuk a  see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
1130,calquence   acalabrutinib ,https   t co w  aqpuk a  see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll  
1131,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1132,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1133,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1134,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1135,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1136,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1137,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1138,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1139,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1140,calquence   acalabrutinib ,https   t co w  aqpuk a  in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil  
1141,calquence   acalabrutinib ,https   t co w  aqpuk a  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
1142,calquence   acalabrutinib ,https   t co w  aqpuk a  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
1143,calquence   acalabrutinib ,https   t co w  aqpuk a  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
1144,calquence   acalabrutinib ,https   t co w  aqpuk a  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
1145,calquence   acalabrutinib ,https   t co w  aqpuk a  calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  
1146,the asco post,acalabrutinib with or without obinutuzumab vs chlorambucil obinutuzumab in previously untreated cll https   t co u qb uz  k  leusm  hematology
1147,        , pulse                                     calquence           https   t co fkhkgezwec https   t co ihgkkypgth
1148,australianprescriber,new drug  https   t co r dzg rzr 
1149,medtech  pulse,                    calquence                  pulsebeatnews https   t co uhaw yzszy
1150,national comprehensive cancer network  nccn ,asco    final results from ascend trial of acalabrutinib in resistant cll  learn more from jnccn     at https   t co jhg ihcr d  https   t co  wmjv xscw
1151,         ,btk   acalabrutinib cll                  https   t co lmnyeaa ut  carenet https   t co qbyx szxsg
1152,ahealthierphilly,within three days of starting the cancer drug  most of the patients on supplemental oxygen experienced a large drop in inflammation and improved breathing  https   t co fpde qhvn 
1153,medivizor,acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia  via  medivizor  https   t co gl tkhwkic  leukemia
1154,redacci n m dica, industriafarmac utica   acalabrutinib  de  astrazenecaes  muestra eficacia en  leucemia linfoc tica  los resultados se presentaron durante el congreso anual de la asociaci n europea de  hematolog a      https   t co h zqvvwf p https   t co tpru p rse
1155,   ,                  calavi                      btk    acalabrutinib                      covid                                        https   t co kgzdxd c j
1156,medivizor,new  acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia https   t co gl tkhwkic via  medivizor  leukemia
1157,hemomeeting,now dra adriana scheliga brought to us the highlights of target therapy in cll with acalabrutinib  https   t co js e dwvqo  cll  acalabrutinib  leukemia https   t co    fhsy  z
1158,ciencia,acalabrutinib  de astrazeneca  muestra eficacia en leucemia linfoc tica https   t co k  p ixjhb
1159,ice ,small case study using acalabrutinib  a btk inhibitor  to reduce macrophage activation and il   production in severe covid      fairly favorable results   https   t co azvhnjprab  note side effects profile includes a risk of neutropenia and anemia  however 
1160,lab tests online es,acalabrutinib  de astrazeneca  muestra eficacia en leucemia linfoc tica https   t co vnpjtkwdxy
1161,dr virendra singh,blood samples from covid   pts showed that levels of interleukin    a major cytokine associated with hyper inflammation decreased after treatment with acalabrutinib  counts of lymphocytes  also rapidly improved in most pts  low lymphocyte counts associated with worse outcome 
1162,australianprescriber,https   t co r dzg rzr 
1163,dough, abbv catalysts  several data   focus on additional rinvoq phase   data in atopic derm in       skyrizi phase    motivate  data in cd induction in       bi voltaire  x interchangeability study read out on biosimilar humira  head to head calquence imbruvica data in r r cll        
1164,michael wang  md,loxo     is a novel reversible btk inhibitor  it likely attacks an protein epitome different from that of the irreversible btk inhibitors such as ibrutinib  acalabrutinib and zanubrutinib  therefore and in theory  it should still work in prior btk inhibitor resistant lymphoma  https   t co lawmx tsx 
1165,lu chen  nobias, ruxolitinib boosts sars cov   replication in vitro  quite expected  probably the same for other jak stat  e g    baricitinib  amp  btk inhibitor like  acalabrutinib  timing is critical   got many requests to test remdesivir   dexamethason baricitinib combo  no  don t make sense  https   t co ktal ac zt
1166,    ,                 calquence                                        https   t co t hyji gzm  prtimes jp  
1167,medivizor,new  acalabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia https   t co gl tkhwkic via  medivizor  leukemia
1168,ematoinfo, eha  virtual   ace cl     trial is very important because of the long follow up of    months with acalabrutinib  we asked alessandra tedeschi a comment  https   t co nrujjwiyuu
1169,hemomeeting,dr alan skarbnik showed the data of ascend trail  the results and the role of  acalabrutinib for patients with  cll rr  ehavirtual  eha    leukemia https   t co zy m onpxx
1170,ahealthierphilly,within three days of starting the cancer drug  most of the patients on supplemental oxygen experienced a large drop in inflammation and improved breathing  https   t co iosryrrcvw
1171,australianprescriber,https   t co r dzg rzr 
1172,kevin marcelo,acalabrutinib aumenta la supervivencia libre de progresi n recidivante o leucemia linfoc tica cr nica refractaria   ecancer https   t co rd emnwebb
1173,ddnews online, ascentagepharma to test its bcl   inhibitor apg      vs r r cll sll in collab w   acertapharma  ph b    clinicaltrials to evaluate monotherapy or combo w  acerta s  btk inhibitor  acalabrutinib  https   t co joavdxfl h  oncology  leukemia  lymphoma https   t co b kium s  
1174,survivornet,the newly approved drug could offer patients a longer remission  improved quality of life  and possibly a long term management treatment option https   t co flo czjrcn
1175,corriere nazionale,con acalabrutinib rapido miglioramento dei sintomi di covid    in forma grave secondo i dati di uno studio pubblicato su science immunology https   t co gggdvmp o 
1176,newsrelea se,                             calquence                                        https   t co ozatp s  v
1177,     ,                            calquence                                        https   t co bviksg rvy
1178,pr times    ,                 calquence                                    https   t co dng i zgjk https   t co jglqk fypb
1179,pr times    ,                 calquence                                    https   t co rilbufwbor https   t co bcak zrmdg
1180,oyecricket com,ascentage  acerta to evaluate apg       calquence combo in r r cll sll https   t co r gvbh won
1181,revista caretas,el acalabrutinib  usado en el tratamiento contra la leucemia  bloquear a la prote na btk que provoca la propagaci n de la covid     especialistas no descartan que se aplique para los casos graves en el per   https   t co  ruc   xp 
1182,onclive com,results showed that     of patients with relapsed refractory disease who received acalabrutinib were alive and free from disease progression at    months versus     of patients who received physician s choice of rituximab plus idelalisib or bendamustine  https   t co katk  qnzw
1183,lymphomaaction,results of a study published recently in  thelancet show that acalabrutinib   a type of targeted drug called a cell signal blocker   could be an effective new chemo free treatment option for chronic lymphocytic leukaemia  cll   read more here  gt  https   t co ilau   c r  sundayread https   t co  k axyisrp
1184,vjhemonc,great to hear about the safety of  acalabrutinib monotherapy in mature b cell malignancies from  richardfurmanmd of  weillcornell  watch the interview here   https   t co  kft ihhbm    eha  virtual  vjhemonc  eha hematology  lymsm  leusm  eha    hemonc  ehatrending
1185,australianprescriber,https   t co r dzg rzr 
1186,ahealthierphilly,within three days of starting the cancer drug  most of the patients on supplemental oxygen experienced a large drop in inflammation and improved breathing  https   t co lb mxrqiau
1187,onclive com,acalabrutinib continued to show favorable efficacy with a tolerable safety profile in patients with relapsed refractory chronic lymphocytic leukemia   leusm https   t co decaypltjf
1188,farmaciahuap,phase     trial of acalabrutinib plus    by dr  dr  thomas witzig eha library  jun                  https   t co ysjh qguug
1189,cll advocates network,dr john byrd talking about acalabrutinib in treatment naive cll  comparisons to other btk inhibitors maybe less side effects and fortunate to have these options for patients  less than     have hypertension after   years   patients living longer on btk https   t co lso wa hr 
1190,lymphoma hub,live q amp a  eha  virtual paolo ghia   myunisr  summarized the final data from ascend trial that evaluated acalabrutinib vs idelalisib rituximab or bendamustine rituximab in r r  cll  pfs was prolonged with acalabrutinib vs idr br overall  amp  in pts with del   p  tp   mutations  lymsm https   t co ybdkjmaann
1191,revista caretas,reapertura de centros comerciales buscar impulsar econom a  la  oit advierte de un posible incremento del trabajo infantil  el acalabrutinib  usado en el tratamiento contra la leucemia  bloquear a la prote na btk que provoca la propagaci n de  covid     https   t co thxc jykqr
1192,     ,acalabrutinib                               carenet        carenet  https   t co ckmavrv d 
1193,revista caretas,el acalabrutinib  usado en el tratamiento contra la leucemia  bloquear a la prote na btk que provoca la propagaci n de la covid     especialistas no descartan que se aplique para los casos graves en el per   https   t co  ycq gmb i
1194,revista caretas,reapertura de centros comerciales buscar impulsar econom a  la  oit advierte de un posible incremento del trabajo infantil  el acalabrutinib  usado en el tratamiento contra la leucemia  bloquear a la prote na btk que provoca la propagaci n de  covid     https   t co mciurbaxfw https   t co ztbh cqssr
1195,michael wang  md,our heavily cited study  published in the lancet  reported that acalabrutinib treatment provided r r mantle cell lymphoma patients a high rate of durable responses      overall response      complete response  with a favorable safety profile     https   t co ebsnye doa
1196,ematoinfo,gli update presentati ad  eha  virtual  confermano l efficacia di acalabrutinib nel trattamento della leucemia linfatica cronica rendendolo un interessante opzione terapeutica  anche prima linea  la parole di alessandra tedeschi https   t co  mqod ki b
1197,marseille immunopole,effectivement  ce ne sont pas les r sultats pr liminaires de  forcetrial mais ceux d un essai exploratoire de  l inhibiteur de btk  acalabrutinib chez les patients atteints d une forme s v re de  covid    nous jugeons cette information int ressante donc nous la partageons  https   t co lby mro xp
1198,lymphoma hub,congress    eha  virtual   john byrd   osuccc james  presented data from the ace cl     trial of acalabrutinib monotherapy for treatment na ve  cll patients  results show durable remissions and long term tolerability  lymsm https   t co mejbgsuiln
1199,toxiven,a drug to treat allergic reactions   acalabrutinib  a bruton s kinase inhibitor completely prevented ige mediated  anaphylaxis in a novel  humanized mouse model and prevented death during severe anaphylaxis  could this be a solution to treat allergies  https   t co  hllo we y
1200,revista caretas, caretasencasa la cloroquina  la azitromicina  el ritonavir y la ivermectina son usados para tratar casos graves de  covid    a estos  en los  ltimos d as  se les suma el acalabrutinib  usado para el tratamiento de leucemia  https   t co  ycq gdltq
1201,onclive com,acalabrutinib demonstrates favorable long term efficacy in cll  myunisr  eha hematology  leusm  eha  virtual https   t co  d  bzuvtq
1202,czeekv,                   covid                              db              acalabrutinib               calquence         https   t co iojry vqp 
1203,hlc,research conducted by  theusonetwork a  mckesson organization  has found that patients acutely ill with covid    have seen rapid improvements when treated with the cancer drug acalabrutinib https   t co doz mdixat
1204,revista caretas,  atenci n el acalabrutinib  usado en el tratamiento contra la leucemia  bloquear a la prote na btk que provoca la propagaci n de la covid     especialistas no descartan que se aplique para los casos graves en el per   https   t co  ycq gdltq
1205,marseille immunopole, btkinhibitor  acalabrutinib in  severecovid   encouraging preliminary data  supplemental oxygen group  oxygenation improved       patients discharged on room air   mechanical ventilation group      patients extubated  roschewskimd et al   sciimmunology https   t co gfu drmpu  https   t co vofuotgllb
1206,apostz,could acalabrutinib be used to treat covid       medical news bulletin https   t co mjczjktrws
1207,medical news bulletin,could acalabrutinib be used to treat covid       covid    coronavirus  pandemic  coronavirustreatment https   t co fkhuewwkch https   t co e n mk myl
1208,clinical cancer research,acalabrutinib pharmacodynamics in patients with chronic lymphocytic leukemia  https   t co  dycyjguuw  cl https   t co o   oaghjf
1209,wcm englander institute for precision medicine,follow the link to watch  engipm member richard r  furman  md   richardfurmanmd  discuss the safety of acalabrutinib as a monotherapy in hematologic malignancies   precisionmedicine   https   t co pukhgbmztk https   t co xqiee bks 
1210,pharmanewsintel,a  clinicaltrial found that astrazeneca s calquence showed improvement in chronic lymphocytic leukemia patients just a week after a separate study uncovered calquence helped some hospitalized  covid    patients  https   t co qpzjedrspd
1211,saber vivir,los m dicos han publicado sus conclusiones en la revista science immunology  consideran que la clave est  en la prote na btk y que este f rmaco inhibe    covid    salud  acalabrutinib  https   t co yaz no alu
1212,demiurgetech,demiurge ai based  covid    clinicaltrials outcome predictions put to the public test               failure for   acalabrutinib   nct            astrazeneca and acerta pharma b v 
1213,ematoinfo,da paolo ghia un focus sui dati dell analisi  finale dello studio ascend presentato ad  eha  virtual con ulteriori evidenze per acalabrutinib nella leucemia linfatica cronica  https   t co mimmirwjw 
1214,revista caretas,ma ana en caretas  el pa s avanza con la reactivaci n econ mica e impulsa a los comercios  la oit advierte de un dr stico incremento del trabajo infantil  el acalabrutinib bloquear a la prote na que provoca la propagaci n de la  covid      esto y m s en  caretassequedaencasa https   t co mwgaknlbua
1215,wish tv,a medication originally designed to treat cancer reduces inflammation and the need for supplemental oxygen in coronavirus infected patients  researchers have found  https   t co  rfnn zihj
1216,cco hepatitis,dr   jeff sharman shares his expert insights  amp  discusses new exploratory dataset on the use of  acalabrutinib as a therapy for patients with  covid    infection  amp  severe acute respiratory distress syndrome  ards   https   t co jxdfyyztfs  theusonetwork https   t co poiqcw l e
1217,cancernetwork   home of the journal oncology ,both the phase   ace cl     trial and the pivotal phase   ascend trial showed the long term efficacy and tolerability of acalabrutinib in patients with chronic lymphocytic leukemia  https   t co pdysrg  zc
1218,mckesson corporation,a therapy typically used to treat patients with blood cancer is showing improvement in some covid    patients  us oncology research physicians put their expertise to work in the fight against the pandemic  read more in  forbes  https   t co  jwaig o a
1219,ematoinfo, eha  virtual    ascend trial confirm the clinical benefit of treatment with acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  we asked paolo ghia a comment  https   t co seza tjwh 
1220,teens get cancer too,finding   inhibition of bruton tyrosine kinase for severe  covid    meaning  scientists may have found a target for a drug  acalabrutinib that looks promising and can move towards randomized controlled clinical trial  did we get it right   sciencemagazine https   t co a mkbjv pq
1221,pharma news,new phase ii data indicate regimen of truxima   biosimilar rituximab   lenalidomide and acalabrutinib  r a  may be well tolerated and effective in relapsed refractory aggressive b cell lymphoma https   t co ykjhqyrogq  news  pharma  pharmiweb
1222,pharma news,new phase ii data indicate regimen of truxima   biosimilar rituximab   lenalidomide and acalabrutinib  r a  may be well tolerated and effective in relapsed refractory aggressive b cell lymphoma https   t co pjuzjszour  news  pharma  pharmiweb
1223,australianprescriber,https   t co r dzg rzr 
1224,jerry lee,pharmacodynamic analysis of btk inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib https   t co tdgzyhoyap
1225,kit kay mak,first anticancer drug that has shown promising results for covid    treatment  https   t co nj dlcjqtl   acalabrutinib  bruton tyrosine kinase  btk  inhibitor  approved by fda and indicated for the treatment of chronic lymphocytic https   t co hhmwln jum https   t co n qf zylpb
1226,abej, ascend  the phase    randomized trial of acalabrutinib versus investigator s choice of idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory cll   will be published online at https   t co  azs lwsam   acalibrutinib in r r cll   rct
1227,jeff karp  pronouns  he him his ,cancer drug may reduce symptoms of severe covid      acalabrutinib https   t co ccg  sogg 
1228,andreas charalambous,btk inhibitor   acalabrutinib to treat covid     https   t co vbi porqea  oncoalert
1229,saber vivir,m dicos del hospital walter reed  en maryland  estados unidos  han descubierto que el medicamento  acalabrutinib  utilizado en algunos c nceres  puede ser una soluci n    covid     https   t co yaz no alu
1230,the cancer letter,btk inhibitors in  covid      just metaphorically  treatment with tocilizumab and anakinra is like cutting the limbs off a tree  but treatment with acalabrutinib is like cutting the tree down from the trunk   https   t co piu yk  ju https   t co  hqzdhxv z
1231,iflyplaces,dexamethasone is available as an oral and is pretty widely available and cheap ish  roughly similar concept as as acalabrutinib i tweeted about last week  reduction in inflammation appears to improve outcomes  response is not bigly though  only     of pts better than    though https   t co s    vlvu 
1232,the asco post,acalabrutinib vs idelalisib rituximab or bendamustine rituximab for relapsed or refractory cll  ascend trial https   t co tr tdj mi   leusm  hematology
1233,mednet,acalabrutinib met of zonder obinutuzumab vs  chloorambucil en obinutuzmab als eerstelijnsbehandeling voor cll https   t co  zaelyokxk https   t co ivwjfwuecn
1234,ahealthierphilly,within three days of starting the cancer drug  most of the patients on supplemental oxygen experienced a large drop in inflammation and improved breathing  https   t co z srmqx p 
1235,tribeca  knowledge,jefferies analysts suggest the biggest hit to  pharma companies from coronavirus in the european union will be on new drug launches like novo nordisk s rybelsus or astrazeneca s calquence   https   t co fuy  yk  f
1236,drug discovery world,astrazeneca presents results from calquence  acalabrutinib  oncology trials  https   t co b dq  tqm    astrazeneca  leukemia  oncology  clinicaltrials  calquencetrials  biopharmaceutical  biotechnology  pharmaceutical  drugdevelopment  drugdiscovery  ddw  drugdiscoveryworld https   t co sbtzcysndu
1237,emanuel vila, acalabrutinib inhibe  btk mejorando cuadro  hipoxia  covid    estos datos nos hacen pensar que el momento ideal para administrar el tratamiento es cuando empieza la tormenta de citoquinas  antes de que se hayan producido da os muy graves   se ala baselga https   t co yhss  sb z
1238,emanuel vila, covid    hypoxia  inhibitor  btk  gene  acalabrutinib  ibrutinib  given the lack of  hypoxia in the other covid   infected wm patients on full dose ibrutinib ibrutinib was increased to     mg d on days    and    a rapid improvement in oxygenation followed https   t co tvn  kvezk
1239,living safely,missed it   cytokine storm   acalabrutinib assists in calming down in  covid    patients in study   ont  https   t co bgfm ujn y
1240,le n waxtein  m ,early data show potential benefit of acalabrutinib in severe covid    https   t co lmdhncpd e
1241,rafael h carrasco,healthday reports  acalabrutinib promising for treatment of severe covid    june          physician s briefing https   t co vizmtbdikg
1242,beyond conventional cancer therapies,medscape   acalabrutinib  calquence  astrazeneca   a bruton tyrosine kinase  btk  inhibitor  showed early signs it may improve outcomes quickly for patients with severe  covid     a case study of    patients has found   https   t co mwo heh s 
1243,rock pop     ,la compa  a que administra acalabrutinib  iniciar  ensayos cl nicos en personas de algunos de los pa ses m s afectados por la epidemia  entre ellos  chile    qu dateencasa  qu dateenradio https   t co  rbrstzwga
1244,biopharmaasia,long term efficacy and tolerability showed by calquence for patients with chronic lymphocytic leukaemia in two trials   https   t co ocbfsnothb
1245, stoncology,new phase ii data indicate regimen of  truxima   biosimilar  rituximab    lenalidomide and  acalabrutinib  r a  may be well tolerated and effective in relapsed refractory aggressive  bcelllymphoma  eha   https   t co ydde l rs 
1246,roberto bonin,nuovi dati di fase ii indicano che un regime combinato di truxima  lenalidomide e acalabrutinib pu  essere ben tollerato ed efficace nella terapia del linfoma a cellule b aggressivo refrattario recidivato https   t co cecckgdubf
1247,julie lakeview,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co mtuzjwqjwu https   t co s xedoyzod
1248,tecnomedicina,nuovi dati di fase ii indicano che un regime combinato di truxima  lenalidomide e acalabrutinib pu  essere ben tollerato ed efficace nella terapia del linfoma a cellule b aggressivo refrattario recidivato https   t co meuqybcjxw
1249,zc,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co  mogtmhzeq https   t co zxpwfygdph
1250,swedish biotech,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co iukyp gfsx https   t co jyky yipde
1251,investor news,new phase ii data indicate regimen of truxima   lenalidomide and acalabrutinib may be well tolerated and effective in relapsed refractory aggressive b    https   t co  ohzoe k f
1252,financial carnivores,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co qqolq ttbu https   t co tygmvb i w
1253,         ,acalabrutinib                               https   t co lmnyeaa ut  carenet https   t co uaevn pjsr
1254,pharmacutical daily,new phase ii data indicate regimen of truxima   biosimilar rituximab   lenalidomide and acalabrutinib  r a  may be well tolerated and effective in relapsed refractory aggressive b cell lymphoma https   t co jpbnzqfz  
1255,crwe world,new phase ii data indicate regimen of truxima   biosimilar rituximab   lenalidomide and acalabrutinib  r a  may be  https   t co vpkrmqcqxk
1256,     ,                                           calquence                                            https   t co fpbin wzbh
1257,bw france,de nouvelles donn es de phase ii indiquent qu un traitement combinant truxima   rituximab biosimilaire   l nalidomide et acalabrutinib  r a  pourrait  tre efficace et bien tol r  par les patients atteints d un lymphome   cellules b agressif    https   t co   luwjjxcq https   t co zidu bghw 
1258,business wire dutch,nieuwe fase ii gegevens geven aan dat regime van truxima   biosimilar rituximab   lenalidomide en acalabrutinib  r a  wellicht goed wordt verdragen en effectief is bij recidief refractair agressief b cellymfoom https   t co nio  y  t  https   t co w  tj d yv
1259,business wire german,neue phase ii daten deuten auf gute vertr glichkeit und wirksamkeit des therapieschemas mit truxima   rituximab biosimilar   lenalidomid und acalabrutinib  r a  bei rezidivierten refrakt ren aggressiven b zell lymphomen hin https   t co  vvkaqyosb https   t co jkdgyd  su
1260,businesswire spanish,los nuevos datos de fase ii indican que el r gimen de truxima   biosimilar de rituximab   lenalidomida y acalabrutinib  r a  puede ser bien tolerado y efectivo en el linfoma de c lulas b agresivo recidivante refractario https   t co ygj cid ee https   t co hts  pxfdj
1261,latest news from business wire,new phase ii data indicate regimen of truxima   biosimilar rituximab   lenalidomide and acalabrutinib  r a  may be well tolerated and effective in relapsed refractory aggressive b cell lymphoma https   t co f rucdjthd https   t co idllgv tul
1262,businesswire italian,nuovi dati di fase ii indicano che un regime combinato di truxima   rituximab biosimilare   lenalidomide e acalabrutinib  r a  pu  essere ben tollerato ed efficace nella terapia del linfoma a cellule b aggressivo refrattario recidivato https   t co w sq dby k https   t co  rftdtdzgg
1263,antonio guerrero,la  tormenta de citoquinas  de la covid     podr a ser calmada  con acalabrutinib seg n publicaci n en sciece  de un estudio observacional con    pacientes  pero se precisa un ensayo cl nico aleatorizado prospectivo  para establecer su posible papel terap utico  coronavirus https   t co hhijak iip
1264,        ,     acalabrutinib                                                                                                                     https   t co b h v fgym
1265,jorge duque,https   t co jvgnabcqxz
1266,haberdar,kanser ilac  acalabrutinib  a  r covid    vakalar nda potansiyel bir tedavi stratejisi olabilir  https   t co iewipcmyu  https   t co gaepkloulb
1267,birg n gazetesi,kanser ilac  acalabrutinib  a  r covid    vakalar nda potansiyel bir tedavi stratejisi olabilir https   t co otsclau uu https   t co yhmmznxchj
1268,hikmet ge kil  ,did u say majority     sciimmunology  acalabrutinib  a selective btk inhibitor  was administered off label to    patients hospitalized with severe covid     over a       day treatment course  acalabrutinib improved oxygenation in a majority of patients     https   t co kinsbs hwh
1269,randall brenneman, these patients get in trouble because their house is on fire in their lungs   dr  staudt said   this drug  acalabrutinib can put out this inflammatory fire by disabling macrophages    covid    talkingheads https   t co hweujgqskd
1270,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co pjfvxmmizb
1271,medicina e informazione,leucemia linfatica cronica  dimostrata l efficacia e la tollerabilit  a lungo termine di acalabrutinib i risultati di due studi presentati al     congresso eha  european hematology association   https   t co r kxhvzc   https   t co  icyzjsfzz
1272,haberdar,kanser ilac  acalabrutinib  a  r covid    vakalar nda potansiyel bir tedavi stratejisi olabilir  https   t co iewipcmyu  https   t co wepezsbrco
1273,angelo piemontese,leucemia linfatica cronica  dimostrata affidabilit  e tollerabilit  di acalabrutinib https   t co ools ufwoi
1274,meedo,at end of an off label observational study on  acalabrutinib as a covid   immunomodulatory treatment    out of    supplemental oxygen patients were breathing room air  amp    out of   mechanical ventilation patients were extubated w    of   breathing room air  https   t co   tjom wov
1275,birg n gazetesi,kanser ilac  acalabrutinib  a  r covid    vakalar nda potansiyel bir tedavi stratejisi olabilir https   t co prdgyooutz https   t co  qitfnf ae
1276,    ,jco  ascend  phase iii  randomized trial of acalabrutinib vs idelalisib rituximab or bendamustine rituximab in relapsed or refractory cll https   t co qnyqkpsqpz  btk  pi k  syk  bcl                      
1277,lymphoma   myeloma connect,final results from ascend are available  presented by dr  paolo ghia at  eha  virtual    lymsm  oncology  https   t co d api pqae
1278,andreas sofroniou,early data from a clinical study suggest that blocking the bruton tyrosine kinase  btk  protein provided clinical benefit to a small group of patients with severe covid     https   t co o qqpn ajn
1279,stephen richards,from https   t co s  o krpx  and https   t co  fexholqvk  is calquence the cause of the covid    outbreak  celebrating inclusion and diversity during lgbtqa pride month https   t co rwpaazw vz
1280,policenama,coronavirus                                                                                           coronavirus  bloodcancer  policenama  policenama  https   t co vwrnet dcv
1281,    ,the lancet  acalabrutinib w  or w o obinutuzumab vs chlorambucil and obinutuzmab for treatment naive cll  elevate tn   a randomised  controlled  phase   trial https   t co g qayogxeq                                                 
1282,hamid mazloomi,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients   biospace https   t co v k  cvpkx  jobs
1283,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co  jq wr n d
1284,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co q  udrka a
1285,virginslayerincelius,sciencemagazine  a new off label observational study suggests that the fda approved drug acalabrutinib  already used to treat several b cell cancers  may help calm the hyperinflammatory  cytokinestorm immune response associated with severe cases of  covi  https   t co lli c erq 
1286,science magazine,a new off label observational study suggests that the fda approved drug acalabrutinib  already used to treat several b cell cancers  may help calm the hyperinflammatory  cytokinestorm immune response associated with severe cases of  covid    https   t co shfblo hib https   t co  kkx qkqb 
1287,karan, han dicho acalabrutinib en lasexta noche   covid     
1288,toby eyre, acalabrutinib in  l  cll  phase ii trial n      m median fup    d c to date    aes    spm    infection     pd tox profile      g  htn  early headache orr     cr      m dor       m efs      interesting to see non trial data here uk eams scheme in time   eha  virtual  cll  lymsm https   t co nuyudeokda
1289,pat salber  md  mba,a small study of seriously ill covid    patients administered acalabrutinib  a btk inhibitor and repurposed lymphoma drug  showed very promising results  covid    infectiousdisease  pharmacyandpharmacology  researchanddevelopment https   t co dqdburqru  https   t co ovrzecw tc
1290,stephanie,btk inhibitor acalabrutinib  inhibition of bruton tyrosine kinase in patients with severe covid    https   t co yrkk dhkrd
1291,ruth ann crystal  md,coronavirus can set off a  cytokine storm   these drugs may calm it  https   t co njdtvkmwci    tocilizumab  actemra  blocks il     remdesivir   acalabrutinib  calquence  is a btk inhibitor   cytosorb blood filter used in europe and others https   t co  g cwlvb o
1292,cambio  ,en ee  uu  dieron con un f rmaco capaz de vencer las formas m s graves de la  covid    el hallazgo se produjo gracias al descubrimiento de la prote na que podr a ser clave en la reacci n hiperinflamatoria que produce la enfermedad  la prote na btk  https   t co k ebbbp gl https   t co  smvafaljv
1293,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co bhhxwshxl 
1294,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co mgk opllqi
1295, stoncology, calquence showed long term efficacy and tolerability for patients with  chroniclymphocyticleukaemia in two trials  azn  eha   https   t co upp pxk tz
1296,cuaderno de ciencia,proponen al f rmaco acalabrutinib para frenar la respuesta inmune hiperinflamatoria mediada por citoquinas que se produce en pacientes graves de  covid    https   t co xhphbxxfoi
1297,benlazar s m amin ,acalabrutinib   g un  cll  eha     https   t co qdg eqg n 
1298,marcela saeblima,acalabrutinib  new drug for covid   hyperinflammatory immune response   don t start buying it for yourselves please  https   t co ewimz  loh
1299,graniteshares europe, azn calquence showed long term efficacy and tolerability for patients with chronic lymphocytic  leukaemia in two trials  astrazeneca  oncology  singlestocketps  https   t co fry jxmcfv
1300,smart industry news,detailed results from the phase ii ace cl     trial and the pivotal phase iii ascend trial showed the long term efficacy and tolerability of  calquence in chronic lymphocytic  leukaemia   astrazeneca   chronicdiseases   astrazeneca   https   t co grvzcw qtf
1301,ahealthierphilly,within three days of starting the cancer drug  most of the patients on supplemental oxygen experienced a large drop in inflammation and improved breathing  https   t co iv  cdheri
1302,virginslayerincelius,sciencemagazine  a new off label observational study suggests that the fda approved drug acalabrutinib  already used to treat several b cell cancers  may help calm the hyperinflammatory  cytokinestorm immune response associated with severe cases of  covi  https   t co yr  qfr m 
1303,alejandro sifuentes,https   t co  scgbxltba
1304,science magazine,a new off label observational study suggests that the fda approved drug acalabrutinib  already used to treat several b cell cancers  may help calm the hyperinflammatory  cytokinestorm immune response associated with severe cases of  covid    https   t co d k yu e j https   t co   mxsootie
1305,cambio  ,estados unidos dio con un f rmaco que vence las formas m s graves de la  covid    el hallazgo se produjo gracias al descubrimiento de la prote na que podr a ser clave en la reacci n hiperinflamatoria que produce la enfermedad  la prote na btk  https   t co k ebbbp gl https   t co b hyh pqjd
1306,i am biotech,  forbes   astrazeneca cancer drug showed  improvement  in small group of hospitalized  covid   patients  https   t co kx nimln q
1307, id science,acalabrutinib como medicamento para tratar la hiperinflamaci n en pacientes covid    https   t co yq umejaon https   t co   q zqk x 
1308,ph,https   t co wgwizmzceu
1309,acfc,acalabrutinib como medicamento para tratar la hiperinflamaci n en pacientes covid    https   t co iyfhjqcwuq https   t co vzgt qmm  
1310,dar o hiven,se encuentra una prote na letal btk en el coronavirus y su posible f rmaco acalabrutinib  https   t co ibx d   bw a trav s de  economiaed 
1311,yerson gutierrez ch ,parece que ya no se necesitan las vacunas contra covid     nuevo estudio en ee uu  muestran que el acalabrutinib  medicamento contra el c ncer mata al virus  incluso estando en uci te recuperas 
1312,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co clkecpclgy
1313,muzaffar qazilbash,coronavirus can set off a  cytokine storm   these drugs may calm it   tocilizumab   anakinra  acalabrutinib   covid    coronavirus https   t co  goxn vky 
1314,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co  nbd nhzui
1315,australianprescriber,new drug  https   t co r dzg rzr 
1316,wcm lymphoma,dr  richard furman details  asco    research showing acalabrutinib to be very well tolerated in treatment of a wide range of b cell malignancies  including chronic lymphocytic  leukemia   cll   amp   waldenstroms  via  oncologytimes  https   t co zpwxa qacp
1317,lpd,leucemia  terapia con acalabrutinib efficace e tollerata https   t co u  nnmv fs
1318,safh, inhibition of bruton tyrosine kinase in patients with severe covid      science immunology   acalabrutinib  https   t co qihgd ebmg https   t co hwcslllnh 
1319,diario hoy,    coronavirus    pruebanf rmaco    coronavirus   probaron un f rmaco usado contra el c ncer  se trata del acalabrutinib   https   t co c  wrv dyj v a  diariohoynet https   t co gj ikwzqds
1320,mpr,start your weekend by getting all the latest covid   news in   minutes  this week s pod   antibody test accuracy   treatments in children   potential benefit of acalabrutinib   the who walk back comments  and  many states lodge record hospitalizations https   t co f opvslflu
1321,tap clinical trial network, stellar update  patient recruitment to cohort   of stellar continued today  allowing access to  acalabrutinib monotherapy  tc bec says   thanks to research nurses sian and jess  pi dr fox and the rest of the research team for your continued work on the trial     drchrispfox
1322,stray,coronavirus can set off a  cytokine storm   these drugs may calm it    the cancer drug calquence  made by astrazeneca and also called acalabrutinib  can cut off the cytokine supply at its source   https   t co nktuvwcaws
1323,al  ciudadano,encontraron f rmaco que vence las formas m s graves de la covid    https   t co vx  cqdrlm
1324,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co axp uyoqdd
1325,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co dxtznlcxmu
1326,healthday news,healthday reports  acalabrutinib promising for treatment of severe covid     coronavirus https   t co d doq md j
1327,nasdaq, azn astrazeneca calquence showed long term efficacy  amp  tolerability for patients with chronic lymphocytic leukaemia in two trials  ace cl     trial showed an overall response rate of     with a sustained safety profile for previously untreated patients after more than four years
1328,europawire,in pivotal ascend trial      of patients with relapsed or refractory disease treated with calquence remained progression free at    months vs      for comparators https   t co  g mitybtq  leukaemia  calquence  acalabrutinib  eha  virtual https   t co rqksnijnnb
1329,europawire,ace cl     trial showed an overall response rate of     with a sustained safety profile for previously untreated patients after more than four years https   t co  g mitybtq  leukaemia  calquence  acalabrutinib  eha  virtual
1330,europawire,detailed results from both the phase ii ace cl     and the pivotal phase iii ascend trials showed long term efficacy  amp  tolerability of  calquence   acalabrutinib  in chronic lymphocytic  leukaemia  they will be presented during the  eha  virtual https   t co  g mitybtq https   t co a eovtegy 
1331,cerca soluzioni cruciverba,leucemia linfatica cronica  dimostrata l efficacia e la tollerabilit  a lungo termine di acalabrutinib     leucemia  linfatica  cronica   https   t co recfnbzzup
1332,matt willemsen,btk inhibitor acalabrutinib shows early promise for covid        within   to   days after receiving acalabrutinib  most patients in the supplemental oxygen group had a steep drop in inflammation and breathing improved  https   t co tlz ljbkyc
1333,sociedad qu mica de panam ,un estudio  con    pacientes con covid    que requirieron hospitalizaci n por bajos niveles de ox geno y un cuadro de inflamaci n  demostr  que el medicamento acalabrutinib es ben fico sobre todo si se administra al inicio de la tormenta de citoquinas   https   t co abavcd  zb
1334,life science sweden,resultat fr n tv  nya studier pekar p  att l ngtidseffekten  r mycket god vid behandling med calquence till patienter med kronisk lymfatisk leukemi    leukemi  astrazeneca  lifesciencesweden  pharma https   t co bwxloucjrc
1335,medinews,nello studio ace cl     acalabrutinib dimostra un tasso di risposta globale del     e un profilo di sicurezza prolungato nel trattamento di  pazienti con  leucemia linfatica cronica non pretrattati   oncology            https   t co h qbfp   e https   t co rlkajrj gc
1336,ritrattodellasalute,acalabrutinib   efficace e tollerato a lungo termine nel trattamento della  leucemia linfatica cronica  llc   la forma pi  comune di leucemia dell adulto  salute https   t co wq  okd rl
1337,company news hq,calquence showed long term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials https   t co liln rbm m
1338,luis m ruiz,tras los  xitos en nuestras salas de tocilizumab   lopinavir  rendesivir  hidroxicloro y dem s vedettes   llega a muestras pantallas la nueva promesa de nombre impronunciable    acalabrutinib   
1339,ana l pez,acalabrutinib en covid    https   t co o g mznl b
1340,al  ciudadano,encuentran prote na clave que causa la inflamaci n mortal del coronavirus https   t co luzkhdpmgy
1341,freddy pizart  r n ,medscape  btk inhibitor acalabrutinib may improve outcomes quickly in severe covid     a case study of    patients suggests  https   t co d jeho     https   t co parrzhymy 
1342,cambio  ,en ee  uu  dieron con un f rmaco capaz de vencer las formas m s graves de la covid     podr a ser clave en la reacci n hiperinflamatoria que produce el virus  la prote na btk  el descubrimiento da esperanza en la consecuci n de un tratamiento  https   t co k ebbbp gl https   t co bt umaavsb
1343,cision news,calquence showed long term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials https   t co qwnimfnz i
1344,daniel lopez,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co yrikwxjqfs
1345,voz entrerriana,patients with severe covid    have a hyperinflammatory immune response suggestive of macrophage activation   bruton tyrosine kinase  btk  regulates macrophage signaling and activation  acalabrutinib selective btk inhibitor  traduc   https   t co ffwzyzba b https   t co zdu k zosw
1346,himanshu singh,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co xnlofj yg 
1347,function  st,these drugs  amp  devices that purify blood are being tested to fight covid induced cytokine storm https   t co d   nh xtt scientists identified cancer drug calquence  acalabrutinib  can cut off cytokine supply at its source  icmrdelhi  csir ind  csiriict  mohfw india  drharshvardhan
1348,memeo,parece que ya no se necesitan las vacunas contra covid    nuevo estudio en ee uu  muestran que el acalabrutinib  medicamento contra el c ncer mata al virus  incluso estando en uci te recuperas
1349,aldo sol s  ,una esperanza para los pacientes de coronavirus en estado cr tico  probaron con  xito el acalabrutinib un f rmaco ya existente  https   t co hhjk bhszn
1350,radio chaparrastique       fm, estadosunidos     investigadores observaron que el uso del medicamento  acalabrutinib  un f rmaco usado en el tratamiento de varios tipos de c ncer de sangre  proporcion  beneficios cl nicos en los pacientes cr ticos por  covid    https   t co kscxw pcnq
1351,carlos arturo  lvarez moreno,el acalabrutinib  inhibidor de la tirosina quinasa de bruton  btk   podria ser  til en el tratamiento de casos severos de  covid     sciencemagazine publica estudio de mejor a con su administraci n en    pacientes  ahora toca hacer un ensayo clinico https   t co ycri  aajg https   t co kxkuudy h 
1352,felix a ,leyendo sobre la inflamacion provocada por el covid haran estudios con pacientes de paises mas afectados y no aparece panam   triste    con un medicamento q bloquea la prote na btk llamado acalabrutinib  y aqu  x q no  supongo q la oms no ha aprobado tal cosa  susalaaabaaoo
1353,fausto hiraldo zabal,astrazeneca to start calquence in covid    trial https   t co mqp boc f  via  mailonline
1354,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co ap d mrv c
1355,mercy durango,exciting news from dr   monticelli  medical oncologist with rocky mountain cancer centers at penrose   amp  dr   roshon  chief of medical staff for penrose st  francis  who are helping pioneer the use of calquence  a cancer drug  to benefit covid    patients  https   t co tvzlyblnle https   t co    h  tkjz
1356,barricada azul, acalabrutinib un f rmaco de astrazeneca que trata la inflamaci n en pacientes de cancer se ha probado efectivo en pacientes de covid con neumonia   hallada la prote na clave que causa una inflamaci n mortal en la covid    barricadanews via  lavanguardia  https   t co shkoc pezs
1357,daniel murriel,hidroxicloroquina  ivermectina  remdesivir  etc y ahora el acalabrutinib aparecen en escena pero el numero de muertos se incrementa dia a dia    https   t co hmk  hj n 
1358,latina pe,  el acalabrutinib fue probado en casos de covid    y logr  combatir con  xito a la enfermedad en estados avanzados    https   t co f vvutonhi
1359,enrique l pez        c    covidserespira covid ,encontraron f rmaco que vence las formas m s graves de la  covid   https   t co ucgal lq w
1360,wenachile,encuentran prote na clave que causa la inflamaci n mortal del coronavirus https   t co u z  m j n    covid  
1361,vasyl pawlowsky,evan kirstel  remotework on twitter   i knew coke was good for u   amp gt   doctors are mixing a new drug with coca cola to help cure  coronavirus patients   irmaraste  https   t co oympdvmcsm    twitter https   t co j  rikxeyj
1362,medscape pharmacists,btk inhibitor acalabrutinib may improve outcomes quickly in severe  covid     a case study of    patients suggests  https   t co nxo gs th 
1363,miguel angel grullon c ,estudio cl nico se ala acalabrutinib  medicamento para combatir el c ncer  inhibe reacci n inflamatoria descontrolada y mejora niveles de oxigenaci n en pacientes con covid    grave    inhibition of bruton tyrosine kinase in patients with severe covid    https   t co or q furrp
1364,apunte digital,prueban con  xito el acalabrutinib para pacientes con coronavirus en estado grave https   t co drkm exnmv
1365,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito f rmaco acalabrutinib https   t co  glefgrc  
1366,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito un f rmaco acalabrutinib https   t co  ur ykhghj
1367,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito un f rmaco acalabrutinib https   t co evo wth hg
1368,victoria mendoza,encuentran prote na clave que causa la inflamaci n mortal del coronavirus https   t co  jecdoezgv  news suite https   t co rzsbjf i h
1369,leon    ,si se salva alguna vida    bienvenida sea this news      aun hoy    sigo creyendo en la comunidad cientifica medica    no all is money      waiting good news   of the  acalabrutinib  este    y no sea otro fake para amasar money    https   t co jgkxqdcskh
1370,arabmedical pro,acalabrutinib            covid                         https   t co ars fqsv k https   t co tcxwyxrqe 
1371,victoria recche,acalabrutinib  regacarlos
1372,john damianos  m d ,a case study of    patients suggests that btk inhibitor  acalabrutinib may rapidly improve outcomes in severe  covid      medicine  science  coronavirus  pandemic  publichealth   https   t co moa gaysqj
1373,ahmet duran, acalabrutinib ald ktan sonraki   ila   g n i inde  tamamlay c  oksijen grubundaki hastalar n  o unda iltihaplanmada belirgin bir d     vard  ve nefes almada d zelme oldu   https   t co a   vzechv
1374,leon    ,  acalabrutinib    waiting good news      i believe  https   t co hmeynevwhw
1375,medscape,btk inhibitor acalabrutinib may improve outcomes quickly in severe covid     a case study of    patients suggests  https   t co rbk lnhhd 
1376,pat salber  md  mba,a small study of seriously ill covid    patients administered acalabrutinib  a btk inhibitor and repurposed lymphoma drug  showed very promising results  covid    infectiousdisease  pharmacyandpharmacology  researchanddevelopment https   t co dqdburqru  https   t co  xzrvgtlf 
1377,stray,                 calquence                    calavi      https   t co eenzbx y h
1378,el d namo,encuentran prote na clave que causa la inflamaci n mortal del coronavirus https   t co f violxecv
1379,cambio  ,m dicos en estados unidos dieron con un f rmaco capaz de combatir y vencer las formas m s graves de la  covid   covid    https   t co k ebbbp gl
1380,apunte digital,prueban con  xito el acalabrutinib para pacientes con coronavirus en estado grave https   t co  honmbuemq
1381,apunte digital,prueban con  xito el acalabrutinib para pacientes con coronavirus en estado grave https   t co rs yae le 
1382,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito un f rmaco ya existente  el acalabrutinib https   t co yb j lydxs
1383,apunte digital,prueban con  xito el acalabrutinib para pacientes con coronavirus en estado grave https   t co orpo rcwtf
1384,apunte digital,prueban con  xito el acalabrutinib para pacientes con coronavirus en estado grave https   t co dsqhvufljg
1385,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito un f rmaco ya existente  el acalabrutinib https   t co   nsd cjzg
1386,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito un f rmaco ya existente  el acalabrutinib https   t co jumcalq  p
1387,apunte digital,buena noticia para pacientes de coronavirus graves  prueban con  xito un f rmaco ya existente  el acalabrutinib https   t co a h m bhe 
1388,p gina central jujuy,el estudio fue desarrollado para probar si el bloqueo de la prote na btk con acalabrutinib reducir a la inflamaci n y mejorar a el resultado cl nico para pacientes hospitalizados con covid    en estado cr tico https   t co  unxbxihdq
1389,a construir  pa s ,    un medicamento que se usa actualmente para tratar pacientes con linfoma  c ncer de las c lulas sangu neas  puede ser efectivo para ayudar a los pacientes con  covid     con formas m s agudas de la enfermedad     calquence  producido por astrazeneca https   t co  vfxxjwah 
1390,el grillo de yucat n,acalabrutinib  el nuevo medicamento que  salvar a  a personas contagiadas de covid    https   t co ponugfsrvj
1391,benjam n n  ez vega,resultados inesperados  a n en experimentaci n  el producto es bienvenido   benjam n n  ez vega    le administraron acalabrutinib  un f rmaco de astrazeneca especialmente dise ado para bloquear la btk y aprobado para el tratamiento de algunos c nceres 
1392,alejandro  alex  barbagelata,cytokine storm  btk inhibitor acalabrutinib shows early promise for covid    https   t co t qpbkwtxn via  medscape
1393,daniel lopez,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co qrj qjft i
1394,manuel muro,acalabrutinib  f rmaco para bloquear la btk  tirosina kinasa de bruton  y aprobado para el tratamiento de algunos c nceres  y aplicado a    pacientes covid   con buenos resultados en   de ellos  disminuyendo la tormenta de citoquinas ocasionada  https   t co z  vtzch  
1395,radio mambi      ,una esperanza para los pacientes de coronavirus en estado cr tico  probaron con  xito un f rmaco ya existenteel uso del acalabrutinib  usado contra el c ncer  logr  combatir con  xito a la enfermedad en estados avanzados   noticias   
1396, scar peraza, eeuu   investigadores observaron que el uso del medicamento  acalabrutinib   un f rmaco usado en el tratamiento de varios tipos de c ncer de sangre  proporcion  beneficios cl nicos en los pacientes cr ticos por  covid    https   t co zxw  nvu b
1397,opr, eeuu   investigadores observaron que el uso del medicamento  acalabrutinib   un f rmaco usado en el tratamiento de varios tipos de c ncer de sangre  proporcion  beneficios cl nicos en los pacientes cr ticos por  covid    https   t co xikpnqrlpg
1398,itr noticias   oficial, eeuu   investigadores observaron que el uso del medicamento  acalabrutinib   un f rmaco usado en el tratamiento de varios tipos de c ncer de sangre  proporcion  beneficios cl nicos en los pacientes cr ticos por  covid    https   t co reb kixyd 
1399,noticias  visi n, estadosunidos     investigadores observaron que el uso del medicamento  acalabrutinib  un f rmaco usado en el tratamiento de varios tipos de c ncer de sangre  proporcion  beneficios cl nicos en los pacientes cr ticos por  covid     n v https   t co xp zwq  r 
1400,loreto noticias,el uso del acalabrutinib  usado contra el c ncer  logr  combatir con  xito a la enfermedad en estados avanzados  el remedio inhibe una prote na   covid     https   t co   ecqqowwj
1401,patricio s nchez  , una esperanza para los pacientes de coronavirus en estado cr tico  probaron con  xito un f rmaco ya existente    infobae  acalabrutinib https   t co  oighzvt  
1402,rock pop     ,la compa  a que administra acalabrutinib  iniciar  ensayos cl nicos en personas de algunos de los pa ses m s afectados por la epidemia  entre ellos  chile    qu dateencasa  qu dateenradio https   t co  rbrstzwga
1403,pawel,f rmaco acalabrutinib https   t co   cqkobefq
1404,gupta gastro,if your favorite soft drink also doubles as a chemical solvent   well  that s a little disconcerting  nevertheless  check out these promising preliminary findings with the use of  calquence in critical  covid   patients  https   t co ed aprtd s
1405,m et,hola  pablofuente  he le do una noticia referente a este medicamento acalabrutinib  no se si lo has comentado o sabes algo  gracias y un saludo 
1406,cate shanahan  md,i predict acalabrutinib will actually work  it reduces inflammation by combatting pufa induced oxidation  article  btk inhibitor acalabrutinib shows early promise for covid    https   t co  mctdgjrox via  medscape  drdrew  draseemmalhotra
1407,karlos  wear a fucking mask ,acalabrutinib    
1408,tweets,                  calquence              https   t co jmpryzsfd                                                                    
1409,pedro vall n,acalabrutinib  aprended ese nombre por si acaso   josepcorbella https   t co e us tduhi
1410,linda dudek    ,doctors are mixing a new drug with coca cola to help cure coronavirus patients  smartnews  https   t co wktvjo  be
1411,newsrelea se,                             calquence                                           https   t co ffellz ws 
1412,jos  manuel bautista,el f rmaco acalabrutinib  un inhibidor que controla la inflamaci n  mejora la oxigenaci n en la mayor a de los pacientes de covid     a menudo en un plazo de   a   d as sin toxicidad perceptible   https   t co wqj w  gss
1413,maria da gloria,cancer drug acalabrutinib shows potential for covid    patients in respiratory distress   phillyvoice https   t co qa hnddd f
1414, recortes salvajes,calquence   acalabrutinib   un f rmaco anticanceroso de  astrazeneca especialmente dise ado para bloquear la  proteinabtk  interruptor central que regula toda la tormenta de citoquinas que provoca el coronavirus  https   t co z pddwregp https   t co aiww  rr e https   t co ueds u ah  https   t co k qhr faf 
1415,natsume             ,                      calquence                                                    covid   https   t co sbjhkydvls
1416,david garc a marco,acalabrutinib en covid https   t co xvmg a xgi
1417,gorka orive,el acalabrutinib  un inhibidor de la enzima tirosina quinasa de bruton  en    pacientes con covid   grave mejora su capacidad de oxigenaci n y reduce la inflamaci n  sin mostrar efectos t xicos   a ado en un hilo un plus de info   https   t co rntusffsky https   t co rdl upszv 
1418,joan carles contel,hallada la prote na clave que causa una inflamaci n mortal en  covid   y primeros resultados con acalabrutinib para luchar contra la tormenta de citoquinas https   t co  mvbf  q y
1419,        ,                       calquence                                                                                                       https   t co ztegylbvru
1420,pr times    ,                 calquence                                     https   t co qum ludw i
1421,aamaldives,doctors are mixing a new drug with coca cola to help cure  coronavirus patients   bgr  covid    https   t co iphxroxq e
1422,pr times    ,                 calquence                                     https   t co ztzg hdxcd
1423,australianprescriber,https   t co r dzg rzr 
1424,saud nasser aldosery,doctors are mixing a new drug with coca cola to help cure coronavirus patients                             https   t co rkxfdbech 
1425,ceprofar   centro de profesionales farmac uticos,estudios observacionales de  acalabrutinib contra  covid   nota de  vanesalop para clar n   sociedad con la opini n de  ceprofar   https   t co agx uacevn
1426,convenience store news ,credit  chris writes doctors are mixing a new drug with  cocacola to help cure  coronavirus patients https   t co ea  vbu sh    beverages https   t co  c q ds en
1427,marc kaufman md ms  ,early data show potential benefit of acalabrutinib in severe covid    https   t co kctf wtitc
1428,aaa,wow  calquence from   astrazeneca   good old classic   cocacola  to treat mild to moderate   non intubated covid     ok  i wonder if   pepsi works too     bgr   doctors are mixing a new drug with coca cola to help cure coronavirus patients   https   t co lxxqw lhw 
1429,evan kirstel  b b,i knew coke was good for u   gt   doctors are mixing a new drug with coca cola to help cure  coronavirus patients   irmaraste   https   t co wtvbsee  g
1430,healthit and biotech,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co   xbeo tne https   t co ww mlv sxr
1431,truth studio,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co lypxw o j  https   t co  hamklywky
1432,teresa masia perales,btk inhibitor acalabrutinib shows early promise for covid    https   t co  e   vrozv via  medscape
1433,mysmallcap,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co yrceskpbk  https   t co grx iiwmmz
1434,barbara lazarus,doctors are mixing a new drug with coca cola to help cure coronavirus patients   bgr https   t co  eepu kmzl
1435,duarte  ,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co hmxkjqftwr
1436,bernard a fox,just heard dr  lstaudtm  thenci  nihclinicalcntr present data on off label use  btk inhib  acalabrutinib for  sarscov   covid    great story  amazing oxygen response with impact on cytokines crp  amp  lymphocyte count   baselga   astrazeneca  roschewskimd  wilsonwyndham  ncidirector https   t co foy lifykg
1437,jt badenov,doctors are mixing calquence with coca cola to help cure coronavirus patients  it s awesome  unless trump recommends it   https   t co fpliyx bt 
1438,denise, https   t co   q ma w  
1439,sharon k  gilbert,also  not a parody article  honest   doctors are mixing a new drug with coca cola to help cure coronavirus patients   bgr https   t co va pmwdrgc
1440,geekinfonow,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co  kxpdek r 
1441,benyam muluneh,acalabrutinib in r r cll  keep in mind these patients were btki naive  https   t co npyznddwey
1442,onclive com,dr  nicole lamanna  columbiacancer   awandoc  utswnews  dr  jan burger  mdandersonnews   richardfurmanmd  nyphospital  dr  javier a  pinilla ibarz   moffittnews  discusses the ascend acalabrutinib trial in r r cll  learn more  https   t co w vztawmam  lymsm https   t co xeh qtub  
1443,chris smith,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co  emoq   b  https   t co  yqgiz  nx
1444,news actualizadas,doctors are mixing a new drug with coca cola to help cure coronavirus patients  https   t co xriechdmah
1445,bgr com,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co piqcmhjg   https   t co dy a neyov
1446,noah swint,doctors are mixing a new drug with coca cola to help cure coronavirus patients https   t co  fck rccku
1447,asco publications,acalabrutinib versus investigator s choice therapy in chronic lymphocytic leukemia   the ascend trial https   t co fftj  dzxq  cll  leusm  jco https   t co vt tjgml t
1448,  wrex,possible treatment  calquence has sown promise for treating patients with covid     but more research needs to be done on the drug used to treat blood cancer  https   t co xmimye az 
1449,univadis es,el f rmaco acalabrutinib  aprobado por la  fda para el tratamiento de varios tipos de c ncer de linfocitos b  mejor  los niveles de oxigenaci n y disminuy  los marcadores moleculares de inflamaci n en la mayor parte de una muestra de    pacientes      https   t co   mw qhedf https   t co  mclbszgy 
1450,sweta entomon     staysafe   ,btk inhibitor acalabrutinib shows early promise for covid      modifiedvikas   https   t co aik gkkpu  via  medscape
1451,theriaque officiel,l anticanc reux  acalabrutinib semble d int r t dans le  covid    s v re  donn es non randomis es  inhibiteur de tyrosine kinase de bruton  btk  science immunology https   t co tjwycvwi  
1452,diario de chiapas,       se trata del  medicamento calquence  aprobado para tratar el linfoma y que pertenece a una  clase conocida como inhibidores de btk      comenta y rt   https   t co  yi c nklj  https   t co fwnzo gtxq
1453,syrian is not white,btk inhibitor acalabrutinib shows early promise for covid     https   t co aa t z klo
1454,atoxquiteran,astrazeneca s calquence shows promising clinical improvement in covid    patients https   t co   u yu omx
1455,erwin loh, calquence   acalabrutinib   a bruton s tyrosine kinase   btk  inhibitor  reduced markers of  inflammation and improved clinical outcomes of  coronavirus patients with severe  covid   disease  finds a new study in  science  immunology    june         link https   t co xq  k tcje
1456,carlos f  camargo  ph d    dre          ,btk inhibitor acalabrutinib shows early promise for covid    https   t co  y h gbejc
1457,josh marshall,btk inhibitor acalabrutinib shows early promise for covid    https   t co tdreh y bj via  medscape
1458,crwe world,acalabrutinib showcases long term tolerability across b cell malignancies https   t co  cna u rrh
1459,mundo sano,se trata del medicamento calquence  aprobado para tratar el linfoma y que pertenece a una clase conocida como inhibidores de btk   https   t co gdtysoxdrd
1460,biociencia,btk inhibitor acalabrutinib shows early promise for covid    https   t co ne rogqhge a trav s de  medscape
1461,ahealthierphilly,acalabrutinib  a drug approved to treat blood cancers  successfully reduced respiratory distress and inflammation in a small group of patients  according to a study led by the national cancer institute  https   t co nep  xw ux
1462,para,btk inhibitor acalabrutinib shows early promise for covid    https   t co ph ytubc x
1463,onclive com,acalabrutinib showcases long term tolerability across b cell malignancies  richardfurmanmd  weillcornell  nyphospital https   t co sp unlsq p
1464,andy vermaut,btk inhibitor acalabrutinib shows early promise for covid    https   t co tgcchy smt https   t co mkal fwsfq
1465,ann marie,https   t co cjwjoayupq
1466,colorado headlines,research finds cancer drug may benefit advanced covid    patients https   t co rycqkezrib  more news https   t co r  lrrq gg  rapid improvements have been seen in acutely ill patients with covid    treated with the cancer drug acalabrutinib  calquence   https   t co  eoeyhbwcl
1467,oncology nursing news,long term data presented at  asco   demonstrated that acalabrutinib  calquence  is safe and effective in patients with treatment na ve chronic lymphocytic leukemia  https   t co znba t g i
1468,vanessa k abrahamson,rapid improvements have been seen in acutely ill patients with covid    treated with the cancer drug acalabrutinib  calquence  by researchers  including physicians within the us oncology network  the network   results of the exploratory research  which w  https   t co hulryix ga
1469,immuno oncology,acalabrutinib showcases long term tolerability across b cell malignancies https   t co afqdwkryo 
1470,psbr,early data from a clinical study suggest that blocking the bruton tyrosine kinase  btk  protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe  covid      medicalresearch https   t co ayzngvcg y
1471,pat salber  md  mba,a small study of seriously ill covid    patients administered acalabrutinib  a btk inhibitor and repurposed lymphoma drug  showed very promising results  covid    infectiousdisease  pharmacyandpharmacology  researchanddevelopment https   t co dqdburqru  https   t co aazbhqprck
1472,ecare vault  inc , calquence showed promising clinical improvement in majority of    hospitalized  covid   patients   https   t co t wu jbbj  mednews https   t co eysytuhg b
1473,pierre b zier,l acalabrutinib serait b n fique pour les patients gravement atteints   un m dicament contre le cancer pour aider des malades de la covid   jdq   https   t co   tzbubmij
1474,cancernetwork   home of the journal oncology ,a recent study  sparking further trials for investigation  saw improved clinical outcomes and reduced markers of inflammation for patients with severe covid    after treatment with acalabrutinib  a selective btk inhibitor  https   t co jxkxxsprdl https   t co hsyg fe mm
1475,epidemiology publishers feed,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients  epidemiology  medtwitter  https   t co iqcs gjbrg
1476,pharmacy now ,astrazeneca s calquence shows promise in hospitalized covid    patients  https   t co tutzcgbfcg
1477,london strategy ,astrazeneca says new analysis shows that its bruton s tyrosine kinase  btk  inhibitor calquence  acalabrutinib  cut markers of inflammation and improved clinical outcomes of patients with severe covid    disease   astrazeneca  covi https   t co  kgzuughe  https   t co oc obs xrg
1478,the pmi  pharmaceutical managers  institute , marketwatch   astrazeneca s  calquence shows promise for covid       improved markers of inflammation and reduced oxygen requirements were seen in most patients  astrazeneca  pharmatimes https   t co qjf se nuz   covid    covid  vaccine  vaccines https   t co xhb a  mec
1479,health evangelists,acalabrutinib blocks the bruton tyrosine kinase  btk  protein and is approved to treat some blood cancers   interesting  let us know in the comments    kawasaki https   t co cv cx wfzy
1480,         ,             jco                   acalabrutinib         https   t co azvayvpfwn
1481,daily coronavirus news    , clinical improvement found after administration of acalabrutinib for  patients with covid      social reach  low https   t co zr khe  ba
1482,phillyvoice,cancer drug shows potential for covid    patients in respiratory distress https   t co ffkiprmvv 
1483,around the globe news,a recent study done on the drug showed that  acalabrutinib can prove to be beneficial for  covid  patients  the study is being done on a preliminary basis and the drug has not been approved as a treatment for covid    patients yet  https   t co  bio t pnr
1484,around the globe news,amid the search for a  covid  vaccine  doctors have been repurposing various drugs to give symptomatic relief to the patients  among them is a cancer drug acalabrutinib  commercially available as calquence   by a british swedish pharmaceutical company   astrazeneca  https   t co s dp darya
1485,phil from montreal,le rem de scrabble du jour   acalabrutinib  elle d sactive la tyrosine kinase de bruton  btk  qui fait des siennes avec la cytokine   j esp re qu il vous reste des lettres  mathbernier  lussid https   t co  wgdllqr o
1486,sitaravammaputrsamba,astrazeneca s cancer drug acalabrutinib likely to help in treating covid    patients with breathing difficulties and inflammation   firstpost https   t co cwor hjhdt
1487,plony  m d  for trump     ,https   t co dzhfyhanks
1488,dough, azn not many big pharma have impressive slate of new drugs continued strong high single  low double digit product sales growth in      driven by new launches  tagrisso  imfinzi lynparza  fasenra faxiga  calquence roxadustat best in breed big pharma imho chart all ready out dated https   t co in  dlbm p
1489,waggoner lab,acalabrutinib targets activated btk in macrophages and was associated with reduced inflammation and clinical improvement in covid     https   t co  unr fwcyw
1490,m nica, researchers observed that the off label use of the cancer drug acalabrutinib  a btk inhibitor that is approved to treat several blood cancers  was associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients  https   t co nv m  k fu
1491,redivex news,astrazeneca s calquence shows positive effect in hospitalized covid patients https   t co kbuuqqdojj  investing  stocks
1492,thiago carvalho, acalabrutinib  a selective btk inhibitor  was administered off label to    patients hospitalized with severe covid        on supplemental oxygen    on mechanical ventilation      of whom had increasing oxygen requirements at baseline   https   t co jrjcvf  e 
1493,h   news canada fr,l acalabrutinib serait b n fique pour les patients gravement atteints https   t co bz ql jvro
1494,le journal de montr al,l acalabrutinib serait b n fique pour les patients gravement atteints  https   t co   fofu yfk
1495,cancer research institute,researchers at the  nih unveil early data suggesting that blocking the bruton tyrosine kinase  btk  protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe covid      cim   https   t co d ugplnsne
1496,martin capote,favipiravir  acalabrutinib    la gente que busca tratamiento para el covid    escuch  demasiado a las ketchup  https   t co axxznibqr 
1497,giuseppe limandri,astrazeneca s calquence shows promise as  coronavirus treatment https   t co ziq vsilw 
1498,victor torres,el acalabrutinib muestra una mejora  r pida  en un peque o grupo de pacientes con covid    grave  estudio seg n los hallazgos del estudio publicados en science immunology referencia  https   t co ilqo uggel fuente  science immunology
1499,cure magazine, collectively  these results support acalabrutinib  calquence  use in upfront cll   said dr  john c  byrd  https   t co gmdxrw w y
1500,bonny wright ,btk inhibitor showing value in treatment of covid   patients  acalabrutinib   wikipedia https   t co  tqah qwyj
1501,salvadorschwartzmann,un tratamiento contra el c ncer podr a ser  til en casos severos de coronavirus  el acalabrutinib fue probado con buenos resultados en    pacientes  advierten que faltan estudios m s completos     y que es muy caro
1502,amir,acalabrutinib shows  rapid  improvement in small group of patients with severe covid     study https   t co c  e cfupk via  docguide
1503,lou,acalabrutinib shows  rapid  improvement in small group of patients with severe covid     study https   t co onjehaywwt via  docguide
1504,sandeep saluja,any  antiviral should be tried early  without even waiting for report  in later stages drugs like acalabrutinib or tocilizumab may be better for cost considerations  i would venture agents like  curcumin  andrographis or  ldn if using hydroxychloroquine do not forget zinc 
1505,peter nash,acalabrutinib shows  rapid  improvement in small group of patients with severe covid     study https   t co x gp aiugt via  docguide  btkinhibitor  covid   btk inhib fenebrutinib didnt work for sle  did for ra  but covid    
1506,pharmaceutical,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co  xkkl bvrn https   t co ksqjthyajn
1507,paul,acalabrutinib shows  rapid  improvement in small group of patients with severe covid     study https   t co ucrkefymoa via  docguide
1508,nigelj,acalabrutinib shows  rapid  improvement in small group of patients with severe covid     study https   t co wjmuqumhj  via  docguide
1509,medicalnewser com,potential cytokine storm treatment identified for severe covid    patients    treating covid    patients with respiratory distress with acalabrutinib  a bruton tyrosine kinase  btk  inhibitor reduced     https   t co dgiuwk mb  https   t co lfd  twtxl
1510,medicalnewser com,astrazeneca reports results of calquence  acalabrutinib  in calavi study for hospitalized covid    patients    shots   the calavi program involves assessing of calquence   bsc vs bsc as monothx  in patients hospitalized with     https   t co omjfeykry  https   t co lzkmxekdrt
1511,phillyvoice,acalabrutinib  a drug approved to treat blood cancers  successfully reduced respiratory distress and inflammation in a small group of patients  according to a study led by the national cancer institute https   t co uvsrcpbtee
1512,biocalifornia,astrazeneca s blood cancer drug calquence may benefit severely ill covid    patients https   t co sjgrhbyhkc https   t co iuznt dyet
1513,medihelp solutions,astrazeneca s cancer drug acalabrutinib likely to help in treating covid    patients with breathing    https   t co e pgcrd xl
1514,zenopa recruitment,study reports promising covid    results for az s calquence https   t co rwdxsq byh https   t co  mgbm kjyz
1515,david ledger,az  calquence shows promise for covid    https   t co jako syatn https   t co yrsqngti l
1516,denni    evindekal  stayhome  restaacasa,inhibition of bruton tyrosine kinase in patients with  severe  covid     acalabrutinib was administered off label to    patients hospitalized with severe covid     it improved  oxygenation in majority  amp  had no discernable  toxicity 
1517,noticias  nfasis, vidaysalud   investigaciones recientes sugieren que el tratamiento con  acalabrutinib puede ser efectivo porque su objetivo del btk  es hiperactivo en las c lulas inmunes graves  covid      conoce m s    https   t co hostl gmft
1518,ahealthierphilly,cancer drug shows potential for covid    patients in respiratory distress https   t co mljzktfgki
1519,pharmatimes,az  calquence shows promise for covid    https   t co pgfmf wpfh  pharmanews  news
1520,             ,azn                                             calquence                                                               covid                                                                                           https   t co  y tyaii s
1521,pharmastar,con acalabrutinib rapido miglioramento dei sintomi di covid grave  studio su science immunology  https   t co jmg kqkcaz https   t co mesancqgno
1522,ahealthierphilly,acalabrutinib  a drug approved to treat blood cancers  successfully reduced respiratory distress and inflammation in a small group of patients  according to a study led by the national cancer institute  https   t co iy tl vcxu
1523,global business alliance,  astrazenecaus s blood cancer drug  calquence  shows potiential in helping later stage  covid   patients  https   t co oplcu gadf via  forbes  globalconnections https   t co mvfs ou  d
1524,living safely,public health   cytokine storm   acalabrutinib assists in calming down in  covid    patients in study   ont  https   t co bgfm ujn y
1525,ecare vault  inc , az   calquence shows promise for  covid    https   t co guvjhte oi
1526,synergy healthcare  llc,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co rsmipdedrk
1527,cheryl lubbert,something hopeful to start your week off   coronavirus  treatment  covid   https   t co hszcjxayag
1528,nci media relations,media availability  early data from a clinical study led by  thenci suggest that a small number of patients with  covid   saw improvement in overactive immune response and respiratory distress after receiving acalabrutinib off label   https   t co spozcaygak  cancerresearch https   t co lqfjq wub 
1529,hashim,astrazeneca has reported positive data from a case series involving its blood cancer drug calquence  acalabrutinib  for the treatment of hospitalized patients with severe covid     data showed that the drug reduced laboratory markers of inflammation  amp  improved clinical outcomes 
1530,krishan maggon,calquence showed promising clinical improvement in majority of    hospitalised covid    patients https   t co ocoq rshoe https   t co  ecsqfwmuf
1531,meghan mott,new study of  astrazeneca cancer drug calquence  acalabrutinib  suggests it may calm the cytokine storm in severely ill patients w   covid    administered via  cocacola slurry   https   t co zh v   cd 
1532,ebd group,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients via  forbes https   t co   oxbdzefz
1533,refigure,find out how cancer drug acalabrutinib may help to treat the severe forms of  covid    from this article  https   t co zjioro pvw image cc by     https   t co gzik mwukp
1534,satokun,cytokine storm  acalabrutinib assists in calming down in  covid    patients in study https   t co tve yr yzb
1535,rvgsm,astrazeneca s cancer drug acalabrutinib likely to help in treating covid    patients with breathing difficulties and inflammation  https   t co btyqvisqyo  kiranshaw
1536,dr darren r flower, covid    repurposing  early  rct data suggests blocking bruton tyrosine kinase with  cancer  drug acalabrutinib helps patients with severe covid     improving oxygenation without apparent toxicity  https   t co gevqftvi o  coronavirus  medicine  hplovecraft  newhaven https   t co xl acsn k 
1537,david ledger,calquence showed promising clinical improvement in majority of    hospitalised covid    patients https   t co cyjnu opwe https   t co j cw ta gw
1538,amesh adalja,i think one of the lasting impacts of  covid   is going to be the realization that many immunomodulatory oncologic drugs likely have some positive impact on those with severe infectious disease syndromes  https   t co v iqfrxrls
1539,john markarian,coronavirus astra pharm  drug potential repurpose drug calquence  designed for cancer  limited study  calquence with supp  oxygen  found the most severe cases recovered        going into trial for larger study refer to forbes  amp  science immunology for articles
1540,liberalfish, researchers observed that the off label use of the cancer drug acalabrutinib  a btk inhibitor that is approved to treat several blood cancers  was associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients   https   t co cthfvyfc x
1541,cheryl amber dotson,cytokine storm  acalabrutinib assists in calming down in covid    patients in study   outbreak news today https   t co ue em w qp
1542,nnankya,treating covid    patients with respiratory distress with acalabrutinib  a bruton tyrosine kinase  btk  inhibitor reduced inflammation and improved their breathing within three days   covid  cytokinestorm  infectiousdiseases  drugd https   t co n inolpl e https   t co ejixskpazs
1543,barry curry,az  calquence shows promise for covid    https   t co rtjczqpjlh https   t co kwcadl sur
1544,    ,awesomecapital  astrazeneca s calquence shows positive effect in h    https   t co vntdridl f
1545,journal of clinical and cellular immunology,astrazeneca s  cancer drug acalabrutinib likely to help in treating  covid     patients with breathing difficulties and  inflammation https   t co euydnwgwmi
1546,                 ,astrazeneca  azn  calquence         covid                                           https   t co srofahqkwa
1547,medihelp solutions,cytokine storm  acalabrutinib assists in calming down in covid    patients in study https   t co hor fadbcy
1548,pharmashots   incisive news in   shots,astrazeneca reports results of calquence  acalabrutinib  in calavi study for hospitalized covid    patients  astrazeneca  https   t co kzgk o qhf https   t co ozxryc xbq
1549,jon angelo,astrazeneca s btk inhibitor calquence shows promise in aiding recovery of severe covid    patients   https   t co  tt j  te   pharmaceutical
1550,everything pharma,az  calquence shows promise for covid    https   t co vfx wkgdwt
1551,pharma trader,az  calquence shows promise for covid    https   t co lrhpyjdgzi
1552,investor news,astrazeneca s calquence shows positive effect in hospitalized covid patients  azn  coronavirus  covid     https   t co owju zojyu
1553,firstpost,a study showed that  acalabrutinib reduced the levels of interleukin    il    in the blood  which is otherwise responsible for creating inflammation in the bodies of  covid   patients   https   t co c uv szpib
1554,breaking news, azn   astrazeneca s calquence shows positive effect in hospitalized covid patients https   t co ugyrpiyt k
1555,sitefocus,complex event analysis on latest news                 pst  top news focus     germany troops trump    republican trump    calquence covid    drug  https   t co ak puuzcmi
1556,european pharmaceutical review,treating  covid   patients with respiratory distress with acalabrutinib  a bruton tyrosine kinase  btk  inhibitor reduced inflammation and improved their breathing within three days   clinicaltrials  inflammation  healthnews  cv   read on  https   t co rssbvzfbg  https   t co qu tz rqtm
1557, mariuskarma,forbestech  astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co  tajrjhr q
1558,pharmafocus,astrazeneca s btk inhibitor calquence shows promise in aiding recovery of severe  covid   patients https   t co y huykdaq  https   t co  b jzl nkg
1559,sharon k  gilbert,intriguing  but this is a very small study    cytokine storm  acalabrutinib assists in calming down in covid    patients in study  https   t co oshctkvcze
1560,roots analysis, researchhighlight acalabrutinib  an approved anti cancer drug  found to reduce the inflammatory responses in patients hospitalized for  covid     for details  click below  https   t co thjpkfekqr
1561,sitefocus,complex event analysis on latest news                 pst  top news focus     calquence covid    drug    calquence covid    national cancer institute    calquence covid    medical  https   t co ugwtf ncyi
1562,kfl      , der bruton kinase  btk  inhibitor acalabrutinib  der zur behandlung bestimmter lymphome entwickelt wurde  hat in einer offenen studie in science immunology den zytokinsturm bei patienten abgeschw cht  die an covid    erkrankt waren   https   t co bxm mz wvy
1563,forbes tech,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co ga uaoosob
1564,deutsches  rzteblatt,btk inhibitor zeigt klinische wirkung bei covid      bethesda   der bruton kinase  btk  inhibitor acalabrutinib  der zur behandlung bestimmter lymphome entwickelt wurde  hat in einer offenen studie in  https   t co  ttpmshbny  studie  covid    biologika  btkinhibitor https   t co gijowso  e
1565,pharmacrowd,az  calquence shows promise for covid    https   t co trz xb ley https   t co w b kfpnnp
1566,career biotech, jobs az  calquence shows promise for covid    https   t co slx  mbw d  pharmanews
1567,wind rose,  n                             calquence    acalabrutinib                                                                                                    https   t co mgqql nhzl
1568,matt willemsen,approved drug may help calm cytokine storm in covid        acalabrutinib improved the oxygenation levels and decreased molecular markers of inflammation in a majority of    covid    patients  https   t co dxt ocp y 
1569,clinicaltrialsarena,astrazeneca s calquence improves outcomes in covid    patients https   t co wxlrzu  vw https   t co  i ikwblp 
1570,sakalmedia,                                                                             https   t co  dgb  loym   bloodcancer  acalabrutinib  scienceimmunologyjournal  corona  coronavirus  coronacure  marathinews  sakal  sakalnews
1571,stray,cll                                     bloomberg   calquence                                                                                 https   t co xxnobzc jj
1572,arthur james lobo,astrazeneca s calquence improves outcomes in covid    patients https   t co reh xbcyao via  clinical trials arena
1573,journal of cancer research and immuno oncology,study identifies potential approach to treat patients with severe  covid    early data from a clinical study suggest that blocking the  bruton tyrosine kinase  btk  protein with the cancer drug  acalabrutinib provided clinical benefit to a small group of patients with covid    https   t co  dhbwbbtpr
1574,indoximity   ,ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia https   t co xrzgyqhvlg  oncology
1575,el diario ntr guadalajara,el estudio aplic  el medicamento contra el c ncer acalabrutinib a un grupo de pacientes con covid    grave  obteniendo buenos resultados https   t co vqjxi wxz 
1576,hakeem shalaby,                                                                                      acalabrutinib     mg                                                                                                                                                                          
1577,silex        ,               covid                         btk         acalabrutinib                           crp il                                       nci   https   t co exjsyhsup 
1578,nanotrac technologies,news medical approved drug could help dampen massive immune response associated with severe covid     the drug acalabrutinib  fda approved for the treatment of several types of b cell cancers  improved the oxygenation levels  https   t co zubxbflu w  cytokine via  newsmedical https   t co aqslr  efv
1579,sy investing, covid    azn data from acalabrutinib  calquence   btk inhibitor  usage in    severe patients    discharge rates             of supplemental oxygen cohort  amp            of mech vent cohort             patients on mech vents extubated   sciimmunology paper  https   t co kag efimpa https   t co go wzqr tu
1580,health evangelists,acalabrutinib blocked the protein bruton tyrosine kinase  btk  in covid    patients    blocked  bruton  protein  patient https   t co ifp nrszlu
1581,health evangelists,acalabrutinib  a btk inhibitor  is approved to treat several blood cancers  it is associated with reduced respiratory distress and a reduction in overactive immune response   what is your take  give us a comment below    btk  journal  blood https   t co gmyvfm liq
1582,laboratorio de gen tica molecular  fo  unam,https   t co ypxtsf tup
1583,nathan vardi,here is some inside color about this study https   t co bnexgifzjx https   t co sbucm y cv
1584, destroytheaadhaar    twilightofthegods,uk hospitals to trial five new drugs in search for coronavirus treatment     heparin    bemcentinib    medi        calquence    zilucoplan   mybmc  authackeray  drmuffi  cipla global medi     is also for  cytokinestorm  https   t co nql bx azb
1585,ways rock,cytokine storm  acalabrutinib assists in calming down in covid    patients in study   outbreak news today https   t co lczfr j va
1586,exbulletin,cytokine storm  acalabrutinib helps calm covid    patients under study https   t co s wshyrwu 
1587,outbreak news,cytokine storm  acalabrutinib assists in calming down in  covid    patients in study https   t co zi rmmntni
1588,nonya bidniss,approved drug acalabrutinib  an oral drug  may help calm cytokine storm in covid    patients by inhibiting an enzyme involved with macrophage activation   https   t co dpnyfeg i 
1589,arsalan ashraf,acalabrutinib may reduce  cytokine storm  in severe covid    patients  study  the drug acalabrutinib  fda approved for the treatment of several types of b cell cancers  improved the oxygenation levels and decreased molecular mar    https   t co  slsugvdqu
1590,nazish jawad,antineoplastic drug acalabrutinib may have potential as treatment of covid   with respiratory distress pending randomized controlled trial   early data on potential approach to treat severe covid    https   t co yyzgioeomb
1591,roman jerala,acalabrutinib  zdravilo  ki se uporablja za zdravljenje b celi nih limfomov je pokazalo dobre rezultate pri zdravljenju pacientov z resnim  covid    zdravilo inibira encim  ki igra pomembno vlogo pri vnetju  tako da je zmanj alo vnetje in potrebo po dodatnem kisiku za paciente  https   t co tbadnzprvc
1592,nonsell com,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients    how coronavirus impact economy  us market news   source  forbes   https   t co lbg j  fep https   t co bl mg frmo
1593,salud juntos,abordar la inflamaci n excesiva con un inhibidor de la tirosina quinasa de bruton como el acalabrutinib puede ser una estrategia terap utica eficaz en pacientes con covid    grave  https   t co binrk xzfh
1594,the daily protein,blood cancer drug calquence from astrazenca shows positive signs in covid    treatments   health tips and  news  https   t co pxhebha eb
1595,primo k,este medicamento puede calmar la tormenta de citoquinas en pacientes con coronavirus estudio revela que el medicamento acalabrutinib  aprobado por la fda  puede calmar la tormenta de citoquinas en pacientes con coronavirus  https   t co   q lhlzb  https   t co mryjnxaj r
1596,dr l boominathan phd,probiotic based chemotherapy  pct  targeting cancer stem cells and immune inhibitory receptors in cll and in advanced metastatic cancers  a pharmaceutical mixture encompassing acalabrutinib  and probiotic lactobacillus rhamnosus   https   t co gjdd fvfph https   t co ihpbuegrvr
1597,armin hamidian,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients  https   t co dd dmoz md
1598,armin hamidian,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co gxcui gnu 
1599,masudkarim          ,astrazeneca s blood cancer drug shows promise https   t co kttfyfox k  covid    calquence  fe via  febdonline
1600,mw gunter,early data from a clinical study suggest that blocking the bruton tyrosine kinase  btk  protein with the cancer drug acalabrutinib provided clinical benefit to a small group of patients with severe covid     https   t co quuopxkp y https   t co bs clmh yb
1601,vishnu live,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients via  forbes https   t co rb shhl zb
1602,tom andrews , study shows that acalabrutinib  a bruton tyrosine kinase  btk  inhibitor can treat severe respiratory distress in covid    patients   https   t co np xzwmalb
1603,dr  dave on call,interesting study by roschewski et al  in science immunology  acalabrutinib  selective btk inh   given off label to patients  n     w  severe  covid    noted favorable results  more randomized studies needed   drdaveoncall https   t co k byjsovcb
1604,ruth ann crystal  md,  new drug to treat covid severe covid    s hyperinflammatory immune response suggests macrophage activation   acalabrutinib  a bruton tyrosine kinase  btk  inhibitor  decreases inflammation and improves oxygen levels in patients with severe covid    https   t co iwdpdcsde  https   t co  yhqec zfx
1605,bargad, apto  at the end of acalabrutinib treatment               patients in the supplemental oxygen cohort had been discharged on room air  and           patients in the mechanical ventilation cohort had been successfully extubated  with           discharged on room air       https   t co fxo bwrfzt
1606,jorgenponder   om coronavirusepidemin,cacncermedicinen acalabrutinib ser v ldigt lovande ut  liten studie  ingen kontrollgrupp men bra resultat  amp  en st rre studie ska nu g ras  acalabrutinib modulerar immunf rsvaret   https   t co htgnwfcogt https   t co lv fog ccl
1607,benlazar s m amin ,acalabrutinib  fda approved drug may help calm cytokine storm in  covid    https   t co brabmdvbvx
1608,iflyplaces,calquence does bigly in cll and mcl markets  it s an interesting idea  just shows how certain moas can be impactful across different disease areas  this is why we shouldn t dismiss drug ideas so early  wait till there is good data  who knows this cancer drug could help with rona https   t co vpmtyhpomo
1609,delthia ricks  ,cancer drug tests  nat l cancer institute is testing a drug called acalabrutinib in     covid patients w  severe disease  drug blocks an enzyme below the cell surface  bruton tyrosine kinase  btk is linked w  the hyperinflammatory response  cytokine storm https   t co krdrzuvlo  https   t co n jludry x
1610,robert west  phd,study identifies potential approach to treat severe respiratory distress in patients with  covid   https   t co   qqjwjcvv     sciimmunology  inhibition of bruton  tyrosinekinase in patients with severe covid    https   t co cbuvnbgubj  btk  acalabrutinib  cytokinestorm https   t co kllul o ln
1611,viralflex,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co qdbbzitnim
1612,cafepharma,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co mn y xvvxo
1613,mercado digital   ,coronavirushace   hora                               reuters  foto de archivo del logo de astrazeneca en la bolsa de nueva york           por ludwig burger fr ncfort    jun  reuters    el medicamento contra el c ncer calquence de astrazeneca  lon   https   t co kaky qamsl https   t co jxaei lj w
1614,c digo libre,calquence  medicamento contra el c ncer de astrazeneca  ha mostrado indicios de que puede ayudar a los pacientes hospitalizados por covid     https   t co xvnm zem g
1615,antibiotic steward  bassam ghanem,the results of this study were used to inform the trial design of the calavi  acalabrutinib  randomized  controlled clinical trial  sponsored by astrazeneca  which will examine the safety and efficacy of acalabrutinib in patients with severe  covid   https   t co xnkwngflpj
1616,extradigital com do,el medicamento contra el c ncer  leucemia  calquence de la empresa farmac utica astrazeneca ha mostrado indicios de que puede ayudar a los pacientes hospitalizados con covid    a superar lo peor de la enfermedad  en       para m s informaci n  visitanos https   t co qdjtzoogw  https   t co cv  d  elz
1617,jean pierre lavergne,l acalabrutinib  inhibiteur s lectif de la btk  donne des r sultats spectaculaires sur des patients covid    sous oxyg ne  https   t co xbdg doia 
1618,alex covarrubias,nuevo estudio sugiere que el medicamento  acalabrutinib aprobado por fda  se usa para tratar varios tipos de c ncer de c lulas b  puede ayudar a disminuir el proceso inflamatorio mejor conocido como  tormenta de cotocinas  producido en pacientes con cuadros severos por  sarscov  https   t co blgcbzjmyk
1619,bionews central, early data from a  clinicalstudy suggest that blocking the  brutontyrosinekinase  btk  protein provided  clinicalbenefit to a small group of patients with  severecovid      covid    acalabrutinib  covid  treatment  acuterespiratorydistresssyndrome  ards https   t co   vcg nwom
1620,oncology times,study finds single agent acalabrutinib superior in relapsed chronic lymphocytic  leukemia https   t co  yzjs hrow  leusm  cancer  saturdaythoughts via  myunisr https   t co  gjzcchfw 
1621,funops com,astrazeneca s cancer drug calquence has shown initial signs of helping hospitalized covid    patients get through the worst of the disease in frankfurt   eleven patients had been on oxygen when they started the       day         funops  funopspakistan   coronavirus  pakistan https   t co mw xcddco 
1622,cary adams,small number of  covid   patients but how exciting that a  cancer drug is  associated with reduced respiratory distress and a reduction in the overactive immune response in most of the treated patients   thanks to  ncicancerctrl and  niaid from  uicc https   t co   tds gcjm
1623,forbes science,in a study of    sick covid    patients  those who were on supplemental oxygen did better with the blood cancer drug than those on ventilators   https   t co heyao jvui https   t co q ejxltayt
1624,prof john, covid   i btk inhibitors repurposed to target pathological monocyte   macrophage activation  amp  dampen  cytokinestorm in sars cov   infection     sciimmunology     acalabrutinib    ibrutinib    lymphoma    cll     celentyxltd     https   t co  qgnac psh
1625,scienzer,study identifies potential approach to treat severe respiratory distress in patients with  covid    https   t co afphrexfvn   covid  research   coronavirusresponse   covid  treatment   coronavirustreatment
1626,bob turner,acalabrutinib is an oral medication used to treat lymphoma and cll  it is used here to blunt the immunological storm of cytokines induced by  covid   https   t co hnmlkmgjp 
1627,mr graham,these findings suggest that acalabrutinib may have been effective because its target  btk  is hyperactive in severe covid    immune cells  https   t co nsytgm dna
1628,jill hamer wilson   ,hope for a treatment option for severe covid      cancer drug  acalabrutinib  btk inhibitor  which is used to treat blood cancers  https   t co x ychgfhvo
1629,debuglies,the cancer drug  acalabrutinib reduced respiratory distress in  covid   patients https   t co vw gfokapz via  debugliesnews  health  healthcare  healthylifestyle  healthylife  covid     coronavirus  coronavid    covid  pandemic  coronavirusoutbreak  coronalockdown  covid     https   t co bioognlktb
1630,ifor williams,fascinating back story from  nathanvardi  forbes on early events that led to study on off label use of  acalabrutinib btk inhibitor drug in  covid    pneumonia published in june   issue of  sciimmunology by team from  thenci  astrazeneca  theusonetwork https   t co fnk  sslce
1631,medicalnewser com,astrazeneca blood cancer drug shows signs of helping covid    patients  health news  et healthworld    reuters stefan wermuth file photo by ludwig burger frankfurt   astrazeneca s cancer drug calquence has shown initial     https   t co c pcrdcgxd https   t co i qecez  x
1632,tendenciastech, tecnolog a   estudio revela que el medicamento acalabrutinib  aprobado por la fda  puede calmar la tormenta de citoquinas en pacientes con coronavirus   noticias  tendenciastech https   t co hqbvfiufil https   t co hdnqlutqml
1633,amir faisal, over a       day treatment course  acalabrutinib improved oxygenation in a majority of patients  often within     days  and had no discernable toxicity  https   t co   tlpwduqc
1634,deccan herald,according to the researchers  the cancer drug acalabrutinib blocked the protein bruton tyrosine kinase  btk  in  covid   patients  and provided clinical benefit   https   t co cwqoboqqm 
1635,business journal,astrazeneca s blood cancer drug calquence shows initial signs of helping patients business journal https   t co ine fceei 
1636,business today, coronavirus  astrazeneca s blood cancer drug calquence shows initial signs of helping patients https   t co  vcdnoyvx 
1637,medimagazine,covid     acalabrutinib efficace per il trattamento di gravi difficolt  respiratorie https   t co jsjg wsyyl
1638,dr virendra singh,patients with severe covid    had higher activity of the btk protein and greater production of il    these findings suggest that acalabrutinib may have been effective because its target  btk  is hyperactive in severe covid    immune cells 
1639,dr virendra singh,covid   use of btk inhibitor ca drug acalabrutinib     mg twice daily orally use to treat blood ca was associated with reduced respiratory distress  amp a reduction in overactive immune response in most of treated pts    of these    patients were able to come off supplemental oxygen
1640,dr  mauricio bernal ,https   t co englbggmyl  acalabrutinib dosis      mg por v a oral dos veces al d a durante    d as  pacientes con ox geno suplementario  y    d as  pacientes con ventilaci n mec nica   https   t co izczbrziib
1641,yaeshora,calquence  medicamento contra el c ncer  puede ayudar a pacientes con covid    https   t co wzmphrril  https   t co  ullxpbofa
1642,ese migue,calquence  medicamento contra el c ncer  puede ayudar a pacientes con covid    https   t co xnhvrfq ud https   t co rsrs l  wz
1643,medicalnewser com,calquence showed promising clinical improvement in majority of    hospitalised covid    patients    results published in science immunology showed that calquence  acalabrutinib   a bruton s tyrosine kinase  btk  inhibitor  reduced      https   t co mftvnwl zw https   t co ozywtns mg
1644,   ,                btk     acalabrutinib          az             nf  b                        il   il           btk            https   t co gea ylols 
1645,pressreleasepoint,https   t co c wbocoydm calquence showed promising clinical improvement in majority of    hospitalised covid    patients
1646,la disidente,calquence  medicamento contra el c ncer  puede ayudar a pacientes con covid    https   t co oqxz tnwwp https   t co  q xfn swm
1647,the mexico post,el medicamento contra el c ncer calquence de  astrazeneca ha mostrado indicios de que puede ayudar a los pacientes hospitalizados con  covid    a superar lo peor de la enfermeda  https   t co lpalzyalgh
1648,dr timos papagatsias,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co tlwxkzhans  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  biotech  pharma  pharmaceutical  productmarketing  healthcare https   t co f r  lx po
1649,tariq janjua md,bruton tyrosine kinase  btk inhibitor  acalabrutinib improved outcome in  ards from  covid   https   t co d kqdm  cg
1650,proceso,la pruebas de la farmac utica brit nica tienen el respaldo de institutos nacionales de salud de estados unidos   https   t co pku   crcb
1651,john p  leonard  md,interesting   hypothesis generating study to be followed by randomized trial which will be of interest   disagree that one can say  as in the abstract   acalabrutinib improved oxygenation  given the lack of a control group and fact that of course most patients improve w support https   t co  doiv p yb
1652,australianprescriber,https   t co r dzg rzr 
1653,american capital rec,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co jt  df gju https   t co vzagocfa b
1654,k pavithran,acalabrutinib   a btk inhibitor reduces cytokine storm in covid    https   t co vphofvo  y
1655,lcw, cov    researchers observed that the off label use of the cancer drug acalabrutinib  a btk inhibitor that is approved to treat several blood cancers  was associated w  reduced respiratory distress  amp  a reduction in the overactive immune response in most   https   t co dgwxohtbiy
1656,world pharma news,calquence showed promising clinical improvement in majority of    hospitalised covid    patients https   t co wwna  yqvr https   t co bnii ey ph
1657,joseph aslan,acalabrutinib for covid     https   t co  g ytx ttg  clotmaster
1658,fav store,calquence showed promising clinical improvement in majority of    hospitalised covid    patients https   t co jzmqxvknbi
1659,kenneth bodin,acalabrutinib kan vara v rd att l gga p  minnet  nu n r det blir tydligare att den kritiska sjukdomen  r kardiovaskul r s  kommer flera nya approacher till l kemedel  bra 
1660,contrar plica,el medicamento contra el  c ncer calquence de  astrazeneca mostr  indicios de que puede ayudar a pacientes hospitalizados con  covid   a superar lo peor de la enfermedad   https   t co icunaz nuk
1661,company news hq,calquence showed promising clinical improvement in majority of    hospitalised covid    patients https   t co w tczr hvu
1662,roland baker,science  inhibition of bruton tyrosine kinase in patients with severe covid      jun        over a       day treatment course  acalabrutinib improved oxygenation in a majority of patients    https   t co annyg mqtj
1663,antibiotic steward  bassam ghanem,this prospective study of patients with severe  covid   highlights the potential benefit of btk inhibitor  acalabrutinib  and has led to a confirmatory international prospective randomized controlled clinical trial  https   t co vgas ug un https   t co lsyojz eko https   t co bg ohcnhoj
1664,        ahmd saleh,                                                                                                       remdesivir                                                                                           acalabrutinib  selective bruton tyrosine kinase                            https   t co eetjvqpz t
1665,radio tepeaca,internacional  el medicamento contra el c ncer calquence  de astrazeneca  ha mostrado indicios de que puede ayudar a los pacientes hospitalizados con covid    a superar lo peor de la enfermedad  en momentos en que los investigadores se esfuerzan por readaptar los tratamientos https   t co x vlevohxq
1666,news  ,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co wgl  fopdj
1667,health news, astrazeneca s calquence showed improvement in small group of hospitalized covid    patients  https   t co ktulsnzzti  health  pharma
1668,tekcrispy,estudio revela que el medicamento acalabrutinib  aprobado por la fda  puede calmar la tormenta de citoquinas en pacientes con coronavirus  https   t co inflofipxl https   t co  cseai  k 
1669, diario  horas, toma eso  coronavirus      el medicamento calquence de astrazeneca ha mostrado indicios de que puede ayudar a los pacientes hospitalizados con  covid   a superar lo peor de la enfermedad https   t co wt nlolaz 
1670,edn tv hn, edninforma el medicamento contra el c ncer calquence de astrazeneca ha mostrado indicios de que puede ayudar a los pacientes hospitalizados con covid    a superar lo peor de la enfermedad   edntv  medicamento  astrazeneca  pacientes  hospitalizados  covid    enfermedad https   t co efu gepzyb
1671,            ,science immunology                                      bruton tyrosine kinase  btk                            acalabrutinib il                                   https   t co yk axmkpj 
1672,benexact,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co hbwshmsdbq https   t co wmfgfflkoe
1673,chicagoschoolofyoga,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co   aldrqopv https   t co  br fdn f 
1674,aid      recruitment solutions,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients https   t co spw hlxcso
1675,dr  thomas kloss,acalabrutinib scheint bei schweren pulmonalen covid    erkrankungen hilfreich   inhibition of bruton tyrosine kinase in patients with severe covid    https   t co fvvbwtxvtz
1676,national cancer institute,study identifies potential approach to treat severe respiratory distress in patients with  covid   https   t co  acbklc k   coronavirus  sciimmunology  reposted  https   t co  zs xrbkrr
1677,the purple society,study identifies potential approach to treat severe respiratory distress in patients with covid     cancerresearch https   t co pinnzdtk q
1678,llz consulting,calquence showed promising clinical improvement in majority of    hospitalised  covid    patients   https   t co q gz kc do
1679,firstword pharma,astrazeneca s calquence shows  rapid  improvement in small group of patients with severe covid     study https   t co  wbag bfnc
1680,ronald m  chavin,           many drugs ending in  mab or  nib will be effective against late covid     will they have less side effects  cost much less  or be more available than actemra  tocilizumab   https   t co ktfr wsqkf https   t co jon c  wfm https   t co  jwlijshtd https   t co  by jkpkte
1681,lucy gorelli,interleukin    il     a major cytokine associated with hyperinflammation in severe covid     decreased after treatment with acalabrutinib a btk inhibitor  counts of lymphocytes  improved https   t co qyzfgzjjod
1682,graniteshares europe, azn news calquence showed promising clinical improvement in majority of    hospitalised  covid   patients  ongoing global trials aim to confirm findings   btkinhibitor  inflammation  singlestocketps  https   t co t ib cbsxg
1683,nanotrac technologies,scitechdaily fda approved drug may help calm cytokine storm in covid     the drug acalabrutinib  fda approved for the treatment of several types of b cell cancers  improved the oxygenation levels and decreased molecular markers  https   t co hudfgb jym  health via  scitechdaily  https   t co  jnh  jrkf
1684,dagens industri,astra zeneca uppger sig ha uppn tt  lovande kliniska f rb ttringar  f r flertalet av de    covid    patienter som behandlats med blodcancerl kemedlet calquence  https   t co nkgk bs p 
1685,omni ekonomi,astra zenecas kliniska studie med l kemedlet calquence hos    stycken covid    patienter visade lovande resultat  enligt ett pressmeddelande  https   t co csgwgwrsn 
1686,cure cancer now,early data on potential approach to treat severe covid    https   t co mzpvvvkhrc
1687,  adam grant,  astrazeneca  calquence  acalabrutinib  effective as a btk inhibitor deoxygenation from hyperinflammatory immune responses in  covid   patients  https   t co txiccvqjym   covid  coronavirus  covid     pandemic  quarantine  quaratinelife  covid      covid      coronavirusfacts https   t co kvm bvywfx
1688,swog cancer research network,early data on potential approach to treat severe covid    https   t co qyq qpdscy
1689,medical dialogues,acalabrutinib is new option to calm cytokine storm in severe covid     cytokinestorm  acalabrutinib  covid    coronavirus  covid    corona https   t co ykgnqpo ez
1690,virginslayerincelius,sciencemagazine  a new off label observational study suggests that the fda approved drug acalabrutinib  already used to treat several b cell cancers  may help calm the hyperinflammatory  cytokinestorm immune response associated with severe cases of  covi  https   t co mhkardmfen
1691,the jerusalem post,  astrazeneca s  cancer drug calquence has shown initial signs of helping hospitalized  covid   patients get through the worst of the disease  as researchers scramble to repurpose existing treatments to help fight the deadly infection   https   t co x lxxjtfk 
1692,josie b ,looks like a blood cancer drug could help patients with  covid    small study but still good news  https   t co kpovnedv  
1693,wallstbetsdotcom,astrazeneca says calquence  promising  in treating hospitalized covid patients       azn results published in science immunology showed that calquence reduced markers of inflammation and improved clinical outcomes of patients with severe covid    disease 
1694,cision news,calquence showed promising clinical improvement in majority of    hospitalised covid    patients https   t co aegkhpbkaq
1695,meagan phelan,acalabrutinib  fda approved for several types of b cell cancers  improved the oxygenation levels and decreased molecular markers of inflammation in a majority of    patients hospitalized for the treatment of severe  covid    sciimmunology  https   t co bpyxe xmho
1696,mrs d onofrio, these findings should not be considered clinical advice but are being shared to assist the public health response to covid      early data on potential approach to treat severe covid    https   t co u wpoxsswn
1697,patricia kime,blood cancer drug shows promise in treating severe cases of  covid   via  nih https   t co obxmgim ea
1698,gualestrit,astrazeneca anuncia que calquence  un medicamento para tratar el c ncer  muestra signos de ayudar a pacientes de  covid   hospitalizados    reuters   azn      
1699,al,astrazeneca s cancer drug calquence shows initial signs of helping hospitalised covid    patients 
1700,chet,calquence reportedly shows initial signs of helping covid    patients
1701,paul marc, azn june    reuters    astrazeneca s azn l cancer drug calquence has shown initial signs of helping hospitalised covid    patients get through the worst of the disease  as researchers scramble to repurpose existing treatments to help fight the deadly infection 
1702,kubsv,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients via  forbes https   t co jbxmksyamt
1703,rick, azn https   t co w g vn prm
1704,science magazine,a new off label observational study suggests that the fda approved drug acalabrutinib  already used to treat several b cell cancers  may help calm the hyperinflammatory  cytokinestorm immune response associated with severe cases of  covid    https   t co d k yu e j https   t co tvfqxjkmh 
1705,jeremy,astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs
1706,wallstbetsdotcom,astrazeneca s calquence shows signs of helping covid    patients  reuters says       azn   show related items  gt  gt 
1707,nathan vardi,astrazeneca s calquence showed improvement in small group of hospitalized covid    patients via  forbes https   t co wzfqdjmq x
1708,sharp street trading insights,astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs  pump it    spy  qqq  trading  stocks
1709,newsfreak, breaking  astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs https   t co dq nr wckk
1710,breaking market news,astrazeneca s cancer drug calquence shows initial signs of helping hospitalised covid    patients    azn
1711,breaking market news,astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs
1712,redbox global,astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs
1713,first squawk,astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs
1714,livesquawk,astrazeneca s cancer drug calquence said to show initial signs of helping hospitalised covid    patients   rtrs
1715, scipak es,un nuevo estudio de observaci n no indicado en la etiqueta sugiere que el medicamento acalabrutinib aprobado por la fda  puede ayudar a calmar la respuesta inmunitaria de la tormenta de citocinas hiperinflamatorias asociada con casos graves de  covid   https   t co vtx zme bw
1716,chan cheah,our fellow  kathari         presenting at friday lymphoma lunch the latest on the management of  richters transformation  including new data from  drmdavids vr epoch data presented at  asco   and ongoing uk randomised acalabrutinib study  tobyeyre     lymsm  cllsm https   t co xn tollk w
1717,australianprescriber,https   t co r dzg rzr   acalabrutinib  calquence  mantlecelllymphona  chronic lymphocytic leukaemia
1718,doctiplus,visita el post en facebook https   t co s kserudcx el acalabrutinib se usa para tratar linfoma de c lulas del manto  mcl  un c ncer de crecimiento r pido que empieza en las c lulas del sistema inmune  que ya ha sido tratado con al menos otro medicamento de quimioterapia  el aca  https   t co e vd dsh  
1719,oncology times,in case you missed this from  asco    study finds single agent acalabrutinib superior in relapsed chronic lymphocytic  leukemia https   t co  yzjs hrow  leusm  cancer  ascendstudy via  myunisr https   t co bldamfpyvd
1720,michael wang  md,this study led by me and my colleagues and published in leukemia  reports the follow up study of acalabrutinib monotherapy in the treatment of relapsed refractory mantle cell lymphoma  mcl https   t co hvge bjjev
1721,naturerevclinoncol,data from the phase iii ascend trial demonstrate that acalabrutinib significantly improved pfs compared with idelalisib plus rituximab or bendamustine plus rituximab and has an acceptable safety profile in patients with r r cll  https   t co ap mktd hj   leusm  hemeonc
1722,joewhitworth,is this revolutionary or as grant came from acerta pharma  maker of acalabrutinib    of the btk inhibitors studied   should findings be discarded  or is it somewhere in between   allergen  anaphylaxis https   t co bngdvwui n
1723,francesco bertoni,phase iii  randomized trial of  acalabrutinib versus  idelalisib plus  rituximab or bendamustine plus  rituximab in r r chronic lymphocytic  leukemia  cll  https   t co  hk w y  z
1724,delveinsight,the data presented at  asco     by  acertapharma showed  acalabrutinib  a second generation bruton tyrosine kinase  btk  inhibitor  helped  cll patients live longer without progression of the  disease  https   t co zx mxrummd
1725,manam,uk hospitals enrolling   drugs in sarscov  treatment trial   nebulised heparin   bemcentinib  medi       acalabrutinib   zilucoplan  rajeshtope    drharshvardhan  arvindkejriwal  cmomaharashtra  authackeray
1726,antibiotic steward  bassam ghanem,uk hospitals to trial five new drugs in search for coronavirus treatment the five drugs will initially enter the program which can be disclosed for the first time  nebulised heparin   bemcentinib  medi       acalabrutinib   zilucoplan  covid    accord   https   t co jkwknuz oc
1727,julien potet,  new drugs now tested for severe  covid   in the uk  including  heparin  i had never heard of the other    calquence  bemcentinib  medi      zilucoplan  https   t co w bwavreqp
1728,catherine leong,five new drugs are to be trialled in    hospitals across the country in the race to find a treatment for  covid     heparin   bemcentinib   medi        calquence   zilucoplan   safety and  efficacy https   t co syw sdwg p
1729,oncology times,new from  asco    study finds single agent acalabrutinib superior in relapsed chronic lymphocytic  leukemia https   t co  yzjs hrow  leusm  cancer  ascendstudy via  myunisr https   t co ihfsppsqnt
1730,g ms p,there are currently no fda approved treatments for co    remdesivir  hydroxychloroquin chloroquine  azithromycin convalescent plasma actemra tocilizumab  calquence  acalabrutinib xeljanz  tofacitinib jakafi  ruxolitinib olumiant  baricitinib kineret  on and  on  realdonaldtrump
1731,weill cornell medicine,dr  richard furman   richardfurmanmd  of  wcmclymphoma and   wcm meyercancer presents at  asco       safety of acalabrutinib monotherapy in hematologic malignancies  pooled analysis from clinical trials      asco abstract         https   t co ly eufz os
1732,cancer medicine,poster  safety of acalabrutinib monotherapy in hematologic malignancies  pooled analysis from clinical trials   michaelwangmd  virtual  asco   runs through sun  may     follow   mdandersonnews  at https   t co e p butl z  https   t co d ofdovgrz
1733,cancer medicine,poster  acalabrutinib in treatment na ve cll  mature results from phii study demonstrating durable remissions  amp  long term tolerability   wwierda  leukemiamda  virtual  asco   runs through sun  may     follow   mdandersonnews  at https   t co e p butl z  https   t co t vr v nki
1734,clinowl oncology,ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia  https   t co dxyqflsxbf    thewiderwiserview https   t co y yqu  zdl
1735,mariam alasfour,cll update  ibrutinib continues to be highly effective for relapsed refractory cll    median f u   yrs not curative but achieving sustained deep remissions   acalabrutinib w  lower side effect profile than ibrutinib except for headache  remains unknown pathophys     asco    cll
1736,lymphoma hub,congress    asco     ascend trial   final results  presented by paolo ghia of  sanraffaelemi  acalabrutinib continues to demonstrate its efficacy and safety after longer follow up in patients with r r  cll  lymsm https   t co nauhbbwwav
1737,benlazar s m amin ,ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic  leukemia  cll https   t co qzcnuqvopn
1738,toby eyre,excellent to see ascend published  the first novel vs novel agent trial published in  cll  clear pfs benefit for  acalabrutinib over br or idela r in r r  cll  lymsm  ascend  phase iii  randomized trial of acalabrutinib vs idelalisib r  or br in r r cll https   t co q rudtcqga https   t co zatifdyktk
1739,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll    asco  
1740,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll    asco  
1741,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll    asco  
1742,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll    asco  
1743,calquence   acalabrutinib ,https   t co w  aqpuk a see if calquence can be used to treat your adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll    asco  
1744,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1745,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1746,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1747,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1748,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1749,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1750,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1751,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1752,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1753,calquence   acalabrutinib ,https   t co w  aqpuk a in a study of     chronic lymphocytic leukemia  cll  patients   l calquence obinutuzumab demonstrated     relative risk reduction  hr          ci              p lt        in disease progression or death vs gcib  obinutuzumab chlorambucil    asco  
1754,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll    asco  
1755,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll    asco  
1756,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll    asco  
1757,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll    asco  
1758,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll    asco  
1759,filippo masini,ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia https   t co sbycetpeyo
1760,paperbirds hematology,new article  ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia  https   t co uflzbqljzr  cll  leusm  hematology
1761,australianprescriber,https   t co r dzg rzr 
1762,ali alahmari ,ascend  phase iii  randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia https   t co lksodbfhzo
1763,paperbirds hematology,new clinical trial acalabrutinib  lenalidomide  and rituximab for the treatment of cd   positive stage iii iv  grade    a follicular lymphoma https   t co iolg  s a   fl  lymsm  hematology
1764,trialbulletin,treatment with acalabrutinib post blood or marrow transplantation in subjects with mantle cell lymphoma  status  not yet recruiting   condition summary  mantle cell lymphoma https   t co i sk  yhrx
1765,curehuntr, clinicaltrial treatment with acalabrutinib post blood or marrow transplantation in subjects with mantle cell lymphoma https   t co u  qy vadh
1766,paperbirds hematology,new clinical trial  treatment with acalabrutinib post blood or marrow transplantation in subjects with mantle cell lymphoma https   t co xgf  eb c   mcl  lymsm  hematology
1767,australianprescriber,https   t co r dzg rzr 
1768,leukaemia foundation,bruce  who was diagnosed with chronic lymphocytic leukaemia  cll  in       shares why he chose to delay chemotherapy in the hopes he d gain access to a trial for a new targeted therapy  https   t co  zgiaur ub  bloodcancer  targetedtherapy
1769,michael wang  md,published in the expert review of clinical pharmacology  led by dr  jurczak  the authors discussed the potential of a novel btk inhibitor  acalabrutinib in the clinical applications for the treatment of relapsed refractory mantle cell lymphoma   https   t co  sqr s  zu
1770,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is an oral treatment option for adult patients with chronic lymphocytic leukemia  cll  and small lymphocytic lymphoma  sll    asco   https   t co hdix szjow
1771,s bastien berniot        jemeferaivacciner,coronavirus   le calquence  un traitement efficace contre les chocs cytokiniques   https   t co a cjq qwhj
1772,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1773,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1774,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1775,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1776,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1777,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1778,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1779,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1780,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1781,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1782,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1783,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1784,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1785,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1786,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1787,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1788,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1789,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1790,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1791,calquence   acalabrutinib ,https   t co w  aqpuk a calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy   asco  
1792,laurent pradal,coronavirus   le calquence  un traitement efficace contre les chocs cytokiniques   https   t co rc dlyzqeg
1793,lymphoma hub,elevate tn interim analysis   acalabrutinib  alone or with obinutuzumab  is a safe and effective chemo free option in patients with untreated chronic lymphocytic leukemia  cll   https   t co ziyzidr o   jeff sharman  lymsm https   t co ddygq zwla
1794, covid evidence,https   t co k gfhg  vk   acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with covid      condition    covid    intervention    drug  acalabrutinib sponsors     https   t co kezl ijy q  coronavirus  sars cov    covid  
1795,taylor   francis medicine and health,an in depth evaluation of acalabrutinib for the treatment of mantle cell lymphoma  https   t co  jybpqfobh https   t co   euutn wp
1796,lymphoma hub,read the updated results of a phase ii trial that assessed the efficacy and safety of acalabrutinib in patients with r r  cll and  sll   results from the long term follow up are promising    https   t co  ioexbgvq   lymsm https   t co egocrpohqa
1797, covid evidence,https   t co k gfhg  vk   acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with covid     calavi  calquence against the virus   condition    covid    intervention     https   t co  x bc ch f  coronavirus  sars cov    covid  
1798,australianprescriber,https   t co r dzg rzr 
1799,mike thompson  md  phd  fasco,   astrazeneca announces calavi trial  ace id      to examine acalabrutinib for patients with covid     april           matthew fowler  cancernetwrk https   t co xkg afm ek  caxtx  ccc        ncov  covid  clinicaltrials  nct         az press release  https   t co p mymhbz i
1800,industrie pharma magazine,covid      interview de marisol urbieta  astrazeneca   nous allons tester acalabrutinib dans le syndrome de d tresse respiratoire  https   t co  uku tbjq   covid   
1801,dr  andy evens,off study and assuming access to all rx  should obinutuzuman be given concurrent with acalabrutinib for all pts with untreated cll  chanyooncheah    cllsm https   t co z dwsfm vw
1802,lu chen  nobias,https   t co  wrcoljyhi acalabrutinib trial for severe  covid   from  thenci  historically we have found btk inhibitors increase the risk of fungal infection  indicating immunosuppressive effect  it s an interesting repurposing  but just like jak il   no one knows if it will work
1803,sylvie latieule ,ce soir marisol urbieta  directrice m dicale oncologie france chez astrazeneca  nous explique que l acalabrutinib va  tre test  en traitement des  temp tes de cytokines  dans la lutte contre de sras cov      ipm pharma nicolas viudez astrazeneca https   t co ld p vq t 
1804,fabien pr vots,frenchnewtech covid       nous allons tester acalabrutinib dans le syndrome de d tresse respiratoire  https   t co nqn hbdsrq  industrie  pharma  actus https   t co i blqhbcuu
1805,cure magazine,calquence may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia  according to the updated phase   results of an ongoing study  https   t co en n zxeac
1806,dough,baml  azn oncology feedback  po raised to       buy   united kingdom tagrisso adjuvant dfs should be solid  debates os  amp safety in earlier pts  confident in sizeable op    bullish lynparza in  l ovarian approved prostate  imminent calquence uptake on efficacy outstanding safety
1807,cure magazine,calquence may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia  according to the updated phase   results of an ongoing study  https   t co en n zxeac
1808,australianprescriber,https   t co r dzg rzr 
1809,         ,cll     acalabrutinib  iii      lancet https   t co lmnyeaa ut  carenet https   t co sqvwcnqcsv
1810,targeted oncology,this expert discussed the importance of analyzing treatment outcomes in real world patients with cll compared with only reviewing data from clinical trials that do not represent all patients seen in the community setting  https   t co tmpwppfe p  leukemias
1811,targeted oncology,dr  leslie discussed the importance of analyzing treatment outcomes in real world patients with cll compared with only reviewing data from clinical trials that do not represent all patients seen in the community setting  https   t co tmpwppfe p  cllsm  leusm
1812,targeted oncology, i think the importance of real world data is becoming more and more transparent as we have these agents rapidly entering our treatment landscape   https   t co tmpwppfe p  leukemias
1813,mike thompson  md  phd  fasco,   astrazeneca announces calavi trial  ace id      to examine acalabrutinib for patients with covid     april           matthew fowler  cancernetwrk https   t co xkg af pnc  caxtx  ccc        ncov  covid  clinicaltrials  nct         az press release  https   t co p mymhjyba
1814,anastasios raptis  md,acalabrutinib with or without obinutuzumab vs chlorambucil obinutuzumab in patients with previously untreated cll   the asco post https   t co lhq ifrhco
1815,paperbirds hematology,new article  acalabrutinib   a new option in cll  https   t co  ebahdmghs  cll  leusm  hematology
1816,fernando a  navarro,  novedad    glosario de covid      ver nica saladrigas  menda lerenda y  paz g polledo  m s de      entradas  de ab  abg  abnormal taste  absolute ethanol y acalabrutinib  a zero patient  zinc ionophore  zingerol y zoonosis  consulta en l nea  https   t co   ftz ftaz https   t co u gyc sd r
1817,                     ,                             m                   m                  m       calquence    m                          https   t co m ybfcrhyt
1818,medscape education,highlights from  medscapelive  optimizing the use of btk inhibitors in  cll  skills challenge and clinical pearls       ibrutinib and acalabrutinib  drug drug interactions https   t co jrcxmrk xz
1819,medscape education,highlights from  medscapelive  optimizing the use of btk inhibitors in  cll  skills challenge and clinical pearls       ibrutinib vs acalabrutinib  dosing https   t co  fapsdtmbn
1820,farmaonco, acalabrutinib   a new option in cll https   t co  vjh flhqj
1821,australianprescriber, calquence  chroniclymphocyticleukaemia  mantlecelllymphoma  acalabrutinib  https   t co r dzg rzr 
1822,dr  andy evens,indeed  kudos     what about the cd   antibody  ie  the hr for progression free survival between acalabrutinib obinutuzumab and acalabrutinib monotherapy was           ci            post hoc analysis       cll  lymsm https   t co jv voscea 
1823,univadis,in einer gro en vergleichsstudie verl ngerte der bruton kinase inhibitor acalabrutinib das progressionsfreie  berleben von erstmals behandelten patienten mit chronisch lymphatischer leuk mie  cll  erheblich  nach   jahren betrug der anteil       https   t co cxejb mhc  https   t co zpvkroxpz 
1824,    ,                 calquence                    calavi              https   t co jsnebnhvd   jijicom    
1825,phil   kinzler,seriously  why do all the covid    treatment medications sound like planets from  guardians of the galaxy     remdesivir  favipiravir  tocilizumab  baricitinib  acalabrutinib https   t co p egkzbh i
1826,gnhindiapharma,acalabrutinib  calquence  https   t co w ljpiiejg https   t co wolbw ph k
1827,tom gara,basic covid bros are out there talking about chloroquine  people who think they know what s up are talking about remdesivir  but me  i m floating above you all  serenely whispering  tocilizumab  acalabrutinib  favipiravir https   t co tvrncascdg
1828,dough,baml  azn ln  astrazeneca   q     eps beat  guide maintained  buy    buy   united kingdom buy driven by best in class growth and launches that offer upside to cons  calquence  l  enhertu  roxa china and farxiga hf 
1829,buried on page ,astrazeneca to begin calquence study for coronavirus treatment https   t co zwiwx   aj
1830,cl nica hallwang, acalabrutinib con o sin  obinutuzumab mejor  la supervivencia libre de progresi n sobre la  quimioinmunoterapia con obinutuzumab clorambucilo  lo cual brinda una opci n de tratamiento libre de quimioterapia con un perfil de efectos secundarios aceptable   https   t co cmdznkb  l
1831,hallwang clinic,acalabrutinib with or without obinutuzumab improved progression free survival over obinutuzumab chlorambucil chemoimmunotherapy  providing a chemotherapy free therapy option with an acceptable side effect profile in symptomatic  chroniclymphocyticleukemia https   t co ap  cgpafk
1832,australianprescriber,https   t co jpia  b  a  mantlecelllymphoma  calquence  ceftazidime  acalabrutinib
1833,    ,                                                 calquence                                                                             https   t co qxrrzzpouw
1834,famela and friends,use of a burton kinase inhibitor called acalabrutinib for treatment of  covid     burton kinase plays a role in b cell develoment   clinicaltrial   maga        coronavirus  https   t co wtel qm ju
1835,chris yeh,a mainstream pub  politico  finally went through the clinical trials database to lay out covid    drugs in trials  https   t co txokyvvvpi note that unlike iv infused remdesivir  acalabrutinib  baricitinib  amp  favipiravir are tablets   tocilizumab is injected 
1836,australianprescriber,https   t co r dzg rzr 
1837,victor yosefmelt campos,astrazeneca announces calavi trial to examine acalabrutinib for patients with covid    https   t co wbfuopy ug
1838,  h sante,astrazeneca to test impact of cancer drug calquence on coronavirus patients  power belongs to god https   t co jmwzuefx y
1839,newsrelea se,                             calquence                    calavi      https   t co lqv ruy t 
1840,australianprescriber,https   t co r dzg rzr   calquence  acalabrutinib  mantlecelllymphoma  chroniclymphocyticleukaemia
1841,katie wilkinson,i m organizing some distinguished lab alum speakers for our zoom lab meetings  our first speaker next week is a former ms student now working at astrazeneca  formerly at acerta  and they have a covid drug in trials  https   t co xmwrveodku
1842,excelya,astrazeneca begins clinical trial of blood cancer drug calquence for covid    patients https   t co rlzaoou kq  businessnews  cambridge  coronavirus  health  lifescience https   t co zbaol hwfx
1843,the asco post,elevate tn  acalabrutinib with or without obinutuzumab vs chlorambucil obinutuzumab in patients with previously untreated cll https   t co  pfbfsolvw  leusm  hematology
1844,medwave,cll             btk   acalabrutinib elevate tn   https   t co bvwsprkobw
1845,the james,a therapy developed at the james is improving quality of life for some  leukemia patients by reducing side effects associated with previous drugs  learn more about acalabrutinib  which was recently approved for the treatment of  cll and other blood cancers 
1846,australianprescriber,new drug  https   t co e oqgx udh  calquence  chroniclymphocyticleukaemia  mantlecelllymphoma  acalabrutinib
1847,anastasios raptis  md,acalabrutinib with or without obinutuzumab vs chlorambucil obinutuzumab in patients with previously untreated cll   the asco post https   t co cclkxpx l 
1848,wwfhtx,a study by  astrazeneca is showing promising results in later stage  covid   patients https   t co vqdop jbfu
1849,michael wang  md, in this phase   study  acalabrutinib with or without obinutuzumab significantly improved pfs over obinutuzumab chlorambucil therapy in treatment na ve cll patients  this provides a chemotherapy free treatment option with an acceptable side effect profile  https   t co chafjlm p 
1850,carthera,astrazeneca to test blood cancer drug  calquence in  covid   after nih sees  some clinical benefit  via  fiercepharma   https   t co  kteatup   https   t co f  dunhxb 
1851,shohta kadomura hospital pharmacist, btk  tki     acalabrutinib  covid    sarscov                                                 https   t co d jtjugyvy
1852,                        ,              btk    calquence  acalabrutinib                                  https   t co allfhlzc f
1853,clinicalsourcing,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit     pharma  covidtreatments  covid   https   t co sgfnv nhqe
1854,       com,                         calquence                    calavi      https   t co spbhyegp p
1855,    ,                  calquence                    calavi             pdf  https   t co p ew dglaz
1856,cure magazine,calquence  acalabrutinib  may be a safe and effective treatment option for patients with relapsed or refractory chronic lymphocytic leukemia  according to the updated phase   results of an ongoing study  https   t co en n zxeac
1857,nlsdays,  astrazeneca has launched a major trial investigating the effectiveness of a biotherapeutic in the treatment of cytokine storms in patients with covid     we can t wait to hear your latest updates at  nlsdays      read more about the trial here  https   t co j cqmtubat https   t co  zd  hwn  
1858,        ,                 calquence                    calavi        pr times https   t co bqn wjxzhi https   t co o p flivqq
1859,        ,                       calquence                    calavi          https   t co a mm  ixzc
1860,pr times    ,                 calquence                    calavi      https   t co d l nbusyi
1861,pr times    ,                 calquence                    calavi      https   t co  yyv zdntm
1862,medshadow foundation,in the effort to find a treatment for covid     scientists have a theory that calquence  acalbrutinib   a cancer drug  might be a possibility   covid    coronavirus  https   t co wzfpbuditt
1863,mhc,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for  https   t co fxixhw pmi
1864,oncology nursing news,in case you missed it  acalabrutinib  calquence   a btk inhibitor approved for the treatment of patients with certain types of leukemia and lymphoma  is being explored as a treatment for cytokine storm in patients with covid     https   t co kgtwyh  c 
1865,luminasllc,astrazeneca initiated a clinical trial of calquence  acalabrutinib  for the treatment of the immune response associated with covid    infection in patients  learn more about the calavi trial below  https   t co styokaxbyx    luminasllc  covid    coronavirus  covidclinicaltrial
1866,ned pagliarulo,interesting comment from nih director francis collins on  azn s calquence  company just launched a study of the drug in covid    patients  background here   https   t co pkg law ic https   t co fogcuknica
1867,ais health,datapoint  for the treatment of chronic lymphocytic leukemia  calquence holds preferred formulary status for just    of covered lives  which grows to     with prior authorization and or step therapy https   t co ek d bzear
1868,the cancer letter,  covidncancer updates   astrazeneca trial to test calquence in  covid   patients  clinical trial accruals at  oneoncology increase   americancancer society opens covid    tracking study  read more  https   t co gxb  b lss https   t co tmv tpf  w
1869,zach brennan,collins said he was surprised to see astrazeneca s acalabrutinib having some effect in covid    patients   says we ll see what happens in the trial
1870,tom heston,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial  https   t co  gammbghgy
1871,nurse times,  nurse times   nurse times coronavirus  allo studio farmaco per trattare la tempesta di citochine associata all infezione   si tratta di acalabrutinib  inibitore della tirosina chinasi di bruton  lo  https   t co cw ftp  he informazione sanit   serio ed affidabile  nursetimes https   t co db g zpido
1872,renalrcts,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial  https   t co t ewlkraei
1873,l michael posey,pnn for apr       lancet  acalabrutinib for treatment naive cll   covid   in the u s  fda  sars cov   tests  pnn journalwatch  https   t co bspthslrbd https   t co wvapjtkupk
1874,paul brackley,a global clinical trial from  astrazeneca will assess a blood cancer drug for use in treating the sickest  covid   patients https   t co ua   anulr https   t co pnxi oiydg
1875,deniztural,selektif bruton s tyrosine kinase inhibit r   acalabrutinib  calquence  covid   sitokin f rt nas nda etkinli ini ara t racak faziii  al  ma tasarland    announces calavi trial to examine acalabrutinib for patients with covid    https   t co cxb bzqjwa
1876,olivier elemento,astrazeneca s calquence  btk inhibitor  shows early promise for covid    patients  https   t co sipdok grq
1877,paul lopez,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co qnlluzbtm   healthcare  transformation https   t co tcnxcxtwmw
1878,persimmon tree investments, apto   may be potential support for  azn s calquence  btk inhibitor  efficacy in treating covid    respiratory symptoms    the thing about  apto s cg      as a pan btk flt  inhibitor   
1879,rahumj,         acalabrutinib  btk                  btk                   btk       https   t co ykbelhtwyh
1880,rahumj, given the well documented role of the protein btk in regulating inflammation  it is possible that inhibiting btk with acalabrutinib could provide clinical benefit in patients with advanced covid    lung disease  https   t co xfxjoxgb m
1881,clinowl, articles  acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial  https   t co bhhinopk d    thewiderwiserview
1882,onclive com,long term follow up data from the phase i ii ace cl     study showed that median values had yet to be reached for dor  efs  or pfs with single agent acalabrutinib in patients with relapsed refractory chronic lymphocytic  leukemia   cll  lylsm https   t co nb cxxzyxk
1883,targeted oncology,this btk inhibitor will be explored in a clinical trial to treat exaggerated immune response  or cytokine storm  in patients who are severely ill with covid     https   t co uz esrpbqc  covid    btk
1884,real tonarino agetin          ,covid             acalabrutinib                                                                      astrazeneca acerta pharma b v 
1885,tap clinical trial network,this is the same drug being investigated in the tap stellar  clinicaltrial  a phase ii  randomised study of chop r in combination with  acalabrutinib compared to chop r in patients with newly diagnosed  richterssyndrome https   t co f azdc dxz
1886,raul cordoba  md  phd, oncoalert  acalabrutinib with or without  obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  cll  elevate tn   a randomised  controlled  phase   trial     thelancet   cllsm  leusm  lymsm  https   t co h uwcbszow
1887,rioh,congratulations to  v banerji who co authored a new article in  thelancet with the results of a phase iii rct in  cll  the central finding was  acalabrutinib with or without obinutuzumab provides a chemotherapy free treatment option  https   t co qfacymsezb
1888,nathan twala,acalabrutinib btk inhibitor may have immunomodulatory effects against covid    cytokine storm   atanas   sminaev      dna rna uni  grawoig https   t co    rfid tq
1889,onclive com,results from a phase i ii study showed that benefit with single agent acalabrutinib continued well over   years after treatment initiation in patients with relapsed refractory chronic lymphocytic  leukemia   cll  lylsm https   t co yqcnld qwj
1890,oncology nursing news,acalabrutinib  a btk inhibitor approved for the treatment of patients with chronic lymphocytic leukemia and mantle cell lymphoma  is now being explored in patients with covid      https   t co kgtwyhid f
1891, nal metin tokat,astrazeneca announces calavi trial to examine acalabrutinib for patients with covid      cancer network  https   t co oawllvg ey
1892,cancernetwork   home of the journal oncology ,astrazeneca announced it will be conducting a global clinical trial  calavi  to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the covid    infection     astrazeneca  https   t co bs sye hjm https   t co  kbichjhdv
1893,anthony mato,acalabrutinib for the initial treatment of chronic lymphocytic leukaemia   the lancet very insightful editorial by   drmdavids    danafarber   https   t co leclhssaeb
1894, covid evidence,https   t co k gfhg  vk   acalabrutinib study with best supportive care versus best supportive care in subjects hospitalized with covid     calavi  calquence against the virus   condition    covid    intervention     https   t co srlpsrywma  coronavirus  sars cov    covid  
1895,deborah stephens,this important study supported the approval of frontline  acalabrutinib for  cll patients  congrats to  jeff sharman  thelancet https   t co h  oexsrso
1896,fraser dove international,read all about it   the top   news stories shaping pharma this week   article     https   t co lr b nzthd article     https   t co md yzo m   article     https   t co rlwuh wznu   roundup    thisweek    pharmaforecast https   t co  diyuim r 
1897,pharma journalist,astrazeneca initiates calavi clinical trial with calquence against covid      pandemic  covid     clinicaltrial  clinicalresearch  vaccine  research  pharmaceutical  lungs https   t co i  ruaigtf
1898,myelomadad,can  bloodcancer drugs help treat  coronavirus    myeloma  leukemia  calquence  selinexor  nathanvardi  astrazeneca  karyopharm  ahlstromjenny  clinicaltrials  https   t co hooeykdhqh
1899,            ,overheden kunnen nu alleen maar doemdenken mbt  coronavirus binnekort testen van meerdere kansrijke therapie n beschikbaar  o a  remdesivir  calquence en firazyr   dit kunnen stuk voor stuk gamechangers zijn en de ic capaciteit niet meer de beperkende factor maken   thinkpositive
1900,pharma business int,calquence to clinic is  fastest launch  of any trial in astrazeneca history https   t co pnbl urxy 
1901,oncology tribune,       az   bkt   acalabrutinib covid                        https   t co nm ecejrse  oncologytribune
1902,           ,astrazeneca begins clinical trial of calquence as covid    treatment   https   t co qybnzv iux
1903,toby eyre,elevate tn out in  thelancet  big pfs adv for  acalabrutinib      obin  vs obin chl  great news for  cll patients to have front line  acalabrutinib licensed and approved for use     cll  lymsm  congrats  jeff sharman and co authors  https   t co igdz d xfb
1904,krishan maggon,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial https   t co dk py ydnv https   t co cs nwsse  
1905,krishan maggon,acalabrutinib for the initial treatment of chronic lymphocytic leukaemia https   t co ishvv d og https   t co  slbx mk x
1906,clinowl, comment  acalabrutinib for the initial treatment of chronic lymphocytic leukaemia  https   t co t vkyc i h    thewiderwiserview
1907,chan cheah,elevate tn out in  thelancet      from dr sharman et al   great data for acalabrutinib  and added pfs benefit of adding obinutuzmab       cllsm https   t co chv h kjp 
1908,juan marquet,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial https   t co  iymicuhem
1909,immuno oncology,acalabrutinib long term benefit in cll captured in published data https   t co j edc  zr 
1910,young hematologists,acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment naive chronic lymphocytic leukaemia  elevate tn   a randomised  controlled  phase   trial  the lancet  link in  https   t co fbba zkke 
1911,return to sender,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co vbhe rzald
1912,wayne radinsky,astrazeneca is starting a clinical trial on a drug called calquence  acalabrutinib  as a treatment against the covid     cytokine storm  overreaction by the immune system  calquence is actually a btk inhibitor originally developed to treat leukemia  https   t co rrzbjz  ci
1913,crwe world,acalabrutinib long term benefit in cll captured in published data https   t co cygdq ud k
1914,we work for health   virginia, icymi   astrazeneca s calquence shows early promise for  covid   patients  https   t co bcjhviqnmt https   t co evidgi upa
1915,jeff sharman,phase   study results leading to fda approval of  acalabrutinib for untreated cll   good evidence of safety and efficacy   grateful for the team that brought this to fruition https   t co fy xlhbgzb
1916,immunotherapypapers,acalabrutinib long term benefit in cll captured in published data https   t co tjboghvvc 
1917,onclive com,acalabrutinib long term benefit in cll captured in published data  bloodjournal  lylsm https   t co grszrqg yd
1918,jason broderick,acalabrutinib long term benefit in cll captured in published data https   t co  zaqdbj x 
1919,anna lubas,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit     pharma  covidtreatments  covid   https   t co  mt abdvas
1920,biopoint inc , the calavi trial will evaluate the safety and efficacy of adding calquence to best supportive care to reduce mortality and the need for assisted ventilation   https   t co blurokluie  biopharma  pharmaceuticals  pharma  covid   https   t co    uupshjc
1921,jonathan faison, apto could become  covid   play as well with best safety tolerability profile for btk  early clinical data with acalabrutinib suggested that a decrease in inflammation caused by btk inhibitors reduces the severity of covid    induced respiratory distress https   t co  miiymlcyn
1922,targeted oncology,strong scientific evidence supports the hypothesis that btk inhibition  as with acalabrutinib  can reduce the production of inflammatory cytokines that are associated with respiratory complications of covid     https   t co ego yyywgi  covid    coronavirus
1923,biocanrx   canada s immunotherapy network,new trial lead by  astrazeneca will study  leukemia drug as covid    treatment  https   t co n v  l ukz via  biopharmadive
1924,earle burgess,covid   trial watch  pending randomized p  study with acalabrutinib  btk inhibitor  in severely ill patients   https   t co l rwetuw d
1925,maria rejane rocha,medicamento calquence  da astrazeneca  obt m resultados promissores contra covid    https   t co t hsjwpu  
1926,cpl life sciences,  astrazeneca will initiate a randomised  global clinical trial to assess the potential of calquence  acalabrutinib  in the treatment of the exaggerated immune response  cytokine storm  associated with covid    infection in severely ill patients  https   t co  gsnlro ba
1927, gulleyj ,this could be very interesting  astrazeneca announces calavi trial to examine acalabrutinib for patients with  covid    https   t co fxxbmvsmvo
1928,michael rynne,great news for patients in the uk with acalabrutinib available for treatment naive patients it would be good to see these options here in ireland during  covid    michaelodwyermd  gmcrotty  ruthclifford   bloodcancerirl  cancertrials ie  cllireland  janrynne https   t co tehcmimr f
1929,onclive com,cytokine storm  a type of severe immune overreaction that has presented in severely ill patients with  covid    can cause life threatening respiratory complications https   t co  oljjqh by
1930,pharmasources com,astrazeneca initiates calquence clinical trial against covid    https   t co chaut i tk  covid    https   t co nvuuqzspzh
1931,vshariharakrishnan,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit  https   t co  rxk  qwbi
1932,jorie graham,astrazeneca announces calavi trial to examine acalabrutinib for patients with covid    https   t co mzmqhxxn m
1933,targeted oncology,the calavi clinical trial is being initiated to explore the potential of acalabrutinib to treat exaggerated immune response  or cytokine storm  in patients who are severely ill with covid     https   t co ego yyq  g  covid  
1934,biggomamma,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials     https   t co getxpg jzm via  mailonline
1935,surviving myeloma,blood cancer drugs lead the way severe  covid   treatment clinical trials   https   t co wsow sljva
1936,biopharmamash,new post  astrazeneca s cancer drug calquence to be tested on covid    patients https   t co quvsarenhj
1937,dragana obradovic, calquence   acalabrutinib   btk inhibitor  covid   https   t co imcxhfkkrv
1938,medscape oncology,cll specialists discuss novel agents acalabrutinib  obinutuzumab  and venetoclax  https   t co pqfdbxfczq
1939,sarasmallmd,acalabrutinib covid    trial launching https   t co sz  jtblwc via  onclive
1940,covid   clinical trials   research  covidmune com, covid    clinicaltrial      assessing acalabrutinib  which is a  lymphoma drug that inhibits burton s tyrosine kinase   i wonder why they think this will work on  covid     this is a     plus patient trial supported by  pharma  astrazeneca  https   t co  fvqlvsohz
1941,dr t  comeau   md,acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  updated phase   results   blood   american society of hematology https   t co   qn nr  h
1942,big bio philly,astrazeneca will be exploring the applications of its btk inhibitor  calquence which is currently approved to treat chronic lymphocytic leukemia and mantle cell lymphoma  to tackle the respiratory complications of covid       azn  https   t co tbmnmelwfr
1943,pharmacyweek  kevin ,astrazeneca to test cancer drug for covid     astrazeneca will start a clinical trial to see if its cancer drug calquence can suppress the excessive immune response covid    triggers in some patients  the drugmaker said april      https   t co kpampc  vk https   t co ewlppgmha 
1944,edwin van bloois  phd, pharma  biotech  clinicaltrial  coronavirus  https   t co ouumxlkydz
1945,david ledger,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co sqx i qldu https   t co  ual oz  s
1946,mcgill oncology,cancer medicine to be tested on covid     astrazeneca plc will start testing its new cancer medicine calquence  a treatment for lymphoma  may reduce the severity of respiratory distress along with best supportive care  will help reduce the need to place patients on ventilators 
1947,hugojuliao,https   t co l w rwefzu
1948,          ,someone cut trump in on the action  he ll push it at his daily briefings  turns out a cancer drug developed in  netherlands by  astrazeneca might just be effective against  covid    it s called  calquence  amp  they ve started testing on     patients  paywall  https   t co pp  tmupkh
1949,forbes brasil, forbesbr   medicamento calquence  da astrazeneca  obt m resultados promissores contra covid     https   t co gqcxva wjo   forbesbrasil  forbes https   t co ryplgmhc h
1950,hospimedica com,astrazeneca begins global clinical trial of calquence to treat covid    infection astrazeneca  cambridgeshire     https   t co eaxy izxpb https   t co ok  qbeijz
1951,dr tomohiro,          calquence                calquence                                https   t co lygxlfagkz  youtube    
1952,sharky sarah,astrazeneca to study leukemia drug as covid    treatment   biopharma dive https   t co x mdj toda
1953,diving news,astrazeneca to study leukemia drug as covid    treatment   biopharma dive https   t co f  svhexdv
1954,biopharma dive, azn is the latest drugmaker to test whether one of its existing drugs could help thwart the potentially lethal immune response some covid    patients experience    https   t co  b ccbpg k
1955,patient power,chronic lymphocytic leukemia   today  experts from  osuccc james and  mdandersonnews discuss btk inhibitors  like ibrutinib or acalabrutinib  impact for patients during  covid   in today s live  cll webinar  ask questions and look for details here  https   t co affwcfklex   leusm https   t co  weqwpxh y
1956,dalia elgamal,acalabrutinib to be tested as treatment of exaggerated covid    related immune response https   t co g rfxvkzve via  targetedonc
1957,aspen biosciences,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit     covid   https   t co l xcv  tup
1958,gatos gatopoulos,https   t co bf nrxhjzp
1959,gatos gatopoulos,https   t co qqrr dtlpy
1960,emilio mordini,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit     scoopit https   t co fj ptad ps
1961,asoii,astrazeneca to begin calquence study for coronavirus treatment https   t co or yowfdnl https   t co zv noxyqfu
1962,i am biotech,  astrazeneca to test impact of  cancer drug calquence on  coronavirus patients https   t co cdtobzgrmr
1963,david ledger,az to test calquence for covid    https   t co ii pyml dp https   t co aerupmudu 
1964,cde news, astrazeneca initiates  calavi clinical trial with  calquence against  covid    https   t co cc  av c b https   t co lwwww cdvr
1965,adi singh,astrazeneca initiates calavi study evaluating calquence  acalabrutinib  against covid       pharmashots  astrazeneca  calquence  acalabrutinib  covid   https   t co p l uchgow
1966,shawn friend,astrazeneca is conducting a phase   trial of its btk inhibitor calquence  acalabrutinib  for treatment of exaggerated immune response in covid    patients  https   t co  ofstahgcz  coronavirus  covid    coronapandemic  coronaoutbreak
1967,prestige scientific,astrazeneca is conducting a phase   trial of its btk inhibitor calquence  acalabrutinib  for treatment of exaggerated immune response in covid    patients  https   t co rhsthywioi  coronavirus  covid    coronapandemic  coronaoutbreak
1968,miguel angel grullon c ,astrazeneca to study btk inhibitor calquence as treatment for cytokine storm associated with covid    infection   el dise o calavi se basa en  evidencia cient fica s lida  que respalda el papel de la v a btk en la producci n de citocinas inflamatorias  https   t co tksbvyp   
1969,silas inman,acalabrutinib covid    trial launching https   t co yb f  t pn
1970,ewallace,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co h  wjfg xd
1971,ssbmt               ,acalabrutinib  covid   trial launching https   t co  nikqz hyt via  onclive
1972,nikolaos m  mastrogiorgis,                                                                  calquence     astrazeneca https   t co  cdz  wyqd
1973,plexus ventures, astrazeneca to test impact of  cancer drug  calquence on  coronavirus patients https   t co g hhd  zcn  nytimes  astrazeneca
1974,mddigitastv, coronavirus    astrazeneca to start calquence in covid    trial  https   t co d  m zfzcz
1975,bb xydb             ,covid       astrazeneca btk   calquence             insights  pharma                   https   t co cuwqtfcoa 
1976,  robert,astrazeneca to start calquence in covid    trial https   t co jbdlf mo g  mailonline
1977,clinithink,astrazeneca have revealed plans to launch a global clinical trial to look at using calquence  currently used to treat blood cancers  to reduce the respiratory harm caused by coronavirus  this could potentially cut deaths  amp  reduce the need for ventilation in patients  go well az 
1978,the business network,coronavirus  astrazeneca rushes through testing of potential treatment after  encouraging  trial https   t co gugb sgri  https   t co sx zmv  pt
1979,rocky,blood cancer drug shows promise in treating coronavirus a drug normally used to treat blood cancer may be able to also help fight coronavirus  according to forbes researchers at the national cancer institute gave calquence to a small group of late stage   https   t co xham wyomr
1980,olatunde ayodeji,british drug company launches trial of potential covid    treatment after encouraging early signs https   t co  sufsuiypf
1981,healthtalk,blodkreftlegemidlet calquence skal testes p  sv rt syke covid    pasienter i en global klinisk studie   rsaken er at legemidlet har vist lovende resultater p  covid    pasienter som er p  intensivbehandling og i respirator  https   t co puwo  vhgq  covid    korona
1982,ulla nyman,cytokinstorm   handlar det om v der  nej det  r den  verreaktion fr n immunf rsvaret som vissa covid    patienter r kar ut f r och som ger sv ra lungskador  nu testar  astrazenecase ett l kemedel https   t co svofc  vjv  ikem se
1983,insider cyprus,                                             calquence    world  covid    https   t co gxlhlas  b https   t co  obmg x yv
1984,pharmashots   incisive news in   shots,astrazeneca initiates calavi study evaluating calquence  acalabrutinib  against covid     astrazeneca  https   t co  ju wbiju  https   t co  slenq zma
1985,capital gr,                                                                  calquence     astrazeneca https   t co mqoljnmdjy
1986,martijn antonisse,hopefully a lead to some relieve in the  covid    battle with potential medicine of  astrazenecanl https   t co npdyrw vdc
1987,sergey minaev,astrazeneca to start calquence in covid    trial  https   t co yomxlokvue
1988,aaa, encouraging news     independent    coronavirus  astrazeneca rushes through testing of potential treatment after  encouraging  trial    covid    https   t co agv g   fb
1989,stray,                                                                    calquence                                                      https   t co nutt g o  
1990,diogenis charalampidis,                                                                  calquence     astrazeneca https   t co rxwrtn khz
1991,cathlene sareli,british drug company launches trial of potential covid    treatment after encouraging early signs https   t co gfy inb el
1992,tenstarsdesign ,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co  dicor h y
1993,jennifer a  ng,astrazeneca to test impact of cancer drug calquence on coronavirus patients   article  amp    reuters https   t co hxhp  jx  
1994,onclive com,acalabrutinib  a btk inhibitor approved for the treatment of patients with cll and mcl  is being explored in the calavi trial as a treatment for cytokine storm in patients with  covid   https   t co  aidaqhxmx
1995,eipg,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit  https   t co m  caa k i
1996,scherazad falcon,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co  efxht cj 
1997,jared o    ,coronavirus  astrazeneca rushes through testing of potential treatment after  encouraging  trial  smartnews  https   t co rdwolvlurf
1998,shunta sanders, exclusive  astrazeneca s calquence shows early promise for covid    patients  https   t co  dbxhjwpz 
1999,fav store,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co cxo lw dmf https   t co f  bq wndr
2000,world pharma news,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co kddx r ena https   t co kts  zvoyw
2001,webwire,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co  dum  law 
2002,onconews,a astrazeneca anunciou o in cio do estudo calavi para avaliar a efic cia do inibidor de btk acalabrutinibe no tto da hipercitocinemia associada   infec  o por  covid     o medicamento   indicado para o tto da llc e mcl em segunda linha   https   t co ujkbfzaapw  onconews https   t co w fksvt jm
2003,cure cancer now,pharmacodynamic analysis of btk inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib https   t co n ykil i w
2004,httpp   ,calquence  un medicamento contra la leucemia podr a ser la soluci n pr xima contra el coronaviru   https   t co qdsgkhdp d  googlealerts
2005,prof david sebag  ,so   profbigg  and         pwmjohnson what is your take on the potential for bruton tki inhibition to mitigate the covid   cytokine storm    drsrbrown    hockadayanna    leedjulia   haem  haematology    https   t co pxvrnetvki
2006,                   insights  pharma   ,covid       astrazeneca btk   calquence           https   t co ifuzzkjwca
2007,kim kovarik,https   t co otvzjjrgsb  some hope  please 
2008,maisa, azn  said on tuesday it would start a clinical trial of its cancer drug calquence to assess its potential to control the exaggerated immune system response associated with covid    infection in severely ill patients 
2009,world news in tweets,british drug company launches trial of potential covid    treatment after encouraging early signs https   t co obwcdxok c https   t co s msfymhrb  newsintweets  worldnewsintweets  newsintweetscom
2010,the independent,british drug company launches trial of potential covid    treatment after encouraging early signs https   t co c uuzxzrsq
2011,crwe world,acalabrutinib covid    trial launching https   t co oqdb vwmfs
2012,anand c  patel,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes is it the btk inhibition or off target activities   covid     https   t co j bgijeqyy
2013,boya wang,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co coruusfluo
2014,dorothy,astrazeneca to start calquence in covid    trial https   t co ctunubmsqq via  mailonline
2015,djgolden,astrazeneca to start calquence in covid    trial  astrazeneca said there was anecdotal evidence of calquence improving the condition of ventilated and intensive care patients   https   t co fve x pxjv via  mailonline
2016,zorgnl,pharmascrip   astrazeneca s covid    taskforce starts with calquence trial https   t co  cme lz tf   pharmascrip https   t co izxunbd qj https   t co ysdhg jzrr
2017,coronavirus host   space,astrazeneca testet die wirkung des krebsmedikaments calquence auf    twittersmash https   t co otos pkhv 
2018,daily mail u k ,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials https   t co a y hnqo p
2019,bcaba network,coronavirus  astrazeneca rushes through testing of potential treatment after  encouraging  trial https   t co v x eacbjz https   t co ik     a  
2020,pablo aq, while china approved early stage human tests for two experimental vaccines on tuesday  british firm astrazeneca confirmed plans to launch a global clinical trial testing one of its drugs for treatment  calquence  which is currently used to treat some blood cancers   covid   https   t co sj chmgwus
2021,lakshmin nandagopal, acalabrutinib for  cytokinestorm in covid  interesting idea  https   t co iplsbbgrw 
2022,onclive com,acalabrutinib  covid   trial launching https   t co ahbqfgj us
2023,jason broderick,acalabrutinib  covid   trial launching https   t co pp vfjwjh   covid  pandemic  coronavirus
2024,prasad wakchaure  phd      ,astrazeneca to test impact of cancer drug calquence on coronavirus patients  a drug called acalabrutinib may act as an immunosuppressant   https   t co npcr kke t
2025,            ,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co  vru s onk
2026,giuseppe limandri,astrazeneca launches drug   calquence   trial for  coronavirus treatment    https   t co drlxat mg 
2027,phrma,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co  pbxllvsio via  reuters
2028,gmpnews net,astrazeneca initiates clinical trial with calquence against covid      https   t co  wisz os r https   t co vowd h msm
2029,greg johnson,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co uwwemivs g
2030,stephen d cruze,https   t co lf  otwnf 
2031,delaware bio, membercompany  astrazeneca making big moves toward a clinical trial   read more here  https   t co novswjgxuv
2032,andrew schorr,could a btk inhibitor like ibrutinib or acalabrutinib either prevent complications of covid   or treat them successfully in the sickest patients   experts from ohio state and md anderson in tomorrow s live cll webinar  https   t co zuedc e  a  cllsm  astrazeneca  abbvie  covid  
2033,scrip,astrazeneca s covid    taskforce starts with calquence trial https   t co m ytwmia    pharmascrip
2034,sarah hickman,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co wlfnoadaq 
2035,g  scott weston,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit  https   t co qzvgzo tvn
2036,qbox,positive news on the coronavirus front as pharmaceutical company astrazeneca is rushing their medical trials for a drug that may be able to help people with late term symptoms  even those already on ventilators   learn more in this article from forbes  https   t co  gbtyozi j
2037,manasranjan rout,https   t co  aasdtn tc
2038,blood journal,acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  updated phase   results https   t co ixorsywjnt  leusm  cll https   t co yfkj r dde
2039,sputnik ar,                  calquence                                                                                                         https   t co jof otagnu
2040,pyrus,exclusive  astrazeneca s calquence shows early promise for covid    patients   early  but promising science      michaelwangmd     interested in your perspective https   t co hqgilm kkv
2041,                   insights  pharma   ,astrazeneca to test blood cancer drug calquence in covid    after nih sees  some clinical benefit  https   t co mkhhi w  g
2042,the dude,astra zenecas l kemedel mot blodcancer  calquence  har anv nts p  allvarligt virussjuka i usa och vissa patienter blev avsev rt hj lpta  svpol  coronavirussverige  covid  
2043,nigel bradley,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co msjnkrllql
2044,astrazenecaus,we are actively exploring the potential of our medicines as a possible therapy for symptoms of covid     we have several clinical trials underway to help in the fight against the global pandemic  https   t co jmac oc tm https   t co hwse f wyn
2045,ancora ai cancer clinical trials for all,could a cancer treatment save covid    patients   astrazeneca will launch a  clinicaltrial to test the use of its blood  cancer drug calquence in the treatment of patients infected by the  coronavirus  https   t co j swehpd r
2046,jasmine the european cat,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co j xgcdpk w
2047,yasmin abdulghafour,https   t co ip ivkyqhy
2048,the independent,british drug company launches trial of potential covid    treatment after encouraging early signs https   t co  ln  x xyu
2049,vinay prasad md mph,wow  everything is promising until someone randomizes   exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co  g  lrkno 
2050,cp graduate academy,  astrazeneca has unveiled plans for a randomised  global  clinicaltrial to test whether calquence  acalabrutinib  could be used to treat the exaggerated immune response  cytokine storm  linked with covid    infection in severely ill patients  https   t co  xtduneyif
2051,sy investing, covid    azn astrazeneca will initiate a randomized  global clinical trial   calavi   to assess calquence  btki  in the treatment of the exaggerated immune response associated with covid    infection in severely ill patients   cytokinestorm  https   t co bhho omiay
2052,avi cohen     ,exclusive  astrazeneca s calquence shows early promise for covid    patients  https   t co  q xwc  zk
2053,market intelligence  healthcare,  astrazeneca plans to test its blood cancer drug calquence in certain patients with  covid   associated cytokine storm under a two part global trial https   t co zefg ftikq  azn  coronavirus https   t co uwm f xnu 
2054,europawire,the goal of the trial is to evaluate the efficacy and safety of adding calquence to best supportive care  bsc  to reduce mortality and the need for assisted ventilation in patients with life threatening covid    symptoms https   t co mvrjoyay k  covid    calquence  calavi https   t co c kqd q nj
2055,europawire,the trial  called calavi  is based on early clinical data with calquence demonstrating that a decrease in inflammation caused by btk inhibition appears to reduce the severity of covid    induced respiratory distress https   t co mvrjoyay k  covid    calquence  calavi
2056,europawire,astrazeneca to begin a randomised  global clinical trial to assess the potential of  calquence  acalabrutinib  in the treatment of the exaggerated immune response  cytokine storm  associated with  covid   infection in severely ill patients https   t co mvrjoyay k  calavi https   t co cdufdyuqt 
2057,europawire,covid     astrazeneca to start clinical trial to assess calquence potential in reducing mortality and need for assisted ventilation in patients https   t co mvrjoyay k  covid    calquence  calavi  astrazeneca https   t co  fe qmlxs 
2058,diana hedrick,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co  lvvomrfh 
2059,ned pagliarulo, azn to test calquence  its btk inhibitor for cancer  in patients with extreme immune responses to covid       https   t co ijb  ah l   every company  it seems  has a drug they think could work in calming cytokine storms    
2060,agha,                                            calquence                                                                     covid                                                                   
2061,lillian albert,astrazeneca to start calquence in covid    trial gl https   t co  t skv  dq
2062,ant pope, astrazeneca to start  calquence in  covid     trial https   t co kiwovetobs via  thisismoney  tweetuk    rt  fda  cocacola  ukhashtags
2063,el cierre digital,calquence  un medicamento contra la leucemia podr a ser la soluci n pr xima contra el coronavirus  https   t co m vaudcag 
2064,yasar hasan,https   t co xrsgdokxqz
2065,rttnews top stories,astrazeneca to test blood cancer drug calquence for covid    patients https   t co rdvp gt  x  news  breaking  rttnews https   t co yd zvmwsek
2066,conquer the patient voice,results of a new study showed that almost half of the patients with chronic lymphocytic leukemia  cll  responded to initial treatment with a   drug combination therapy  https   t co  brs  fszu
2067,clinicaltrialsdata, azn astrazeneca initiates calavi clinical trial with calquence against covid     a randomised  global clinical trial to assess the potential of calquence  acalabrutinib  in the treatment of the exaggerated immune response  cytokine storm  associated with covid    infection in   
2068,nasdaq, azn astrazeneca initiates calavi clinical trial with calquence against covid     a randomised  global clinical trial to assess the potential of calquence  acalabrutinib  in the treatment of the exaggerated immune response  cytokine storm  associated with covid    infection in   
2069,pressreleasepoint,https   t co jv tmujgxo astrazeneca initiates calavi clinical trial with calquence against covid   
2070,budimirka vuletic,astra zenica  vedsko britanska farmaceutska kompanija po inje globalno klini ko testiranje lijeka calquence za suzbijanje smrtnosti od covid     ovaj lijek se koristi protiv nekih tipova leukemije  cancera krvi  https   t co s  ymzorro
2071,pharmatimes,az to test calquence for covid    https   t co  zfscxwqmx  lifesciences  pharma
2072,omer haghi,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co lijccozdf  https   t co t yrh d tx
2073,ashish ranjan swain,astrazeneca to start calquence in covid    trial https   t co qvtbdomfkt  mailonline
2074,charlespollackmd,important issue particularly for younger covid victims astrazeneca to study btk inhibitor calquence as treatment for cytokine storm associated with covid    infection  https   t co vspxwm bap via  fwpharma
2075,rizonson o kodee,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co  ul gmduue
2076,sj lefevre,new news exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co ll kjiu eq via  ajbcsurveys  trending  breakingnews https   t co puag  s ft
2077,juan c ivancevich md,nci is involved with administration of off label use of  acalabrutinib in a small number of selected patients with severe  covid    https   t co qcsj rn rn
2078,mike judin,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co h z psathm
2079,julia chidley,astrazeneca to start calquence in covid    trial https   t co pcpg wxkzs via  mailonline
2080,open outcrier, azn        pre  astrazeneca to start calquence in covid    trial   reuters  https   t co isztxcsetb
2081,exppharma,  astrazeneca to test impact of  cancer drug  calquence on  coronavirus patients https   t co u asqjf ec   pharma  pharmanews  coronavirus  covid  india  indiaincfightscovid   https   t co byq  k jqn
2082,zarnescu  valentin,c e  elaboreaza  plan de relansare ec  de      mld euro acalabrutinib vandut de astrazeneca sub numele de calquence a aratat semne pozitive la o serie de subiecti cu covid    din us acest medicament e folosit in schema de tratament vs leucemie franta dr didier raoult criticat dur
2083,investors squad, azn inicia el ensayo cl nico calavi con calquence contra  covid  
2084,company news hq,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co l qqtn ebr
2085,barrington james,astrazeneca to start calquence in covid    trial    lifeatbj  barringtonjames  drugtrial  clinicaltrial  https   t co  ymtiqvute https   t co lbzmm v v 
2086,briefing com, azn  astrazeneca initiates calavi clinical trial with calquence against covid    https   t co kpwkoccxxn
2087,foreign confidential,exclusive   astrazeneca  calquence shows early promise for  coronavirus patients https   t co snwszhxybh
2088,john lauerman,can a cancer drug fight covid     astrazeneca is starting a trial of lymphoma treatment calquence to see if it can reduce damage from inflammation  marthefourcade  https   t co fpuweza tr
2089,irmeli viinanen,astrazeneca s calquence shows early promise for  covid   patients via  forbes https   t co pjbllevwdz
2090,biopharmaasia,astrazeneca initiates calavi clinical trial against covid    with calquence   https   t co yanugg ol 
2091,julianna tatelbaum,astrazeneca soars     as the pharma giant announces it will start clinical trial of its cancer drug calquence to assess its potential to control the immune response to  covid      this is aimed at reducing mortality  amp  the need for assisted ventilation in patients in severe cases 
2092,daily mail u k ,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials https   t co  huknq tb 
2093,the fly,astrazeneca initiates calavi clinical trial with calquence against covid     azn https   t co zwaeaibh v
2094,jon angelo,astrazeneca to pit blood cancer drug calquence against covid    with the company s fastest ever trial launch   https   t co uxdelqlh x  pharmaceutical
2095,new model adviser,pharmaceutical giant  astrazeneca has announced the start of a clinical trial to assess the use of its calquence drug in the treatment of patients infected by the  coronavirus coronavirus  https   t co  o kd  mol
2096,wealth manager,shares in pharma giant astrazeneca surge towards the top of the  ftse    after it announced the start of a clinical trial to assess the use of its calquence drug in treating the  coronavirus    dan grote  investment  markets  finance https   t co jyfbsnynuj
2097,reuters,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co gbep zqjhc https   t co uznslhfe e
2098,hargreaves lansdown,astrazeneca to start calquence in covid    trial   from reuters https   t co iisgtzbn l
2099,bio stocks , azn initiates calavi clinical trial with calquence against  covid   https   t co p a jee gr
2100,pharmafocus,astrazeneca to pit blood cancer drug calquence against  covid   with the company s fastest ever trial launch https   t co zncunitenl https   t co votn ottvx
2101,downtown news,cv update  a drug used to treat some blood cancers could be given to covid    patients  it s thought calquence  made by astrazeneca  may reduce harm to the respiratory system  https   t co tuxkt yzrh
2102,cool fm news,cv update  a drug used to treat some blood cancers could be given to covid    patients  it s thought calquence  made by astrazeneca  may reduce harm to the respiratory system  https   t co pvb quf ml
2103,downtowncountry news,cv update  a drug used to treat some blood cancers could be given to covid    patients  it s thought calquence  made by astrazeneca  may reduce harm to the respiratory system  https   t co znltacyh y
2104,thearticletrunk,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co a kvete  y
2105,thestreet, azn s  leukemia treatment  calquence  could ease coronavirus symptoms and reduce the need for respirators in severly ill patients  the company said  https   t co  oisiwh bw
2106,heart news east,the  cambridge based pharmaceutical giant astrazeneca is planning a trial to look into whether one of its existing drugs could help coronavirus patients calquence is currently used to treat some blood cancers  cambridgeshire   heartnews https   t co   rg pibec
2107,working capital consulting,astrazeneca shares have jumped by    as the pharmaceuticals giant started testing its calquence drug to try and help treat severely ill covid    patients   covid    https   t co rrgyel tjb
2108,daniel,astrazeneca to start calquence in covid    trial from reuters via  hlinvest https   t co se mye q  
2109,antoine gara,https   t co fmgtwjhllh
2110,commercial awareness,astrazeneca is set to begin clinical trials to test its calquence drug s effectiveness in the treatment of severe coronavirus patients  the pharmaceutical giant s shares shot up on the ftse     in early trading after saying it would begin a clinical trial  https   t co ylu nvabkw
2111,nordic life science,astrazeneca initiates clinical trial with calquence against covid    https   t co z eklira  
2112,career biotech, jobs az to test calquence for covid    https   t co vqmjmfgzep  biotechnews  pharmanews
2113,the pmi  pharmaceutical managers  institute , marketwatch az to test  calquence for  covid    the moves follows  strong scientific evidence  indicating the role of the btk pathway in the production of inflammatory cytokines    astrazeneca  https   t co bslguvx rs https   t co dl au vcgb
2114,colormered   ,astrazeneca to trial calquence to treat covid    patients https   t co wbzusx  bg via  pharmatechfocus
2115,drspock      phd  ,az to start calquence in cv   trial  yeah   i bet all these pharmaceutical giants are rushing around like bees at the moment to try  amp  get a huge payday  in doing so they will keep trying a multitude of different expensive drugs in the hope one may work    https   t co hjmfeof y 
2116,kate      ,astrazeneca to start calquence in covid    trial https   t co yimuw kdqj via https   t co ykczxw wgk
2117,firstword pharma,astrazeneca to study btk inhibitor calquence as treatment for cytokine storm associated with  covid   infection https   t co  eqedn b q  azn
2118,chitraders, azn astrazeneca to test impact of cancer drug calquence on  coronavirus patients https   t co hzn wiisfp
2119,maths nilsson,astrazeneca startar klinisk pr vning av substans som verkar kunna  lugna  den inflammatoriska reaktionen som skapar stora problem i covid    https   t co  wyrtpikb 
2120,oliver haill wfh,astra s new tests to see if calquence drug can be used to treat severe coronavirus effects  is the fastest launch of any clinical trial in the history of astrazeneca  https   t co strwqmjkpa
2121,altizem,astrazeneca to test calquence for covid         healthcare  covid      https   t co nd me  izo https   t co aug ahkgkl
2122,citywire,update  shares in astrazeneca have surged towards the top of the ftse     after they announced the start of a clinical trial to assess the use of its calquence drug in the treatment of patients infected by the coronavirus  read more  fundfanatic https   t co d zdkrfnzu
2123,stranger than fiction news,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials  after it showed benefit for patients in intensive care https   t co bn bgpuhab via  mailonline
2124,saleh stevens,az to test calquence for covid    https   t co vog  jfbby https   t co h ex uaxpq
2125,get your world on,https   t co tx  igzafi
2126,jimmys post,astrazeneca to start calquence in covid    trial https   t co qtgtrbnyeb
2127,thearticletrunk,update   astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co b sbkkj uf
2128,      recruitment,az to test calquence for covid    https   t co qu f lktaa  covid    coronavirus  global  clinicaltrial  immuneresponse  scientificevidence  clinicaldata  respiratory  drug  mortality  ventilation  clinicalbenefit  patients  clinicaltrial  icu  itu  ventilators  us  europe
2129,mack murray iii,this is starting to feel like the early days of hiv treatment when chemo drugs in the catalogue get thrown at the problem to see what works   https   t co ihazljrsfy
2130,odenoracle,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials  after it showed benefit for patients in intensive care 
2131,emg gold,astrazeneca is set to begin clinical trials of its cancer drug calquence to assess its potential as a cure for covid       covid    coronavirusupdates https   t co o vo  dzst
2132,chorley chicken,astrazeneca to test impact of cancer drug calquence on coronavirus patients  https   t co iiq idaigw   https   t co yjx ayie   https   t co tgyl arjdi
2133,medicine briefly,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co  skdbyim e    vigorbot  medicine
2134,lucas wyrsch,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co mctiagsvq 
2135,buddug light,the new drug  calquence  is a tyrosine kinase inhibitor  tki  that acts to suppress a pivotal point in the immune response cascade sometimes resulting in the potentially fatal cytokine storm in covid     egcg  epigallocatechin gallate  is also a tki  that is present in green tea  https   t co t tbrcjfnz
2136,sheikh anvakh                            ,a drug far more dangerous  amp  expensive than hydroxychloroquine  someone has been doing some behind the scenes discrediting  amp  lobbying  or am i being cynical   astrazeneca to start calquence in covid    trial https   t co dalgzajwmz via  mailonline
2137,reuters uk,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co fjtrfo o   https   t co wew nmumas
2138,kristin gustavsen,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co  css  mj r via  cisionsverige
2139,  h sante,astrazeneca to start calquence in covid    trial https   t co dpi gblmqq
2140,l kemedelsv rlden,astrazeneca testar cancerl kemedel mot covid      svmed  covid    l kemedel https   t co vkv  kgkkw via  l kemedelsv rlden
2141,lbc news,pharmaceutical giant astrazeneca is set to test the impact of its cancer drug calquence on coronavirus patients   https   t co l qcde pmh
2142,john b tawn,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials  after it showed benefit for patients in intensive care  via https   t co solyfq fjs https   t co avaszvwgmp
2143,aakash jagadeesh b,https   t co i sahjrgvn  azn  coronavirus
2144,roslund,astra zenecas l kemedel calquence  som  r det senaste hoppet f r att behandla coronaviruset  har visat lovande resultat bland intensivv rdspatienter med covid     det skriver forbes 
2145,mywaypress,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co g pah hzgj
2146,ocs channel,astrazeneca to start calquence in covid    trial https   t co f gd   dty https   t co nvzciud yz
2147,investor news,update   astrazeneca to test impact of cancer drug calquence on coronavirus patients  azn  gsk  coronavirus  covid     https   t co teyw rrax 
2148,israel stagman, astrazeneca to test impact of cancer drug calquence on coronavirus patients  by reuters via nyt https   t co fcmbr fdp 
2149,ranjeet m,this is a good news emerging  the fight against corona can be conclusively won only with vaccine   exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co hmgqrxvqdx
2150,vanya aleksandrova  ,brief astrazeneca initiates trial with calquence against covid      article  amp    reuters https   t co ack  bhtlj
2151,onthefritz,astrazeneca to start  calquence trial  the trial is expected to open for enrollment in the coming days in the united states and several countries in europe   covid       https   t co obds pnww 
2152,aldo sterone,uk  astra zeneca obtient l autorisation de tester un m dicament pour leuc mie sur des malades de covid     il coute       euros la boite de    comprim s   https   t co xalspgtgkm
2153,devdiscourse,astrazeneca to test impact of cancer drug calquence on coronavirus patients https   t co klatlrajwu
2154,bistosh world,astrazeneca to start calquence in covid    trial https   t co  l ehsdhsb https   t co guuwkchx  
2155,                   insights  pharma   ,      covid           astrazeneca  btk      calquence                  https   t co tmhrdur wx
2156,su de en alg rie,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co l p oejpo  via  cisionsverige
2157,adam fraise,astrazeneca to start calquence in covid    trial   article  amp    reuters https   t co r   lb nx 
2158,daily mail u k ,pharmaceutical giant astrazeneca rushes its blood cancer drug calquence into coronavirus trials https   t co wffxyfh vh
2159,laleh,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co xylwmsj ig via  cisionsverige
2160,team mckimmie  vhit     ,this sounds encouraging  small molecule inhibitor that inhibits btk dependent cytokines associated with lung pathology  manufacture can be scaled up more easily than eg biologics  trials under way  anecdotal reports  patients already on it are protected  https   t co f oht jxt 
2161,medicine briefly,astrazeneca to start calquence in covid    trial https   t co vm hpxdhii    vigorbot  medicine
2162,benjamin cheah md,another immunomodulatory drug jumps on the  covid   bandwagon   https   t co czqiynpl i
2163,graniteshares europe, azn initiates calavi clinical trial with calquence against  covid      https   t co d nbe  tag
2164,biotoday,astrazeneca initiates calavi clinical trial with calquence against covid    covid         btk                  astrazeneca btk   calquence                       covid             calavi      https   t co x gxfcxat 
2165,lorena delgado varas,astrazeneca initiates calavi clinical trial with calquence against covid     really hope it has good results  https   t co dvbeqo dr 
2166,kungens kurva,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co v  ubvtzin via  cisionsverige
2167,chorley chicken,astrazeneca to start calquence in covid    trial  https   t co iiq idaigw   https   t co awa  a  fe https   t co o c  rwxmp
2168,samtiden,medicin  astra zeneca inleder tester av l kemedlet calquence mot covid      l kemedlet har potential att hj lpa sv rt sjuka coronapatienter   https   t co fev suvhyq
2169,david madden,astrazeneca to start calquence in covid    trial  https   t co wl uafbmdm   azn    
2170,kaj jakobsson,light at the end of the  corona   tunnel   astrazeneca initiates calavi clinical trial with calquence against covid    https   t co bk b    xj via  cisionsverige   covid     covid    covid  sweden  scottadamssays  cernovich
2171,st foreign desk,astrazeneca to start calquence in covid    trial https   t co kmrpp ihfv
2172,the straits times,astrazeneca to start calquence in covid    trial https   t co ywmqbymq y
2173,devdiscourse,astrazeneca to start calquence in covid    trial https   t co ybwgxopr u
2174,g teborgs posten,astra zeneca inleder tester av l kemedlet calquence mot covid      l kemedlet har potential att hj lpa sv rt sjuka coronapatienter  https   t co   pc  e ns
2175,pani blondynka,astrazeneca rozpoczyna testy leku przeciwko  covid     https   t co kikjzsoz v
2176,jonas medin,bra nyheter fr n astra  https   t co iib  plpxv
2177,stefan fahlander,l t oss hoppas att det lyckas  https   t co nxo wbasvw
2178,matti wallin,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co ns dvhcpal via  cisionsverige
2179,john wilander, the trial  called calavi  is based on early clinical data with calquence demonstrating that a decrease in inflammation caused by btk inhibition appears to reduce the severity of covid    induced respiratory distress   https   t co hmqyownnbp
2180,stefan laurell,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co n  fyak  v via  cisionsverige
2181,bio station,this js interesting   azn will test their   btk    calquence as a treatment of cytokine storm associated with  covid    infection in severely ill patients   bgne   novn   next   https   t co vcyjtc mu 
2182,syed abutalib,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co whfubt m s
2183,mathieu rappas,https   t co ufmm uxbe 
2184,cision news,astrazeneca initiates calavi clinical trial with calquence against covid    https   t co pimicc  jz
2185,forbes science,the blood cancer drug has been given to a small number of sick u s  patients and massive clinical trials are being launched to determine its efficacy  as well as that of imbruvica   https   t co x yx l nhk https   t co jofrctseh 
2186,dabloguiman,something to keep an eye on  acalabrutinib seems to have potent anti inflammatory effect and suppresses the cytokine storm associated with late  covid    covid  ards  covid      https   t co vzpz k o p
2187,s wanee,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co uedwifxrjg
2188,pengyu yang,btk inhibitors have an anti inflammatory benefit  potentially for cytokine storm   astrazeneca s calquence shows early promise for covid    patients https   t co oagkxlwlks
2189,michael blaiss  md,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co rggor  okv
2190,peterdfokes, within    hours the company had completed drafting a covid    clinical trial  amp  submitted it to the fda  the fastest study he has ever seen put together in his    year career    astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co fnygpcr  p
2191,kenneth farber,could btk inhibitors attenuate cytokine storm caused by covid    exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co pprkiouiqe
2192,cafepharma,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co sqec nwasf
2193,buried on page ,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co g mddxsbf 
2194,chris manfuso,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co rzjlcmxmxg https   t co  onfxrhozm
2195,shouting at people in my underpants,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co bufeqntplg amazing discovery   acalabrutinib  amp  ibrutinib  the latter drug was my  cll drug  appear to be useful in damping down cytokine storm that is killing some  covid   patients
2196,eipg,astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co xjqogpj wp
2197,mm   ,                                                        astrazeneca s calquence shows early promise for covid    patients https   t co gf ch xusy
2198,vineeth sukrithan, astrazeneca is advising doctors to give the drug through a tube in a solution made up of coca cola  which due to its acidity properly liquefies the powder    acalabrutinib and coca cola to the rescue  who knew  covid    covid      davidsteensma  drsidmukherjee  erictopol
2199,maria badillo  msn rn ocn ccrp,very interesting  well  since our team is well versed with both calquence and imbruvica  we can help out with patient education  that s just a thought    https   t co  bidgnwwp 
2200,    ,awesomecapital  astrazeneca s calquence shows early promise for co    https   t co zs usl zed
2201,john p  leonard  md,btk inhibitors for covid    hmmm     https   t co rkleewshps
2202,howard green  md,wow  btk inhibitors in late stage severe coronavirus infections  astrazeneca s calquence shows early promise for covid    patients https   t co rflcycmcxb
2203,john nosta,astrazeneca s calquence shows early promise for  covid   patients via  forbes https   t co  ourrgsvq   coronavirus
2204,joe,if it was a    m mcap company claiming treatment for  covid   with cancer drug i will pass  but this is  azn if calquence  amp  imbruvica are known as btki works  so  tapto     too   astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co t ajx h  e
2205,  datos digital,exclusive  astrazeneca s calquence shows early promise for covid    patients    analytics  googleads  facebookads https   t co ilupbek q 
2206,grant beasley, apto   interesting discussion in forbes on btk inhibitors being used in covid patients  exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co z nrycmbae
2207,kristen breland,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co kyv    vsi
2208,joel padre,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co y  osohkan
2209,the peoples pharmacy,exclusive  astrazeneca s calquence shows early promise for covid    patients   forbes https   t co hkyaz  o v
2210,steven bertoni,is this the shelter from the cytokine storm  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co ukek ukkpr
2211,dr timos papagatsias,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co  ojroprhow  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  pharmaceutical  healthcare  biotech  productmarketing  pharma https   t co aeigf  dcr
2212,dots kate,         calquence    https   t co  q i tyndg
2213,michael noer,exclusive  astrazeneca s calquence shows early promise for covid    patients  forbes  nathanvardi
2214,global capital asset management, british drug giant  astrazeneca is rushing forward a big clinical trial for its blood cancer drug calquence because it has shown early promising results in later stage covid    patients those in intensive care units and on  ventilators  https   t co m etkegvdo
2215,pharmafactz,   tyrosine kinase inhibitors   suffix  tinib   imatinib   cml and all  erlotinib   non small cell lung cancer  sunitinib   renal cell carcinoma  acalabrutinib   mantle cell lymphoma  lapatinib   breast cancer  dasatinib   ph  cml   all  nilotinib   cml  bosutinib   cml
2216,antoine gara,big exclusive from my colleague  nathanvardi https   t co  dehvlehto could the biggest coronavirus breakthrough come from a leukemia drug 
2217,whatmoney,https   t co fd ttzsuns     https   t co fd ttzsuns 
2218,omondi nyangla,british drug giant  astrazeneca is rushing forward a big clinical trial for its blood cancer drug calquence because it s shown early promising results in later stage covid    patients those in intensive care units and on ventilators https   t co  mrramttea https   t co  f ipcx  x
2219,forbes,british drug giant astrazeneca is rushing forward a big clinical trial for its blood cancer drug calquence because it has shown early promising results in later stage covid    patients those in intensive care units and on ventilators https   t co lfpqw tmpp https   t co  h gc flfl
2220,matthew herper,another interesting approach against covid     btk inhibitors  by  nathanvardi  https   t co isg juidmp
2221,dough, azn forecast best in class growth          e sales cagr  with dramatic underlying ebit margin growth from     fy  a to     fy  e  driving mid teens ebit cagr  an impressive launch portfolio  key launches include calquence in cll  recently approved  enhertu  in post kadcyla https   t co mupmltzvfp
2222,janet novack,exclusive  astrazeneca s calquence shows early promise for covid    patients via  forbes https   t co avhp yfuvf
2223,health news, exclusive  astrazeneca s calquence shows early promise for covid    patients  https   t co lkjimvc  d  health  pharma
2224,nathan vardi,   astrazeneca rushing forward     patient trial for calquence in covid    patients  here is my exclusive story  let me explain why it s important  https   t co pfceghkquu
2225,chicagoschoolofyoga,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co kcxtrrmcmg https   t co dipya rdbj
2226,benexact,exclusive  astrazeneca s calquence shows early promise for covid    patients https   t co mxc ykeic  https   t co twbizguan 
2227,onclive com,btk inhibitors  such as ibrutinib and acalabrutinib  have dramatically changed the treatment landscape of cll  says  awandoc of  utswnews  leukemia https   t co akjrjl rsu
2228,raul cordoba  md  phd, oncoalert  acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  cll  updated phase   results     bloodjournal    american society of hematology   ash hematology   cllsm  leusm  lymsm  https   t co mdiddahptk
2229,benlazar s m amin ,acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  updated phase   results   blood   american society of hematology  cll  leusm https   t co enyjznsw m https   t co irc orhg b
2230,garbi e lizeaga,antitumor potency of an anti cd   chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib https   t co bpyfwo   y
2231,aloysius pendergast,acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  updated phase   results   blood   american society of hematology https   t co gm jy uxyk
2232,tribeca  knowledge,jefferies analysts suggest the biggest hit to pharma companies from coronavirus in the european union will be on new drug launches like novo nordisk s rybelsus or astrazeneca s calquence      are you involved in launching a new medicine in       then our free new launch guid  https   t co je u ton  
2233,tribeca  knowledge,jefferies analysts suggest the biggest hit to pharma companies from coronavirus in the european union will be on new drug launches like novo nordisk s rybelsus or astrazeneca s calquence      are you involved in launching a new medicine in       then our  https   t co rvcoc gqzz https   t co vewzkryato
2234,onclive com,the addition of acalabrutinib to the combination of venetoclax and obinutuzumab was shown to be highly active in patients with newly diagnosed cll  eliciting deep and durable responses that improved over time  leukemia  danafarber https   t co oxbu  e ss
2235,dough, abbv catalysts  close  agn acquisition in  may           rinvoq ph   data in atopic derm in mid      skyrizi ph   motivate  data in cd induction in       bi voltaire x interchangeability study read out on biosimilar humira  head to head calquence  imbruvica data in r r cll      
2236,ali alahmari ,second generation btk inhibitors impair the anti fungal response of macrophages and neutrophils from cll patients   acalabrutinib has potential risk of infections by it impairs the anti microbial  innate immune response https   t co mybnozskfe
2237,paperbirds hematology,new article  acalabrutinib and its therapeutic potential in the treatment of chronic lymphocytic leukemia  a short review on emerging data  https   t co yrhwrxwsl   cll  leusm  hematology
2238,onclive com,benjamin l  lampson  md  phd  of  danafarber discusses the primary efficacy and safety findings from the ongoing phase ii trial with acalabrutinib  venetoclax  and obinutuzumab in frontline cll  leukemia https   t co vspgfpi k 
2239,crwe world,acalabrutinib triplet impresses in frontline cll  advances to phase iii study https   t co ji wbussoj
2240,onclive com,acalabrutinib triplet impresses in frontline cll  advances to phase iii study  leukemia  danafarber https   t co  fohpzhug 
2241,conquer the patient voice,results of a new study showed that almost half of the patients with chronic lymphocytic leukemia  cll  responded to initial treatment with a   drug combination therapy  including calquence  gazyva  and venclexta sequentially  https   t co  brs  fszu
2242,targeted oncology,dr  sharman discussed the secondary end points from the phase iii elevate tn trial  which evaluated the role of acalabrutinib  either as a single agent or in combination with obinutuzumab in treatment naive chronic lymphocytic leukemia  https   t co tabcasruqq  leusm  leukemias
2243,cancernetwork   home of the journal oncology , icymi  lori leslie  md  from the john theurer cancer center noted the importance of real world data in determining potentially different toxicity profiles in these btk inhibitors     lorilesliemd  jtcancercenter https   t co etagmyy mz https   t co zcpf zmtuc
2244,pharmafactz,  tyrosine kinase inhibitors   prefix  inib   imatinib   cml and all  erlotinib   non small cell lung cancer  sunitinib   renal cell carcinoma  acalabrutinib   mantle cell lymphoma  lapatinib   breast cancer  dasatinib   ph  cml   all  nilotinib   cml  bosutinib   cml
2245,michael rynne,will this  acalabrutinib  early access programme extend to irish patients who have few first line options   janrynne  cllireland https   t co tehcmimr f
2246,targeted oncology,overall  dr  sharman said it is important to alert patients that headaches as an adverse event can occur with this treatment  but these do tend to pass in time  according to these findings  https   t co tabcasruqq  cllsm  leusm
2247,onclive soss,  awandoc discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia  utswnews  leusm https   t co pwdjecrjwf
2248, siguemeytesigodevuelta, para cu les condiciones o enfermedades se prescribe el acalabrutinib  https   t co   vdonpm y
2249,toby eyre,great news for  cll pts in the uk that  astrazeneca will provide  acalabrutinib for frontline patients during the  covid   era in an early access programme    great to see industry supportive in these challenging times     cll  lymsm  covid  
2250, siguemeytesigodevuelta,https   t co jkejnj mk 
2251,vjhemonc,video  acalabrutinib  venetoclax and obinutuzumab upfront for  cll w   drmdavids of  danafarber  https   t co xkmp zdsid   leusm  immunoonc  ash    ash hematology  vjhemonc
2252,naturerevclinoncol,in a phase ii trial in pts with r r cll  the btk inhibitor acalabrutinib was well tolerated and yielded an orr of        and an estimated    month pfs of       with bid dosing  vs       and        respectively  with qd dosing  https   t co wawzjz blt  leusm
2253,ali alahmari ,clinical and biological implications of target occupancy in cll treated with the btk inhibitor acalabrutinib   blood   american society of hematology https   t co l iaerrga 
2254,value based cancer care,acalabrutinib monotherapy in patients with relapsed refractory cll     month follow up of a phase   study https   t co th yx bu l
2255,clinowl haematology,clinical and biological implications of target occupancy in cll treated with the btk inhibitor acalabrutinib  https   t co  n foelaiu    haematology  thewiderwiserview
2256,iwmf,new iwmf acalabrutinib and      updated rituximab fact sheets  https   t co xqw f w y 
2257,paperbirds hematology,new article  clinical and biological implications of target occupancy in cll treated with the btk inhibitor acalabrutinib  https   t co t   eqkv l  cll  leusm  hematology
2258,javier de la serna,acalabrutinib plus obinutuzumab in treatment naive and relapsed refractory chronic lymphocytic leukemia https   t co es oefyuvp
2259,the james,a therapy developed at the james is improving quality of life for some  leukemia patients by reducing side effects associated with previous drugs  learn more about acalabrutinib  which was recently approved for the treatment of  cll and other blood cancers 
2260,anthony mato,very proud of my former student krista isaac for writing this excellent review  acalabrutinib and its therapeutic potential in the treatment of chroni   cmar   uva   https   t co xrcu bjmt 
2261,oncology tube,phase   elevate tn study in cll  seattlecca  chaitra ujjani  md  associate professor   seattlecca university of washington  fred hutchinson cancer research center  tells us about the results of the phase   elevate tn study  investigating acalabrutinib  https   t co     h snuw https   t co ju xr jv r
2262,the asco post,acalabrutinib plus obinutuzumab superior to obinutuzumab plus chlorambucil as front line treatment of cll https   t co  mjjsculk   leusm  hematology  ash  
2263,cancer discovery,from the march issue  acalabrutinib plus obinutuzumab in treatment na ve and relapsed refractory chronic lymphocytic  leukemia   ohiostate  cll  clinicaltrial https   t co hxcc jgdvh https   t co bkonlyhoqi
2264,the asco post,acalabrutinib plus obinutuzumab superior to obinutuzumab plus chlorambucil as front line treatment of cll https   t co  mjjsccksv  leusm  hematology
2265,motilal oswal financial services ltd,the receipt of this import and market permission paves way for the launch of acalabrutinib    mg capsules  calquence  in india  subject to the receipt of related statutory approvals and licenses   momarketupdates
2266,medical dialogues,astrazeneca pharma india gets dcgi nod for calquence acalabrutinib    mg capsules  astrazeneca pharma india  drugs controller general of india  acalabrutinib capsules  lymphocytic leukaemia  dcgi  astrazeneca https   t co a  xty  hr
2267,onclive soss,  drmdavids  of  danafarber  discusses exciting data with acalabrutinib in chronic lymphocytic leukemia  leusm https   t co q zhnjwwqt
2268,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2269,iiflmarkets,astrazeneca pharma received import and market permission from dcgi for calquence https   t co  u gv zwpy
2270,the paper link,trend up       overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2271,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2272,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2273,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2274,the paper link,trend up         overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2275,the paper link,trend new   overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2276,dr timos papagatsias,astrazeneca pharma india ltd receives permission for calquence  from dcgi   equity bulls https   t co   blpivskh  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  pharma  healthcare  biotech  pharmaceutical  productmarketing https   t co odkziryszz
2277,equitybulls com,astrazeneca pharma india ltd receives permission for calquence  from dcgi   astrazenecapharmaindia  permission  calquence  dcgi   https   t co ufj nzmgv  https   t co gjnslghjez
2278,dr  luis villela,hi dr  michaelwangmd  can i ask you about use of acalabrutinib in first line in mcl  i know acala si off label in first line but  any experience in first line combining cytarabine 
2279,tap clinical trial network,our tc  bec  was pleased to open  derriford hosp to recruitment for stellar yesterday  we look forward to working with you on this phase ii  randomised study of chop r in combination with acalabrutinib compared to chop r in patients with newly diagnosed  richterssyndrome 
2280,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2281,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodxwxpc
2282,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2283,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2284,the paper link,trend up        overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2285,the paper link,trend new   overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2286,the paper link,trend new   overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodxwxpc
2287,the paper link,trend new   overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2288,paperbirds hematology,new article  rumpel leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib  https   t co obibwiwmo   cll  leusm  hematology
2289,aus gov  news,tag   auspar  acalabrutinib https   t co rmnghjn f 
2290,tga australia,new  auspar for  calquence   acalabrutinib  for the treatment of chronic lymphocytic  leukaemia  cll  small lymphocytic  lymphoma  sll   https   t co zjd  qybl  https   t co  y fpf ebl
2291,the paper link,trend new   overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2292,onclive com,watch  dr  awan on utilizing acalabrutinib in  cll  leukemia  utswcancer  awandoc https   t co ldjuvs fuy
2293,onclive soss,  awandoc on utilizing acalabrutinib in cll  utswcancer  utswnews  leusm https   t co pwdjeciuup
2294,targeted oncology,dr  ryan discussed the data on how physicians are currently using acalabrutinib as treatment of patients with mantle cell lymphoma in the real world setting  https   t co ezzipxbjht  bloodcancer
2295,rd   ,acalabrutinib shows promise in relapsed refractory mantle cell lymphoma https   t co wdq w qdc    rd     raredisease  mantlecelllymphoma https   t co sdeqtvlfpi
2296,pressreleasepoint,https   t co imp  xyhdw project orbis  fda approves acalabrutinib for cll and sll
2297,the paper link,trend new   overman m  et al  j immunother cancer    randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co cwvodyeyoc
2298, siguemeytesigodevuelta,https   t co   vdoo xwy
2299,tap clinical trial network,our trial coordinator bec was on site at  cruk bi  beatson yesterday carrying out the siv for stellar  clinicaltrial  a phase ii  randomised study of chop r in combination with acalabrutinib compared to chop r in patients with newly diagnosed  richterssyndrome   nhsggc  cltap https   t co  s pxzjwgp
2300,journal for immunotherapy of cancer,new  jitc article  randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer  michael overman  aiims     https   t co dl klc yny https   t co pjsukrznds
2301,lymphoma papers,randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   lymphoma  lymsm https   t co fjw cnev q
2302,tga australia,new  auspar for  calquence   acalabrutinib  for the treatment of  mantle cell lymphoma  https   t co jfrddnqzlc https   t co cpc kjxcfl
2303,aus gov  news,tag   auspar  acalabrutinib https   t co   bbxvbriz
2304,anirban maitra,from  michael overman  amp   cancermedmda colleagues in  jitcancer   a randomized trial of btk inhibitor acalabrutinib v combo with pembro in advanced  pre treated  pancreaticcancer https   t co  qgjryqhcz unfortunately despite compelling preclinical data  the trial was negative  https   t co  woms yxpu
2305,onclive com,a number of therapeutic options have become available in the frontline setting for patients with cll  most recently the second generation btk inhibitor acalabrutinib  leukemia  gotohem  osuccc james https   t co n ze jtjq 
2306,genericdrugs,calquence acalabrutinib     mg              mcl  calquence                                  mcl       https   t co jac a r iv
2307,onclive com,jennifer woyach  md  of  osuccc james discusses the advances in the frontline setting for patients with  cll  and other strategies that are under investigation in this space  leukemia  gotohem https   t co cwokhj  y 
2308,scitrus,today s pick on  oncology   randomized phase ii study of the bruton tyrosine kinase inhibitor acalabrutinib  alone or with pembrolizumab in patients with advanced pancreatic cancer   https   t co wst thqx v https   t co eunnne vkk
2309,oncology learning network,jeff sharman  md   jeff sharman discusses results from the elevate tn trial  which led to the fda approval of acalabrutinib for the management of patients with treatment na ve  cll  listen here  https   t co  sokviww u https   t co  qqgoipuaj
2310,ash clinical news,presented by  jeff sharman at  ash    acalabrutinib  alone or with obinutuzumab  led to greater improvements in progression free survival  compared with obinutuzumab plus chlorambucil  in patients with treatment na ve chronic lymphocytic  leukemia   cll  https   t co xy kkda pl
2311,raul cordoba  md  phd,real world analysis explores current role of  acalabrutinib in  mcl mantle cell  lymphoma  lymsm  rwd  rwe https   t co  tai xyxep
2312,targeted oncology,in our interview  dr  ryan discussed the data on how physicians are currently using acalabrutinib as treatment of patients with mantle cell lymphoma in the real world setting   https   t co ezzipxjijj  mclsm  lymsm
2313,trip database,new trip  acalabrutinib  calquence    mantle cell lymphoma  mcl  https   t co  bsttvep c
2314,tap clinical trial network,we ve just completed the stellar site initiation for  derriford hosp  stellar is a phase ii  randomised study of chop r in combination with acalabrutinib compared to chop r in patients with newly diagnosed  richterssyndrome    clinicaltrials  cltap
2315,targeted oncology,acalabrutinib has demonstrated promising responses and safety in patients with relapsed refractory mcl  however  investigators recently sought to discover how physicians are using acalabrutinib in the real world setting  https   t co ezzipxbjht  mantlecelllymphoma  lymphoma
2316,targeted oncology,dr  ryan discussed the data on how physicians are currently using acalabrutinib as treatment of patients with mcl in the real world setting  https   t co ezzipxbjht  lymsm  mclsm
2317,targeted oncology,two btk inhibitors are available for cll  acalabrutinib and ibrutinib  with acalabrutinib  patients experience less arthralgias compared with ibrutinib  he notes that the rates of bruising and bleeding  however  appear similar between the   agents  https   t co qsnjfsjufm  leusm
2318,targeted oncology,dr  sharman discussed what differentiates acalabrutinib from other btk inhibitors available in chronic lymphocytic leukemia  https   t co qsnjfsjufm  leusm
2319,mednet,acalabrutinib bij macroglobulinemie van waldenstr m https   t co  jrkhn v p https   t co uglshnmnly
2320,shohta kadomura hospital pharmacist, cll           triplet therapy with  acalabrutinib   venetoclax  and  obinutuzumab in patients with treatment na ve chronic lymphocytic leukemia   value based cancer care                https   t co kl hvewdp 
2321,wcm lymphoma,dr  richard furman speaks on use of acalabrutinib as monotherapy in treatment of chronic lymphocytic leukemia   cll   via  onclive  https   t co ira yzzkwh
2322,targeted oncology,dr  sharman discussed what differentiates acalabrutinib from other btk inhibitors available in chronic lymphocytic leukemia  https   t co qsnjfsjufm  leusm
2323,saeid shamsian md,acalabrutinib monotherapy active in waldenstr m macroglobulinemia   oncology learning network https   t co up ebqr cp
2324,trip database,new trip  acalabrutinib  calquence    mantle cell lymphoma  mcl  https   t co  bsttvnefe
2325,jdiegotr,inhibidores de btk  btk   tirosina quinasa de bruton  desempe a un papel central en la maduraci n de las c lulas b  ejemplos  acalabrutinib  calquence  indicaci n  linfoma de c lulas del manto efectos secundarios    trombocitopenia   leucopenia   anemia   fatiga   dolor de cabeza https   t co tqg yn cps
2326,ph abdulluh,btk inhibitors  btk   bruton s tyrosine kinase  it plays a core role in b cell maturation   examples   acalabrutinib  calquence   indication   mantle cell lymphoma  side effects     thrombocytopenia   leucopenia   anemia   fatigue   headache
2327,pharmafactz,btk inhibitors  btk   bruton s tyrosine kinase  it plays a core role in b cell maturation   examples   acalabrutinib  calquence   indication   mantle cell lymphoma  side effects     thrombocytopenia   leucopenia   anemia   fatigue   headache
2328,benlazar s m amin ,acalabrutinib monotherapy in patients with  waldenstr m macroglobulinemia   mmsm https   t co ujqlwhxzss https   t co gqgy jsjrz
2329,paperbirds hematology,new article  pharmacodynamic analysis of btk inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib  https   t co faoaxls sf  cll  leusm  hematology
2330,lymphoma papers,acalabrutinib monotherapy in patients with waldenstr m macroglobulinemia  a single arm  multicentre  phase   study   lymphoma  lymsm https   t co vrbnrltog 
2331,cure cancer now,pharmacodynamic analysis of btk inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib https   t co  e tovnxdy
2332,onclive com,the third btk inhibitor to gain  fdaoncology approval  zanubrutinib joins ibrutinib and acalabrutinib  which are both indicated for adults with  mcl who have received    prior therapy  lymphoma  bannermdandersn https   t co   uvcdu k 
2333,onclive soss,  lorilesliemd discusses a retrospective analysis of real world patients with chronic lymphocytic leukemia who were treated with acalabrutinib  calquence   jtcancercenter  leusm https   t co   mqjw xiv
2334,cancernetwork   home of the journal oncology , icymi  the triplet regimen consisting of acalabrutinib  venetoclax  and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia  https   t co q z  ckxae https   t co jsvsb tag 
2335,the james,an  ohiostate developed treatment is improving quality of life for some  leukemia patients by reducing side effects  click to learn more about acalabrutinib  recently approved for the treatment of cll and other blood cancers 
2336,onclive com,watch  dr  davids on exciting data with acalabrutinib in  cll  leukemia  drmdavids  danafarber https   t co c rmsrhnim
2337,juan lopez mattei,    yo pt with htn  paroxysmal af  savr  gt    yrs ago with hematological malignancy being tx with acalabrutinib with good response  on asa    mg   apixiban   mg bid that had an ugib   wk ago  what will you change   cardioonc  datsunian  avirupguha  cardiooncology  eimanjahangir
2338,renal cell carcinoma,acalabrutinib and anticd   car tcell therapy for the treatment of bcell lymphoma  this phase iii trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with bcell lymphoma  acalabrutinib may  https   t co kijfzosbe   renalcell  kidneycancer
2339,paperbirds hematology,new clinical trial acalabrutinib and anti cd   car t cell therapy for the treatment of b cell lymphoma https   t co   s lscri   fl  lymsm  hematology
2340,paperbirds hematology,new clinical trial  acalabrutinib and anti cd   car t cell therapy for the treatment of b cell lymphoma https   t co kyhwtdypq   dlbcl  lymsm  hematology
2341,paperbirds hematology,new clinical trial  acalabrutinib and anti cd   car t cell therapy for the treatment of b cell lymphoma https   t co qqfuhnxe s  tcl  lymsm  hematology
2342,vjhemonc,video  resistance to acalabrutinib in cll is mediated by btk mutations w  jennifer woyach of  ohiostate  https   t co  ikhnwaeem   leusm  hemeonc  ash    ash hematology  vjhemonc
2343,onclive com,watch  dr  davids on exciting data with acalabrutinib in  cll  leukemia  drmdavids  danafarber  harvardmed https   t co wy fpauq  
2344,vjhemonc,video  elevate tn  approval of acalabrutinib for adult cll w   jeff sharman of  wvcancer  https   t co yyre sipub   leusm  lymsm  hemeonc  ash    ash hematology  vjhemonc
2345,onclive com,  awandoc of  utswnews discusses the introduction of acalabrutinib into  cll as well as other paradigm shifting advances with btk inhibitors  novel combinations  and emerging agents  leukemia https   t co tpadn qzjg
2346,hematology advisor,combining acalabrutinib with obinutuzumab may be safe and effective among patients with treatment naive or relapsed refractory  cll https   t co  wjgpunexo
2347,clinicaloncologynews,  jeff sharman from  wvcancer discusses elevate tn results showing benefits of acalabrutinib in cll  https   t co ovvp sb ni
2348, siguemeytesigodevuelta,https   t co jkejnj mk 
2349,adam kittai,acalabrutinib for cll  exciting times to be treating  cll especially at  osuccc james elevate tn  https   t co c tkmeer  
2350,ash clinical news,time limited frontline therapy with acalabrutinib  venetoclax  and obinutuzumab leads to encouraging rates of complete remission with high rates of undetectable measurable residual disease in chronic lymphocytic  leukemia   cll  https   t co khpjcsqogj
2351,raj chakraborty, gt     overall response rate with single agent acalabrutinib in waldenstrom s macroglobulinemia with  gt     remaing progression free at   years  https   t co h off ipk   lymsm  thelancethaem https   t co zpvqhdnabt
2352,lymphomaaction,an update in last month s  thelancethaem highlighted a possible new treatment for people with waldenstr m s macroglobulinaemia called acalabrutinib which has the potential to cause fewer side effects than ibrutinib  read more  https   t co hg tycteko  wmukinfo  bloodcancer  lymsm
2353,early phase clinical trials unit  oxford,accept trial  acalabrutinib   rchop in  l dlbcl phi ii  has finished recruiting    tussle between southampton  amp  oxford who would be top recruiter  ston beat us by        good oxford effort    great study   looking forward to results     lymsm  southamptonctu  ouh research https   t co owzktyrgnm
2354,aonn ,real world study defines acalabrutinib users https   t co  yofa lv   https   t co qemtoxkeot
2355,braeden lichti,fda nod for calquence in cll  via phramatimes  https   t co  b qglizjs
2356,the lynx group,responses to acalabrutinib monotherapy in relapsed refractory cll are durable https   t co ugsznm en 
2357,oncology tube,phase iii elevate tn trial  ash    ash  theusonetwork  jeff sharman  md of  theusonetwork discusses the phase iii elevate tn trial          read here  https   t co ga xrnnbyv https   t co cygljs jaj https   t co by j vrvzd
2358,leukaemia care,today  we re featuring another video from the american society of hematology  ash       conference   here  dr george follows describes how the elevate clinical trial  presented at ash  shows that acalabrutinib is an effective treatment option for cll patients https   t co kfxiwyrqxi
2359,treximo, with over        new cases anticipated this year in the u s  alone  today s approval of calquence provides new hope for patients with one of the most common types of adult leukemia   https   t co ehzkjcbeqz
2360,medivizor,evaluating acalabrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia https   t co nzsx j yx  via  medivizor  leukemia
2361,medivizor,evaluating acalabrutinib plus obinutuzumab in patients with chronic lymphocytic leu    from  medivizor  https   t co nzsx j yx   leukemia
2362,medivizor,check out  evaluating acalabrutinib plus obinutuzumab in patients with chronic lympho    https   t co nzsx j yx  via  medivizor  leukemia
2363,medivizor,new by  medivizor  evaluating acalabrutinib plus obinutuzumab in patients with chronic lymphocytic l    https   t co nzsx j yx   leukemia
2364,medivizor,evaluating acalabrutinib plus obinutuzumab in patients with chronic lymphocytic leu     via  medivizor  https   t co nzsx j yx   leukemia
2365,medivizor,new  evaluating acalabrutinib plus obinutuzumab in patients with chronic lymphocytic     https   t co nzsx j yx  via  medivizor  leukemia
2366,lia palomba,acalabrutinib monotherapy in patients with waldenstr m macroglobulinemia  a single arm  multicentre  phase   study   the lancet haematology https   t co   byinvpx 
2367,oncology tube,calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukemia  full results from phase iii elevate tn trial showed     of patients on calquence combined with  https   t co estk bfowy https   t co wzenhst xj
2368,quiet flows the dan,calquence  get the fuck outta here  pay me to come up with names   here s a freebie  it s for leukemia  okay  i ve got it  lukanol  lu ka nol  https   t co  nyjkvm dm
2369,acir org,antitumor potency of an anti cd   chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib  celgene originally published in journal of immunotherapy https   t co wf  zckamc read our digest   gt  https   t co kwooh jg d https   t co  dahodjiya
2370,ash clinical news,the  us fda granted a supplemental approval to acalabrutinib for the treatment of adults with chronic lymphocytic  leukemia   cll  or small lymphocytic  lymphoma   sll  https   t co o o mogrvt
2371,mauricio ambriz,en macroglobulinemia de waldenstr m  monoterapia con acalabrutinib es activa  con un perfil de seguridad manejable en pacientes sin tratamiento previo  reca da o enfermedad refractaria   lancet haematol       doi  https   t co wbvwcmzqyd https   t co qf njgrggq
2372,molecularmatch,fda approved calquence as initial or subsequent therapy for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma  https   t co getwpqvf  
2373,naturerevclinoncol,in a phase ib ii study of acalabrutinib plus obinutuzumab in patients with cll  orrs were     and          and    crs  in treatment na ve and r r disease  respectively  at    months  pfs was     and          of pts had  grade    toxicities  https   t co j  qteh nd  leusm  hemeonc
2374,the james,an  ohiostate developed treatment is improving quality of life for some  leukemia patients by reducing side effects  learn more about acalabrutinib  recently approved for the treatment of  cll and other blood cancers 
2375,toby eyre, acalabrutinib in  wm high orr in  l and r r pts median time to best response short     m    m pfs     in r r pts  highly active and well tolerated great uk presence on the authorship    well done  ouh research and  drjamkothari for contribution  lymsm  lymphoma https   t co ke  hwo tj
2376,graham collins,great results of a acalabrutinib in wm  mainly relapsed   roger owen first author          orr rate         of rel ref pts came off during study   only    g    af   most common g    aes neutropenia  amp  pneumonia  lymsm https   t co qwgl nbnvo
2377,uk chronic lymphocytic leukaemia  cll  forum,the uk cll forum paper of the month   acalabrutinib in  cll  here are some thoughts from the forum    https   t co noia grfuj   cll  blooducation https   t co  ezvz mboj
2378,lysa lymphoma, st study of acalabrutinib in     pts with waldenstr m macroglobulinemia with     orr in treatment na ve and r r patients      of    treatment naive patients and    of    r r pts discontinued treatment on study  lysalymphoma contributed to study enrollment https   t co r  hw nifi
2379,              ,   cll btk   acalabrutinib                  pfs     https   t co q u re  gi
2380,targeted oncology,dr  leslie discussed toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real word clinics  https   t co xlxyqz  zy  leusm
2381,sujeet kumar, nd gen btk inhibitors acalabrutinib and zanubrutinib have been reported to have lower bleeding rates compared with ibrutinib in clinical trials  this finding suggests that off target effects of ibrutinib may contribute to bleeding 
2382,brian mattys,  jeff sharman  discussed results of phase iii elevate tn study of acalabrutinib  calquence  combined w  obinutuzumab  gazyva   compared w  acalabrutinib alone or obinutuzumab   chlorambucil  leukeran   wvcancer  ash   https   t co g anfcmhci
2383,naturerevclinoncol,in an update analysis of a phase ii trial of acalabrutinib for patients with r r cll  the orr was     and the median dor and pfs were not been reached  the estimated    month pfs was      https   t co stgauyf b   leusm  hemeonc
2384,paperbirds hematology,new article  acalabrutinib plus obinutuzumab in treatment naive and relapsed refractory chronic lymphocytic leukemia  https   t co fltommlsum  cll  leusm  hematology
2385,cancer discovery,recently published  acalabrutinib plus obinutuzumab in treatment na ve and relapsed refractory chronic lymphocytic  leukemia   ohiostate   cll  clinicaltrial https   t co  xjuf xrjy https   t co ywe nmz v 
2386,journal le soir,une perc e contre le type de leuc mie le plus r pandu   astrazeneca canada a annonc  aujourd hui que  sant  canada avait homologu  l utilisation orale de calquence   ac      https   t co efla ufww     actualit s https   t co pj ntahylw
2387,cancer discovery,recently published  acalabrutinib plus obinutuzumab in treatment na ve and relapsed refractory chronic lymphocytic  leukemia  ohiostate  cll  clinicaltrial https   t co  acf n v f https   t co qzensbfbg 
2388,the asco post,in the clinic  acalabrutinib for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma https   t co ujofswmufe  lymsm  leusm  hematology
2389,naturerevclinoncol,preclinical studies indicate that anti cd   car t cell function is improved by treatment with the bruton tyrosine kinase inhibitors ibrutinib or acalabrutinib  owing to skewing toward a memory like  type   t helper cell phenotype  https   t co drbfg c qw  immunoonc  hemeonc
2390,targeted oncology,dr  leslie discussed toxicities and outcomes observed in patients with chronic lymphocytic leukemia treated with acalabrutinib in real word clinics  https   t co xlxyqz  zy  leusm
2391,patty watkins,https   t co zjhjcnhluq 
2392,chimeric antigen receptor t cell  car t ,antitumor potency of an anti cd    car t chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib https   t co   scgbdssc
2393,onclive soss,although the fixed duration of venetoclax and obinutuzumab is efficacious  the data with ibrutinib and acalabrutinib appear more robust in select patients with newly diagnosed cll  says jennifer woyach  md  of  osuccc james https   t co oai zioppe
2394,carlo franzini,leucemia linfatica cronica  maggiore efficacia di calquence in monoterapia rispetto alla chemioimmunoterapia standard https   t co apbg eeynl
2395, memory,antitumor potency of an anti cd   chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib  https   t co  uys zuw    pubmed  memory
2396,lymphoma papers,antitumor potency of an anti cd   chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib   lymphoma  lymsm https   t co qji wmgbnu
2397,cancernetwork   home of the journal oncology , icymi  acalabrutinib alone and in combination with obinutuzumab significantly improved progression free survival  compared with obinutuzumab plus chlorambucil in treatment na ve patients with chronic lymphocytic leukemia  https   t co f zyare ia https   t co nw trsjnbl
2398,tumorimmunopapers,antitumor potency of an anti cd   chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib  https   t co bxz frc cl
2399,paperbirds hematology,new article  antitumor potency of an anti cd   chimeric antigen receptor t cell therapy  lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib  https   t co vszvwpnwck  cll  leusm  hematology
2400,prof john, kinaseinhibitors  cll   in cellae veritas     realcellsmatter     importance of assessing covalent inhibitors against real cells  jpet journal    ibrutinib  acalabrutinib   nice work from  pharmacyclics  abbvie    celentyxltd   https   t co iua hmhccr https   t co somdexvdid
2401,onclive com,acalabrutinib alone or in combination improves pfs in frontline  cll  leukemia https   t co dr pug jqd
2402,onclive com,acalabrutinib triplet highly active in frontline  cll  leukemia https   t co m   w  tal
2403,onclive soss,   dr  mato on ibrutinib versus acalabrutinib in cll https   t co pcxftmljow
2404,becca peterson,from the formation of the  pelotonia institute of immuno oncology in collaboration with the  greatestteamever to the fda approval of  acalabrutinib  in      our researchers  donors  and leaders created the infrastructure to support even more discoveries and new therapies in       https   t co wqhji sjfi
2405,onclive com,acalabrutinib benefit in  cll sustained with long term follow up  leukemia https   t co qo jj iuth
2406,onclive com,sharman showcases frontline acalabrutinib activity in  cll  leukemia https   t co enyqjkaw d
2407,targeted oncology,acalabrutinib  a highly selective btk inhibitor  as a single agent or inc ombinatoin with obinutuzumab is a safe and effective treatment for patients with treatment naive chronic lymphocytic leukemia  according to dr  sharman  https   t co za g lk qz  cllsm
2408,prof  dr  h   smail sar ,kasim   aralik      fda onaylari   acalabrutinib  atezolizumab  crizanlizumab  enfortumabvedotin  enzalutamid  fda  givosiran  hematoloji  hematolojiistanbul  kansertedavisi  luspatercept  memorialata ehirhematoloji  onkoloji  profdrhisari  trastuzumabde https   t co c varh lhz https   t co  d gw mi q
2409,targeted oncology,dr  sharman discussed the updated elevate tn data and ongoing research that is poised to define the optimal role of acalabrutinib in cll at the      ash annual meeting  https   t co za g lk qz  cllsm
2410,targeted oncology,this trial evaluated acalabrutinib  as a single agent or in combination with obinutuzumab versus obinutuzumab  plus chlorambucil in patients with treatment na ve chronic lymphocytic leukemia  https   t co sibt afsu   leusm
2411,onclive com,watch  dr  lampson on safety and efficacy of acalabrutinib  venetoclax  and obinutuzumab in  cll  leukemia  ash      ash   https   t co tdgfszhwve
2412,benlazar s m amin ,acalabrutinib monotherapy in patients with r r  cll  leusm  https   t co bnjavyg ws https   t co pfexl l qf
2413,onclive com,acalabrutinib alone or in combination improves pfs in frontline  cll  leukemia  ash      ash   https   t co hvlanqkujm
2414,m ,phenomenal timeline of  rtor  projectorbis approval of acalabrutinib in additional indications  cll  sll https   t co tq xkmbyl 
2415,lymphoma papers,acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  updated phase   results   lymphoma  lymsm https   t co   olnydyiz
2416,oncology learning network,single agent acalabrutinib is safe and active in the treatment of patients with treatment na ve or relapsed refractory waldenstrom macroglobulinemia  wm  according to results from a phase   study  read more on oln  https   t co xy icxkgce https   t co dbk emawlq
2417,onclive com,   in november       the fda approved acalabrutinib for  cll  leukemia  onclivecountsdown     https   t co  nlwhpxdb 
2418,paperbirds hematology,new article  acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  updated phase   results  https   t co a zpztjwrx  cll  leusm  hematology
2419,healthit and biotech,with strong pfs data in hand  astrazeneca s calquence sets sights on imbruvica https   t co  zjqklrhgq https   t co   o   lfmu
2420,toby eyre, acalabrutinib phase ii r r  cll   bloodjournal n     median   lines af    major bleed    orr     cr       m pfs     headache  diarrhoea  fatigue common self limiting del  p ck  pfs  similar pfs to resonate for  prior lines pre  ibrutinib rct will determine if safety diff genuine https   t co qv upfee a
2421,matthew rehrl  md ms  ,i did one tweet about a calquence ad  and now  the twitter  thinks i have lymphoma    
2422,michael wang  md,the development of a new drug includes many steps  chemical synthesis  in vitro and in vivo testing  target identification  toxicology  patent application  clinical trial phase    them phase     for fda approval  majority fails but acalabrutinib won in  mcl  https   t co pory  oqmq
2423,matthew rehrl  md ms  ,the science and the scientists behind advanced cancer therapies are simply amazing   but are direct to patient ads the way to go     is the lymphoma calquence  experience  a protected  open water swim   or  worse  a kayak trip    what s a better way to inform patients of options  https   t co pn  eo arv
2424,paperbirds hematology,new article  relative selectivity of covalent inhibitors requires assessment of inactivation kinetics and cellular occupancy  a case study of ibrutinib and acalabrutinib  https   t co rvyj ynowb  cll  leusm  hematology
2425,lymphoma papers,acalabrutinib monotherapy in patients with waldenstr m macroglobulinemia  a single arm  multicentre  phase   study   lymphoma  lymsm https   t co vrbnrltog 
2426,amanda marie,i wonder if i should stay on imbruvica or if calquence is a good move  time to text my onc    https   t co li o ppjwx
2427,tim fenske,orelabrutinib for mcl    highly active and less toxic than ibrutinib  sounds very similar to acalabrutinib and zanubrutinib    eventually we could have more btk inhibitors than statins   https   t co uwvqzu x n
2428,onclive com,acalabrutinib triplet highly active in frontline  cll  leukemia https   t co  cmtyaphm 
2429,onclive com,acalabrutinib benefit in  cll sustained with long term follow up  leukemia https   t co c igg iisk
2430,onclive com,sharman showcases frontline acalabrutinib activity in  cll  leukemia https   t co jvf diwero
2431,michael wang  md,at ash      i also visited the astrazenica booth  after leading the pivotal trial on acalabrutinib  i was often asked which drug  ibrutinib  is better  i have always avoided answering this question because the answer should come from scientific data which does not exist  https   t co ob cpiyl d
2432,targeted oncology,acalabrutinib  a highly selective btk inhibitor  as a single agent or inc ombinatoin with obinutuzumab is a safe and effective treatment for patients with treatment naive chronic lymphocytic leukemia  according to dr  sharman  https   t co za g lk qz  cllsm
2433,the lancet haematology,new research a phase   study by roger owen and colleagues shows that acalabrutinib is active as single agent therapy with a manageable safety profile in patients with waldenstr m macroglobulinemia   wmsm https   t co wqh smnsgn https   t co kci y  biz
2434,benlazar s m amin ,acalabrutinib monotherapy in patients with  waldenstr m macroglobulinemia  mmsm https   t co ujqlwhxzss https   t co m xg d gs 
2435,lymphoma hub,phase iii elevate tn  study   a summary of the data presented by  jeff sharman at the  ash   meeting on acalabrutinib   obinutuzumab vs acalabrutinib alone vs obinutuzumab   chlorambucil in patients with treatment naive cll  read more here  https   t co  tgodjv hg    lymsm https   t co uvy y xawm
2436,nicolas zarjevski, thelancethaematology  waldentr m  acalabrutinib acalabrutinib  en monoth rapie  pour le traitement de patients atteints de la macroglobulin mie de waldenstr m    tude de phase     simple bras  multicentrique https   t co  mbvvsdmrr
2437,oncology tube,calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukemia https   t co  ftb tfjvp https   t co  ogqtec da
2438,     ,                            calquence                                           https   t co vmqdclgkrv
2439,a watcher,                              calquence                                                                               btk               https   t co bwbitkf fy
2440,re how net,astrazeneca co   ltd  significantly prolongs the time to progression or death of patients with chronic lymphocytic leukemia who have not been treated with astrazeneca s acalabrutinib  calquence  https   t co wehibjknph https   t co y wu ua g 
2441,pr times    ,                 calquence                                    https   t co a symxqjzz https   t co fdwjgdcyvl
2442,pr times    ,                 calquence                                    https   t co par h xaxa https   t co k ufkrrqbo
2443,wcm lymphoma,dr  richard furman s speedy summary of long term follow up data in r r  cll patients treated with acalabrutinib monotherapy  via  ash    https   t co  i x lspmf
2444,i  health,read more about  acalabrutinib in  cll from our interview with jeff sharman  md  https   t co nmmwipqnwi   leukemia  wednesdaywisdom  hematology  oncology  oncologist  physician  cancer  clinicaltrial  elevatetn  obinutuzumab  ash   https   t co ezmfivklkz
2445,onclive soss,james n  gerson  md  discusses the use of ibrutinib  acalabrutinib  and venetoclax in r r mcl https   t co tvirg jax 
2446,onclive com,the selective btk inhibitor acalabrutinib  either as a single agent or in combination with obinutuzumab  has proven to be a safe and effective treatment option for patients with previously untreated  cll  leukemia  jeff sharman  theusonetwork  wvcancer https   t co tjmmxwx e 
2447,targeted oncology,dr  sharman discussed the safety profile demonstrated in the phase iii elevate tn trial  which evaluated acalabrutinib as a single agent or in combination with obinutuzumab in patients with treatment na ve chronic lymphocytic leukemia  https   t co sibt afsu   leusm
2448,professione farmacia, leucemialinfaticacronica  acalabrutinib in prima linea  da solo o in combinazione  allontana la progressione  ash    pharmastar    ecm https   t co rfwcujufqg
2449,medical evidence   , leucemialinfaticacronica  acalabrutinib in prima linea  da solo o in combinazione  allontana la progressione  ash    pharmastar    ecm https   t co rsq dmm q 
2450,epocrates, newindicationnotification calquence  acalabrutinib  now approved for chronic lymphocytic leukemia small lymphocytic lymphoma https   t co tdi lxnvtn
2451,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2452,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2453,calquence   acalabrutinib ,calquence has a new indication for chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2454,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2455,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2456,calquence   acalabrutinib ,calquence has a new indication for chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2457,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2458,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2459,calquence   acalabrutinib ,calquence has a new indication for chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2460,sarah williams,in this interview with i  health   jeff sharman of  wvcancer discusses his research on  acalabrutinib  alone or with  obinutuzumab  for chronic lymphocytic  leukemia  https   t co kaie yjiaj  ash    cll  hematology  oncology  leusm  cancernews
2461,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2462,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2463,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2464,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2465,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2466,medinews, leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o morte nei pazienti non precedentemente trattati  tumore  salute https   t co qgeg bzbob https   t co  wt zfrqr 
2467,ritrattodellasalute,i risultati di tollerabilit  e sicurezza  fattori fondamentali per questa popolazione di pazienti  si sono inoltre rivelati incoraggianti nei due bracci di trattamento con acalabrutinib  tumore  leucemia https   t co  iyktua ah
2468,lecancer fr,avec un suivi plus important  que donne l acalabrutinib dans le lymphome   cellules du manteau en rechute ou       https   t co  wl   yvfj
2469,i  health,jeff sharman  md  discusses  acalabrutinib  alone or with  obinutuzumab  for patients with chronic lymphocytic  leukemia   ash     https   t co nmmwipqnwi
2470,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2471,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2472,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2473,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2474,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2475,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2476,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2477,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2478,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2479,calquence   acalabrutinib ,calquence is for the treatment of mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2480,calquence   acalabrutinib ,calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2481,calquence   acalabrutinib ,calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2482,calquence   acalabrutinib ,calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2483,calquence   acalabrutinib ,calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2484,calquence   acalabrutinib ,calquence is a treatment option for mantle cell lymphoma  mcl  in adult patients who have received at least one prior therapy  https   t co  cukbfperj
2485,the asco post,jeff p  sharman  md  on cll  trial results on acalabrutinib  obinutuzumab  and chlorambucil https   t co n z w   ix  leusm  hematology  ash    ash      jeff sharman https   t co  pwl rxmzz
2486,crwe world,sharman showcases frontline acalabrutinib activity in cll https   t co acngyhgrmy
2487,onclive com,sharman showcases frontline acalabrutinib activity in  cll  leukemia  jeff sharman  wvcancer  theusonetwork https   t co ycanmy  wj
2488,hcp feed,sharman showcases frontline acalabrutinib activity in cll  https   t co sk gcvckzi 
2489,salutedomani,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o morte nei pazienti non precedentemente trattati https   t co plsumwrt r
2490,i malati invisibili,tumori rari   leucemia linfatica cronica  l inibitore di btk di nuova generazione acalabrutinib allontana la progressione sia da solo che in combinazione   comitatoimalatiinvisibili  imalatiinvisibili  comitatoimi  comitatoimionlus https   t co qofycrpgax
2491,paul d  rennert,zanubrutinib ash data were quite strong  but acalabrutinib looked v v good  not a head head trial tho    need to look at discontinuations too    this is ibrutinib s weak spot https   t co e a  vsv  
2492,simon rule,i ve always said that this is my favourite btki and we were using it before acalabrutinib was in phase i  someone dropped the ball here https   t co byc fbb ju
2493,daniel garcia estrada  retire ,acalabrutinib  calquence  nuevas indicaciones aprobadas para adultos con leucemia linfoc tica cr nica  cll  o linfoma linfoc tico peque o  sll 
2494,salutedomani,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o morte nei pazienti non precedentemente trattati https   t co plsumwrt r
2495,medwave,          cll             sll            calquence         product approvals  drug  https   t co  pplbp cmc
2496,copd news,acalabrutinib for the treatment of chronic graft versus host disease  this phase ii trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease  acalabrutinib may be an effective treatment for graftversushost  https   t co wjkgdavdzq
2497,salutedomani,leucemia linfatica cronica   acalabrutinib migliora significativamente  https   t co km pibgjuw salutedomani podcast
2498,labofine,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co bzpnxzk fs
2499,labofine,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say https   t co qnpb mlccj
2500,saluteh   com,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o mo    https   t co eptvir uib
2501,salutedomani,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o mo    https   t co ymfuwbstxz
2502,antonio caperna,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o mo    https   t co  eaudw ly 
2503,derma news ok,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o mo    https   t co fsezoaojvh
2504,salutedomani,leucemia linfatica cronica   acalabrutinib migliora significativamente il tempo libero da  https   t co o zec fvqn
2505,zazoom social news,leucemia linfatica cronica  acalabrutinib migliora significativamente il tempo libero da progressione o morte     leucemia  linfatica  cronica   https   t co eqxn  xcpv
2506,charnwood molecular,have you checked out our chemist s blog lately  there s been updates on calquence  vascepa and oxbryta amongst other subjects  https   t co injkhvxs    chemistry  med  chem  pharma https   t co  sbggudm  
2507,chelli miller,with strong pfs data in hand  astrazeneca s calquence sets sights on imbruvica https   t co ieblybixnv https   t co   bbhrsik 
2508,biopharmadevice,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co wbdckaleun https   t co u m nkykty
2509,cancernetwork   home of the journal oncology ,the triplet regimen consisting of acalabrutinib  venetoclax  and obinutuzumab appeared highly active as frontline therapy for patients with chronic lymphocytic leukemia  https   t co zqg rfbqxy https   t co uekk dzaky
2510,targeted oncology,we had the chance to speak with dr  furman at  ash     to discuss the    month follow up data of acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  https   t co caqqrvpia   leusm  cllsm
2511,raimo skottman,astrazeneca s calquence approved in the us for adult patients with chronic lymphocytic leukaemia https   t co kt cha shu
2512,luis pereira lopez,calquence  acalabrutinib  mejora la supervivencia libre de progresi n en leucemia linfoc tica cr nica https   t co rnml sd j   astrazeneca
2513,acobur,https   t co phtkptsakz astrazeneca prueba que calquence prolonga la vida de pacientes con leucemia https   t co   pspfokct
2514,renovatio biom dica,calquence  acalabrutinib  mejora la supervivencia libre de progresi n en leucemia linfoc tica cr nica https   t co ojy faoxax
2515,cancernetwork   home of the journal oncology ,acalabrutinib alone and in combination with obinutuzumab significantly improved progression free survival  compared with obinutuzumab plus chlorambucil in treatment na ve patients with chronic lymphocytic leukemia  https   t co n omqpw vh https   t co hqltjaent 
2516,onclive com,as previously reported  acalabrutinib led to objective responses in     to     of patients with  cll  leukemia  ash      ash    richardfurmanmd  weillcornell  wcmclymphoma https   t co h rwtlvclk
2517,pharma regulatory,astrazeneca s calquence steps up in first line cll  https   t co blvlnmstl   pharma  regulatory
2518,im m dico,calquence  acalabrutinib  mejora la supervivencia libre de progresi n en pacientes con  leucemia linfoc tica cr nica  seg n los resultados completos del ensayo fase iii elevate tn presentados por  astrazeneca en  ash      astrazenecaes  https   t co y pz ydqjr
2519,zorgnl,pharmascrip   astrazeneca s calquence steps up in first line cll https   t co dqfby inlw   pharmascrip https   t co ppa hsfewd https   t co lxkm e hyz
2520,onclive com,watch  dr  lampson on safety and efficacy of acalabrutinib  venetoclax  and obinutuzumab in  cll  leukemia  ash      ash    danafarber https   t co pghr hdmg 
2521,biopharma dive,merck s surprise buyout of arqule will heat up competition in a class of cancer drugs that includes abbvie and j amp j s imbruvica and astrazeneca s calquence  https   t co  wdojenwvh
2522,scrip,astrazeneca s calquence steps up in first line cll https   t co hogj nblzp  pharmascrip
2523,redacci n m dica,astrazeneca demuestra que calquence prolonga la vida de pacientes con  leucemia linfoc tica cr nica https   t co mpcz nlyfn
2524,acta sanitaria,presentaci n de  astrazenecaes sobre datos de calquence en leucemia linfoc tica cr nica   https   t co wmyxst mxf
2525,bioportfolio   eli lilly   news and research,leukemia rivals try to stay ahead as merck lilly chase  merck amp    s surprise buyout of arqule will heat up competition in a class of cancer drugs that includes abbvie and j amp amp j amp    s imbruvica and astrazeneca amp    s calquence  https   t co oul cwa ot  elililly
2526,pharma news,acalabrutinib  calquence  significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia https   t co krbfhcswwp  news  pharma  pharmiweb
2527,francisco acedo,calquence  acalabrutinib  de  astrazeneca prolonga significativamente el tiempo que los  pacientes con  leucemia linfoc tica cr nica no tratada previamente viven sin progresi n de la enfermedad
2528,plexus ventures, astrazeneca s  calquence boosts  pfs in  cll patients https   t co ghxhuc vg   pharmatimes  astrazeneca  acalabrutinib
2529,david ledger,az  calquence boosts pfs in cll patients https   t co qyz z cwoz https   t co dh s o fpp
2530,lampgen clinical research,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll   fiercepharma https   t co jzxph    b  cancer  clinicalresearch  oncology  clinicaltrials  leukemia  drugdevelopment
2531,targeted oncology,we spoke with dr  furman from  weillcornell on the long term data of acalabrutinib monotherapy in patients with relapsed refractory cll  https   t co caqqrvpia   cllsm  ash  
2532,theriaque officiel,l   acalabrutinib  inhibiteur de la kinase  fait ses preuves en premi re ligne dans la leuc mie lympho de chronique seul ou associ    l   obinutuzumab  pr vention secondaire de la  https   t co vvt t i lw
2533,      recruitment,az  calquence boosts pfs in cll patients https   t co ixr mewam    news  pharmatimes  clinicalresearch  research  phaseiii  haematology  leukaemia  cll  randd
2534,carlo franzini,acalabrutinib  un inibitore della tirosin kinasi di bruton  ha ottenuto la designazione di terapia fortemente innovativa nel linfoma mantellare https   t co wfqqga igb
2535,onclive com,patients with relapsed refractory  cll had ongoing benefits    months after starting treatment with the btk inhibitor acalabrutinib  leukemia  ash      ash    richardfurmanmd  weillcornell  wcmclymphoma https   t co  uewamsmur
2536,saeed valadbaygi,   month follow up  data of acalabrutinib monotherapy in r r cll  targeted oncology https   t co vesirpbjmj https   t co jasvebskun
2537,medwirenews, ash    watch our interview with jeff sharman   jeff sharman  from the us oncology network on the elevate tn trial  treatment na ve chronic lymphocytic leukaemia  cll patients treated with  acalabrutinib versus  chlorambucil in addition to  obinutuzumab https   t co jwsgxqjb h
2538,biospace,with strong pfs data in hand   astrazeneca s calquence sets sights on imbruvica  https   t co bgodqtkqcu
2539,targeted oncology,at  ash    dr  furman discussed the    month follow up data of acalabrutinib monotherapy in patients with relapsed refractory chronic lymphocytic leukemia  https   t co caqqrvpia   leukemias
2540,saeed valadbaygi,with strong pfs  data in hand  astrazeneca s calquence sets sights on imbruvica  biospace https   t co n s fad az
2541,dr  andre goy,toxicities and outcomes of acalabrutinib treated patients with chronic lymphocytic leukemia  a retrospective analysis of real world patients  ash    ash hematology  hackensackumc org
2542,alex keown,with strong pfs data in hand  astrazeneca s calquence sets sights on imbruvica   biospace https   t co q bqhff xo  jobs  ash      astrazeneca
2543,onclive com,acalabrutinib benefit in  cll sustained with long term follow up  leukemia  ash      ash    richardfurmanmd  weillcornell https   t co vnli maioi
2544,philly bio,full results from phase iii elevate tn trial showed     of patients on calquence combined with obinutuzumab vs      of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at    months   https   t co skarnjfrzw
2545,healthycarnivores,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co l tgguqir  https   t co bnab xejku
2546,biocalifornia,with strong pfs data in hand  astrazeneca s calquence sets sights on imbruvica https   t co  ydrgukbtq https   t co vlenxeqoxv
2547,pharmaceutical market europe,astrazeneca s calquence impresses in previously untreated cll   pmlive https   t co  xsdwbnare
2548,pharmafocus,astrazeneca s trial of  leukaemia drug calquence yields positive results https   t co  defy b s  https   t co npvcdvqxmy
2549,onclive com,in the phase ii study      of patients treated with avo achieved undetectable minimal residual disease in the bone marrow after only   monthly cycles of therapy  which improved to       after cycle     cll  leukemia  ash      ash    danafarber https   t co dqubhxmfae
2550,about medtech,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co xwdapbdtfo https   t co qqmtygteb 
2551,ecare vault  inc ,az   calquence boosts pfs in  cllpatients https   t co  sheanmttn
2552,pharma business int,calquence boosts survival in cll patients  astrazeneca data shows https   t co poapfwhnae
2553,lukabiotech,astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co bhnrvapu g
2554,saleh stevens,az  calquence boosts pfs in cll patients https   t co gcrpbybhhg https   t co pbdgbcwoc 
2555,jon gardner,fda looks back on calquence tripartite review in cll sll under project orbis   ash    azn https   t co y  m qmox 
2556,kelly norsworthy  md,dr  nicholas richardson of   fdaoncology  presenting on approval of acalabrutinib with  projectorbis  a new   fdaoncology  initiative for concurrent submission and review of new drug applications across regulatory agencies internationally  https   t co eunaaf mdn
2557,us oncology network,congratulations  jeff sharman  md  on your oral presentation of elevate tn during  ash    read more from  hemonctoday  https   t co awr  ls zu https   t co fk hrqovey
2558,dr arun achuthan,ash    az s calquence throws gauntlet down to imbruvica https   t co lpl ln iqn
2559,dr arun achuthan,ash    az s calquence throws gauntlet down to imbruvica https   t co l rvp uchp via  pharmaphorum
2560,everything pharma,az  calquence boosts pfs in cll patients https   t co ndmid tmjk
2561,pharma trader,az  calquence boosts pfs in cll patients https   t co shpyhqgjik
2562,barry curry,az  calquence boosts pfs in cll patients https   t co q tlwg n i https   t co  demot lvn
2563,pharmashots   incisive news in   shots,astrazeneca reports results of calquence  acalabrutinib  in p iii elevate tn study for previously untreated chronic lymphocytic leukemia  astrazeneca https   t co ntaizsegw 
2564,breaking data,how will your brand respond  hems oncs provide insights on data for  acalabrutinib  acalabrutinib   venetoclax   obinutuzumab  ibrutinib   rituximab  ibrutinib   venetoclax  zanubrutinib  ibrutinib  learn more with the breaking data  ash   cll rapid impact report  https   t co  e  mxwuxo
2565,mr markku hakali,https   t co kslz j o y
2566,briefing com, azn  astrazeneca  calquence significantly prolonged the time patients lived without disease progression or death in    https   t co ot i xap j
2567,cellworkslife,acalabrutinib regimens improve pfs in treatment na ve patients with  cll  https   t co isr b  vqe
2568,jon angelo,astrazeneca s trial of leukaemia drug calquence yields positive results   https   t co ci tdakneq  pharmaceutical
2569,pharmafocus,astrazeneca s trial of leukaemia drug calquence yields positive results https   t co  defy b s  https   t co hnisv uktb
2570,cafepharma,ash    az s calquence throws gauntlet down to imbruvica https   t co qghmomgeis
2571,pharmatimes,az  calquence boosts pfs in cll patients https   t co hxx kqeyfm  healthcare  pharma
2572,onclive com,at a median follow up of      months  the combo of the btk inhibitor with obinutuzumab led to a     reduction in the risk of disease progression or death compared with obinutuzumab chlorambucil  cll  ash      ash    jeff sharman  wvcancer  theusonetwork https   t co wkjdpjp   
2573,career biotech, jobs calquence significantly prolonged time patients lived without disease progression or  https   t co vpqlt vgby
2574,pharma regulatory,calquence significantly prolonged time patients lived without disease progression or death in previously untreated cll  https   t co  rpa n cnc  pharma  regulatory
2575, stoncology, calquence significantly prolonged the time patients lived without disease progression or death in previously untreated  chroniclymphocyticleukaemia  azn https   t co sjcfvkt jj
2576,bruce meyers,https   t co rx qp  r s
2577,tweets,elevate tn   ascend                                 https   t co vjxzhbmrrp      ascend    calquence  calquence       cll  cll     
2578,oncology tribune,                calquence                  cll                   https   t co c e rxp mw  oncologytribune
2579,     ,                            calquence                 cll                   https   t co phclrjttaj
2580,majalah farmasetika,https   t co mfalyjcbai   calquence  acalarutinib  adalah obat baru untuk kanker leukemia  yaitu mantle cell lymphoma  mcl  dan chronic lymphocytic leukimia  cll    pada      food and drug administration u s  government  fda  telah menyetujui calquence s  https   t co p  i sweml https   t co nzietmeckd
2581,info farmasi terkini,https   t co fxw r eb x   calquence  acalarutinib  adalah obat baru untuk kanker leukemia  yaitu mantle cell lymphoma  mcl  dan chronic lymphocytic leukimia  cll    pada      food and drug administration u s  government  https   t co payd xa mb
2582,              ,                       calquence                 cll      https   t co kw lxthhka
2583,a watcher,                              calquence                  cll                                                    https   t co fqjj  nknb
2584,pr times    ,                 calquence                 cll                 https   t co d vsi bknx https   t co sszdmpvxvb
2585,pr times    ,                 calquence                 cll                 https   t co fe a pg tb https   t co  if rk  bm
2586,wcm lymphoma,dr  richard furman reports results of a long term follow up study of r r  cll patients treated w  acalabrutinib  https   t co gcrwro wcd  ash   https   t co yngiqujawo
2587,amber koehler  pa c,excellent summary by dr  woyach of the  ohiostate experience with acalabrutinib in  cll  prior btki intolerance  female sex    of prior therapies  ldh   amp  del  p assoc w  incr risk for acalabrutinib d c by univariate analysis      of pts w progression had btk mutations   ash   https   t co hureauelcm
2588,lymphoma hub,congress    ash     jennifer woyach from  osuccc james discusses mechanisms of resistance to acalabrutinib in patients with cll   lymsm https   t co  qw dyrnek
2589,mark geyer  m d ,dr  woyach of  osuccc james presents on characteristics of pts discontinuing acalabrutinib and mechanisms of resistance to acala        w  cll progression had btk mutations  mainly btk c   s   median time from mutation detection to relapse    mon   ash    cllsm
2590,chan cheah,dr woyach   btk c    mutations present in acalabrutinib resistant cll and precede clinical relapse by a median of    months   cllsm  ash   https   t co s  okfrvae
2591,jeff sharman,acalabrutinib treatment superior to obinutuzumab plus chlorambucil in treatment na ve cll    usoncology  wvci  https   t co me  noxg f
2592,matthew davids  md  mmsc,and some nice coverage of our ph  avo study for  l cll from  danafarber here at  ash     triplet therapy with acalabrutinib has activity in chronic lymphocytic leukemia https   t co xemhrx exj via  targetedonc
2593,pharmaphorum,  astrazeneca updates calquence data in first line chronic lymphocytic leukaemia at  ash    laying down a challenge to blockbuster rival imbruvica https   t co ze  nkyjv 
2594,onclive com,the triplet of acalabrutinib  venetoclax  and obinutuzumab is highly active as frontline therapy for patients with  cll  leukemia  ash      ash    danafarber https   t co bynumyxe  
2595,contacto sciencelink,ash     acalabrutinib con o sin obinutuzumab mejora la slp en llc   sciencelink https   t co xgohmd lhb
2596,targeted oncology,after cycle          of patients achieved a complete response with undetectable mrd in the bone marrow  this rate was relatively unchanged         after cycle     said dr  lampson  https   t co xrekcmshsw  leusm  leukemia
2597,ash clinical news,acalabrutinib led to improved progression free survival compared with obinutuzumab   chlorambucil in patients with treatment na ve chronic lymphocytic  leukemia   cll   according to findings presented by  jeff sharman of  wvcancer at  ash   https   t co xy kkda pl
2598,firstword pharma,astrazeneca s btk inhibitor calquence significantly delays disease progression  death in previously untreated cll https   t co z z ruyde   azn  ash  
2599,silas inman,acalabrutinib triplet highly active in frontline cll https   t co m qh wfqmj  ash  
2600,the asco post,  us fda approves acalabrutinib for cll sll as part of project orbis https   t co  xrwcbuwua  leusm  lymsm  hematology  fdaoncology
2601,oncology board,front line acalabrutinib regimen appears safe  induces complete response in chronic lymphocytic leukemia   healio  front line acalabrutinib regimen appears safe  induces complete response in chronic lymphocytic leukemia  healio https   t co lxqsvdtkt  https   t co hfu aohrmw
2602,pharmacrowd,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co lub qo zcj https   t co jdtkefsxol
2603,phil talamo,exciting to see acalabrutinib data presented at ash this weekend  which we know was just recently approved a few weeks ago for the treatment of cll    gt  acalabrutinib alone or in combination improves pfs in frontline cll https   t co ejlsod k e via  onclive
2604,                   insights  pharma   ,           amp     astrazeneca btk   calquence cll   ph                 astrazeneca                  https   t co   rdmi tiy
2605,                   insights  pharma   ,astrazeneca btk   calquence cll   ph                https   t co   rdmhqsr 
2606,eipg,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co gw pxqz vk
2607,curehuntr, clinicaltrial acalabrutinib in combination with r ice for relapsed or refractory lymphoma https   t co fqxqup itc
2608,trialbulletin,acalabrutinib in combination with r ice for relapsed or refractory lymphoma  status  not yet recruiting   condition summary  diffuse large b cell lymphoma  chronic lymphocytic leukemia  small lymphocytic leukemia  marginal zone lymphoma https   t co i  hkquobp
2609,continental clinical,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co hi tfzinv 
2610,dr timos papagatsias,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co tvrvgjeqjc  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  healthcare  productmarketing  pharmaceutical  pharma  biotech https   t co vttpizwgec
2611,newexpressnews,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co vj agfnqau https   t co zp yvmympv
2612,analyst land news,ash  astrazeneca s calquence posts sky high survival numbers in previously untreated cll https   t co ifrrtac ia https   t co sjapeadn s
2613,veterans health,https   t co flrbroleri
2614,aloysius pendergast,acalabrutinib treatment superior to obinutuzumab plus chlorambucil in treatment na ve cll https   t co  sydevwnsq via  ash clinical news
2615,dave hughes,cll following the footsteps of  myeloma  taking novel agents and adding them up front for better responses  now up to triplet  acalabrutinib  venetoclax  obinutuzumab  avo   ash      oncopharm
2616,michael rynne,positive updates for  cll patients from  ash   on new treatment options  ibrutinib plus venetoclax     of patients achieve mrdu  complete remission  after    months of treatment  acalabrutinib also looks promising   nylcandcll  janrynne https   t co fpndde g q
2617,onclive com,acalabrutinib as a single agent or in combo with obinutuzumab led to a statistically significant improvement in pfs compared with obinutuzumab plus chlorambucil in treatment na ve patients with  cll  ash      ash    jeff sharman  wvcancer  theusonetwork https   t co hdv pyrfzd
2618,targeted oncology,we saw a statistically significant improvement in pfs with acalabrutinib as a single agent or in combination with obinutuzumab in treatment na ve cll compared with obinutuzumab plus chlorambucil in the phase iii elevate tn trial at  ash    https   t co vddhwfkiqn  leusm
2619,targeted oncology,dr  lampson  lead author  presented the findings at the  ash   from this phase ii study of patients with cll treated with frontline avo triplet  comprised of acalabrutinib  venetoclax  plus obinutuzumab  https   t co xrekcmshsw
2620,onclive com,acalabrutinib triplet highly active in frontline cll  danafarber  ash      ash    lylsm https   t co t s k ne f
2621,ash clinical news,check out our on location coverage for highlights from the first day of  ash    including a look at acalabrutinib in previously untreated chronic lymphocytic  leukemia  leusm  https   t co xy kkda pl
2622,hemonc today,news from  ash    front line acalabrutinib   calquencehcp   astrazeneca  regimen appears safe  induces complete responses in chronic lymphocytic leukemia     patients  overall response rate         complete responses    study from ben lampson  danafarber https   t co     qylc   https   t co kjvdcwoiqv
2623,brian skorney,huge calquence booth at  ash    i remember when it was just wayne at a stand on a  x  square https   t co lqumqy vis
2624,onclive com,acalabrutinib alone or in combination improves pfs in frontline cll  wvcancer  ash      ash    cll  lylsm https   t co oz f r jzc
2625,qollor,it s time for us to make a spl  ash     brands ask us questions   qollor answers them    first up   who s winning leukemia       venclexta    imbruvica    calquence    gazya  check back daily for more answers  or  let tell us what you need to  knownow  https   t co bd xyxju b
2626,ayushi chauhan,mechanism remains uncertain  interestingly  the headache responds well to caffeine as seen in clinic experience with dr  bruce cheson  no such thing as too much coffee   ash    acalabrutinib  cll  lombardicancer https   t co uzbwsxyygd
2627,toby eyre,headache  mostly grade      in        but can be a tricky early problem with  acalabrutinib  why should a more selective btk inhibitor cause an ae not associated with the less selective  ibrutinib    ash    cll  lymsm https   t co idpz chvtr
2628,watzan,q  what are the top brands in leukemia at  ash      a  venclexta  imbruvica  calquence   qollor   knownow https   t co u tpetz x 
2629,jon gardner,those of you who carried on for your  ash     flight missed out on a series of video ads from amgen  followed quickly by calquence  imbruvica  novartis and kite  in baggage claim   ash    nvs  gild  azn  jnj  abbv
2630,raakhee shah,triple therapy first line for cll  acalabrutinib  venetoclax and obinutuzumab  ash     will the nhs be able to fund  what do you do at relapse 
2631,hemonc today,acalabrutinib  astrazenecaus extends pfs in treatment naive chronic lymphocytic  leukemia  ash    theusonetwork https   t co h  fa scxr https   t co ixbkgyk  y
2632,dr  paul desantis  pharmd, ash    fyi  after patients d c ibrutinib due to tox  they dont require another therapy on average for   yrs  very slow uptake for calquence analyst are wrong on overl y optimistic view of calqunce in  l cll gt   ramp uptake will be slow likely peak at     in     yrs imho  lymsm
2633,cancer news,calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukemia  full results from phase iii elevate tn trial showed    of patients on calquence combined with  https   t co tlbaolu px
2634,trading news,astrazeneca   calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukemia   https   t co fbknz u hp  full results from phase iii elevate tn trial showed  https   t co  zmbqwwrdq  companynews
2635,flylemurs,astrazeneca says calquence combination improved survival in leukemia patients https   t co yxqbbddosw see the rest of the story here   https   t co tnmxlcjeqv provides the latest financial news as it breaks  known as a leader in market intelligence  the fly s real time  streami 
2636,amber koehler  pa c,phase   trial of acalabrutinib  venetoclax  and obinutuzumab   starting w acala x  month seems to decrease risk of infusion rxn with obin  starting ven on c  decreases risk of tls   cll  ash   https   t co dlhhdc rqj
2637,dr  luis villela,acalabrutinib   obinutuzumab   venetoclax in cll  interesting outcome  around     bm mrd neg  after cycle    https   t co i b ntcffw
2638,lymphoma hub,congress    ash     benjamin lampson   danafarber  presents phase ii data using acalabrutinib  venetoclax  and obinutuzumab as frontline cll therapy  a high proportion of patients achieved bm umrd  amp  cr with this triplet combo  including patients with tp   mutated disease  lymsm https   t co ndqm oiv a
2639,mark geyer  m d ,acalabrutinib followed by obinutuzumab and then venetoclax ramp up  avo  w  duration of therapy guided by mrd is an active time limited approach w  ven timing assuring most pts low risk for tls        w  umrd in bm at c   v few pts at c    will pts w  tp   loss do as well   ash  
2640,latest news from business wire,calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukemia https   t co zsuwezagzt https   t co f gjy yklp
2641,astrazenecaus,we re presenting innovative new research in  bloodcancer at  ash    check out our press release for more on the results of our elevate tn trial in chronic lymphocytic  leukemia  cll    https   t co fvxuhuzsa  https   t co e nrp eats
2642,mark geyer  m d ,acalabrutinib   obinutuzumab beats chlorambucil   obinutuzumab for pfs in untreated pts  no surprise  as with ibrutinib  role of obinutuzumab unclear  now how to choose a frontline btki    but nice to have options   ash    cllsm
2643,investor news,calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocy    azn https   t co poczsftfng
2644,sigrid sk nland,conclusions from the elevate tn study on acalabrutinib in  cll presented by jeff sharman at  ash     blodkreft nor  olav ljosne https   t co z pjdidffs
2645,cancer medicine, elevate tn  phase   study of acalabrutinib combo w obinutuzumab or alone vs o chlorambucil in treatment naive cll   session      sat  dec        am  hall d  level    orange co conv ctr    wwierda  leukemiamda  ash    ash     https   t co edjpv  iip
2646,amber koehler  pa c,  jeff sharman presenting on elevate tn   curves show improved pfs and increased cr with addition of obinutuzumab to acalabrutinib  although study not powered to detect benefit of adding obinutuzumab to acalabrutinib alone   cll  ash   https   t co ahf j afy 
2647,alberto l pez garc a,here are the results from elevate in  pfs      m     vs      ash    acalabrutinib https   t co buzmznk  w
2648,marcio,elevate study in cll  acalabrutinib   obinotuzumab vs acala alone vs   chlorambucil   obinotuzumab in newly diagnosed unfit patients  one case of invasive aspergillosis in the acalabrutinib arm  is selective btk inhibitor also associated with aspergillosis 
2649,the lancet haematology,jeff sharman opens the cll morning session results of the elevate tn phase   trial  acalabrutinib   obinutuzumab or acalabrutinib monotherapy significantly improved pfs vs obinutuzumab   chrorambucil  trial powered for pfs comparison between combination tx   cll  leusm  ash   https   t co  rz zturvr
2650,miguel canales,elevate study  g acala vs  g chl  do we need g in combination with acalabrutinib https   t co  bzndp n k
2651,cision news,calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia https   t co ephqshsxfj
2652,alan skarbnik,our abstract for acalabrutinib     obinutuzumab for tn cll opening  ash   very exciting presentation by  jeff sharman https   t co b ueqe rmm
2653,alan skarbnik,acalabrutinib   obinutuzumab  but not acala monotherapy  provide ofs benefit over gchl in ighv mutated patients  no real benefit in adding g in unmutated  should g be added only in mutated pts  food for thought  https   t co vdogrbtl n
2654,curehuntr, clinicaltrial acalabrutinib for the treatment of ibrutinib intolerant mantle cell lymphoma https   t co usjt zoctw
2655,trialbulletin,acalabrutinib for the treatment of ibrutinib intolerant mantle cell lymphoma  status  not yet recruiting   condition summary  mantle cell lymphoma https   t co l vskidfhr
2656,lung cancer news,acalabrutinib for the treatment of ibrutinibintolerant mantle cell lymphoma  this phase ii trial studies how well acalabrutinib works in treating patients with mantle cell lymphoma that cannot tolerate ibrutinib  acalabrutinib may stop the growth of  https   t co d djnch nk
2657,health canada and phac,accelerated approval of chronic lymphocytic leukemia  cll  treatment calquence provides canadian  cancer patients with more treatment options  projectorbis https   t co jkeyn bueo  drugandmeddevice https   t co qir retyoq
2658,sant  canada et l aspc,l homologation acc l r e de calquence  qui sert   traiter la leuc mie lympho de chronique  llc   offre d autres options de traitement aux canadiens atteints du  cancer  projetorbis https   t co  vscccof g  m dicamentsetinstrumentsm dicaux https   t co  rmbt wbxz
2659,nycdoc  , ash   wonder if long term outcome curves w  calquence or  brukinsa will be meaningfully better in  mcl  lymsm  azn  bgne https   t co afcwj cbgd
2660,paperbirds hematology,new clinical trial  acalabrutinib for the treatment of ibrutinib intolerant mantle cell lymphoma https   t co kjt nvht r  mcl  lymsm  hematology
2661,paperbirds hematology,new clinical trial  acalabrutinib in combination with r ice for relapsed or refractory lymphoma https   t co  ajzfqdfk   dlbcl  lymsm  hematology
2662,paperbirds hematology,new clinical trial  acalabrutinib in combination with r ice for relapsed or refractory lymphoma https   t co  fehsvltpa  cll  leusm  hematology
2663,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2664,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2665,calquence   acalabrutinib ,calquence has a new indication for chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2666,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2667,calquence   acalabrutinib ,calquence is now available for adult patients with chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2668,calquence   acalabrutinib ,calquence has a new indication for chronic lymphocytic leukemia  cll   https   t co  cukbfperj
2669,brian mattys,in randomized multicenter open label phase iii elevante tn  ace cl      trial researchers evaluated safety  amp  efficacy of acalabrutinib alone or in combination w  obinutuzumab  gazyva   vs  chlorambucil  obinutuzumab in     treatment na ve patients w  cll https   t co bezgkpeftm
2670,onclive soss,acalabrutinib and ibrutinib are being compared in a head to head trial in the relapsed refractory setting in patients with deletion   p or   q  says  anthonymatomd of  sloan kettering  leusm https   t co qigyvo zbt
2671,biorealty  inc ,acalabrutinib has been approved  https   t co  rxstujctu    fda  therapy   approved  cll  scl
2672,patient worthy,iycmi  calquence has received us fda approval to benefit adults with cll https   t co fcmefiztu   leukemia  cancer  chroniclymphocyticleukemia  cll  llsusa
2673,onclive soss,dr  mato on ibrutinib versus acalabrutinib in cll  leusm https   t co mee y  muk
2674,biotechobserver,jeezus i m seeing a million calquence advertisements in my feed   anyone else getting this 
2675,cure magazine,the food and drug administration s approval of calquence  acalabrutinib  for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma offers an exciting treatment option  according to dr  john c  byrd  https   t co kg  z rgah
2676,carnivoreshealth,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co tccnlbsnx  https   t co afvyt     
2677,drug topics,the fda has approved acalabrutinib  calquence  astrazeneca  for the treatment of adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   https   t co  mckz  gmk https   t co rdffkm hef
2678,acobur,https   t co rdtpxrk bf astrazeneca presenta datos de calquence para leucemia linfoc tica cr nica https   t co qjgewwwetj
2679,im m dico,  astrazeneca presentar  los datos del ensayo fase iii elevate tn de calquence  acalabrutinib  en  leucemia linfoc tica cr nica en primera l nea  as  como otros avances en c nceres hematol gicos  en  ash    astrazenecaes  https   t co lkvsg tsox
2680,olderpreneurs,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co uicodzlrgd https   t co mag skkudf
2681,raul cordoba  md  phd, ash    oncoalert    ash  rc top   abstracts  preliminary safety and efficacy results from a phase   study of acalabrutinib  venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia  cll   https   t co bbpmzcicdq   lymsm
2682,raul cordoba  md  phd, ash    oncoalert    ash  rc top   abstracts  elevate tn  phase   study of acalabrutinib combined with obinutuzumab  o  or alone vs o plus chlorambucil  clb  in patients  pts  with treatment naive chronic lymphocytic leukemia  cll    https   t co chwvqdzqfo   lymsm
2683,i  health,the  fda has just granted supplemental approval to  acalabrutinib for patients with chronic lymphocytic  leukemia   cll  or small lymphocytic  lymphoma   sll   https   t co fbtwrrlbic
2684,pharma jonpi  ,astrazeneca presentar  en diciembre los primeros datos de  calquence  en leucemia linfoc tica cr nica  https   t co sg xc  zmj
2685,redacci n m dica, industria    astrazenecaes presenta datos de calquence para leucemia linfoc tica cr nica   https   t co rllvwaew q
2686,i  health,today s  fridayfact is from the recent  fda approval of  acalabrutinib for  cll  amp   sll  https   t co fbtwrrlbic   dyk  leukemia  lymphoma  chroniclymphocyticleukemia  smalllymphocyticlymphoma  fdaapproval  oncology  hematology  hematologist  oncologist https   t co jq u yslrg
2687,redacci n m dica, industriafarmac utica astrazeneca presenta datos de calquence para leucemia linfoc tica cr nica https   t co rllvwanlfs
2688,lifestyle profesional  by el neuropediatra ,v a  lifestyleprofe  astrazeneca presenta nuevos datos de calquence en leucemia linfoc tica cr nica https   t co unynajoahy  actasanitaria  esalud  marketingparamedicos  saluddigital
2689,acta sanitaria,nuevos datos de  astrazenecaes sobre calquence en leucemia linfoc tica cr nica   https   t co  epvax jnt
2690,aus gov  news,tag   calquence https   t co a d iivfbl
2691,living safely,missed them  us food and drug administration  drug approvals  updates and changes as of thursday  november      calquence  nda            deferasirox  anda            givlaari  nda          and many others  https   t co u jsfd xry
2692,esmo   eur  oncology,fda approves acalabrutinib for cll and sll  evidence for efficacy is based on results from the elevate tn and ascend studies https   t co xw l k ciw   lymsm  leusm https   t co vawgl  mqx
2693,lymphoma hub,news   the  us fda approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia   cll  or small lymphocytic  lymphoma  sll   https   t co pz cdddlas  lymsm https   t co lhvbjbmtlr
2694,cognitrex consultants,cognitrexcancerdigest  fda approves astrazeneca s calquence to treat lymp    https   t co c u dm k t
2695,drugs com,weekly drug news  in fda drug approval news this week  oxbryta  a novel agent which targets the root cause of sickle cell disease  is cleared  plus  xcopri is ok d for partial onset seizures and calquence gains a new cancer use  https   t co vnjhyx zx  https   t co dliufywomt
2696,viglya, fda takes second action under international collaboration  approves new treatment option for patients with  chroniclymphocyticleukemia  calquence https   t co syjyieotth  ddnewsusfda  viglya growth
2697,catherine cohen,title  calquence approved to treat cll  sllcategory  health newscreated                      amlast editorial review                      https   t co znjc xtbxp
2698,medscape pharmacists, acalabrutinib has been approved for cll and sll in the us  australia and canada     https   t co oilmpysjqw
2699,francis abat,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia   biospace https   t co pyupcsg kn  jobs
2700,claude h volmar  phd, leukemia  astrazeneca  fda https   t co  u  kuh eh
2701,times of news ,calquence approved to treat cll  sll https   t co h osalamly https   t co  dzlbprvzl
2702,shohta kadomura hospital pharmacist,cll sll                         ven               calquence receives fda approval for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma   cll  sll   acalabrutinib https   t co omf yh h b
2703,chester quan  od,calquence approved to treat cll  sll https   t co   l lah ty
2704,curehuntr, clinicaltrial study to investigate the use of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia https   t co u ycqwkv y
2705,esmo   eur  oncology,  fda approves acalabrutinib for cll and sll  evidence for efficacy is based on the results from the elevate tn and ascend studies   https   t co  d vzssun    lylcl  lymphoma https   t co qhj r gylx
2706,clinicaloncologynews,fda approves calquence for cll and sll
2707,bionews,fda approves calquence as treatment option for adults with cll and sll https   t co xkmz wkk o https   t co o kucbncqk
2708,vcapital,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co qlplxcobxt https   t co x  wj zv x
2709,contentpro io,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co cj wpdy nh https   t co njaxfsjmxe
2710,trialbulletin,study to investigate the use of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia  status  not yet recruiting   condition summary  chronic lymphocytic leukemia  binet staging system https   t co zbatakstpx
2711,swedish biotech,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co txwdoevla  https   t co fjpeqe e u
2712,medical sales,calquence approved to treat cll  sll https   t co cp vye jow
2713,chelli miller,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co mjrdorp ku https   t co nda mota w
2714,medical evidence   , leucemialinfatica cronica  fda approva acalabrutinib  pharmastar    ecm https   t co s dznpoyup
2715,professione farmacia, leucemialinfatica cronica  fda approva acalabrutinib  pharmastar    ecm https   t co wevaynbbhf
2716,paperbirds hematology,new clinical trial  study to investigate the use of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia https   t co j vpvrzanu  cll  leusm  hematology
2717,medivizor,new  how effective and safe is acalabrutinib compared to other treatments     https   t co nqzekygjpt via  medivizor  nonhodgkinslymphoma
2718,informatori it,leucemia linfatica cronica  fda approva acalabrutinib https   t co  lckmocb p  informatori  news  isf  pharma  farmaci  informatoriscientifici
2719,arab medical pro,calquence                cll   sll https   t co  emt ok oh
2720,arabmedical pro,calquence                cll   sllhttps   arabmedical pro other oncology calquence  d  a  d     d     d  b  d  aa d     d  af d  a   d     d  b  d     d  a  d  ac cll  d   c sll    https   t co wszif u sm
2721,dr  daniel c,calquence approved to treat cll  sll https   t co srlwtndswy
2722,fitness diet,calquence approved to treat cll  sll  title  calquence approved to treat cll  sll category  health news created                      am last editorial review                      am https   t co sa ikyvph 
2723,ahmed eliwa,calquence approved to treat cll  sll https   t co gt tbyowfi
2724,pierrettej cazeau  sdg  unwomen csw  ,fda approves astrazeneca s calquence in chronic lymphoma   pharmafile https   t co cowuhg ptw
2725,hcrffngo sdg  csw   cric   whm  ,fda approves astrazeneca s calquence in chronic lymphoma   pharmafile https   t co rtzt ywinp
2726,e  kingreen  md,calquence approved to treat cll  sll https   t co lxy icqz b
2727,medivizor,check out  how effective and safe is acalabrutinib compared to other treat    https   t co nqzekygjpt via  medivizor  nonhodgkinslymphoma
2728,tga australia,media release  acalabrutinib receives tga approval for cll and sll cancers the tga has approved the use of  acalabrutinib  calquence   for the treatment of patients with chronic  lymphocytic  leukaemia and small lymphocytic leukaemia  find out more  https   t co  kvik zxvt https   t co ld  rzegxf
2729,wcm lymphoma,people with untreated mantle cell  lymphoma   mcl  may be eligible for this  clinicaltrial open  weillcornell  nyphospital  https   t co nirg ksgwr  lymsm https   t co u usj ztgd
2730,new drug approvals,fda approves calquence for adults with chronic lymphocytic leukemia   https   t co brlcu alip
2731,drugs com,fda approves calquence for adults with chronic lymphocytic leukemia   https   t co nshwel ml 
2732,adil med monitor,acalabrutinib now approved for treatment of adults with cll  sll https   t co i  afl wvi
2733,mpr,trial results showed that calquence had a longer pfs compared with those who received obinutuzumab plus chlorambucil   https   t co eepxub    
2734,thomas s n chal,astrazeneca scores again  calquence approved for cll as btk race heats up https   t co vdbunejn z https   t co bqpedxtepq
2735,zdravmedinfo,fda          acalabrutinib                                                   https   t co sllpltlttm                   
2736,dr  linex,calquence   uses  side effects  interactions  amp  more https   t co useclcov g https   t co krj r yb y
2737,dr  linex,acalabrutinib   uses  side effects  interactions  amp  more https   t co zgk vyqqli https   t co bzqhdayx s
2738,david ledger,fda nod for calquence in cll https   t co hu kbcqoat https   t co gmrk  gmui
2739,medscape,acalabrutinib has been approved for cll and sll in the us  australia and canada     https   t co gzt  t lkm
2740,pharmafocus, fda approves astrazeneca s calquence in chronic  lymphoma https   t co gz  vpkvep https   t co jjdvrv wpd
2741,jon angelo,fda approves astrazeneca s calquence in chronic lymphoma   https   t co gtfbazw vl  pharmaceutical
2742,pharma regulatory,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia  https   t co f e ng  nf  pharma  regulatory
2743,pharma regulatory,astrazeneca s calquence catches up with imbruvica s cll claim  https   t co  alxgqitm   pharma  regulatory
2744,cafepharma,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co lizlae ayz
2745,derrick,check this out too  keeping track of approvals  two novel drugs  givlaari and xcopri   a project orbis collaboration  calquence  and another humira biosimilar https   t co tbijkkjwld
2746,onclive com,watch  dr  mato on ibrutinib versus acalabrutinib in cll  cllsm  leukemia  sloan kettering https   t co lcpanziv c
2747,the james,patients with two types of  leukemia have a new treatment option with the fda approval of acalabrutinib  learn how the therapy  developed at the james  improves outcomes by blocking a protein in  cancer cells 
2748,corixis,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co qe vlpbeqy https   t co xq txka  z
2749,pharmaceutical,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co  jnwxxqsis https   t co docpqrak  
2750,bio talent,fda nod for calquence in cll https   t co  j wgzph f https   t co k qdlrgp j
2751,medivizor,how effective and safe is acalabrutinib compared to other treatments for     via  medivizor  https   t co nqzekygjpt  nonhodgkinslymphoma
2752,biotechnology,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co ce dnwqm t https   t co ygtnthisgt
2753,biocalifornia,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia https   t co bmrrrrbjw  https   t co bn ibpnr g
2754,medivizor,new by  medivizor  how effective and safe is acalabrutinib compared to other treatments f    https   t co nqzekygjpt  nonhodgkinslymphoma
2755,easy body fitness,calquence approved to treat cll  sll   digestive https   t co dctjpvzud 
2756,investor news,astrazeneca announced that the fda approved the label expansion of its btk inhibitor  calquence  as a treatment for     rhhby  azn  biib  gild https   t co dvummx  xl
2757,aus gov  news,tag   acalabrutinib receives tga approval for cll and sll cancers https   t co tkkm mbxnr
2758,cancernetwork   home of the journal oncology ,as part of project orbis  the fda has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma  https   t co  exfjfo us https   t co bjfdczoo v
2759,chocolatiere phys,how effective and safe is acalabrutinib compared to other treatments for patients with mantle cell lymphoma    medivizor https   t co xlmhz f zy via  rightrelevance thanks  medivizor
2760,medivizor,how effective and safe is acalabrutinib compared to other treatments for    from  medivizor  https   t co nqzekygjpt  nonhodgkinslymphoma
2761,medivizor,how effective and safe is acalabrutinib compared to other treatments for p    https   t co nqzekygjpt via  medivizor  nonhodgkinslymphoma
2762,cll society inc ,https   t co xlvgrnkomh https   t co knugwulopi
2763,tom henry,project orbis https   t co grzxbprokd  the simultaneous approval of calquence  acalabrutinib  for cll by us  canada and australia shows promise of this project to get oncology breakthroughs to patients sooner   cllsociety  lumerehq  cll  fda
2764,yanbo zhang,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co  smrtrhkug
2765,cellworkslife, fda approves acalabrutinib to treat  cll sll  https   t co v  zdbdisn
2766,phana,            calquence            cll   sll        calquence  acalabrutinib                                                               cll    sll                                  https   t co d  osjyyzo
2767,        gmp,fda          acalabrutinib                                                     https   t co r p zimarg https   t co ucnhtmbozl
2768,zorgnl,pharmascrip   astrazeneca s calquence catches up with imbruvica s cll claim https   t co  ybwtll u    pharmascrip https   t co v pyddzyzy https   t co  fcnvqysr 
2769,medscape oncology,acalabrutinib has been approved for cll and sll in the us  australia and canada   bloodcancers  https   t co zlydtljbr 
2770,scrip,astrazeneca s calquence catches up with imbruvica s cll claim https   t co h  kxrbu    pharmascrip
2771,stayin  alive  body  mind  spirit,fda approves acalabrutinib to treat cll sll https   t co  mnxphllmb
2772,fav store,calquence approved to treat cll  sll https   t co f  e  yjb  https   t co yf d cfyn 
2773,regulatory jobs,the us food and drug administration   fda  has approved astrazeneca s calquence  acalabrutinib  for chronic lymphocytic leukaemia  cll  and small lymphocytic lymphoma  sll   https   t co ajdsqcrwyi https   t co ffqsyuttzn
2774,it recruiter,another win for astrazeneca https   t co  u  rykbj 
2775,be healthy news,calquence approved to treat cll  sll https   t co ejhd nzvip
2776,investor news,astrazeneca says the fda approved calquence as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic ly    azn https   t co ipx us   a
2777,onclive com,the approval of acalabrutinib  which was done under the fda s project orbis initiative  was based on   phase iii randomized trials elevate tn and ascend  leukemia  lymphoma https   t co mfuliqs  u
2778,vijaya l,fda has approved acalabrutinib for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma as an initial or subsequent therapy  for more updates on hematology or cancer  ps  https   t co gpasuikrff   hematologyconferences  cancerconferences   hematology  cancer https   t co wf twpue w
2779,yiping yang  md  phd,congratulations to drs  john byrd and jen woyach  osuccc james hematology for the fda approval of the second generation btk inhibitor  acalabrutinib for treating cll https   t co bn saf  fg
2780,eipg,astrazeneca scores again  calquence approved for cll as btk race heats up   https   t co  myadosdun
2781,shm,acalabrutinib in cll long term f u study  acknowledging the limitations of cross trial comparisons  ibrutinib achieved a     cr rate vs    here after long term follow up  so far imbruvica wins   https   t co x ia f xoe
2782,fa technologies,calquence approved to treat cll  sll https   t co zu muwcge  https   t co  wpyskqh s
2783,bionest partners,astrazeneca s calquence steps up to challenge imbruvica with big  cll green light without head to head data  can calquence steal away market share from imbruvica   azn  oncology  pharma  https   t co tsmorhulbt https   t co yemb vfknn
2784,biocentury,friday s company news roundup includes a label expansion for astrazeneca s calquence under project orbis  a collaboration between fda  canada and australia  plus news from viiv  neon  horizon  sk bio and wuxi vaccines  azn  ntgn https   t co  wot q sfj
2785,zaspera,calquence approved to treat cll  sll   https   t co cnu jg bo  mednews https   t co odqrxp xhe https   t co jrzd rvuhy
2786,              ,      fda approves acalabrutinib for cll indication https   t co e miwbiseg
2787,arab medical pro,calquence                cll   sll https   t co azc giogaf
2788,arabmedical pro,calquence                cll   sllhttps   arabmedical pro other pharmacy calquence  d  a  d     d     d  b  d  aa d     d  af d  a   d     d  b  d     d  a  d  ac cll  d   c sll  https   t co opizpdvmut
2789,endpoints news,astrazeneca scores again  calquence approved for cll as btk race heats up https   t co dy apexynr  azn
2790,pharmaceutical market europe,astrazeneca wins fda approval for calquence in chronic lymphoma   pmlive https   t co uwvo ioupt
2791,onsvegas,calquence   acalabrutinib   efficacy and safety of a btk inhibitor in adult patients with previously treated mantle cell lymphoma  location fleming s date dec                pm       pm  rsvp jason mcdonald                 jason mcdonald  astrazeneca com by            https   t co uukb yakbf
2792,mazen m,calquence approved to treat cll  sll   https   t co ywqh rknq  https   t co t kjbohpbe
2793,calquence   acalabrutinib ,we re here to help your patients who are taking calquence throughout their journey 
2794,calquence   acalabrutinib ,learn about the resources for your patients taking calquence 
2795,calquence   acalabrutinib ,talk to your patients about calquence 
2796,calquence   acalabrutinib ,we re here to help your patients who are taking calquence throughout their journey 
2797,calquence   acalabrutinib ,learn about the resources for your patients taking calquence 
2798,calquence   acalabrutinib ,talk to your patients about calquence 
2799,calquence   acalabrutinib ,we re here to help your patients who are taking calquence throughout their journey 
2800,calquence   acalabrutinib ,learn about the resources for your patients taking calquence 
2801,calquence   acalabrutinib ,talk to your patients about calquence 
2802,calquence   acalabrutinib ,we re here to help your patients who are taking calquence throughout their journey 
2803,calquence   acalabrutinib ,learn about the resources for your patients taking calquence 
2804,calquence   acalabrutinib ,talk to your patients about calquence 
2805,cancercare,the u s  fda approved calquence   acalabrutinib  capsules for the treatment of adult patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   https   t co ilcamnpsyj
2806,the oncologist,astrazeneca s calquence wins fda approval for chronic lymphocytic leukemia   biospace https   t co zqjxexhfnx https   t co  cmevkjw g
2807,medical xpress,calquence approved to treat  cll  sll https   t co po ilbgehc
2808,ali alahmari ,project orbis  fda approves acalabrutinib for cll and sll https   t co kn tihswpd
2809,chseaton,fda approves calquence for adults with chronic lymphocytic leukemia https   t co cfmku lqju
2810,drugs com, calquence approved to treat cll  sll   https   t co bsjjiaopox
2811,mdedge,the fda approves acalabrutinib for adults with  cll or  sll  https   t co imv i xfib
2812,mdedge hematology   oncology,the fda approves acalabrutinib for adults with  cll or  sll  https   t co so vb jjdf
2813,biopharma dive,key fda approval expands use into more common chronic lymphocytic leukemia  although doctors have already been prescribing it in that disease https   t co wlx   m cy
2814,dr  carsten wenzel,fda nod for calquence in cll https   t co emarwcv ix https   t co nhuaohbskd
2815,the james,patients with two types of  leukemia have a new treatment option with the fda approval of acalabrutinib  learn how the therapy  developed at the james  improves outcomes by blocking a protein in  cancer cells 
2816,bernie marini,acalabrutinib fda approved  based on surrogate endpoint of pfs  it s like the esomeprazole of btki   metoodrug  thebarislowforfdaapproval  cllsm  https   t co  xhguegnfr
2817,lung cancer news,calquence ok boosts astrazeneca s challenge to imbruvica  the new fda approval expands calquence amp    s use into a more common blood cancer although doctors have already been prescribing it in that disease  https   t co dh  gxca n
2818,cancer news,calquence ok boosts astrazeneca s challenge to imbruvica  the new fda approval expands calquence amp    s use into a more common blood cancer although doctors have already been prescribing it in that disease  https   t co rpe  e   e
2819,access wallstreet,astrazeneca gets fda nod for calquence line extension in cll https   t co hzkhqffc n
2820,pharmatimes,fda nod for calquence in cll https   t co d  wsezu g  pharmanews  healthcare
2821,trustwell law group  llp,  this approval  gives patients another option that might be useful if intolerance to ibrutinib or acalabrutinib occurs  it is possible that brukinsa will have a superior safety profile compared to ibrutinib    lymphoma https   t co auxhv  d  
2822,paladin  , fda takes second action under international collaboration project orbis  approves new treatment option for patients with chronic lymphocytic  leukemia calquence  acalabrutinib    https   t co ubblfajf d
2823,client pharma ltd,the us food and drug administration  fda  has approved astrazeneca s calquence  acalabrutinib  for chronic lymphocytic leukaemia  cll  and small lymphocytic lymphoma  sll    https   t co uqiwuuzwe  https   t co vaggja pbo
2824,saleh stevens,fda nod for calquence in cll https   t co tkklwrrwnl https   t co czyuh lz t
2825,dr timos papagatsias,astrazeneca scores again  calquence approved for cll as btk race heats up https   t co  zflznmwcu  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  biotech  pharmaceutical  productmarketing  healthcare  pharma https   t co  w aydwkas
2826,mr markku hakali,https   t co vmmtz  wv 
2827,the world of cros,astrazeneca scores again  calquence approved for cll as btk race heats up https   t co nbdh drpcw
2828,pharmacrowd,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co wtkzrqzakc
2829,targeted oncology,the fda approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma as either an initial or subsequent therapy  https   t co  zxcq zbpw  leusm
2830,claude waddington,fda nod for az s  calquence sets up new  imbruvica showdown https   t co rsyegmmwgv
2831,tina witte,astrazeneca s calquence garners fda approval for chronic lymphocytic leukaemia  small lymphocytic lymphoma  https   t co mlpugdbcqg
2832,dr arun achuthan,fda nod for az s calquence sets up new imbruvica showdown https   t co ejo eur ic via  pharmaphorum
2833,pallawi torka,amazing  roswellpark grand rounds talk by  nitinjainmd from  mdandersonnews on upfront therapy in  cll today    ifcgx  very promising for young fit pts with good risk disease  real potential for  cure   ibrutinib va acalabrutinib vs obinutuzumab venetoclax for the rest  https   t co jnkeuravvo
2834,emilylevitch i health,the  fda has just granted supplemental approval to  acalabrutinib for patients with chronic lymphocytic leukemia  cll  or small lymphocytic lymphoma  sll   https   t co ofbjugyc o
2835,pharmaphorum,  us fda approval of  astrazeneca s calquence in chronic lymphocytic  leukaemia sets up showdown with abbvie and j amp j s imbruvica https   t co vcerjtwh   https   t co qufsyqwash
2836,casper paardekooper, six months after first boasting about phase iii data  astrazeneca has earned expanded fda approval for its btk inhibitor calquence  the drug will now be used to treat one of the most common adult blood cancers  chronic lymphocytic https   t co uguphyvozj https   t co yyiruyscvx
2837,endpoints news,astrazeneca scores again  calquence approved for cll as btk race heats up https   t co dy apexynr
2838,career biotech, jobs fda nod for calquence in cll https   t co hhsacdagnm  pharmatimes
2839,pharma regulatory,fda nod for calquence in cll  https   t co xfbhdyjmgb  pharma  regulatory
2840,the pharma letter,calquence wins broader label in the usa https   t co ob   oqtdu  astrazeneca  astrazenecaus  pharma
2841,drug store news,as part of an international collaboration  the fda has approved astrazeneca s new treatment option for patients with chronic lymphocytic leukemia  https   t co varxtnntms https   t co c rdacuyrf
2842,pharma business int,calquence approved in us for chronic lymphocytic leukaemia https   t co j yjeuiwab
2843,flatbio,fda approves acalabrutinib for cll sll  collaborating w   tgagovau  amp   govcanhealth   projectorbis may expand to  singapore  healthsciencesauthority  amp   switzerland  fdaoncology  fdamedia  ascopost  hematology   lymsm  astrazeneca  zacharybrennan  rapsorg   https   t co wnshvimmep https   t co  uoollungk
2844,pharma regulatory,astrazeneca wins fda approval for calquence in chronic lymphoma  https   t co wtpmkqh  s  pharma  regulatory
2845, stoncology, calquence approved in the us for adult patients with  chroniclymphocyticleukaemia https   t co uq jmxzjoi
2846,pharmastate,pharma industry news     november        roche launches atezolizumab in india   laurus labs vidakhapatnam units usfda inspection   completed   astrazeneca s calquence approved by usfda  pharmaindustrynews  roche  laurus  zydus  calquence  novo  merz  https   t co w wjogyrcu
2847,dough, azn baml astrazeneca calquence cll approval   months early with strong label
2848,firstword pharma,astrazeneca s calquence garners fda approval for chronic lymphocytic leukaemia  small lymphocytic lymphoma https   t co yjce wymhi  azn
2849,jorge e  oliveira         ,fda approves acalabrutinib for cll https   t co  e pshttpq via  onclive
2850,researchpool, azn  astrazeneca astrazeneca  calquence approved in a record time for cll   buy vs  neutral       p vs      p         astrazeneca   buy vs  neutral       p vs      p        calquence approved in a record time for cll calquence approved  https   t co aidrtnd  n  equity  stocks https   t co piymyz esn
2851,naturerevclinoncol,yesterday  the fda granted a second approval under its international project orbis collaboration  in the form of acalabrutinib for the treatment of pts with newly diagnosed or previously treated  cll or sll  https   t co odouv oz q  leusm  lymsm  hemeonc
2852,barbara jacoby,fda approves acalabrutinib for cll https   t co fgrdgnikii
2853,krizs n szilvia  md, fda granted supplemental approval to acalabrutinib for the treatment of adults with  cll or  sll  leukemia  https   t co wj tvkxcti  onclive haszn lat val
2854,pharmashots   incisive news in   shots,astrazeneca s calquence  acalabrutinib  receives the us fda s approval for chronic lymphocytic leukemia under the project orbis  astrazeneca https   t co  twiobap u
2855,career biotech, jobs fda approves astrazeneca s calquence to treat lymphocytic cancers https   t co rdjsdedt    drugdiscovery
2856,krishan maggon,fda takes second action under international collaboration  approves new treatment option calquence  acalabrutinib  astrazeneca  for patients with chronic lymphocytic leukemia   fda https   t co wcicdlnvse https   t co tbu jyynxu
2857,caner saygin  md,acalabrutinib  an irreversible selective btki  is now fda approved for cll sll  https   t co dfbgqsplgs
2858,oncology tribune,       cll sll    acalabrutinib   fda      fda  https   t co vntitz cdi  oncologytribune
2859,deborah stephens,the fda approved the second generation btk inhibitor acalabrutinib today for patients with  cll   humbled to participate in the trials that made this possible    huntsmancancer https   t co fyczxfebzz
2860,saeed valadbaygi,fda approves azn s calquence  glyc s  data to be delayed  enlv withdraws offering  nasdaq https   t co by k  zuuu https   t co  afeztlbek
2861,rttnews top stories,fda approves azn s calquence  glyc s data to be delayed  enlv withdraws offering https   t co  yyxrbjiqi  news  breaking  rttnews https   t co bibm d pro
2862,bitcoin headline news,fda approves azn s calquence  glyc s data to be delayed  enlv withdraws offering https   t co nzhn guhd  https   t co ziflszklty https   t co zj mpplzty
2863,bichoy gabra  r ph   ph d ,on november          the  fda approved  calquence   acalabrutinib  for adults with chronic lymphocytic leukemia   cll  or small lymphocytic lymphoma   sll    calquence prescribing information https   t co wyyyru yie https   t co  nxq xerr 
2864,snowdome foundation,wonderful to see fda  tga and canadian regulatory authorities working together to approve a new treatment for refractory  relapsed cll   acalabrutinib is a  nd generation btk and was shown to be more effective and more tolerable than usual treatments    https   t co bgeczavnk 
2865,fda daily,fda approves calquence for adults with chronic lymphocytic leukemia   https   t co lir ivaj o
2866,junaid  jay  abdulghani  md phd,project orbis  fda approves acalabrutinib for cll and sll https   t co zt wvkkbdy   orbis  fda  acalabrutinib  cll  sll
2867,eipg,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co v  lnrssrt
2868,onclive com,the  us fda has approved acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma  leukemia  lymphoma https   t co ekcgj opni
2869,newexpressnews,fda approves calquence for adults with chronic lymphocytic leukemia https   t co  gbcturb t
2870,living safely,regulatory news  us food  amp  drug administration  drug approvals  updates and or changes as of thursday  november      calquence  nda            deferasirox  anda            givlaari  nda          and many others   fda  https   t co u jsfd xry
2871,biopharmcatalyst,biotech updates          glyc data delay       azn calquence fda approval intra day offerings  ontx        bpth       enlv withdraws offering pipeline updates  biib  enta  entx  imrn  iova  sny  tnxp  xers https   t co ckrtptccap
2872,fda daily,fda approves acalabrutinib for cll and sll   https   t co vkurco gdd
2873,cafepharma,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co mptwygqkjd
2874,hcp feed,fda approves acalabrutinib for cll and sll  https   t co drpazqedz  
2875,tom henry  mba  rph  cph,fda approves acalabrutinib for cll https   t co bpohcjsm b via  onclive
2876,jeff szer,fda approves acalabrutinib for cll sll as part of project orbis   the asco post https   t co s ozxzlevh tremendous initiative  orbis  with   reg agencies acting in concert 
2877,astrazenecaus,the  us fda has approved our treatment for certain patients with chronic lymphocytic  leukemia  cll   https   t co g j zrxkox https   t co tasyvuxxbl
2878,    ,us  australia  canada approve new drug for blood cancers https   t co io  ods  c via  medscape   acalabrutinib
2879,octagonchem,astrazeneca s calquence  acalabrutinib  is approved by fda for adult patients with chronic lymphocytic leukaemia  cll  or small lymphocytic lymphoma  sll  
2880,cll society inc ,fda approves calquence for chronic lymphocytic leukemia under international collaboration https   t co vd psjepof
2881,cancer news,project orbis fda approves acalabrutinib for cll and sll  oncology newsburst https   t co ng nwjcg q
2882,lymphoma research foundation,fda update  on november           the u s  food and drug administration  fda  approved the use of acalabrutinib  calquence  astrazeneca  for adult patients with chronic lymphocytic leukemia small lymphocytic lymphoma   https   t co  uh fzjp b
2883,the asco post,  us fda approves acalabrutinib for cll sll as part of project orbis https   t co xra nxiogb  hematology   lymsm
2884,specialtyptimes,fda approves acalabrutinib for cll indication more  https   t co vkpignax i https   t co pvbtmzlaxc
2885,michael hallek,good to have an additional option for  cll  sll patients  head to head comparison of  acalabrutinib vs   ibrutinib eagerly awaited  fda approves new treatment option for patients with cll  https   t co oks plr zh
2886,contacto sciencelink,fda aprueba acalabrutinib en el tratamiento de la llc   sciencelink https   t co w q plw p 
2887,fda oncology, projectorbis  on nov           fda  approved acalabrutinib  calquence  astrazeneca  for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma  more info and link to drug label  https   t co ldt ijz  i
2888,pharm digest,project orbis  fda approves acalabrutinib for cll and sll https   t co k epvurrdc
2889,sigrid sk nland,new drug approved for  cll  the btk inhibitor acalabrutinib will give more treatment options for the patients   targetedtherapy  https   t co   yizupgnk
2890,crwe world,calquence approved in the us for adult patients with chronic lymphocytic leukemia https   t co tlyxhxevj 
2891,the oncologist,project orbis  fda approves acalabrutinib for cll and sll   https   t co g xavei i 
2892,diagnostics news,calquence approved in the us for adult patients with chronic lymphocytic leukemia  two phase iii calquence trials demonstrated superior progressionfree survival across multiple settings while maintaining favorable tolerabilitycalquence combined with  https   t co gzf rnudj 
2893,analyst land news,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co th qqjaao 
2894,    ,awesomecapital  fda oks astrazeneca s calquence for lymphocytic le    https   t co n elttxdoc
2895,otc dynamics  inc , azn calquence approved in the us for adult patients with chronic lymphocytic leukemia https   t co rmxvninrod
2896,tontarn chutima,elevate tn and ascend trials comparing calquence to commonly used tx regimens  acalabrutinib demonstrated a clinically meaningful improvement in pfs in patients across multiple settings  while maintaining its favorable tolerability and safety profile   https   t co terzxbu   
2897,kelley d  carlstrom  pharmd  bcop,another indication for acalabrutinib   does anyone else start singing supercalafragilistic   when seeing this drug name       drugnames  pharmacists  oncologypharmacists https   t co  ofenmrtry
2898,financial journal, astrazeneca has announced us fda has approved calquence  acalabrutinib  for adult patients with chronic lymphocytic leukaemia  more analysis on https   t co ufz upjvyp
2899,investor news,fda oks astrazeneca s calquence for lymphocytic leukemia  azn https   t co ipx us   a
2900,breaking news, azn   fda oks astrazeneca s calquence for lymphocytic leukemia https   t co sqdeocv xv
2901,oncopharm,fyi  this week s pod on zanubrutinib was recorded before acalabrutinib s cll sll approval   https   t co pfhaqi i i
2902,jason broderick,fda approves acalabrutinib for cll https   t co pceqrihduu
2903,s o p a,fda approves acalabrutinib for cll sll https   t co   ptdmkwef via  targetedonc
2904,lisa astor,approved  the  fda has approved acalabrutinib for patients with cll or sll  https   t co tjuunatwo 
2905,cision news,calquence approved in cll in the us https   t co srf jnp gd
2906,jeff sharman,getting ready for an exciting ash     fda approves acalabrutinib for cll https   t co nsgkt wyhs via  onclive
2907,dr  paul desantis  pharmd,how not to announce a new drug approval   copy paste error switching any grade aes for gr   aes  oncology at az https   t co q d ccyzs  https   t co fjbh pbpys
2908,dr timos papagatsias,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co  mqcj u ek  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  pharma  pharmaceutical  healthcare  biotech  productmarketing
2909,carly helfand,astrazeneca s calquence steps up to challenge imbruvica with big cll green light  https   t co hi jhrbjai  azn  abbv  jnj  pharma
2910,cision news,calquence approved in the us for adult patients with chronic lymphocytic leukaemia https   t co m byqi qny
2911,kerri wachter,fda approves acalabrutinib for cll https   t co dh nilv  a via  onclive
2912,phil talamo,breaking   the fda has approved acalabrutinib  a  nd generation btk inhibitor  for patients with cll or sll   this is the  nd agent approved under the fda s project orbis    gt fda approves acalabrutinib for cll https   t co vju o xs o via  onclive
2913,newexpressnews,astrazeneca s calquence steps up to challenge imbruvica with big cll green light https   t co dbdgjdgjfa https   t co  gukzl hxy
2914,the medical letter,fda grants supplemental approval to calquence  acalabrutinib  for the treatment of adults with chronic lymphocytic  leukemia   cll  or small lymphocytic  lymphoma   sll   https   t co apbg axdui
2915,amber koehler  pa c,great news   fdaoncology approves acalabrutinib for use in  cll 
2916,joe birkett crest,excellent news  now another and maybe more effective treatment option than ibrutinib   fda approves acalabrutinib for cll sll https   t co yvlpsuydeu
2917,pharma regulatory,astrazeneca s calquence steps up to challenge imbruvica with big cll green light  https   t co  syaoghpo   pharma  regulatory
2918,oncology nursing news,breaking  the fda has approved acalabrutinib  calquence  for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma  https   t co zu azrreff
2919,dr  paul desantis  pharmd,calquence approved in cll     secondary malignancy    not sure what imbruvica s is   but seems high  graham  gc
2920,atopp summit,breaking  oncopharm news  as part of the  fdaoncology  projectorbis  acalabrutinib has been approved for patients with cll and sll    leukemia  lymphoma  lymsm  leuksm   https   t co my p pgxzh  via  onclive
2921,hcp feed,fda approves acalabrutinib for cll  https   t co vauldbt  h 
2922,matthew davids  md  mmsc,acalabrutinib now fda approved for cll sll   great to have more therapeutic options for patients  https   t co  m vr ef  
2923,naveen pemmaraju  md,fda takes second action under international collaboration  approves new treatment option for patients with chronic lymphocytic leukemia     fdaoncology    us fda   acalabrutinib  leusm  cllsm  https   t co bwllcrday 
2924,chocolatiere phys,fda approves calquence for chronic lymphocytic leukemia under international collaboration https   t co lppd vwimr via  rightrelevance thanks  hemonctoday
2925,cure magazine,breaking  the  us fda has granted supplemental approval to calquence  acalabrutinib  for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma  https   t co ddwqme ep 
2926,anastasios raptis  md,one more tool to treat cll  fda approves acalabrutinib for cll
2927,immuno oncology,fda approves acalabrutinib for cll https   t co fjbnl g wb
2928,alan skarbnik,acalabrutinib approved for cll   happy for our patients and proud ro have contributed to the frontline phase iii trial that led to this approval  more data to be presented at ash   cllsm  novanthealth https   t co twbox mle 
2929,fda oncology,this just in  our second  projectorbis action  acalabrutinib for cll and sll  https   t co nowgxopfuk
2930,silas inman,fda approves acalabrutinib for cll https   t co lr xegxan   lymsm
2931,oncology strategies,fda approves acalabrutinib for cll https   t co  iqekfbeaa via  onclive
2932,onclive com,breaking   us fda approves acalabrutinib for cll  lylsm https   t co opcc mqkwh
2933,healio,  us fda approves calquence for chronic lymphocytic  leukemia under international collaboration   https   t co  ljzo uvox
2934,hemonc today,  us fda approves calquence for chronic lymphocytic  leukemia under international collaboration   https   t co yc gubrlle
2935,jacob bell,fda highlights another project orbis success   azn s calquence approved for cll and sll https   t co  ot  duvkk
2936,calquence   acalabrutinib ,we re here to help your patients who are taking calquence throughout their journey 
2937,calquence   acalabrutinib ,learn about the resources for your patients taking calquence 
2938,calquence   acalabrutinib ,talk to your patients about calquence 
2939,lung cancer news,acalabrutinib and venetoclax with or without early obinutuzumab for the treatment of high risk recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma  this phase ii trial studies how well acalabrutinib and venetoclax with or  https   t co pojhzbxd z
2940,paperbirds hematology,new clinical trial  acalabrutinib and venetoclax with or without early obinutuzumab for the treatment of high risk  recurrent  or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma https   t co afnkarko r  cll  leusm  hematology
2941,lymphoma   myeloma connect,stay tuned for our update from ash newsletter  including the elevate tn study on  acalabrutinib     obinutuzumab vs  obinutuzumab    chlorambucil in  cll  https   t co  irgwy hzf   lymsm  oncology  meded https   t co  sesfmdg r
2942,renal cell carcinoma,an indepth evaluation of acalabrutinib for the treatment of mantlecell lymphoma   regimens involving intensive immunochemotherapy followed by highdose therapy and autologous stem cell transplant represent the standard treatment  https   t co  xasoxxvpm  renalcell  kidneycancer
2943,i  health, tuesdaynewsday in previously untreated chronic lymphocytic leukemia   cll    acalabrutinib improves progression free survival alone or in combination with  obinutuzumab  https   t co ugspmf uvy
2944,paperbirds hematology,new article  an in depth evaluation of acalabrutinib for the treatment of mantle cell lymphoma  https   t co iqlswqovye  mcl  lymsm  hematology
2945,lymphoma papers,an in depth evaluation of acalabrutinib for the treatment of mantle cell lymphoma   lymphoma  lymsm https   t co k hffuckmu
2946,nathalia le hen,pascal soriot     la chine est pour astrazeneca aussi profitable que l europe      beigeneusa  usa  pharma  biotech  china  us fda  health  calquence  celgene  brukinsa  astrazeneca  china  drugs  oncology  imbruvica  mantlecelllymphoma     lesechos  https   t co r khf  f c
2947,michael wang  md,ibrutinib has been used around the globe  acalabrutinib is also picking up  zanubrutinib has been studied in both oriental and western populations and therefore will be used for these patients  the new fda approval is a positive step forward  https   t co qhdyggmc  
2948,cancer news,beigene fda cancer drug nod seen as breakthrough for chinese biopharma  the drug branded as brukinsa will go up against j amp amp j and abbvie amp    s imbruvica and astrazeneca amp    s calquence in lymphoma  https   t co qtafwg dhf
2949,biopharma dive,brukinsa will go up against j amp j and abbvie s imbruvica and astrazeneca s calquence in lymphoma  https   t co rfqnou pzo
2950,paperbirds hematology,new article  elevate tn  phase   study of acalabrutinib combined with obinutuzumab  o  or alone vs o plus chlorambucil  clb  in patients  pts  with treatment naive chronic lymphocytic leukemia  cll   https   t co pwowyjk ca  cll  leusm  hematology
2951,paperbirds hematology,new article  preliminary safety and efficacy results from a phase   study of acalabrutinib  venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia  cll   https   t co   zgg l rz  cll  leusm  hematology
2952,michael wang  md,it has been a great honor for me to take part in the  development of   fda approved irreversible btk inhibitors ibrutinib  acalabrutinib and zanubrutinib  our patients are having great benefits  we are working on a whole new class of reversible btk inhibitors  stay tuned 
2953,sarah williams,in previously untreated chronic lymphocytic leukemia   cll    acalabrutinib improves pfs either alone or in combination with  obinutuzumab  interim results of phase   elevate tn trial to be presented by  jeff sharman at  ash    https   t co tm   amjna  hematology  cancernews
2954,lymphoma   myeloma connect,interesting discussion on the phase   elevate tn trial with  acalabrutinib      obinutuzumab vs obinutuzumab    chlorambucil in  cll   data to be presented at  ash     oncology  meded  lymsm https   t co qzdck csha
2955,toby eyre,first experience  acalabrutinib outside  cll trials n         l     r r     r r prior btki prior intol to ibr in          of intol pts  median fup  m dc      n     aes      n      orr      short fup but interesting early data of ibr intol population nice wk  maryam yazdy  ash   https   t co cx  ooeeht
2956,lymphoma papers,matching adjusted indirect comparisons of the efficacy and safety of acalabrutinib versus other targeted therapies in relapsed refractory mantle cell lymphoma   lymphoma  lymsm https   t co x xlg  sm 
2957,paperbirds hematology,new article  matching adjusted indirect comparisons of the efficacy and safety of acalabrutinib versus other targeted therapies in relapsed refractory mantle cell lymphoma  https   t co   eqhsropp  mcl  lymsm  hematology
2958,toby eyre,selectivity of btk inhibition and btk occupancy does not seem to affect ultimate mechanism of resistance  monitoring for pts pre clinical relapse has potential with this agent as well as ibrutinib  acalabrutinib  ash   https   t co oz nygyfey
2959,toby eyre,woyach et al btk mut key mech resistance to  acalabrutinib in  cll  btk c    in             c   s in     c   r c   y in      pt btk c   s co existing plcg  mut          screened every     cycles     pt mut detect at median     m from initiation  time from mut  gt relapse   m  ash   https   t co moisltilge
2960,maria badillo  msn rn ocn ccrp,at the  aonn     conference ready to present our poster about managing adverse events in pts with r r mcl treated with acalabrutinib clinical experience from the mdacc     pts of this     trial are dr   michaelwangmd   mcl  mdandersonnews
2961,talal hilal  ,i will not comment on chlorambucil obinutuzumab control arm  just pointing out that addition of obinutuzumab to acalabrutinib leads to     increase in grade   aes  mostly neutropenia  and more pneumonias  also note that if there is a  significant  diff  in pfs  it appears minimal https   t co lsgdl  o n
2962,carlo franzini,leucemia linfatica cronica  maggiore efficacia di calquence in monoterapia rispetto alla chemioimmunoterapia standard https   t co apbg eeynl
2963,lymphoma   myeloma connect,data from the phase   elevate tn trial to be presented at  ash   by  jeff sharman et al    acalabrutinib    obinutuzumab reduced the risk of progression or death by     vs obinutuzumab    chlorambucil in patients with treatment naive  cll  lymsm https   t co vd z ga g 
2964,oncology tribune,          btk   acalabrutinib    elevate tn        ash         https   t co ml j rb ef  oncologytribune
2965,paperbirds hematology,new article  evaluating acalabrutinib in the treatment of mantle cell lymphoma  design  development  and place in therapy  https   t co lmujzbd l   mcl  lymphoma  hematology
2966,astrazenecaus,at  ash    we re presenting new advancements across our robust  hematology portfolio  including breakthrough phase iii data from our elevate tn study in chronic lymphocytic  leukemia  cll   https   t co  ibudsecrt https   t co w    pnvt 
2967, stoncology, calquence data to show improved progression free survival in phase iii front line  chroniclymphocyticleukaemia trial at  ash   https   t co kjwfaq pls
2968,pharmacutical daily,calquence  data to show improved progression free survival in phase iii front line chronic lymphocytic leukemia at ash      annual meeting https   t co z wanezkfb
2969,saeed valadbaygi,calquence   data to show improved progression free survival in phase iii front line chronic lymphocytic leukemia at ash      annual meeting  business wire https   t co x z z zpiy https   t co vb ulvl br
2970,crwe world,calquence  data to show improved progression free survival in phase iii front line chronic lymphocytic leukemia at  https   t co  zzqycqik 
2971,renal cell carcinoma,calquence  data to show improved progressionfree survival in phase iii frontline chronic lymphocytic leukemia at ash      annual meeting  robust earlystage pipeline advancements and presentations across multiple scientific platforms demonstrate potential  https   t co  qkvftdmnq
2972,cll society inc ,ash      abstracts are out and let s start with this one that shows how good a combination acalabrutinib and obinutuzumab make in terms of progression free survival in cll 
2973,mr markku hakali,https   t co  ww  cfbad
2974,alan skarbnik,ash abstracts are online   elevate tn trial showing outcomes of acalabrutinib with or without obinutuzumab in treatment naive cll     mos pfs     for acala  o      acala mono  food for thought  proud to be a co author on this study   jeff sharman  novanthealth  jtcancercenter https   t co y idhce xc
2975,cision news,calquence data to show improved progression free https   t co fezrrblnps
2976,cision news,calquence data to show improved progression free survival in phase iii front line chronic lymphocytic leukaemia trial at ash      annual meeting https   t co ofkcnp uhj
2977,onclive com,watch  dr  wang on addition of acalabrutinib to bendamustine rituximab in mcl  mclsm  lymphoma  michaelwangmd  mdandersonnews https   t co tn zcocfbb
2978,dough,baml  azn busy year end for pipeline newsflow focus will remain on other newsflow including calquence  l cll data ash abstract  th nov roxadustat  anaemia  piii cv data asn  th nov and ds      pivotal destiny breast   at sabcs   th dec
2979,ajay nooka  md  mph,  winshipatemory    sagarlonialmd   jonathonbcohen  jonathon cohen elevating obinutizumab   acalabrutinib at the state of science summit https   t co j ywu fxcd
2980,clinicaltherapeutics,matching adjusted indirect comparisons of the efficacy and safety of acalabrutinib versus other targeted therapies in relapsed refractory mantle cell lymphoma https   t co jr sozest  https   t co p gee zetg
2981,health canada and phac,health canada has authorized calquence  acalabrutinib  for adults with mantle cell lymphoma  mcl  who have tried at least one prior therapy  https   t co dc gnsejcc  drugandmeddevice  cancer https   t co dbmertrrej
2982,sant  canada et l aspc,sant  canada a homologu  calquence  acalabrutinib  pour les adultes atteints de lymphome   cellules du manteau  lcm  ayant essay  au moins un traitement  https   t co aizeqjhix   m dicamentsetinstrumentsm dicaux  cancer https   t co udkyjcruxc
2983,eipg,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say https   t co atj b mifs
2984,cafepharma,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say https   t co ijysv iheh
2985,fiercepharma,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say https   t co  nd   gm r
2986,dr timos papagatsias,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say https   t co  ynv ay rf  gt  gt  gt  https   t co hta isohwv  strategy  competitiveintelligence  marketing  pharma  biotech  healthcare  productmarketing  pharmaceutical https   t co cwjggpzic 
2987,worldcatholicnews,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say https   t co wscnvtowf  via  winway health blog
2988,pharma regulatory,is abbvie s imbruvica concerned about az s rising calquence  we ve got this covered  execs say  https   t co   b pwsmkx  pharma  regulatory
2989,dr  paul desantis  pharmd,          call prediction  calquence will be dead on arrival in  l cll after approval  max peak market share of  lt         imbruvica data too good broad across  l risk status subtypes  at best calquence can hope to match these data  and hope for nccn language based on tolerability
2990,graham collins,stellar trial in richters transformation   integrating acalabrutinib into the treatment pathway  very important  ncri partners study led by  annaschuh   awful disease in desperate need of treatment advances  lymsm https   t co tqm onsha 
2991,targeted oncology,dr  siddiqi discussed how she sees acalabrutinib fitting into the treatment landscape for patients with chronic lymphocytic leukemia following the results from the phase iii ascend trial  https   t co bkpxftuybk  leukemia  leusm
2992,targeted oncology, the primary reason patients discontinued the trial was intolerance in     to     of patients   said lead study author dr  rogers  https   t co b rftj  nw  leukemia
2993,biopharma dive,competitive data from a calquence leukemia study could help  azn add to its growing oncology sales  https   t co  jstyjqmoy
2994,targeted oncology,btk inhibitor acalabrutinib demonstrated a high rate of response  prolonged survival  and high tolerability in patients with chronic lymphocytic leukemia who demonstrated intolerance to ibrutinib    https   t co b rftj  nw  leusm  leukemia
2995,michael wang  md,getting ready to present at  chum with  mcgilloncogy on acalabrutinib in b cell lymphoma  with my colleague julie durocher from astrazeneca  https   t co jr kmwvx d
2996,michael wang  md,delivered grand round on advances of lymphoma therapy in mcgill university  acalabrutinib was approved for relapsed  mantlecelllymphoma in canada about   weeks ago  faculties are using it  with eric kader from astrazeneca this beautiful montr al morning  https   t co wafzkamdv 
2997,michael wang  md,getting ready to present about acalabrutinib on b cell lymphoma  thanks to the invitation from astrazeneca  my colleague paul vardanis  https   t co du wvosxao
2998,jonathan friedberg,our  swog study now in press  five year outcomes of s     study of r hyper cvad vs r bendamustine in mantle cell lymphoma pre asct  continued favorable outcomes with r b  supports  eaonc study of r b with acalabrutinib     cytarabine   https   t co kqdte qjmf
2999,,
3000,,
3001,,
3002,,
3003,,
3004,,
3005,,
3006,,
3007,,
3008,,
3009,,
3010,,
3011,,
3012,,
3013,,
3014,,
3015,,
3016,,
3017,,
3018,,
3019,,
3020,,
3021,,
3022,,
3023,,
3024,,
3025,,
3026,,
3027,,
3028,,
3029,,
3030,,
3031,,
3032,,
3033,,
3034,,
3035,,
3036,,
3037,,
3038,,
3039,,
3040,,
3041,,
3042,,
3043,,
3044,,
3045,,
3046,,
3047,,
3048,,
3049,,
3050,,
3051,,
3052,,
3053,,
3054,,
3055,,
3056,,
3057,,
3058,,
3059,,
3060,,
3061,,
3062,,
3063,,
3064,,
3065,,
3066,,
3067,,
3068,,
3069,,
3070,,
3071,,
3072,,
3073,,
3074,,
3075,,
3076,,
3077,,
3078,,
3079,,
3080,,
3081,,
3082,,
3083,,
3084,,
3085,,
3086,,
3087,,
3088,,
3089,,
3090,,
3091,,
3092,,
3093,,
3094,,
3095,,
3096,,
3097,,
3098,,
3099,,
3100,,
3101,,
3102,,
3103,,
3104,,
3105,,
3106,,
3107,,
3108,,
3109,,
3110,,
3111,,
3112,,
3113,,
3114,,
3115,,
3116,,
3117,,
3118,,
3119,,
3120,,
3121,,
3122,,
3123,,
3124,,
3125,,
3126,,
3127,,
3128,,
3129,,
3130,,
3131,,
3132,,
3133,,
3134,,
3135,,
3136,,
3137,,
3138,,
3139,,
3140,,
3141,,
3142,,
3143,,
3144,,
3145,,
3146,,
3147,,
3148,,
3149,,
3150,,
3151,,
3152,,
3153,,
3154,,
3155,,
3156,,
3157,,
3158,,
3159,,
3160,,
3161,,
3162,,
3163,,
3164,,
3165,,
3166,,
3167,,
3168,,
3169,,
3170,,
3171,,
3172,,
3173,,
3174,,
3175,,
3176,,
3177,,
3178,,
3179,,
3180,,
3181,,
3182,,
3183,,
3184,,
3185,,
3186,,
3187,,
3188,,
3189,,
3190,,
3191,,
3192,,
3193,,
3194,,
3195,,
3196,,
3197,,
3198,,
3199,,
3200,,
3201,,
3202,,
3203,,
3204,,
3205,,
3206,,
3207,,
3208,,
3209,,
3210,,
3211,,
3212,,
3213,,
3214,,
3215,,
3216,,
3217,,
3218,,
3219,,
3220,,
3221,,
3222,,
3223,,
3224,,
3225,,
3226,,
3227,,
3228,,
3229,,
3230,,
3231,,
3232,,
3233,,
3234,,
3235,,
3236,,
3237,,
3238,,
3239,,
3240,,
3241,,
3242,,
3243,,
3244,,
3245,,
3246,,
3247,,
3248,,
3249,,
3250,,
3251,,
3252,,
3253,,
3254,,
3255,,
3256,,
3257,,
3258,,
3259,,
3260,,
3261,,
3262,,
3263,,
3264,,
3265,,
3266,,
3267,,
3268,,
3269,,
3270,,
3271,,
3272,,
3273,,
3274,,
3275,,
3276,,
3277,,
3278,,
3279,,
3280,,
3281,,
3282,,
3283,,
3284,,
3285,,
3286,,
3287,,
3288,,
3289,,
3290,,
3291,,
3292,,
3293,,
3294,,
3295,,
3296,,
3297,,
3298,,
3299,,
3300,,
3301,,
3302,,
3303,,
3304,,
3305,,
3306,,
3307,,
3308,,
3309,,
3310,,
3311,,
3312,,
3313,,
3314,,
3315,,
3316,,
3317,,
3318,,
3319,,
3320,,
3321,,
3322,,
3323,,
3324,,
3325,,
3326,,
3327,,
3328,,
3329,,
3330,,
3331,,
3332,,
3333,,
3334,,
3335,,
3336,,
3337,,
3338,,
3339,,
3340,,
3341,,
3342,,
3343,,
3344,,
3345,,
3346,,
3347,,
3348,,
3349,,
3350,,
3351,,
3352,,
3353,,
3354,,
3355,,
3356,,
3357,,
3358,,
3359,,
3360,,
3361,,
3362,,
3363,,
3364,,
3365,,
3366,,
3367,,
3368,,
3369,,
3370,,
3371,,
3372,,
3373,,
3374,,
3375,,
3376,,
3377,,
3378,,
3379,,
3380,,
3381,,
3382,,
3383,,
3384,,
3385,,
3386,,
3387,,
3388,,
3389,,
3390,,
3391,,
3392,,
3393,,
3394,,
3395,,
3396,,
3397,,
3398,,
3399,,
3400,,
3401,,
3402,,
3403,,
3404,,
3405,,
3406,,
3407,,
3408,,
3409,,
3410,,
3411,,
3412,,
3413,,
3414,,
3415,,
3416,,
3417,,
3418,,
3419,,
3420,,
3421,,
3422,,
3423,,
3424,,
3425,,
3426,,
3427,,
3428,,
3429,,
3430,,
3431,,
3432,,
3433,,
3434,,
3435,,
3436,,
3437,,
3438,,
3439,,
3440,,
3441,,
3442,,
3443,,
3444,,
3445,,
3446,,
3447,,
3448,,
3449,,
3450,,
3451,,
3452,,
3453,,
3454,,
3455,,
3456,,
3457,,
3458,,
3459,,
3460,,
3461,,
3462,,
3463,,
3464,,
3465,,
3466,,
3467,,
3468,,
3469,,
3470,,
3471,,
3472,,
3473,,
3474,,
3475,,
3476,,
3477,,
3478,,
3479,,
3480,,
3481,,
3482,,
3483,,
3484,,
3485,,
3486,,
3487,,
3488,,
3489,,
3490,,
3491,,
3492,,
3493,,
3494,,
3495,,
3496,,
3497,,
3498,,
3499,,
3500,,
3501,,
3502,,
3503,,
3504,,
3505,,
3506,,
3507,,
3508,,
3509,,
3510,,
3511,,
3512,,
3513,,
3514,,
3515,,
3516,,
3517,,
3518,,
3519,,
3520,,
3521,,
3522,,
3523,,
3524,,
3525,,
3526,,
3527,,
3528,,
3529,,
3530,,
3531,,
3532,,
3533,,
3534,,
3535,,
3536,,
3537,,
3538,,
3539,,
3540,,
3541,,
3542,,
3543,,
3544,,
3545,,
3546,,
3547,,
3548,,
3549,,
3550,,
3551,,
3552,,
3553,,
3554,,
3555,,
3556,,
3557,,
3558,,
3559,,
3560,,
3561,,
3562,,
3563,,
3564,,
3565,,
3566,,
3567,,
3568,,
3569,,
3570,,
3571,,
3572,,
3573,,
3574,,
3575,,
3576,,
3577,,
3578,,
3579,,
3580,,
3581,,
3582,,
3583,,
3584,,
3585,,
3586,,
3587,,
3588,,
3589,,
3590,,
3591,,
3592,,
3593,,
3594,,
3595,,
3596,,
3597,,
3598,,
3599,,
3600,,
3601,,
3602,,
3603,,
3604,,
3605,,
3606,,
3607,,
3608,,
3609,,
3610,,
3611,,
3612,,
3613,,
3614,,
3615,,
3616,,
3617,,
3618,,
3619,,
3620,,
3621,,
3622,,
3623,,
3624,,
3625,,
3626,,
3627,,
3628,,
3629,,
3630,,
3631,,
3632,,
3633,,
3634,,
3635,,
3636,,
3637,,
3638,,
3639,,
3640,,
3641,,
3642,,
3643,,
3644,,
3645,,
3646,,
3647,,
3648,,
3649,,
3650,,
3651,,
3652,,
3653,,
3654,,
3655,,
3656,,
3657,,
3658,,
3659,,
3660,,
3661,,
3662,,
3663,,
3664,,
3665,,
3666,,
3667,,
3668,,
3669,,
3670,,
3671,,
3672,,
3673,,
3674,,
3675,,
3676,,
3677,,
3678,,
3679,,
3680,,
3681,,
3682,,
3683,,
3684,,
3685,,
3686,,
3687,,
3688,,
3689,,
3690,,
3691,,
3692,,
3693,,
3694,,
3695,,
3696,,
3697,,
3698,,
3699,,
3700,,
3701,,
3702,,
3703,,
3704,,
3705,,
3706,,
3707,,
3708,,
3709,,
3710,,
3711,,
3712,,
3713,,
3714,,
3715,,
3716,,
3717,,
3718,,
3719,,
3720,,
3721,,
3722,,
3723,,
3724,,
3725,,
3726,,
3727,,
3728,,
3729,,
3730,,
3731,,
3732,,
3733,,
3734,,
3735,,
3736,,
3737,,
3738,,
3739,,
3740,,
3741,,
3742,,
3743,,
3744,,
3745,,
3746,,
3747,,
3748,,
3749,,
3750,,
3751,,
3752,,
3753,,
3754,,
3755,,
3756,,
3757,,
3758,,
3759,,
3760,,
3761,,
3762,,
3763,,
3764,,
3765,,
3766,,
3767,,
3768,,
3769,,
3770,,
3771,,
3772,,
3773,,
3774,,
3775,,
3776,,
3777,,
3778,,
3779,,
3780,,
3781,,
3782,,
3783,,
3784,,
3785,,
3786,,
3787,,
3788,,
3789,,
3790,,
3791,,
3792,,
3793,,
3794,,
3795,,
3796,,
3797,,
3798,,
3799,,
3800,,
3801,,
3802,,
3803,,
3804,,
3805,,
3806,,
3807,,
3808,,
3809,,
3810,,
3811,,
3812,,
3813,,
3814,,
3815,,
3816,,
3817,,
3818,,
3819,,
3820,,
3821,,
3822,,
3823,,
3824,,
3825,,
3826,,
3827,,
3828,,
3829,,
3830,,
3831,,
3832,,
3833,,
3834,,
3835,,
3836,,
3837,,
3838,,
3839,,
3840,,
3841,,
3842,,
3843,,
3844,,
3845,,
3846,,
3847,,
3848,,
3849,,
3850,,
3851,,
3852,,
3853,,
3854,,
3855,,
3856,,
3857,,
3858,,
3859,,
3860,,
3861,,
3862,,
3863,,
3864,,
3865,,
3866,,
3867,,
3868,,
3869,,
3870,,
3871,,
3872,,
3873,,
3874,,
3875,,
3876,,
3877,,
3878,,
3879,,
3880,,
3881,,
3882,,
3883,,
3884,,
3885,,
3886,,
3887,,
3888,,
3889,,
3890,,
3891,,
3892,,
3893,,
3894,,
3895,,
3896,,
3897,,
3898,,
3899,,
3900,,
3901,,
3902,,
3903,,
3904,,
3905,,
3906,,
3907,,
3908,,
3909,,
3910,,
3911,,
3912,,
3913,,
3914,,
3915,,
3916,,
3917,,
3918,,
3919,,
3920,,
3921,,
3922,,
3923,,
3924,,
3925,,
3926,,
3927,,
3928,,
3929,,
3930,,
3931,,
3932,,
3933,,
3934,,
3935,,
3936,,
3937,,
3938,,
3939,,
3940,,
3941,,
3942,,
3943,,
3944,,
3945,,
3946,,
3947,,
3948,,
3949,,
3950,,
3951,,
3952,,
3953,,
3954,,
3955,,
3956,,
3957,,
3958,,
3959,,
3960,,
3961,,
3962,,
3963,,
3964,,
3965,,
3966,,
3967,,
3968,,
3969,,
3970,,
3971,,
3972,,
3973,,
3974,,
3975,,
3976,,
3977,,
3978,,
3979,,
3980,,
3981,,
3982,,
3983,,
3984,,
3985,,
3986,,
3987,,
3988,,
3989,,
3990,,
3991,,
3992,,
3993,,
3994,,
3995,,
3996,,
3997,,
3998,,
3999,,
4000,,
4001,,
4002,,
4003,,
4004,,
4005,,
4006,,
4007,,
4008,,
4009,,
4010,,
4011,,
4012,,
4013,,
4014,,
4015,,
4016,,
4017,,
4018,,
4019,,
4020,,
4021,,
4022,,
4023,,
4024,,
4025,,
4026,,
4027,,
4028,,
4029,,
4030,,
4031,,
4032,,
4033,,
4034,,
4035,,
4036,,
4037,,
4038,,
4039,,
4040,,
4041,,
4042,,
4043,,
4044,,
4045,,
4046,,
4047,,
4048,,
4049,,
4050,,
4051,,
4052,,
4053,,
4054,,
4055,,
4056,,
4057,,
4058,,
4059,,
4060,,
4061,,
4062,,
4063,,
4064,,
4065,,
4066,,
4067,,
4068,,
4069,,
4070,,
4071,,
4072,,
4073,,
4074,,
4075,,
4076,,
4077,,
4078,,
4079,,
4080,,
4081,,
4082,,
4083,,
4084,,
4085,,
4086,,
4087,,
4088,,
4089,,
4090,,
4091,,
4092,,
4093,,
4094,,
4095,,
4096,,
4097,,
4098,,
4099,,
4100,,
4101,,
4102,,
4103,,
4104,,
4105,,
4106,,
4107,,
4108,,
4109,,
4110,,
4111,,
4112,,
4113,,
4114,,
4115,,
4116,,
4117,,
4118,,
4119,,
4120,,
4121,,
4122,,
4123,,
4124,,
4125,,
4126,,
4127,,
4128,,
4129,,
4130,,
4131,,
4132,,
4133,,
4134,,
4135,,
4136,,
4137,,
4138,,
4139,,
4140,,
4141,,
4142,,
4143,,
4144,,
4145,,
4146,,
4147,,
4148,,
4149,,
4150,,
4151,,
4152,,
4153,,
4154,,
4155,,
4156,,
4157,,
4158,,
4159,,
4160,,
4161,,
4162,,
4163,,
4164,,
4165,,
4166,,
4167,,
4168,,
4169,,
4170,,
4171,,
4172,,
4173,,
4174,,
4175,,
4176,,
4177,,
4178,,
4179,,
4180,,
4181,,
4182,,
4183,,
4184,,
4185,,
4186,,
4187,,
4188,,
4189,,
4190,,
4191,,
4192,,
4193,,
4194,,
4195,,
4196,,
4197,,
4198,,
4199,,
4200,,
4201,,
4202,,
4203,,
4204,,
4205,,
4206,,
4207,,
4208,,
4209,,
4210,,
4211,,
4212,,
4213,,
4214,,
4215,,
4216,,
4217,,
4218,,
4219,,
4220,,
4221,,
4222,,
4223,,
4224,,
4225,,
4226,,
4227,,
4228,,
4229,,
4230,,
4231,,
4232,,
4233,,
4234,,
4235,,
4236,,
4237,,
4238,,
4239,,
4240,,
4241,,
4242,,
4243,,
4244,,
4245,,
4246,,
4247,,
4248,,
4249,,
4250,,
4251,,
4252,,
4253,,
4254,,
4255,,
4256,,
4257,,
4258,,
4259,,
4260,,
4261,,
4262,,
4263,,
4264,,
4265,,
4266,,
4267,,
4268,,
4269,,
4270,,
4271,,
4272,,
4273,,
4274,,
4275,,
4276,,
4277,,
4278,,
4279,,
4280,,
4281,,
4282,,
4283,,
4284,,
4285,,
4286,,
4287,,
4288,,
4289,,
4290,,
4291,,
4292,,
4293,,
4294,,
4295,,
4296,,
4297,,
4298,,
4299,,
4300,,
4301,,
4302,,
4303,,
4304,,
4305,,
4306,,
4307,,
4308,,
4309,,
4310,,
4311,,
4312,,
4313,,
4314,,
4315,,
4316,,
4317,,
4318,,
4319,,
4320,,
4321,,
4322,,
4323,,
4324,,
4325,,
4326,,
4327,,
4328,,
4329,,
4330,,
4331,,
4332,,
4333,,
4334,,
4335,,
4336,,
4337,,
4338,,
4339,,
4340,,
4341,,
4342,,
4343,,
4344,,
4345,,
4346,,
4347,,
4348,,
4349,,
4350,,
4351,,
4352,,
4353,,
4354,,
4355,,
4356,,
4357,,
4358,,
4359,,
4360,,
4361,,
4362,,
4363,,
4364,,
4365,,
4366,,
4367,,
4368,,
4369,,
4370,,
4371,,
4372,,
4373,,
4374,,
4375,,
4376,,
4377,,
4378,,
4379,,
4380,,
4381,,
4382,,
4383,,
4384,,
4385,,
4386,,
4387,,
4388,,
4389,,
4390,,
4391,,
4392,,
4393,,
4394,,
4395,,
4396,,
4397,,
4398,,
4399,,
4400,,
4401,,
4402,,
4403,,
4404,,
4405,,
4406,,
4407,,
4408,,
4409,,
4410,,
4411,,
4412,,
4413,,
4414,,
4415,,
4416,,
4417,,
4418,,
4419,,
4420,,
4421,,
4422,,
4423,,
4424,,
4425,,
4426,,
4427,,
4428,,
4429,,
4430,,
4431,,
4432,,
4433,,
4434,,
4435,,
4436,,
4437,,
4438,,
4439,,
4440,,
4441,,
4442,,
4443,,
4444,,
4445,,
4446,,
4447,,
4448,,
4449,,
4450,,
4451,,
4452,,
4453,,
4454,,
4455,,
4456,,
4457,,
4458,,
4459,,
4460,,
4461,,
4462,,
4463,,
4464,,
4465,,
4466,,
4467,,
4468,,
4469,,
4470,,
4471,,
4472,,
4473,,
4474,,
4475,,
4476,,
4477,,
4478,,
4479,,
4480,,
4481,,
4482,,
4483,,
4484,,
4485,,
4486,,
4487,,
4488,,
4489,,
4490,,
4491,,
4492,,
4493,,
4494,,
4495,,
4496,,
4497,,
4498,,
4499,,
4500,,
4501,,
4502,,
4503,,
4504,,
4505,,
4506,,
4507,,
4508,,
4509,,
4510,,
4511,,
4512,,
4513,,
4514,,
4515,,
4516,,
4517,,
4518,,
4519,,
4520,,
4521,,
4522,,
4523,,
4524,,
4525,,
4526,,
4527,,
4528,,
4529,,
4530,,
4531,,
4532,,
4533,,
4534,,
4535,,
4536,,
4537,,
4538,,
4539,,
4540,,
4541,,
4542,,
4543,,
4544,,
4545,,
4546,,
4547,,
4548,,
4549,,
4550,,
4551,,
4552,,
4553,,
4554,,
4555,,
4556,,
4557,,
4558,,
4559,,
4560,,
4561,,
4562,,
4563,,
4564,,
4565,,
4566,,
4567,,
4568,,
4569,,
4570,,
4571,,
4572,,
4573,,
4574,,
4575,,
4576,,
4577,,
4578,,
4579,,
4580,,
4581,,
4582,,
4583,,
4584,,
4585,,
4586,,
4587,,
4588,,
4589,,
4590,,
4591,,
4592,,
4593,,
4594,,
4595,,
4596,,
4597,,
4598,,
4599,,
4600,,
4601,,
4602,,
4603,,
4604,,
4605,,
4606,,
4607,,
4608,,
4609,,
4610,,
4611,,
4612,,
4613,,
4614,,
4615,,
4616,,
4617,,
4618,,
4619,,
4620,,
4621,,
4622,,
4623,,
4624,,
4625,,
4626,,
4627,,
4628,,
4629,,
4630,,
4631,,
4632,,
4633,,
4634,,
4635,,
4636,,
4637,,
4638,,
4639,,
4640,,
4641,,
4642,,
4643,,
4644,,
4645,,
4646,,
4647,,
4648,,
4649,,
4650,,
4651,,
4652,,
4653,,
4654,,
4655,,
4656,,
4657,,
4658,,
4659,,
4660,,
4661,,
4662,,
4663,,
4664,,
4665,,
4666,,
4667,,
4668,,
4669,,
4670,,
4671,,
4672,,
4673,,
4674,,
4675,,
4676,,
4677,,
4678,,
4679,,
4680,,
4681,,
4682,,
4683,,
4684,,
4685,,
4686,,
4687,,
4688,,
4689,,
4690,,
4691,,
4692,,
4693,,
4694,,
4695,,
4696,,
4697,,
4698,,
4699,,
4700,,
4701,,
4702,,
4703,,
4704,,
4705,,
4706,,
4707,,
4708,,
4709,,
4710,,
4711,,
4712,,
4713,,
4714,,
4715,,
4716,,
4717,,
4718,,
4719,,
4720,,
4721,,
4722,,
4723,,
4724,,
4725,,
4726,,
4727,,
4728,,
4729,,
4730,,
4731,,
4732,,
4733,,
4734,,
4735,,
4736,,
4737,,
4738,,
4739,,
4740,,
4741,,
4742,,
4743,,
4744,,
4745,,
4746,,
4747,,
4748,,
4749,,
4750,,
4751,,
4752,,
4753,,
4754,,
4755,,
4756,,
4757,,
4758,,
4759,,
4760,,
4761,,
4762,,
4763,,
4764,,
4765,,
4766,,
4767,,
4768,,
4769,,
4770,,
4771,,
4772,,
4773,,
4774,,
4775,,
4776,,
4777,,
4778,,
4779,,
4780,,
4781,,
4782,,
4783,,
4784,,
4785,,
4786,,
4787,,
4788,,
4789,,
4790,,
4791,,
4792,,
4793,,
4794,,
4795,,
4796,,
4797,,
4798,,
4799,,
4800,,
4801,,
4802,,
4803,,
4804,,
4805,,
4806,,
4807,,
4808,,
4809,,
4810,,
4811,,
4812,,
4813,,
4814,,
4815,,
4816,,
4817,,
4818,,
4819,,
4820,,
4821,,
4822,,
4823,,
4824,,
4825,,
4826,,
4827,,
4828,,
4829,,
4830,,
4831,,
4832,,
4833,,
4834,,
4835,,
4836,,
4837,,
4838,,
4839,,
4840,,
4841,,
4842,,
4843,,
4844,,
4845,,
4846,,
4847,,
4848,,
4849,,
4850,,
4851,,
4852,,
4853,,
4854,,
4855,,
4856,,
4857,,
4858,,
4859,,
4860,,
4861,,
4862,,
4863,,
4864,,
4865,,
4866,,
4867,,
4868,,
4869,,
4870,,
4871,,
4872,,
4873,,
4874,,
4875,,
4876,,
4877,,
4878,,
4879,,
4880,,
4881,,
4882,,
4883,,
4884,,
4885,,
4886,,
4887,,
4888,,
4889,,
4890,,
4891,,
4892,,
4893,,
4894,,
4895,,
4896,,
4897,,
4898,,
4899,,
4900,,
4901,,
4902,,
4903,,
4904,,
4905,,
4906,,
4907,,
4908,,
4909,,
4910,,
4911,,
4912,,
4913,,
4914,,
4915,,
4916,,
4917,,
4918,,
4919,,
4920,,
4921,,
4922,,
4923,,
4924,,
4925,,
4926,,
4927,,
4928,,
4929,,
4930,,
4931,,
4932,,
4933,,
4934,,
4935,,
4936,,
4937,,
4938,,
4939,,
4940,,
4941,,
4942,,
4943,,
4944,,
4945,,
4946,,
4947,,
4948,,
4949,,
4950,,
4951,,
4952,,
4953,,
4954,,
4955,,
4956,,
4957,,
4958,,
4959,,
4960,,
4961,,
4962,,
4963,,
4964,,
4965,,
4966,,
4967,,
4968,,
4969,,
4970,,
4971,,
4972,,
4973,,
4974,,
4975,,
4976,,
4977,,
4978,,
4979,,
4980,,
4981,,
4982,,
4983,,
4984,,
4985,,
4986,,
4987,,
4988,,
4989,,
4990,,
4991,,
4992,,
4993,,
4994,,
4995,,
4996,,
4997,,
4998,,
4999,,
5000,,
5001,,
5002,,
5003,,
5004,,
5005,,
5006,,
5007,,
5008,,
5009,,
5010,,
5011,,
5012,,
5013,,
5014,,
5015,,
5016,,
5017,,
5018,,
5019,,
5020,,
5021,,
5022,,
5023,,
5024,,
5025,,
5026,,
5027,,
5028,,
5029,,
5030,,
5031,,
5032,,
5033,,
5034,,
5035,,
5036,,
5037,,
5038,,
5039,,
5040,,
5041,,
5042,,
5043,,
5044,,
5045,,
5046,,
5047,,
5048,,
5049,,
5050,,
5051,,
5052,,
5053,,
5054,,
5055,,
5056,,
5057,,
5058,,
5059,,
5060,,
5061,,
5062,,
5063,,
5064,,
5065,,
5066,,
5067,,
5068,,
5069,,
5070,,
5071,,
5072,,
5073,,
5074,,
5075,,
5076,,
5077,,
5078,,
5079,,
5080,,
5081,,
5082,,
5083,,
5084,,
5085,,
5086,,
5087,,
5088,,
5089,,
5090,,
5091,,
5092,,
5093,,
5094,,
5095,,
5096,,
5097,,
5098,,
5099,,
5100,,
5101,,
5102,,
5103,,
5104,,
5105,,
5106,,
5107,,
5108,,
5109,,
5110,,
5111,,
5112,,
5113,,
5114,,
5115,,
5116,,
5117,,
5118,,
5119,,
5120,,
5121,,
5122,,
5123,,
5124,,
5125,,
5126,,
5127,,
5128,,
5129,,
5130,,
5131,,
5132,,
5133,,
5134,,
5135,,
5136,,
5137,,
5138,,
5139,,
5140,,
5141,,
5142,,
5143,,
5144,,
5145,,
5146,,
5147,,
5148,,
5149,,
5150,,
5151,,
5152,,
5153,,
5154,,
5155,,
5156,,
5157,,
5158,,
5159,,
5160,,
5161,,
5162,,
5163,,
5164,,
5165,,
5166,,
5167,,
5168,,
5169,,
5170,,
5171,,
5172,,
5173,,
5174,,
5175,,
5176,,
5177,,
5178,,
5179,,
5180,,
5181,,
5182,,
5183,,
5184,,
5185,,
5186,,
5187,,
5188,,
5189,,
5190,,
5191,,
5192,,
5193,,
5194,,
5195,,
5196,,
5197,,
5198,,
5199,,
5200,,
5201,,
5202,,
5203,,
5204,,
5205,,
5206,,
5207,,
5208,,
5209,,
5210,,
5211,,
5212,,
5213,,
5214,,
5215,,
5216,,
5217,,
5218,,
5219,,
5220,,
5221,,
5222,,
5223,,
5224,,
5225,,
5226,,
5227,,
5228,,
5229,,
5230,,
5231,,
5232,,
5233,,
5234,,
5235,,
5236,,
5237,,
5238,,
5239,,
5240,,
5241,,
5242,,
5243,,
5244,,
5245,,
5246,,
5247,,
5248,,
5249,,
5250,,
5251,,
5252,,
5253,,
5254,,
5255,,
5256,,
5257,,
5258,,
5259,,
5260,,
5261,,
5262,,
5263,,
5264,,
5265,,
5266,,
5267,,
5268,,
5269,,
5270,,
5271,,
5272,,
5273,,
5274,,
5275,,
5276,,
5277,,
5278,,
5279,,
5280,,
5281,,
5282,,
5283,,
5284,,
5285,,
5286,,
5287,,
5288,,
5289,,
5290,,
5291,,
5292,,
5293,,
5294,,
5295,,
5296,,
5297,,
5298,,
5299,,
5300,,
5301,,
5302,,
5303,,
5304,,
5305,,
5306,,
5307,,
5308,,
5309,,
5310,,
5311,,
5312,,
5313,,
5314,,
5315,,
5316,,
5317,,
5318,,
5319,,
5320,,
5321,,
5322,,
5323,,
5324,,
5325,,
5326,,
5327,,
5328,,
5329,,
5330,,
5331,,
5332,,
5333,,
5334,,
5335,,
5336,,
5337,,
5338,,
5339,,
5340,,
5341,,
5342,,
5343,,
5344,,
5345,,
5346,,
5347,,
5348,,
5349,,
5350,,
5351,,
5352,,
5353,,
5354,,
5355,,
5356,,
5357,,
5358,,
5359,,
5360,,
5361,,
5362,,
5363,,
5364,,
5365,,
5366,,
5367,,
5368,,
5369,,
5370,,
5371,,
5372,,
5373,,
5374,,
5375,,
5376,,
5377,,
5378,,
5379,,
5380,,
5381,,
5382,,
5383,,
5384,,
5385,,
5386,,
5387,,
5388,,
5389,,
5390,,
5391,,
5392,,
5393,,
5394,,
5395,,
5396,,
5397,,
5398,,
5399,,
5400,,
5401,,
5402,,
5403,,
5404,,
5405,,
5406,,
5407,,
5408,,
5409,,
5410,,
5411,,
5412,,
5413,,
5414,,
5415,,
5416,,
5417,,
5418,,
5419,,
5420,,
5421,,
5422,,
5423,,
5424,,
5425,,
5426,,
5427,,
5428,,
5429,,
5430,,
5431,,
5432,,
5433,,
5434,,
5435,,
5436,,
5437,,
5438,,
5439,,
5440,,
5441,,
5442,,
5443,,
5444,,
5445,,
5446,,
5447,,
5448,,
5449,,
5450,,
5451,,
5452,,
5453,,
5454,,
5455,,
5456,,
5457,,
5458,,
5459,,
5460,,
5461,,
5462,,
5463,,
5464,,
5465,,
5466,,
5467,,
5468,,
5469,,
5470,,
5471,,
5472,,
5473,,
5474,,
5475,,
5476,,
5477,,
5478,,
5479,,
5480,,
5481,,
5482,,
5483,,
5484,,
5485,,
5486,,
5487,,
5488,,
5489,,
5490,,
5491,,
5492,,
5493,,
5494,,
5495,,
5496,,
5497,,
5498,,
5499,,
5500,,
5501,,
5502,,
5503,,
5504,,
5505,,
5506,,
5507,,
5508,,
5509,,
5510,,
5511,,
5512,,
5513,,
5514,,
5515,,
5516,,
5517,,
5518,,
5519,,
5520,,
5521,,
5522,,
5523,,
5524,,
5525,,
5526,,
5527,,
5528,,
5529,,
5530,,
5531,,
5532,,
5533,,
5534,,
5535,,
5536,,
5537,,
5538,,
5539,,
5540,,
5541,,
5542,,
5543,,
5544,,
5545,,
5546,,
5547,,
5548,,
5549,,
5550,,
5551,,
5552,,
5553,,
5554,,
5555,,
5556,,
5557,,
5558,,
5559,,
5560,,
5561,,
5562,,
5563,,
5564,,
5565,,
5566,,
5567,,
5568,,
5569,,
5570,,
5571,,
5572,,
5573,,
5574,,
5575,,
5576,,
5577,,
5578,,
5579,,
5580,,
5581,,
5582,,
5583,,
5584,,
5585,,
5586,,
5587,,
5588,,
5589,,
5590,,
5591,,
5592,,
5593,,
5594,,
5595,,
5596,,
5597,,
5598,,
5599,,
5600,,
5601,,
5602,,
5603,,
5604,,
5605,,
5606,,
5607,,
5608,,
5609,,
5610,,
5611,,
5612,,
5613,,
5614,,
5615,,
5616,,
5617,,
5618,,
5619,,
5620,,
5621,,
5622,,
5623,,
5624,,
5625,,
5626,,
5627,,
5628,,
5629,,
5630,,
5631,,
5632,,
5633,,
5634,,
5635,,
5636,,
5637,,
5638,,
5639,,
5640,,
5641,,
5642,,
5643,,
5644,,
5645,,
5646,,
5647,,
5648,,
5649,,
5650,,
5651,,
5652,,
5653,,
5654,,
5655,,
5656,,
5657,,
5658,,
5659,,
5660,,
5661,,
5662,,
5663,,
5664,,
5665,,
5666,,
5667,,
5668,,
5669,,
5670,,
5671,,
5672,,
5673,,
5674,,
5675,,
5676,,
5677,,
5678,,
5679,,
5680,,
5681,,
5682,,
5683,,
5684,,
5685,,
5686,,
5687,,
5688,,
5689,,
5690,,
5691,,
5692,,
5693,,
5694,,
5695,,
5696,,
5697,,
5698,,
5699,,
5700,,
5701,,
5702,,
5703,,
5704,,
5705,,
5706,,
5707,,
5708,,
5709,,
5710,,
5711,,
5712,,
5713,,
5714,,
5715,,
5716,,
5717,,
5718,,
5719,,
5720,,
5721,,
5722,,
5723,,
5724,,
5725,,
5726,,
5727,,
5728,,
5729,,
5730,,
5731,,
5732,,
5733,,
5734,,
5735,,
5736,,
5737,,
5738,,
5739,,
5740,,
5741,,
5742,,
5743,,
5744,,
5745,,
5746,,
5747,,
5748,,
5749,,
5750,,
5751,,
5752,,
5753,,
5754,,
5755,,
5756,,
5757,,
5758,,
5759,,
5760,,
5761,,
5762,,
5763,,
5764,,
5765,,
5766,,
5767,,
5768,,
5769,,
5770,,
5771,,
5772,,
5773,,
5774,,
5775,,
5776,,
5777,,
5778,,
5779,,
5780,,
5781,,
5782,,
5783,,
5784,,
5785,,
5786,,
5787,,
5788,,
5789,,
5790,,
5791,,
5792,,
5793,,
5794,,
5795,,
5796,,
5797,,
5798,,
5799,,
5800,,
5801,,
5802,,
5803,,
5804,,
5805,,
5806,,
5807,,
5808,,
5809,,
5810,,
5811,,
5812,,
5813,,
5814,,
5815,,
5816,,
5817,,
5818,,
5819,,
5820,,
5821,,
5822,,
5823,,
5824,,
5825,,
5826,,
5827,,
5828,,
5829,,
5830,,
5831,,
5832,,
5833,,
5834,,
5835,,
5836,,
5837,,
5838,,
5839,,
5840,,
5841,,
5842,,
5843,,
5844,,
5845,,
5846,,
5847,,
5848,,
5849,,
5850,,
5851,,
5852,,
5853,,
5854,,
5855,,
5856,,
5857,,
5858,,
5859,,
5860,,
5861,,
5862,,
5863,,
5864,,
5865,,
5866,,
5867,,
5868,,
5869,,
5870,,
5871,,
5872,,
5873,,
5874,,
5875,,
5876,,
5877,,
5878,,
5879,,
5880,,
5881,,
5882,,
5883,,
5884,,
5885,,
5886,,
5887,,
5888,,
5889,,
5890,,
5891,,
5892,,
5893,,
5894,,
5895,,
5896,,
5897,,
5898,,
5899,,
5900,,
5901,,
5902,,
5903,,
5904,,
5905,,
5906,,
5907,,
5908,,
5909,,
5910,,
5911,,
5912,,
5913,,
5914,,
5915,,
5916,,
5917,,
5918,,
5919,,
5920,,
5921,,
5922,,
5923,,
5924,,
5925,,
5926,,
5927,,
5928,,
5929,,
5930,,
5931,,
5932,,
5933,,
5934,,
5935,,
5936,,
5937,,
5938,,
5939,,
5940,,
5941,,
5942,,
5943,,
5944,,
5945,,
5946,,
5947,,
5948,,
5949,,
5950,,
5951,,
5952,,
5953,,
5954,,
5955,,
5956,,
5957,,
5958,,
5959,,
5960,,
5961,,
5962,,
5963,,
5964,,
5965,,
5966,,
5967,,
5968,,
5969,,
5970,,
5971,,
5972,,
5973,,
5974,,
5975,,
5976,,
5977,,
5978,,
5979,,
5980,,
5981,,
5982,,
5983,,
5984,,
5985,,
5986,,
5987,,
5988,,
5989,,
5990,,
5991,,
5992,,
5993,,
5994,,
5995,,
5996,,
5997,,
5998,,
5999,,
6000,,
6001,,
6002,,
6003,,
6004,,
6005,,
6006,,
6007,,
6008,,
6009,,
6010,,
6011,,
6012,,
6013,,
6014,,
6015,,
6016,,
6017,,
6018,,
6019,,
6020,,
6021,,
6022,,
6023,,
6024,,
6025,,
6026,,
6027,,
6028,,
6029,,
6030,,
6031,,
6032,,
6033,,
6034,,
6035,,
6036,,
6037,,
6038,,
6039,,
6040,,
6041,,
6042,,
6043,,
6044,,
6045,,
6046,,
6047,,
6048,,
6049,,
6050,,
6051,,
6052,,
6053,,
6054,,
6055,,
6056,,
6057,,
6058,,
6059,,
6060,,
6061,,
6062,,
6063,,
6064,,
6065,,
6066,,
6067,,
6068,,
6069,,
6070,,
6071,,
6072,,
6073,,
6074,,
6075,,
6076,,
6077,,
6078,,
6079,,
6080,,
6081,,
6082,,
6083,,
6084,,
6085,,
6086,,
6087,,
6088,,
6089,,
6090,,
6091,,
6092,,
6093,,
6094,,
6095,,
6096,,
6097,,
6098,,
6099,,
6100,,
6101,,
6102,,
6103,,
6104,,
6105,,
6106,,
6107,,
6108,,
6109,,
6110,,
6111,,
6112,,
6113,,
6114,,
6115,,
6116,,
6117,,
6118,,
6119,,
6120,,
6121,,
6122,,
6123,,
6124,,
6125,,
6126,,
6127,,
6128,,
6129,,
6130,,
6131,,
6132,,
6133,,
6134,,
6135,,
6136,,
6137,,
6138,,
6139,,
6140,,
6141,,
6142,,
6143,,
6144,,
6145,,
6146,,
6147,,
6148,,
6149,,
6150,,
6151,,
6152,,
6153,,
6154,,
6155,,
6156,,
6157,,
6158,,
6159,,
6160,,
6161,,
6162,,
6163,,
6164,,
6165,,
6166,,
6167,,
6168,,
6169,,
6170,,
6171,,
6172,,
6173,,
6174,,
6175,,
6176,,
6177,,
6178,,
6179,,
6180,,
6181,,
6182,,
6183,,
6184,,
6185,,
6186,,
6187,,
6188,,
6189,,
6190,,
6191,,
6192,,
6193,,
6194,,
6195,,
6196,,
6197,,
6198,,
6199,,
6200,,
6201,,
6202,,
6203,,
6204,,
6205,,
6206,,
6207,,
6208,,
6209,,
6210,,
6211,,
6212,,
6213,,
6214,,
6215,,
6216,,
6217,,
6218,,
6219,,
6220,,
6221,,
6222,,
6223,,
6224,,
6225,,
6226,,
6227,,
6228,,
6229,,
6230,,
6231,,
6232,,
6233,,
6234,,
6235,,
6236,,
6237,,
6238,,
6239,,
6240,,
6241,,
6242,,
6243,,
6244,,
6245,,
6246,,
6247,,
6248,,
6249,,
6250,,
6251,,
6252,,
6253,,
6254,,
6255,,
6256,,
6257,,
6258,,
6259,,
6260,,
6261,,
6262,,
6263,,
6264,,
6265,,
6266,,
6267,,
6268,,
6269,,
6270,,
6271,,
6272,,
6273,,
6274,,
6275,,
6276,,
6277,,
6278,,
6279,,
6280,,
6281,,
6282,,
6283,,
6284,,
6285,,
6286,,
6287,,
6288,,
6289,,
6290,,
6291,,
6292,,
6293,,
6294,,
6295,,
6296,,
6297,,
6298,,
6299,,
6300,,
6301,,
6302,,
6303,,
6304,,
6305,,
6306,,
6307,,
6308,,
6309,,
6310,,
6311,,
6312,,
6313,,
6314,,
6315,,
6316,,
6317,,
6318,,
6319,,
6320,,
6321,,
6322,,
6323,,
6324,,
6325,,
6326,,
6327,,
6328,,
6329,,
6330,,
6331,,
6332,,
6333,,
6334,,
6335,,
6336,,
6337,,
6338,,
6339,,
6340,,
6341,,
6342,,
6343,,
6344,,
6345,,
6346,,
6347,,
6348,,
6349,,
6350,,
6351,,
6352,,
6353,,
6354,,
6355,,
6356,,
6357,,
6358,,
6359,,
6360,,
6361,,
6362,,
6363,,
6364,,
6365,,
6366,,
6367,,
6368,,
6369,,
6370,,
6371,,
6372,,
6373,,
6374,,
6375,,
6376,,
6377,,
6378,,
6379,,
6380,,
6381,,
6382,,
6383,,
6384,,
6385,,
6386,,
6387,,
6388,,
6389,,
6390,,
6391,,
6392,,
6393,,
6394,,
6395,,
6396,,
6397,,
6398,,
6399,,
6400,,
6401,,
6402,,
6403,,
6404,,
6405,,
6406,,
6407,,
6408,,
6409,,
6410,,
6411,,
6412,,
6413,,
6414,,
6415,,
6416,,
6417,,
6418,,
6419,,
6420,,
6421,,
6422,,
6423,,
6424,,
6425,,
6426,,
6427,,
6428,,
6429,,
6430,,
6431,,
6432,,
6433,,
6434,,
6435,,
6436,,
6437,,
6438,,
6439,,
6440,,
6441,,
6442,,
6443,,
6444,,
6445,,
6446,,
6447,,
6448,,
6449,,
6450,,
6451,,
6452,,
6453,,
6454,,
6455,,
6456,,
6457,,
6458,,
6459,,
6460,,
6461,,
6462,,
6463,,
6464,,
6465,,
6466,,
6467,,
6468,,
6469,,
6470,,
6471,,
6472,,
6473,,
6474,,
6475,,
6476,,
6477,,
6478,,
6479,,
6480,,
6481,,
6482,,
6483,,
6484,,
6485,,
6486,,
6487,,
6488,,
6489,,
6490,,
6491,,
6492,,
6493,,
6494,,
6495,,
6496,,
6497,,
6498,,
6499,,
6500,,
6501,,
6502,,
6503,,
6504,,
6505,,
6506,,
6507,,
6508,,
6509,,
6510,,
6511,,
6512,,
6513,,
6514,,
6515,,
6516,,
6517,,
6518,,
6519,,
6520,,
6521,,
6522,,
6523,,
6524,,
6525,,
6526,,
6527,,
6528,,
6529,,
6530,,
6531,,
6532,,
6533,,
6534,,
6535,,
6536,,
6537,,
6538,,
6539,,
6540,,
6541,,
6542,,
6543,,
6544,,
6545,,
6546,,
6547,,
6548,,
6549,,
6550,,
6551,,
6552,,
6553,,
6554,,
6555,,
6556,,
6557,,
6558,,
6559,,
6560,,
6561,,
6562,,
6563,,
6564,,
6565,,
6566,,
6567,,
6568,,
6569,,
6570,,
6571,,
6572,,
6573,,
6574,,
6575,,
6576,,
6577,,
6578,,
6579,,
6580,,
6581,,
6582,,
6583,,
6584,,
6585,,
6586,,
6587,,
6588,,
6589,,
6590,,
6591,,
6592,,
6593,,
6594,,
6595,,
6596,,
6597,,
6598,,
6599,,
6600,,
6601,,
6602,,
6603,,
6604,,
6605,,
6606,,
6607,,
6608,,
6609,,
6610,,
6611,,
6612,,
6613,,
6614,,
6615,,
6616,,
6617,,
6618,,
6619,,
6620,,
6621,,
6622,,
6623,,
6624,,
6625,,
6626,,
6627,,
6628,,
6629,,
6630,,
6631,,
6632,,
6633,,
6634,,
6635,,
6636,,
6637,,
6638,,
6639,,
6640,,
6641,,
6642,,
6643,,
6644,,
6645,,
6646,,
6647,,
6648,,
6649,,
6650,,
6651,,
6652,,
6653,,
6654,,
6655,,
6656,,
6657,,
6658,,
6659,,
6660,,
6661,,
6662,,
6663,,
6664,,
6665,,
6666,,
6667,,
6668,,
6669,,
6670,,
6671,,
6672,,
6673,,
6674,,
6675,,
6676,,
6677,,
6678,,
6679,,
6680,,
6681,,
6682,,
6683,,
6684,,
6685,,
6686,,
6687,,
6688,,
6689,,
6690,,
6691,,
6692,,
6693,,
6694,,
6695,,
6696,,
6697,,
6698,,
6699,,
6700,,
6701,,
6702,,
6703,,
6704,,
6705,,
6706,,
6707,,
6708,,
6709,,
6710,,
6711,,
6712,,
6713,,
6714,,
6715,,
6716,,
6717,,
6718,,
6719,,
6720,,
6721,,
6722,,
6723,,
6724,,
6725,,
6726,,
6727,,
6728,,
6729,,
6730,,
6731,,
6732,,
6733,,
6734,,
6735,,
6736,,
6737,,
6738,,
6739,,
6740,,
6741,,
6742,,
6743,,
6744,,
6745,,
6746,,
6747,,
6748,,
6749,,
6750,,
6751,,
6752,,
6753,,
6754,,
6755,,
6756,,
6757,,
6758,,
6759,,
6760,,
6761,,
6762,,
6763,,
6764,,
6765,,
6766,,
6767,,
6768,,
6769,,
6770,,
6771,,
6772,,
6773,,
6774,,
6775,,
6776,,
6777,,
6778,,
6779,,
6780,,
6781,,
6782,,
6783,,
6784,,
6785,,
6786,,
6787,,
6788,,
6789,,
6790,,
6791,,
6792,,
6793,,
6794,,
6795,,
6796,,
6797,,
6798,,
6799,,
6800,,
6801,,
6802,,
6803,,
6804,,
6805,,
6806,,
6807,,
6808,,
6809,,
6810,,
6811,,
6812,,
6813,,
6814,,
6815,,
6816,,
6817,,
6818,,
6819,,
6820,,
6821,,
6822,,
6823,,
6824,,
6825,,
6826,,
6827,,
6828,,
6829,,
6830,,
6831,,
6832,,
6833,,
6834,,
6835,,
6836,,
6837,,
6838,,
6839,,
6840,,
6841,,
6842,,
6843,,
6844,,
6845,,
6846,,
6847,,
6848,,
6849,,
6850,,
6851,,
6852,,
6853,,
6854,,
6855,,
6856,,
6857,,
6858,,
6859,,
6860,,
6861,,
6862,,
6863,,
6864,,
6865,,
6866,,
6867,,
6868,,
6869,,
6870,,
6871,,
6872,,
6873,,
6874,,
6875,,
6876,,
6877,,
6878,,
6879,,
6880,,
6881,,
6882,,
6883,,
6884,,
6885,,
6886,,
6887,,
6888,,
6889,,
6890,,
6891,,
6892,,
6893,,
6894,,
6895,,
6896,,
6897,,
6898,,
6899,,
6900,,
6901,,
6902,,
6903,,
6904,,
6905,,
6906,,
6907,,
6908,,
6909,,
6910,,
6911,,
6912,,
6913,,
6914,,
6915,,
6916,,
6917,,
6918,,
6919,,
6920,,
6921,,
6922,,
6923,,
6924,,
6925,,
6926,,
6927,,
6928,,
6929,,
6930,,
6931,,
6932,,
6933,,
6934,,
6935,,
6936,,
6937,,
6938,,
6939,,
6940,,
6941,,
6942,,
6943,,
6944,,
6945,,
6946,,
6947,,
6948,,
6949,,
6950,,
6951,,
6952,,
6953,,
6954,,
6955,,
6956,,
6957,,
6958,,
6959,,
6960,,
6961,,
6962,,
6963,,
6964,,
6965,,
6966,,
6967,,
6968,,
6969,,
6970,,
6971,,
6972,,
6973,,
6974,,
6975,,
6976,,
6977,,
6978,,
6979,,
6980,,
6981,,
6982,,
6983,,
6984,,
6985,,
6986,,
6987,,
6988,,
6989,,
6990,,
6991,,
6992,,
6993,,
6994,,
6995,,
6996,,
6997,,
6998,,
6999,,
7000,,
7001,,
7002,,
7003,,
7004,,
7005,,
7006,,
7007,,
7008,,
7009,,
7010,,
7011,,
7012,,
7013,,
7014,,
7015,,
7016,,
7017,,
7018,,
7019,,
7020,,
7021,,
7022,,
7023,,
7024,,
7025,,
7026,,
7027,,
7028,,
7029,,
7030,,
7031,,
7032,,
7033,,
7034,,
7035,,
7036,,
7037,,
7038,,
7039,,
7040,,
7041,,
7042,,
7043,,
7044,,
7045,,
7046,,
7047,,
7048,,
7049,,
7050,,
7051,,
7052,,
7053,,
7054,,
7055,,
7056,,
7057,,
7058,,
7059,,
7060,,
7061,,
7062,,
7063,,
7064,,
7065,,
7066,,
7067,,
7068,,
7069,,
7070,,
7071,,
7072,,
7073,,
7074,,
7075,,
7076,,
7077,,
7078,,
7079,,
7080,,
7081,,
7082,,
7083,,
7084,,
7085,,
7086,,
7087,,
7088,,
7089,,
7090,,
7091,,
7092,,
7093,,
7094,,
7095,,
7096,,
7097,,
7098,,
7099,,
7100,,
7101,,
7102,,
7103,,
7104,,
7105,,
7106,,
7107,,
7108,,
7109,,
7110,,
7111,,
7112,,
7113,,
7114,,
7115,,
7116,,
7117,,
7118,,
7119,,
7120,,
7121,,
7122,,
7123,,
7124,,
7125,,
7126,,
7127,,
7128,,
7129,,
7130,,
7131,,
7132,,
7133,,
7134,,
7135,,
7136,,
7137,,
7138,,
7139,,
7140,,
7141,,
7142,,
7143,,
7144,,
7145,,
7146,,
7147,,
7148,,
7149,,
7150,,
7151,,
7152,,
7153,,
7154,,
7155,,
7156,,
7157,,
7158,,
7159,,
7160,,
7161,,
7162,,
7163,,
7164,,
7165,,
7166,,
7167,,
7168,,
7169,,
7170,,
7171,,
7172,,
7173,,
7174,,
7175,,
7176,,
7177,,
7178,,
7179,,
7180,,
7181,,
7182,,
7183,,
7184,,
7185,,
7186,,
7187,,
7188,,
7189,,
7190,,
7191,,
7192,,
7193,,
7194,,
7195,,
7196,,
7197,,
7198,,
7199,,
7200,,
7201,,
7202,,
7203,,
7204,,
7205,,
7206,,
7207,,
7208,,
7209,,
7210,,
7211,,
7212,,
7213,,
7214,,
7215,,
7216,,
7217,,
7218,,
7219,,
7220,,
7221,,
7222,,
7223,,
7224,,
7225,,
7226,,
7227,,
7228,,
7229,,
7230,,
7231,,
7232,,
7233,,
7234,,
7235,,
7236,,
7237,,
7238,,
7239,,
7240,,
7241,,
7242,,
7243,,
7244,,
7245,,
7246,,
7247,,
7248,,
7249,,
7250,,
7251,,
7252,,
7253,,
7254,,
7255,,
7256,,
7257,,
7258,,
7259,,
7260,,
7261,,
7262,,
7263,,
7264,,
7265,,
7266,,
7267,,
7268,,
7269,,
7270,,
7271,,
7272,,
7273,,
7274,,
7275,,
7276,,
7277,,
7278,,
7279,,
7280,,
7281,,
7282,,
7283,,
7284,,
7285,,
7286,,
7287,,
7288,,
7289,,
7290,,
7291,,
7292,,
7293,,
7294,,
7295,,
7296,,
7297,,
7298,,
7299,,
7300,,
7301,,
7302,,
7303,,
7304,,
7305,,
7306,,
7307,,
7308,,
7309,,
7310,,
7311,,
7312,,
7313,,
7314,,
7315,,
7316,,
7317,,
7318,,
7319,,
7320,,
7321,,
7322,,
7323,,
7324,,
7325,,
7326,,
7327,,
7328,,
7329,,
7330,,
7331,,
7332,,
7333,,
7334,,
7335,,
7336,,
7337,,
7338,,
7339,,
7340,,
7341,,
7342,,
7343,,
7344,,
7345,,
7346,,
7347,,
7348,,
7349,,
7350,,
7351,,
7352,,
7353,,
7354,,
7355,,
7356,,
7357,,
7358,,
7359,,
7360,,
7361,,
7362,,
7363,,
7364,,
7365,,
7366,,
7367,,
7368,,
7369,,
7370,,
7371,,
7372,,
7373,,
7374,,
7375,,
7376,,
7377,,
7378,,
7379,,
7380,,
7381,,
7382,,
7383,,
7384,,
7385,,
7386,,
7387,,
7388,,
7389,,
7390,,
7391,,
7392,,
7393,,
7394,,
7395,,
7396,,
7397,,
7398,,
7399,,
7400,,
7401,,
7402,,
7403,,
7404,,
7405,,
7406,,
7407,,
7408,,
7409,,
7410,,
7411,,
7412,,
7413,,
7414,,
7415,,
7416,,
7417,,
7418,,
7419,,
7420,,
7421,,
7422,,
7423,,
7424,,
7425,,
7426,,
7427,,
7428,,
7429,,
7430,,
7431,,
7432,,
7433,,
7434,,
7435,,
7436,,
7437,,
7438,,
7439,,
7440,,
7441,,
7442,,
7443,,
7444,,
7445,,
7446,,
7447,,
7448,,
7449,,
7450,,
7451,,
7452,,
7453,,
7454,,
7455,,
7456,,
7457,,
7458,,
7459,,
7460,,
7461,,
7462,,
7463,,
7464,,
7465,,
7466,,
7467,,
7468,,
7469,,
7470,,
7471,,
7472,,
7473,,
7474,,
7475,,
7476,,
7477,,
7478,,
7479,,
7480,,
7481,,
7482,,
7483,,
7484,,
7485,,
7486,,
7487,,
7488,,
7489,,
7490,,
7491,,
7492,,
7493,,
7494,,
7495,,
7496,,
7497,,
7498,,
7499,,
7500,,
7501,,
7502,,
7503,,
7504,,
7505,,
7506,,
7507,,
7508,,
7509,,
7510,,
7511,,
7512,,
7513,,
7514,,
7515,,
7516,,
7517,,
7518,,
7519,,
7520,,
7521,,
7522,,
7523,,
7524,,
7525,,
7526,,
7527,,
7528,,
7529,,
7530,,
7531,,
7532,,
7533,,
7534,,
7535,,
7536,,
7537,,
7538,,
7539,,
7540,,
7541,,
7542,,
7543,,
7544,,
7545,,
7546,,
7547,,
7548,,
7549,,
7550,,
7551,,
7552,,
7553,,
7554,,
7555,,
7556,,
7557,,
7558,,
7559,,
7560,,
7561,,
7562,,
7563,,
7564,,
7565,,
7566,,
7567,,
7568,,
7569,,
7570,,
7571,,
7572,,
7573,,
7574,,
7575,,
7576,,
7577,,
7578,,
7579,,
7580,,
7581,,
7582,,
7583,,
7584,,
7585,,
7586,,
7587,,
7588,,
7589,,
7590,,
7591,,
7592,,
7593,,
7594,,
7595,,
7596,,
7597,,
7598,,
7599,,
7600,,
7601,,
7602,,
7603,,
7604,,
7605,,
7606,,
7607,,
7608,,
7609,,
7610,,
7611,,
7612,,
7613,,
7614,,
7615,,
7616,,
7617,,
7618,,
7619,,
7620,,
7621,,
7622,,
7623,,
7624,,
7625,,
7626,,
7627,,
7628,,
7629,,
7630,,
7631,,
7632,,
7633,,
7634,,
7635,,
7636,,
7637,,
7638,,
7639,,
7640,,
7641,,
7642,,
7643,,
7644,,
7645,,
7646,,
7647,,
7648,,
7649,,
7650,,
7651,,
7652,,
7653,,
7654,,
7655,,
7656,,
7657,,
7658,,
7659,,
7660,,
7661,,
7662,,
7663,,
7664,,
7665,,
7666,,
7667,,
7668,,
7669,,
7670,,
7671,,
7672,,
7673,,
7674,,
7675,,
7676,,
7677,,
7678,,
7679,,
7680,,
7681,,
7682,,
7683,,
7684,,
7685,,
7686,,
7687,,
7688,,
7689,,
7690,,
7691,,
7692,,
7693,,
7694,,
7695,,
7696,,
7697,,
7698,,
7699,,
7700,,
7701,,
7702,,
7703,,
7704,,
7705,,
7706,,
7707,,
7708,,
7709,,
7710,,
7711,,
7712,,
7713,,
7714,,
7715,,
7716,,
7717,,
7718,,
7719,,
7720,,
7721,,
7722,,
7723,,
7724,,
7725,,
7726,,
7727,,
7728,,
7729,,
7730,,
7731,,
7732,,
7733,,
7734,,
7735,,
7736,,
7737,,
7738,,
7739,,
7740,,
7741,,
7742,,
7743,,
7744,,
7745,,
7746,,
7747,,
7748,,
7749,,
7750,,
7751,,
7752,,
7753,,
7754,,
7755,,
7756,,
7757,,
7758,,
7759,,
7760,,
7761,,
7762,,
7763,,
7764,,
7765,,
7766,,
7767,,
7768,,
7769,,
7770,,
7771,,
7772,,
7773,,
7774,,
7775,,
7776,,
7777,,
7778,,
7779,,
7780,,
7781,,
7782,,
7783,,
7784,,
7785,,
7786,,
7787,,
7788,,
7789,,
7790,,
7791,,
7792,,
7793,,
7794,,
7795,,
7796,,
7797,,
7798,,
7799,,
7800,,
7801,,
7802,,
7803,,
7804,,
7805,,
7806,,
7807,,
7808,,
7809,,
7810,,
7811,,
7812,,
7813,,
7814,,
7815,,
7816,,
7817,,
7818,,
7819,,
7820,,
7821,,
7822,,
7823,,
7824,,
7825,,
7826,,
7827,,
7828,,
7829,,
7830,,
7831,,
7832,,
7833,,
7834,,
7835,,
7836,,
7837,,
7838,,
7839,,
7840,,
7841,,
7842,,
7843,,
7844,,
7845,,
7846,,
7847,,
7848,,
7849,,
7850,,
7851,,
7852,,
7853,,
7854,,
7855,,
7856,,
7857,,
7858,,
7859,,
7860,,
7861,,
7862,,
7863,,
7864,,
7865,,
7866,,
7867,,
7868,,
7869,,
7870,,
7871,,
7872,,
7873,,
7874,,
7875,,
7876,,
7877,,
7878,,
7879,,
7880,,
7881,,
7882,,
7883,,
7884,,
7885,,
7886,,
7887,,
7888,,
7889,,
7890,,
7891,,
7892,,
7893,,
7894,,
7895,,
7896,,
7897,,
7898,,
7899,,
7900,,
7901,,
7902,,
7903,,
7904,,
7905,,
7906,,
7907,,
7908,,
7909,,
7910,,
7911,,
7912,,
7913,,
7914,,
7915,,
7916,,
7917,,
7918,,
7919,,
7920,,
7921,,
7922,,
7923,,
7924,,
7925,,
7926,,
7927,,
7928,,
7929,,
7930,,
7931,,
7932,,
7933,,
7934,,
7935,,
7936,,
7937,,
7938,,
7939,,
7940,,
7941,,
7942,,
7943,,
7944,,
7945,,
7946,,
7947,,
7948,,
7949,,
7950,,
7951,,
7952,,
7953,,
7954,,
7955,,
7956,,
7957,,
7958,,
7959,,
7960,,
7961,,
7962,,
7963,,
7964,,
7965,,
7966,,
7967,,
7968,,
7969,,
7970,,
7971,,
7972,,
7973,,
7974,,
7975,,
7976,,
7977,,
7978,,
7979,,
7980,,
7981,,
7982,,
7983,,
7984,,
7985,,
7986,,
7987,,
7988,,
7989,,
7990,,
7991,,
7992,,
7993,,
7994,,
7995,,
7996,,
7997,,
7998,,
7999,,
8000,,
8001,,
8002,,
8003,,
8004,,
8005,,
8006,,
8007,,
8008,,
8009,,
8010,,
8011,,
8012,,
8013,,
8014,,
8015,,
8016,,
8017,,
8018,,
8019,,
8020,,
8021,,
8022,,
8023,,
8024,,
8025,,
8026,,
8027,,
8028,,
8029,,
8030,,
8031,,
8032,,
8033,,
8034,,
8035,,
8036,,
8037,,
8038,,
8039,,
8040,,
8041,,
8042,,
8043,,
8044,,
8045,,
8046,,
8047,,
8048,,
8049,,
8050,,
8051,,
8052,,
8053,,
8054,,
8055,,
8056,,
8057,,
8058,,
8059,,
8060,,
8061,,
8062,,
8063,,
8064,,
8065,,
8066,,
8067,,
8068,,
8069,,
8070,,
8071,,
8072,,
8073,,
8074,,
8075,,
8076,,
8077,,
8078,,
8079,,
8080,,
8081,,
8082,,
8083,,
8084,,
8085,,
8086,,
8087,,
8088,,
8089,,
8090,,
8091,,
8092,,
8093,,
8094,,
8095,,
8096,,
8097,,
8098,,
8099,,
8100,,
8101,,
8102,,
8103,,
8104,,
8105,,
8106,,
8107,,
8108,,
8109,,
8110,,
8111,,
8112,,
8113,,
8114,,
8115,,
8116,,
8117,,
8118,,
8119,,
8120,,
8121,,
8122,,
8123,,
8124,,
8125,,
8126,,
8127,,
8128,,
8129,,
8130,,
8131,,
8132,,
8133,,
8134,,
8135,,
8136,,
8137,,
8138,,
8139,,
8140,,
8141,,
8142,,
8143,,
8144,,
8145,,
8146,,
8147,,
8148,,
8149,,
8150,,
8151,,
8152,,
8153,,
8154,,
8155,,
8156,,
8157,,
8158,,
8159,,
8160,,
8161,,
8162,,
8163,,
8164,,
8165,,
8166,,
8167,,
8168,,
8169,,
8170,,
8171,,
8172,,
8173,,
8174,,
8175,,
8176,,
8177,,
8178,,
8179,,
8180,,
8181,,
8182,,
8183,,
8184,,
8185,,
8186,,
8187,,
8188,,
8189,,
8190,,
8191,,
8192,,
8193,,
8194,,
8195,,
8196,,
8197,,
8198,,
8199,,
8200,,
8201,,
8202,,
8203,,
8204,,
8205,,
8206,,
8207,,
8208,,
8209,,
8210,,
8211,,
8212,,
8213,,
8214,,
8215,,
8216,,
8217,,
8218,,
8219,,
8220,,
8221,,
8222,,
8223,,
8224,,
8225,,
8226,,
8227,,
8228,,
8229,,
8230,,
8231,,
8232,,
8233,,
8234,,
8235,,
8236,,
8237,,
8238,,
8239,,
8240,,
8241,,
8242,,
8243,,
8244,,
8245,,
8246,,
8247,,
8248,,
8249,,
8250,,
8251,,
8252,,
8253,,
8254,,
8255,,
8256,,
8257,,
8258,,
8259,,
8260,,
8261,,
8262,,
8263,,
8264,,
8265,,
8266,,
8267,,
8268,,
8269,,
8270,,
8271,,
8272,,
8273,,
8274,,
8275,,
8276,,
8277,,
8278,,
8279,,
8280,,
8281,,
8282,,
8283,,
8284,,
8285,,
8286,,
8287,,
8288,,
8289,,
8290,,
8291,,
8292,,
8293,,
8294,,
8295,,
8296,,
8297,,
8298,,
8299,,
8300,,
8301,,
8302,,
8303,,
8304,,
8305,,
8306,,
8307,,
8308,,
8309,,
8310,,
8311,,
8312,,
8313,,
8314,,
8315,,
8316,,
8317,,
8318,,
8319,,
8320,,
8321,,
8322,,
8323,,
8324,,
8325,,
8326,,
8327,,
8328,,
8329,,
8330,,
8331,,
8332,,
8333,,
8334,,
8335,,
8336,,
8337,,
8338,,
8339,,
8340,,
8341,,
8342,,
8343,,
8344,,
8345,,
8346,,
8347,,
8348,,
8349,,
8350,,
8351,,
8352,,
8353,,
8354,,
8355,,
8356,,
8357,,
8358,,
8359,,
8360,,
8361,,
8362,,
8363,,
8364,,
8365,,
8366,,
8367,,
8368,,
8369,,
8370,,
8371,,
8372,,
8373,,
8374,,
8375,,
8376,,
8377,,
8378,,
8379,,
8380,,
8381,,
8382,,
8383,,
8384,,
8385,,
8386,,
8387,,
8388,,
8389,,
8390,,
8391,,
8392,,
8393,,
8394,,
8395,,
8396,,
8397,,
8398,,
8399,,
8400,,
8401,,
8402,,
8403,,
8404,,
8405,,
8406,,
8407,,
8408,,
8409,,
8410,,
8411,,
8412,,
8413,,
8414,,
8415,,
8416,,
8417,,
8418,,
8419,,
8420,,
8421,,
8422,,
8423,,
8424,,
8425,,
8426,,
8427,,
8428,,
8429,,
8430,,
8431,,
8432,,
8433,,
8434,,
8435,,
8436,,
8437,,
8438,,
8439,,
8440,,
8441,,
8442,,
8443,,
8444,,
8445,,
8446,,
8447,,
8448,,
8449,,
8450,,
8451,,
8452,,
8453,,
8454,,
8455,,
8456,,
8457,,
8458,,
8459,,
8460,,
8461,,
8462,,
8463,,
8464,,
8465,,
8466,,
8467,,
8468,,
8469,,
8470,,
8471,,
8472,,
8473,,
8474,,
8475,,
8476,,
8477,,
8478,,
8479,,
8480,,
8481,,
8482,,
8483,,
8484,,
8485,,
8486,,
8487,,
8488,,
8489,,
8490,,
8491,,
8492,,
8493,,
8494,,
8495,,
8496,,
8497,,
8498,,
8499,,
8500,,
8501,,
8502,,
8503,,
8504,,
8505,,
8506,,
8507,,
8508,,
8509,,
8510,,
8511,,
8512,,
8513,,
8514,,
8515,,
8516,,
8517,,
8518,,
8519,,
8520,,
8521,,
8522,,
8523,,
8524,,
8525,,
8526,,
8527,,
8528,,
8529,,
8530,,
8531,,
8532,,
8533,,
8534,,
8535,,
8536,,
8537,,
8538,,
8539,,
8540,,
8541,,
8542,,
8543,,
8544,,
8545,,
8546,,
8547,,
8548,,
8549,,
8550,,
8551,,
8552,,
8553,,
8554,,
8555,,
8556,,
8557,,
8558,,
8559,,
8560,,
8561,,
8562,,
8563,,
8564,,
8565,,
8566,,
8567,,
8568,,
8569,,
8570,,
8571,,
8572,,
8573,,
8574,,
8575,,
8576,,
8577,,
8578,,
8579,,
8580,,
8581,,
8582,,
8583,,
8584,,
8585,,
8586,,
8587,,
8588,,
8589,,
8590,,
8591,,
8592,,
8593,,
8594,,
8595,,
8596,,
8597,,
8598,,
8599,,
8600,,
8601,,
8602,,
8603,,
8604,,
8605,,
8606,,
8607,,
8608,,
8609,,
8610,,
8611,,
8612,,
8613,,
8614,,
8615,,
8616,,
8617,,
8618,,
8619,,
8620,,
8621,,
8622,,
8623,,
8624,,
8625,,
8626,,
8627,,
8628,,
8629,,
8630,,
8631,,
8632,,
8633,,
8634,,
8635,,
8636,,
8637,,
8638,,
8639,,
8640,,
8641,,
8642,,
8643,,
8644,,
8645,,
8646,,
8647,,
8648,,
8649,,
8650,,
8651,,
8652,,
8653,,
8654,,
8655,,
8656,,
8657,,
8658,,
8659,,
8660,,
8661,,
8662,,
8663,,
8664,,
8665,,
8666,,
8667,,
8668,,
8669,,
8670,,
8671,,
8672,,
8673,,
8674,,
8675,,
8676,,
8677,,
8678,,
8679,,
8680,,
8681,,
8682,,
8683,,
8684,,
8685,,
8686,,
8687,,
8688,,
8689,,
8690,,
8691,,
8692,,
8693,,
8694,,
8695,,
8696,,
8697,,
8698,,
8699,,
8700,,
8701,,
8702,,
8703,,
8704,,
8705,,
8706,,
8707,,
8708,,
8709,,
8710,,
8711,,
8712,,
8713,,
8714,,
8715,,
8716,,
8717,,
8718,,
8719,,
8720,,
8721,,
8722,,
8723,,
8724,,
8725,,
8726,,
8727,,
8728,,
8729,,
8730,,
8731,,
8732,,
8733,,
8734,,
8735,,
8736,,
8737,,
8738,,
8739,,
8740,,
8741,,
8742,,
8743,,
8744,,
8745,,
8746,,
8747,,
8748,,
8749,,
8750,,
8751,,
8752,,
8753,,
8754,,
8755,,
8756,,
8757,,
8758,,
8759,,
8760,,
8761,,
8762,,
8763,,
8764,,
8765,,
8766,,
8767,,
8768,,
8769,,
8770,,
8771,,
8772,,
8773,,
8774,,
8775,,
8776,,
8777,,
8778,,
8779,,
8780,,
8781,,
8782,,
8783,,
8784,,
8785,,
8786,,
8787,,
8788,,
8789,,
8790,,
8791,,
8792,,
8793,,
8794,,
8795,,
8796,,
8797,,
8798,,
8799,,
8800,,
8801,,
8802,,
8803,,
8804,,
8805,,
8806,,
8807,,
8808,,
8809,,
8810,,
8811,,
8812,,
8813,,
8814,,
8815,,
8816,,
8817,,
8818,,
8819,,
8820,,
8821,,
8822,,
8823,,
8824,,
8825,,
8826,,
8827,,
8828,,
8829,,
8830,,
8831,,
8832,,
8833,,
8834,,
8835,,
8836,,
8837,,
8838,,
8839,,
8840,,
8841,,
8842,,
8843,,
8844,,
8845,,
8846,,
8847,,
8848,,
8849,,
8850,,
8851,,
8852,,
8853,,
8854,,
8855,,
8856,,
8857,,
8858,,
8859,,
8860,,
8861,,
8862,,
8863,,
8864,,
8865,,
8866,,
8867,,
8868,,
8869,,
8870,,
8871,,
8872,,
8873,,
8874,,
8875,,
8876,,
8877,,
8878,,
8879,,
8880,,
8881,,
8882,,
8883,,
8884,,
8885,,
8886,,
8887,,
8888,,
8889,,
8890,,
8891,,
8892,,
8893,,
8894,,
8895,,
8896,,
8897,,
8898,,
8899,,
8900,,
8901,,
8902,,
8903,,
8904,,
8905,,
8906,,
8907,,
8908,,
8909,,
8910,,
8911,,
8912,,
8913,,
8914,,
8915,,
8916,,
8917,,
8918,,
8919,,
8920,,
8921,,
8922,,
8923,,
8924,,
8925,,
8926,,
8927,,
8928,,
8929,,
8930,,
8931,,
8932,,
8933,,
8934,,
8935,,
8936,,
8937,,
8938,,
8939,,
8940,,
8941,,
8942,,
8943,,
8944,,
8945,,
8946,,
8947,,
8948,,
8949,,
8950,,
8951,,
8952,,
8953,,
8954,,
8955,,
8956,,
8957,,
8958,,
8959,,
8960,,
8961,,
8962,,
8963,,
8964,,
8965,,
8966,,
8967,,
8968,,
8969,,
8970,,
8971,,
8972,,
8973,,
8974,,
8975,,
8976,,
8977,,
8978,,
8979,,
8980,,
8981,,
8982,,
8983,,
8984,,
8985,,
8986,,
8987,,
8988,,
8989,,
8990,,
8991,,
8992,,
8993,,
8994,,
8995,,
8996,,
8997,,
8998,,
8999,,
9000,,
9001,,
9002,,
9003,,
9004,,
9005,,
9006,,
9007,,
9008,,
9009,,
9010,,
9011,,
9012,,
9013,,
9014,,
9015,,
9016,,
9017,,
9018,,
9019,,
9020,,
9021,,
9022,,
9023,,
9024,,
9025,,
9026,,
9027,,
9028,,
9029,,
9030,,
9031,,
9032,,
9033,,
9034,,
9035,,
9036,,
9037,,
9038,,
9039,,
9040,,
9041,,
9042,,
9043,,
9044,,
9045,,
9046,,
9047,,
9048,,
9049,,
9050,,
9051,,
9052,,
9053,,
9054,,
9055,,
9056,,
9057,,
9058,,
9059,,
9060,,
9061,,
9062,,
9063,,
9064,,
9065,,
9066,,
9067,,
9068,,
9069,,
9070,,
9071,,
9072,,
9073,,
9074,,
9075,,
9076,,
9077,,
9078,,
9079,,
9080,,
9081,,
9082,,
9083,,
9084,,
9085,,
9086,,
9087,,
9088,,
9089,,
9090,,
9091,,
9092,,
9093,,
9094,,
9095,,
9096,,
9097,,
9098,,
9099,,
9100,,
9101,,
9102,,
9103,,
9104,,
9105,,
9106,,
9107,,
9108,,
9109,,
9110,,
9111,,
9112,,
9113,,
9114,,
9115,,
9116,,
9117,,
9118,,
9119,,
9120,,
9121,,
9122,,
9123,,
9124,,
9125,,
9126,,
9127,,
9128,,
9129,,
9130,,
9131,,
9132,,
9133,,
9134,,
9135,,
9136,,
9137,,
9138,,
9139,,
9140,,
9141,,
9142,,
9143,,
9144,,
9145,,
9146,,
9147,,
9148,,
9149,,
9150,,
9151,,
9152,,
9153,,
9154,,
9155,,
9156,,
9157,,
9158,,
9159,,
9160,,
9161,,
9162,,
9163,,
9164,,
9165,,
9166,,
9167,,
9168,,
9169,,
9170,,
9171,,
9172,,
9173,,
9174,,
9175,,
9176,,
9177,,
9178,,
9179,,
9180,,
9181,,
9182,,
9183,,
9184,,
9185,,
9186,,
9187,,
9188,,
9189,,
9190,,
9191,,
9192,,
9193,,
9194,,
9195,,
9196,,
9197,,
9198,,
9199,,
9200,,
9201,,
9202,,
9203,,
9204,,
9205,,
9206,,
9207,,
9208,,
9209,,
9210,,
9211,,
9212,,
9213,,
9214,,
9215,,
9216,,
9217,,
9218,,
9219,,
9220,,
9221,,
9222,,
9223,,
9224,,
9225,,
9226,,
9227,,
9228,,
9229,,
9230,,
9231,,
9232,,
9233,,
9234,,
9235,,
9236,,
9237,,
9238,,
9239,,
9240,,
9241,,
9242,,
9243,,
9244,,
9245,,
9246,,
9247,,
9248,,
9249,,
9250,,
9251,,
9252,,
9253,,
9254,,
9255,,
9256,,
9257,,
9258,,
9259,,
9260,,
9261,,
9262,,
9263,,
9264,,
9265,,
9266,,
9267,,
9268,,
9269,,
9270,,
9271,,
9272,,
9273,,
9274,,
9275,,
9276,,
9277,,
9278,,
9279,,
9280,,
9281,,
9282,,
9283,,
9284,,
9285,,
9286,,
9287,,
9288,,
9289,,
9290,,
9291,,
9292,,
9293,,
9294,,
9295,,
9296,,
9297,,
9298,,
9299,,
9300,,
9301,,
9302,,
9303,,
9304,,
9305,,
9306,,
9307,,
9308,,
9309,,
9310,,
9311,,
9312,,
9313,,
9314,,
9315,,
9316,,
9317,,
9318,,
9319,,
9320,,
9321,,
9322,,
9323,,
9324,,
9325,,
9326,,
9327,,
9328,,
9329,,
9330,,
9331,,
9332,,
9333,,
9334,,
9335,,
9336,,
9337,,
9338,,
9339,,
9340,,
9341,,
9342,,
9343,,
9344,,
9345,,
9346,,
9347,,
9348,,
9349,,
9350,,
9351,,
9352,,
9353,,
9354,,
9355,,
9356,,
9357,,
9358,,
9359,,
9360,,
9361,,
9362,,
9363,,
9364,,
9365,,
9366,,
9367,,
9368,,
9369,,
9370,,
9371,,
9372,,
9373,,
9374,,
9375,,
9376,,
9377,,
9378,,
9379,,
9380,,
9381,,
9382,,
9383,,
9384,,
9385,,
9386,,
9387,,
9388,,
9389,,
9390,,
9391,,
9392,,
9393,,
9394,,
9395,,
9396,,
9397,,
9398,,
9399,,
9400,,
9401,,
9402,,
9403,,
9404,,
9405,,
9406,,
9407,,
9408,,
9409,,
9410,,
9411,,
9412,,
9413,,
9414,,
9415,,
9416,,
9417,,
9418,,
9419,,
9420,,
9421,,
9422,,
9423,,
9424,,
9425,,
9426,,
9427,,
9428,,
9429,,
9430,,
9431,,
9432,,
9433,,
9434,,
9435,,
9436,,
9437,,
9438,,
9439,,
9440,,
9441,,
9442,,
9443,,
9444,,
9445,,
9446,,
9447,,
9448,,
9449,,
9450,,
9451,,
9452,,
9453,,
9454,,
9455,,
9456,,
9457,,
9458,,
9459,,
9460,,
9461,,
9462,,
9463,,
9464,,
9465,,
9466,,
9467,,
9468,,
9469,,
9470,,
9471,,
9472,,
9473,,
9474,,
9475,,
9476,,
9477,,
9478,,
9479,,
9480,,
9481,,
9482,,
9483,,
9484,,
9485,,
9486,,
9487,,
9488,,
9489,,
9490,,
9491,,
9492,,
9493,,
9494,,
9495,,
9496,,
9497,,
9498,,
9499,,
9500,,
9501,,
9502,,
9503,,
9504,,
9505,,
9506,,
9507,,
9508,,
9509,,
9510,,
9511,,
9512,,
9513,,
9514,,
9515,,
9516,,
9517,,
9518,,
9519,,
9520,,
9521,,
9522,,
9523,,
9524,,
9525,,
9526,,
9527,,
9528,,
9529,,
9530,,
9531,,
9532,,
9533,,
9534,,
9535,,
9536,,
9537,,
9538,,
9539,,
9540,,
9541,,
9542,,
9543,,
9544,,
9545,,
9546,,
9547,,
9548,,
9549,,
9550,,
9551,,
9552,,
9553,,
9554,,
9555,,
9556,,
9557,,
9558,,
9559,,
9560,,
9561,,
9562,,
9563,,
9564,,
9565,,
9566,,
9567,,
9568,,
9569,,
9570,,
9571,,
9572,,
9573,,
9574,,
9575,,
9576,,
9577,,
9578,,
9579,,
9580,,
9581,,
9582,,
9583,,
9584,,
9585,,
9586,,
9587,,
9588,,
9589,,
9590,,
9591,,
9592,,
9593,,
9594,,
9595,,
9596,,
9597,,
9598,,
9599,,
9600,,
9601,,
9602,,
9603,,
9604,,
9605,,
9606,,
9607,,
9608,,
9609,,
9610,,
9611,,
9612,,
9613,,
9614,,
9615,,
9616,,
9617,,
9618,,
9619,,
9620,,
9621,,
9622,,
9623,,
9624,,
9625,,
9626,,
9627,,
9628,,
9629,,
9630,,
9631,,
9632,,
9633,,
9634,,
9635,,
9636,,
9637,,
9638,,
9639,,
9640,,
9641,,
9642,,
9643,,
9644,,
9645,,
9646,,
9647,,
9648,,
9649,,
9650,,
9651,,
9652,,
9653,,
9654,,
9655,,
9656,,
9657,,
9658,,
9659,,
9660,,
9661,,
9662,,
9663,,
9664,,
9665,,
9666,,
9667,,
9668,,
9669,,
9670,,
9671,,
9672,,
9673,,
9674,,
9675,,
9676,,
9677,,
9678,,
9679,,
9680,,
9681,,
9682,,
9683,,
9684,,
9685,,
9686,,
9687,,
9688,,
9689,,
9690,,
9691,,
9692,,
9693,,
9694,,
9695,,
9696,,
9697,,
9698,,
9699,,
9700,,
9701,,
9702,,
9703,,
9704,,
9705,,
9706,,
9707,,
9708,,
9709,,
9710,,
9711,,
9712,,
9713,,
9714,,
9715,,
9716,,
9717,,
9718,,
9719,,
9720,,
9721,,
9722,,
9723,,
9724,,
9725,,
9726,,
9727,,
9728,,
9729,,
9730,,
9731,,
9732,,
9733,,
9734,,
9735,,
9736,,
9737,,
9738,,
9739,,
9740,,
9741,,
9742,,
9743,,
9744,,
9745,,
9746,,
9747,,
9748,,
9749,,
9750,,
9751,,
9752,,
9753,,
9754,,
9755,,
9756,,
9757,,
9758,,
9759,,
9760,,
9761,,
9762,,
9763,,
9764,,
9765,,
9766,,
9767,,
9768,,
9769,,
9770,,
9771,,
9772,,
9773,,
9774,,
9775,,
9776,,
9777,,
9778,,
9779,,
9780,,
9781,,
9782,,
9783,,
9784,,
9785,,
9786,,
9787,,
9788,,
9789,,
9790,,
9791,,
9792,,
9793,,
9794,,
9795,,
9796,,
9797,,
9798,,
9799,,
9800,,
9801,,
9802,,
9803,,
9804,,
9805,,
9806,,
9807,,
9808,,
9809,,
9810,,
9811,,
9812,,
9813,,
9814,,
9815,,
9816,,
9817,,
9818,,
9819,,
9820,,
9821,,
9822,,
9823,,
9824,,
9825,,
9826,,
9827,,
9828,,
9829,,
9830,,
9831,,
9832,,
9833,,
9834,,
9835,,
9836,,
9837,,
9838,,
9839,,
9840,,
9841,,
9842,,
9843,,
9844,,
9845,,
9846,,
9847,,
9848,,
9849,,
9850,,
9851,,
9852,,
9853,,
9854,,
9855,,
9856,,
9857,,
9858,,
9859,,
9860,,
9861,,
9862,,
9863,,
9864,,
9865,,
9866,,
9867,,
9868,,
9869,,
9870,,
9871,,
9872,,
9873,,
9874,,
9875,,
9876,,
9877,,
9878,,
9879,,
9880,,
9881,,
9882,,
9883,,
9884,,
9885,,
9886,,
9887,,
9888,,
9889,,
9890,,
9891,,
9892,,
9893,,
9894,,
9895,,
9896,,
9897,,
9898,,
9899,,
9900,,
9901,,
9902,,
9903,,
9904,,
9905,,
9906,,
9907,,
9908,,
9909,,
9910,,
9911,,
9912,,
9913,,
9914,,
9915,,
9916,,
9917,,
9918,,
9919,,
9920,,
9921,,
9922,,
9923,,
9924,,
9925,,
9926,,
9927,,
9928,,
9929,,
9930,,
9931,,
9932,,
9933,,
9934,,
9935,,
9936,,
9937,,
9938,,
9939,,
9940,,
9941,,
9942,,
9943,,
9944,,
9945,,
9946,,
9947,,
9948,,
9949,,
9950,,
9951,,
9952,,
9953,,
9954,,
9955,,
9956,,
9957,,
9958,,
9959,,
9960,,
9961,,
9962,,
9963,,
9964,,
9965,,
9966,,
9967,,
9968,,
9969,,
9970,,
9971,,
9972,,
9973,,
9974,,
9975,,
9976,,
9977,,
9978,,
9979,,
9980,,
9981,,
9982,,
9983,,
9984,,
9985,,
9986,,
9987,,
9988,,
9989,,
9990,,
9991,,
9992,,
9993,,
9994,,
9995,,
9996,,
9997,,
9998,,
9999,,
10000,,
10001,,
10002,,
10003,,
10004,,
10005,,
10006,,
10007,,
10008,,
10009,,
10010,,
10011,,
10012,,
10013,,
10014,,
10015,,
10016,,
10017,,
10018,,
10019,,
10020,,
10021,,
10022,,
10023,,
10024,,
10025,,
10026,,
10027,,
10028,,
10029,,
10030,,
10031,,
10032,,
10033,,
10034,,
10035,,
10036,,
10037,,
10038,,
10039,,
10040,,
10041,,
10042,,
10043,,
10044,,
10045,,
10046,,
10047,,
10048,,
10049,,
10050,,
10051,,
10052,,
10053,,
10054,,
10055,,
10056,,
10057,,
10058,,
10059,,
10060,,
10061,,
10062,,
10063,,
10064,,
10065,,
10066,,
10067,,
10068,,
10069,,
10070,,
10071,,
10072,,
10073,,
10074,,
10075,,
10076,,
10077,,
10078,,
10079,,
10080,,
10081,,
10082,,
10083,,
10084,,
10085,,
10086,,
10087,,
10088,,
10089,,
10090,,
10091,,
10092,,
10093,,
10094,,
10095,,
10096,,
10097,,
10098,,
10099,,
10100,,
10101,,
10102,,
10103,,
10104,,
10105,,
10106,,
10107,,
10108,,
10109,,
10110,,
10111,,
10112,,
10113,,
10114,,
10115,,
10116,,
10117,,
10118,,
10119,,
10120,,
10121,,
10122,,
10123,,
10124,,
10125,,
10126,,
10127,,
10128,,
10129,,
10130,,
10131,,
10132,,
10133,,
10134,,
10135,,
10136,,
10137,,
10138,,
10139,,
10140,,
10141,,
10142,,
10143,,
10144,,
10145,,
10146,,
10147,,
10148,,
10149,,
10150,,
10151,,
10152,,
10153,,
10154,,
10155,,
10156,,
10157,,
10158,,
10159,,
10160,,
10161,,
10162,,
10163,,
10164,,
10165,,
10166,,
10167,,
10168,,
10169,,
10170,,
10171,,
10172,,
10173,,
10174,,
10175,,
10176,,
10177,,
10178,,
10179,,
10180,,
10181,,
10182,,
10183,,
10184,,
10185,,
10186,,
10187,,
10188,,
10189,,
10190,,
10191,,
10192,,
10193,,
10194,,
10195,,
10196,,
10197,,
10198,,
10199,,
10200,,
10201,,
10202,,
10203,,
10204,,
10205,,
10206,,
10207,,
10208,,
10209,,
10210,,
10211,,
10212,,
10213,,
10214,,
10215,,
10216,,
10217,,
10218,,
10219,,
10220,,
10221,,
10222,,
10223,,
10224,,
10225,,
10226,,
10227,,
10228,,
10229,,
10230,,
10231,,
10232,,
10233,,
10234,,
10235,,
10236,,
10237,,
10238,,
10239,,
10240,,
10241,,
10242,,
10243,,
10244,,
10245,,
10246,,
10247,,
10248,,
10249,,
10250,,
10251,,
10252,,
10253,,
10254,,
10255,,
10256,,
10257,,
10258,,
10259,,
10260,,
10261,,
10262,,
10263,,
10264,,
10265,,
10266,,
10267,,
10268,,
10269,,
10270,,
10271,,
10272,,
10273,,
10274,,
10275,,
10276,,
10277,,
10278,,
10279,,
10280,,
10281,,
10282,,
10283,,
10284,,
10285,,
10286,,
10287,,
10288,,
10289,,
10290,,
10291,,
10292,,
10293,,
10294,,
10295,,
10296,,
10297,,
10298,,
10299,,
10300,,
10301,,
10302,,
10303,,
10304,,
10305,,
10306,,
10307,,
10308,,
10309,,
10310,,
10311,,
10312,,
10313,,
10314,,
10315,,
10316,,
10317,,
10318,,
10319,,
10320,,
10321,,
10322,,
10323,,
10324,,
10325,,
10326,,
10327,,
10328,,
10329,,
10330,,
10331,,
10332,,
10333,,
10334,,
10335,,
10336,,
10337,,
10338,,
10339,,
10340,,
10341,,
10342,,
10343,,
10344,,
10345,,
10346,,
10347,,
10348,,
10349,,
10350,,
10351,,
10352,,
10353,,
10354,,
10355,,
10356,,
10357,,
10358,,
10359,,
10360,,
10361,,
10362,,
10363,,
10364,,
10365,,
10366,,
10367,,
10368,,
10369,,
10370,,
10371,,
10372,,
10373,,
10374,,
10375,,
10376,,
10377,,
10378,,
10379,,
10380,,
10381,,
10382,,
10383,,
10384,,
10385,,
10386,,
10387,,
10388,,
10389,,
10390,,
10391,,
10392,,
10393,,
10394,,
10395,,
10396,,
10397,,
10398,,
10399,,
10400,,
10401,,
10402,,
10403,,
10404,,
10405,,
10406,,
10407,,
10408,,
10409,,
10410,,
10411,,
10412,,
10413,,
10414,,
10415,,
10416,,
10417,,
10418,,
10419,,
10420,,
10421,,
10422,,
10423,,
10424,,
10425,,
10426,,
10427,,
10428,,
10429,,
10430,,
10431,,
10432,,
10433,,
10434,,
10435,,
10436,,
10437,,
10438,,
10439,,
10440,,
10441,,
10442,,
10443,,
10444,,
10445,,
10446,,
10447,,
10448,,
10449,,
10450,,
10451,,
10452,,
10453,,
10454,,
10455,,
10456,,
10457,,
10458,,
10459,,
10460,,
10461,,
10462,,
10463,,
10464,,
10465,,
10466,,
10467,,
10468,,
10469,,
10470,,
10471,,
10472,,
10473,,
10474,,
10475,,
10476,,
10477,,
10478,,
10479,,
10480,,
10481,,
10482,,
10483,,
10484,,
10485,,
10486,,
10487,,
10488,,
10489,,
10490,,
10491,,
10492,,
10493,,
10494,,
10495,,
10496,,
10497,,
10498,,
10499,,
10500,,
10501,,
10502,,
10503,,
10504,,
10505,,
10506,,
10507,,
10508,,
10509,,
10510,,
10511,,
10512,,
10513,,
10514,,
10515,,
10516,,
10517,,
10518,,
10519,,
10520,,
10521,,
10522,,
10523,,
10524,,
10525,,
10526,,
10527,,
10528,,
10529,,
10530,,
10531,,
10532,,
10533,,
10534,,
10535,,
10536,,
10537,,
10538,,
10539,,
10540,,
10541,,
10542,,
10543,,
10544,,
10545,,
10546,,
10547,,
10548,,
10549,,
10550,,
10551,,
10552,,
10553,,
10554,,
10555,,
10556,,
10557,,
10558,,
10559,,
10560,,
10561,,
10562,,
10563,,
10564,,
10565,,
10566,,
10567,,
10568,,
10569,,
10570,,
10571,,
10572,,
10573,,
10574,,
10575,,
10576,,
10577,,
10578,,
10579,,
10580,,
10581,,
10582,,
10583,,
10584,,
10585,,
10586,,
10587,,
10588,,
10589,,
10590,,
10591,,
10592,,
10593,,
10594,,
10595,,
10596,,
10597,,
10598,,
10599,,
10600,,
10601,,
10602,,
10603,,
10604,,
10605,,
10606,,
10607,,
10608,,
10609,,
10610,,
10611,,
10612,,
10613,,
10614,,
10615,,
10616,,
10617,,
10618,,
10619,,
10620,,
10621,,
10622,,
10623,,
10624,,
10625,,
10626,,
10627,,
10628,,
10629,,
10630,,
10631,,
10632,,
10633,,
10634,,
10635,,
10636,,
10637,,
10638,,
10639,,
10640,,
10641,,
10642,,
10643,,
10644,,
10645,,
10646,,
10647,,
10648,,
10649,,
10650,,
10651,,
10652,,
10653,,
10654,,
10655,,
10656,,
10657,,
10658,,
10659,,
10660,,
10661,,
10662,,
10663,,
10664,,
10665,,
10666,,
10667,,
10668,,
10669,,
10670,,
10671,,
10672,,
10673,,
10674,,
10675,,
10676,,
10677,,
10678,,
10679,,
10680,,
10681,,
10682,,
10683,,
10684,,
10685,,
10686,,
10687,,
10688,,
10689,,
10690,,
10691,,
10692,,
10693,,
10694,,
10695,,
10696,,
10697,,
10698,,
10699,,
10700,,
10701,,
10702,,
10703,,
10704,,
10705,,
10706,,
10707,,
10708,,
10709,,
10710,,
10711,,
10712,,
10713,,
10714,,
10715,,
10716,,
10717,,
10718,,
10719,,
10720,,
10721,,
10722,,
10723,,
10724,,
10725,,
10726,,
10727,,
10728,,
10729,,
10730,,
10731,,
10732,,
10733,,
10734,,
10735,,
10736,,
10737,,
10738,,
10739,,
10740,,
10741,,
10742,,
10743,,
10744,,
10745,,
10746,,
10747,,
10748,,
10749,,
10750,,
10751,,
10752,,
10753,,
10754,,
10755,,
10756,,
10757,,
10758,,
10759,,
10760,,
10761,,
10762,,
10763,,
10764,,
10765,,
10766,,
10767,,
10768,,
10769,,
10770,,
10771,,
10772,,
10773,,
10774,,
10775,,
10776,,
10777,,
10778,,
10779,,
10780,,
10781,,
10782,,
10783,,
10784,,
10785,,
10786,,
10787,,
10788,,
10789,,
10790,,
10791,,
10792,,
10793,,
10794,,
10795,,
10796,,
10797,,
10798,,
10799,,
10800,,
10801,,
10802,,
10803,,
10804,,
10805,,
10806,,
10807,,
10808,,
10809,,
10810,,
10811,,
10812,,
10813,,
10814,,
10815,,
10816,,
10817,,
10818,,
10819,,
10820,,
10821,,
10822,,
10823,,
10824,,
10825,,
10826,,
10827,,
10828,,
10829,,
10830,,
10831,,
10832,,
10833,,
10834,,
10835,,
10836,,
10837,,
10838,,
10839,,
10840,,
10841,,
10842,,
10843,,
10844,,
10845,,
10846,,
10847,,
10848,,
10849,,
10850,,
10851,,
10852,,
10853,,
10854,,
10855,,
10856,,
10857,,
10858,,
10859,,
10860,,
10861,,
10862,,
10863,,
10864,,
10865,,
10866,,
10867,,
10868,,
10869,,
10870,,
10871,,
10872,,
10873,,
10874,,
10875,,
10876,,
10877,,
10878,,
10879,,
10880,,
10881,,
10882,,
10883,,
10884,,
10885,,
10886,,
10887,,
10888,,
10889,,
10890,,
10891,,
10892,,
10893,,
10894,,
10895,,
10896,,
10897,,
10898,,
10899,,
10900,,
10901,,
10902,,
10903,,
10904,,
10905,,
10906,,
10907,,
10908,,
10909,,
10910,,
10911,,
10912,,
10913,,
10914,,
10915,,
10916,,
10917,,
10918,,
10919,,
10920,,
10921,,
10922,,
10923,,
10924,,
10925,,
10926,,
10927,,
10928,,
10929,,
10930,,
10931,,
10932,,
10933,,
10934,,
10935,,
10936,,
10937,,
10938,,
10939,,
10940,,
10941,,
10942,,
10943,,
10944,,
10945,,
10946,,
10947,,
10948,,
10949,,
10950,,
10951,,
10952,,
10953,,
10954,,
10955,,
10956,,
10957,,
10958,,
10959,,
10960,,
10961,,
10962,,
10963,,
10964,,
10965,,
10966,,
10967,,
10968,,
10969,,
10970,,
10971,,
10972,,
10973,,
10974,,
10975,,
10976,,
10977,,
10978,,
10979,,
10980,,
10981,,
10982,,
10983,,
10984,,
10985,,
10986,,
10987,,
10988,,
10989,,
10990,,
10991,,
10992,,
10993,,
10994,,
10995,,
10996,,
10997,,
10998,,
10999,,
11000,,
11001,,
11002,,
11003,,
11004,,
11005,,
11006,,
11007,,
11008,,
11009,,
11010,,
11011,,
11012,,
11013,,
11014,,
11015,,
11016,,
11017,,
11018,,
11019,,
11020,,
11021,,
11022,,
11023,,
11024,,
11025,,
11026,,
11027,,
11028,,
11029,,
11030,,
11031,,
11032,,
11033,,
11034,,
11035,,
11036,,
11037,,
11038,,
11039,,
11040,,
11041,,
11042,,
11043,,
11044,,
11045,,
11046,,
11047,,
11048,,
11049,,
11050,,
11051,,
11052,,
11053,,
11054,,
11055,,
11056,,
11057,,
11058,,
11059,,
11060,,
11061,,
11062,,
11063,,
11064,,
11065,,
11066,,
11067,,
11068,,
11069,,
11070,,
11071,,
11072,,
11073,,
11074,,
11075,,
11076,,
11077,,
11078,,
11079,,
11080,,
11081,,
11082,,
11083,,
11084,,
11085,,
11086,,
11087,,
11088,,
11089,,
11090,,
11091,,
11092,,
11093,,
11094,,
11095,,
11096,,
11097,,
11098,,
11099,,
11100,,
11101,,
11102,,
11103,,
11104,,
11105,,
11106,,
11107,,
11108,,
11109,,
11110,,
11111,,
11112,,
11113,,
11114,,
11115,,
11116,,
11117,,
11118,,
11119,,
11120,,
11121,,
11122,,
11123,,
11124,,
11125,,
11126,,
11127,,
11128,,
11129,,
11130,,
11131,,
11132,,
11133,,
11134,,
11135,,
11136,,
11137,,
11138,,
11139,,
11140,,
11141,,
11142,,
11143,,
11144,,
11145,,
11146,,
11147,,
11148,,
11149,,
11150,,
11151,,
11152,,
11153,,
11154,,
11155,,
11156,,
11157,,
11158,,
11159,,
11160,,
11161,,
11162,,
11163,,
11164,,
11165,,
11166,,
11167,,
11168,,
11169,,
11170,,
11171,,
11172,,
11173,,
11174,,
11175,,
11176,,
11177,,
11178,,
11179,,
11180,,
11181,,
11182,,
11183,,
11184,,
11185,,
11186,,
11187,,
11188,,
11189,,
11190,,
11191,,
11192,,
11193,,
11194,,
11195,,
11196,,
11197,,
11198,,
11199,,
11200,,
11201,,
11202,,
11203,,
11204,,
11205,,
11206,,
11207,,
11208,,
11209,,
11210,,
11211,,
11212,,
11213,,
11214,,
11215,,
11216,,
11217,,
11218,,
11219,,
11220,,
11221,,
11222,,
11223,,
11224,,
11225,,
11226,,
11227,,
11228,,
11229,,
11230,,
11231,,
11232,,
11233,,
11234,,
11235,,
11236,,
11237,,
11238,,
11239,,
11240,,
11241,,
11242,,
11243,,
11244,,
11245,,
11246,,
11247,,
11248,,
11249,,
11250,,
11251,,
11252,,
11253,,
11254,,
11255,,
11256,,
11257,,
11258,,
11259,,
11260,,
11261,,
11262,,
11263,,
11264,,
11265,,
11266,,
11267,,
11268,,
11269,,
11270,,
11271,,
11272,,
11273,,
11274,,
11275,,
11276,,
11277,,
11278,,
11279,,
11280,,
11281,,
11282,,
11283,,
11284,,
11285,,
11286,,
11287,,
11288,,
11289,,
11290,,
11291,,
11292,,
11293,,
11294,,
11295,,
11296,,
11297,,
11298,,
11299,,
11300,,
11301,,
11302,,
11303,,
11304,,
11305,,
11306,,
11307,,
11308,,
11309,,
11310,,
11311,,
11312,,
11313,,
11314,,
11315,,
11316,,
11317,,
11318,,
11319,,
11320,,
11321,,
11322,,
11323,,
11324,,
11325,,
11326,,
11327,,
11328,,
11329,,
11330,,
11331,,
11332,,
11333,,
11334,,
11335,,
11336,,
11337,,
11338,,
11339,,
11340,,
11341,,
11342,,
11343,,
11344,,
11345,,
11346,,
11347,,
11348,,
11349,,
11350,,
11351,,
11352,,
11353,,
11354,,
11355,,
11356,,
11357,,
11358,,
11359,,
11360,,
11361,,
11362,,
11363,,
11364,,
11365,,
11366,,
11367,,
11368,,
11369,,
11370,,
11371,,
11372,,
11373,,
11374,,
11375,,
11376,,
11377,,
11378,,
11379,,
11380,,
11381,,
11382,,
11383,,
11384,,
11385,,
11386,,
11387,,
11388,,
11389,,
11390,,
11391,,
11392,,
11393,,
11394,,
11395,,
11396,,
11397,,
11398,,
11399,,
11400,,
11401,,
11402,,
11403,,
11404,,
11405,,
11406,,
11407,,
11408,,
11409,,
11410,,
11411,,
11412,,
11413,,
11414,,
11415,,
11416,,
11417,,
11418,,
11419,,
11420,,
11421,,
11422,,
11423,,
11424,,
11425,,
11426,,
11427,,
11428,,
11429,,
11430,,
11431,,
11432,,
11433,,
11434,,
11435,,
11436,,
11437,,
11438,,
11439,,
11440,,
11441,,
11442,,
11443,,
11444,,
11445,,
11446,,
11447,,
11448,,
11449,,
11450,,
11451,,
11452,,
11453,,
11454,,
11455,,
11456,,
11457,,
11458,,
11459,,
11460,,
11461,,
11462,,
11463,,
11464,,
11465,,
11466,,
11467,,
11468,,
11469,,
11470,,
11471,,
11472,,
11473,,
11474,,
11475,,
11476,,
11477,,
11478,,
11479,,
11480,,
11481,,
11482,,
11483,,
11484,,
11485,,
11486,,
11487,,
11488,,
11489,,
11490,,
11491,,
11492,,
11493,,
11494,,
11495,,
11496,,
11497,,
11498,,
11499,,
11500,,
11501,,
11502,,
11503,,
11504,,
11505,,
11506,,
11507,,
11508,,
11509,,
11510,,
11511,,
11512,,
11513,,
11514,,
11515,,
11516,,
11517,,
11518,,
11519,,
11520,,
11521,,
11522,,
11523,,
11524,,
11525,,
11526,,
11527,,
11528,,
11529,,
11530,,
11531,,
11532,,
11533,,
11534,,
11535,,
11536,,
11537,,
11538,,
11539,,
11540,,
11541,,
11542,,
11543,,
11544,,
11545,,
11546,,
11547,,
11548,,
11549,,
11550,,
11551,,
11552,,
11553,,
11554,,
11555,,
11556,,
11557,,
11558,,
11559,,
11560,,
11561,,
11562,,
11563,,
11564,,
11565,,
11566,,
11567,,
11568,,
11569,,
11570,,
11571,,
11572,,
11573,,
11574,,
11575,,
11576,,
11577,,
11578,,
11579,,
11580,,
11581,,
11582,,
11583,,
11584,,
11585,,
11586,,
11587,,
11588,,
11589,,
11590,,
11591,,
11592,,
11593,,
11594,,
11595,,
11596,,
11597,,
11598,,
11599,,
11600,,
11601,,
11602,,
11603,,
11604,,
11605,,
11606,,
11607,,
11608,,
11609,,
11610,,
11611,,
11612,,
11613,,
11614,,
11615,,
11616,,
11617,,
11618,,
11619,,
11620,,
11621,,
11622,,
11623,,
11624,,
11625,,
11626,,
11627,,
11628,,
11629,,
11630,,
11631,,
11632,,
11633,,
11634,,
11635,,
11636,,
11637,,
11638,,
11639,,
11640,,
11641,,
11642,,
11643,,
11644,,
11645,,
11646,,
11647,,
11648,,
11649,,
11650,,
11651,,
11652,,
11653,,
11654,,
11655,,
11656,,
11657,,
11658,,
11659,,
11660,,
11661,,
11662,,
11663,,
11664,,
11665,,
11666,,
11667,,
11668,,
11669,,
11670,,
11671,,
11672,,
11673,,
11674,,
11675,,
11676,,
11677,,
11678,,
11679,,
11680,,
11681,,
11682,,
11683,,
11684,,
11685,,
11686,,
11687,,
11688,,
11689,,
11690,,
11691,,
11692,,
11693,,
11694,,
11695,,
11696,,
11697,,
11698,,
11699,,
11700,,
11701,,
11702,,
11703,,
11704,,
11705,,
11706,,
11707,,
11708,,
11709,,
11710,,
11711,,
11712,,
11713,,
11714,,
11715,,
11716,,
11717,,
11718,,
11719,,
11720,,
11721,,
11722,,
11723,,
11724,,
11725,,
11726,,
11727,,
11728,,
11729,,
11730,,
11731,,
11732,,
11733,,
11734,,
11735,,
11736,,
11737,,
11738,,
11739,,
11740,,
11741,,
11742,,
11743,,
11744,,
11745,,
11746,,
11747,,
11748,,
11749,,
11750,,
11751,,
11752,,
11753,,
11754,,
11755,,
11756,,
11757,,
11758,,
11759,,
11760,,
11761,,
11762,,
11763,,
11764,,
11765,,
11766,,
11767,,
11768,,
11769,,
11770,,
11771,,
11772,,
11773,,
11774,,
11775,,
11776,,
11777,,
11778,,
11779,,
11780,,
11781,,
11782,,
11783,,
11784,,
11785,,
11786,,
11787,,
11788,,
11789,,
11790,,
11791,,
11792,,
11793,,
11794,,
11795,,
11796,,
11797,,
11798,,
11799,,
11800,,
11801,,
11802,,
11803,,
11804,,
11805,,
11806,,
11807,,
11808,,
11809,,
11810,,
11811,,
11812,,
11813,,
11814,,
11815,,
11816,,
11817,,
11818,,
11819,,
11820,,
11821,,
11822,,
11823,,
11824,,
11825,,
11826,,
11827,,
11828,,
11829,,
11830,,
11831,,
11832,,
11833,,
11834,,
11835,,
11836,,
11837,,
11838,,
11839,,
11840,,
11841,,
11842,,
11843,,
11844,,
11845,,
11846,,
11847,,
11848,,
11849,,
11850,,
11851,,
11852,,
11853,,
11854,,
11855,,
11856,,
11857,,
11858,,
11859,,
11860,,
11861,,
11862,,
11863,,
11864,,
11865,,
11866,,
11867,,
11868,,
11869,,
11870,,
11871,,
11872,,
11873,,
11874,,
11875,,
11876,,
11877,,
11878,,
11879,,
11880,,
11881,,
11882,,
11883,,
11884,,
11885,,
11886,,
11887,,
11888,,
11889,,
11890,,
11891,,
11892,,
11893,,
11894,,
11895,,
11896,,
11897,,
11898,,
11899,,
11900,,
11901,,
11902,,
11903,,
11904,,
11905,,
11906,,
11907,,
11908,,
11909,,
11910,,
11911,,
11912,,
11913,,
11914,,
11915,,
11916,,
11917,,
11918,,
11919,,
11920,,
11921,,
11922,,
11923,,
11924,,
11925,,
11926,,
11927,,
11928,,
11929,,
11930,,
11931,,
11932,,
11933,,
11934,,
11935,,
11936,,
11937,,
11938,,
11939,,
11940,,
11941,,
11942,,
11943,,
11944,,
11945,,
11946,,
11947,,
11948,,
11949,,
11950,,
11951,,
11952,,
11953,,
11954,,
11955,,
11956,,
11957,,
11958,,
11959,,
11960,,
11961,,
11962,,
11963,,
11964,,
11965,,
11966,,
11967,,
11968,,
11969,,
11970,,
11971,,
11972,,
11973,,
11974,,
11975,,
11976,,
11977,,
11978,,
11979,,
11980,,
11981,,
11982,,
11983,,
11984,,
11985,,
11986,,
11987,,
11988,,
11989,,
11990,,
11991,,
11992,,
11993,,
11994,,
11995,,
11996,,
11997,,
11998,,
11999,,
12000,,
12001,,
12002,,
12003,,
12004,,
12005,,
12006,,
12007,,
12008,,
12009,,
12010,,
12011,,
12012,,
12013,,
12014,,
12015,,
12016,,
12017,,
12018,,
12019,,
12020,,
12021,,
12022,,
12023,,
12024,,
12025,,
12026,,
12027,,
12028,,
12029,,
12030,,
12031,,
12032,,
12033,,
12034,,
12035,,
12036,,
12037,,
12038,,
12039,,
12040,,
12041,,
12042,,
12043,,
12044,,
12045,,
12046,,
12047,,
12048,,
12049,,
12050,,
12051,,
12052,,
12053,,
12054,,
12055,,
12056,,
12057,,
12058,,
12059,,
12060,,
12061,,
12062,,
12063,,
12064,,
12065,,
12066,,
12067,,
12068,,
12069,,
12070,,
12071,,
12072,,
12073,,
12074,,
12075,,
12076,,
12077,,
12078,,
12079,,
12080,,
12081,,
12082,,
12083,,
12084,,
12085,,
12086,,
12087,,
12088,,
12089,,
12090,,
12091,,
12092,,
12093,,
12094,,
12095,,
12096,,
12097,,
12098,,
12099,,
12100,,
12101,,
12102,,
12103,,
12104,,
12105,,
12106,,
12107,,
12108,,
12109,,
12110,,
12111,,
12112,,
12113,,
12114,,
12115,,
12116,,
12117,,
12118,,
12119,,
12120,,
12121,,
12122,,
12123,,
12124,,
12125,,
12126,,
12127,,
12128,,
12129,,
12130,,
12131,,
12132,,
12133,,
12134,,
12135,,
12136,,
12137,,
12138,,
12139,,
12140,,
12141,,
12142,,
12143,,
12144,,
12145,,
12146,,
12147,,
12148,,
12149,,
12150,,
12151,,
12152,,
12153,,
12154,,
12155,,
12156,,
12157,,
12158,,
12159,,
12160,,
12161,,
12162,,
12163,,
12164,,
12165,,
12166,,
12167,,
12168,,
12169,,
12170,,
12171,,
12172,,
12173,,
12174,,
12175,,
12176,,
12177,,
12178,,
12179,,
12180,,
12181,,
12182,,
12183,,
12184,,
12185,,
12186,,
12187,,
12188,,
12189,,
12190,,
12191,,
12192,,
12193,,
12194,,
12195,,
12196,,
12197,,
12198,,
12199,,
12200,,
12201,,
12202,,
12203,,
12204,,
12205,,
12206,,
12207,,
12208,,
12209,,
12210,,
12211,,
12212,,
12213,,
12214,,
12215,,
12216,,
12217,,
12218,,
12219,,
12220,,
12221,,
12222,,
12223,,
12224,,
12225,,
12226,,
12227,,
12228,,
12229,,
12230,,
12231,,
12232,,
12233,,
12234,,
12235,,
12236,,
12237,,
12238,,
12239,,
12240,,
12241,,
12242,,
12243,,
12244,,
12245,,
12246,,
12247,,
12248,,
12249,,
12250,,
12251,,
12252,,
12253,,
12254,,
12255,,
12256,,
12257,,
12258,,
12259,,
12260,,
12261,,
12262,,
12263,,
12264,,
12265,,
12266,,
12267,,
12268,,
12269,,
12270,,
12271,,
12272,,
12273,,
12274,,
12275,,
12276,,
12277,,
12278,,
12279,,
12280,,
12281,,
12282,,
12283,,
12284,,
12285,,
12286,,
12287,,
12288,,
12289,,
12290,,
12291,,
12292,,
12293,,
12294,,
12295,,
12296,,
12297,,
12298,,
12299,,
12300,,
12301,,
12302,,
12303,,
12304,,
12305,,
12306,,
12307,,
12308,,
12309,,
12310,,
12311,,
12312,,
12313,,
12314,,
12315,,
12316,,
12317,,
12318,,
12319,,
12320,,
12321,,
12322,,
12323,,
12324,,
12325,,
12326,,
12327,,
12328,,
12329,,
12330,,
12331,,
12332,,
12333,,
12334,,
12335,,
12336,,
12337,,
12338,,
12339,,
12340,,
12341,,
12342,,
12343,,
12344,,
12345,,
12346,,
12347,,
12348,,
12349,,
12350,,
12351,,
12352,,
12353,,
12354,,
12355,,
12356,,
12357,,
12358,,
12359,,
12360,,
12361,,
12362,,
12363,,
12364,,
12365,,
12366,,
12367,,
12368,,
12369,,
12370,,
12371,,
12372,,
12373,,
12374,,
12375,,
12376,,
12377,,
12378,,
12379,,
12380,,
12381,,
12382,,
12383,,
12384,,
12385,,
12386,,
12387,,
12388,,
12389,,
12390,,
12391,,
12392,,
12393,,
12394,,
12395,,
12396,,
12397,,
12398,,
12399,,
12400,,
12401,,
12402,,
12403,,
12404,,
12405,,
12406,,
12407,,
12408,,
12409,,
12410,,
12411,,
12412,,
12413,,
12414,,
12415,,
12416,,
12417,,
12418,,
12419,,
12420,,
12421,,
12422,,
12423,,
12424,,
12425,,
12426,,
12427,,
12428,,
12429,,
12430,,
12431,,
12432,,
12433,,
12434,,
12435,,
12436,,
12437,,
12438,,
12439,,
12440,,
12441,,
12442,,
12443,,
12444,,
12445,,
12446,,
12447,,
12448,,
12449,,
12450,,
12451,,
12452,,
12453,,
12454,,
12455,,
12456,,
12457,,
12458,,
12459,,
12460,,
12461,,
12462,,
12463,,
12464,,
12465,,
12466,,
12467,,
12468,,
12469,,
12470,,
12471,,
12472,,
12473,,
12474,,
12475,,
12476,,
12477,,
12478,,
12479,,
12480,,
12481,,
12482,,
12483,,
12484,,
12485,,
12486,,
12487,,
12488,,
12489,,
12490,,
12491,,
12492,,
12493,,
12494,,
12495,,
12496,,
12497,,
12498,,
12499,,
12500,,
12501,,
12502,,
12503,,
12504,,
12505,,
12506,,
12507,,
12508,,
12509,,
12510,,
12511,,
12512,,
12513,,
12514,,
12515,,
12516,,
12517,,
12518,,
12519,,
12520,,
12521,,
12522,,
12523,,
12524,,
12525,,
12526,,
12527,,
12528,,
12529,,
12530,,
12531,,
12532,,
12533,,
12534,,
12535,,
12536,,
12537,,
12538,,
12539,,
12540,,
12541,,
12542,,
12543,,
12544,,
12545,,
12546,,
12547,,
12548,,
12549,,
12550,,
12551,,
12552,,
12553,,
12554,,
12555,,
12556,,
12557,,
12558,,
12559,,
12560,,
12561,,
12562,,
12563,,
12564,,
12565,,
12566,,
12567,,
12568,,
12569,,
12570,,
12571,,
12572,,
12573,,
12574,,
12575,,
12576,,
12577,,
12578,,
12579,,
12580,,
12581,,
12582,,
12583,,
12584,,
12585,,
12586,,
12587,,
12588,,
12589,,
12590,,
12591,,
12592,,
12593,,
12594,,
12595,,
12596,,
12597,,
12598,,
12599,,
12600,,
12601,,
12602,,
12603,,
12604,,
12605,,
12606,,
12607,,
12608,,
12609,,
12610,,
12611,,
12612,,
12613,,
12614,,
12615,,
12616,,
12617,,
12618,,
12619,,
12620,,
12621,,
12622,,
12623,,
12624,,
12625,,
12626,,
12627,,
12628,,
12629,,
12630,,
12631,,
12632,,
12633,,
12634,,
12635,,
12636,,
12637,,
12638,,
12639,,
12640,,
12641,,
12642,,
12643,,
12644,,
12645,,
12646,,
12647,,
12648,,
12649,,
12650,,
12651,,
12652,,
12653,,
12654,,
12655,,
12656,,
12657,,
12658,,
12659,,
12660,,
12661,,
12662,,
12663,,
12664,,
12665,,
12666,,
12667,,
12668,,
12669,,
12670,,
12671,,
12672,,
12673,,
12674,,
12675,,
12676,,
12677,,
12678,,
12679,,
12680,,
12681,,
12682,,
12683,,
12684,,
12685,,
12686,,
12687,,
12688,,
12689,,
12690,,
12691,,
12692,,
12693,,
12694,,
12695,,
12696,,
12697,,
12698,,
12699,,
12700,,
12701,,
12702,,
12703,,
12704,,
12705,,
12706,,
12707,,
12708,,
12709,,
12710,,
12711,,
12712,,
12713,,
12714,,
12715,,
12716,,
12717,,
12718,,
12719,,
12720,,
12721,,
12722,,
12723,,
12724,,
12725,,
12726,,
12727,,
12728,,
12729,,
12730,,
12731,,
12732,,
12733,,
12734,,
12735,,
12736,,
12737,,
12738,,
12739,,
12740,,
12741,,
12742,,
12743,,
12744,,
12745,,
12746,,
12747,,
12748,,
12749,,
12750,,
12751,,
12752,,
12753,,
12754,,
12755,,
12756,,
12757,,
12758,,
12759,,
12760,,
12761,,
12762,,
12763,,
12764,,
12765,,
12766,,
12767,,
12768,,
12769,,
12770,,
12771,,
12772,,
12773,,
12774,,
12775,,
12776,,
12777,,
12778,,
12779,,
12780,,
12781,,
12782,,
12783,,
12784,,
12785,,
12786,,
12787,,
12788,,
12789,,
12790,,
12791,,
12792,,
12793,,
12794,,
12795,,
12796,,
12797,,
12798,,
12799,,
12800,,
12801,,
12802,,
12803,,
12804,,
12805,,
12806,,
12807,,
12808,,
12809,,
12810,,
12811,,
12812,,
12813,,
12814,,
12815,,
12816,,
12817,,
12818,,
12819,,
12820,,
12821,,
12822,,
12823,,
12824,,
12825,,
12826,,
12827,,
12828,,
12829,,
12830,,
12831,,
12832,,
12833,,
12834,,
12835,,
12836,,
12837,,
12838,,
12839,,
12840,,
12841,,
12842,,
12843,,
12844,,
12845,,
12846,,
12847,,
12848,,
12849,,
12850,,
12851,,
12852,,
12853,,
12854,,
12855,,
12856,,
12857,,
12858,,
12859,,
12860,,
12861,,
12862,,
12863,,
12864,,
12865,,
12866,,
12867,,
12868,,
12869,,
12870,,
12871,,
12872,,
12873,,
12874,,
12875,,
12876,,
12877,,
12878,,
12879,,
12880,,
12881,,
12882,,
12883,,
12884,,
12885,,
12886,,
12887,,
12888,,
12889,,
12890,,
12891,,
12892,,
12893,,
12894,,
12895,,
12896,,
12897,,
12898,,
12899,,
12900,,
12901,,
12902,,
12903,,
12904,,
12905,,
12906,,
12907,,
12908,,
12909,,
12910,,
12911,,
12912,,
12913,,
12914,,
12915,,
12916,,
12917,,
12918,,
12919,,
12920,,
12921,,
12922,,
12923,,
12924,,
12925,,
12926,,
12927,,
12928,,
12929,,
12930,,
12931,,
12932,,
12933,,
12934,,
12935,,
12936,,
12937,,
12938,,
12939,,
12940,,
12941,,
12942,,
12943,,
12944,,
12945,,
12946,,
12947,,
12948,,
12949,,
12950,,
12951,,
12952,,
12953,,
12954,,
12955,,
12956,,
12957,,
12958,,
12959,,
12960,,
12961,,
12962,,
12963,,
12964,,
12965,,
12966,,
12967,,
12968,,
12969,,
12970,,
12971,,
12972,,
12973,,
12974,,
12975,,
12976,,
12977,,
12978,,
12979,,
12980,,
12981,,
12982,,
12983,,
12984,,
12985,,
12986,,
12987,,
12988,,
12989,,
12990,,
12991,,
12992,,
12993,,
12994,,
12995,,
12996,,
12997,,
12998,,
12999,,
13000,,
13001,,
13002,,
13003,,
13004,,
13005,,
13006,,
13007,,
13008,,
13009,,
13010,,
13011,,
13012,,
13013,,
13014,,
13015,,
13016,,
13017,,
13018,,
13019,,
13020,,
13021,,
13022,,
13023,,
13024,,
13025,,
13026,,
13027,,
13028,,
13029,,
13030,,
13031,,
13032,,
13033,,
13034,,
13035,,
13036,,
13037,,
13038,,
13039,,
13040,,
13041,,
13042,,
13043,,
13044,,
13045,,
13046,,
13047,,
13048,,
13049,,
13050,,
13051,,
13052,,
13053,,
13054,,
13055,,
13056,,
13057,,
13058,,
13059,,
13060,,
13061,,
13062,,
13063,,
13064,,
13065,,
13066,,
13067,,
13068,,
13069,,
13070,,
13071,,
13072,,
13073,,
13074,,
13075,,
13076,,
13077,,
13078,,
13079,,
13080,,
13081,,
13082,,
13083,,
13084,,
13085,,
13086,,
13087,,
13088,,
13089,,
13090,,
13091,,
13092,,
13093,,
13094,,
13095,,
13096,,
13097,,
13098,,
13099,,
13100,,
13101,,
13102,,
13103,,
13104,,
13105,,
13106,,
13107,,
13108,,
13109,,
13110,,
13111,,
13112,,
13113,,
13114,,
13115,,
13116,,
13117,,
13118,,
13119,,
13120,,
13121,,
13122,,
13123,,
13124,,
13125,,
13126,,
13127,,
13128,,
13129,,
13130,,
13131,,
13132,,
13133,,
13134,,
13135,,
13136,,
13137,,
13138,,
13139,,
13140,,
13141,,
13142,,
13143,,
13144,,
13145,,
13146,,
13147,,
13148,,
13149,,
13150,,
13151,,
13152,,
13153,,
13154,,
13155,,
13156,,
13157,,
13158,,
13159,,
13160,,
13161,,
13162,,
13163,,
13164,,
13165,,
13166,,
13167,,
13168,,
13169,,
13170,,
13171,,
13172,,
13173,,
13174,,
13175,,
13176,,
13177,,
13178,,
13179,,
13180,,
13181,,
13182,,
13183,,
13184,,
13185,,
13186,,
13187,,
13188,,
13189,,
13190,,
13191,,
13192,,
13193,,
13194,,
13195,,
13196,,
13197,,
13198,,
13199,,
13200,,
13201,,
13202,,
13203,,
13204,,
13205,,
13206,,
13207,,
13208,,
13209,,
13210,,
13211,,
13212,,
13213,,
13214,,
13215,,
13216,,
13217,,
13218,,
13219,,
13220,,
13221,,
13222,,
13223,,
13224,,
13225,,
13226,,
13227,,
13228,,
13229,,
13230,,
13231,,
13232,,
13233,,
13234,,
13235,,
13236,,
13237,,
13238,,
13239,,
13240,,
13241,,
13242,,
13243,,
13244,,
13245,,
13246,,
13247,,
13248,,
13249,,
13250,,
13251,,
13252,,
13253,,
13254,,
13255,,
13256,,
13257,,
13258,,
13259,,
13260,,
13261,,
13262,,
13263,,
13264,,
13265,,
13266,,
13267,,
13268,,
13269,,
13270,,
13271,,
13272,,
13273,,
13274,,
13275,,
13276,,
13277,,
13278,,
13279,,
13280,,
13281,,
13282,,
13283,,
13284,,
13285,,
13286,,
13287,,
13288,,
13289,,
13290,,
13291,,
13292,,
13293,,
13294,,
13295,,
13296,,
13297,,
13298,,
13299,,
13300,,
13301,,
13302,,
13303,,
13304,,
13305,,
13306,,
13307,,
13308,,
13309,,
13310,,
13311,,
13312,,
13313,,
13314,,
13315,,
13316,,
13317,,
13318,,
13319,,
13320,,
13321,,
13322,,
13323,,
13324,,
13325,,
13326,,
13327,,
13328,,
13329,,
13330,,
13331,,
13332,,
13333,,
13334,,
13335,,
13336,,
13337,,
13338,,
13339,,
13340,,
13341,,
13342,,
13343,,
13344,,
13345,,
13346,,
13347,,
13348,,
13349,,
13350,,
13351,,
13352,,
13353,,
13354,,
13355,,
13356,,
13357,,
13358,,
13359,,
13360,,
13361,,
13362,,
13363,,
13364,,
13365,,
13366,,
13367,,
13368,,
13369,,
13370,,
13371,,
13372,,
13373,,
13374,,
13375,,
13376,,
13377,,
13378,,
13379,,
13380,,
13381,,
13382,,
13383,,
13384,,
13385,,
13386,,
13387,,
13388,,
13389,,
13390,,
13391,,
13392,,
13393,,
13394,,
13395,,
13396,,
13397,,
13398,,
13399,,
13400,,
13401,,
13402,,
13403,,
13404,,
13405,,
13406,,
13407,,
13408,,
13409,,
13410,,
13411,,
13412,,
13413,,
13414,,
13415,,
13416,,
13417,,
13418,,
13419,,
13420,,
13421,,
13422,,
13423,,
13424,,
13425,,
13426,,
13427,,
13428,,
13429,,
13430,,
13431,,
13432,,
13433,,
13434,,
13435,,
13436,,
13437,,
13438,,
13439,,
13440,,
13441,,
13442,,
13443,,
13444,,
13445,,
13446,,
13447,,
13448,,
13449,,
13450,,
13451,,
13452,,
13453,,
13454,,
13455,,
13456,,
13457,,
13458,,
13459,,
13460,,
13461,,
13462,,
13463,,
13464,,
13465,,
13466,,
13467,,
13468,,
13469,,
13470,,
13471,,
13472,,
13473,,
13474,,
13475,,
13476,,
13477,,
13478,,
13479,,
13480,,
13481,,
13482,,
13483,,
13484,,
13485,,
13486,,
13487,,
13488,,
13489,,
13490,,
13491,,
13492,,
13493,,
13494,,
13495,,
13496,,
13497,,
13498,,
13499,,
13500,,
13501,,
13502,,
13503,,
13504,,
13505,,
13506,,
13507,,
13508,,
13509,,
13510,,
13511,,
13512,,
13513,,
13514,,
13515,,
13516,,
13517,,
13518,,
13519,,
13520,,
13521,,
13522,,
13523,,
13524,,
13525,,
13526,,
13527,,
13528,,
13529,,
13530,,
13531,,
13532,,
13533,,
13534,,
13535,,
13536,,
13537,,
13538,,
13539,,
13540,,
13541,,
13542,,
13543,,
13544,,
13545,,
13546,,
13547,,
13548,,
13549,,
13550,,
13551,,
13552,,
13553,,
13554,,
13555,,
13556,,
13557,,
13558,,
13559,,
13560,,
13561,,
13562,,
13563,,
13564,,
13565,,
13566,,
13567,,
13568,,
13569,,
13570,,
13571,,
13572,,
13573,,
13574,,
13575,,
13576,,
13577,,
13578,,
13579,,
13580,,
13581,,
13582,,
13583,,
13584,,
13585,,
13586,,
13587,,
13588,,
13589,,
13590,,
13591,,
13592,,
13593,,
13594,,
13595,,
13596,,
13597,,
13598,,
13599,,
13600,,
13601,,
13602,,
13603,,
13604,,
13605,,
13606,,
13607,,
13608,,
13609,,
13610,,
13611,,
13612,,
13613,,
13614,,
13615,,
13616,,
13617,,
13618,,
13619,,
13620,,
13621,,
13622,,
13623,,
13624,,
13625,,
13626,,
13627,,
13628,,
13629,,
13630,,
13631,,
13632,,
13633,,
13634,,
13635,,
13636,,
13637,,
13638,,
13639,,
13640,,
13641,,
13642,,
13643,,
13644,,
13645,,
13646,,
13647,,
13648,,
13649,,
13650,,
13651,,
13652,,
13653,,
13654,,
13655,,
13656,,
13657,,
13658,,
13659,,
13660,,
13661,,
13662,,
13663,,
13664,,
13665,,
13666,,
13667,,
13668,,
13669,,
13670,,
13671,,
13672,,
13673,,
13674,,
13675,,
13676,,
13677,,
13678,,
13679,,
13680,,
13681,,
13682,,
13683,,
13684,,
13685,,
13686,,
13687,,
13688,,
13689,,
13690,,
13691,,
13692,,
13693,,
13694,,
13695,,
13696,,
13697,,
13698,,
13699,,
13700,,
13701,,
13702,,
13703,,
13704,,
13705,,
13706,,
13707,,
13708,,
13709,,
13710,,
13711,,
13712,,
13713,,
13714,,
13715,,
13716,,
13717,,
13718,,
13719,,
13720,,
13721,,
13722,,
13723,,
13724,,
13725,,
13726,,
13727,,
13728,,
13729,,
13730,,
13731,,
13732,,
13733,,
13734,,
13735,,
13736,,
13737,,
13738,,
13739,,
13740,,
13741,,
13742,,
13743,,
13744,,
13745,,
13746,,
13747,,
13748,,
13749,,
13750,,
13751,,
13752,,
13753,,
13754,,
13755,,
13756,,
13757,,
13758,,
13759,,
13760,,
13761,,
13762,,
13763,,
13764,,
13765,,
13766,,
13767,,
13768,,
13769,,
13770,,
13771,,
13772,,
13773,,
13774,,
13775,,
13776,,
13777,,
13778,,
13779,,
13780,,
13781,,
13782,,
13783,,
13784,,
13785,,
13786,,
13787,,
13788,,
13789,,
13790,,
13791,,
13792,,
13793,,
13794,,
13795,,
13796,,
13797,,
13798,,
13799,,
13800,,
13801,,
13802,,
13803,,
13804,,
13805,,
13806,,
13807,,
13808,,
13809,,
13810,,
13811,,
13812,,
13813,,
13814,,
13815,,
13816,,
13817,,
13818,,
13819,,
13820,,
13821,,
13822,,
13823,,
13824,,
13825,,
13826,,
13827,,
13828,,
13829,,
13830,,
13831,,
13832,,
13833,,
13834,,
13835,,
13836,,
13837,,
13838,,
13839,,
13840,,
13841,,
13842,,
13843,,
13844,,
13845,,
13846,,
13847,,
13848,,
13849,,
13850,,
13851,,
13852,,
13853,,
13854,,
13855,,
13856,,
13857,,
13858,,
13859,,
13860,,
13861,,
13862,,
13863,,
13864,,
13865,,
13866,,
13867,,
13868,,
13869,,
13870,,
13871,,
13872,,
13873,,
13874,,
13875,,
13876,,
13877,,
13878,,
13879,,
13880,,
13881,,
13882,,
13883,,
13884,,
13885,,
13886,,
13887,,
13888,,
13889,,
13890,,
13891,,
13892,,
13893,,
13894,,
13895,,
13896,,
13897,,
13898,,
13899,,
13900,,
13901,,
13902,,
13903,,
13904,,
13905,,
13906,,
13907,,
13908,,
13909,,
13910,,
13911,,
13912,,
13913,,
13914,,
13915,,
13916,,
13917,,
13918,,
13919,,
13920,,
13921,,
13922,,
13923,,
13924,,
13925,,
13926,,
13927,,
13928,,
13929,,
13930,,
13931,,
13932,,
13933,,
13934,,
13935,,
13936,,
13937,,
13938,,
13939,,
13940,,
13941,,
13942,,
13943,,
13944,,
13945,,
13946,,
13947,,
13948,,
13949,,
13950,,
13951,,
13952,,
13953,,
13954,,
13955,,
13956,,
13957,,
13958,,
13959,,
13960,,
13961,,
13962,,
13963,,
13964,,
13965,,
13966,,
13967,,
13968,,
13969,,
13970,,
13971,,
13972,,
13973,,
13974,,
13975,,
13976,,
13977,,
13978,,
13979,,
13980,,
13981,,
13982,,
13983,,
13984,,
13985,,
13986,,
13987,,
13988,,
13989,,
13990,,
13991,,
13992,,
13993,,
13994,,
13995,,
13996,,
13997,,
13998,,
13999,,
14000,,
14001,,
14002,,
14003,,
14004,,
14005,,
14006,,
14007,,
14008,,
14009,,
14010,,
14011,,
14012,,
14013,,
14014,,
14015,,
14016,,
14017,,
14018,,
14019,,
14020,,
14021,,
14022,,
14023,,
14024,,
14025,,
14026,,
14027,,
14028,,
14029,,
14030,,
14031,,
14032,,
14033,,
14034,,
14035,,
14036,,
14037,,
14038,,
14039,,
14040,,
14041,,
14042,,
14043,,
14044,,
14045,,
14046,,
14047,,
14048,,
14049,,
14050,,
14051,,
14052,,
14053,,
14054,,
14055,,
14056,,
14057,,
14058,,
14059,,
14060,,
14061,,
14062,,
14063,,
14064,,
14065,,
14066,,
14067,,
14068,,
14069,,
14070,,
14071,,
14072,,
14073,,
14074,,
14075,,
14076,,
14077,,
14078,,
14079,,
14080,,
14081,,
14082,,
14083,,
14084,,
14085,,
14086,,
14087,,
14088,,
14089,,
14090,,
14091,,
14092,,
14093,,
14094,,
14095,,
14096,,
14097,,
14098,,
14099,,
14100,,
14101,,
14102,,
14103,,
14104,,
14105,,
14106,,
14107,,
14108,,
14109,,
14110,,
14111,,
14112,,
14113,,
14114,,
14115,,
14116,,
14117,,
14118,,
14119,,
14120,,
14121,,
14122,,
14123,,
14124,,
14125,,
14126,,
14127,,
14128,,
14129,,
14130,,
14131,,
14132,,
14133,,
14134,,
14135,,
14136,,
14137,,
14138,,
14139,,
14140,,
14141,,
14142,,
14143,,
14144,,
14145,,
14146,,
14147,,
14148,,
14149,,
14150,,
14151,,
14152,,
14153,,
14154,,
14155,,
14156,,
14157,,
14158,,
14159,,
14160,,
14161,,
14162,,
14163,,
14164,,
14165,,
14166,,
14167,,
14168,,
14169,,
14170,,
14171,,
14172,,
14173,,
14174,,
14175,,
14176,,
14177,,
14178,,
14179,,
14180,,
14181,,
14182,,
14183,,
14184,,
14185,,
14186,,
14187,,
14188,,
14189,,
14190,,
14191,,
14192,,
14193,,
14194,,
14195,,
14196,,
14197,,
14198,,
14199,,
14200,,
14201,,
14202,,
14203,,
14204,,
14205,,
14206,,
14207,,
14208,,
14209,,
14210,,
14211,,
14212,,
14213,,
14214,,
14215,,
14216,,
14217,,
14218,,
14219,,
14220,,
14221,,
14222,,
14223,,
14224,,
14225,,
14226,,
14227,,
14228,,
14229,,
14230,,
14231,,
14232,,
14233,,
14234,,
14235,,
14236,,
14237,,
14238,,
14239,,
14240,,
14241,,
14242,,
14243,,
14244,,
14245,,
14246,,
14247,,
14248,,
14249,,
14250,,
14251,,
14252,,
14253,,
14254,,
14255,,
14256,,
14257,,
14258,,
14259,,
14260,,
14261,,
14262,,
14263,,
14264,,
14265,,
14266,,
14267,,
14268,,
14269,,
14270,,
14271,,
14272,,
14273,,
14274,,
14275,,
14276,,
14277,,
14278,,
14279,,
14280,,
14281,,
14282,,
14283,,
14284,,
14285,,
14286,,
14287,,
14288,,
14289,,
14290,,
14291,,
14292,,
14293,,
14294,,
14295,,
14296,,
14297,,
14298,,
14299,,
14300,,
14301,,
14302,,
14303,,
14304,,
14305,,
14306,,
14307,,
14308,,
14309,,
14310,,
14311,,
14312,,
14313,,
14314,,
14315,,
14316,,
14317,,
14318,,
14319,,
14320,,
14321,,
14322,,
14323,,
14324,,
14325,,
14326,,
14327,,
14328,,
14329,,
14330,,
14331,,
14332,,
14333,,
14334,,
14335,,
14336,,
14337,,
14338,,
14339,,
14340,,
14341,,
14342,,
14343,,
14344,,
14345,,
14346,,
14347,,
14348,,
14349,,
14350,,
14351,,
14352,,
14353,,
14354,,
14355,,
14356,,
14357,,
14358,,
14359,,
14360,,
14361,,
14362,,
14363,,
14364,,
14365,,
14366,,
14367,,
14368,,
14369,,
14370,,
14371,,
14372,,
14373,,
14374,,
14375,,
14376,,
14377,,
14378,,
14379,,
14380,,
14381,,
14382,,
14383,,
14384,,
14385,,
14386,,
14387,,
14388,,
14389,,
14390,,
14391,,
14392,,
14393,,
14394,,
14395,,
14396,,
14397,,
14398,,
14399,,
14400,,
14401,,
14402,,
14403,,
14404,,
14405,,
14406,,
14407,,
14408,,
14409,,
14410,,
14411,,
14412,,
14413,,
14414,,
14415,,
14416,,
14417,,
14418,,
14419,,
14420,,
14421,,
14422,,
14423,,
14424,,
14425,,
14426,,
14427,,
14428,,
14429,,
14430,,
14431,,
14432,,
14433,,
14434,,
14435,,
14436,,
14437,,
14438,,
14439,,
14440,,
14441,,
14442,,
14443,,
14444,,
14445,,
14446,,
14447,,
14448,,
14449,,
14450,,
14451,,
14452,,
14453,,
14454,,
14455,,
14456,,
14457,,
14458,,
14459,,
14460,,
14461,,
14462,,
14463,,
14464,,
14465,,
14466,,
14467,,
14468,,
14469,,
14470,,
14471,,
14472,,
14473,,
14474,,
14475,,
14476,,
14477,,
14478,,
14479,,
14480,,
14481,,
14482,,
14483,,
14484,,
14485,,
14486,,
14487,,
14488,,
14489,,
14490,,
14491,,
14492,,
14493,,
14494,,
14495,,
14496,,
14497,,
14498,,
14499,,
14500,,
14501,,
14502,,
14503,,
14504,,
14505,,
14506,,
14507,,
14508,,
14509,,
14510,,
14511,,
14512,,
14513,,
14514,,
14515,,
14516,,
14517,,
14518,,
14519,,
14520,,
14521,,
14522,,
14523,,
14524,,
14525,,
14526,,
14527,,
14528,,
14529,,
14530,,
14531,,
14532,,
14533,,
14534,,
14535,,
14536,,
14537,,
14538,,
14539,,
14540,,
14541,,
14542,,
14543,,
14544,,
14545,,
14546,,
14547,,
14548,,
14549,,
14550,,
14551,,
14552,,
14553,,
14554,,
14555,,
14556,,
14557,,
14558,,
14559,,
14560,,
14561,,
14562,,
14563,,
14564,,
14565,,
14566,,
14567,,
14568,,
14569,,
14570,,
14571,,
14572,,
14573,,
14574,,
14575,,
14576,,
14577,,
14578,,
14579,,
14580,,
14581,,
14582,,
14583,,
14584,,
14585,,
14586,,
14587,,
14588,,
14589,,
14590,,
14591,,
14592,,
14593,,
14594,,
14595,,
14596,,
14597,,
14598,,
14599,,
14600,,
14601,,
14602,,
14603,,
14604,,
14605,,
14606,,
14607,,
14608,,
14609,,
14610,,
14611,,
14612,,
14613,,
14614,,
14615,,
14616,,
14617,,
14618,,
14619,,
14620,,
14621,,
14622,,
14623,,
14624,,
14625,,
14626,,
14627,,
14628,,
14629,,
14630,,
14631,,
14632,,
14633,,
14634,,
14635,,
14636,,
14637,,
14638,,
14639,,
14640,,
14641,,
14642,,
14643,,
14644,,
14645,,
14646,,
14647,,
14648,,
14649,,
14650,,
14651,,
14652,,
14653,,
14654,,
14655,,
14656,,
14657,,
14658,,
14659,,
14660,,
14661,,
14662,,
14663,,
14664,,
14665,,
14666,,
14667,,
14668,,
14669,,
14670,,
14671,,
14672,,
14673,,
14674,,
14675,,
14676,,
14677,,
14678,,
14679,,
14680,,
14681,,
14682,,
14683,,
14684,,
14685,,
14686,,
14687,,
14688,,
14689,,
14690,,
14691,,
14692,,
14693,,
14694,,
14695,,
14696,,
14697,,
14698,,
14699,,
14700,,
14701,,
14702,,
14703,,
14704,,
14705,,
14706,,
14707,,
14708,,
14709,,
14710,,
14711,,
14712,,
14713,,
14714,,
14715,,
14716,,
14717,,
14718,,
14719,,
14720,,
14721,,
14722,,
14723,,
14724,,
14725,,
14726,,
14727,,
14728,,
14729,,
14730,,
14731,,
14732,,
14733,,
14734,,
14735,,
14736,,
14737,,
14738,,
14739,,
14740,,
14741,,
14742,,
14743,,
14744,,
14745,,
14746,,
14747,,
14748,,
14749,,
14750,,
14751,,
14752,,
14753,,
14754,,
14755,,
14756,,
14757,,
14758,,
14759,,
14760,,
14761,,
14762,,
14763,,
14764,,
14765,,
14766,,
14767,,
14768,,
14769,,
14770,,
14771,,
14772,,
14773,,
14774,,
14775,,
14776,,
14777,,
14778,,
14779,,
14780,,
14781,,
14782,,
14783,,
14784,,
14785,,
14786,,
14787,,
14788,,
14789,,
14790,,
14791,,
14792,,
14793,,
14794,,
14795,,
14796,,
14797,,
14798,,
14799,,
14800,,
14801,,
14802,,
14803,,
14804,,
14805,,
14806,,
14807,,
14808,,
14809,,
14810,,
14811,,
14812,,
14813,,
14814,,
14815,,
14816,,
14817,,
14818,,
14819,,
14820,,
14821,,
14822,,
14823,,
14824,,
14825,,
14826,,
14827,,
14828,,
14829,,
14830,,
14831,,
14832,,
14833,,
14834,,
14835,,
14836,,
14837,,
14838,,
14839,,
14840,,
14841,,
14842,,
14843,,
14844,,
14845,,
14846,,
14847,,
14848,,
14849,,
14850,,
14851,,
14852,,
14853,,
14854,,
14855,,
14856,,
14857,,
14858,,
14859,,
14860,,
14861,,
14862,,
14863,,
14864,,
14865,,
14866,,
14867,,
14868,,
14869,,
14870,,
14871,,
14872,,
14873,,
14874,,
14875,,
14876,,
14877,,
14878,,
14879,,
14880,,
14881,,
14882,,
14883,,
14884,,
14885,,
14886,,
14887,,
14888,,
14889,,
14890,,
14891,,
14892,,
14893,,
14894,,
14895,,
14896,,
14897,,
14898,,
14899,,
14900,,
14901,,
14902,,
14903,,
14904,,
14905,,
14906,,
14907,,
14908,,
14909,,
14910,,
14911,,
14912,,
14913,,
14914,,
14915,,
14916,,
14917,,
14918,,
14919,,
14920,,
14921,,
14922,,
14923,,
14924,,
14925,,
14926,,
14927,,
14928,,
14929,,
14930,,
14931,,
14932,,
14933,,
14934,,
14935,,
14936,,
14937,,
14938,,
14939,,
14940,,
14941,,
14942,,
14943,,
14944,,
14945,,
14946,,
14947,,
14948,,
14949,,
14950,,
14951,,
14952,,
14953,,
14954,,
14955,,
14956,,
14957,,
14958,,
14959,,
14960,,
14961,,
14962,,
14963,,
14964,,
14965,,
14966,,
14967,,
14968,,
14969,,
14970,,
14971,,
14972,,
14973,,
14974,,
14975,,
14976,,
14977,,
14978,,
14979,,
14980,,
14981,,
14982,,
14983,,
14984,,
14985,,
14986,,
14987,,
14988,,
14989,,
14990,,
14991,,
14992,,
14993,,
14994,,
14995,,
14996,,
14997,,
14998,,
14999,,
15000,,
15001,,
15002,,
15003,,
15004,,
15005,,
15006,,
15007,,
15008,,
15009,,
15010,,
15011,,
15012,,
15013,,
15014,,
15015,,
15016,,
15017,,
15018,,
15019,,
15020,,
15021,,
15022,,
15023,,
15024,,
15025,,
15026,,
15027,,
15028,,
15029,,
15030,,
15031,,
15032,,
15033,,
15034,,
15035,,
15036,,
15037,,
15038,,
15039,,
15040,,
15041,,
15042,,
15043,,
15044,,
15045,,
15046,,
15047,,
15048,,
15049,,
15050,,
15051,,
15052,,
15053,,
15054,,
15055,,
15056,,
15057,,
15058,,
15059,,
15060,,
15061,,
15062,,
15063,,
15064,,
15065,,
15066,,
15067,,
15068,,
15069,,
15070,,
15071,,
15072,,
15073,,
15074,,
15075,,
15076,,
15077,,
15078,,
15079,,
15080,,
15081,,
15082,,
15083,,
15084,,
15085,,
15086,,
15087,,
15088,,
15089,,
15090,,
15091,,
15092,,
15093,,
15094,,
15095,,
15096,,
15097,,
15098,,
15099,,
15100,,
15101,,
15102,,
15103,,
15104,,
15105,,
15106,,
15107,,
15108,,
15109,,
15110,,
15111,,
15112,,
15113,,
15114,,
15115,,
15116,,
15117,,
15118,,
15119,,
15120,,
15121,,
15122,,
15123,,
15124,,
15125,,
15126,,
15127,,
15128,,
15129,,
15130,,
15131,,
15132,,
15133,,
15134,,
15135,,
15136,,
15137,,
15138,,
15139,,
15140,,
15141,,
15142,,
15143,,
15144,,
15145,,
15146,,
15147,,
15148,,
15149,,
15150,,
15151,,
15152,,
15153,,
15154,,
15155,,
15156,,
15157,,
15158,,
15159,,
15160,,
15161,,
15162,,
15163,,
15164,,
15165,,
15166,,
15167,,
15168,,
15169,,
15170,,
15171,,
15172,,
15173,,
15174,,
15175,,
15176,,
15177,,
15178,,
15179,,
15180,,
15181,,
15182,,
15183,,
15184,,
15185,,
15186,,
15187,,
15188,,
15189,,
15190,,
15191,,
15192,,
15193,,
15194,,
15195,,
15196,,
15197,,
15198,,
15199,,
15200,,
15201,,
15202,,
15203,,
15204,,
15205,,
15206,,
15207,,
15208,,
15209,,
15210,,
15211,,
15212,,
15213,,
15214,,
15215,,
15216,,
15217,,
15218,,
15219,,
15220,,
15221,,
15222,,
15223,,
15224,,
15225,,
15226,,
15227,,
15228,,
15229,,
15230,,
15231,,
15232,,
15233,,
15234,,
15235,,
15236,,
15237,,
15238,,
15239,,
15240,,
15241,,
15242,,
15243,,
15244,,
15245,,
15246,,
15247,,
15248,,
15249,,
15250,,
15251,,
15252,,
15253,,
15254,,
15255,,
15256,,
15257,,
15258,,
15259,,
15260,,
15261,,
15262,,
15263,,
15264,,
15265,,
15266,,
15267,,
15268,,
15269,,
15270,,
15271,,
15272,,
15273,,
15274,,
15275,,
15276,,
15277,,
15278,,
15279,,
15280,,
15281,,
15282,,
15283,,
15284,,
15285,,
15286,,
15287,,
15288,,
15289,,
15290,,
15291,,
15292,,
15293,,
15294,,
15295,,
15296,,
15297,,
15298,,
15299,,
15300,,
15301,,
15302,,
15303,,
15304,,
15305,,
15306,,
15307,,
15308,,
15309,,
15310,,
15311,,
15312,,
15313,,
15314,,
15315,,
15316,,
15317,,
15318,,
15319,,
15320,,
15321,,
15322,,
15323,,
15324,,
15325,,
15326,,
15327,,
15328,,
15329,,
15330,,
15331,,
15332,,
15333,,
15334,,
15335,,
15336,,
15337,,
15338,,
15339,,
15340,,
15341,,
15342,,
15343,,
15344,,
15345,,
15346,,
15347,,
15348,,
15349,,
15350,,
15351,,
15352,,
15353,,
15354,,
15355,,
15356,,
15357,,
15358,,
15359,,
15360,,
15361,,
15362,,
15363,,
15364,,
15365,,
15366,,
15367,,
15368,,
15369,,
15370,,
15371,,
15372,,
15373,,
15374,,
15375,,
15376,,
15377,,
15378,,
15379,,
15380,,
15381,,
15382,,
15383,,
15384,,
15385,,
15386,,
15387,,
15388,,
15389,,
15390,,
15391,,
15392,,
15393,,
15394,,
15395,,
15396,,
15397,,
15398,,
15399,,
15400,,
15401,,
15402,,
15403,,
15404,,
15405,,
15406,,
15407,,
15408,,
15409,,
15410,,
15411,,
15412,,
15413,,
15414,,
15415,,
15416,,
15417,,
15418,,
15419,,
15420,,
15421,,
15422,,
15423,,
15424,,
15425,,
15426,,
15427,,
15428,,
15429,,
15430,,
15431,,
15432,,
15433,,
15434,,
15435,,
15436,,
15437,,
15438,,
15439,,
15440,,
15441,,
15442,,
15443,,
15444,,
15445,,
15446,,
15447,,
15448,,
15449,,
15450,,
15451,,
15452,,
15453,,
15454,,
15455,,
15456,,
15457,,
15458,,
15459,,
15460,,
15461,,
15462,,
15463,,
15464,,
15465,,
15466,,
15467,,
15468,,
15469,,
15470,,
15471,,
15472,,
15473,,
15474,,
15475,,
15476,,
15477,,
15478,,
15479,,
15480,,
15481,,
15482,,
15483,,
15484,,
15485,,
15486,,
15487,,
15488,,
15489,,
15490,,
15491,,
15492,,
15493,,
15494,,
15495,,
15496,,
15497,,
15498,,
15499,,
15500,,
15501,,
15502,,
15503,,
15504,,
15505,,
15506,,
15507,,
15508,,
15509,,
15510,,
15511,,
15512,,
15513,,
15514,,
15515,,
15516,,
15517,,
15518,,
15519,,
15520,,
15521,,
15522,,
15523,,
15524,,
15525,,
15526,,
15527,,
15528,,
15529,,
15530,,
15531,,
15532,,
15533,,
15534,,
15535,,
15536,,
15537,,
15538,,
15539,,
15540,,
15541,,
15542,,
15543,,
15544,,
15545,,
15546,,
15547,,
15548,,
15549,,
15550,,
15551,,
15552,,
15553,,
15554,,
15555,,
15556,,
15557,,
15558,,
15559,,
15560,,
15561,,
15562,,
15563,,
15564,,
15565,,
15566,,
15567,,
15568,,
15569,,
15570,,
15571,,
15572,,
15573,,
15574,,
15575,,
15576,,
15577,,
15578,,
15579,,
15580,,
15581,,
15582,,
15583,,
15584,,
15585,,
15586,,
15587,,
15588,,
15589,,
15590,,
15591,,
15592,,
15593,,
15594,,
15595,,
15596,,
15597,,
15598,,
15599,,
15600,,
15601,,
15602,,
15603,,
15604,,
15605,,
15606,,
15607,,
15608,,
15609,,
15610,,
15611,,
15612,,
15613,,
15614,,
15615,,
15616,,
15617,,
15618,,
15619,,
15620,,
15621,,
15622,,
15623,,
15624,,
15625,,
15626,,
15627,,
15628,,
15629,,
15630,,
15631,,
15632,,
15633,,
15634,,
15635,,
15636,,
15637,,
15638,,
15639,,
15640,,
15641,,
15642,,
15643,,
15644,,
15645,,
15646,,
15647,,
15648,,
15649,,
15650,,
15651,,
15652,,
15653,,
15654,,
15655,,
15656,,
15657,,
15658,,
15659,,
15660,,
15661,,
15662,,
15663,,
15664,,
15665,,
15666,,
15667,,
15668,,
15669,,
15670,,
15671,,
15672,,
15673,,
15674,,
15675,,
15676,,
15677,,
15678,,
15679,,
15680,,
15681,,
15682,,
15683,,
15684,,
15685,,
15686,,
15687,,
15688,,
15689,,
15690,,
15691,,
15692,,
15693,,
15694,,
15695,,
15696,,
15697,,
15698,,
15699,,
15700,,
15701,,
15702,,
15703,,
15704,,
15705,,
15706,,
15707,,
15708,,
15709,,
15710,,
15711,,
15712,,
15713,,
15714,,
15715,,
15716,,
15717,,
15718,,
15719,,
15720,,
15721,,
15722,,
15723,,
15724,,
15725,,
15726,,
15727,,
15728,,
15729,,
15730,,
15731,,
15732,,
15733,,
15734,,
15735,,
15736,,
15737,,
15738,,
15739,,
15740,,
15741,,
15742,,
15743,,
15744,,
15745,,
15746,,
15747,,
15748,,
15749,,
15750,,
15751,,
15752,,
15753,,
15754,,
15755,,
15756,,
15757,,
15758,,
15759,,
15760,,
15761,,
15762,,
15763,,
15764,,
15765,,
15766,,
15767,,
15768,,
15769,,
15770,,
15771,,
15772,,
15773,,
15774,,
15775,,
15776,,
15777,,
15778,,
15779,,
15780,,
15781,,
15782,,
15783,,
15784,,
15785,,
15786,,
15787,,
15788,,
15789,,
15790,,
15791,,
15792,,
15793,,
15794,,
15795,,
15796,,
15797,,
15798,,
15799,,
15800,,
15801,,
15802,,
15803,,
15804,,
15805,,
15806,,
15807,,
15808,,
15809,,
15810,,
15811,,
15812,,
15813,,
15814,,
15815,,
15816,,
15817,,
15818,,
15819,,
15820,,
15821,,
15822,,
15823,,
15824,,
15825,,
15826,,
15827,,
15828,,
15829,,
15830,,
15831,,
15832,,
15833,,
15834,,
15835,,
15836,,
15837,,
15838,,
15839,,
15840,,
15841,,
15842,,
15843,,
15844,,
15845,,
15846,,
15847,,
15848,,
15849,,
15850,,
15851,,
15852,,
15853,,
15854,,
15855,,
15856,,
15857,,
15858,,
15859,,
15860,,
15861,,
15862,,
15863,,
15864,,
15865,,
15866,,
15867,,
15868,,
15869,,
15870,,
15871,,
15872,,
15873,,
15874,,
15875,,
15876,,
15877,,
15878,,
15879,,
15880,,
15881,,
15882,,
15883,,
15884,,
15885,,
15886,,
15887,,
15888,,
15889,,
15890,,
15891,,
15892,,
15893,,
15894,,
15895,,
15896,,
15897,,
15898,,
15899,,
15900,,
15901,,
15902,,
15903,,
15904,,
15905,,
15906,,
15907,,
15908,,
15909,,
15910,,
15911,,
15912,,
15913,,
15914,,
15915,,
15916,,
15917,,
15918,,
15919,,
15920,,
15921,,
15922,,
15923,,
15924,,
15925,,
15926,,
15927,,
15928,,
15929,,
15930,,
15931,,
15932,,
15933,,
15934,,
15935,,
15936,,
15937,,
15938,,
15939,,
15940,,
15941,,
15942,,
15943,,
15944,,
15945,,
15946,,
15947,,
15948,,
15949,,
15950,,
15951,,
15952,,
15953,,
15954,,
15955,,
15956,,
15957,,
15958,,
15959,,
15960,,
15961,,
15962,,
15963,,
15964,,
15965,,
15966,,
15967,,
15968,,
15969,,
15970,,
15971,,
15972,,
15973,,
15974,,
15975,,
15976,,
15977,,
15978,,
15979,,
15980,,
15981,,
15982,,
15983,,
15984,,
15985,,
15986,,
15987,,
15988,,
15989,,
15990,,
15991,,
15992,,
15993,,
15994,,
15995,,
15996,,
15997,,
15998,,
15999,,
16000,,
16001,,
16002,,
16003,,
16004,,
16005,,
16006,,
16007,,
16008,,
16009,,
16010,,
16011,,
16012,,
16013,,
16014,,
16015,,
16016,,
16017,,
16018,,
16019,,
16020,,
16021,,
16022,,
16023,,
16024,,
16025,,
16026,,
16027,,
16028,,
16029,,
16030,,
16031,,
16032,,
16033,,
16034,,
16035,,
16036,,
16037,,
16038,,
16039,,
16040,,
16041,,
16042,,
16043,,
16044,,
16045,,
16046,,
16047,,
16048,,
16049,,
16050,,
16051,,
16052,,
16053,,
16054,,
16055,,
16056,,
16057,,
16058,,
16059,,
16060,,
16061,,
16062,,
16063,,
16064,,
16065,,
16066,,
16067,,
16068,,
16069,,
16070,,
16071,,
16072,,
16073,,
16074,,
16075,,
16076,,
16077,,
16078,,
16079,,
16080,,
16081,,
16082,,
16083,,
16084,,
16085,,
16086,,
16087,,
16088,,
16089,,
16090,,
16091,,
16092,,
16093,,
16094,,
16095,,
16096,,
16097,,
16098,,
16099,,
16100,,
16101,,
16102,,
16103,,
16104,,
16105,,
16106,,
16107,,
16108,,
16109,,
16110,,
16111,,
16112,,
16113,,
16114,,
16115,,
16116,,
16117,,
16118,,
16119,,
16120,,
16121,,
16122,,
16123,,
16124,,
16125,,
16126,,
16127,,
16128,,
16129,,
16130,,
16131,,
16132,,
16133,,
16134,,
16135,,
16136,,
16137,,
16138,,
16139,,
16140,,
16141,,
16142,,
16143,,
16144,,
16145,,
16146,,
16147,,
16148,,
16149,,
16150,,
16151,,
16152,,
16153,,
16154,,
16155,,
16156,,
16157,,
16158,,
16159,,
16160,,
16161,,
16162,,
16163,,
16164,,
16165,,
16166,,
16167,,
16168,,
16169,,
16170,,
16171,,
16172,,
16173,,
16174,,
16175,,
16176,,
16177,,
16178,,
16179,,
16180,,
16181,,
16182,,
16183,,
16184,,
16185,,
16186,,
16187,,
16188,,
16189,,
16190,,
16191,,
16192,,
16193,,
16194,,
16195,,
16196,,
16197,,
16198,,
16199,,
16200,,
16201,,
16202,,
16203,,
16204,,
16205,,
16206,,
16207,,
16208,,
16209,,
16210,,
16211,,
16212,,
16213,,
16214,,
16215,,
16216,,
16217,,
16218,,
16219,,
16220,,
16221,,
16222,,
16223,,
16224,,
16225,,
16226,,
16227,,
16228,,
16229,,
16230,,
16231,,
16232,,
16233,,
16234,,
16235,,
16236,,
16237,,
16238,,
16239,,
16240,,
16241,,
16242,,
16243,,
16244,,
16245,,
16246,,
16247,,
16248,,
16249,,
16250,,
16251,,
16252,,
16253,,
16254,,
16255,,
16256,,
16257,,
16258,,
16259,,
16260,,
16261,,
16262,,
16263,,
16264,,
16265,,
16266,,
16267,,
16268,,
16269,,
16270,,
16271,,
16272,,
16273,,
16274,,
16275,,
16276,,
16277,,
16278,,
16279,,
16280,,
16281,,
16282,,
16283,,
16284,,
16285,,
16286,,
16287,,
16288,,
16289,,
16290,,
16291,,
16292,,
16293,,
16294,,
16295,,
16296,,
16297,,
16298,,
16299,,
16300,,
16301,,
16302,,
16303,,
16304,,
16305,,
16306,,
16307,,
16308,,
16309,,
16310,,
16311,,
16312,,
16313,,
16314,,
16315,,
16316,,
16317,,
16318,,
16319,,
16320,,
16321,,
16322,,
16323,,
16324,,
16325,,
16326,,
16327,,
16328,,
16329,,
16330,,
16331,,
16332,,
16333,,
16334,,
16335,,
16336,,
16337,,
16338,,
16339,,
16340,,
16341,,
16342,,
16343,,
16344,,
16345,,
16346,,
16347,,
16348,,
16349,,
16350,,
16351,,
16352,,
16353,,
16354,,
16355,,
16356,,
16357,,
16358,,
16359,,
16360,,
16361,,
16362,,
16363,,
16364,,
16365,,
16366,,
16367,,
16368,,
16369,,
16370,,
16371,,
16372,,
16373,,
16374,,
16375,,
16376,,
16377,,
16378,,
16379,,
16380,,
16381,,
16382,,
16383,,
16384,,
16385,,
16386,,
16387,,
16388,,
16389,,
16390,,
16391,,
16392,,
16393,,
16394,,
16395,,
16396,,
16397,,
16398,,
16399,,
16400,,
16401,,
16402,,
16403,,
16404,,
16405,,
16406,,
16407,,
16408,,
16409,,
16410,,
16411,,
16412,,
16413,,
16414,,
16415,,
16416,,
16417,,
16418,,
16419,,
16420,,
16421,,
16422,,
16423,,
16424,,
16425,,
16426,,
16427,,
16428,,
16429,,
16430,,
16431,,
16432,,
16433,,
16434,,
16435,,
16436,,
16437,,
16438,,
16439,,
16440,,
16441,,
16442,,
16443,,
16444,,
16445,,
16446,,
16447,,
16448,,
16449,,
16450,,
16451,,
16452,,
16453,,
16454,,
16455,,
16456,,
16457,,
16458,,
16459,,
16460,,
16461,,
16462,,
16463,,
16464,,
16465,,
16466,,
16467,,
16468,,
16469,,
16470,,
16471,,
16472,,
16473,,
16474,,
16475,,
16476,,
16477,,
16478,,
16479,,
16480,,
16481,,
16482,,
16483,,
16484,,
16485,,
16486,,
16487,,
16488,,
16489,,
16490,,
16491,,
16492,,
16493,,
16494,,
16495,,
16496,,
16497,,
16498,,
16499,,
16500,,
16501,,
16502,,
16503,,
16504,,
16505,,
16506,,
16507,,
16508,,
16509,,
16510,,
16511,,
16512,,
16513,,
16514,,
16515,,
16516,,
16517,,
16518,,
16519,,
16520,,
16521,,
16522,,
16523,,
16524,,
16525,,
16526,,
16527,,
16528,,
16529,,
16530,,
16531,,
16532,,
16533,,
16534,,
16535,,
16536,,
16537,,
16538,,
16539,,
16540,,
16541,,
16542,,
16543,,
16544,,
16545,,
16546,,
16547,,
16548,,
16549,,
16550,,
16551,,
16552,,
16553,,
16554,,
16555,,
16556,,
16557,,
16558,,
16559,,
16560,,
16561,,
16562,,
16563,,
16564,,
16565,,
16566,,
16567,,
16568,,
16569,,
16570,,
16571,,
16572,,
16573,,
16574,,
16575,,
16576,,
16577,,
16578,,
16579,,
16580,,
16581,,
16582,,
16583,,
16584,,
16585,,
16586,,
16587,,
16588,,
16589,,
16590,,
16591,,
16592,,
16593,,
16594,,
16595,,
16596,,
16597,,
16598,,
16599,,
16600,,
16601,,
16602,,
16603,,
16604,,
16605,,
16606,,
16607,,
16608,,
16609,,
16610,,
16611,,
16612,,
16613,,
16614,,
16615,,
16616,,
16617,,
16618,,
16619,,
16620,,
16621,,
16622,,
16623,,
16624,,
16625,,
16626,,
16627,,
16628,,
16629,,
16630,,
16631,,
16632,,
16633,,
16634,,
16635,,
16636,,
16637,,
16638,,
16639,,
16640,,
16641,,
16642,,
16643,,
16644,,
16645,,
16646,,
16647,,
16648,,
16649,,
16650,,
16651,,
16652,,
16653,,
16654,,
16655,,
16656,,
16657,,
16658,,
16659,,
16660,,
16661,,
16662,,
16663,,
16664,,
16665,,
16666,,
16667,,
16668,,
16669,,
16670,,
16671,,
16672,,
16673,,
16674,,
16675,,
16676,,
16677,,
16678,,
16679,,
16680,,
16681,,
16682,,
16683,,
16684,,
16685,,
16686,,
16687,,
16688,,
16689,,
16690,,
16691,,
16692,,
16693,,
16694,,
16695,,
16696,,
16697,,
16698,,
16699,,
16700,,
16701,,
16702,,
16703,,
16704,,
16705,,
16706,,
16707,,
16708,,
16709,,
16710,,
16711,,
16712,,
16713,,
16714,,
16715,,
16716,,
16717,,
16718,,
16719,,
16720,,
16721,,
16722,,
16723,,
16724,,
16725,,
16726,,
16727,,
16728,,
16729,,
16730,,
16731,,
16732,,
16733,,
16734,,
16735,,
16736,,
16737,,
16738,,
16739,,
16740,,
16741,,
16742,,
16743,,
16744,,
16745,,
16746,,
16747,,
16748,,
16749,,
16750,,
16751,,
16752,,
16753,,
16754,,
16755,,
16756,,
16757,,
16758,,
16759,,
16760,,
16761,,
16762,,
16763,,
16764,,
16765,,
16766,,
16767,,
16768,,
16769,,
16770,,
16771,,
16772,,
16773,,
16774,,
16775,,
16776,,
16777,,
16778,,
16779,,
16780,,
16781,,
16782,,
16783,,
16784,,
16785,,
16786,,
16787,,
16788,,
16789,,
16790,,
16791,,
16792,,
16793,,
16794,,
16795,,
16796,,
16797,,
16798,,
16799,,
16800,,
16801,,
16802,,
16803,,
16804,,
16805,,
16806,,
16807,,
16808,,
16809,,
16810,,
16811,,
16812,,
16813,,
16814,,
16815,,
16816,,
16817,,
16818,,
16819,,
16820,,
16821,,
16822,,
16823,,
16824,,
16825,,
16826,,
16827,,
16828,,
16829,,
16830,,
16831,,
16832,,
16833,,
16834,,
16835,,
16836,,
16837,,
16838,,
16839,,
16840,,
16841,,
16842,,
16843,,
16844,,
16845,,
16846,,
16847,,
16848,,
16849,,
16850,,
16851,,
16852,,
16853,,
16854,,
16855,,
16856,,
16857,,
16858,,
16859,,
16860,,
16861,,
16862,,
16863,,
16864,,
16865,,
16866,,
16867,,
16868,,
16869,,
16870,,
16871,,
16872,,
16873,,
16874,,
16875,,
16876,,
16877,,
16878,,
16879,,
16880,,
16881,,
16882,,
16883,,
16884,,
16885,,
16886,,
16887,,
16888,,
16889,,
16890,,
16891,,
16892,,
16893,,
16894,,
16895,,
16896,,
16897,,
16898,,
16899,,
16900,,
16901,,
16902,,
16903,,
16904,,
16905,,
16906,,
16907,,
16908,,
16909,,
16910,,
16911,,
16912,,
16913,,
16914,,
16915,,
16916,,
16917,,
16918,,
16919,,
16920,,
16921,,
16922,,
16923,,
16924,,
16925,,
16926,,
16927,,
16928,,
16929,,
16930,,
16931,,
16932,,
16933,,
16934,,
16935,,
16936,,
16937,,
16938,,
16939,,
16940,,
16941,,
16942,,
16943,,
16944,,
16945,,
16946,,
16947,,
16948,,
16949,,
16950,,
16951,,
16952,,
16953,,
16954,,
16955,,
16956,,
16957,,
16958,,
16959,,
16960,,
16961,,
16962,,
16963,,
16964,,
16965,,
16966,,
16967,,
16968,,
16969,,
16970,,
16971,,
16972,,
16973,,
16974,,
16975,,
16976,,
16977,,
16978,,
16979,,
16980,,
16981,,
16982,,
16983,,
16984,,
16985,,
16986,,
16987,,
16988,,
16989,,
16990,,
16991,,
16992,,
16993,,
16994,,
16995,,
16996,,
16997,,
16998,,
16999,,
17000,,
17001,,
17002,,
17003,,
17004,,
17005,,
17006,,
17007,,
17008,,
17009,,
17010,,
17011,,
17012,,
17013,,
17014,,
17015,,
17016,,
17017,,
17018,,
17019,,
17020,,
17021,,
17022,,
17023,,
17024,,
17025,,
17026,,
17027,,
17028,,
17029,,
17030,,
17031,,
17032,,
17033,,
17034,,
17035,,
17036,,
17037,,
17038,,
17039,,
17040,,
17041,,
17042,,
17043,,
17044,,
17045,,
17046,,
17047,,
17048,,
17049,,
17050,,
17051,,
17052,,
17053,,
17054,,
17055,,
17056,,
17057,,
17058,,
17059,,
17060,,
17061,,
17062,,
17063,,
17064,,
17065,,
17066,,
17067,,
17068,,
17069,,
17070,,
17071,,
17072,,
17073,,
17074,,
17075,,
17076,,
17077,,
17078,,
17079,,
17080,,
17081,,
17082,,
17083,,
17084,,
17085,,
17086,,
17087,,
17088,,
17089,,
17090,,
17091,,
17092,,
17093,,
17094,,
17095,,
17096,,
17097,,
17098,,
17099,,
17100,,
17101,,
17102,,
17103,,
17104,,
17105,,
17106,,
17107,,
17108,,
17109,,
17110,,
17111,,
17112,,
17113,,
17114,,
17115,,
17116,,
17117,,
17118,,
17119,,
17120,,
17121,,
17122,,
17123,,
17124,,
17125,,
17126,,
17127,,
17128,,
17129,,
17130,,
17131,,
17132,,
17133,,
17134,,
17135,,
17136,,
17137,,
17138,,
17139,,
17140,,
17141,,
17142,,
17143,,
17144,,
17145,,
17146,,
17147,,
17148,,
17149,,
17150,,
17151,,
17152,,
17153,,
17154,,
17155,,
17156,,
17157,,
17158,,
17159,,
17160,,
17161,,
17162,,
17163,,
17164,,
17165,,
17166,,
17167,,
17168,,
17169,,
17170,,
17171,,
17172,,
17173,,
17174,,
17175,,
17176,,
17177,,
17178,,
17179,,
17180,,
17181,,
17182,,
17183,,
17184,,
17185,,
17186,,
17187,,
17188,,
17189,,
17190,,
17191,,
17192,,
17193,,
17194,,
17195,,
17196,,
17197,,
17198,,
17199,,
17200,,
17201,,
17202,,
17203,,
17204,,
17205,,
17206,,
17207,,
17208,,
17209,,
17210,,
17211,,
17212,,
17213,,
17214,,
17215,,
17216,,
17217,,
17218,,
17219,,
17220,,
17221,,
17222,,
17223,,
17224,,
17225,,
17226,,
17227,,
17228,,
17229,,
17230,,
17231,,
17232,,
17233,,
17234,,
17235,,
17236,,
17237,,
17238,,
17239,,
17240,,
17241,,
17242,,
17243,,
17244,,
17245,,
17246,,
17247,,
17248,,
17249,,
17250,,
17251,,
17252,,
17253,,
17254,,
17255,,
17256,,
17257,,
17258,,
17259,,
17260,,
17261,,
17262,,
17263,,
17264,,
17265,,
17266,,
17267,,
17268,,
17269,,
17270,,
17271,,
17272,,
17273,,
17274,,
17275,,
17276,,
17277,,
17278,,
17279,,
17280,,
17281,,
17282,,
17283,,
17284,,
17285,,
17286,,
17287,,
17288,,
17289,,
17290,,
17291,,
17292,,
17293,,
17294,,
17295,,
17296,,
17297,,
17298,,
17299,,
17300,,
17301,,
17302,,
17303,,
17304,,
17305,,
17306,,
17307,,
17308,,
17309,,
17310,,
17311,,
17312,,
17313,,
17314,,
17315,,
17316,,
17317,,
17318,,
17319,,
17320,,
17321,,
17322,,
17323,,
17324,,
17325,,
17326,,
17327,,
17328,,
17329,,
17330,,
17331,,
17332,,
17333,,
17334,,
17335,,
17336,,
17337,,
17338,,
17339,,
17340,,
17341,,
17342,,
17343,,
17344,,
17345,,
17346,,
17347,,
17348,,
17349,,
17350,,
17351,,
17352,,
17353,,
17354,,
17355,,
17356,,
17357,,
17358,,
17359,,
17360,,
17361,,
17362,,
17363,,
17364,,
17365,,
17366,,
17367,,
17368,,
17369,,
17370,,
17371,,
17372,,
17373,,
17374,,
17375,,
17376,,
17377,,
17378,,
17379,,
17380,,
17381,,
17382,,
17383,,
17384,,
17385,,
17386,,
17387,,
17388,,
17389,,
17390,,
17391,,
17392,,
17393,,
17394,,
17395,,
17396,,
17397,,
17398,,
17399,,
17400,,
17401,,
17402,,
17403,,
17404,,
17405,,
17406,,
17407,,
17408,,
17409,,
17410,,
17411,,
17412,,
17413,,
17414,,
17415,,
17416,,
17417,,
17418,,
17419,,
17420,,
17421,,
17422,,
17423,,
17424,,
17425,,
17426,,
17427,,
17428,,
17429,,
17430,,
17431,,
17432,,
17433,,
17434,,
17435,,
17436,,
17437,,
17438,,
17439,,
17440,,
17441,,
17442,,
17443,,
17444,,
17445,,
17446,,
17447,,
17448,,
17449,,
17450,,
17451,,
17452,,
17453,,
17454,,
17455,,
17456,,
17457,,
17458,,
17459,,
17460,,
17461,,
17462,,
17463,,
17464,,
17465,,
17466,,
17467,,
17468,,
17469,,
17470,,
17471,,
17472,,
17473,,
17474,,
17475,,
17476,,
17477,,
17478,,
17479,,
17480,,
17481,,
17482,,
17483,,
17484,,
17485,,
17486,,
17487,,
17488,,
17489,,
17490,,
17491,,
17492,,
17493,,
17494,,
17495,,
17496,,
17497,,
17498,,
17499,,
17500,,
17501,,
17502,,
17503,,
17504,,
17505,,
17506,,
17507,,
17508,,
17509,,
17510,,
17511,,
17512,,
17513,,
17514,,
17515,,
17516,,
17517,,
17518,,
17519,,
17520,,
17521,,
17522,,
17523,,
17524,,
17525,,
17526,,
17527,,
17528,,
17529,,
17530,,
17531,,
17532,,
17533,,
17534,,
17535,,
17536,,
17537,,
17538,,
17539,,
17540,,
17541,,
17542,,
17543,,
17544,,
17545,,
17546,,
17547,,
17548,,
17549,,
17550,,
17551,,
17552,,
17553,,
17554,,
17555,,
17556,,
17557,,
17558,,
17559,,
17560,,
17561,,
17562,,
17563,,
17564,,
17565,,
17566,,
17567,,
17568,,
17569,,
17570,,
17571,,
17572,,
17573,,
17574,,
17575,,
17576,,
17577,,
17578,,
17579,,
17580,,
17581,,
17582,,
17583,,
17584,,
17585,,
17586,,
17587,,
17588,,
17589,,
17590,,
17591,,
17592,,
17593,,
17594,,
17595,,
17596,,
17597,,
17598,,
17599,,
17600,,
17601,,
17602,,
17603,,
17604,,
17605,,
17606,,
17607,,
17608,,
17609,,
17610,,
17611,,
17612,,
17613,,
17614,,
17615,,
17616,,
17617,,
17618,,
17619,,
17620,,
17621,,
17622,,
17623,,
17624,,
17625,,
17626,,
17627,,
17628,,
17629,,
17630,,
17631,,
17632,,
17633,,
17634,,
17635,,
17636,,
17637,,
17638,,
17639,,
17640,,
17641,,
17642,,
17643,,
17644,,
17645,,
17646,,
17647,,
17648,,
17649,,
17650,,
17651,,
17652,,
17653,,
17654,,
17655,,
17656,,
17657,,
17658,,
17659,,
17660,,
17661,,
17662,,
17663,,
17664,,
17665,,
17666,,
17667,,
17668,,
17669,,
17670,,
17671,,
17672,,
17673,,
17674,,
17675,,
17676,,
17677,,
17678,,
17679,,
17680,,
17681,,
17682,,
17683,,
17684,,
17685,,
17686,,
17687,,
17688,,
17689,,
17690,,
17691,,
17692,,
17693,,
17694,,
17695,,
17696,,
17697,,
17698,,
17699,,
17700,,
17701,,
17702,,
17703,,
17704,,
17705,,
17706,,
17707,,
17708,,
17709,,
17710,,
17711,,
17712,,
17713,,
17714,,
17715,,
17716,,
17717,,
17718,,
17719,,
17720,,
17721,,
17722,,
17723,,
17724,,
17725,,
17726,,
17727,,
17728,,
17729,,
17730,,
17731,,
17732,,
17733,,
17734,,
17735,,
17736,,
17737,,
17738,,
17739,,
17740,,
17741,,
17742,,
17743,,
17744,,
17745,,
17746,,
17747,,
17748,,
17749,,
17750,,
17751,,
17752,,
17753,,
17754,,
17755,,
17756,,
17757,,
17758,,
17759,,
17760,,
17761,,
17762,,
17763,,
17764,,
17765,,
17766,,
17767,,
17768,,
17769,,
17770,,
17771,,
17772,,
17773,,
17774,,
17775,,
17776,,
17777,,
17778,,
17779,,
17780,,
17781,,
17782,,
17783,,
17784,,
17785,,
17786,,
17787,,
17788,,
17789,,
17790,,
17791,,
17792,,
17793,,
17794,,
17795,,
17796,,
17797,,
17798,,
17799,,
17800,,
17801,,
17802,,
17803,,
17804,,
17805,,
17806,,
17807,,
17808,,
17809,,
17810,,
17811,,
17812,,
17813,,
17814,,
17815,,
17816,,
17817,,
17818,,
17819,,
17820,,
17821,,
17822,,
17823,,
17824,,
17825,,
17826,,
17827,,
17828,,
17829,,
17830,,
17831,,
17832,,
17833,,
17834,,
17835,,
17836,,
17837,,
17838,,
17839,,
17840,,
17841,,
17842,,
17843,,
17844,,
17845,,
17846,,
17847,,
17848,,
17849,,
17850,,
17851,,
17852,,
17853,,
17854,,
17855,,
17856,,
17857,,
17858,,
17859,,
17860,,
17861,,
17862,,
17863,,
17864,,
17865,,
17866,,
17867,,
17868,,
17869,,
17870,,
17871,,
17872,,
17873,,
17874,,
17875,,
17876,,
17877,,
17878,,
17879,,
17880,,
17881,,
17882,,
17883,,
17884,,
17885,,
17886,,
17887,,
17888,,
17889,,
17890,,
17891,,
17892,,
17893,,
17894,,
17895,,
17896,,
17897,,
17898,,
17899,,
17900,,
17901,,
17902,,
17903,,
17904,,
17905,,
17906,,
17907,,
17908,,
17909,,
17910,,
17911,,
17912,,
17913,,
17914,,
17915,,
17916,,
17917,,
17918,,
17919,,
17920,,
17921,,
17922,,
17923,,
17924,,
17925,,
17926,,
17927,,
17928,,
17929,,
17930,,
17931,,
17932,,
17933,,
17934,,
17935,,
17936,,
17937,,
17938,,
17939,,
17940,,
17941,,
17942,,
17943,,
17944,,
17945,,
17946,,
17947,,
17948,,
17949,,
17950,,
17951,,
17952,,
17953,,
17954,,
17955,,
17956,,
17957,,
17958,,
17959,,
17960,,
17961,,
17962,,
17963,,
17964,,
17965,,
17966,,
17967,,
17968,,
17969,,
17970,,
17971,,
17972,,
17973,,
17974,,
17975,,
17976,,
17977,,
17978,,
17979,,
17980,,
17981,,
17982,,
17983,,
17984,,
17985,,
17986,,
17987,,
17988,,
17989,,
17990,,
17991,,
17992,,
17993,,
17994,,
17995,,
17996,,
17997,,
17998,,
17999,,
18000,,
18001,,
18002,,
18003,,
18004,,
18005,,
18006,,
18007,,
18008,,
18009,,
18010,,
18011,,
18012,,
18013,,
18014,,
18015,,
18016,,
18017,,
18018,,
18019,,
18020,,
18021,,
18022,,
18023,,
18024,,
18025,,
18026,,
18027,,
18028,,
18029,,
18030,,
18031,,
18032,,
18033,,
18034,,
18035,,
18036,,
18037,,
18038,,
18039,,
18040,,
18041,,
18042,,
18043,,
18044,,
18045,,
18046,,
18047,,
18048,,
18049,,
18050,,
18051,,
18052,,
18053,,
18054,,
18055,,
18056,,
18057,,
18058,,
18059,,
18060,,
18061,,
18062,,
18063,,
18064,,
18065,,
18066,,
18067,,
18068,,
18069,,
18070,,
18071,,
18072,,
18073,,
18074,,
18075,,
18076,,
18077,,
18078,,
18079,,
18080,,
18081,,
18082,,
18083,,
18084,,
18085,,
18086,,
18087,,
18088,,
18089,,
18090,,
18091,,
18092,,
18093,,
18094,,
18095,,
18096,,
18097,,
18098,,
18099,,
18100,,
18101,,
18102,,
18103,,
18104,,
18105,,
18106,,
18107,,
18108,,
18109,,
18110,,
18111,,
18112,,
18113,,
18114,,
18115,,
18116,,
18117,,
18118,,
18119,,
18120,,
18121,,
18122,,
18123,,
18124,,
18125,,
18126,,
18127,,
18128,,
18129,,
18130,,
18131,,
18132,,
18133,,
18134,,
18135,,
18136,,
18137,,
18138,,
18139,,
18140,,
18141,,
18142,,
18143,,
18144,,
18145,,
18146,,
18147,,
18148,,
18149,,
18150,,
18151,,
18152,,
18153,,
18154,,
18155,,
18156,,
18157,,
18158,,
18159,,
18160,,
18161,,
18162,,
18163,,
18164,,
18165,,
18166,,
18167,,
18168,,
18169,,
18170,,
18171,,
18172,,
18173,,
18174,,
18175,,
18176,,
18177,,
18178,,
18179,,
18180,,
18181,,
18182,,
18183,,
18184,,
18185,,
18186,,
18187,,
18188,,
18189,,
18190,,
18191,,
18192,,
18193,,
18194,,
18195,,
18196,,
18197,,
18198,,
18199,,
18200,,
18201,,
18202,,
18203,,
18204,,
18205,,
18206,,
18207,,
18208,,
18209,,
18210,,
18211,,
18212,,
18213,,
18214,,
18215,,
18216,,
18217,,
18218,,
18219,,
18220,,
18221,,
18222,,
18223,,
18224,,
18225,,
18226,,
18227,,
18228,,
18229,,
18230,,
18231,,
18232,,
18233,,
18234,,
18235,,
18236,,
18237,,
18238,,
18239,,
18240,,
18241,,
18242,,
18243,,
18244,,
18245,,
18246,,
18247,,
18248,,
18249,,
18250,,
18251,,
18252,,
18253,,
18254,,
18255,,
18256,,
18257,,
18258,,
18259,,
18260,,
18261,,
18262,,
18263,,
18264,,
18265,,
18266,,
18267,,
18268,,
18269,,
18270,,
18271,,
18272,,
18273,,
18274,,
18275,,
18276,,
18277,,
18278,,
18279,,
18280,,
18281,,
18282,,
18283,,
18284,,
18285,,
18286,,
18287,,
18288,,
18289,,
18290,,
18291,,
18292,,
18293,,
18294,,
18295,,
18296,,
18297,,
18298,,
18299,,
18300,,
18301,,
18302,,
18303,,
18304,,
18305,,
18306,,
18307,,
18308,,
18309,,
18310,,
18311,,
18312,,
18313,,
18314,,
18315,,
18316,,
18317,,
18318,,
18319,,
18320,,
18321,,
18322,,
18323,,
18324,,
18325,,
18326,,
18327,,
18328,,
18329,,
18330,,
18331,,
18332,,
18333,,
18334,,
18335,,
18336,,
18337,,
18338,,
18339,,
18340,,
18341,,
18342,,
18343,,
18344,,
18345,,
18346,,
18347,,
18348,,
18349,,
18350,,
18351,,
18352,,
18353,,
18354,,
18355,,
18356,,
18357,,
18358,,
18359,,
18360,,
18361,,
18362,,
18363,,
18364,,
18365,,
18366,,
18367,,
18368,,
18369,,
18370,,
18371,,
18372,,
18373,,
18374,,
18375,,
18376,,
18377,,
18378,,
18379,,
18380,,
18381,,
18382,,
18383,,
18384,,
18385,,
18386,,
18387,,
18388,,
18389,,
18390,,
18391,,
18392,,
18393,,
18394,,
18395,,
18396,,
18397,,
18398,,
18399,,
18400,,
18401,,
18402,,
18403,,
18404,,
18405,,
18406,,
18407,,
18408,,
18409,,
18410,,
18411,,
18412,,
18413,,
18414,,
18415,,
18416,,
18417,,
18418,,
18419,,
18420,,
18421,,
18422,,
18423,,
18424,,
18425,,
18426,,
18427,,
18428,,
18429,,
18430,,
18431,,
18432,,
18433,,
18434,,
18435,,
18436,,
18437,,
18438,,
18439,,
18440,,
18441,,
18442,,
18443,,
18444,,
18445,,
18446,,
18447,,
18448,,
18449,,
18450,,
18451,,
18452,,
18453,,
18454,,
18455,,
18456,,
18457,,
18458,,
18459,,
18460,,
18461,,
18462,,
18463,,
18464,,
18465,,
18466,,
18467,,
18468,,
18469,,
18470,,
18471,,
18472,,
18473,,
18474,,
18475,,
18476,,
18477,,
18478,,
18479,,
18480,,
18481,,
18482,,
18483,,
18484,,
18485,,
18486,,
18487,,
18488,,
18489,,
18490,,
18491,,
18492,,
18493,,
18494,,
18495,,
18496,,
18497,,
18498,,
18499,,
18500,,
18501,,
18502,,
18503,,
18504,,
18505,,
18506,,
18507,,
18508,,
18509,,
18510,,
18511,,
18512,,
18513,,
18514,,
18515,,
18516,,
18517,,
18518,,
18519,,
18520,,
18521,,
18522,,
18523,,
18524,,
18525,,
18526,,
18527,,
18528,,
18529,,
18530,,
18531,,
18532,,
18533,,
18534,,
18535,,
18536,,
18537,,
18538,,
18539,,
18540,,
18541,,
18542,,
18543,,
18544,,
18545,,
18546,,
18547,,
18548,,
18549,,
18550,,
18551,,
18552,,
18553,,
18554,,
18555,,
18556,,
18557,,
18558,,
18559,,
18560,,
18561,,
18562,,
18563,,
18564,,
18565,,
18566,,
18567,,
18568,,
18569,,
18570,,
18571,,
18572,,
18573,,
18574,,
18575,,
18576,,
18577,,
18578,,
18579,,
18580,,
18581,,
18582,,
18583,,
18584,,
18585,,
18586,,
18587,,
18588,,
18589,,
18590,,
18591,,
18592,,
18593,,
18594,,
18595,,
18596,,
18597,,
18598,,
18599,,
18600,,
18601,,
18602,,
18603,,
18604,,
18605,,
18606,,
18607,,
18608,,
18609,,
18610,,
18611,,
18612,,
18613,,
18614,,
18615,,
18616,,
18617,,
18618,,
18619,,
18620,,
18621,,
18622,,
18623,,
18624,,
18625,,
18626,,
18627,,
18628,,
18629,,
18630,,
18631,,
18632,,
18633,,
18634,,
18635,,
18636,,
18637,,
18638,,
18639,,
18640,,
18641,,
18642,,
18643,,
18644,,
18645,,
18646,,
18647,,
18648,,
18649,,
18650,,
18651,,
18652,,
18653,,
18654,,
18655,,
18656,,
18657,,
18658,,
18659,,
18660,,
18661,,
18662,,
18663,,
18664,,
18665,,
18666,,
18667,,
18668,,
18669,,
18670,,
18671,,
18672,,
18673,,
18674,,
18675,,
18676,,
18677,,
18678,,
18679,,
18680,,
18681,,
18682,,
18683,,
18684,,
18685,,
18686,,
18687,,
18688,,
18689,,
18690,,
18691,,
18692,,
18693,,
18694,,
18695,,
18696,,
18697,,
18698,,
18699,,
18700,,
18701,,
18702,,
18703,,
18704,,
18705,,
18706,,
18707,,
18708,,
18709,,
18710,,
18711,,
18712,,
18713,,
18714,,
18715,,
18716,,
18717,,
18718,,
18719,,
18720,,
18721,,
18722,,
18723,,
18724,,
18725,,
18726,,
18727,,
18728,,
18729,,
18730,,
18731,,
18732,,
18733,,
18734,,
18735,,
18736,,
18737,,
18738,,
18739,,
18740,,
18741,,
18742,,
18743,,
18744,,
18745,,
18746,,
18747,,
18748,,
18749,,
18750,,
18751,,
18752,,
18753,,
18754,,
18755,,
18756,,
18757,,
18758,,
18759,,
18760,,
18761,,
18762,,
18763,,
18764,,
18765,,
18766,,
18767,,
18768,,
18769,,
18770,,
18771,,
18772,,
18773,,
18774,,
18775,,
18776,,
18777,,
18778,,
18779,,
18780,,
18781,,
18782,,
18783,,
18784,,
18785,,
18786,,
18787,,
18788,,
18789,,
18790,,
18791,,
18792,,
18793,,
18794,,
18795,,
18796,,
18797,,
18798,,
18799,,
18800,,
18801,,
18802,,
18803,,
18804,,
18805,,
18806,,
18807,,
18808,,
18809,,
18810,,
18811,,
18812,,
18813,,
18814,,
18815,,
18816,,
18817,,
18818,,
18819,,
18820,,
18821,,
18822,,
18823,,
18824,,
18825,,
18826,,
18827,,
18828,,
18829,,
18830,,
18831,,
18832,,
18833,,
18834,,
18835,,
18836,,
18837,,
18838,,
18839,,
18840,,
18841,,
18842,,
18843,,
18844,,
18845,,
18846,,
18847,,
18848,,
18849,,
18850,,
18851,,
18852,,
18853,,
18854,,
18855,,
18856,,
18857,,
18858,,
18859,,
18860,,
18861,,
18862,,
18863,,
18864,,
18865,,
18866,,
18867,,
18868,,
18869,,
18870,,
18871,,
18872,,
18873,,
18874,,
18875,,
18876,,
18877,,
18878,,
18879,,
18880,,
18881,,
18882,,
18883,,
18884,,
18885,,
18886,,
18887,,
18888,,
18889,,
18890,,
18891,,
18892,,
18893,,
18894,,
18895,,
18896,,
18897,,
18898,,
18899,,
18900,,
18901,,
18902,,
18903,,
18904,,
18905,,
18906,,
18907,,
18908,,
18909,,
18910,,
18911,,
18912,,
18913,,
18914,,
18915,,
18916,,
18917,,
18918,,
18919,,
18920,,
18921,,
18922,,
18923,,
18924,,
18925,,
18926,,
18927,,
18928,,
18929,,
18930,,
18931,,
18932,,
18933,,
18934,,
18935,,
18936,,
18937,,
18938,,
18939,,
18940,,
18941,,
18942,,
18943,,
18944,,
18945,,
18946,,
18947,,
18948,,
18949,,
18950,,
18951,,
18952,,
18953,,
18954,,
18955,,
18956,,
18957,,
18958,,
18959,,
18960,,
18961,,
18962,,
18963,,
18964,,
18965,,
18966,,
18967,,
18968,,
18969,,
18970,,
18971,,
18972,,
18973,,
18974,,
18975,,
18976,,
18977,,
18978,,
18979,,
18980,,
18981,,
18982,,
18983,,
18984,,
18985,,
18986,,
18987,,
18988,,
18989,,
18990,,
18991,,
18992,,
18993,,
18994,,
18995,,
18996,,
18997,,
18998,,
18999,,
19000,,
19001,,
19002,,
19003,,
19004,,
19005,,
19006,,
19007,,
19008,,
19009,,
19010,,
19011,,
19012,,
19013,,
19014,,
19015,,
19016,,
19017,,
19018,,
19019,,
19020,,
19021,,
19022,,
19023,,
19024,,
19025,,
19026,,
19027,,
19028,,
19029,,
19030,,
19031,,
19032,,
19033,,
19034,,
19035,,
19036,,
19037,,
19038,,
19039,,
19040,,
19041,,
19042,,
19043,,
19044,,
19045,,
19046,,
19047,,
19048,,
19049,,
19050,,
19051,,
19052,,
19053,,
19054,,
19055,,
19056,,
19057,,
19058,,
19059,,
19060,,
19061,,
19062,,
19063,,
19064,,
19065,,
19066,,
19067,,
19068,,
19069,,
19070,,
19071,,
19072,,
19073,,
19074,,
19075,,
19076,,
19077,,
19078,,
19079,,
19080,,
19081,,
19082,,
19083,,
19084,,
19085,,
19086,,
19087,,
19088,,
19089,,
19090,,
19091,,
19092,,
19093,,
19094,,
19095,,
19096,,
19097,,
19098,,
19099,,
19100,,
19101,,
19102,,
19103,,
19104,,
19105,,
19106,,
19107,,
19108,,
19109,,
19110,,
19111,,
19112,,
19113,,
19114,,
19115,,
19116,,
19117,,
19118,,
19119,,
19120,,
19121,,
19122,,
19123,,
19124,,
19125,,
19126,,
19127,,
19128,,
19129,,
19130,,
19131,,
19132,,
19133,,
19134,,
19135,,
19136,,
19137,,
19138,,
19139,,
19140,,
19141,,
19142,,
19143,,
19144,,
19145,,
19146,,
19147,,
19148,,
19149,,
19150,,
19151,,
19152,,
19153,,
19154,,
19155,,
19156,,
19157,,
19158,,
19159,,
19160,,
19161,,
19162,,
19163,,
19164,,
19165,,
19166,,
19167,,
19168,,
19169,,
19170,,
19171,,
19172,,
19173,,
19174,,
19175,,
19176,,
19177,,
19178,,
19179,,
19180,,
19181,,
19182,,
19183,,
19184,,
19185,,
19186,,
19187,,
19188,,
19189,,
19190,,
19191,,
19192,,
19193,,
19194,,
19195,,
19196,,
19197,,
19198,,
19199,,
19200,,
19201,,
19202,,
19203,,
19204,,
19205,,
19206,,
19207,,
19208,,
19209,,
19210,,
19211,,
19212,,
19213,,
19214,,
19215,,
19216,,
19217,,
19218,,
19219,,
19220,,
19221,,
19222,,
19223,,
19224,,
19225,,
19226,,
19227,,
19228,,
19229,,
19230,,
19231,,
19232,,
19233,,
19234,,
19235,,
19236,,
19237,,
19238,,
19239,,
19240,,
19241,,
19242,,
19243,,
19244,,
19245,,
19246,,
19247,,
19248,,
19249,,
19250,,
19251,,
19252,,
19253,,
19254,,
19255,,
19256,,
19257,,
19258,,
19259,,
19260,,
19261,,
19262,,
19263,,
19264,,
19265,,
19266,,
19267,,
19268,,
19269,,
19270,,
19271,,
19272,,
19273,,
19274,,
19275,,
19276,,
19277,,
19278,,
19279,,
19280,,
19281,,
19282,,
19283,,
19284,,
19285,,
19286,,
19287,,
19288,,
19289,,
19290,,
19291,,
19292,,
19293,,
19294,,
19295,,
19296,,
19297,,
19298,,
19299,,
19300,,
19301,,
19302,,
19303,,
19304,,
19305,,
19306,,
19307,,
19308,,
19309,,
19310,,
19311,,
19312,,
19313,,
19314,,
19315,,
19316,,
19317,,
19318,,
19319,,
19320,,
19321,,
19322,,
19323,,
19324,,
19325,,
19326,,
19327,,
19328,,
19329,,
19330,,
19331,,
19332,,
19333,,
19334,,
19335,,
19336,,
19337,,
19338,,
19339,,
19340,,
19341,,
19342,,
19343,,
19344,,
19345,,
19346,,
19347,,
19348,,
19349,,
19350,,
19351,,
19352,,
19353,,
19354,,
19355,,
19356,,
19357,,
19358,,
19359,,
19360,,
19361,,
19362,,
19363,,
19364,,
19365,,
19366,,
19367,,
19368,,
19369,,
19370,,
19371,,
19372,,
19373,,
19374,,
19375,,
19376,,
19377,,
19378,,
19379,,
19380,,
19381,,
19382,,
19383,,
19384,,
19385,,
19386,,
19387,,
19388,,
19389,,
19390,,
19391,,
19392,,
19393,,
19394,,
19395,,
19396,,
19397,,
19398,,
19399,,
19400,,
19401,,
19402,,
19403,,
19404,,
19405,,
19406,,
19407,,
19408,,
19409,,
19410,,
19411,,
19412,,
19413,,
19414,,
19415,,
19416,,
19417,,
19418,,
19419,,
19420,,
19421,,
19422,,
19423,,
19424,,
19425,,
19426,,
19427,,
19428,,
19429,,
19430,,
19431,,
19432,,
19433,,
19434,,
19435,,
19436,,
19437,,
19438,,
19439,,
19440,,
19441,,
19442,,
19443,,
19444,,
19445,,
19446,,
19447,,
19448,,
19449,,
19450,,
19451,,
19452,,
19453,,
19454,,
19455,,
19456,,
19457,,
19458,,
19459,,
19460,,
19461,,
19462,,
19463,,
19464,,
19465,,
19466,,
19467,,
19468,,
19469,,
19470,,
19471,,
19472,,
19473,,
19474,,
19475,,
19476,,
19477,,
19478,,
19479,,
19480,,
19481,,
19482,,
19483,,
19484,,
19485,,
19486,,
19487,,
19488,,
19489,,
19490,,
19491,,
19492,,
19493,,
19494,,
19495,,
19496,,
19497,,
19498,,
19499,,
19500,,
19501,,
19502,,
19503,,
19504,,
19505,,
19506,,
19507,,
19508,,
19509,,
19510,,
19511,,
19512,,
19513,,
19514,,
19515,,
19516,,
19517,,
19518,,
19519,,
19520,,
19521,,
19522,,
19523,,
19524,,
19525,,
19526,,
19527,,
19528,,
19529,,
19530,,
19531,,
19532,,
19533,,
19534,,
19535,,
19536,,
19537,,
19538,,
19539,,
19540,,
19541,,
19542,,
19543,,
19544,,
19545,,
19546,,
19547,,
19548,,
19549,,
19550,,
19551,,
19552,,
19553,,
19554,,
19555,,
19556,,
19557,,
19558,,
19559,,
19560,,
19561,,
19562,,
19563,,
19564,,
19565,,
19566,,
19567,,
19568,,
19569,,
19570,,
19571,,
19572,,
19573,,
19574,,
19575,,
19576,,
19577,,
19578,,
19579,,
19580,,
19581,,
19582,,
19583,,
19584,,
19585,,
19586,,
19587,,
19588,,
19589,,
19590,,
19591,,
19592,,
19593,,
19594,,
19595,,
19596,,
19597,,
19598,,
19599,,
19600,,
19601,,
19602,,
19603,,
19604,,
19605,,
19606,,
19607,,
19608,,
19609,,
19610,,
19611,,
19612,,
19613,,
19614,,
19615,,
19616,,
19617,,
19618,,
19619,,
19620,,
19621,,
19622,,
19623,,
19624,,
19625,,
19626,,
19627,,
19628,,
19629,,
19630,,
19631,,
19632,,
19633,,
19634,,
19635,,
19636,,
19637,,
19638,,
19639,,
19640,,
19641,,
19642,,
19643,,
19644,,
19645,,
19646,,
19647,,
19648,,
19649,,
19650,,
19651,,
19652,,
19653,,
19654,,
19655,,
19656,,
19657,,
19658,,
19659,,
19660,,
19661,,
19662,,
19663,,
19664,,
19665,,
19666,,
19667,,
19668,,
19669,,
19670,,
19671,,
19672,,
19673,,
19674,,
19675,,
19676,,
19677,,
19678,,
19679,,
19680,,
19681,,
19682,,
19683,,
19684,,
19685,,
19686,,
19687,,
19688,,
19689,,
19690,,
19691,,
19692,,
19693,,
19694,,
19695,,
19696,,
19697,,
19698,,
19699,,
19700,,
19701,,
19702,,
19703,,
19704,,
19705,,
19706,,
19707,,
19708,,
19709,,
19710,,
19711,,
19712,,
19713,,
19714,,
19715,,
19716,,
19717,,
19718,,
19719,,
19720,,
19721,,
19722,,
19723,,
19724,,
19725,,
19726,,
19727,,
19728,,
19729,,
19730,,
19731,,
19732,,
19733,,
19734,,
19735,,
19736,,
19737,,
19738,,
19739,,
19740,,
19741,,
19742,,
19743,,
19744,,
19745,,
19746,,
19747,,
19748,,
19749,,
19750,,
19751,,
19752,,
19753,,
19754,,
19755,,
19756,,
19757,,
19758,,
19759,,
19760,,
19761,,
19762,,
19763,,
19764,,
19765,,
19766,,
19767,,
19768,,
19769,,
19770,,
19771,,
19772,,
19773,,
19774,,
19775,,
19776,,
19777,,
19778,,
19779,,
19780,,
19781,,
19782,,
19783,,
19784,,
19785,,
19786,,
19787,,
19788,,
19789,,
19790,,
19791,,
19792,,
19793,,
19794,,
19795,,
19796,,
19797,,
19798,,
19799,,
19800,,
19801,,
19802,,
19803,,
19804,,
19805,,
19806,,
19807,,
19808,,
19809,,
19810,,
19811,,
19812,,
19813,,
19814,,
19815,,
19816,,
19817,,
19818,,
19819,,
19820,,
19821,,
19822,,
19823,,
19824,,
19825,,
19826,,
19827,,
19828,,
19829,,
19830,,
19831,,
19832,,
19833,,
19834,,
19835,,
19836,,
19837,,
19838,,
19839,,
19840,,
19841,,
19842,,
19843,,
19844,,
19845,,
19846,,
19847,,
19848,,
19849,,
19850,,
19851,,
19852,,
19853,,
19854,,
19855,,
19856,,
19857,,
19858,,
19859,,
19860,,
19861,,
19862,,
19863,,
19864,,
19865,,
19866,,
19867,,
19868,,
19869,,
19870,,
19871,,
19872,,
19873,,
19874,,
19875,,
19876,,
19877,,
19878,,
19879,,
19880,,
19881,,
19882,,
19883,,
19884,,
19885,,
19886,,
19887,,
19888,,
19889,,
19890,,
19891,,
19892,,
19893,,
19894,,
19895,,
19896,,
19897,,
19898,,
19899,,
19900,,
19901,,
19902,,
19903,,
19904,,
19905,,
19906,,
19907,,
19908,,
19909,,
19910,,
19911,,
19912,,
19913,,
19914,,
19915,,
19916,,
19917,,
19918,,
19919,,
19920,,
19921,,
19922,,
19923,,
19924,,
19925,,
19926,,
19927,,
19928,,
19929,,
19930,,
19931,,
19932,,
19933,,
19934,,
19935,,
19936,,
19937,,
19938,,
19939,,
19940,,
19941,,
19942,,
19943,,
19944,,
19945,,
19946,,
19947,,
19948,,
19949,,
19950,,
19951,,
19952,,
19953,,
19954,,
19955,,
19956,,
19957,,
19958,,
19959,,
19960,,
19961,,
19962,,
19963,,
19964,,
19965,,
19966,,
19967,,
19968,,
19969,,
19970,,
19971,,
19972,,
19973,,
19974,,
19975,,
19976,,
19977,,
19978,,
19979,,
19980,,
19981,,
19982,,
19983,,
19984,,
19985,,
19986,,
19987,,
19988,,
19989,,
19990,,
19991,,
19992,,
19993,,
19994,,
19995,,
19996,,
19997,,
19998,,
19999,,
20000,,
20001,,
20002,,
20003,,
20004,,
20005,,
20006,,
20007,,
20008,,
20009,,
20010,,
20011,,
20012,,
20013,,
20014,,
20015,,
20016,,
20017,,
20018,,
20019,,
20020,,
20021,,
20022,,
20023,,
20024,,
20025,,
20026,,
20027,,
20028,,
20029,,
20030,,
20031,,
20032,,
20033,,
20034,,
20035,,
20036,,
20037,,
20038,,
20039,,
20040,,
20041,,
20042,,
20043,,
20044,,
20045,,
20046,,
20047,,
20048,,
20049,,
20050,,
20051,,
20052,,
20053,,
20054,,
20055,,
20056,,
20057,,
20058,,
20059,,
20060,,
20061,,
20062,,
20063,,
20064,,
20065,,
20066,,
20067,,
20068,,
20069,,
20070,,
20071,,
20072,,
20073,,
20074,,
20075,,
20076,,
20077,,
20078,,
20079,,
20080,,
20081,,
20082,,
20083,,
20084,,
20085,,
20086,,
20087,,
20088,,
20089,,
20090,,
20091,,
20092,,
20093,,
20094,,
20095,,
20096,,
20097,,
20098,,
20099,,
20100,,
20101,,
20102,,
20103,,
20104,,
20105,,
20106,,
20107,,
20108,,
20109,,
20110,,
20111,,
20112,,
20113,,
20114,,
20115,,
20116,,
20117,,
20118,,
20119,,
20120,,
20121,,
20122,,
20123,,
20124,,
20125,,
20126,,
20127,,
20128,,
20129,,
20130,,
20131,,
20132,,
20133,,
20134,,
20135,,
20136,,
20137,,
20138,,
20139,,
20140,,
20141,,
20142,,
20143,,
20144,,
20145,,
20146,,
20147,,
20148,,
20149,,
20150,,
20151,,
20152,,
20153,,
20154,,
20155,,
20156,,
20157,,
20158,,
20159,,
20160,,
20161,,
20162,,
20163,,
20164,,
20165,,
20166,,
20167,,
20168,,
20169,,
20170,,
20171,,
20172,,
20173,,
20174,,
20175,,
20176,,
20177,,
20178,,
20179,,
20180,,
20181,,
20182,,
20183,,
20184,,
20185,,
20186,,
20187,,
20188,,
20189,,
20190,,
20191,,
20192,,
20193,,
20194,,
20195,,
20196,,
20197,,
20198,,
20199,,
20200,,
20201,,
20202,,
20203,,
20204,,
20205,,
20206,,
20207,,
20208,,
20209,,
20210,,
20211,,
20212,,
20213,,
20214,,
20215,,
20216,,
20217,,
20218,,
20219,,
20220,,
20221,,
20222,,
20223,,
20224,,
20225,,
20226,,
20227,,
20228,,
20229,,
20230,,
20231,,
20232,,
20233,,
20234,,
20235,,
20236,,
20237,,
20238,,
20239,,
20240,,
20241,,
20242,,
20243,,
20244,,
20245,,
20246,,
20247,,
20248,,
20249,,
20250,,
20251,,
20252,,
20253,,
20254,,
20255,,
20256,,
20257,,
20258,,
20259,,
20260,,
20261,,
20262,,
20263,,
20264,,
20265,,
20266,,
20267,,
20268,,
20269,,
20270,,
20271,,
20272,,
20273,,
20274,,
20275,,
20276,,
20277,,
20278,,
20279,,
20280,,
20281,,
20282,,
20283,,
20284,,
20285,,
20286,,
20287,,
20288,,
20289,,
20290,,
20291,,
20292,,
20293,,
20294,,
20295,,
20296,,
20297,,
20298,,
20299,,
20300,,
20301,,
20302,,
20303,,
20304,,
20305,,
20306,,
20307,,
20308,,
20309,,
20310,,
20311,,
20312,,
20313,,
20314,,
20315,,
20316,,
20317,,
20318,,
20319,,
20320,,
20321,,
20322,,
20323,,
20324,,
20325,,
20326,,
20327,,
20328,,
20329,,
20330,,
20331,,
20332,,
20333,,
20334,,
20335,,
20336,,
20337,,
20338,,
20339,,
20340,,
20341,,
20342,,
20343,,
20344,,
20345,,
20346,,
20347,,
20348,,
20349,,
20350,,
20351,,
20352,,
20353,,
20354,,
20355,,
20356,,
20357,,
20358,,
20359,,
20360,,
20361,,
20362,,
20363,,
20364,,
20365,,
20366,,
20367,,
20368,,
20369,,
20370,,
20371,,
20372,,
20373,,
20374,,
20375,,
20376,,
20377,,
20378,,
20379,,
20380,,
20381,,
20382,,
20383,,
20384,,
20385,,
20386,,
20387,,
20388,,
20389,,
20390,,
20391,,
20392,,
20393,,
20394,,
20395,,
20396,,
20397,,
20398,,
20399,,
20400,,
20401,,
20402,,
20403,,
20404,,
20405,,
20406,,
20407,,
20408,,
20409,,
20410,,
20411,,
20412,,
20413,,
20414,,
20415,,
20416,,
20417,,
20418,,
20419,,
20420,,
20421,,
20422,,
20423,,
20424,,
20425,,
20426,,
20427,,
20428,,
20429,,
20430,,
20431,,
20432,,
20433,,
20434,,
20435,,
20436,,
20437,,
20438,,
20439,,
20440,,
20441,,
20442,,
20443,,
20444,,
20445,,
20446,,
20447,,
20448,,
20449,,
20450,,
20451,,
20452,,
20453,,
20454,,
20455,,
20456,,
20457,,
20458,,
20459,,
20460,,
20461,,
20462,,
20463,,
20464,,
20465,,
20466,,
20467,,
20468,,
20469,,
20470,,
20471,,
20472,,
20473,,
20474,,
20475,,
20476,,
20477,,
20478,,
20479,,
20480,,
20481,,
20482,,
20483,,
20484,,
20485,,
20486,,
20487,,
20488,,
20489,,
20490,,
20491,,
20492,,
20493,,
20494,,
20495,,
20496,,
20497,,
20498,,
20499,,
20500,,
20501,,
20502,,
20503,,
20504,,
20505,,
20506,,
20507,,
20508,,
20509,,
20510,,
20511,,
20512,,
20513,,
20514,,
20515,,
20516,,
20517,,
20518,,
20519,,
20520,,
20521,,
20522,,
20523,,
20524,,
20525,,
20526,,
20527,,
20528,,
20529,,
20530,,
20531,,
20532,,
20533,,
20534,,
20535,,
20536,,
20537,,
20538,,
20539,,
20540,,
20541,,
20542,,
20543,,
20544,,
20545,,
20546,,
20547,,
20548,,
20549,,
20550,,
20551,,
20552,,
20553,,
20554,,
20555,,
20556,,
20557,,
20558,,
20559,,
20560,,
20561,,
20562,,
20563,,
20564,,
20565,,
20566,,
20567,,
20568,,
20569,,
20570,,
20571,,
20572,,
20573,,
20574,,
20575,,
20576,,
20577,,
20578,,
20579,,
20580,,
20581,,
20582,,
20583,,
20584,,
20585,,
20586,,
20587,,
20588,,
20589,,
20590,,
20591,,
20592,,
20593,,
20594,,
20595,,
20596,,
20597,,
20598,,
20599,,
20600,,
20601,,
20602,,
20603,,
20604,,
20605,,
20606,,
20607,,
20608,,
20609,,
20610,,
20611,,
20612,,
20613,,
20614,,
20615,,
20616,,
20617,,
20618,,
20619,,
20620,,
20621,,
20622,,
20623,,
20624,,
20625,,
20626,,
20627,,
20628,,
20629,,
20630,,
20631,,
20632,,
20633,,
20634,,
20635,,
20636,,
20637,,
20638,,
20639,,
20640,,
20641,,
20642,,
20643,,
20644,,
20645,,
20646,,
20647,,
20648,,
20649,,
20650,,
20651,,
20652,,
20653,,
20654,,
20655,,
20656,,
20657,,
20658,,
20659,,
20660,,
20661,,
20662,,
20663,,
20664,,
20665,,
20666,,
20667,,
20668,,
20669,,
20670,,
20671,,
20672,,
20673,,
20674,,
20675,,
20676,,
20677,,
20678,,
20679,,
20680,,
20681,,
20682,,
20683,,
20684,,
20685,,
20686,,
20687,,
20688,,
20689,,
20690,,
20691,,
20692,,
20693,,
20694,,
20695,,
20696,,
20697,,
20698,,
20699,,
20700,,
20701,,
20702,,
20703,,
20704,,
20705,,
20706,,
20707,,
20708,,
20709,,
20710,,
20711,,
20712,,
20713,,
20714,,
20715,,
20716,,
20717,,
20718,,
20719,,
20720,,
20721,,
20722,,
20723,,
20724,,
20725,,
20726,,
20727,,
20728,,
20729,,
20730,,
20731,,
20732,,
20733,,
20734,,
20735,,
20736,,
20737,,
20738,,
20739,,
20740,,
20741,,
20742,,
20743,,
20744,,
20745,,
20746,,
20747,,
20748,,
20749,,
20750,,
20751,,
20752,,
20753,,
20754,,
20755,,
20756,,
20757,,
20758,,
20759,,
20760,,
20761,,
20762,,
20763,,
20764,,
20765,,
20766,,
20767,,
20768,,
20769,,
20770,,
20771,,
20772,,
20773,,
20774,,
20775,,
20776,,
20777,,
20778,,
20779,,
20780,,
20781,,
20782,,
20783,,
20784,,
20785,,
20786,,
20787,,
20788,,
20789,,
20790,,
20791,,
20792,,
20793,,
20794,,
20795,,
20796,,
20797,,
20798,,
20799,,
20800,,
20801,,
20802,,
20803,,
20804,,
20805,,
20806,,
20807,,
20808,,
20809,,
20810,,
20811,,
20812,,
20813,,
20814,,
20815,,
20816,,
20817,,
20818,,
20819,,
20820,,
20821,,
20822,,
20823,,
20824,,
20825,,
20826,,
20827,,
20828,,
20829,,
20830,,
20831,,
20832,,
20833,,
20834,,
20835,,
20836,,
20837,,
20838,,
20839,,
20840,,
20841,,
20842,,
20843,,
20844,,
20845,,
20846,,
20847,,
20848,,
20849,,
20850,,
20851,,
20852,,
20853,,
20854,,
20855,,
20856,,
20857,,
20858,,
20859,,
20860,,
20861,,
20862,,
20863,,
20864,,
20865,,
20866,,
20867,,
20868,,
20869,,
20870,,
20871,,
20872,,
20873,,
20874,,
20875,,
20876,,
20877,,
20878,,
20879,,
20880,,
20881,,
20882,,
20883,,
20884,,
20885,,
20886,,
20887,,
20888,,
20889,,
20890,,
20891,,
20892,,
20893,,
20894,,
20895,,
20896,,
20897,,
20898,,
20899,,
20900,,
20901,,
20902,,
20903,,
20904,,
20905,,
20906,,
20907,,
20908,,
20909,,
20910,,
20911,,
20912,,
20913,,
20914,,
20915,,
20916,,
20917,,
20918,,
20919,,
20920,,
20921,,
20922,,
20923,,
20924,,
20925,,
20926,,
20927,,
20928,,
20929,,
20930,,
20931,,
20932,,
20933,,
20934,,
20935,,
20936,,
20937,,
20938,,
20939,,
20940,,
20941,,
20942,,
20943,,
20944,,
20945,,
20946,,
20947,,
20948,,
20949,,
20950,,
20951,,
20952,,
20953,,
20954,,
20955,,
20956,,
20957,,
20958,,
20959,,
20960,,
20961,,
20962,,
20963,,
20964,,
20965,,
20966,,
20967,,
20968,,
20969,,
20970,,
20971,,
20972,,
20973,,
20974,,
20975,,
20976,,
20977,,
20978,,
20979,,
20980,,
20981,,
20982,,
20983,,
20984,,
20985,,
20986,,
20987,,
20988,,
20989,,
20990,,
20991,,
20992,,
20993,,
20994,,
20995,,
20996,,
20997,,
20998,,
20999,,
21000,,
21001,,
21002,,
21003,,
21004,,
21005,,
21006,,
21007,,
21008,,
21009,,
21010,,
21011,,
21012,,
21013,,
21014,,
21015,,
21016,,
21017,,
21018,,
21019,,
21020,,
21021,,
21022,,
21023,,
21024,,
21025,,
21026,,
21027,,
21028,,
21029,,
21030,,
21031,,
21032,,
21033,,
21034,,
21035,,
21036,,
21037,,
21038,,
21039,,
21040,,
21041,,
21042,,
21043,,
21044,,
21045,,
21046,,
21047,,
21048,,
21049,,
21050,,
21051,,
21052,,
21053,,
21054,,
21055,,
21056,,
21057,,
21058,,
21059,,
21060,,
21061,,
21062,,
21063,,
21064,,
21065,,
21066,,
21067,,
21068,,
21069,,
21070,,
21071,,
21072,,
21073,,
21074,,
21075,,
21076,,
21077,,
21078,,
21079,,
21080,,
21081,,
21082,,
21083,,
21084,,
21085,,
21086,,
21087,,
21088,,
21089,,
21090,,
21091,,
21092,,
21093,,
21094,,
21095,,
21096,,
21097,,
21098,,
21099,,
21100,,
21101,,
21102,,
21103,,
21104,,
21105,,
21106,,
21107,,
21108,,
21109,,
21110,,
21111,,
21112,,
21113,,
21114,,
21115,,
21116,,
21117,,
21118,,
21119,,
21120,,
21121,,
21122,,
21123,,
21124,,
21125,,
21126,,
21127,,
21128,,
21129,,
21130,,
21131,,
21132,,
21133,,
21134,,
21135,,
21136,,
21137,,
21138,,
21139,,
21140,,
21141,,
21142,,
21143,,
21144,,
21145,,
21146,,
21147,,
21148,,
21149,,
21150,,
21151,,
21152,,
21153,,
21154,,
21155,,
21156,,
21157,,
21158,,
21159,,
21160,,
21161,,
21162,,
21163,,
21164,,
21165,,
21166,,
21167,,
21168,,
21169,,
21170,,
21171,,
21172,,
21173,,
21174,,
21175,,
21176,,
21177,,
21178,,
21179,,
21180,,
21181,,
21182,,
21183,,
21184,,
21185,,
21186,,
21187,,
21188,,
21189,,
21190,,
21191,,
21192,,
21193,,
21194,,
21195,,
21196,,
21197,,
21198,,
21199,,
21200,,
21201,,
21202,,
21203,,
21204,,
21205,,
21206,,
21207,,
21208,,
21209,,
21210,,
21211,,
21212,,
21213,,
21214,,
21215,,
21216,,
21217,,
21218,,
21219,,
21220,,
21221,,
21222,,
21223,,
21224,,
21225,,
21226,,
21227,,
21228,,
21229,,
21230,,
21231,,
21232,,
21233,,
21234,,
21235,,
21236,,
21237,,
21238,,
21239,,
21240,,
21241,,
21242,,
21243,,
21244,,
21245,,
21246,,
21247,,
21248,,
21249,,
21250,,
21251,,
21252,,
21253,,
21254,,
21255,,
21256,,
21257,,
21258,,
21259,,
21260,,
21261,,
21262,,
21263,,
21264,,
21265,,
21266,,
21267,,
21268,,
21269,,
21270,,
21271,,
21272,,
21273,,
21274,,
21275,,
21276,,
21277,,
21278,,
21279,,
21280,,
21281,,
21282,,
21283,,
21284,,
21285,,
21286,,
21287,,
21288,,
21289,,
21290,,
21291,,
21292,,
21293,,
21294,,
21295,,
21296,,
21297,,
21298,,
21299,,
21300,,
21301,,
21302,,
21303,,
21304,,
21305,,
21306,,
21307,,
21308,,
21309,,
21310,,
21311,,
21312,,
21313,,
21314,,
21315,,
21316,,
21317,,
21318,,
21319,,
21320,,
21321,,
21322,,
21323,,
21324,,
21325,,
21326,,
21327,,
21328,,
21329,,
21330,,
21331,,
21332,,
21333,,
21334,,
21335,,
21336,,
21337,,
21338,,
21339,,
21340,,
21341,,
21342,,
21343,,
21344,,
21345,,
21346,,
21347,,
21348,,
21349,,
21350,,
21351,,
21352,,
21353,,
21354,,
21355,,
21356,,
21357,,
21358,,
21359,,
21360,,
21361,,
21362,,
21363,,
21364,,
21365,,
21366,,
21367,,
21368,,
21369,,
21370,,
21371,,
21372,,
21373,,
21374,,
21375,,
21376,,
21377,,
21378,,
21379,,
21380,,
21381,,
21382,,
21383,,
21384,,
21385,,
21386,,
21387,,
21388,,
21389,,
21390,,
21391,,
21392,,
21393,,
21394,,
21395,,
21396,,
21397,,
21398,,
21399,,
21400,,
21401,,
21402,,
21403,,
21404,,
21405,,
21406,,
21407,,
21408,,
21409,,
21410,,
21411,,
21412,,
21413,,
21414,,
21415,,
21416,,
21417,,
21418,,
21419,,
21420,,
21421,,
21422,,
21423,,
21424,,
21425,,
21426,,
21427,,
21428,,
21429,,
21430,,
21431,,
21432,,
21433,,
21434,,
21435,,
21436,,
21437,,
21438,,
21439,,
21440,,
21441,,
21442,,
21443,,
21444,,
21445,,
21446,,
21447,,
21448,,
21449,,
21450,,
21451,,
21452,,
21453,,
21454,,
21455,,
21456,,
21457,,
21458,,
21459,,
21460,,
21461,,
21462,,
21463,,
21464,,
21465,,
21466,,
21467,,
21468,,
21469,,
21470,,
21471,,
21472,,
21473,,
21474,,
21475,,
21476,,
21477,,
21478,,
21479,,
21480,,
21481,,
21482,,
21483,,
21484,,
21485,,
21486,,
21487,,
21488,,
21489,,
21490,,
21491,,
21492,,
21493,,
21494,,
21495,,
21496,,
21497,,
21498,,
21499,,
21500,,
21501,,
21502,,
21503,,
21504,,
21505,,
21506,,
21507,,
21508,,
21509,,
21510,,
21511,,
21512,,
21513,,
21514,,
21515,,
21516,,
21517,,
21518,,
21519,,
21520,,
21521,,
21522,,
21523,,
21524,,
21525,,
21526,,
21527,,
21528,,
21529,,
21530,,
21531,,
21532,,
21533,,
21534,,
21535,,
21536,,
21537,,
21538,,
21539,,
21540,,
21541,,
21542,,
21543,,
21544,,
21545,,
21546,,
21547,,
21548,,
21549,,
21550,,
21551,,
21552,,
21553,,
21554,,
21555,,
21556,,
21557,,
21558,,
21559,,
21560,,
21561,,
21562,,
21563,,
21564,,
21565,,
21566,,
21567,,
21568,,
21569,,
21570,,
21571,,
21572,,
21573,,
21574,,
21575,,
21576,,
21577,,
21578,,
21579,,
21580,,
21581,,
21582,,
21583,,
21584,,
21585,,
21586,,
21587,,
21588,,
21589,,
21590,,
21591,,
21592,,
21593,,
21594,,
21595,,
21596,,
21597,,
21598,,
21599,,
21600,,
21601,,
21602,,
21603,,
21604,,
21605,,
21606,,
21607,,
21608,,
21609,,
21610,,
21611,,
21612,,
21613,,
21614,,
21615,,
21616,,
21617,,
21618,,
21619,,
21620,,
21621,,
21622,,
21623,,
21624,,
21625,,
21626,,
21627,,
21628,,
21629,,
21630,,
21631,,
21632,,
21633,,
21634,,
21635,,
21636,,
21637,,
21638,,
21639,,
21640,,
21641,,
21642,,
21643,,
21644,,
21645,,
21646,,
21647,,
21648,,
21649,,
21650,,
21651,,
21652,,
21653,,
21654,,
21655,,
21656,,
21657,,
21658,,
21659,,
21660,,
21661,,
21662,,
21663,,
21664,,
21665,,
21666,,
21667,,
21668,,
21669,,
21670,,
21671,,
21672,,
21673,,
21674,,
21675,,
21676,,
21677,,
21678,,
21679,,
21680,,
21681,,
21682,,
21683,,
21684,,
21685,,
21686,,
21687,,
21688,,
21689,,
21690,,
21691,,
21692,,
21693,,
21694,,
21695,,
21696,,
21697,,
21698,,
21699,,
21700,,
21701,,
21702,,
21703,,
21704,,
21705,,
21706,,
21707,,
21708,,
21709,,
21710,,
21711,,
21712,,
21713,,
21714,,
21715,,
21716,,
21717,,
21718,,
21719,,
21720,,
21721,,
21722,,
21723,,
21724,,
21725,,
21726,,
21727,,
21728,,
21729,,
21730,,
21731,,
21732,,
21733,,
21734,,
21735,,
21736,,
21737,,
21738,,
21739,,
21740,,
21741,,
21742,,
21743,,
21744,,
21745,,
21746,,
21747,,
21748,,
21749,,
21750,,
21751,,
21752,,
21753,,
21754,,
21755,,
21756,,
21757,,
21758,,
21759,,
21760,,
21761,,
21762,,
21763,,
21764,,
21765,,
21766,,
21767,,
21768,,
21769,,
21770,,
21771,,
21772,,
21773,,
21774,,
21775,,
21776,,
21777,,
21778,,
21779,,
21780,,
21781,,
21782,,
21783,,
21784,,
21785,,
21786,,
21787,,
21788,,
21789,,
21790,,
21791,,
21792,,
21793,,
21794,,
21795,,
21796,,
21797,,
21798,,
21799,,
21800,,
21801,,
21802,,
21803,,
21804,,
21805,,
21806,,
21807,,
21808,,
21809,,
21810,,
21811,,
21812,,
21813,,
21814,,
21815,,
21816,,
21817,,
21818,,
21819,,
21820,,
21821,,
21822,,
21823,,
21824,,
21825,,
21826,,
21827,,
21828,,
21829,,
21830,,
21831,,
21832,,
21833,,
21834,,
21835,,
21836,,
21837,,
21838,,
21839,,
21840,,
21841,,
21842,,
21843,,
21844,,
21845,,
21846,,
21847,,
21848,,
21849,,
21850,,
21851,,
21852,,
21853,,
21854,,
21855,,
21856,,
21857,,
21858,,
21859,,
21860,,
21861,,
21862,,
21863,,
21864,,
21865,,
21866,,
21867,,
21868,,
21869,,
21870,,
21871,,
21872,,
21873,,
21874,,
21875,,
21876,,
21877,,
21878,,
21879,,
21880,,
21881,,
21882,,
21883,,
21884,,
21885,,
21886,,
21887,,
21888,,
21889,,
21890,,
21891,,
21892,,
21893,,
21894,,
21895,,
21896,,
21897,,
21898,,
21899,,
21900,,
21901,,
21902,,
21903,,
21904,,
21905,,
21906,,
21907,,
21908,,
21909,,
21910,,
21911,,
21912,,
21913,,
21914,,
21915,,
21916,,
21917,,
21918,,
21919,,
21920,,
21921,,
21922,,
21923,,
21924,,
21925,,
21926,,
21927,,
21928,,
21929,,
21930,,
21931,,
21932,,
21933,,
21934,,
21935,,
21936,,
21937,,
21938,,
21939,,
21940,,
21941,,
21942,,
21943,,
21944,,
21945,,
21946,,
21947,,
21948,,
21949,,
21950,,
21951,,
21952,,
21953,,
21954,,
21955,,
21956,,
21957,,
21958,,
21959,,
21960,,
21961,,
21962,,
21963,,
21964,,
21965,,
21966,,
21967,,
21968,,
21969,,
21970,,
21971,,
21972,,
21973,,
21974,,
21975,,
21976,,
21977,,
21978,,
21979,,
21980,,
21981,,
21982,,
21983,,
21984,,
21985,,
21986,,
21987,,
21988,,
21989,,
21990,,
21991,,
21992,,
21993,,
21994,,
21995,,
21996,,
21997,,
21998,,
21999,,
22000,,
22001,,
22002,,
22003,,
22004,,
22005,,
22006,,
22007,,
22008,,
22009,,
22010,,
22011,,
22012,,
22013,,
22014,,
22015,,
22016,,
22017,,
22018,,
22019,,
22020,,
22021,,
22022,,
22023,,
22024,,
22025,,
22026,,
22027,,
22028,,
22029,,
22030,,
22031,,
22032,,
22033,,
22034,,
22035,,
22036,,
22037,,
22038,,
22039,,
22040,,
22041,,
22042,,
22043,,
22044,,
22045,,
22046,,
22047,,
22048,,
22049,,
22050,,
22051,,
22052,,
22053,,
22054,,
22055,,
22056,,
22057,,
22058,,
22059,,
22060,,
22061,,
22062,,
22063,,
22064,,
22065,,
22066,,
22067,,
22068,,
22069,,
22070,,
22071,,
22072,,
22073,,
22074,,
22075,,
22076,,
22077,,
22078,,
22079,,
22080,,
22081,,
22082,,
22083,,
22084,,
22085,,
22086,,
22087,,
22088,,
22089,,
22090,,
22091,,
22092,,
22093,,
22094,,
22095,,
22096,,
22097,,
22098,,
22099,,
22100,,
22101,,
22102,,
22103,,
22104,,
22105,,
22106,,
22107,,
22108,,
22109,,
22110,,
22111,,
22112,,
22113,,
22114,,
22115,,
22116,,
22117,,
22118,,
22119,,
22120,,
22121,,
22122,,
22123,,
22124,,
22125,,
22126,,
22127,,
22128,,
22129,,
22130,,
22131,,
22132,,
22133,,
22134,,
22135,,
22136,,
22137,,
22138,,
22139,,
22140,,
22141,,
22142,,
22143,,
22144,,
22145,,
22146,,
22147,,
22148,,
22149,,
22150,,
22151,,
22152,,
22153,,
22154,,
22155,,
22156,,
22157,,
22158,,
22159,,
22160,,
22161,,
22162,,
22163,,
22164,,
22165,,
22166,,
22167,,
22168,,
22169,,
22170,,
22171,,
22172,,
22173,,
22174,,
22175,,
22176,,
22177,,
22178,,
22179,,
22180,,
22181,,
22182,,
22183,,
22184,,
22185,,
22186,,
22187,,
22188,,
22189,,
22190,,
22191,,
22192,,
22193,,
22194,,
22195,,
22196,,
22197,,
22198,,
22199,,
22200,,
22201,,
22202,,
22203,,
22204,,
22205,,
22206,,
22207,,
22208,,
22209,,
22210,,
22211,,
22212,,
22213,,
22214,,
22215,,
22216,,
22217,,
22218,,
22219,,
22220,,
22221,,
22222,,
22223,,
22224,,
22225,,
22226,,
22227,,
22228,,
22229,,
22230,,
22231,,
22232,,
22233,,
22234,,
22235,,
22236,,
22237,,
22238,,
22239,,
22240,,
22241,,
22242,,
22243,,
22244,,
22245,,
22246,,
22247,,
22248,,
22249,,
22250,,
22251,,
22252,,
22253,,
22254,,
22255,,
22256,,
22257,,
22258,,
22259,,
22260,,
22261,,
22262,,
22263,,
22264,,
22265,,
22266,,
22267,,
22268,,
22269,,
22270,,
22271,,
22272,,
22273,,
22274,,
22275,,
22276,,
22277,,
22278,,
22279,,
22280,,
22281,,
22282,,
22283,,
22284,,
22285,,
22286,,
22287,,
22288,,
22289,,
22290,,
22291,,
22292,,
22293,,
22294,,
22295,,
22296,,
22297,,
22298,,
22299,,
22300,,
22301,,
22302,,
22303,,
22304,,
22305,,
22306,,
22307,,
22308,,
22309,,
22310,,
22311,,
22312,,
22313,,
22314,,
22315,,
22316,,
22317,,
22318,,
22319,,
22320,,
22321,,
22322,,
22323,,
22324,,
22325,,
22326,,
22327,,
22328,,
22329,,
22330,,
22331,,
22332,,
22333,,
22334,,
22335,,
22336,,
22337,,
22338,,
22339,,
22340,,
22341,,
22342,,
22343,,
22344,,
22345,,
22346,,
22347,,
22348,,
22349,,
22350,,
22351,,
22352,,
22353,,
22354,,
22355,,
22356,,
22357,,
22358,,
22359,,
22360,,
22361,,
22362,,
22363,,
22364,,
22365,,
22366,,
22367,,
22368,,
22369,,
22370,,
22371,,
22372,,
22373,,
22374,,
22375,,
22376,,
22377,,
22378,,
22379,,
22380,,
22381,,
22382,,
22383,,
22384,,
22385,,
22386,,
22387,,
22388,,
22389,,
22390,,
22391,,
22392,,
22393,,
22394,,
22395,,
22396,,
22397,,
22398,,
22399,,
22400,,
22401,,
22402,,
22403,,
22404,,
22405,,
22406,,
22407,,
22408,,
22409,,
22410,,
22411,,
22412,,
22413,,
22414,,
22415,,
22416,,
22417,,
22418,,
22419,,
22420,,
22421,,
22422,,
22423,,
22424,,
22425,,
22426,,
22427,,
22428,,
22429,,
22430,,
22431,,
22432,,
22433,,
22434,,
22435,,
22436,,
22437,,
22438,,
22439,,
22440,,
22441,,
22442,,
22443,,
22444,,
22445,,
22446,,
22447,,
22448,,
22449,,
22450,,
22451,,
22452,,
22453,,
22454,,
22455,,
22456,,
22457,,
22458,,
22459,,
22460,,
22461,,
22462,,
22463,,
22464,,
22465,,
22466,,
22467,,
22468,,
22469,,
22470,,
22471,,
22472,,
22473,,
22474,,
22475,,
22476,,
22477,,
22478,,
22479,,
22480,,
22481,,
22482,,
22483,,
22484,,
22485,,
22486,,
22487,,
22488,,
22489,,
22490,,
22491,,
22492,,
22493,,
22494,,
22495,,
22496,,
22497,,
22498,,
22499,,
22500,,
22501,,
22502,,
22503,,
22504,,
22505,,
22506,,
22507,,
22508,,
22509,,
22510,,
22511,,
22512,,
22513,,
22514,,
22515,,
22516,,
22517,,
22518,,
22519,,
22520,,
22521,,
22522,,
22523,,
22524,,
22525,,
22526,,
22527,,
22528,,
22529,,
22530,,
22531,,
22532,,
22533,,
22534,,
22535,,
22536,,
22537,,
22538,,
22539,,
22540,,
22541,,
22542,,
22543,,
22544,,
22545,,
22546,,
22547,,
22548,,
22549,,
22550,,
22551,,
22552,,
22553,,
22554,,
22555,,
22556,,
22557,,
22558,,
22559,,
22560,,
22561,,
22562,,
22563,,
22564,,
22565,,
22566,,
22567,,
22568,,
22569,,
22570,,
22571,,
22572,,
22573,,
22574,,
22575,,
22576,,
22577,,
22578,,
22579,,
22580,,
22581,,
22582,,
22583,,
22584,,
22585,,
22586,,
22587,,
22588,,
22589,,
22590,,
22591,,
22592,,
22593,,
22594,,
22595,,
22596,,
22597,,
22598,,
22599,,
22600,,
22601,,
22602,,
22603,,
22604,,
22605,,
22606,,
22607,,
22608,,
22609,,
22610,,
22611,,
22612,,
22613,,
22614,,
22615,,
22616,,
22617,,
22618,,
22619,,
22620,,
22621,,
22622,,
22623,,
22624,,
22625,,
22626,,
22627,,
22628,,
22629,,
22630,,
22631,,
22632,,
22633,,
22634,,
22635,,
22636,,
22637,,
22638,,
22639,,
22640,,
22641,,
22642,,
22643,,
22644,,
22645,,
22646,,
22647,,
22648,,
22649,,
22650,,
22651,,
22652,,
22653,,
22654,,
22655,,
22656,,
22657,,
22658,,
22659,,
22660,,
22661,,
22662,,
22663,,
22664,,
22665,,
22666,,
22667,,
22668,,
22669,,
22670,,
22671,,
22672,,
22673,,
22674,,
22675,,
22676,,
22677,,
22678,,
22679,,
22680,,
22681,,
22682,,
22683,,
22684,,
22685,,
22686,,
22687,,
22688,,
22689,,
22690,,
22691,,
22692,,
22693,,
22694,,
22695,,
22696,,
22697,,
22698,,
22699,,
22700,,
22701,,
22702,,
22703,,
22704,,
22705,,
22706,,
22707,,
22708,,
22709,,
22710,,
22711,,
22712,,
22713,,
22714,,
22715,,
22716,,
22717,,
22718,,
22719,,
22720,,
22721,,
22722,,
22723,,
22724,,
22725,,
22726,,
22727,,
22728,,
22729,,
22730,,
22731,,
22732,,
22733,,
22734,,
22735,,
22736,,
22737,,
22738,,
22739,,
22740,,
22741,,
22742,,
22743,,
22744,,
22745,,
22746,,
22747,,
22748,,
22749,,
22750,,
22751,,
22752,,
22753,,
22754,,
22755,,
22756,,
22757,,
22758,,
22759,,
22760,,
22761,,
22762,,
22763,,
22764,,
22765,,
22766,,
22767,,
22768,,
22769,,
22770,,
22771,,
22772,,
22773,,
22774,,
22775,,
22776,,
22777,,
22778,,
22779,,
22780,,
22781,,
22782,,
22783,,
22784,,
22785,,
22786,,
22787,,
22788,,
22789,,
22790,,
22791,,
22792,,
22793,,
22794,,
22795,,
22796,,
22797,,
22798,,
22799,,
22800,,
22801,,
22802,,
22803,,
22804,,
22805,,
22806,,
22807,,
22808,,
22809,,
22810,,
22811,,
22812,,
22813,,
22814,,
22815,,
22816,,
22817,,
22818,,
22819,,
22820,,
22821,,
22822,,
22823,,
22824,,
22825,,
22826,,
22827,,
22828,,
22829,,
22830,,
22831,,
22832,,
22833,,
22834,,
22835,,
22836,,
22837,,
22838,,
22839,,
22840,,
22841,,
22842,,
22843,,
22844,,
22845,,
22846,,
22847,,
22848,,
22849,,
22850,,
22851,,
22852,,
22853,,
22854,,
22855,,
22856,,
22857,,
22858,,
22859,,
22860,,
22861,,
22862,,
22863,,
22864,,
22865,,
22866,,
22867,,
22868,,
22869,,
22870,,
22871,,
22872,,
22873,,
22874,,
22875,,
22876,,
22877,,
22878,,
22879,,
22880,,
22881,,
22882,,
22883,,
22884,,
22885,,
22886,,
22887,,
22888,,
22889,,
22890,,
22891,,
22892,,
22893,,
22894,,
22895,,
22896,,
22897,,
22898,,
22899,,
22900,,
22901,,
22902,,
22903,,
22904,,
22905,,
22906,,
22907,,
22908,,
22909,,
22910,,
22911,,
22912,,
22913,,
22914,,
22915,,
22916,,
22917,,
22918,,
22919,,
22920,,
22921,,
22922,,
22923,,
22924,,
22925,,
22926,,
22927,,
22928,,
22929,,
22930,,
22931,,
22932,,
22933,,
22934,,
22935,,
22936,,
22937,,
22938,,
22939,,
22940,,
22941,,
22942,,
22943,,
22944,,
22945,,
22946,,
22947,,
22948,,
22949,,
22950,,
22951,,
22952,,
22953,,
22954,,
22955,,
22956,,
22957,,
22958,,
22959,,
22960,,
22961,,
22962,,
22963,,
22964,,
22965,,
22966,,
22967,,
22968,,
22969,,
22970,,
22971,,
22972,,
22973,,
22974,,
22975,,
22976,,
22977,,
22978,,
22979,,
22980,,
22981,,
22982,,
22983,,
22984,,
22985,,
22986,,
22987,,
22988,,
22989,,
22990,,
22991,,
22992,,
22993,,
22994,,
22995,,
22996,,
22997,,
22998,,
22999,,
23000,,
23001,,
23002,,
23003,,
23004,,
23005,,
23006,,
23007,,
23008,,
23009,,
23010,,
23011,,
23012,,
23013,,
23014,,
23015,,
23016,,
23017,,
23018,,
23019,,
23020,,
23021,,
23022,,
23023,,
23024,,
23025,,
23026,,
23027,,
23028,,
23029,,
23030,,
23031,,
23032,,
23033,,
23034,,
23035,,
23036,,
23037,,
23038,,
23039,,
23040,,
23041,,
23042,,
23043,,
23044,,
23045,,
23046,,
23047,,
23048,,
23049,,
23050,,
23051,,
23052,,
23053,,
23054,,
23055,,
23056,,
23057,,
23058,,
23059,,
23060,,
23061,,
23062,,
23063,,
23064,,
23065,,
23066,,
23067,,
23068,,
23069,,
23070,,
23071,,
23072,,
23073,,
23074,,
23075,,
23076,,
23077,,
23078,,
23079,,
23080,,
23081,,
23082,,
23083,,
23084,,
23085,,
23086,,
23087,,
23088,,
23089,,
23090,,
23091,,
23092,,
23093,,
23094,,
23095,,
23096,,
23097,,
23098,,
23099,,
23100,,
23101,,
23102,,
23103,,
23104,,
23105,,
23106,,
23107,,
23108,,
23109,,
23110,,
23111,,
23112,,
23113,,
23114,,
23115,,
23116,,
23117,,
23118,,
23119,,
23120,,
23121,,
23122,,
23123,,
23124,,
23125,,
23126,,
23127,,
23128,,
23129,,
23130,,
23131,,
23132,,
23133,,
23134,,
23135,,
23136,,
23137,,
23138,,
23139,,
23140,,
23141,,
23142,,
23143,,
23144,,
23145,,
23146,,
23147,,
23148,,
23149,,
23150,,
23151,,
23152,,
23153,,
23154,,
23155,,
23156,,
23157,,
23158,,
23159,,
23160,,
23161,,
23162,,
23163,,
23164,,
23165,,
23166,,
23167,,
23168,,
23169,,
23170,,
23171,,
23172,,
23173,,
23174,,
23175,,
23176,,
23177,,
23178,,
23179,,
23180,,
23181,,
23182,,
23183,,
23184,,
23185,,
23186,,
23187,,
23188,,
23189,,
23190,,
23191,,
23192,,
23193,,
23194,,
23195,,
23196,,
23197,,
23198,,
23199,,
23200,,
23201,,
23202,,
23203,,
23204,,
23205,,
23206,,
23207,,
23208,,
23209,,
23210,,
23211,,
23212,,
23213,,
23214,,
23215,,
23216,,
23217,,
23218,,
23219,,
23220,,
23221,,
23222,,
23223,,
23224,,
23225,,
23226,,
23227,,
23228,,
23229,,
23230,,
23231,,
23232,,
23233,,
23234,,
23235,,
23236,,
23237,,
23238,,
23239,,
23240,,
23241,,
23242,,
23243,,
23244,,
23245,,
23246,,
23247,,
23248,,
23249,,
23250,,
23251,,
23252,,
23253,,
23254,,
23255,,
23256,,
23257,,
23258,,
23259,,
23260,,
23261,,
23262,,
23263,,
23264,,
23265,,
23266,,
23267,,
23268,,
23269,,
23270,,
23271,,
23272,,
23273,,
23274,,
23275,,
23276,,
23277,,
23278,,
23279,,
23280,,
23281,,
23282,,
23283,,
23284,,
23285,,
23286,,
23287,,
23288,,
23289,,
23290,,
23291,,
23292,,
23293,,
23294,,
23295,,
23296,,
23297,,
23298,,
23299,,
23300,,
23301,,
23302,,
23303,,
23304,,
23305,,
23306,,
23307,,
23308,,
23309,,
23310,,
23311,,
23312,,
23313,,
23314,,
23315,,
23316,,
23317,,
23318,,
23319,,
23320,,
23321,,
23322,,
23323,,
23324,,
23325,,
23326,,
23327,,
23328,,
23329,,
23330,,
23331,,
23332,,
23333,,
23334,,
23335,,
23336,,
23337,,
23338,,
23339,,
23340,,
23341,,
23342,,
23343,,
23344,,
23345,,
23346,,
23347,,
23348,,
23349,,
23350,,
23351,,
23352,,
23353,,
23354,,
23355,,
23356,,
23357,,
23358,,
23359,,
23360,,
23361,,
23362,,
23363,,
23364,,
23365,,
23366,,
23367,,
23368,,
23369,,
23370,,
23371,,
23372,,
23373,,
23374,,
23375,,
23376,,
23377,,
23378,,
23379,,
23380,,
23381,,
23382,,
23383,,
23384,,
23385,,
23386,,
23387,,
23388,,
23389,,
23390,,
23391,,
23392,,
23393,,
23394,,
23395,,
23396,,
23397,,
23398,,
23399,,
23400,,
23401,,
23402,,
23403,,
23404,,
23405,,
23406,,
23407,,
23408,,
23409,,
23410,,
23411,,
23412,,
23413,,
23414,,
23415,,
23416,,
23417,,
23418,,
23419,,
23420,,
23421,,
23422,,
23423,,
23424,,
23425,,
23426,,
23427,,
23428,,
23429,,
23430,,
23431,,
23432,,
23433,,
23434,,
23435,,
23436,,
23437,,
23438,,
23439,,
23440,,
23441,,
23442,,
23443,,
23444,,
23445,,
23446,,
23447,,
23448,,
23449,,
23450,,
23451,,
23452,,
23453,,
23454,,
23455,,
23456,,
23457,,
23458,,
23459,,
23460,,
23461,,
23462,,
23463,,
23464,,
23465,,
23466,,
23467,,
23468,,
23469,,
23470,,
23471,,
23472,,
23473,,
23474,,
23475,,
23476,,
23477,,
23478,,
23479,,
23480,,
23481,,
23482,,
23483,,
23484,,
23485,,
23486,,
23487,,
23488,,
23489,,
23490,,
23491,,
23492,,
23493,,
23494,,
23495,,
23496,,
23497,,
23498,,
23499,,
23500,,
23501,,
23502,,
23503,,
23504,,
23505,,
23506,,
23507,,
23508,,
23509,,
23510,,
23511,,
23512,,
23513,,
23514,,
23515,,
23516,,
23517,,
23518,,
23519,,
23520,,
23521,,
23522,,
23523,,
23524,,
23525,,
23526,,
23527,,
23528,,
23529,,
23530,,
23531,,
23532,,
23533,,
23534,,
23535,,
23536,,
23537,,
23538,,
23539,,
23540,,
23541,,
23542,,
23543,,
23544,,
23545,,
23546,,
23547,,
23548,,
23549,,
23550,,
23551,,
23552,,
23553,,
23554,,
23555,,
23556,,
23557,,
23558,,
23559,,
23560,,
23561,,
23562,,
23563,,
23564,,
23565,,
23566,,
23567,,
23568,,
23569,,
23570,,
23571,,
23572,,
23573,,
23574,,
23575,,
23576,,
23577,,
23578,,
23579,,
23580,,
23581,,
23582,,
23583,,
23584,,
23585,,
23586,,
23587,,
23588,,
23589,,
23590,,
23591,,
23592,,
23593,,
23594,,
23595,,
23596,,
23597,,
23598,,
23599,,
23600,,
23601,,
23602,,
23603,,
23604,,
23605,,
23606,,
23607,,
23608,,
23609,,
23610,,
23611,,
23612,,
23613,,
23614,,
23615,,
23616,,
23617,,
23618,,
23619,,
23620,,
23621,,
23622,,
23623,,
23624,,
23625,,
23626,,
23627,,
23628,,
23629,,
23630,,
23631,,
23632,,
23633,,
23634,,
23635,,
23636,,
23637,,
23638,,
23639,,
23640,,
23641,,
23642,,
23643,,
23644,,
23645,,
23646,,
23647,,
23648,,
23649,,
23650,,
23651,,
23652,,
23653,,
23654,,
23655,,
23656,,
23657,,
23658,,
23659,,
23660,,
23661,,
23662,,
23663,,
23664,,
23665,,
23666,,
23667,,
23668,,
23669,,
23670,,
23671,,
23672,,
23673,,
23674,,
23675,,
23676,,
23677,,
23678,,
23679,,
23680,,
23681,,
23682,,
23683,,
23684,,
23685,,
23686,,
23687,,
23688,,
23689,,
23690,,
23691,,
23692,,
23693,,
23694,,
23695,,
23696,,
23697,,
23698,,
23699,,
23700,,
23701,,
23702,,
23703,,
23704,,
23705,,
23706,,
23707,,
23708,,
23709,,
23710,,
23711,,
23712,,
23713,,
23714,,
23715,,
23716,,
23717,,
23718,,
23719,,
23720,,
23721,,
23722,,
23723,,
23724,,
23725,,
23726,,
23727,,
23728,,
23729,,
23730,,
23731,,
23732,,
23733,,
23734,,
23735,,
23736,,
23737,,
23738,,
23739,,
23740,,
23741,,
23742,,
23743,,
23744,,
23745,,
23746,,
23747,,
23748,,
23749,,
23750,,
23751,,
23752,,
23753,,
23754,,
23755,,
23756,,
23757,,
23758,,
23759,,
23760,,
23761,,
23762,,
23763,,
23764,,
23765,,
23766,,
23767,,
23768,,
23769,,
23770,,
23771,,
23772,,
23773,,
23774,,
23775,,
23776,,
23777,,
23778,,
23779,,
23780,,
23781,,
23782,,
23783,,
23784,,
23785,,
23786,,
23787,,
23788,,
23789,,
23790,,
23791,,
23792,,
23793,,
23794,,
23795,,
23796,,
23797,,
23798,,
23799,,
23800,,
23801,,
23802,,
23803,,
23804,,
23805,,
23806,,
23807,,
23808,,
23809,,
23810,,
23811,,
23812,,
23813,,
23814,,
23815,,
23816,,
23817,,
23818,,
23819,,
23820,,
23821,,
23822,,
23823,,
23824,,
23825,,
23826,,
23827,,
23828,,
23829,,
23830,,
23831,,
23832,,
23833,,
23834,,
23835,,
23836,,
23837,,
23838,,
23839,,
23840,,
23841,,
23842,,
23843,,
23844,,
23845,,
23846,,
23847,,
23848,,
23849,,
23850,,
23851,,
23852,,
23853,,
23854,,
23855,,
23856,,
23857,,
23858,,
23859,,
23860,,
23861,,
23862,,
23863,,
23864,,
23865,,
23866,,
23867,,
23868,,
23869,,
23870,,
23871,,
23872,,
23873,,
23874,,
23875,,
23876,,
23877,,
23878,,
23879,,
23880,,
23881,,
23882,,
23883,,
23884,,
23885,,
23886,,
23887,,
23888,,
23889,,
23890,,
23891,,
23892,,
23893,,
23894,,
23895,,
23896,,
23897,,
23898,,
23899,,
23900,,
23901,,
23902,,
23903,,
23904,,
23905,,
23906,,
23907,,
23908,,
23909,,
23910,,
23911,,
23912,,
23913,,
23914,,
23915,,
23916,,
23917,,
23918,,
23919,,
23920,,
23921,,
23922,,
23923,,
23924,,
23925,,
23926,,
23927,,
23928,,
23929,,
23930,,
23931,,
23932,,
23933,,
23934,,
23935,,
23936,,
23937,,
23938,,
23939,,
23940,,
23941,,
23942,,
23943,,
23944,,
23945,,
23946,,
23947,,
23948,,
23949,,
23950,,
23951,,
23952,,
23953,,
23954,,
23955,,
23956,,
23957,,
23958,,
23959,,
23960,,
23961,,
23962,,
23963,,
23964,,
23965,,
23966,,
23967,,
23968,,
23969,,
23970,,
23971,,
23972,,
23973,,
23974,,
23975,,
23976,,
23977,,
23978,,
23979,,
23980,,
23981,,
23982,,
23983,,
23984,,
23985,,
23986,,
23987,,
23988,,
23989,,
23990,,
23991,,
23992,,
23993,,
23994,,
23995,,
23996,,
23997,,
23998,,
23999,,
24000,,
24001,,
24002,,
24003,,
24004,,
24005,,
24006,,
24007,,
24008,,
24009,,
24010,,
24011,,
24012,,
24013,,
24014,,
24015,,
24016,,
24017,,
24018,,
24019,,
24020,,
24021,,
24022,,
24023,,
24024,,
24025,,
24026,,
24027,,
24028,,
24029,,
24030,,
24031,,
24032,,
24033,,
24034,,
24035,,
24036,,
24037,,
24038,,
24039,,
24040,,
24041,,
24042,,
24043,,
24044,,
24045,,
24046,,
24047,,
24048,,
24049,,
24050,,
24051,,
24052,,
24053,,
24054,,
24055,,
24056,,
24057,,
24058,,
24059,,
24060,,
24061,,
24062,,
24063,,
24064,,
24065,,
24066,,
24067,,
24068,,
24069,,
24070,,
24071,,
24072,,
24073,,
24074,,
24075,,
24076,,
24077,,
24078,,
24079,,
24080,,
24081,,
24082,,
24083,,
24084,,
24085,,
24086,,
24087,,
24088,,
24089,,
24090,,
24091,,
24092,,
24093,,
24094,,
24095,,
24096,,
24097,,
24098,,
24099,,
24100,,
24101,,
24102,,
24103,,
24104,,
24105,,
24106,,
24107,,
24108,,
24109,,
24110,,
24111,,
24112,,
24113,,
24114,,
24115,,
24116,,
24117,,
24118,,
24119,,
24120,,
24121,,
24122,,
24123,,
24124,,
24125,,
24126,,
24127,,
24128,,
24129,,
24130,,
24131,,
24132,,
24133,,
24134,,
24135,,
24136,,
24137,,
24138,,
24139,,
24140,,
24141,,
24142,,
24143,,
24144,,
24145,,
24146,,
24147,,
24148,,
24149,,
24150,,
24151,,
24152,,
24153,,
24154,,
24155,,
24156,,
24157,,
24158,,
24159,,
24160,,
24161,,
24162,,
24163,,
24164,,
24165,,
24166,,
24167,,
24168,,
24169,,
24170,,
24171,,
24172,,
24173,,
24174,,
24175,,
24176,,
24177,,
24178,,
24179,,
24180,,
24181,,
24182,,
24183,,
24184,,
24185,,
24186,,
24187,,
24188,,
24189,,
24190,,
24191,,
24192,,
24193,,
24194,,
24195,,
24196,,
24197,,
24198,,
24199,,
24200,,
24201,,
24202,,
24203,,
24204,,
24205,,
24206,,
24207,,
24208,,
24209,,
24210,,
24211,,
24212,,
24213,,
24214,,
24215,,
24216,,
24217,,
24218,,
24219,,
24220,,
24221,,
24222,,
24223,,
24224,,
24225,,
24226,,
24227,,
24228,,
24229,,
24230,,
24231,,
24232,,
24233,,
24234,,
24235,,
24236,,
24237,,
24238,,
24239,,
24240,,
24241,,
24242,,
24243,,
24244,,
24245,,
24246,,
24247,,
24248,,
24249,,
24250,,
24251,,
24252,,
24253,,
24254,,
24255,,
24256,,
24257,,
24258,,
24259,,
24260,,
24261,,
24262,,
24263,,
24264,,
24265,,
24266,,
24267,,
24268,,
24269,,
24270,,
24271,,
24272,,
24273,,
24274,,
24275,,
24276,,
24277,,
24278,,
24279,,
24280,,
24281,,
24282,,
24283,,
24284,,
24285,,
24286,,
24287,,
24288,,
24289,,
24290,,
24291,,
24292,,
24293,,
24294,,
24295,,
24296,,
24297,,
24298,,
24299,,
24300,,
24301,,
24302,,
24303,,
24304,,
24305,,
24306,,
24307,,
24308,,
24309,,
24310,,
24311,,
24312,,
24313,,
24314,,
24315,,
24316,,
24317,,
24318,,
24319,,
24320,,
24321,,
24322,,
24323,,
24324,,
24325,,
24326,,
24327,,
24328,,
24329,,
24330,,
24331,,
24332,,
24333,,
24334,,
24335,,
24336,,
24337,,
24338,,
24339,,
24340,,
24341,,
24342,,
24343,,
24344,,
24345,,
24346,,
24347,,
24348,,
24349,,
24350,,
24351,,
24352,,
24353,,
24354,,
24355,,
24356,,
24357,,
24358,,
24359,,
24360,,
24361,,
24362,,
24363,,
24364,,
24365,,
24366,,
24367,,
24368,,
24369,,
24370,,
24371,,
24372,,
24373,,
24374,,
24375,,
24376,,
24377,,
24378,,
24379,,
24380,,
24381,,
24382,,
24383,,
24384,,
24385,,
24386,,
24387,,
24388,,
24389,,
24390,,
24391,,
24392,,
24393,,
24394,,
24395,,
24396,,
24397,,
24398,,
24399,,
24400,,
24401,,
24402,,
24403,,
24404,,
24405,,
24406,,
24407,,
24408,,
24409,,
24410,,
24411,,
24412,,
24413,,
24414,,
24415,,
24416,,
24417,,
24418,,
24419,,
24420,,
24421,,
24422,,
24423,,
24424,,
24425,,
24426,,
24427,,
24428,,
24429,,
24430,,
24431,,
24432,,
24433,,
24434,,
24435,,
24436,,
24437,,
24438,,
24439,,
24440,,
24441,,
24442,,
24443,,
24444,,
24445,,
24446,,
24447,,
24448,,
24449,,
24450,,
24451,,
24452,,
24453,,
24454,,
24455,,
24456,,
24457,,
24458,,
24459,,
24460,,
24461,,
24462,,
24463,,
24464,,
24465,,
24466,,
24467,,
24468,,
24469,,
24470,,
24471,,
24472,,
24473,,
24474,,
24475,,
24476,,
24477,,
24478,,
24479,,
24480,,
24481,,
24482,,
24483,,
24484,,
24485,,
24486,,
24487,,
24488,,
24489,,
24490,,
24491,,
24492,,
24493,,
24494,,
24495,,
24496,,
24497,,
24498,,
24499,,
24500,,
24501,,
24502,,
24503,,
24504,,
24505,,
24506,,
24507,,
24508,,
24509,,
24510,,
24511,,
24512,,
24513,,
24514,,
24515,,
24516,,
24517,,
24518,,
24519,,
24520,,
24521,,
24522,,
24523,,
24524,,
24525,,
24526,,
24527,,
24528,,
24529,,
24530,,
24531,,
24532,,
24533,,
24534,,
24535,,
24536,,
24537,,
24538,,
24539,,
24540,,
24541,,
24542,,
24543,,
24544,,
24545,,
24546,,
24547,,
24548,,
24549,,
24550,,
24551,,
24552,,
24553,,
24554,,
24555,,
24556,,
24557,,
24558,,
24559,,
24560,,
24561,,
24562,,
24563,,
24564,,
24565,,
24566,,
24567,,
24568,,
24569,,
24570,,
24571,,
24572,,
24573,,
24574,,
24575,,
24576,,
24577,,
24578,,
24579,,
24580,,
24581,,
24582,,
24583,,
24584,,
24585,,
24586,,
24587,,
24588,,
24589,,
24590,,
24591,,
24592,,
24593,,
24594,,
24595,,
24596,,
24597,,
24598,,
24599,,
24600,,
24601,,
24602,,
24603,,
24604,,
24605,,
24606,,
24607,,
24608,,
24609,,
24610,,
24611,,
24612,,
24613,,
24614,,
24615,,
24616,,
24617,,
24618,,
24619,,
24620,,
24621,,
24622,,
24623,,
24624,,
24625,,
24626,,
24627,,
24628,,
24629,,
24630,,
24631,,
24632,,
24633,,
24634,,
24635,,
24636,,
24637,,
24638,,
24639,,
24640,,
24641,,
24642,,
24643,,
24644,,
24645,,
24646,,
24647,,
24648,,
24649,,
24650,,
24651,,
24652,,
24653,,
24654,,
24655,,
24656,,
24657,,
24658,,
24659,,
24660,,
24661,,
24662,,
24663,,
24664,,
24665,,
24666,,
24667,,
24668,,
24669,,
24670,,
24671,,
24672,,
24673,,
24674,,
24675,,
24676,,
24677,,
24678,,
24679,,
24680,,
24681,,
24682,,
24683,,
24684,,
24685,,
24686,,
24687,,
24688,,
24689,,
24690,,
24691,,
24692,,
24693,,
24694,,
24695,,
24696,,
24697,,
24698,,
24699,,
24700,,
24701,,
24702,,
24703,,
24704,,
24705,,
24706,,
24707,,
24708,,
24709,,
24710,,
24711,,
24712,,
24713,,
24714,,
24715,,
24716,,
24717,,
24718,,
24719,,
24720,,
24721,,
24722,,
24723,,
24724,,
24725,,
24726,,
24727,,
24728,,
24729,,
24730,,
24731,,
24732,,
24733,,
24734,,
24735,,
24736,,
24737,,
24738,,
24739,,
24740,,
24741,,
24742,,
24743,,
24744,,
24745,,
24746,,
24747,,
24748,,
24749,,
24750,,
24751,,
24752,,
24753,,
24754,,
24755,,
24756,,
24757,,
24758,,
24759,,
24760,,
24761,,
24762,,
24763,,
24764,,
24765,,
24766,,
24767,,
24768,,
24769,,
24770,,
24771,,
24772,,
24773,,
24774,,
24775,,
24776,,
24777,,
24778,,
24779,,
24780,,
24781,,
24782,,
24783,,
24784,,
24785,,
24786,,
24787,,
24788,,
24789,,
24790,,
24791,,
24792,,
24793,,
24794,,
24795,,
24796,,
24797,,
24798,,
24799,,
24800,,
24801,,
24802,,
24803,,
24804,,
24805,,
24806,,
24807,,
24808,,
24809,,
24810,,
24811,,
24812,,
24813,,
24814,,
24815,,
24816,,
24817,,
24818,,
24819,,
24820,,
24821,,
24822,,
24823,,
24824,,
24825,,
24826,,
24827,,
24828,,
24829,,
24830,,
24831,,
24832,,
24833,,
24834,,
24835,,
24836,,
24837,,
24838,,
24839,,
24840,,
24841,,
24842,,
24843,,
24844,,
24845,,
24846,,
24847,,
24848,,
24849,,
24850,,
24851,,
24852,,
24853,,
24854,,
24855,,
24856,,
24857,,
24858,,
24859,,
24860,,
24861,,
24862,,
24863,,
24864,,
24865,,
24866,,
24867,,
24868,,
24869,,
24870,,
24871,,
24872,,
24873,,
24874,,
24875,,
24876,,
24877,,
24878,,
24879,,
24880,,
24881,,
24882,,
24883,,
24884,,
24885,,
24886,,
24887,,
24888,,
24889,,
24890,,
24891,,
24892,,
24893,,
24894,,
24895,,
24896,,
24897,,
24898,,
24899,,
24900,,
24901,,
24902,,
24903,,
24904,,
24905,,
24906,,
24907,,
24908,,
24909,,
24910,,
24911,,
24912,,
24913,,
24914,,
24915,,
24916,,
24917,,
24918,,
24919,,
24920,,
24921,,
24922,,
24923,,
24924,,
24925,,
24926,,
24927,,
24928,,
24929,,
24930,,
24931,,
24932,,
24933,,
24934,,
24935,,
24936,,
24937,,
24938,,
24939,,
24940,,
24941,,
24942,,
24943,,
24944,,
24945,,
24946,,
24947,,
24948,,
24949,,
24950,,
24951,,
24952,,
24953,,
24954,,
24955,,
24956,,
24957,,
24958,,
24959,,
24960,,
24961,,
24962,,
24963,,
24964,,
24965,,
24966,,
24967,,
24968,,
24969,,
24970,,
24971,,
24972,,
24973,,
24974,,
24975,,
24976,,
24977,,
24978,,
24979,,
24980,,
24981,,
24982,,
24983,,
24984,,
24985,,
24986,,
24987,,
24988,,
24989,,
24990,,
24991,,
24992,,
24993,,
24994,,
24995,,
24996,,
24997,,
24998,,
24999,,
25000,,
25001,,
25002,,
25003,,
25004,,
25005,,
25006,,
25007,,
25008,,
25009,,
25010,,
25011,,
25012,,
25013,,
25014,,
25015,,
25016,,
25017,,
25018,,
25019,,
25020,,
25021,,
25022,,
25023,,
25024,,
25025,,
25026,,
25027,,
25028,,
25029,,
25030,,
25031,,
25032,,
25033,,
25034,,
25035,,
25036,,
25037,,
25038,,
25039,,
25040,,
25041,,
25042,,
25043,,
25044,,
25045,,
25046,,
25047,,
25048,,
25049,,
25050,,
25051,,
25052,,
25053,,
25054,,
25055,,
25056,,
25057,,
25058,,
25059,,
25060,,
25061,,
25062,,
25063,,
25064,,
25065,,
25066,,
25067,,
25068,,
25069,,
25070,,
25071,,
25072,,
25073,,
25074,,
25075,,
25076,,
25077,,
25078,,
25079,,
25080,,
25081,,
25082,,
25083,,
25084,,
25085,,
25086,,
25087,,
25088,,
25089,,
25090,,
25091,,
25092,,
25093,,
25094,,
25095,,
25096,,
25097,,
25098,,
25099,,
25100,,
25101,,
25102,,
25103,,
25104,,
25105,,
25106,,
25107,,
25108,,
25109,,
25110,,
25111,,
25112,,
25113,,
25114,,
25115,,
25116,,
25117,,
25118,,
25119,,
25120,,
25121,,
25122,,
25123,,
25124,,
25125,,
25126,,
25127,,
25128,,
25129,,
25130,,
25131,,
25132,,
25133,,
25134,,
25135,,
25136,,
25137,,
25138,,
25139,,
25140,,
25141,,
25142,,
25143,,
25144,,
25145,,
25146,,
25147,,
25148,,
25149,,
25150,,
25151,,
25152,,
25153,,
25154,,
25155,,
25156,,
25157,,
25158,,
25159,,
25160,,
25161,,
25162,,
25163,,
25164,,
25165,,
25166,,
25167,,
25168,,
25169,,
25170,,
25171,,
25172,,
25173,,
25174,,
25175,,
25176,,
25177,,
25178,,
25179,,
25180,,
25181,,
25182,,
25183,,
25184,,
25185,,
25186,,
25187,,
25188,,
25189,,
25190,,
25191,,
25192,,
25193,,
25194,,
25195,,
25196,,
25197,,
25198,,
25199,,
25200,,
25201,,
25202,,
25203,,
25204,,
25205,,
25206,,
25207,,
25208,,
25209,,
25210,,
25211,,
25212,,
25213,,
25214,,
25215,,
25216,,
25217,,
25218,,
25219,,
25220,,
25221,,
25222,,
25223,,
25224,,
25225,,
25226,,
25227,,
25228,,
25229,,
25230,,
25231,,
25232,,
25233,,
25234,,
25235,,
25236,,
25237,,
25238,,
25239,,
25240,,
25241,,
25242,,
25243,,
25244,,
25245,,
25246,,
25247,,
25248,,
25249,,
25250,,
25251,,
25252,,
25253,,
25254,,
25255,,
25256,,
25257,,
25258,,
25259,,
25260,,
25261,,
25262,,
25263,,
25264,,
25265,,
25266,,
25267,,
25268,,
25269,,
25270,,
25271,,
25272,,
25273,,
25274,,
25275,,
25276,,
25277,,
25278,,
25279,,
25280,,
25281,,
25282,,
25283,,
25284,,
25285,,
25286,,
25287,,
25288,,
25289,,
25290,,
25291,,
25292,,
25293,,
25294,,
25295,,
25296,,
25297,,
25298,,
25299,,
25300,,
25301,,
25302,,
25303,,
25304,,
25305,,
25306,,
25307,,
25308,,
25309,,
25310,,
25311,,
25312,,
25313,,
25314,,
25315,,
25316,,
25317,,
25318,,
25319,,
25320,,
25321,,
25322,,
25323,,
25324,,
25325,,
25326,,
25327,,
25328,,
25329,,
25330,,
25331,,
25332,,
25333,,
25334,,
25335,,
25336,,
25337,,
25338,,
25339,,
25340,,
25341,,
25342,,
25343,,
25344,,
25345,,
25346,,
25347,,
25348,,
25349,,
25350,,
25351,,
25352,,
25353,,
25354,,
25355,,
25356,,
25357,,
25358,,
25359,,
25360,,
25361,,
25362,,
25363,,
25364,,
25365,,
25366,,
25367,,
25368,,
25369,,
25370,,
25371,,
25372,,
25373,,
25374,,
25375,,
25376,,
25377,,
25378,,
25379,,
25380,,
25381,,
25382,,
25383,,
25384,,
25385,,
25386,,
25387,,
25388,,
25389,,
25390,,
25391,,
25392,,
25393,,
25394,,
25395,,
25396,,
25397,,
25398,,
25399,,
25400,,
25401,,
25402,,
25403,,
25404,,
25405,,
25406,,
25407,,
25408,,
25409,,
25410,,
25411,,
25412,,
25413,,
25414,,
25415,,
25416,,
25417,,
25418,,
25419,,
25420,,
25421,,
25422,,
25423,,
25424,,
25425,,
25426,,
25427,,
25428,,
25429,,
25430,,
25431,,
25432,,
25433,,
25434,,
25435,,
25436,,
25437,,
25438,,
25439,,
25440,,
25441,,
25442,,
25443,,
25444,,
25445,,
25446,,
25447,,
25448,,
25449,,
25450,,
25451,,
25452,,
25453,,
25454,,
25455,,
25456,,
25457,,
25458,,
25459,,
25460,,
25461,,
25462,,
25463,,
25464,,
25465,,
25466,,
25467,,
25468,,
25469,,
25470,,
25471,,
25472,,
25473,,
25474,,
25475,,
25476,,
25477,,
25478,,
25479,,
25480,,
25481,,
25482,,
25483,,
25484,,
25485,,
25486,,
25487,,
25488,,
25489,,
25490,,
25491,,
25492,,
25493,,
25494,,
25495,,
25496,,
25497,,
25498,,
25499,,
25500,,
25501,,
25502,,
25503,,
25504,,
25505,,
25506,,
25507,,
25508,,
25509,,
25510,,
25511,,
25512,,
25513,,
25514,,
25515,,
25516,,
25517,,
25518,,
25519,,
25520,,
25521,,
25522,,
25523,,
25524,,
25525,,
25526,,
25527,,
25528,,
25529,,
25530,,
25531,,
25532,,
25533,,
25534,,
25535,,
25536,,
25537,,
25538,,
25539,,
25540,,
25541,,
25542,,
25543,,
25544,,
25545,,
25546,,
25547,,
25548,,
25549,,
25550,,
25551,,
25552,,
25553,,
25554,,
25555,,
25556,,
25557,,
25558,,
25559,,
25560,,
25561,,
25562,,
25563,,
25564,,
25565,,
25566,,
25567,,
25568,,
25569,,
25570,,
25571,,
25572,,
25573,,
25574,,
25575,,
25576,,
25577,,
25578,,
25579,,
25580,,
25581,,
25582,,
25583,,
25584,,
25585,,
25586,,
25587,,
25588,,
25589,,
25590,,
25591,,
25592,,
25593,,
25594,,
25595,,
25596,,
25597,,
25598,,
25599,,
25600,,
25601,,
25602,,
25603,,
25604,,
25605,,
25606,,
25607,,
25608,,
25609,,
25610,,
25611,,
25612,,
25613,,
25614,,
25615,,
25616,,
25617,,
25618,,
25619,,
25620,,
25621,,
25622,,
25623,,
25624,,
25625,,
25626,,
25627,,
25628,,
25629,,
25630,,
25631,,
25632,,
25633,,
25634,,
25635,,
25636,,
25637,,
25638,,
25639,,
25640,,
25641,,
25642,,
25643,,
25644,,
25645,,
25646,,
25647,,
25648,,
25649,,
25650,,
25651,,
25652,,
25653,,
25654,,
25655,,
25656,,
25657,,
25658,,
25659,,
25660,,
25661,,
25662,,
25663,,
25664,,
25665,,
25666,,
25667,,
25668,,
25669,,
25670,,
25671,,
25672,,
25673,,
25674,,
25675,,
25676,,
25677,,
25678,,
25679,,
25680,,
25681,,
25682,,
25683,,
25684,,
25685,,
25686,,
25687,,
25688,,
25689,,
25690,,
25691,,
25692,,
25693,,
25694,,
25695,,
25696,,
25697,,
25698,,
25699,,
25700,,
25701,,
25702,,
25703,,
25704,,
25705,,
25706,,
25707,,
25708,,
25709,,
25710,,
25711,,
25712,,
25713,,
25714,,
25715,,
25716,,
25717,,
25718,,
25719,,
25720,,
25721,,
25722,,
25723,,
25724,,
25725,,
25726,,
25727,,
25728,,
25729,,
25730,,
25731,,
25732,,
25733,,
25734,,
25735,,
25736,,
25737,,
25738,,
25739,,
25740,,
25741,,
25742,,
25743,,
25744,,
25745,,
25746,,
25747,,
25748,,
25749,,
25750,,
25751,,
25752,,
25753,,
25754,,
25755,,
25756,,
25757,,
25758,,
25759,,
25760,,
25761,,
25762,,
25763,,
25764,,
25765,,
25766,,
25767,,
25768,,
25769,,
25770,,
25771,,
25772,,
25773,,
25774,,
25775,,
25776,,
25777,,
25778,,
25779,,
25780,,
25781,,
25782,,
25783,,
25784,,
25785,,
25786,,
25787,,
25788,,
25789,,
25790,,
25791,,
25792,,
25793,,
25794,,
25795,,
25796,,
25797,,
25798,,
25799,,
25800,,
25801,,
25802,,
25803,,
25804,,
25805,,
25806,,
25807,,
25808,,
25809,,
25810,,
25811,,
25812,,
25813,,
25814,,
25815,,
25816,,
25817,,
25818,,
25819,,
25820,,
25821,,
25822,,
25823,,
25824,,
25825,,
25826,,
25827,,
25828,,
25829,,
25830,,
25831,,
25832,,
25833,,
25834,,
25835,,
25836,,
25837,,
25838,,
25839,,
25840,,
25841,,
25842,,
25843,,
25844,,
25845,,
25846,,
25847,,
25848,,
25849,,
25850,,
25851,,
25852,,
25853,,
25854,,
25855,,
25856,,
25857,,
25858,,
25859,,
25860,,
25861,,
25862,,
25863,,
25864,,
25865,,
25866,,
25867,,
25868,,
25869,,
25870,,
25871,,
25872,,
25873,,
25874,,
25875,,
25876,,
25877,,
25878,,
25879,,
25880,,
25881,,
25882,,
25883,,
25884,,
25885,,
25886,,
25887,,
25888,,
25889,,
25890,,
25891,,
25892,,
25893,,
25894,,
25895,,
25896,,
25897,,
25898,,
25899,,
25900,,
25901,,
25902,,
25903,,
25904,,
25905,,
25906,,
25907,,
25908,,
25909,,
25910,,
25911,,
25912,,
25913,,
25914,,
25915,,
25916,,
25917,,
25918,,
25919,,
25920,,
25921,,
25922,,
25923,,
25924,,
25925,,
25926,,
25927,,
25928,,
25929,,
25930,,
25931,,
25932,,
25933,,
25934,,
25935,,
25936,,
25937,,
25938,,
25939,,
25940,,
25941,,
25942,,
25943,,
25944,,
25945,,
25946,,
25947,,
25948,,
25949,,
25950,,
25951,,
25952,,
25953,,
25954,,
25955,,
25956,,
25957,,
25958,,
25959,,
25960,,
25961,,
25962,,
25963,,
25964,,
25965,,
25966,,
25967,,
25968,,
25969,,
25970,,
25971,,
25972,,
25973,,
25974,,
25975,,
25976,,
25977,,
25978,,
25979,,
25980,,
25981,,
25982,,
25983,,
25984,,
25985,,
25986,,
25987,,
25988,,
25989,,
25990,,
25991,,
25992,,
25993,,
25994,,
25995,,
25996,,
25997,,
25998,,
25999,,
26000,,
26001,,
26002,,
26003,,
26004,,
26005,,
26006,,
26007,,
26008,,
26009,,
26010,,
26011,,
26012,,
26013,,
26014,,
26015,,
26016,,
26017,,
26018,,
26019,,
26020,,
26021,,
26022,,
26023,,
26024,,
26025,,
26026,,
26027,,
26028,,
26029,,
26030,,
26031,,
26032,,
26033,,
26034,,
26035,,
26036,,
26037,,
26038,,
26039,,
26040,,
26041,,
26042,,
26043,,
26044,,
26045,,
26046,,
26047,,
26048,,
26049,,
26050,,
26051,,
26052,,
26053,,
26054,,
26055,,
26056,,
26057,,
26058,,
26059,,
26060,,
26061,,
26062,,
26063,,
26064,,
26065,,
26066,,
26067,,
26068,,
26069,,
26070,,
26071,,
26072,,
26073,,
26074,,
26075,,
26076,,
26077,,
26078,,
26079,,
26080,,
26081,,
26082,,
26083,,
26084,,
26085,,
26086,,
26087,,
26088,,
26089,,
26090,,
26091,,
26092,,
26093,,
26094,,
26095,,
26096,,
26097,,
26098,,
26099,,
26100,,
26101,,
26102,,
26103,,
26104,,
26105,,
26106,,
26107,,
26108,,
26109,,
26110,,
26111,,
26112,,
26113,,
26114,,
26115,,
26116,,
26117,,
26118,,
26119,,
26120,,
26121,,
26122,,
26123,,
26124,,
26125,,
26126,,
26127,,
26128,,
26129,,
26130,,
26131,,
26132,,
26133,,
26134,,
26135,,
26136,,
26137,,
26138,,
26139,,
26140,,
26141,,
26142,,
26143,,
26144,,
26145,,
26146,,
26147,,
26148,,
26149,,
26150,,
26151,,
26152,,
26153,,
26154,,
26155,,
26156,,
26157,,
26158,,
26159,,
26160,,
26161,,
26162,,
26163,,
26164,,
26165,,
26166,,
26167,,
26168,,
26169,,
26170,,
26171,,
26172,,
26173,,
26174,,
26175,,
26176,,
26177,,
26178,,
26179,,
26180,,
26181,,
26182,,
26183,,
26184,,
26185,,
26186,,
26187,,
26188,,
26189,,
26190,,
26191,,
26192,,
26193,,
26194,,
26195,,
26196,,
26197,,
26198,,
26199,,
26200,,
26201,,
26202,,
26203,,
26204,,
26205,,
26206,,
26207,,
26208,,
26209,,
26210,,
26211,,
26212,,
26213,,
26214,,
26215,,
26216,,
26217,,
26218,,
26219,,
26220,,
26221,,
26222,,
26223,,
26224,,
26225,,
26226,,
26227,,
26228,,
26229,,
26230,,
26231,,
26232,,
26233,,
26234,,
26235,,
26236,,
26237,,
26238,,
26239,,
26240,,
26241,,
26242,,
26243,,
26244,,
26245,,
26246,,
26247,,
26248,,
26249,,
26250,,
26251,,
26252,,
26253,,
26254,,
26255,,
26256,,
26257,,
26258,,
26259,,
26260,,
26261,,
26262,,
26263,,
26264,,
26265,,
26266,,
26267,,
26268,,
26269,,
26270,,
26271,,
26272,,
26273,,
26274,,
26275,,
26276,,
26277,,
26278,,
26279,,
26280,,
26281,,
26282,,
26283,,
26284,,
26285,,
26286,,
26287,,
26288,,
26289,,
26290,,
26291,,
26292,,
26293,,
26294,,
26295,,
26296,,
26297,,
26298,,
26299,,
26300,,
26301,,
26302,,
26303,,
26304,,
26305,,
26306,,
26307,,
26308,,
26309,,
26310,,
26311,,
26312,,
26313,,
26314,,
26315,,
26316,,
26317,,
26318,,
26319,,
26320,,
26321,,
26322,,
26323,,
26324,,
26325,,
26326,,
26327,,
26328,,
26329,,
26330,,
26331,,
26332,,
26333,,
26334,,
26335,,
26336,,
26337,,
26338,,
26339,,
26340,,
26341,,
26342,,
26343,,
26344,,
26345,,
26346,,
26347,,
26348,,
26349,,
26350,,
26351,,
26352,,
26353,,
26354,,
26355,,
26356,,
26357,,
26358,,
26359,,
26360,,
26361,,
26362,,
26363,,
26364,,
26365,,
26366,,
26367,,
26368,,
26369,,
26370,,
26371,,
26372,,
26373,,
26374,,
26375,,
26376,,
26377,,
26378,,
26379,,
26380,,
26381,,
26382,,
26383,,
26384,,
26385,,
26386,,
26387,,
26388,,
26389,,
26390,,
26391,,
26392,,
26393,,
26394,,
26395,,
26396,,
26397,,
26398,,
26399,,
26400,,
26401,,
26402,,
26403,,
26404,,
26405,,
26406,,
26407,,
26408,,
26409,,
26410,,
26411,,
26412,,
26413,,
26414,,
26415,,
26416,,
26417,,
26418,,
26419,,
26420,,
26421,,
26422,,
26423,,
26424,,
26425,,
26426,,
26427,,
26428,,
26429,,
26430,,
26431,,
26432,,
26433,,
26434,,
26435,,
26436,,
26437,,
26438,,
26439,,
26440,,
26441,,
26442,,
26443,,
26444,,
26445,,
26446,,
26447,,
26448,,
26449,,
26450,,
26451,,
26452,,
26453,,
26454,,
26455,,
26456,,
26457,,
26458,,
26459,,
26460,,
26461,,
26462,,
26463,,
26464,,
26465,,
26466,,
26467,,
26468,,
26469,,
26470,,
26471,,
26472,,
26473,,
26474,,
26475,,
26476,,
26477,,
26478,,
26479,,
26480,,
26481,,
26482,,
26483,,
26484,,
26485,,
26486,,
26487,,
26488,,
26489,,
26490,,
26491,,
26492,,
26493,,
26494,,
26495,,
26496,,
26497,,
26498,,
26499,,
26500,,
26501,,
26502,,
26503,,
26504,,
26505,,
26506,,
26507,,
26508,,
26509,,
26510,,
26511,,
26512,,
26513,,
26514,,
26515,,
26516,,
26517,,
26518,,
26519,,
26520,,
26521,,
26522,,
26523,,
26524,,
26525,,
26526,,
26527,,
26528,,
26529,,
26530,,
26531,,
26532,,
26533,,
26534,,
26535,,
26536,,
26537,,
26538,,
26539,,
26540,,
26541,,
26542,,
26543,,
26544,,
26545,,
26546,,
26547,,
26548,,
26549,,
26550,,
26551,,
26552,,
26553,,
26554,,
26555,,
26556,,
26557,,
26558,,
26559,,
26560,,
26561,,
26562,,
26563,,
26564,,
26565,,
26566,,
26567,,
26568,,
26569,,
26570,,
26571,,
26572,,
26573,,
26574,,
26575,,
26576,,
26577,,
26578,,
26579,,
26580,,
26581,,
26582,,
26583,,
26584,,
26585,,
26586,,
26587,,
26588,,
26589,,
26590,,
26591,,
26592,,
26593,,
26594,,
26595,,
26596,,
26597,,
26598,,
26599,,
26600,,
26601,,
26602,,
26603,,
26604,,
26605,,
26606,,
26607,,
26608,,
26609,,
26610,,
26611,,
26612,,
26613,,
26614,,
26615,,
26616,,
26617,,
26618,,
26619,,
26620,,
26621,,
26622,,
26623,,
26624,,
26625,,
26626,,
26627,,
26628,,
26629,,
26630,,
26631,,
26632,,
26633,,
26634,,
26635,,
26636,,
26637,,
26638,,
26639,,
26640,,
26641,,
26642,,
26643,,
26644,,
26645,,
26646,,
26647,,
26648,,
26649,,
26650,,
26651,,
26652,,
26653,,
26654,,
26655,,
26656,,
26657,,
26658,,
26659,,
26660,,
26661,,
26662,,
26663,,
26664,,
26665,,
26666,,
26667,,
26668,,
26669,,
26670,,
26671,,
26672,,
26673,,
26674,,
26675,,
26676,,
26677,,
26678,,
26679,,
26680,,
26681,,
26682,,
26683,,
26684,,
26685,,
26686,,
26687,,
26688,,
26689,,
26690,,
26691,,
26692,,
26693,,
26694,,
26695,,
26696,,
26697,,
26698,,
26699,,
26700,,
26701,,
26702,,
26703,,
26704,,
26705,,
26706,,
26707,,
26708,,
26709,,
26710,,
26711,,
26712,,
26713,,
26714,,
26715,,
26716,,
26717,,
26718,,
26719,,
26720,,
26721,,
26722,,
26723,,
26724,,
26725,,
26726,,
26727,,
26728,,
26729,,
26730,,
26731,,
26732,,
26733,,
26734,,
26735,,
26736,,
26737,,
26738,,
26739,,
26740,,
26741,,
26742,,
26743,,
26744,,
26745,,
26746,,
26747,,
26748,,
26749,,
26750,,
26751,,
26752,,
26753,,
26754,,
26755,,
26756,,
26757,,
26758,,
26759,,
26760,,
26761,,
26762,,
26763,,
26764,,
26765,,
26766,,
26767,,
26768,,
26769,,
26770,,
26771,,
26772,,
26773,,
26774,,
26775,,
26776,,
26777,,
26778,,
26779,,
26780,,
26781,,
26782,,
26783,,
26784,,
26785,,
26786,,
26787,,
26788,,
26789,,
26790,,
26791,,
26792,,
26793,,
26794,,
26795,,
26796,,
26797,,
26798,,
26799,,
26800,,
26801,,
26802,,
26803,,
26804,,
26805,,
26806,,
26807,,
26808,,
26809,,
26810,,
26811,,
26812,,
26813,,
26814,,
26815,,
26816,,
26817,,
26818,,
26819,,
26820,,
26821,,
26822,,
26823,,
26824,,
26825,,
26826,,
26827,,
26828,,
26829,,
26830,,
26831,,
26832,,
26833,,
26834,,
26835,,
26836,,
26837,,
26838,,
26839,,
26840,,
26841,,
26842,,
26843,,
26844,,
26845,,
26846,,
26847,,
26848,,
26849,,
26850,,
26851,,
26852,,
26853,,
26854,,
26855,,
26856,,
26857,,
26858,,
26859,,
26860,,
26861,,
26862,,
26863,,
26864,,
26865,,
26866,,
26867,,
26868,,
26869,,
26870,,
26871,,
26872,,
26873,,
26874,,
26875,,
26876,,
26877,,
26878,,
26879,,
26880,,
26881,,
26882,,
26883,,
26884,,
26885,,
26886,,
26887,,
26888,,
26889,,
26890,,
26891,,
26892,,
26893,,
26894,,
26895,,
26896,,
26897,,
26898,,
26899,,
26900,,
26901,,
26902,,
26903,,
26904,,
26905,,
26906,,
26907,,
26908,,
26909,,
26910,,
26911,,
26912,,
26913,,
26914,,
26915,,
26916,,
26917,,
26918,,
26919,,
26920,,
26921,,
26922,,
26923,,
26924,,
26925,,
26926,,
26927,,
26928,,
26929,,
26930,,
26931,,
26932,,
26933,,
26934,,
26935,,
26936,,
26937,,
26938,,
26939,,
26940,,
26941,,
26942,,
26943,,
26944,,
26945,,
26946,,
26947,,
26948,,
26949,,
26950,,
26951,,
26952,,
26953,,
26954,,
26955,,
26956,,
26957,,
26958,,
26959,,
26960,,
26961,,
26962,,
26963,,
26964,,
26965,,
26966,,
26967,,
26968,,
26969,,
26970,,
26971,,
26972,,
26973,,
26974,,
26975,,
26976,,
26977,,
26978,,
26979,,
26980,,
26981,,
26982,,
26983,,
26984,,
26985,,
26986,,
26987,,
26988,,
26989,,
26990,,
26991,,
26992,,
26993,,
26994,,
26995,,
26996,,
26997,,
26998,,
26999,,
27000,,
27001,,
27002,,
27003,,
27004,,
27005,,
27006,,
27007,,
27008,,
27009,,
27010,,
27011,,
27012,,
27013,,
27014,,
27015,,
27016,,
27017,,
27018,,
27019,,
27020,,
27021,,
27022,,
27023,,
27024,,
27025,,
27026,,
27027,,
27028,,
27029,,
27030,,
27031,,
27032,,
27033,,
27034,,
27035,,
27036,,
27037,,
27038,,
27039,,
27040,,
27041,,
27042,,
27043,,
27044,,
27045,,
27046,,
27047,,
27048,,
27049,,
27050,,
27051,,
27052,,
27053,,
27054,,
27055,,
27056,,
27057,,
27058,,
27059,,
27060,,
27061,,
27062,,
27063,,
27064,,
27065,,
27066,,
27067,,
27068,,
27069,,
27070,,
27071,,
27072,,
27073,,
27074,,
27075,,
27076,,
27077,,
27078,,
27079,,
27080,,
27081,,
27082,,
27083,,
27084,,
27085,,
27086,,
27087,,
27088,,
27089,,
27090,,
27091,,
27092,,
27093,,
27094,,
27095,,
27096,,
27097,,
27098,,
27099,,
27100,,
27101,,
27102,,
27103,,
27104,,
27105,,
27106,,
27107,,
27108,,
27109,,
27110,,
27111,,
27112,,
27113,,
27114,,
27115,,
27116,,
27117,,
27118,,
27119,,
27120,,
27121,,
27122,,
27123,,
27124,,
27125,,
27126,,
27127,,
27128,,
27129,,
27130,,
27131,,
27132,,
27133,,
27134,,
27135,,
27136,,
27137,,
27138,,
27139,,
27140,,
27141,,
27142,,
27143,,
27144,,
27145,,
27146,,
27147,,
27148,,
27149,,
27150,,
27151,,
27152,,
27153,,
27154,,
27155,,
27156,,
27157,,
27158,,
27159,,
27160,,
27161,,
27162,,
27163,,
27164,,
27165,,
27166,,
27167,,
27168,,
27169,,
27170,,
27171,,
27172,,
27173,,
27174,,
27175,,
27176,,
27177,,
27178,,
27179,,
27180,,
27181,,
27182,,
27183,,
27184,,
27185,,
27186,,
27187,,
27188,,
27189,,
27190,,
27191,,
27192,,
27193,,
27194,,
27195,,
27196,,
27197,,
27198,,
27199,,
27200,,
27201,,
27202,,
27203,,
27204,,
27205,,
27206,,
27207,,
27208,,
27209,,
27210,,
27211,,
27212,,
27213,,
27214,,
27215,,
27216,,
27217,,
27218,,
27219,,
27220,,
27221,,
27222,,
27223,,
27224,,
27225,,
27226,,
27227,,
27228,,
27229,,
27230,,
27231,,
27232,,
27233,,
27234,,
27235,,
27236,,
27237,,
27238,,
27239,,
27240,,
27241,,
27242,,
27243,,
27244,,
27245,,
27246,,
27247,,
27248,,
27249,,
27250,,
27251,,
27252,,
27253,,
27254,,
27255,,
27256,,
27257,,
27258,,
27259,,
27260,,
27261,,
27262,,
27263,,
27264,,
27265,,
27266,,
27267,,
27268,,
27269,,
27270,,
27271,,
27272,,
27273,,
27274,,
27275,,
27276,,
27277,,
27278,,
27279,,
27280,,
27281,,
27282,,
27283,,
27284,,
27285,,
27286,,
27287,,
27288,,
27289,,
27290,,
27291,,
27292,,
27293,,
27294,,
27295,,
27296,,
27297,,
27298,,
27299,,
27300,,
27301,,
27302,,
27303,,
27304,,
27305,,
27306,,
27307,,
27308,,
27309,,
27310,,
27311,,
27312,,
27313,,
27314,,
27315,,
27316,,
27317,,
27318,,
27319,,
27320,,
27321,,
27322,,
27323,,
27324,,
27325,,
27326,,
27327,,
27328,,
27329,,
27330,,
27331,,
27332,,
27333,,
27334,,
27335,,
27336,,
27337,,
27338,,
27339,,
27340,,
27341,,
27342,,
27343,,
27344,,
27345,,
27346,,
27347,,
27348,,
27349,,
27350,,
27351,,
27352,,
27353,,
27354,,
27355,,
27356,,
27357,,
27358,,
27359,,
27360,,
27361,,
27362,,
27363,,
27364,,
27365,,
27366,,
27367,,
27368,,
27369,,
27370,,
27371,,
27372,,
27373,,
27374,,
27375,,
27376,,
27377,,
27378,,
27379,,
27380,,
27381,,
27382,,
27383,,
27384,,
27385,,
27386,,
27387,,
27388,,
27389,,
27390,,
27391,,
27392,,
27393,,
27394,,
27395,,
27396,,
27397,,
27398,,
27399,,
27400,,
27401,,
27402,,
27403,,
27404,,
27405,,
27406,,
27407,,
27408,,
27409,,
27410,,
27411,,
27412,,
27413,,
27414,,
27415,,
27416,,
27417,,
27418,,
27419,,
27420,,
27421,,
27422,,
27423,,
27424,,
27425,,
27426,,
27427,,
27428,,
27429,,
27430,,
27431,,
27432,,
27433,,
27434,,
27435,,
27436,,
27437,,
27438,,
27439,,
27440,,
27441,,
27442,,
27443,,
27444,,
27445,,
27446,,
27447,,
27448,,
27449,,
27450,,
27451,,
27452,,
27453,,
27454,,
27455,,
27456,,
27457,,
27458,,
27459,,
27460,,
27461,,
27462,,
27463,,
27464,,
27465,,
27466,,
27467,,
27468,,
27469,,
27470,,
27471,,
27472,,
27473,,
27474,,
27475,,
27476,,
27477,,
27478,,
27479,,
27480,,
27481,,
27482,,
27483,,
27484,,
27485,,
27486,,
27487,,
27488,,
27489,,
27490,,
27491,,
27492,,
27493,,
27494,,
27495,,
27496,,
27497,,
27498,,
27499,,
27500,,
27501,,
27502,,
27503,,
27504,,
27505,,
27506,,
27507,,
27508,,
27509,,
27510,,
27511,,
27512,,
27513,,
27514,,
27515,,
27516,,
27517,,
27518,,
27519,,
27520,,
27521,,
27522,,
27523,,
27524,,
27525,,
27526,,
27527,,
27528,,
27529,,
27530,,
27531,,
27532,,
27533,,
27534,,
27535,,
27536,,
27537,,
27538,,
27539,,
27540,,
27541,,
27542,,
27543,,
27544,,
27545,,
27546,,
27547,,
27548,,
27549,,
27550,,
27551,,
27552,,
27553,,
27554,,
27555,,
27556,,
27557,,
27558,,
27559,,
27560,,
27561,,
27562,,
27563,,
27564,,
27565,,
27566,,
27567,,
27568,,
27569,,
27570,,
27571,,
27572,,
27573,,
27574,,
27575,,
27576,,
27577,,
27578,,
27579,,
27580,,
27581,,
27582,,
27583,,
27584,,
27585,,
27586,,
27587,,
27588,,
27589,,
27590,,
27591,,
27592,,
27593,,
27594,,
27595,,
27596,,
27597,,
27598,,
27599,,
27600,,
27601,,
27602,,
27603,,
27604,,
27605,,
27606,,
27607,,
27608,,
27609,,
27610,,
27611,,
27612,,
27613,,
27614,,
27615,,
27616,,
27617,,
27618,,
27619,,
27620,,
27621,,
27622,,
27623,,
27624,,
27625,,
27626,,
27627,,
27628,,
27629,,
27630,,
27631,,
27632,,
27633,,
27634,,
27635,,
27636,,
27637,,
27638,,
27639,,
27640,,
27641,,
27642,,
27643,,
27644,,
27645,,
27646,,
27647,,
27648,,
27649,,
27650,,
27651,,
27652,,
27653,,
27654,,
27655,,
27656,,
27657,,
27658,,
27659,,
27660,,
27661,,
27662,,
27663,,
27664,,
27665,,
27666,,
27667,,
27668,,
27669,,
27670,,
27671,,
27672,,
27673,,
27674,,
27675,,
27676,,
27677,,
27678,,
27679,,
27680,,
27681,,
27682,,
27683,,
27684,,
27685,,
27686,,
27687,,
27688,,
27689,,
27690,,
27691,,
27692,,
27693,,
27694,,
27695,,
27696,,
27697,,
27698,,
27699,,
27700,,
27701,,
27702,,
27703,,
27704,,
27705,,
27706,,
27707,,
27708,,
27709,,
27710,,
27711,,
27712,,
27713,,
27714,,
27715,,
27716,,
27717,,
27718,,
27719,,
27720,,
27721,,
27722,,
27723,,
27724,,
27725,,
27726,,
27727,,
27728,,
27729,,
27730,,
27731,,
27732,,
27733,,
27734,,
27735,,
27736,,
27737,,
27738,,
27739,,
27740,,
27741,,
27742,,
27743,,
27744,,
27745,,
27746,,
27747,,
27748,,
27749,,
27750,,
27751,,
27752,,
27753,,
27754,,
27755,,
27756,,
27757,,
27758,,
27759,,
27760,,
27761,,
27762,,
27763,,
27764,,
27765,,
27766,,
27767,,
27768,,
27769,,
27770,,
27771,,
27772,,
27773,,
27774,,
27775,,
27776,,
27777,,
27778,,
27779,,
27780,,
27781,,
27782,,
27783,,
27784,,
27785,,
27786,,
27787,,
27788,,
27789,,
27790,,
27791,,
27792,,
27793,,
27794,,
27795,,
27796,,
27797,,
27798,,
27799,,
27800,,
27801,,
27802,,
27803,,
27804,,
27805,,
27806,,
27807,,
27808,,
27809,,
27810,,
27811,,
27812,,
27813,,
27814,,
27815,,
27816,,
27817,,
27818,,
27819,,
27820,,
27821,,
27822,,
27823,,
27824,,
27825,,
27826,,
27827,,
27828,,
27829,,
27830,,
27831,,
27832,,
27833,,
27834,,
27835,,
27836,,
27837,,
27838,,
27839,,
27840,,
27841,,
27842,,
27843,,
27844,,
27845,,
27846,,
27847,,
27848,,
27849,,
27850,,
27851,,
27852,,
27853,,
27854,,
27855,,
27856,,
27857,,
27858,,
27859,,
27860,,
27861,,
27862,,
27863,,
27864,,
27865,,
27866,,
27867,,
27868,,
27869,,
27870,,
27871,,
27872,,
27873,,
27874,,
27875,,
27876,,
27877,,
27878,,
27879,,
27880,,
27881,,
27882,,
27883,,
27884,,
27885,,
27886,,
27887,,
27888,,
27889,,
27890,,
27891,,
27892,,
27893,,
27894,,
27895,,
27896,,
27897,,
27898,,
27899,,
27900,,
27901,,
27902,,
27903,,
27904,,
27905,,
27906,,
27907,,
27908,,
27909,,
27910,,
27911,,
27912,,
27913,,
27914,,
27915,,
27916,,
27917,,
27918,,
27919,,
27920,,
27921,,
27922,,
27923,,
27924,,
27925,,
27926,,
27927,,
27928,,
27929,,
27930,,
27931,,
27932,,
27933,,
27934,,
27935,,
27936,,
27937,,
27938,,
27939,,
27940,,
27941,,
27942,,
27943,,
27944,,
27945,,
27946,,
27947,,
27948,,
27949,,
27950,,
27951,,
27952,,
27953,,
27954,,
27955,,
27956,,
27957,,
27958,,
27959,,
27960,,
27961,,
27962,,
27963,,
27964,,
27965,,
27966,,
27967,,
27968,,
27969,,
27970,,
27971,,
27972,,
27973,,
27974,,
27975,,
27976,,
27977,,
27978,,
27979,,
27980,,
27981,,
27982,,
27983,,
27984,,
27985,,
27986,,
27987,,
27988,,
27989,,
27990,,
27991,,
27992,,
27993,,
27994,,
27995,,
27996,,
27997,,
27998,,
27999,,
28000,,
28001,,
28002,,
28003,,
28004,,
28005,,
28006,,
28007,,
28008,,
28009,,
28010,,
28011,,
28012,,
28013,,
28014,,
28015,,
28016,,
28017,,
28018,,
28019,,
28020,,
28021,,
28022,,
28023,,
28024,,
28025,,
28026,,
28027,,
28028,,
28029,,
28030,,
28031,,
28032,,
28033,,
28034,,
28035,,
28036,,
28037,,
28038,,
28039,,
28040,,
28041,,
28042,,
28043,,
28044,,
28045,,
28046,,
28047,,
28048,,
28049,,
28050,,
28051,,
28052,,
28053,,
28054,,
28055,,
28056,,
28057,,
28058,,
28059,,
28060,,
28061,,
28062,,
28063,,
28064,,
28065,,
28066,,
28067,,
28068,,
28069,,
28070,,
28071,,
28072,,
28073,,
28074,,
28075,,
28076,,
28077,,
28078,,
28079,,
28080,,
28081,,
28082,,
28083,,
28084,,
28085,,
28086,,
28087,,
28088,,
28089,,
28090,,
28091,,
28092,,
28093,,
28094,,
28095,,
28096,,
28097,,
28098,,
28099,,
28100,,
28101,,
28102,,
28103,,
28104,,
28105,,
28106,,
28107,,
28108,,
28109,,
28110,,
28111,,
28112,,
28113,,
28114,,
28115,,
28116,,
28117,,
28118,,
28119,,
28120,,
28121,,
28122,,
28123,,
28124,,
28125,,
28126,,
28127,,
28128,,
28129,,
28130,,
28131,,
28132,,
28133,,
28134,,
28135,,
28136,,
28137,,
28138,,
28139,,
28140,,
28141,,
28142,,
28143,,
28144,,
28145,,
28146,,
28147,,
28148,,
28149,,
28150,,
28151,,
28152,,
28153,,
28154,,
28155,,
28156,,
28157,,
28158,,
28159,,
28160,,
28161,,
28162,,
28163,,
28164,,
28165,,
28166,,
28167,,
28168,,
28169,,
28170,,
28171,,
28172,,
28173,,
28174,,
28175,,
28176,,
28177,,
28178,,
28179,,
28180,,
28181,,
28182,,
28183,,
28184,,
28185,,
28186,,
28187,,
28188,,
28189,,
28190,,
28191,,
28192,,
28193,,
28194,,
28195,,
28196,,
28197,,
28198,,
28199,,
28200,,
28201,,
28202,,
28203,,
28204,,
28205,,
28206,,
28207,,
28208,,
28209,,
28210,,
28211,,
28212,,
28213,,
28214,,
28215,,
28216,,
28217,,
28218,,
28219,,
28220,,
28221,,
28222,,
28223,,
28224,,
28225,,
28226,,
28227,,
28228,,
28229,,
28230,,
28231,,
28232,,
28233,,
28234,,
28235,,
28236,,
28237,,
28238,,
28239,,
28240,,
28241,,
28242,,
28243,,
28244,,
28245,,
28246,,
28247,,
28248,,
28249,,
28250,,
28251,,
28252,,
28253,,
28254,,
28255,,
28256,,
28257,,
28258,,
28259,,
28260,,
28261,,
28262,,
28263,,
28264,,
28265,,
28266,,
28267,,
28268,,
28269,,
28270,,
28271,,
28272,,
28273,,
28274,,
28275,,
28276,,
28277,,
28278,,
28279,,
28280,,
28281,,
28282,,
28283,,
28284,,
28285,,
28286,,
28287,,
28288,,
28289,,
28290,,
28291,,
28292,,
28293,,
28294,,
28295,,
28296,,
28297,,
28298,,
28299,,
28300,,
28301,,
28302,,
28303,,
28304,,
28305,,
28306,,
28307,,
28308,,
28309,,
28310,,
28311,,
28312,,
28313,,
28314,,
28315,,
28316,,
28317,,
28318,,
28319,,
28320,,
28321,,
28322,,
28323,,
28324,,
28325,,
28326,,
28327,,
28328,,
28329,,
28330,,
28331,,
28332,,
28333,,
28334,,
28335,,
28336,,
28337,,
28338,,
28339,,
28340,,
28341,,
28342,,
28343,,
28344,,
28345,,
28346,,
28347,,
28348,,
28349,,
28350,,
28351,,
28352,,
28353,,
28354,,
28355,,
28356,,
28357,,
28358,,
28359,,
28360,,
28361,,
28362,,
28363,,
28364,,
28365,,
28366,,
28367,,
28368,,
28369,,
28370,,
28371,,
28372,,
28373,,
28374,,
28375,,
28376,,
28377,,
28378,,
28379,,
28380,,
28381,,
28382,,
28383,,
28384,,
28385,,
28386,,
28387,,
28388,,
28389,,
28390,,
28391,,
28392,,
28393,,
28394,,
28395,,
28396,,
28397,,
28398,,
28399,,
28400,,
28401,,
28402,,
28403,,
28404,,
28405,,
28406,,
28407,,
28408,,
28409,,
28410,,
28411,,
28412,,
28413,,
28414,,
28415,,
28416,,
28417,,
28418,,
28419,,
28420,,
28421,,
28422,,
28423,,
28424,,
28425,,
28426,,
28427,,
28428,,
28429,,
28430,,
28431,,
28432,,
28433,,
28434,,
28435,,
28436,,
28437,,
28438,,
28439,,
28440,,
28441,,
28442,,
28443,,
28444,,
28445,,
28446,,
28447,,
28448,,
28449,,
28450,,
28451,,
28452,,
28453,,
28454,,
28455,,
28456,,
28457,,
28458,,
28459,,
28460,,
28461,,
28462,,
28463,,
28464,,
28465,,
28466,,
28467,,
28468,,
28469,,
28470,,
28471,,
28472,,
28473,,
28474,,
28475,,
28476,,
28477,,
28478,,
28479,,
28480,,
28481,,
28482,,
28483,,
28484,,
28485,,
28486,,
28487,,
28488,,
28489,,
28490,,
28491,,
28492,,
28493,,
28494,,
28495,,
28496,,
28497,,
28498,,
28499,,
28500,,
28501,,
28502,,
28503,,
28504,,
28505,,
28506,,
28507,,
28508,,
28509,,
28510,,
28511,,
28512,,
28513,,
28514,,
28515,,
28516,,
28517,,
28518,,
28519,,
28520,,
28521,,
28522,,
28523,,
28524,,
28525,,
28526,,
28527,,
28528,,
28529,,
28530,,
28531,,
28532,,
28533,,
28534,,
28535,,
28536,,
28537,,
28538,,
28539,,
28540,,
28541,,
28542,,
28543,,
28544,,
28545,,
28546,,
28547,,
28548,,
28549,,
28550,,
28551,,
28552,,
28553,,
28554,,
28555,,
28556,,
28557,,
28558,,
28559,,
28560,,
28561,,
28562,,
28563,,
28564,,
28565,,
28566,,
28567,,
28568,,
28569,,
28570,,
28571,,
28572,,
28573,,
28574,,
28575,,
28576,,
28577,,
28578,,
28579,,
28580,,
28581,,
28582,,
28583,,
28584,,
28585,,
28586,,
28587,,
28588,,
28589,,
28590,,
28591,,
28592,,
28593,,
28594,,
28595,,
28596,,
28597,,
28598,,
28599,,
28600,,
28601,,
28602,,
28603,,
28604,,
28605,,
28606,,
28607,,
28608,,
28609,,
28610,,
28611,,
28612,,
28613,,
28614,,
28615,,
28616,,
28617,,
28618,,
28619,,
28620,,
28621,,
28622,,
28623,,
28624,,
28625,,
28626,,
28627,,
28628,,
28629,,
28630,,
28631,,
28632,,
28633,,
28634,,
28635,,
28636,,
28637,,
28638,,
28639,,
28640,,
28641,,
28642,,
28643,,
28644,,
28645,,
28646,,
28647,,
28648,,
28649,,
28650,,
28651,,
28652,,
28653,,
28654,,
28655,,
28656,,
28657,,
28658,,
28659,,
28660,,
28661,,
28662,,
28663,,
28664,,
28665,,
28666,,
28667,,
28668,,
28669,,
28670,,
28671,,
28672,,
28673,,
28674,,
28675,,
28676,,
28677,,
28678,,
28679,,
28680,,
28681,,
28682,,
28683,,
28684,,
28685,,
28686,,
28687,,
28688,,
28689,,
28690,,
28691,,
28692,,
28693,,
28694,,
28695,,
28696,,
28697,,
28698,,
28699,,
28700,,
28701,,
28702,,
28703,,
28704,,
28705,,
28706,,
28707,,
28708,,
28709,,
28710,,
28711,,
28712,,
28713,,
28714,,
28715,,
28716,,
28717,,
28718,,
28719,,
28720,,
28721,,
28722,,
28723,,
28724,,
28725,,
28726,,
28727,,
28728,,
28729,,
28730,,
28731,,
28732,,
28733,,
28734,,
28735,,
28736,,
28737,,
28738,,
28739,,
28740,,
28741,,
28742,,
28743,,
28744,,
28745,,
28746,,
28747,,
28748,,
28749,,
28750,,
28751,,
28752,,
28753,,
28754,,
28755,,
28756,,
28757,,
28758,,
28759,,
28760,,
28761,,
28762,,
28763,,
28764,,
28765,,
28766,,
28767,,
28768,,
28769,,
28770,,
28771,,
28772,,
28773,,
28774,,
28775,,
28776,,
28777,,
28778,,
28779,,
28780,,
28781,,
28782,,
28783,,
28784,,
28785,,
28786,,
28787,,
28788,,
28789,,
28790,,
28791,,
28792,,
28793,,
28794,,
28795,,
28796,,
28797,,
28798,,
28799,,
28800,,
28801,,
28802,,
28803,,
28804,,
28805,,
28806,,
28807,,
28808,,
28809,,
28810,,
28811,,
28812,,
28813,,
28814,,
28815,,
28816,,
28817,,
28818,,
28819,,
28820,,
28821,,
28822,,
28823,,
28824,,
28825,,
28826,,
28827,,
28828,,
28829,,
28830,,
28831,,
28832,,
28833,,
28834,,
28835,,
28836,,
28837,,
28838,,
28839,,
28840,,
28841,,
28842,,
28843,,
28844,,
28845,,
28846,,
28847,,
28848,,
28849,,
28850,,
28851,,
28852,,
28853,,
28854,,
28855,,
28856,,
28857,,
28858,,
28859,,
28860,,
28861,,
28862,,
28863,,
28864,,
28865,,
28866,,
28867,,
28868,,
28869,,
28870,,
28871,,
28872,,
28873,,
28874,,
28875,,
28876,,
28877,,
28878,,
28879,,
28880,,
28881,,
28882,,
28883,,
28884,,
28885,,
28886,,
28887,,
28888,,
28889,,
28890,,
28891,,
28892,,
28893,,
28894,,
28895,,
28896,,
28897,,
28898,,
28899,,
28900,,
28901,,
28902,,
28903,,
28904,,
28905,,
28906,,
28907,,
28908,,
28909,,
28910,,
28911,,
28912,,
28913,,
28914,,
28915,,
28916,,
28917,,
28918,,
28919,,
28920,,
28921,,
28922,,
28923,,
28924,,
28925,,
28926,,
28927,,
28928,,
28929,,
28930,,
28931,,
28932,,
28933,,
28934,,
28935,,
28936,,
28937,,
28938,,
28939,,
28940,,
28941,,
28942,,
28943,,
28944,,
28945,,
28946,,
28947,,
28948,,
28949,,
28950,,
28951,,
28952,,
28953,,
28954,,
28955,,
28956,,
28957,,
28958,,
28959,,
28960,,
28961,,
28962,,
28963,,
28964,,
28965,,
28966,,
28967,,
28968,,
28969,,
28970,,
28971,,
28972,,
28973,,
28974,,
28975,,
28976,,
28977,,
28978,,
28979,,
28980,,
28981,,
28982,,
28983,,
28984,,
28985,,
28986,,
28987,,
28988,,
28989,,
28990,,
28991,,
28992,,
28993,,
28994,,
28995,,
28996,,
28997,,
28998,,
28999,,
29000,,
29001,,
29002,,
29003,,
29004,,
29005,,
29006,,
29007,,
29008,,
29009,,
29010,,
29011,,
29012,,
29013,,
29014,,
29015,,
29016,,
29017,,
29018,,
29019,,
29020,,
29021,,
29022,,
29023,,
29024,,
29025,,
29026,,
29027,,
29028,,
29029,,
29030,,
29031,,
29032,,
29033,,
29034,,
29035,,
29036,,
29037,,
29038,,
29039,,
29040,,
29041,,
29042,,
29043,,
29044,,
29045,,
29046,,
29047,,
29048,,
29049,,
29050,,
29051,,
29052,,
29053,,
29054,,
29055,,
29056,,
29057,,
29058,,
29059,,
29060,,
29061,,
29062,,
29063,,
29064,,
29065,,
29066,,
29067,,
29068,,
29069,,
29070,,
29071,,
29072,,
29073,,
29074,,
29075,,
29076,,
29077,,
29078,,
29079,,
29080,,
29081,,
29082,,
29083,,
29084,,
29085,,
29086,,
29087,,
29088,,
29089,,
29090,,
29091,,
29092,,
29093,,
29094,,
29095,,
29096,,
29097,,
29098,,
29099,,
29100,,
29101,,
29102,,
29103,,
29104,,
29105,,
29106,,
29107,,
29108,,
29109,,
29110,,
29111,,
29112,,
29113,,
29114,,
29115,,
29116,,
29117,,
29118,,
29119,,
29120,,
29121,,
29122,,
29123,,
29124,,
29125,,
29126,,
29127,,
29128,,
29129,,
29130,,
29131,,
29132,,
29133,,
29134,,
29135,,
29136,,
29137,,
29138,,
29139,,
29140,,
29141,,
29142,,
29143,,
29144,,
29145,,
29146,,
29147,,
29148,,
29149,,
29150,,
29151,,
29152,,
29153,,
29154,,
29155,,
29156,,
29157,,
29158,,
29159,,
29160,,
29161,,
29162,,
29163,,
29164,,
29165,,
29166,,
29167,,
29168,,
29169,,
29170,,
29171,,
29172,,
29173,,
29174,,
29175,,
29176,,
29177,,
29178,,
29179,,
29180,,
29181,,
29182,,
29183,,
29184,,
29185,,
29186,,
29187,,
29188,,
29189,,
29190,,
29191,,
29192,,
29193,,
29194,,
29195,,
29196,,
29197,,
29198,,
29199,,
29200,,
29201,,
29202,,
29203,,
29204,,
29205,,
29206,,
29207,,
29208,,
29209,,
29210,,
29211,,
29212,,
29213,,
29214,,
29215,,
29216,,
29217,,
29218,,
29219,,
29220,,
29221,,
29222,,
29223,,
29224,,
29225,,
29226,,
29227,,
29228,,
29229,,
29230,,
29231,,
29232,,
29233,,
29234,,
29235,,
29236,,
29237,,
29238,,
29239,,
29240,,
29241,,
29242,,
29243,,
29244,,
29245,,
29246,,
29247,,
29248,,
29249,,
29250,,
29251,,
29252,,
29253,,
29254,,
29255,,
29256,,
29257,,
29258,,
29259,,
29260,,
29261,,
29262,,
29263,,
29264,,
29265,,
29266,,
29267,,
29268,,
29269,,
29270,,
29271,,
29272,,
29273,,
29274,,
29275,,
29276,,
29277,,
29278,,
29279,,
29280,,
29281,,
29282,,
29283,,
29284,,
29285,,
29286,,
29287,,
29288,,
29289,,
29290,,
29291,,
29292,,
29293,,
29294,,
29295,,
29296,,
29297,,
29298,,
29299,,
29300,,
29301,,
29302,,
29303,,
29304,,
29305,,
29306,,
29307,,
29308,,
29309,,
29310,,
29311,,
29312,,
29313,,
29314,,
29315,,
29316,,
29317,,
29318,,
29319,,
29320,,
29321,,
29322,,
29323,,
29324,,
29325,,
29326,,
29327,,
29328,,
29329,,
29330,,
29331,,
29332,,
29333,,
29334,,
29335,,
29336,,
29337,,
29338,,
29339,,
29340,,
29341,,
29342,,
29343,,
29344,,
29345,,
29346,,
29347,,
29348,,
29349,,
29350,,
29351,,
29352,,
29353,,
29354,,
29355,,
29356,,
29357,,
29358,,
29359,,
29360,,
29361,,
29362,,
29363,,
29364,,
29365,,
29366,,
29367,,
29368,,
29369,,
29370,,
29371,,
29372,,
29373,,
29374,,
29375,,
29376,,
29377,,
29378,,
29379,,
29380,,
29381,,
29382,,
29383,,
29384,,
29385,,
29386,,
29387,,
29388,,
29389,,
29390,,
29391,,
29392,,
29393,,
29394,,
29395,,
29396,,
29397,,
29398,,
29399,,
29400,,
29401,,
29402,,
29403,,
29404,,
29405,,
29406,,
29407,,
29408,,
29409,,
29410,,
29411,,
29412,,
29413,,
29414,,
29415,,
29416,,
29417,,
29418,,
29419,,
29420,,
29421,,
29422,,
29423,,
29424,,
29425,,
29426,,
29427,,
29428,,
29429,,
29430,,
29431,,
29432,,
29433,,
29434,,
29435,,
29436,,
29437,,
29438,,
29439,,
29440,,
29441,,
29442,,
29443,,
29444,,
29445,,
29446,,
29447,,
29448,,
29449,,
29450,,
29451,,
29452,,
29453,,
29454,,
29455,,
29456,,
29457,,
29458,,
29459,,
29460,,
29461,,
29462,,
29463,,
29464,,
29465,,
29466,,
29467,,
29468,,
29469,,
29470,,
29471,,
29472,,
29473,,
29474,,
29475,,
29476,,
29477,,
29478,,
29479,,
29480,,
29481,,
29482,,
29483,,
29484,,
29485,,
29486,,
29487,,
29488,,
29489,,
29490,,
29491,,
29492,,
29493,,
29494,,
29495,,
29496,,
29497,,
29498,,
29499,,
29500,,
29501,,
29502,,
29503,,
29504,,
29505,,
29506,,
29507,,
29508,,
29509,,
29510,,
29511,,
29512,,
29513,,
29514,,
29515,,
29516,,
29517,,
29518,,
29519,,
29520,,
29521,,
29522,,
29523,,
29524,,
29525,,
29526,,
29527,,
29528,,
29529,,
29530,,
29531,,
29532,,
29533,,
29534,,
29535,,
29536,,
29537,,
29538,,
29539,,
29540,,
29541,,
29542,,
29543,,
29544,,
29545,,
29546,,
29547,,
29548,,
29549,,
29550,,
29551,,
29552,,
29553,,
29554,,
29555,,
29556,,
29557,,
29558,,
29559,,
29560,,
29561,,
29562,,
29563,,
29564,,
29565,,
29566,,
29567,,
29568,,
29569,,
29570,,
29571,,
29572,,
29573,,
29574,,
29575,,
29576,,
29577,,
29578,,
29579,,
29580,,
29581,,
29582,,
29583,,
29584,,
29585,,
29586,,
29587,,
29588,,
29589,,
29590,,
29591,,
29592,,
29593,,
29594,,
29595,,
29596,,
29597,,
29598,,
29599,,
29600,,
29601,,
29602,,
29603,,
29604,,
29605,,
29606,,
29607,,
29608,,
29609,,
29610,,
29611,,
29612,,
29613,,
29614,,
29615,,
29616,,
29617,,
29618,,
29619,,
29620,,
29621,,
29622,,
29623,,
29624,,
29625,,
29626,,
29627,,
29628,,
29629,,
29630,,
29631,,
29632,,
29633,,
29634,,
29635,,
29636,,
29637,,
29638,,
29639,,
29640,,
29641,,
29642,,
29643,,
29644,,
29645,,
29646,,
29647,,
29648,,
29649,,
29650,,
29651,,
29652,,
29653,,
29654,,
29655,,
29656,,
29657,,
29658,,
29659,,
29660,,
29661,,
29662,,
29663,,
29664,,
29665,,
29666,,
29667,,
29668,,
29669,,
29670,,
29671,,
29672,,
29673,,
29674,,
29675,,
29676,,
29677,,
29678,,
29679,,
29680,,
29681,,
29682,,
29683,,
29684,,
29685,,
29686,,
29687,,
29688,,
29689,,
29690,,
29691,,
29692,,
29693,,
29694,,
29695,,
29696,,
29697,,
29698,,
29699,,
29700,,
29701,,
29702,,
29703,,
29704,,
29705,,
29706,,
29707,,
29708,,
29709,,
29710,,
29711,,
29712,,
29713,,
29714,,
29715,,
29716,,
29717,,
29718,,
29719,,
29720,,
29721,,
29722,,
29723,,
29724,,
29725,,
29726,,
29727,,
29728,,
29729,,
29730,,
29731,,
29732,,
29733,,
29734,,
29735,,
29736,,
29737,,
29738,,
29739,,
29740,,
29741,,
29742,,
29743,,
29744,,
29745,,
29746,,
29747,,
29748,,
29749,,
29750,,
29751,,
29752,,
29753,,
29754,,
29755,,
29756,,
29757,,
29758,,
29759,,
29760,,
29761,,
29762,,
29763,,
29764,,
29765,,
29766,,
29767,,
29768,,
29769,,
29770,,
29771,,
29772,,
29773,,
29774,,
29775,,
29776,,
29777,,
29778,,
29779,,
29780,,
29781,,
29782,,
29783,,
29784,,
29785,,
29786,,
29787,,
29788,,
29789,,
29790,,
29791,,
29792,,
29793,,
29794,,
29795,,
29796,,
29797,,
29798,,
29799,,
29800,,
29801,,
29802,,
29803,,
29804,,
29805,,
29806,,
29807,,
29808,,
29809,,
29810,,
29811,,
29812,,
29813,,
29814,,
29815,,
29816,,
29817,,
29818,,
29819,,
29820,,
29821,,
29822,,
29823,,
29824,,
29825,,
29826,,
29827,,
29828,,
29829,,
29830,,
29831,,
29832,,
29833,,
29834,,
29835,,
29836,,
29837,,
29838,,
29839,,
29840,,
29841,,
29842,,
29843,,
29844,,
29845,,
29846,,
29847,,
29848,,
29849,,
29850,,
29851,,
29852,,
29853,,
29854,,
29855,,
29856,,
29857,,
29858,,
29859,,
29860,,
29861,,
29862,,
29863,,
29864,,
29865,,
29866,,
29867,,
29868,,
29869,,
29870,,
29871,,
29872,,
29873,,
29874,,
29875,,
29876,,
29877,,
29878,,
29879,,
29880,,
29881,,
29882,,
29883,,
29884,,
29885,,
29886,,
29887,,
29888,,
29889,,
29890,,
29891,,
29892,,
29893,,
29894,,
29895,,
29896,,
29897,,
29898,,
29899,,
29900,,
29901,,
29902,,
29903,,
29904,,
29905,,
29906,,
29907,,
29908,,
29909,,
29910,,
29911,,
29912,,
29913,,
29914,,
29915,,
29916,,
29917,,
29918,,
29919,,
29920,,
29921,,
29922,,
29923,,
29924,,
29925,,
29926,,
29927,,
29928,,
29929,,
29930,,
29931,,
29932,,
29933,,
29934,,
29935,,
29936,,
29937,,
29938,,
29939,,
29940,,
29941,,
29942,,
29943,,
29944,,
29945,,
29946,,
29947,,
29948,,
29949,,
29950,,
29951,,
29952,,
29953,,
29954,,
29955,,
29956,,
29957,,
29958,,
29959,,
29960,,
29961,,
29962,,
29963,,
29964,,
29965,,
29966,,
29967,,
29968,,
29969,,
29970,,
29971,,
29972,,
29973,,
29974,,
29975,,
29976,,
29977,,
29978,,
29979,,
29980,,
29981,,
29982,,
29983,,
29984,,
29985,,
29986,,
29987,,
29988,,
29989,,
29990,,
29991,,
29992,,
29993,,
29994,,
29995,,
29996,,
29997,,
29998,,
29999,,
30000,,
30001,,
30002,,
30003,,
30004,,
30005,,
30006,,
30007,,
30008,,
30009,,
30010,,
30011,,
30012,,
30013,,
30014,,
30015,,
30016,,
30017,,
30018,,
30019,,
30020,,
30021,,
30022,,
30023,,
30024,,
30025,,
30026,,
30027,,
30028,,
30029,,
30030,,
30031,,
30032,,
30033,,
30034,,
30035,,
30036,,
30037,,
30038,,
30039,,
30040,,
30041,,
30042,,
30043,,
30044,,
30045,,
30046,,
30047,,
30048,,
30049,,
30050,,
30051,,
30052,,
30053,,
30054,,
30055,,
30056,,
30057,,
30058,,
30059,,
30060,,
30061,,
30062,,
30063,,
30064,,
30065,,
30066,,
30067,,
30068,,
30069,,
30070,,
30071,,
30072,,
30073,,
30074,,
30075,,
30076,,
30077,,
30078,,
30079,,
30080,,
30081,,
30082,,
30083,,
30084,,
30085,,
30086,,
30087,,
30088,,
30089,,
30090,,
30091,,
30092,,
30093,,
30094,,
30095,,
30096,,
30097,,
30098,,
30099,,
30100,,
30101,,
30102,,
30103,,
30104,,
30105,,
30106,,
30107,,
30108,,
30109,,
30110,,
30111,,
30112,,
30113,,
30114,,
30115,,
30116,,
30117,,
30118,,
30119,,
30120,,
30121,,
30122,,
30123,,
30124,,
30125,,
30126,,
30127,,
30128,,
30129,,
30130,,
30131,,
30132,,
30133,,
30134,,
30135,,
30136,,
30137,,
30138,,
30139,,
30140,,
30141,,
30142,,
30143,,
30144,,
30145,,
30146,,
30147,,
30148,,
30149,,
30150,,
30151,,
30152,,
30153,,
30154,,
30155,,
30156,,
30157,,
30158,,
30159,,
30160,,
30161,,
30162,,
30163,,
30164,,
30165,,
30166,,
30167,,
30168,,
30169,,
30170,,
30171,,
30172,,
30173,,
30174,,
30175,,
30176,,
30177,,
30178,,
30179,,
30180,,
30181,,
30182,,
30183,,
30184,,
30185,,
30186,,
30187,,
30188,,
30189,,
30190,,
30191,,
30192,,
30193,,
30194,,
30195,,
30196,,
30197,,
30198,,
30199,,
30200,,
30201,,
30202,,
30203,,
30204,,
30205,,
30206,,
30207,,
30208,,
30209,,
30210,,
30211,,
30212,,
30213,,
30214,,
30215,,
30216,,
30217,,
30218,,
30219,,
30220,,
30221,,
30222,,
30223,,
30224,,
30225,,
30226,,
30227,,
30228,,
30229,,
30230,,
30231,,
30232,,
30233,,
30234,,
30235,,
30236,,
30237,,
30238,,
30239,,
30240,,
30241,,
30242,,
30243,,
30244,,
30245,,
30246,,
30247,,
30248,,
30249,,
30250,,
30251,,
30252,,
30253,,
30254,,
30255,,
30256,,
30257,,
30258,,
30259,,
30260,,
30261,,
30262,,
30263,,
30264,,
30265,,
30266,,
30267,,
30268,,
30269,,
30270,,
30271,,
30272,,
30273,,
30274,,
30275,,
30276,,
30277,,
30278,,
30279,,
30280,,
30281,,
30282,,
30283,,
30284,,
30285,,
30286,,
30287,,
30288,,
30289,,
30290,,
30291,,
30292,,
30293,,
30294,,
30295,,
30296,,
30297,,
30298,,
30299,,
30300,,
30301,,
30302,,
30303,,
30304,,
30305,,
30306,,
30307,,
30308,,
30309,,
30310,,
30311,,
30312,,
30313,,
30314,,
30315,,
30316,,
30317,,
30318,,
30319,,
30320,,
30321,,
30322,,
30323,,
30324,,
30325,,
30326,,
30327,,
30328,,
30329,,
30330,,
30331,,
30332,,
30333,,
30334,,
30335,,
30336,,
30337,,
30338,,
30339,,
30340,,
30341,,
30342,,
30343,,
30344,,
30345,,
30346,,
30347,,
30348,,
30349,,
30350,,
30351,,
30352,,
30353,,
30354,,
30355,,
30356,,
30357,,
30358,,
30359,,
30360,,
30361,,
30362,,
30363,,
30364,,
30365,,
30366,,
30367,,
30368,,
30369,,
30370,,
30371,,
30372,,
30373,,
30374,,
30375,,
30376,,
30377,,
30378,,
30379,,
30380,,
30381,,
30382,,
30383,,
30384,,
30385,,
30386,,
30387,,
30388,,
30389,,
30390,,
30391,,
30392,,
30393,,
30394,,
30395,,
30396,,
30397,,
30398,,
30399,,
30400,,
30401,,
30402,,
30403,,
30404,,
30405,,
30406,,
30407,,
30408,,
30409,,
30410,,
30411,,
30412,,
30413,,
30414,,
30415,,
30416,,
30417,,
30418,,
30419,,
30420,,
30421,,
30422,,
30423,,
30424,,
30425,,
30426,,
30427,,
30428,,
30429,,
30430,,
30431,,
30432,,
30433,,
30434,,
30435,,
30436,,
30437,,
30438,,
30439,,
30440,,
30441,,
30442,,
30443,,
30444,,
30445,,
30446,,
30447,,
30448,,
30449,,
30450,,
30451,,
30452,,
30453,,
30454,,
30455,,
30456,,
30457,,
30458,,
30459,,
30460,,
30461,,
30462,,
30463,,
30464,,
30465,,
30466,,
30467,,
30468,,
30469,,
30470,,
30471,,
30472,,
30473,,
30474,,
30475,,
30476,,
30477,,
30478,,
30479,,
30480,,
30481,,
30482,,
30483,,
30484,,
30485,,
30486,,
30487,,
30488,,
30489,,
30490,,
30491,,
30492,,
30493,,
30494,,
30495,,
30496,,
30497,,
30498,,
30499,,
30500,,
30501,,
30502,,
30503,,
30504,,
30505,,
30506,,
30507,,
30508,,
30509,,
30510,,
30511,,
30512,,
30513,,
30514,,
30515,,
30516,,
30517,,
30518,,
30519,,
30520,,
30521,,
30522,,
30523,,
30524,,
30525,,
30526,,
30527,,
30528,,
30529,,
30530,,
30531,,
30532,,
30533,,
30534,,
30535,,
30536,,
30537,,
30538,,
30539,,
30540,,
30541,,
30542,,
30543,,
30544,,
30545,,
30546,,
30547,,
30548,,
30549,,
30550,,
30551,,
30552,,
30553,,
30554,,
30555,,
30556,,
30557,,
30558,,
30559,,
30560,,
30561,,
30562,,
30563,,
30564,,
30565,,
30566,,
30567,,
30568,,
30569,,
30570,,
30571,,
30572,,
30573,,
30574,,
30575,,
30576,,
30577,,
30578,,
30579,,
30580,,
30581,,
30582,,
30583,,
30584,,
30585,,
30586,,
30587,,
30588,,
30589,,
30590,,
30591,,
30592,,
30593,,
30594,,
30595,,
30596,,
30597,,
30598,,
30599,,
30600,,
30601,,
30602,,
30603,,
30604,,
30605,,
30606,,
30607,,
30608,,
30609,,
30610,,
30611,,
30612,,
30613,,
30614,,
30615,,
30616,,
30617,,
30618,,
30619,,
30620,,
30621,,
30622,,
30623,,
30624,,
30625,,
30626,,
30627,,
30628,,
30629,,
30630,,
30631,,
30632,,
30633,,
30634,,
30635,,
30636,,
30637,,
30638,,
30639,,
30640,,
30641,,
30642,,
30643,,
30644,,
30645,,
30646,,
30647,,
30648,,
30649,,
30650,,
30651,,
30652,,
30653,,
30654,,
30655,,
30656,,
30657,,
30658,,
30659,,
30660,,
30661,,
30662,,
30663,,
30664,,
30665,,
30666,,
30667,,
30668,,
30669,,
30670,,
30671,,
30672,,
30673,,
30674,,
30675,,
30676,,
30677,,
30678,,
30679,,
30680,,
30681,,
30682,,
30683,,
30684,,
30685,,
30686,,
30687,,
30688,,
30689,,
30690,,
30691,,
30692,,
30693,,
30694,,
30695,,
30696,,
30697,,
30698,,
30699,,
30700,,
30701,,
30702,,
30703,,
30704,,
30705,,
30706,,
30707,,
30708,,
30709,,
30710,,
30711,,
30712,,
30713,,
30714,,
30715,,
30716,,
30717,,
30718,,
30719,,
30720,,
30721,,
30722,,
30723,,
30724,,
30725,,
30726,,
30727,,
30728,,
30729,,
30730,,
30731,,
30732,,
30733,,
30734,,
30735,,
30736,,
30737,,
30738,,
30739,,
30740,,
30741,,
30742,,
30743,,
30744,,
30745,,
30746,,
30747,,
30748,,
30749,,
30750,,
30751,,
30752,,
30753,,
30754,,
30755,,
30756,,
30757,,
30758,,
30759,,
30760,,
30761,,
30762,,
30763,,
30764,,
30765,,
30766,,
30767,,
30768,,
30769,,
30770,,
30771,,
30772,,
30773,,
30774,,
30775,,
30776,,
30777,,
30778,,
30779,,
30780,,
30781,,
30782,,
30783,,
30784,,
30785,,
30786,,
30787,,
30788,,
30789,,
30790,,
30791,,
30792,,
30793,,
30794,,
30795,,
30796,,
30797,,
30798,,
30799,,
30800,,
30801,,
30802,,
30803,,
30804,,
30805,,
30806,,
30807,,
30808,,
30809,,
30810,,
30811,,
30812,,
30813,,
30814,,
30815,,
30816,,
30817,,
30818,,
30819,,
30820,,
30821,,
30822,,
30823,,
30824,,
30825,,
30826,,
30827,,
30828,,
30829,,
30830,,
30831,,
30832,,
30833,,
30834,,
30835,,
30836,,
30837,,
30838,,
30839,,
30840,,
30841,,
30842,,
30843,,
30844,,
30845,,
30846,,
30847,,
30848,,
30849,,
30850,,
30851,,
30852,,
30853,,
30854,,
30855,,
30856,,
30857,,
30858,,
30859,,
30860,,
30861,,
30862,,
30863,,
30864,,
30865,,
30866,,
30867,,
30868,,
30869,,
30870,,
30871,,
30872,,
30873,,
30874,,
30875,,
30876,,
30877,,
30878,,
30879,,
30880,,
30881,,
30882,,
30883,,
30884,,
30885,,
30886,,
30887,,
30888,,
30889,,
30890,,
30891,,
30892,,
30893,,
30894,,
30895,,
30896,,
30897,,
30898,,
30899,,
30900,,
30901,,
30902,,
30903,,
30904,,
30905,,
30906,,
30907,,
30908,,
30909,,
30910,,
30911,,
30912,,
30913,,
30914,,
30915,,
30916,,
30917,,
30918,,
30919,,
30920,,
30921,,
30922,,
30923,,
30924,,
30925,,
30926,,
30927,,
30928,,
30929,,
30930,,
30931,,
30932,,
30933,,
30934,,
30935,,
30936,,
30937,,
30938,,
30939,,
30940,,
30941,,
30942,,
30943,,
30944,,
30945,,
30946,,
30947,,
30948,,
30949,,
30950,,
30951,,
30952,,
30953,,
30954,,
30955,,
30956,,
30957,,
30958,,
30959,,
30960,,
30961,,
30962,,
30963,,
30964,,
30965,,
30966,,
30967,,
30968,,
30969,,
30970,,
30971,,
30972,,
30973,,
30974,,
30975,,
30976,,
30977,,
30978,,
30979,,
30980,,
30981,,
30982,,
30983,,
30984,,
30985,,
30986,,
30987,,
30988,,
30989,,
30990,,
30991,,
30992,,
30993,,
30994,,
30995,,
30996,,
30997,,
30998,,
30999,,
31000,,
31001,,
31002,,
31003,,
31004,,
31005,,
31006,,
31007,,
31008,,
31009,,
31010,,
31011,,
31012,,
31013,,
31014,,
31015,,
31016,,
31017,,
31018,,
31019,,
31020,,
31021,,
31022,,
31023,,
31024,,
31025,,
31026,,
31027,,
31028,,
31029,,
31030,,
31031,,
31032,,
31033,,
31034,,
31035,,
31036,,
31037,,
31038,,
31039,,
31040,,
31041,,
31042,,
31043,,
31044,,
31045,,
31046,,
31047,,
31048,,
31049,,
31050,,
31051,,
31052,,
31053,,
31054,,
31055,,
31056,,
31057,,
31058,,
31059,,
31060,,
31061,,
31062,,
31063,,
31064,,
31065,,
31066,,
31067,,
31068,,
31069,,
31070,,
31071,,
31072,,
31073,,
31074,,
31075,,
31076,,
31077,,
31078,,
31079,,
31080,,
31081,,
31082,,
31083,,
31084,,
31085,,
31086,,
31087,,
31088,,
31089,,
31090,,
31091,,
31092,,
31093,,
31094,,
31095,,
31096,,
31097,,
31098,,
31099,,
31100,,
31101,,
31102,,
31103,,
31104,,
31105,,
31106,,
31107,,
31108,,
31109,,
31110,,
31111,,
31112,,
31113,,
31114,,
31115,,
31116,,
31117,,
31118,,
31119,,
31120,,
31121,,
31122,,
31123,,
31124,,
31125,,
31126,,
31127,,
31128,,
31129,,
31130,,
31131,,
31132,,
31133,,
31134,,
31135,,
31136,,
31137,,
31138,,
31139,,
31140,,
31141,,
31142,,
31143,,
31144,,
31145,,
31146,,
31147,,
31148,,
31149,,
31150,,
31151,,
31152,,
31153,,
31154,,
31155,,
31156,,
31157,,
31158,,
31159,,
31160,,
31161,,
31162,,
31163,,
31164,,
31165,,
31166,,
31167,,
31168,,
31169,,
31170,,
31171,,
31172,,
31173,,
31174,,
31175,,
31176,,
31177,,
31178,,
31179,,
31180,,
31181,,
31182,,
31183,,
31184,,
31185,,
31186,,
31187,,
31188,,
31189,,
31190,,
31191,,
31192,,
31193,,
31194,,
31195,,
31196,,
31197,,
31198,,
31199,,
31200,,
31201,,
31202,,
31203,,
31204,,
31205,,
31206,,
31207,,
31208,,
31209,,
31210,,
31211,,
31212,,
31213,,
31214,,
31215,,
31216,,
31217,,
31218,,
31219,,
31220,,
31221,,
31222,,
31223,,
31224,,
31225,,
31226,,
31227,,
31228,,
31229,,
31230,,
31231,,
31232,,
31233,,
31234,,
31235,,
31236,,
31237,,
31238,,
31239,,
31240,,
31241,,
31242,,
31243,,
31244,,
31245,,
31246,,
31247,,
31248,,
31249,,
31250,,
31251,,
31252,,
31253,,
31254,,
31255,,
31256,,
31257,,
31258,,
31259,,
31260,,
31261,,
31262,,
31263,,
31264,,
31265,,
31266,,
31267,,
31268,,
31269,,
31270,,
31271,,
31272,,
31273,,
31274,,
31275,,
31276,,
31277,,
31278,,
31279,,
31280,,
31281,,
31282,,
31283,,
31284,,
31285,,
31286,,
31287,,
31288,,
31289,,
31290,,
31291,,
31292,,
31293,,
31294,,
31295,,
31296,,
31297,,
31298,,
31299,,
31300,,
31301,,
31302,,
31303,,
31304,,
31305,,
31306,,
31307,,
31308,,
31309,,
31310,,
31311,,
31312,,
31313,,
31314,,
31315,,
31316,,
31317,,
31318,,
31319,,
31320,,
31321,,
31322,,
31323,,
31324,,
31325,,
31326,,
31327,,
31328,,
31329,,
31330,,
31331,,
31332,,
31333,,
31334,,
31335,,
31336,,
31337,,
31338,,
31339,,
31340,,
31341,,
31342,,
31343,,
31344,,
31345,,
31346,,
31347,,
31348,,
31349,,
31350,,
31351,,
31352,,
31353,,
31354,,
31355,,
31356,,
31357,,
31358,,
31359,,
31360,,
31361,,
31362,,
31363,,
31364,,
31365,,
31366,,
31367,,
31368,,
31369,,
31370,,
31371,,
31372,,
31373,,
31374,,
31375,,
31376,,
31377,,
31378,,
31379,,
31380,,
31381,,
31382,,
31383,,
31384,,
31385,,
31386,,
31387,,
31388,,
31389,,
31390,,
31391,,
31392,,
31393,,
31394,,
31395,,
31396,,
31397,,
31398,,
31399,,
31400,,
31401,,
31402,,
31403,,
31404,,
31405,,
31406,,
31407,,
31408,,
31409,,
31410,,
31411,,
31412,,
31413,,
31414,,
31415,,
31416,,
31417,,
31418,,
31419,,
31420,,
31421,,
31422,,
31423,,
31424,,
31425,,
31426,,
31427,,
31428,,
31429,,
31430,,
31431,,
31432,,
31433,,
31434,,
31435,,
31436,,
31437,,
31438,,
31439,,
31440,,
31441,,
31442,,
31443,,
31444,,
31445,,
31446,,
31447,,
31448,,
31449,,
31450,,
31451,,
31452,,
31453,,
31454,,
31455,,
31456,,
31457,,
31458,,
31459,,
31460,,
31461,,
31462,,
31463,,
31464,,
31465,,
31466,,
31467,,
31468,,
31469,,
31470,,
31471,,
31472,,
31473,,
31474,,
31475,,
31476,,
31477,,
31478,,
31479,,
31480,,
31481,,
31482,,
31483,,
31484,,
31485,,
31486,,
31487,,
31488,,
31489,,
31490,,
31491,,
31492,,
31493,,
31494,,
31495,,
31496,,
31497,,
31498,,
31499,,
31500,,
31501,,
31502,,
31503,,
31504,,
31505,,
31506,,
31507,,
31508,,
31509,,
31510,,
31511,,
31512,,
31513,,
31514,,
31515,,
31516,,
31517,,
31518,,
31519,,
31520,,
31521,,
31522,,
31523,,
31524,,
31525,,
31526,,
31527,,
31528,,
31529,,
31530,,
31531,,
31532,,
31533,,
31534,,
31535,,
31536,,
31537,,
31538,,
31539,,
31540,,
31541,,
31542,,
31543,,
31544,,
31545,,
31546,,
31547,,
31548,,
31549,,
31550,,
31551,,
31552,,
31553,,
31554,,
31555,,
31556,,
31557,,
31558,,
31559,,
31560,,
31561,,
31562,,
31563,,
31564,,
31565,,
31566,,
31567,,
31568,,
31569,,
31570,,
31571,,
31572,,
31573,,
31574,,
31575,,
31576,,
31577,,
31578,,
31579,,
31580,,
31581,,
31582,,
31583,,
31584,,
31585,,
31586,,
31587,,
31588,,
31589,,
31590,,
31591,,
31592,,
31593,,
31594,,
31595,,
31596,,
31597,,
31598,,
31599,,
31600,,
31601,,
31602,,
31603,,
31604,,
31605,,
31606,,
31607,,
31608,,
31609,,
31610,,
31611,,
31612,,
31613,,
31614,,
31615,,
31616,,
31617,,
31618,,
31619,,
31620,,
31621,,
31622,,
31623,,
31624,,
31625,,
31626,,
31627,,
31628,,
31629,,
31630,,
31631,,
31632,,
31633,,
31634,,
31635,,
31636,,
31637,,
31638,,
31639,,
31640,,
31641,,
31642,,
31643,,
31644,,
31645,,
31646,,
31647,,
31648,,
31649,,
31650,,
31651,,
31652,,
31653,,
31654,,
31655,,
31656,,
31657,,
31658,,
31659,,
31660,,
31661,,
31662,,
31663,,
31664,,
31665,,
31666,,
31667,,
31668,,
31669,,
31670,,
31671,,
31672,,
31673,,
31674,,
31675,,
31676,,
31677,,
31678,,
31679,,
31680,,
31681,,
31682,,
31683,,
31684,,
31685,,
31686,,
31687,,
31688,,
31689,,
31690,,
31691,,
31692,,
31693,,
31694,,
31695,,
31696,,
31697,,
31698,,
31699,,
31700,,
31701,,
31702,,
31703,,
31704,,
31705,,
31706,,
31707,,
31708,,
31709,,
31710,,
31711,,
31712,,
31713,,
31714,,
31715,,
31716,,
31717,,
31718,,
31719,,
31720,,
31721,,
31722,,
31723,,
31724,,
31725,,
31726,,
31727,,
31728,,
31729,,
31730,,
31731,,
31732,,
31733,,
31734,,
31735,,
31736,,
31737,,
31738,,
31739,,
31740,,
31741,,
31742,,
31743,,
31744,,
31745,,
31746,,
31747,,
31748,,
31749,,
31750,,
31751,,
31752,,
31753,,
31754,,
31755,,
31756,,
31757,,
31758,,
31759,,
31760,,
31761,,
31762,,
31763,,
31764,,
31765,,
31766,,
31767,,
31768,,
31769,,
31770,,
31771,,
31772,,
31773,,
31774,,
31775,,
31776,,
31777,,
31778,,
31779,,
31780,,
31781,,
31782,,
31783,,
31784,,
31785,,
31786,,
31787,,
31788,,
31789,,
31790,,
31791,,
31792,,
31793,,
31794,,
31795,,
31796,,
31797,,
31798,,
31799,,
31800,,
31801,,
31802,,
31803,,
31804,,
31805,,
31806,,
31807,,
31808,,
31809,,
31810,,
31811,,
31812,,
31813,,
31814,,
31815,,
31816,,
31817,,
31818,,
31819,,
31820,,
31821,,
31822,,
31823,,
31824,,
31825,,
31826,,
31827,,
31828,,
31829,,
31830,,
31831,,
31832,,
31833,,
31834,,
31835,,
31836,,
31837,,
31838,,
31839,,
31840,,
31841,,
31842,,
31843,,
31844,,
31845,,
31846,,
31847,,
31848,,
31849,,
31850,,
31851,,
31852,,
31853,,
31854,,
31855,,
31856,,
31857,,
31858,,
31859,,
31860,,
31861,,
31862,,
31863,,
31864,,
31865,,
31866,,
31867,,
31868,,
31869,,
31870,,
31871,,
31872,,
31873,,
31874,,
31875,,
31876,,
31877,,
31878,,
31879,,
31880,,
31881,,
31882,,
31883,,
31884,,
31885,,
31886,,
31887,,
31888,,
31889,,
31890,,
31891,,
31892,,
31893,,
31894,,
31895,,
31896,,
31897,,
31898,,
31899,,
31900,,
31901,,
31902,,
31903,,
31904,,
31905,,
31906,,
31907,,
31908,,
31909,,
31910,,
31911,,
31912,,
31913,,
31914,,
31915,,
31916,,
31917,,
31918,,
31919,,
31920,,
31921,,
31922,,
31923,,
31924,,
31925,,
31926,,
31927,,
31928,,
31929,,
31930,,
31931,,
31932,,
31933,,
31934,,
31935,,
31936,,
31937,,
31938,,
31939,,
31940,,
31941,,
31942,,
31943,,
31944,,
31945,,
31946,,
31947,,
31948,,
31949,,
31950,,
31951,,
31952,,
31953,,
31954,,
31955,,
31956,,
31957,,
31958,,
31959,,
31960,,
31961,,
31962,,
31963,,
31964,,
31965,,
31966,,
31967,,
31968,,
31969,,
31970,,
31971,,
31972,,
31973,,
31974,,
31975,,
31976,,
31977,,
31978,,
31979,,
31980,,
31981,,
31982,,
31983,,
31984,,
31985,,
31986,,
31987,,
31988,,
31989,,
31990,,
31991,,
31992,,
31993,,
31994,,
31995,,
31996,,
31997,,
31998,,
31999,,
32000,,
32001,,
32002,,
32003,,
32004,,
32005,,
32006,,
32007,,
32008,,
32009,,
32010,,
32011,,
32012,,
32013,,
32014,,
32015,,
32016,,
32017,,
32018,,
32019,,
32020,,
32021,,
32022,,
32023,,
32024,,
32025,,
32026,,
32027,,
32028,,
32029,,
32030,,
32031,,
32032,,
32033,,
32034,,
32035,,
32036,,
32037,,
32038,,
32039,,
32040,,
32041,,
32042,,
32043,,
32044,,
32045,,
32046,,
32047,,
32048,,
32049,,
32050,,
32051,,
32052,,
32053,,
32054,,
32055,,
32056,,
32057,,
32058,,
32059,,
32060,,
32061,,
32062,,
32063,,
32064,,
32065,,
32066,,
32067,,
32068,,
32069,,
32070,,
32071,,
32072,,
32073,,
32074,,
32075,,
32076,,
32077,,
32078,,
32079,,
32080,,
32081,,
32082,,
32083,,
32084,,
32085,,
32086,,
32087,,
32088,,
32089,,
32090,,
32091,,
32092,,
32093,,
32094,,
32095,,
32096,,
32097,,
32098,,
32099,,
32100,,
32101,,
32102,,
32103,,
32104,,
32105,,
32106,,
32107,,
32108,,
32109,,
32110,,
32111,,
32112,,
32113,,
32114,,
32115,,
32116,,
32117,,
32118,,
32119,,
32120,,
32121,,
32122,,
32123,,
32124,,
32125,,
32126,,
32127,,
32128,,
32129,,
32130,,
32131,,
32132,,
32133,,
32134,,
32135,,
32136,,
32137,,
32138,,
32139,,
32140,,
32141,,
32142,,
32143,,
32144,,
32145,,
32146,,
32147,,
32148,,
32149,,
32150,,
32151,,
32152,,
32153,,
32154,,
32155,,
32156,,
32157,,
32158,,
32159,,
32160,,
32161,,
32162,,
32163,,
32164,,
32165,,
32166,,
32167,,
32168,,
32169,,
32170,,
32171,,
32172,,
32173,,
32174,,
32175,,
32176,,
32177,,
32178,,
32179,,
32180,,
32181,,
32182,,
32183,,
32184,,
32185,,
32186,,
32187,,
32188,,
32189,,
32190,,
32191,,
32192,,
32193,,
32194,,
32195,,
32196,,
32197,,
32198,,
32199,,
32200,,
32201,,
32202,,
32203,,
32204,,
32205,,
32206,,
32207,,
32208,,
32209,,
32210,,
32211,,
32212,,
32213,,
32214,,
32215,,
32216,,
32217,,
32218,,
32219,,
32220,,
32221,,
32222,,
32223,,
32224,,
32225,,
32226,,
32227,,
32228,,
32229,,
32230,,
32231,,
32232,,
32233,,
32234,,
32235,,
32236,,
32237,,
32238,,
32239,,
32240,,
32241,,
32242,,
32243,,
32244,,
32245,,
32246,,
32247,,
32248,,
32249,,
32250,,
32251,,
32252,,
32253,,
32254,,
32255,,
32256,,
32257,,
32258,,
32259,,
32260,,
32261,,
32262,,
32263,,
32264,,
32265,,
32266,,
32267,,
32268,,
32269,,
32270,,
32271,,
32272,,
32273,,
32274,,
32275,,
32276,,
32277,,
32278,,
32279,,
32280,,
32281,,
32282,,
32283,,
32284,,
32285,,
32286,,
32287,,
32288,,
32289,,
32290,,
32291,,
32292,,
32293,,
32294,,
32295,,
32296,,
32297,,
32298,,
32299,,
32300,,
32301,,
32302,,
32303,,
32304,,
32305,,
32306,,
32307,,
32308,,
32309,,
32310,,
32311,,
32312,,
32313,,
32314,,
32315,,
32316,,
32317,,
32318,,
32319,,
32320,,
32321,,
32322,,
32323,,
32324,,
32325,,
32326,,
32327,,
32328,,
32329,,
32330,,
32331,,
32332,,
32333,,
32334,,
32335,,
32336,,
32337,,
32338,,
32339,,
32340,,
32341,,
32342,,
32343,,
32344,,
32345,,
32346,,
32347,,
32348,,
32349,,
32350,,
32351,,
32352,,
32353,,
32354,,
32355,,
32356,,
32357,,
32358,,
32359,,
32360,,
32361,,
32362,,
32363,,
32364,,
32365,,
32366,,
32367,,
32368,,
32369,,
32370,,
32371,,
32372,,
32373,,
32374,,
32375,,
32376,,
32377,,
32378,,
32379,,
32380,,
32381,,
32382,,
32383,,
32384,,
32385,,
32386,,
32387,,
32388,,
32389,,
32390,,
32391,,
32392,,
32393,,
32394,,
32395,,
32396,,
32397,,
32398,,
32399,,
32400,,
32401,,
32402,,
32403,,
32404,,
32405,,
32406,,
32407,,
32408,,
32409,,
32410,,
32411,,
32412,,
32413,,
32414,,
32415,,
32416,,
32417,,
32418,,
32419,,
32420,,
32421,,
32422,,
32423,,
32424,,
32425,,
32426,,
32427,,
32428,,
32429,,
32430,,
32431,,
32432,,
32433,,
32434,,
32435,,
32436,,
32437,,
32438,,
32439,,
32440,,
32441,,
32442,,
32443,,
32444,,
32445,,
32446,,
32447,,
32448,,
32449,,
32450,,
32451,,
32452,,
32453,,
32454,,
32455,,
32456,,
32457,,
32458,,
32459,,
32460,,
32461,,
32462,,
32463,,
32464,,
32465,,
32466,,
32467,,
32468,,
32469,,
32470,,
32471,,
32472,,
32473,,
32474,,
32475,,
32476,,
32477,,
32478,,
32479,,
32480,,
32481,,
32482,,
32483,,
32484,,
32485,,
32486,,
32487,,
32488,,
32489,,
32490,,
32491,,
32492,,
32493,,
32494,,
32495,,
32496,,
32497,,
32498,,
32499,,
32500,,
32501,,
32502,,
32503,,
32504,,
32505,,
32506,,
32507,,
32508,,
32509,,
32510,,
32511,,
32512,,
32513,,
32514,,
32515,,
32516,,
32517,,
32518,,
32519,,
32520,,
32521,,
32522,,
32523,,
32524,,
32525,,
32526,,
32527,,
32528,,
32529,,
32530,,
32531,,
32532,,
32533,,
32534,,
32535,,
32536,,
32537,,
32538,,
32539,,
32540,,
32541,,
32542,,
32543,,
32544,,
32545,,
32546,,
32547,,
32548,,
32549,,
32550,,
32551,,
32552,,
32553,,
32554,,
32555,,
32556,,
32557,,
32558,,
32559,,
32560,,
32561,,
32562,,
32563,,
32564,,
32565,,
32566,,
32567,,
32568,,
32569,,
32570,,
32571,,
32572,,
32573,,
32574,,
32575,,
32576,,
32577,,
32578,,
32579,,
32580,,
32581,,
32582,,
32583,,
32584,,
32585,,
32586,,
32587,,
32588,,
32589,,
32590,,
32591,,
32592,,
32593,,
32594,,
32595,,
32596,,
32597,,
32598,,
32599,,
32600,,
32601,,
32602,,
32603,,
32604,,
32605,,
32606,,
32607,,
32608,,
32609,,
32610,,
32611,,
32612,,
32613,,
32614,,
32615,,
32616,,
32617,,
32618,,
32619,,
32620,,
32621,,
32622,,
32623,,
32624,,
32625,,
32626,,
32627,,
32628,,
32629,,
32630,,
32631,,
32632,,
32633,,
32634,,
32635,,
32636,,
32637,,
32638,,
32639,,
32640,,
32641,,
32642,,
32643,,
32644,,
32645,,
32646,,
32647,,
32648,,
32649,,
32650,,
32651,,
32652,,
32653,,
32654,,
32655,,
32656,,
32657,,
32658,,
32659,,
32660,,
32661,,
32662,,
32663,,
32664,,
32665,,
32666,,
32667,,
32668,,
32669,,
32670,,
32671,,
32672,,
32673,,
32674,,
32675,,
32676,,
32677,,
32678,,
32679,,
32680,,
32681,,
32682,,
32683,,
32684,,
32685,,
32686,,
32687,,
32688,,
32689,,
32690,,
32691,,
32692,,
32693,,
32694,,
32695,,
32696,,
32697,,
32698,,
32699,,
32700,,
32701,,
32702,,
32703,,
32704,,
32705,,
32706,,
32707,,
32708,,
32709,,
32710,,
32711,,
32712,,
32713,,
32714,,
32715,,
32716,,
32717,,
32718,,
32719,,
32720,,
32721,,
32722,,
32723,,
32724,,
32725,,
32726,,
32727,,
32728,,
32729,,
32730,,
32731,,
32732,,
32733,,
32734,,
32735,,
32736,,
32737,,
32738,,
32739,,
32740,,
32741,,
32742,,
32743,,
32744,,
32745,,
32746,,
32747,,
32748,,
32749,,
32750,,
32751,,
32752,,
32753,,
32754,,
32755,,
32756,,
32757,,
32758,,
32759,,
32760,,
32761,,
32762,,
32763,,
32764,,
32765,,
32766,,
32767,,
32768,,
32769,,
32770,,
32771,,
32772,,
32773,,
32774,,
32775,,
32776,,
32777,,
32778,,
32779,,
32780,,
32781,,
32782,,
32783,,
32784,,
32785,,
32786,,
32787,,
32788,,
32789,,
32790,,
32791,,
32792,,
32793,,
32794,,
32795,,
32796,,
32797,,
32798,,
32799,,
32800,,
32801,,
32802,,
32803,,
32804,,
32805,,
32806,,
32807,,
32808,,
32809,,
32810,,
32811,,
32812,,
32813,,
32814,,
32815,,
32816,,
32817,,
32818,,
32819,,
32820,,
32821,,
32822,,
32823,,
32824,,
32825,,
32826,,
32827,,
32828,,
32829,,
32830,,
32831,,
32832,,
32833,,
32834,,
32835,,
32836,,
32837,,
32838,,
32839,,
32840,,
32841,,
32842,,
32843,,
32844,,
32845,,
32846,,
32847,,
32848,,
32849,,
32850,,
32851,,
32852,,
32853,,
32854,,
32855,,
32856,,
32857,,
32858,,
32859,,
32860,,
32861,,
32862,,
32863,,
32864,,
32865,,
32866,,
32867,,
32868,,
32869,,
32870,,
32871,,
32872,,
32873,,
32874,,
32875,,
32876,,
32877,,
32878,,
32879,,
32880,,
32881,,
32882,,
32883,,
32884,,
32885,,
32886,,
32887,,
32888,,
32889,,
32890,,
32891,,
32892,,
32893,,
32894,,
32895,,
32896,,
32897,,
32898,,
32899,,
32900,,
32901,,
32902,,
32903,,
32904,,
32905,,
32906,,
32907,,
32908,,
32909,,
32910,,
32911,,
32912,,
32913,,
32914,,
32915,,
32916,,
32917,,
32918,,
32919,,
32920,,
32921,,
32922,,
32923,,
32924,,
32925,,
32926,,
32927,,
32928,,
32929,,
32930,,
32931,,
32932,,
32933,,
32934,,
32935,,
32936,,
32937,,
32938,,
32939,,
32940,,
32941,,
32942,,
32943,,
32944,,
32945,,
32946,,
32947,,
32948,,
32949,,
32950,,
32951,,
32952,,
32953,,
32954,,
32955,,
32956,,
32957,,
32958,,
32959,,
32960,,
32961,,
32962,,
32963,,
32964,,
32965,,
32966,,
32967,,
32968,,
32969,,
32970,,
32971,,
32972,,
32973,,
32974,,
32975,,
32976,,
32977,,
32978,,
32979,,
32980,,
32981,,
32982,,
32983,,
32984,,
32985,,
32986,,
32987,,
32988,,
32989,,
32990,,
32991,,
32992,,
32993,,
32994,,
32995,,
32996,,
32997,,
32998,,
32999,,
33000,,
33001,,
33002,,
33003,,
33004,,
33005,,
33006,,
33007,,
33008,,
33009,,
33010,,
33011,,
33012,,
33013,,
33014,,
33015,,
33016,,
33017,,
33018,,
33019,,
33020,,
33021,,
33022,,
33023,,
33024,,
33025,,
33026,,
33027,,
33028,,
33029,,
33030,,
33031,,
33032,,
33033,,
33034,,
33035,,
33036,,
33037,,
33038,,
33039,,
33040,,
33041,,
33042,,
33043,,
33044,,
33045,,
33046,,
33047,,
33048,,
33049,,
33050,,
33051,,
33052,,
33053,,
33054,,
33055,,
33056,,
33057,,
33058,,
33059,,
33060,,
33061,,
33062,,
33063,,
33064,,
33065,,
33066,,
33067,,
33068,,
33069,,
33070,,
33071,,
33072,,
33073,,
33074,,
33075,,
33076,,
33077,,
33078,,
33079,,
33080,,
33081,,
33082,,
33083,,
33084,,
33085,,
33086,,
33087,,
33088,,
33089,,
33090,,
33091,,
33092,,
33093,,
33094,,
33095,,
33096,,
33097,,
33098,,
33099,,
33100,,
33101,,
33102,,
33103,,
33104,,
33105,,
33106,,
33107,,
33108,,
33109,,
33110,,
33111,,
33112,,
33113,,
33114,,
33115,,
33116,,
33117,,
33118,,
33119,,
33120,,
33121,,
33122,,
33123,,
33124,,
33125,,
33126,,
33127,,
33128,,
33129,,
33130,,
33131,,
33132,,
33133,,
33134,,
33135,,
33136,,
33137,,
33138,,
33139,,
33140,,
33141,,
33142,,
33143,,
33144,,
33145,,
33146,,
33147,,
33148,,
33149,,
33150,,
33151,,
33152,,
33153,,
33154,,
33155,,
33156,,
33157,,
33158,,
33159,,
33160,,
33161,,
33162,,
33163,,
33164,,
33165,,
33166,,
33167,,
33168,,
33169,,
33170,,
33171,,
33172,,
33173,,
33174,,
33175,,
33176,,
33177,,
33178,,
33179,,
33180,,
33181,,
33182,,
33183,,
33184,,
33185,,
33186,,
33187,,
33188,,
33189,,
33190,,
33191,,
33192,,
33193,,
33194,,
33195,,
33196,,
33197,,
33198,,
33199,,
33200,,
33201,,
33202,,
33203,,
33204,,
33205,,
33206,,
33207,,
33208,,
33209,,
33210,,
33211,,
33212,,
33213,,
33214,,
33215,,
33216,,
33217,,
33218,,
33219,,
33220,,
33221,,
33222,,
33223,,
33224,,
33225,,
33226,,
33227,,
33228,,
33229,,
33230,,
33231,,
33232,,
33233,,
33234,,
33235,,
33236,,
33237,,
33238,,
33239,,
33240,,
33241,,
33242,,
33243,,
33244,,
33245,,
33246,,
33247,,
33248,,
33249,,
33250,,
33251,,
33252,,
33253,,
33254,,
33255,,
33256,,
33257,,
33258,,
33259,,
33260,,
33261,,
33262,,
33263,,
33264,,
33265,,
33266,,
33267,,
33268,,
33269,,
33270,,
33271,,
33272,,
33273,,
33274,,
33275,,
33276,,
33277,,
33278,,
33279,,
33280,,
33281,,
33282,,
33283,,
33284,,
33285,,
33286,,
33287,,
33288,,
33289,,
33290,,
33291,,
33292,,
33293,,
33294,,
33295,,
33296,,
33297,,
33298,,
33299,,
33300,,
33301,,
33302,,
33303,,
33304,,
33305,,
33306,,
33307,,
33308,,
33309,,
33310,,
33311,,
33312,,
33313,,
33314,,
33315,,
33316,,
33317,,
33318,,
33319,,
33320,,
33321,,
33322,,
33323,,
33324,,
33325,,
33326,,
33327,,
33328,,
33329,,
33330,,
33331,,
33332,,
33333,,
33334,,
33335,,
33336,,
33337,,
33338,,
33339,,
33340,,
33341,,
33342,,
33343,,
33344,,
33345,,
33346,,
33347,,
33348,,
33349,,
33350,,
33351,,
33352,,
33353,,
33354,,
33355,,
33356,,
33357,,
33358,,
33359,,
33360,,
33361,,
33362,,
33363,,
33364,,
33365,,
33366,,
33367,,
33368,,
33369,,
33370,,
33371,,
33372,,
33373,,
33374,,
33375,,
33376,,
33377,,
33378,,
33379,,
33380,,
33381,,
33382,,
33383,,
33384,,
33385,,
33386,,
33387,,
33388,,
33389,,
33390,,
33391,,
33392,,
33393,,
33394,,
33395,,
33396,,
33397,,
33398,,
33399,,
33400,,
33401,,
33402,,
33403,,
33404,,
33405,,
33406,,
33407,,
33408,,
33409,,
33410,,
33411,,
33412,,
33413,,
33414,,
33415,,
33416,,
33417,,
33418,,
33419,,
33420,,
33421,,
33422,,
33423,,
33424,,
33425,,
33426,,
33427,,
33428,,
33429,,
33430,,
33431,,
33432,,
33433,,
33434,,
33435,,
33436,,
33437,,
33438,,
33439,,
33440,,
33441,,
33442,,
33443,,
33444,,
33445,,
33446,,
33447,,
33448,,
33449,,
33450,,
33451,,
33452,,
33453,,
33454,,
33455,,
33456,,
33457,,
33458,,
33459,,
33460,,
33461,,
33462,,
33463,,
33464,,
33465,,
33466,,
33467,,
33468,,
33469,,
33470,,
33471,,
33472,,
33473,,
33474,,
33475,,
33476,,
33477,,
33478,,
33479,,
33480,,
33481,,
33482,,
33483,,
33484,,
33485,,
33486,,
33487,,
33488,,
33489,,
33490,,
33491,,
33492,,
33493,,
33494,,
33495,,
33496,,
33497,,
33498,,
33499,,
33500,,
33501,,
33502,,
33503,,
33504,,
33505,,
33506,,
33507,,
33508,,
33509,,
33510,,
33511,,
33512,,
33513,,
33514,,
33515,,
33516,,
33517,,
33518,,
33519,,
33520,,
33521,,
33522,,
33523,,
33524,,
33525,,
33526,,
33527,,
33528,,
33529,,
33530,,
33531,,
33532,,
33533,,
33534,,
33535,,
33536,,
33537,,
33538,,
33539,,
33540,,
33541,,
33542,,
33543,,
33544,,
33545,,
33546,,
33547,,
33548,,
33549,,
33550,,
33551,,
33552,,
33553,,
33554,,
33555,,
33556,,
33557,,
33558,,
33559,,
33560,,
33561,,
33562,,
33563,,
33564,,
33565,,
33566,,
33567,,
33568,,
33569,,
33570,,
33571,,
33572,,
33573,,
33574,,
33575,,
33576,,
33577,,
33578,,
33579,,
33580,,
33581,,
33582,,
33583,,
33584,,
33585,,
33586,,
33587,,
33588,,
33589,,
33590,,
33591,,
33592,,
33593,,
33594,,
33595,,
33596,,
33597,,
33598,,
33599,,
33600,,
33601,,
33602,,
33603,,
33604,,
33605,,
33606,,
33607,,
33608,,
33609,,
33610,,
33611,,
33612,,
33613,,
33614,,
33615,,
33616,,
33617,,
33618,,
33619,,
33620,,
33621,,
33622,,
33623,,
33624,,
33625,,
33626,,
33627,,
33628,,
33629,,
33630,,
33631,,
33632,,
33633,,
33634,,
33635,,
33636,,
33637,,
33638,,
33639,,
33640,,
33641,,
33642,,
33643,,
33644,,
33645,,
33646,,
33647,,
33648,,
33649,,
33650,,
33651,,
33652,,
33653,,
33654,,
33655,,
33656,,
33657,,
33658,,
33659,,
33660,,
33661,,
33662,,
33663,,
33664,,
33665,,
33666,,
33667,,
33668,,
33669,,
33670,,
33671,,
33672,,
33673,,
33674,,
33675,,
33676,,
33677,,
33678,,
33679,,
33680,,
33681,,
33682,,
33683,,
33684,,
33685,,
33686,,
33687,,
33688,,
33689,,
33690,,
33691,,
33692,,
33693,,
33694,,
33695,,
33696,,
33697,,
33698,,
33699,,
33700,,
33701,,
33702,,
33703,,
33704,,
33705,,
33706,,
33707,,
33708,,
33709,,
33710,,
33711,,
33712,,
33713,,
33714,,
33715,,
33716,,
33717,,
33718,,
33719,,
33720,,
33721,,
33722,,
33723,,
33724,,
33725,,
33726,,
33727,,
33728,,
33729,,
33730,,
33731,,
33732,,
33733,,
33734,,
33735,,
33736,,
33737,,
33738,,
33739,,
33740,,
33741,,
33742,,
33743,,
33744,,
33745,,
33746,,
33747,,
33748,,
33749,,
33750,,
33751,,
33752,,
33753,,
33754,,
33755,,
33756,,
33757,,
33758,,
33759,,
33760,,
33761,,
33762,,
33763,,
33764,,
33765,,
33766,,
33767,,
33768,,
33769,,
33770,,
33771,,
33772,,
33773,,
33774,,
33775,,
33776,,
33777,,
33778,,
33779,,
33780,,
33781,,
33782,,
33783,,
33784,,
33785,,
33786,,
33787,,
33788,,
33789,,
33790,,
33791,,
33792,,
33793,,
33794,,
33795,,
33796,,
33797,,
33798,,
33799,,
33800,,
33801,,
33802,,
33803,,
33804,,
33805,,
33806,,
33807,,
33808,,
33809,,
33810,,
33811,,
33812,,
33813,,
33814,,
33815,,
33816,,
33817,,
33818,,
33819,,
33820,,
33821,,
33822,,
33823,,
33824,,
33825,,
33826,,
33827,,
33828,,
33829,,
33830,,
33831,,
33832,,
33833,,
33834,,
33835,,
33836,,
33837,,
33838,,
33839,,
33840,,
33841,,
33842,,
33843,,
33844,,
33845,,
33846,,
33847,,
33848,,
33849,,
33850,,
33851,,
33852,,
33853,,
33854,,
33855,,
33856,,
33857,,
33858,,
33859,,
33860,,
33861,,
33862,,
33863,,
33864,,
33865,,
33866,,
33867,,
33868,,
33869,,
33870,,
33871,,
33872,,
33873,,
33874,,
33875,,
33876,,
33877,,
33878,,
33879,,
33880,,
33881,,
33882,,
33883,,
33884,,
33885,,
33886,,
33887,,
33888,,
33889,,
33890,,
33891,,
33892,,
33893,,
33894,,
33895,,
33896,,
33897,,
33898,,
33899,,
33900,,
33901,,
33902,,
33903,,
33904,,
33905,,
33906,,
33907,,
33908,,
33909,,
33910,,
33911,,
33912,,
33913,,
33914,,
33915,,
33916,,
33917,,
33918,,
33919,,
33920,,
33921,,
33922,,
33923,,
33924,,
33925,,
33926,,
33927,,
33928,,
33929,,
33930,,
33931,,
33932,,
33933,,
33934,,
33935,,
33936,,
33937,,
33938,,
33939,,
33940,,
33941,,
33942,,
33943,,
33944,,
33945,,
33946,,
33947,,
33948,,
33949,,
33950,,
33951,,
33952,,
33953,,
33954,,
33955,,
33956,,
33957,,
33958,,
33959,,
33960,,
33961,,
33962,,
33963,,
33964,,
33965,,
33966,,
33967,,
33968,,
33969,,
33970,,
33971,,
33972,,
33973,,
33974,,
33975,,
33976,,
33977,,
33978,,
33979,,
33980,,
33981,,
33982,,
33983,,
33984,,
33985,,
33986,,
33987,,
33988,,
33989,,
33990,,
33991,,
33992,,
33993,,
33994,,
33995,,
33996,,
33997,,
33998,,
33999,,
34000,,
34001,,
34002,,
34003,,
34004,,
34005,,
34006,,
34007,,
34008,,
34009,,
34010,,
34011,,
34012,,
34013,,
34014,,
34015,,
34016,,
34017,,
34018,,
34019,,
34020,,
34021,,
34022,,
34023,,
34024,,
34025,,
34026,,
34027,,
34028,,
34029,,
34030,,
34031,,
34032,,
34033,,
34034,,
34035,,
34036,,
34037,,
34038,,
34039,,
34040,,
34041,,
34042,,
34043,,
34044,,
34045,,
34046,,
34047,,
34048,,
34049,,
34050,,
34051,,
34052,,
34053,,
34054,,
34055,,
34056,,
34057,,
34058,,
34059,,
34060,,
34061,,
34062,,
34063,,
34064,,
34065,,
34066,,
34067,,
34068,,
34069,,
34070,,
34071,,
34072,,
34073,,
34074,,
34075,,
34076,,
34077,,
34078,,
34079,,
34080,,
34081,,
34082,,
34083,,
34084,,
34085,,
34086,,
34087,,
34088,,
34089,,
34090,,
34091,,
34092,,
34093,,
34094,,
34095,,
34096,,
34097,,
34098,,
34099,,
34100,,
34101,,
34102,,
34103,,
34104,,
34105,,
34106,,
34107,,
34108,,
34109,,
34110,,
34111,,
34112,,
34113,,
34114,,
34115,,
34116,,
34117,,
34118,,
34119,,
34120,,
34121,,
34122,,
34123,,
34124,,
34125,,
34126,,
34127,,
34128,,
34129,,
34130,,
34131,,
34132,,
34133,,
34134,,
34135,,
34136,,
34137,,
34138,,
34139,,
34140,,
34141,,
34142,,
34143,,
34144,,
34145,,
34146,,
34147,,
34148,,
34149,,
34150,,
34151,,
34152,,
34153,,
34154,,
34155,,
34156,,
34157,,
34158,,
34159,,
34160,,
34161,,
34162,,
34163,,
34164,,
34165,,
34166,,
34167,,
34168,,
34169,,
34170,,
34171,,
34172,,
34173,,
34174,,
34175,,
34176,,
34177,,
34178,,
34179,,
34180,,
34181,,
34182,,
34183,,
34184,,
34185,,
34186,,
34187,,
34188,,
34189,,
34190,,
34191,,
34192,,
34193,,
34194,,
34195,,
34196,,
34197,,
34198,,
34199,,
34200,,
34201,,
34202,,
34203,,
34204,,
34205,,
34206,,
34207,,
34208,,
34209,,
34210,,
34211,,
34212,,
34213,,
34214,,
34215,,
34216,,
34217,,
34218,,
34219,,
34220,,
34221,,
34222,,
34223,,
34224,,
34225,,
34226,,
34227,,
34228,,
34229,,
34230,,
34231,,
34232,,
34233,,
34234,,
34235,,
34236,,
34237,,
34238,,
34239,,
34240,,
34241,,
34242,,
34243,,
34244,,
34245,,
34246,,
34247,,
34248,,
34249,,
34250,,
34251,,
34252,,
34253,,
34254,,
34255,,
34256,,
34257,,
34258,,
34259,,
34260,,
34261,,
34262,,
34263,,
34264,,
34265,,
34266,,
34267,,
34268,,
34269,,
34270,,
34271,,
34272,,
34273,,
34274,,
34275,,
34276,,
34277,,
34278,,
34279,,
34280,,
34281,,
34282,,
34283,,
34284,,
34285,,
34286,,
34287,,
34288,,
34289,,
34290,,
34291,,
34292,,
34293,,
34294,,
34295,,
34296,,
34297,,
34298,,
34299,,
34300,,
34301,,
34302,,
34303,,
34304,,
34305,,
34306,,
34307,,
34308,,
34309,,
34310,,
34311,,
34312,,
34313,,
34314,,
34315,,
34316,,
34317,,
34318,,
34319,,
34320,,
34321,,
34322,,
34323,,
34324,,
34325,,
34326,,
34327,,
34328,,
34329,,
34330,,
34331,,
34332,,
34333,,
34334,,
34335,,
34336,,
34337,,
34338,,
34339,,
34340,,
34341,,
34342,,
34343,,
34344,,
34345,,
34346,,
34347,,
34348,,
34349,,
34350,,
34351,,
34352,,
34353,,
34354,,
34355,,
34356,,
34357,,
34358,,
34359,,
34360,,
34361,,
34362,,
34363,,
34364,,
34365,,
34366,,
34367,,
34368,,
34369,,
34370,,
34371,,
34372,,
34373,,
34374,,
34375,,
34376,,
34377,,
34378,,
34379,,
34380,,
34381,,
34382,,
34383,,
34384,,
34385,,
34386,,
34387,,
34388,,
34389,,
34390,,
34391,,
34392,,
34393,,
34394,,
34395,,
34396,,
34397,,
34398,,
34399,,
34400,,
34401,,
34402,,
34403,,
34404,,
34405,,
34406,,
34407,,
34408,,
34409,,
34410,,
34411,,
34412,,
34413,,
34414,,
34415,,
34416,,
34417,,
34418,,
34419,,
34420,,
34421,,
34422,,
34423,,
34424,,
34425,,
34426,,
34427,,
34428,,
34429,,
34430,,
34431,,
34432,,
34433,,
34434,,
34435,,
34436,,
34437,,
34438,,
34439,,
34440,,
34441,,
34442,,
34443,,
34444,,
34445,,
34446,,
34447,,
34448,,
34449,,
34450,,
34451,,
34452,,
34453,,
34454,,
34455,,
34456,,
34457,,
34458,,
34459,,
34460,,
34461,,
34462,,
34463,,
34464,,
34465,,
34466,,
34467,,
34468,,
34469,,
34470,,
34471,,
34472,,
34473,,
34474,,
34475,,
34476,,
34477,,
34478,,
34479,,
34480,,
34481,,
34482,,
34483,,
34484,,
34485,,
34486,,
34487,,
34488,,
34489,,
34490,,
34491,,
34492,,
34493,,
34494,,
34495,,
34496,,
34497,,
34498,,
34499,,
34500,,
34501,,
34502,,
34503,,
34504,,
34505,,
34506,,
34507,,
34508,,
34509,,
34510,,
34511,,
34512,,
34513,,
34514,,
34515,,
34516,,
34517,,
34518,,
34519,,
34520,,
34521,,
34522,,
34523,,
34524,,
34525,,
34526,,
34527,,
34528,,
34529,,
34530,,
34531,,
34532,,
34533,,
34534,,
34535,,
34536,,
34537,,
34538,,
34539,,
34540,,
34541,,
34542,,
34543,,
34544,,
34545,,
34546,,
34547,,
34548,,
34549,,
34550,,
34551,,
34552,,
34553,,
34554,,
34555,,
34556,,
34557,,
34558,,
34559,,
34560,,
34561,,
34562,,
34563,,
34564,,
34565,,
34566,,
34567,,
34568,,
34569,,
34570,,
34571,,
34572,,
34573,,
34574,,
34575,,
34576,,
34577,,
34578,,
34579,,
34580,,
34581,,
34582,,
34583,,
34584,,
34585,,
34586,,
34587,,
34588,,
34589,,
34590,,
34591,,
34592,,
34593,,
34594,,
34595,,
34596,,
34597,,
34598,,
34599,,
34600,,
34601,,
34602,,
34603,,
34604,,
34605,,
34606,,
34607,,
34608,,
34609,,
34610,,
34611,,
34612,,
34613,,
34614,,
34615,,
34616,,
34617,,
34618,,
34619,,
34620,,
34621,,
34622,,
34623,,
34624,,
34625,,
34626,,
34627,,
34628,,
34629,,
34630,,
34631,,
34632,,
34633,,
34634,,
34635,,
34636,,
34637,,
34638,,
34639,,
34640,,
34641,,
34642,,
34643,,
34644,,
34645,,
34646,,
34647,,
34648,,
34649,,
34650,,
34651,,
34652,,
34653,,
34654,,
34655,,
34656,,
34657,,
34658,,
34659,,
34660,,
34661,,
34662,,
34663,,
34664,,
34665,,
34666,,
34667,,
34668,,
34669,,
34670,,
34671,,
34672,,
34673,,
34674,,
34675,,
34676,,
34677,,
34678,,
34679,,
34680,,
34681,,
34682,,
34683,,
34684,,
34685,,
34686,,
34687,,
34688,,
34689,,
34690,,
34691,,
34692,,
34693,,
34694,,
34695,,
34696,,
34697,,
34698,,
34699,,
34700,,
34701,,
34702,,
34703,,
34704,,
34705,,
34706,,
34707,,
34708,,
34709,,
34710,,
34711,,
34712,,
34713,,
34714,,
34715,,
34716,,
34717,,
34718,,
34719,,
34720,,
34721,,
34722,,
34723,,
34724,,
34725,,
34726,,
34727,,
34728,,
34729,,
34730,,
34731,,
34732,,
34733,,
34734,,
34735,,
34736,,
34737,,
34738,,
34739,,
34740,,
34741,,
34742,,
34743,,
34744,,
34745,,
34746,,
34747,,
34748,,
34749,,
34750,,
34751,,
34752,,
34753,,
34754,,
34755,,
34756,,
34757,,
34758,,
34759,,
34760,,
34761,,
34762,,
34763,,
34764,,
34765,,
34766,,
34767,,
34768,,
34769,,
34770,,
34771,,
34772,,
34773,,
34774,,
34775,,
34776,,
34777,,
34778,,
34779,,
34780,,
34781,,
34782,,
34783,,
34784,,
34785,,
34786,,
34787,,
34788,,
34789,,
34790,,
34791,,
34792,,
34793,,
34794,,
34795,,
34796,,
34797,,
34798,,
34799,,
34800,,
34801,,
34802,,
34803,,
34804,,
34805,,
34806,,
34807,,
34808,,
34809,,
34810,,
34811,,
34812,,
34813,,
34814,,
34815,,
34816,,
34817,,
34818,,
34819,,
34820,,
34821,,
34822,,
34823,,
34824,,
34825,,
34826,,
34827,,
34828,,
34829,,
34830,,
34831,,
34832,,
34833,,
34834,,
34835,,
34836,,
34837,,
34838,,
34839,,
34840,,
34841,,
34842,,
34843,,
34844,,
34845,,
34846,,
34847,,
34848,,
34849,,
34850,,
34851,,
34852,,
34853,,
34854,,
34855,,
34856,,
34857,,
34858,,
34859,,
34860,,
34861,,
34862,,
34863,,
34864,,
34865,,
34866,,
34867,,
34868,,
34869,,
34870,,
34871,,
34872,,
34873,,
34874,,
34875,,
34876,,
34877,,
34878,,
34879,,
34880,,
34881,,
34882,,
34883,,
34884,,
34885,,
34886,,
34887,,
34888,,
34889,,
34890,,
34891,,
34892,,
34893,,
34894,,
34895,,
34896,,
34897,,
34898,,
34899,,
34900,,
34901,,
34902,,
34903,,
34904,,
34905,,
34906,,
34907,,
34908,,
34909,,
34910,,
34911,,
34912,,
34913,,
34914,,
34915,,
34916,,
34917,,
34918,,
34919,,
34920,,
34921,,
34922,,
34923,,
34924,,
34925,,
34926,,
34927,,
34928,,
34929,,
34930,,
34931,,
34932,,
34933,,
34934,,
34935,,
34936,,
34937,,
34938,,
34939,,
34940,,
34941,,
34942,,
34943,,
34944,,
34945,,
34946,,
34947,,
34948,,
34949,,
34950,,
34951,,
34952,,
34953,,
34954,,
34955,,
34956,,
34957,,
34958,,
34959,,
34960,,
34961,,
34962,,
34963,,
34964,,
34965,,
34966,,
34967,,
34968,,
34969,,
34970,,
34971,,
34972,,
34973,,
34974,,
34975,,
34976,,
34977,,
34978,,
34979,,
34980,,
34981,,
34982,,
34983,,
34984,,
34985,,
34986,,
34987,,
34988,,
34989,,
34990,,
34991,,
34992,,
34993,,
34994,,
34995,,
34996,,
34997,,
34998,,
34999,,
35000,,
35001,,
35002,,
35003,,
35004,,
35005,,
35006,,
35007,,
35008,,
35009,,
35010,,
35011,,
35012,,
35013,,
35014,,
35015,,
35016,,
35017,,
35018,,
35019,,
35020,,
35021,,
35022,,
35023,,
35024,,
35025,,
35026,,
35027,,
35028,,
35029,,
35030,,
35031,,
35032,,
35033,,
35034,,
35035,,
35036,,
35037,,
35038,,
35039,,
35040,,
35041,,
35042,,
35043,,
35044,,
35045,,
35046,,
35047,,
35048,,
35049,,
35050,,
35051,,
35052,,
35053,,
35054,,
35055,,
35056,,
35057,,
35058,,
35059,,
35060,,
35061,,
35062,,
35063,,
35064,,
35065,,
35066,,
35067,,
35068,,
35069,,
35070,,
35071,,
35072,,
35073,,
35074,,
35075,,
35076,,
35077,,
35078,,
35079,,
35080,,
35081,,
35082,,
35083,,
35084,,
35085,,
35086,,
35087,,
35088,,
35089,,
35090,,
35091,,
35092,,
35093,,
35094,,
35095,,
35096,,
35097,,
35098,,
35099,,
35100,,
35101,,
35102,,
35103,,
35104,,
35105,,
35106,,
35107,,
35108,,
35109,,
35110,,
35111,,
35112,,
35113,,
35114,,
35115,,
35116,,
35117,,
35118,,
35119,,
35120,,
35121,,
35122,,
35123,,
35124,,
35125,,
35126,,
35127,,
35128,,
35129,,
35130,,
35131,,
35132,,
35133,,
35134,,
35135,,
35136,,
35137,,
35138,,
35139,,
35140,,
35141,,
35142,,
35143,,
35144,,
35145,,
35146,,
35147,,
35148,,
35149,,
35150,,
35151,,
35152,,
35153,,
35154,,
35155,,
35156,,
35157,,
35158,,
35159,,
35160,,
35161,,
35162,,
35163,,
35164,,
35165,,
35166,,
35167,,
35168,,
35169,,
35170,,
35171,,
35172,,
35173,,
35174,,
35175,,
35176,,
35177,,
35178,,
35179,,
35180,,
35181,,
35182,,
35183,,
35184,,
35185,,
35186,,
35187,,
35188,,
35189,,
35190,,
35191,,
35192,,
35193,,
35194,,
35195,,
35196,,
35197,,
35198,,
35199,,
35200,,
35201,,
35202,,
35203,,
35204,,
35205,,
35206,,
35207,,
35208,,
35209,,
35210,,
35211,,
35212,,
35213,,
35214,,
35215,,
35216,,
35217,,
35218,,
35219,,
35220,,
35221,,
35222,,
35223,,
35224,,
35225,,
35226,,
35227,,
35228,,
35229,,
35230,,
35231,,
35232,,
35233,,
35234,,
35235,,
35236,,
35237,,
35238,,
35239,,
35240,,
35241,,
35242,,
35243,,
35244,,
35245,,
35246,,
35247,,
35248,,
35249,,
35250,,
35251,,
35252,,
35253,,
35254,,
35255,,
35256,,
35257,,
35258,,
35259,,
35260,,
35261,,
35262,,
35263,,
35264,,
35265,,
35266,,
35267,,
35268,,
35269,,
35270,,
35271,,
35272,,
35273,,
35274,,
35275,,
35276,,
35277,,
35278,,
35279,,
35280,,
35281,,
35282,,
35283,,
35284,,
35285,,
35286,,
35287,,
35288,,
35289,,
35290,,
35291,,
35292,,
35293,,
35294,,
35295,,
35296,,
35297,,
35298,,
35299,,
35300,,
35301,,
35302,,
35303,,
35304,,
35305,,
35306,,
35307,,
35308,,
35309,,
35310,,
35311,,
35312,,
35313,,
35314,,
35315,,
35316,,
35317,,
35318,,
35319,,
35320,,
35321,,
35322,,
35323,,
35324,,
35325,,
35326,,
35327,,
35328,,
35329,,
35330,,
35331,,
35332,,
35333,,
35334,,
35335,,
35336,,
35337,,
35338,,
35339,,
35340,,
35341,,
35342,,
35343,,
35344,,
35345,,
35346,,
35347,,
35348,,
35349,,
35350,,
35351,,
35352,,
35353,,
35354,,
35355,,
35356,,
35357,,
35358,,
35359,,
35360,,
35361,,
35362,,
35363,,
35364,,
35365,,
35366,,
35367,,
35368,,
35369,,
35370,,
35371,,
35372,,
35373,,
35374,,
35375,,
35376,,
35377,,
35378,,
35379,,
35380,,
35381,,
35382,,
35383,,
35384,,
35385,,
35386,,
35387,,
35388,,
35389,,
35390,,
35391,,
35392,,
35393,,
35394,,
35395,,
35396,,
35397,,
35398,,
35399,,
35400,,
35401,,
35402,,
35403,,
35404,,
35405,,
35406,,
35407,,
35408,,
35409,,
35410,,
35411,,
35412,,
35413,,
35414,,
35415,,
35416,,
35417,,
35418,,
35419,,
35420,,
35421,,
35422,,
35423,,
35424,,
35425,,
35426,,
35427,,
35428,,
35429,,
35430,,
35431,,
35432,,
35433,,
35434,,
35435,,
35436,,
35437,,
35438,,
35439,,
35440,,
35441,,
35442,,
35443,,
35444,,
35445,,
35446,,
35447,,
35448,,
35449,,
35450,,
35451,,
35452,,
35453,,
35454,,
35455,,
35456,,
35457,,
35458,,
35459,,
35460,,
35461,,
35462,,
35463,,
35464,,
35465,,
35466,,
35467,,
35468,,
35469,,
35470,,
35471,,
35472,,
35473,,
35474,,
35475,,
35476,,
35477,,
35478,,
35479,,
35480,,
35481,,
35482,,
35483,,
35484,,
35485,,
35486,,
35487,,
35488,,
35489,,
35490,,
35491,,
35492,,
35493,,
35494,,
35495,,
35496,,
35497,,
35498,,
35499,,
35500,,
35501,,
35502,,
35503,,
35504,,
35505,,
35506,,
35507,,
35508,,
35509,,
35510,,
35511,,
35512,,
35513,,
35514,,
35515,,
35516,,
35517,,
35518,,
35519,,
35520,,
35521,,
35522,,
35523,,
35524,,
35525,,
35526,,
35527,,
35528,,
35529,,
35530,,
35531,,
35532,,
35533,,
35534,,
35535,,
35536,,
35537,,
35538,,
35539,,
35540,,
35541,,
35542,,
35543,,
35544,,
35545,,
35546,,
35547,,
35548,,
35549,,
35550,,
35551,,
35552,,
35553,,
35554,,
35555,,
35556,,
35557,,
35558,,
35559,,
35560,,
35561,,
35562,,
35563,,
35564,,
35565,,
35566,,
35567,,
35568,,
35569,,
35570,,
35571,,
35572,,
35573,,
35574,,
35575,,
35576,,
35577,,
35578,,
35579,,
35580,,
35581,,
35582,,
35583,,
35584,,
35585,,
35586,,
35587,,
35588,,
35589,,
35590,,
35591,,
35592,,
35593,,
35594,,
35595,,
35596,,
35597,,
35598,,
35599,,
35600,,
35601,,
35602,,
35603,,
35604,,
35605,,
35606,,
35607,,
35608,,
35609,,
35610,,
35611,,
35612,,
35613,,
35614,,
35615,,
35616,,
35617,,
35618,,
35619,,
35620,,
35621,,
35622,,
35623,,
35624,,
35625,,
35626,,
35627,,
35628,,
35629,,
35630,,
35631,,
35632,,
35633,,
35634,,
35635,,
35636,,
35637,,
35638,,
35639,,
35640,,
35641,,
35642,,
35643,,
35644,,
35645,,
35646,,
35647,,
35648,,
35649,,
35650,,
35651,,
35652,,
35653,,
35654,,
35655,,
35656,,
35657,,
35658,,
35659,,
35660,,
35661,,
35662,,
35663,,
35664,,
35665,,
35666,,
35667,,
35668,,
35669,,
35670,,
35671,,
35672,,
35673,,
35674,,
35675,,
35676,,
35677,,
35678,,
35679,,
35680,,
35681,,
35682,,
35683,,
35684,,
35685,,
35686,,
35687,,
35688,,
35689,,
35690,,
35691,,
35692,,
35693,,
35694,,
35695,,
35696,,
35697,,
35698,,
35699,,
35700,,
35701,,
35702,,
35703,,
35704,,
35705,,
35706,,
35707,,
35708,,
35709,,
35710,,
35711,,
35712,,
35713,,
35714,,
35715,,
35716,,
35717,,
35718,,
35719,,
35720,,
35721,,
35722,,
35723,,
35724,,
35725,,
35726,,
35727,,
35728,,
35729,,
35730,,
35731,,
35732,,
35733,,
35734,,
35735,,
35736,,
35737,,
35738,,
35739,,
35740,,
35741,,
35742,,
35743,,
35744,,
35745,,
35746,,
35747,,
35748,,
35749,,
35750,,
35751,,
35752,,
35753,,
35754,,
35755,,
35756,,
35757,,
35758,,
35759,,
35760,,
35761,,
35762,,
35763,,
35764,,
35765,,
35766,,
35767,,
35768,,
35769,,
35770,,
35771,,
35772,,
35773,,
35774,,
35775,,
35776,,
35777,,
35778,,
35779,,
35780,,
35781,,
35782,,
35783,,
35784,,
35785,,
35786,,
35787,,
35788,,
35789,,
35790,,
35791,,
35792,,
35793,,
35794,,
35795,,
35796,,
35797,,
35798,,
35799,,
35800,,
35801,,
35802,,
35803,,
35804,,
35805,,
35806,,
35807,,
35808,,
35809,,
35810,,
35811,,
35812,,
35813,,
35814,,
35815,,
35816,,
35817,,
35818,,
35819,,
35820,,
35821,,
35822,,
35823,,
35824,,
35825,,
35826,,
35827,,
35828,,
35829,,
35830,,
35831,,
35832,,
35833,,
35834,,
35835,,
35836,,
35837,,
35838,,
35839,,
35840,,
35841,,
35842,,
35843,,
35844,,
35845,,
35846,,
35847,,
35848,,
35849,,
35850,,
35851,,
35852,,
35853,,
35854,,
35855,,
35856,,
35857,,
35858,,
35859,,
35860,,
35861,,
35862,,
35863,,
35864,,
35865,,
35866,,
35867,,
35868,,
35869,,
35870,,
35871,,
35872,,
35873,,
35874,,
35875,,
35876,,
35877,,
35878,,
35879,,
35880,,
35881,,
35882,,
35883,,
35884,,
35885,,
35886,,
35887,,
35888,,
35889,,
35890,,
35891,,
35892,,
35893,,
35894,,
35895,,
35896,,
35897,,
35898,,
35899,,
35900,,
35901,,
35902,,
35903,,
35904,,
35905,,
35906,,
35907,,
35908,,
35909,,
35910,,
35911,,
35912,,
35913,,
35914,,
35915,,
35916,,
35917,,
35918,,
35919,,
35920,,
35921,,
35922,,
35923,,
35924,,
35925,,
35926,,
35927,,
35928,,
35929,,
35930,,
35931,,
35932,,
35933,,
35934,,
35935,,
35936,,
35937,,
35938,,
35939,,
35940,,
35941,,
35942,,
35943,,
35944,,
35945,,
35946,,
35947,,
35948,,
35949,,
35950,,
35951,,
35952,,
35953,,
35954,,
35955,,
35956,,
35957,,
35958,,
35959,,
35960,,
35961,,
35962,,
35963,,
35964,,
35965,,
35966,,
35967,,
35968,,
35969,,
35970,,
35971,,
35972,,
35973,,
35974,,
35975,,
35976,,
35977,,
35978,,
35979,,
35980,,
35981,,
35982,,
35983,,
35984,,
35985,,
35986,,
35987,,
35988,,
35989,,
35990,,
35991,,
35992,,
35993,,
35994,,
35995,,
35996,,
35997,,
35998,,
35999,,
36000,,
36001,,
36002,,
36003,,
36004,,
36005,,
36006,,
36007,,
36008,,
36009,,
36010,,
36011,,
36012,,
36013,,
36014,,
36015,,
36016,,
36017,,
36018,,
36019,,
36020,,
36021,,
36022,,
36023,,
36024,,
36025,,
36026,,
36027,,
36028,,
36029,,
36030,,
36031,,
36032,,
36033,,
36034,,
36035,,
36036,,
36037,,
36038,,
36039,,
36040,,
36041,,
36042,,
36043,,
36044,,
36045,,
36046,,
36047,,
36048,,
36049,,
36050,,
36051,,
36052,,
36053,,
36054,,
36055,,
36056,,
36057,,
36058,,
36059,,
36060,,
36061,,
36062,,
36063,,
36064,,
36065,,
36066,,
36067,,
36068,,
36069,,
36070,,
36071,,
36072,,
36073,,
36074,,
36075,,
36076,,
36077,,
36078,,
36079,,
36080,,
36081,,
36082,,
36083,,
36084,,
36085,,
36086,,
36087,,
36088,,
36089,,
36090,,
36091,,
36092,,
36093,,
36094,,
36095,,
36096,,
36097,,
36098,,
36099,,
36100,,
36101,,
36102,,
36103,,
36104,,
36105,,
36106,,
36107,,
36108,,
36109,,
36110,,
36111,,
36112,,
36113,,
36114,,
36115,,
36116,,
36117,,
36118,,
36119,,
36120,,
36121,,
36122,,
36123,,
36124,,
36125,,
36126,,
36127,,
36128,,
36129,,
36130,,
36131,,
36132,,
36133,,
36134,,
36135,,
36136,,
36137,,
36138,,
36139,,
36140,,
36141,,
36142,,
36143,,
36144,,
36145,,
36146,,
36147,,
36148,,
36149,,
36150,,
36151,,
36152,,
36153,,
36154,,
36155,,
36156,,
36157,,
36158,,
36159,,
36160,,
36161,,
36162,,
36163,,
36164,,
36165,,
36166,,
36167,,
36168,,
36169,,
36170,,
36171,,
36172,,
36173,,
36174,,
36175,,
36176,,
36177,,
36178,,
36179,,
36180,,
36181,,
36182,,
36183,,
36184,,
36185,,
36186,,
36187,,
36188,,
36189,,
36190,,
36191,,
36192,,
36193,,
36194,,
36195,,
36196,,
36197,,
36198,,
36199,,
36200,,
36201,,
36202,,
36203,,
36204,,
36205,,
36206,,
36207,,
36208,,
36209,,
36210,,
36211,,
36212,,
36213,,
36214,,
36215,,
36216,,
36217,,
36218,,
36219,,
36220,,
36221,,
36222,,
36223,,
36224,,
36225,,
36226,,
36227,,
36228,,
36229,,
36230,,
36231,,
36232,,
36233,,
36234,,
36235,,
36236,,
36237,,
36238,,
36239,,
36240,,
36241,,
36242,,
36243,,
36244,,
36245,,
36246,,
36247,,
36248,,
36249,,
36250,,
36251,,
36252,,
36253,,
36254,,
36255,,
36256,,
36257,,
36258,,
36259,,
36260,,
36261,,
36262,,
36263,,
36264,,
36265,,
36266,,
36267,,
36268,,
36269,,
36270,,
36271,,
36272,,
36273,,
36274,,
36275,,
36276,,
36277,,
36278,,
36279,,
36280,,
36281,,
36282,,
36283,,
36284,,
36285,,
36286,,
36287,,
36288,,
36289,,
36290,,
36291,,
36292,,
36293,,
36294,,
36295,,
36296,,
36297,,
36298,,
36299,,
36300,,
36301,,
36302,,
36303,,
36304,,
36305,,
36306,,
36307,,
36308,,
36309,,
36310,,
36311,,
36312,,
36313,,
36314,,
36315,,
36316,,
36317,,
36318,,
36319,,
36320,,
36321,,
36322,,
36323,,
36324,,
36325,,
36326,,
36327,,
36328,,
36329,,
36330,,
36331,,
36332,,
36333,,
36334,,
36335,,
36336,,
36337,,
36338,,
36339,,
36340,,
36341,,
36342,,
36343,,
36344,,
36345,,
36346,,
36347,,
36348,,
36349,,
36350,,
36351,,
36352,,
36353,,
36354,,
36355,,
36356,,
36357,,
36358,,
36359,,
36360,,
36361,,
36362,,
36363,,
36364,,
36365,,
36366,,
36367,,
36368,,
36369,,
36370,,
36371,,
36372,,
36373,,
36374,,
36375,,
36376,,
36377,,
36378,,
36379,,
36380,,
36381,,
36382,,
36383,,
36384,,
36385,,
36386,,
36387,,
36388,,
36389,,
36390,,
36391,,
36392,,
36393,,
36394,,
36395,,
36396,,
36397,,
36398,,
36399,,
36400,,
36401,,
36402,,
36403,,
36404,,
36405,,
36406,,
36407,,
36408,,
36409,,
36410,,
36411,,
36412,,
36413,,
36414,,
36415,,
36416,,
36417,,
36418,,
36419,,
36420,,
36421,,
36422,,
36423,,
36424,,
36425,,
36426,,
36427,,
36428,,
36429,,
36430,,
36431,,
36432,,
36433,,
36434,,
36435,,
36436,,
36437,,
36438,,
36439,,
36440,,
36441,,
36442,,
36443,,
36444,,
36445,,
36446,,
36447,,
36448,,
36449,,
36450,,
36451,,
36452,,
36453,,
36454,,
36455,,
36456,,
36457,,
36458,,
36459,,
36460,,
36461,,
36462,,
36463,,
36464,,
36465,,
36466,,
36467,,
36468,,
36469,,
36470,,
36471,,
36472,,
36473,,
36474,,
36475,,
36476,,
36477,,
36478,,
36479,,
36480,,
36481,,
36482,,
36483,,
36484,,
36485,,
36486,,
36487,,
36488,,
36489,,
36490,,
36491,,
36492,,
36493,,
36494,,
36495,,
36496,,
36497,,
36498,,
36499,,
36500,,
36501,,
36502,,
36503,,
36504,,
36505,,
36506,,
36507,,
36508,,
36509,,
36510,,
36511,,
36512,,
36513,,
36514,,
36515,,
36516,,
36517,,
36518,,
36519,,
36520,,
36521,,
36522,,
36523,,
36524,,
36525,,
36526,,
36527,,
36528,,
36529,,
36530,,
36531,,
36532,,
36533,,
36534,,
36535,,
36536,,
36537,,
36538,,
36539,,
36540,,
36541,,
36542,,
36543,,
36544,,
36545,,
36546,,
36547,,
36548,,
36549,,
36550,,
36551,,
36552,,
36553,,
36554,,
36555,,
36556,,
36557,,
36558,,
36559,,
36560,,
36561,,
36562,,
36563,,
36564,,
36565,,
36566,,
36567,,
36568,,
36569,,
36570,,
36571,,
36572,,
36573,,
36574,,
36575,,
36576,,
36577,,
36578,,
36579,,
36580,,
36581,,
36582,,
36583,,
36584,,
36585,,
36586,,
36587,,
36588,,
36589,,
36590,,
36591,,
36592,,
36593,,
36594,,
36595,,
36596,,
36597,,
36598,,
36599,,
36600,,
36601,,
36602,,
36603,,
36604,,
36605,,
36606,,
36607,,
36608,,
36609,,
36610,,
36611,,
36612,,
36613,,
36614,,
36615,,
36616,,
36617,,
36618,,
36619,,
36620,,
36621,,
36622,,
36623,,
36624,,
36625,,
36626,,
36627,,
36628,,
36629,,
36630,,
36631,,
36632,,
36633,,
36634,,
36635,,
36636,,
36637,,
36638,,
36639,,
36640,,
36641,,
36642,,
36643,,
36644,,
36645,,
36646,,
36647,,
36648,,
36649,,
36650,,
36651,,
36652,,
36653,,
36654,,
36655,,
36656,,
36657,,
36658,,
36659,,
36660,,
36661,,
36662,,
36663,,
36664,,
36665,,
36666,,
36667,,
36668,,
36669,,
36670,,
36671,,
36672,,
36673,,
36674,,
36675,,
36676,,
36677,,
36678,,
36679,,
36680,,
36681,,
36682,,
36683,,
36684,,
36685,,
36686,,
36687,,
36688,,
36689,,
36690,,
36691,,
36692,,
36693,,
36694,,
36695,,
36696,,
36697,,
36698,,
36699,,
36700,,
36701,,
36702,,
36703,,
36704,,
36705,,
36706,,
36707,,
36708,,
36709,,
36710,,
36711,,
36712,,
36713,,
36714,,
36715,,
36716,,
36717,,
36718,,
36719,,
36720,,
36721,,
36722,,
36723,,
36724,,
36725,,
36726,,
36727,,
36728,,
36729,,
36730,,
36731,,
36732,,
36733,,
36734,,
36735,,
36736,,
36737,,
36738,,
36739,,
36740,,
36741,,
36742,,
36743,,
36744,,
36745,,
36746,,
36747,,
36748,,
36749,,
36750,,
36751,,
36752,,
36753,,
36754,,
36755,,
36756,,
36757,,
36758,,
36759,,
36760,,
36761,,
36762,,
36763,,
36764,,
36765,,
36766,,
36767,,
36768,,
36769,,
36770,,
36771,,
36772,,
36773,,
36774,,
36775,,
36776,,
36777,,
36778,,
36779,,
36780,,
36781,,
36782,,
36783,,
36784,,
36785,,
36786,,
36787,,
36788,,
36789,,
36790,,
36791,,
36792,,
36793,,
36794,,
36795,,
36796,,
36797,,
36798,,
36799,,
36800,,
36801,,
36802,,
36803,,
36804,,
36805,,
36806,,
36807,,
36808,,
36809,,
36810,,
36811,,
36812,,
36813,,
36814,,
36815,,
36816,,
36817,,
36818,,
36819,,
36820,,
36821,,
36822,,
36823,,
36824,,
36825,,
36826,,
36827,,
36828,,
36829,,
36830,,
36831,,
36832,,
36833,,
36834,,
36835,,
36836,,
36837,,
36838,,
36839,,
36840,,
36841,,
36842,,
36843,,
36844,,
36845,,
36846,,
36847,,
36848,,
36849,,
36850,,
36851,,
36852,,
36853,,
36854,,
36855,,
36856,,
36857,,
36858,,
36859,,
36860,,
36861,,
36862,,
36863,,
36864,,
36865,,
36866,,
36867,,
36868,,
36869,,
36870,,
36871,,
36872,,
36873,,
36874,,
36875,,
36876,,
36877,,
36878,,
36879,,
36880,,
36881,,
36882,,
36883,,
36884,,
36885,,
36886,,
36887,,
36888,,
36889,,
36890,,
36891,,
36892,,
36893,,
36894,,
36895,,
36896,,
36897,,
36898,,
36899,,
36900,,
36901,,
36902,,
36903,,
36904,,
36905,,
36906,,
36907,,
36908,,
36909,,
36910,,
36911,,
36912,,
36913,,
36914,,
36915,,
36916,,
36917,,
36918,,
36919,,
36920,,
36921,,
36922,,
36923,,
36924,,
36925,,
36926,,
36927,,
36928,,
36929,,
36930,,
36931,,
36932,,
36933,,
36934,,
36935,,
36936,,
36937,,
36938,,
36939,,
36940,,
36941,,
36942,,
36943,,
36944,,
36945,,
36946,,
36947,,
36948,,
36949,,
36950,,
36951,,
36952,,
36953,,
36954,,
36955,,
36956,,
36957,,
36958,,
36959,,
36960,,
36961,,
36962,,
36963,,
36964,,
36965,,
36966,,
36967,,
36968,,
36969,,
36970,,
36971,,
36972,,
36973,,
36974,,
36975,,
36976,,
36977,,
36978,,
36979,,
36980,,
36981,,
36982,,
36983,,
36984,,
36985,,
36986,,
36987,,
36988,,
36989,,
36990,,
36991,,
36992,,
36993,,
36994,,
36995,,
36996,,
36997,,
36998,,
36999,,
37000,,
37001,,
37002,,
37003,,
37004,,
37005,,
37006,,
37007,,
37008,,
37009,,
37010,,
37011,,
37012,,
37013,,
37014,,
37015,,
37016,,
37017,,
37018,,
37019,,
37020,,
37021,,
37022,,
37023,,
37024,,
37025,,
37026,,
37027,,
37028,,
37029,,
37030,,
37031,,
37032,,
37033,,
37034,,
37035,,
37036,,
37037,,
37038,,
37039,,
37040,,
37041,,
37042,,
37043,,
37044,,
37045,,
37046,,
37047,,
37048,,
37049,,
37050,,
37051,,
37052,,
37053,,
37054,,
37055,,
37056,,
37057,,
37058,,
37059,,
37060,,
37061,,
37062,,
37063,,
37064,,
37065,,
37066,,
37067,,
37068,,
37069,,
37070,,
37071,,
37072,,
37073,,
37074,,
37075,,
37076,,
37077,,
37078,,
37079,,
37080,,
37081,,
37082,,
37083,,
37084,,
37085,,
37086,,
37087,,
37088,,
37089,,
37090,,
37091,,
37092,,
37093,,
37094,,
37095,,
37096,,
37097,,
37098,,
37099,,
37100,,
37101,,
37102,,
37103,,
37104,,
37105,,
37106,,
37107,,
37108,,
37109,,
37110,,
37111,,
37112,,
37113,,
37114,,
37115,,
37116,,
37117,,
37118,,
37119,,
37120,,
37121,,
37122,,
37123,,
37124,,
37125,,
37126,,
37127,,
37128,,
37129,,
37130,,
37131,,
37132,,
37133,,
37134,,
37135,,
37136,,
37137,,
37138,,
37139,,
37140,,
37141,,
37142,,
37143,,
37144,,
37145,,
37146,,
37147,,
37148,,
37149,,
37150,,
37151,,
37152,,
37153,,
37154,,
37155,,
37156,,
37157,,
37158,,
37159,,
37160,,
37161,,
37162,,
37163,,
37164,,
37165,,
37166,,
37167,,
37168,,
37169,,
37170,,
37171,,
37172,,
37173,,
37174,,
37175,,
37176,,
37177,,
37178,,
37179,,
37180,,
37181,,
37182,,
37183,,
37184,,
37185,,
37186,,
37187,,
37188,,
37189,,
37190,,
37191,,
37192,,
37193,,
37194,,
37195,,
37196,,
37197,,
37198,,
37199,,
37200,,
37201,,
37202,,
37203,,
37204,,
37205,,
37206,,
37207,,
37208,,
37209,,
37210,,
37211,,
37212,,
37213,,
37214,,
37215,,
37216,,
37217,,
37218,,
37219,,
37220,,
37221,,
37222,,
37223,,
37224,,
37225,,
37226,,
37227,,
37228,,
37229,,
37230,,
37231,,
37232,,
37233,,
37234,,
37235,,
37236,,
37237,,
37238,,
37239,,
37240,,
37241,,
37242,,
37243,,
37244,,
37245,,
37246,,
37247,,
37248,,
37249,,
37250,,
37251,,
37252,,
37253,,
37254,,
37255,,
37256,,
37257,,
37258,,
37259,,
37260,,
37261,,
37262,,
37263,,
37264,,
37265,,
37266,,
37267,,
37268,,
37269,,
37270,,
37271,,
37272,,
37273,,
37274,,
37275,,
37276,,
37277,,
37278,,
37279,,
37280,,
37281,,
37282,,
37283,,
37284,,
37285,,
37286,,
37287,,
37288,,
37289,,
37290,,
37291,,
37292,,
37293,,
37294,,
37295,,
37296,,
37297,,
37298,,
37299,,
37300,,
37301,,
37302,,
37303,,
37304,,
37305,,
37306,,
37307,,
37308,,
37309,,
37310,,
37311,,
37312,,
37313,,
37314,,
37315,,
37316,,
37317,,
37318,,
37319,,
37320,,
37321,,
37322,,
37323,,
37324,,
37325,,
37326,,
37327,,
37328,,
37329,,
37330,,
37331,,
37332,,
37333,,
37334,,
37335,,
37336,,
37337,,
37338,,
37339,,
37340,,
37341,,
37342,,
37343,,
37344,,
37345,,
37346,,
37347,,
37348,,
37349,,
37350,,
37351,,
37352,,
37353,,
37354,,
37355,,
37356,,
37357,,
37358,,
37359,,
37360,,
37361,,
37362,,
37363,,
37364,,
37365,,
37366,,
37367,,
37368,,
37369,,
37370,,
37371,,
37372,,
37373,,
37374,,
37375,,
37376,,
37377,,
37378,,
37379,,
37380,,
37381,,
37382,,
37383,,
37384,,
37385,,
37386,,
37387,,
37388,,
37389,,
37390,,
37391,,
37392,,
37393,,
37394,,
37395,,
37396,,
37397,,
37398,,
37399,,
37400,,
37401,,
37402,,
37403,,
37404,,
37405,,
37406,,
37407,,
37408,,
37409,,
37410,,
37411,,
37412,,
37413,,
37414,,
37415,,
37416,,
37417,,
37418,,
37419,,
37420,,
37421,,
37422,,
37423,,
37424,,
37425,,
37426,,
37427,,
37428,,
37429,,
37430,,
37431,,
37432,,
37433,,
37434,,
37435,,
37436,,
37437,,
37438,,
37439,,
37440,,
37441,,
37442,,
37443,,
37444,,
37445,,
37446,,
37447,,
37448,,
37449,,
37450,,
37451,,
37452,,
37453,,
37454,,
37455,,
37456,,
37457,,
37458,,
37459,,
37460,,
37461,,
37462,,
37463,,
37464,,
37465,,
37466,,
37467,,
37468,,
37469,,
37470,,
37471,,
37472,,
37473,,
37474,,
37475,,
37476,,
37477,,
37478,,
37479,,
37480,,
37481,,
37482,,
37483,,
37484,,
37485,,
37486,,
37487,,
37488,,
37489,,
37490,,
37491,,
37492,,
37493,,
37494,,
37495,,
37496,,
37497,,
37498,,
37499,,
37500,,
37501,,
37502,,
37503,,
37504,,
37505,,
37506,,
37507,,
37508,,
37509,,
37510,,
37511,,
37512,,
37513,,
37514,,
37515,,
37516,,
37517,,
37518,,
37519,,
37520,,
37521,,
37522,,
37523,,
37524,,
37525,,
37526,,
37527,,
37528,,
37529,,
37530,,
37531,,
37532,,
37533,,
37534,,
37535,,
37536,,
37537,,
37538,,
37539,,
37540,,
37541,,
37542,,
37543,,
37544,,
37545,,
37546,,
37547,,
37548,,
37549,,
37550,,
37551,,
37552,,
37553,,
37554,,
37555,,
37556,,
37557,,
37558,,
37559,,
37560,,
37561,,
37562,,
37563,,
37564,,
37565,,
37566,,
37567,,
37568,,
37569,,
37570,,
37571,,
37572,,
37573,,
37574,,
37575,,
37576,,
37577,,
37578,,
37579,,
37580,,
37581,,
37582,,
37583,,
37584,,
37585,,
37586,,
37587,,
37588,,
37589,,
37590,,
37591,,
37592,,
37593,,
37594,,
37595,,
37596,,
37597,,
37598,,
37599,,
37600,,
37601,,
37602,,
37603,,
37604,,
37605,,
37606,,
37607,,
37608,,
37609,,
37610,,
37611,,
37612,,
37613,,
37614,,
37615,,
37616,,
37617,,
37618,,
37619,,
37620,,
37621,,
37622,,
37623,,
37624,,
37625,,
37626,,
37627,,
37628,,
37629,,
37630,,
37631,,
37632,,
37633,,
37634,,
37635,,
37636,,
37637,,
37638,,
37639,,
37640,,
37641,,
37642,,
37643,,
37644,,
37645,,
37646,,
37647,,
37648,,
37649,,
37650,,
37651,,
37652,,
37653,,
37654,,
37655,,
37656,,
37657,,
37658,,
37659,,
37660,,
37661,,
37662,,
37663,,
37664,,
37665,,
37666,,
37667,,
37668,,
37669,,
37670,,
37671,,
37672,,
37673,,
37674,,
37675,,
37676,,
37677,,
37678,,
37679,,
37680,,
37681,,
37682,,
37683,,
37684,,
37685,,
37686,,
37687,,
37688,,
37689,,
37690,,
37691,,
37692,,
37693,,
37694,,
37695,,
37696,,
37697,,
37698,,
37699,,
37700,,
37701,,
37702,,
37703,,
37704,,
37705,,
37706,,
37707,,
37708,,
37709,,
37710,,
37711,,
37712,,
37713,,
37714,,
37715,,
37716,,
37717,,
37718,,
37719,,
37720,,
37721,,
37722,,
37723,,
37724,,
37725,,
37726,,
37727,,
37728,,
37729,,
37730,,
37731,,
37732,,
37733,,
37734,,
37735,,
37736,,
37737,,
37738,,
37739,,
37740,,
37741,,
37742,,
37743,,
37744,,
37745,,
37746,,
37747,,
37748,,
37749,,
37750,,
37751,,
37752,,
37753,,
37754,,
37755,,
37756,,
37757,,
37758,,
37759,,
37760,,
37761,,
37762,,
37763,,
37764,,
37765,,
37766,,
37767,,
37768,,
37769,,
37770,,
37771,,
37772,,
37773,,
37774,,
37775,,
37776,,
37777,,
37778,,
37779,,
37780,,
37781,,
37782,,
37783,,
37784,,
37785,,
37786,,
37787,,
37788,,
37789,,
37790,,
37791,,
37792,,
37793,,
37794,,
37795,,
37796,,
37797,,
37798,,
37799,,
37800,,
37801,,
37802,,
37803,,
37804,,
37805,,
37806,,
37807,,
37808,,
37809,,
37810,,
37811,,
37812,,
37813,,
37814,,
37815,,
37816,,
37817,,
37818,,
37819,,
37820,,
37821,,
37822,,
37823,,
37824,,
37825,,
37826,,
37827,,
37828,,
37829,,
37830,,
37831,,
37832,,
37833,,
37834,,
37835,,
37836,,
37837,,
37838,,
37839,,
37840,,
37841,,
37842,,
37843,,
37844,,
37845,,
37846,,
37847,,
37848,,
37849,,
37850,,
37851,,
37852,,
37853,,
37854,,
37855,,
37856,,
37857,,
37858,,
37859,,
37860,,
37861,,
37862,,
37863,,
37864,,
37865,,
37866,,
37867,,
37868,,
37869,,
37870,,
37871,,
37872,,
37873,,
37874,,
37875,,
37876,,
37877,,
37878,,
37879,,
37880,,
37881,,
37882,,
37883,,
37884,,
37885,,
37886,,
37887,,
37888,,
37889,,
37890,,
37891,,
37892,,
37893,,
37894,,
37895,,
37896,,
37897,,
37898,,
37899,,
37900,,
37901,,
37902,,
37903,,
37904,,
37905,,
37906,,
37907,,
37908,,
37909,,
37910,,
37911,,
37912,,
37913,,
37914,,
37915,,
37916,,
37917,,
37918,,
37919,,
37920,,
37921,,
37922,,
37923,,
37924,,
37925,,
37926,,
37927,,
37928,,
37929,,
37930,,
37931,,
37932,,
37933,,
37934,,
37935,,
37936,,
37937,,
37938,,
37939,,
37940,,
37941,,
37942,,
37943,,
37944,,
37945,,
37946,,
37947,,
37948,,
37949,,
37950,,
37951,,
37952,,
37953,,
37954,,
37955,,
37956,,
37957,,
37958,,
37959,,
37960,,
37961,,
37962,,
37963,,
37964,,
37965,,
37966,,
37967,,
37968,,
37969,,
37970,,
37971,,
37972,,
37973,,
37974,,
37975,,
37976,,
37977,,
37978,,
37979,,
37980,,
37981,,
37982,,
37983,,
37984,,
37985,,
37986,,
37987,,
37988,,
37989,,
37990,,
37991,,
37992,,
37993,,
37994,,
37995,,
37996,,
37997,,
37998,,
37999,,
38000,,
38001,,
38002,,
38003,,
38004,,
38005,,
38006,,
38007,,
38008,,
38009,,
38010,,
38011,,
38012,,
38013,,
38014,,
38015,,
38016,,
38017,,
38018,,
38019,,
38020,,
38021,,
38022,,
38023,,
38024,,
38025,,
38026,,
38027,,
38028,,
38029,,
38030,,
38031,,
38032,,
38033,,
38034,,
38035,,
38036,,
38037,,
38038,,
38039,,
38040,,
38041,,
38042,,
38043,,
38044,,
38045,,
38046,,
38047,,
38048,,
38049,,
38050,,
38051,,
38052,,
38053,,
38054,,
38055,,
38056,,
38057,,
38058,,
38059,,
38060,,
38061,,
38062,,
38063,,
38064,,
38065,,
38066,,
38067,,
38068,,
38069,,
38070,,
38071,,
38072,,
38073,,
38074,,
38075,,
38076,,
38077,,
38078,,
38079,,
38080,,
38081,,
38082,,
38083,,
38084,,
38085,,
38086,,
38087,,
38088,,
38089,,
38090,,
38091,,
38092,,
38093,,
38094,,
38095,,
38096,,
38097,,
38098,,
38099,,
38100,,
38101,,
38102,,
38103,,
38104,,
38105,,
38106,,
38107,,
38108,,
38109,,
38110,,
38111,,
38112,,
38113,,
38114,,
38115,,
38116,,
38117,,
38118,,
38119,,
38120,,
38121,,
38122,,
38123,,
38124,,
38125,,
38126,,
38127,,
38128,,
38129,,
38130,,
38131,,
38132,,
38133,,
38134,,
38135,,
38136,,
38137,,
38138,,
38139,,
38140,,
38141,,
38142,,
38143,,
38144,,
38145,,
38146,,
38147,,
38148,,
38149,,
38150,,
38151,,
38152,,
38153,,
38154,,
38155,,
38156,,
38157,,
38158,,
38159,,
38160,,
38161,,
38162,,
38163,,
38164,,
38165,,
38166,,
38167,,
38168,,
38169,,
38170,,
38171,,
38172,,
38173,,
38174,,
38175,,
38176,,
38177,,
38178,,
38179,,
38180,,
38181,,
38182,,
38183,,
38184,,
38185,,
38186,,
38187,,
38188,,
38189,,
38190,,
38191,,
38192,,
38193,,
38194,,
38195,,
38196,,
38197,,
38198,,
38199,,
38200,,
38201,,
38202,,
38203,,
38204,,
38205,,
38206,,
38207,,
38208,,
38209,,
38210,,
38211,,
38212,,
38213,,
38214,,
38215,,
38216,,
38217,,
38218,,
38219,,
38220,,
38221,,
38222,,
38223,,
38224,,
38225,,
38226,,
38227,,
38228,,
38229,,
38230,,
38231,,
38232,,
38233,,
38234,,
38235,,
38236,,
38237,,
38238,,
38239,,
38240,,
38241,,
38242,,
38243,,
38244,,
38245,,
38246,,
38247,,
38248,,
38249,,
38250,,
38251,,
38252,,
38253,,
38254,,
38255,,
38256,,
38257,,
38258,,
38259,,
38260,,
38261,,
38262,,
38263,,
38264,,
38265,,
38266,,
38267,,
38268,,
38269,,
38270,,
38271,,
38272,,
38273,,
38274,,
38275,,
38276,,
38277,,
38278,,
38279,,
38280,,
38281,,
38282,,
38283,,
38284,,
38285,,
38286,,
38287,,
38288,,
38289,,
38290,,
38291,,
38292,,
38293,,
38294,,
38295,,
38296,,
38297,,
38298,,
38299,,
38300,,
38301,,
38302,,
38303,,
38304,,
38305,,
38306,,
38307,,
38308,,
38309,,
38310,,
38311,,
38312,,
38313,,
38314,,
38315,,
38316,,
38317,,
38318,,
38319,,
38320,,
38321,,
38322,,
38323,,
38324,,
38325,,
38326,,
38327,,
38328,,
38329,,
38330,,
38331,,
38332,,
38333,,
38334,,
38335,,
38336,,
38337,,
38338,,
38339,,
38340,,
38341,,
38342,,
38343,,
38344,,
38345,,
38346,,
38347,,
38348,,
38349,,
38350,,
38351,,
38352,,
38353,,
38354,,
38355,,
38356,,
38357,,
38358,,
38359,,
38360,,
38361,,
38362,,
38363,,
38364,,
38365,,
38366,,
38367,,
38368,,
38369,,
38370,,
38371,,
38372,,
38373,,
38374,,
38375,,
38376,,
38377,,
38378,,
38379,,
38380,,
38381,,
38382,,
38383,,
38384,,
38385,,
38386,,
38387,,
38388,,
38389,,
38390,,
38391,,
38392,,
38393,,
38394,,
38395,,
38396,,
38397,,
38398,,
38399,,
38400,,
38401,,
38402,,
38403,,
38404,,
38405,,
38406,,
38407,,
38408,,
38409,,
38410,,
38411,,
38412,,
38413,,
38414,,
38415,,
38416,,
38417,,
38418,,
38419,,
38420,,
38421,,
38422,,
38423,,
38424,,
38425,,
38426,,
38427,,
38428,,
38429,,
38430,,
38431,,
38432,,
38433,,
38434,,
38435,,
38436,,
38437,,
38438,,
38439,,
38440,,
38441,,
38442,,
38443,,
38444,,
38445,,
38446,,
38447,,
38448,,
38449,,
38450,,
38451,,
38452,,
38453,,
38454,,
38455,,
38456,,
38457,,
38458,,
38459,,
38460,,
38461,,
38462,,
38463,,
38464,,
38465,,
38466,,
38467,,
38468,,
38469,,
38470,,
38471,,
38472,,
38473,,
38474,,
38475,,
38476,,
38477,,
38478,,
38479,,
38480,,
38481,,
38482,,
38483,,
38484,,
38485,,
38486,,
38487,,
38488,,
38489,,
38490,,
38491,,
38492,,
38493,,
38494,,
38495,,
38496,,
38497,,
38498,,
38499,,
38500,,
38501,,
38502,,
38503,,
38504,,
38505,,
38506,,
38507,,
38508,,
38509,,
38510,,
38511,,
38512,,
38513,,
38514,,
38515,,
38516,,
38517,,
38518,,
38519,,
38520,,
38521,,
38522,,
38523,,
38524,,
38525,,
38526,,
38527,,
38528,,
38529,,
38530,,
38531,,
38532,,
38533,,
38534,,
38535,,
38536,,
38537,,
38538,,
38539,,
38540,,
38541,,
38542,,
38543,,
38544,,
38545,,
38546,,
38547,,
38548,,
38549,,
38550,,
38551,,
38552,,
38553,,
38554,,
38555,,
38556,,
38557,,
38558,,
38559,,
38560,,
38561,,
38562,,
38563,,
38564,,
38565,,
38566,,
38567,,
38568,,
38569,,
38570,,
38571,,
38572,,
38573,,
38574,,
38575,,
38576,,
38577,,
38578,,
38579,,
38580,,
38581,,
38582,,
38583,,
38584,,
38585,,
38586,,
38587,,
38588,,
38589,,
38590,,
38591,,
38592,,
38593,,
38594,,
38595,,
38596,,
38597,,
38598,,
38599,,
38600,,
38601,,
38602,,
38603,,
38604,,
38605,,
38606,,
38607,,
38608,,
38609,,
38610,,
38611,,
38612,,
38613,,
38614,,
38615,,
38616,,
38617,,
38618,,
38619,,
38620,,
38621,,
38622,,
38623,,
38624,,
38625,,
38626,,
38627,,
38628,,
38629,,
38630,,
38631,,
38632,,
38633,,
38634,,
38635,,
38636,,
38637,,
38638,,
38639,,
38640,,
38641,,
38642,,
38643,,
38644,,
38645,,
38646,,
38647,,
38648,,
38649,,
38650,,
38651,,
38652,,
38653,,
38654,,
38655,,
38656,,
38657,,
38658,,
38659,,
38660,,
38661,,
38662,,
38663,,
38664,,
38665,,
38666,,
38667,,
38668,,
38669,,
38670,,
38671,,
38672,,
38673,,
38674,,
38675,,
38676,,
38677,,
38678,,
38679,,
38680,,
38681,,
38682,,
38683,,
38684,,
38685,,
38686,,
38687,,
38688,,
38689,,
38690,,
38691,,
38692,,
38693,,
38694,,
38695,,
38696,,
38697,,
38698,,
38699,,
38700,,
38701,,
38702,,
38703,,
38704,,
38705,,
38706,,
38707,,
38708,,
38709,,
38710,,
38711,,
38712,,
38713,,
38714,,
38715,,
38716,,
38717,,
38718,,
38719,,
38720,,
38721,,
38722,,
38723,,
38724,,
38725,,
38726,,
38727,,
38728,,
38729,,
38730,,
38731,,
38732,,
38733,,
38734,,
38735,,
38736,,
38737,,
38738,,
38739,,
38740,,
38741,,
38742,,
38743,,
38744,,
38745,,
38746,,
38747,,
38748,,
38749,,
38750,,
38751,,
38752,,
38753,,
38754,,
38755,,
38756,,
38757,,
38758,,
38759,,
38760,,
38761,,
38762,,
38763,,
38764,,
38765,,
38766,,
38767,,
38768,,
38769,,
38770,,
38771,,
38772,,
38773,,
38774,,
38775,,
38776,,
38777,,
38778,,
38779,,
38780,,
38781,,
38782,,
38783,,
38784,,
38785,,
38786,,
38787,,
38788,,
38789,,
38790,,
38791,,
38792,,
38793,,
38794,,
38795,,
38796,,
38797,,
38798,,
38799,,
38800,,
38801,,
38802,,
38803,,
38804,,
38805,,
38806,,
38807,,
38808,,
38809,,
38810,,
38811,,
38812,,
38813,,
38814,,
38815,,
38816,,
38817,,
38818,,
38819,,
38820,,
38821,,
38822,,
38823,,
38824,,
38825,,
38826,,
38827,,
38828,,
38829,,
38830,,
38831,,
38832,,
38833,,
38834,,
38835,,
38836,,
38837,,
38838,,
38839,,
38840,,
38841,,
38842,,
38843,,
38844,,
38845,,
38846,,
38847,,
38848,,
38849,,
38850,,
38851,,
38852,,
38853,,
38854,,
38855,,
38856,,
38857,,
38858,,
38859,,
38860,,
38861,,
38862,,
38863,,
38864,,
38865,,
38866,,
38867,,
38868,,
38869,,
38870,,
38871,,
38872,,
38873,,
38874,,
38875,,
38876,,
38877,,
38878,,
38879,,
38880,,
38881,,
38882,,
38883,,
38884,,
38885,,
38886,,
38887,,
38888,,
38889,,
38890,,
38891,,
38892,,
38893,,
38894,,
38895,,
38896,,
38897,,
38898,,
38899,,
38900,,
38901,,
38902,,
38903,,
38904,,
38905,,
38906,,
38907,,
38908,,
38909,,
38910,,
38911,,
38912,,
38913,,
38914,,
38915,,
38916,,
38917,,
38918,,
38919,,
38920,,
38921,,
38922,,
38923,,
38924,,
38925,,
38926,,
38927,,
38928,,
38929,,
38930,,
38931,,
38932,,
38933,,
38934,,
38935,,
38936,,
38937,,
38938,,
38939,,
38940,,
38941,,
38942,,
38943,,
38944,,
38945,,
38946,,
38947,,
38948,,
38949,,
38950,,
38951,,
38952,,
38953,,
38954,,
38955,,
38956,,
38957,,
38958,,
38959,,
38960,,
38961,,
38962,,
38963,,
38964,,
38965,,
38966,,
38967,,
38968,,
38969,,
38970,,
38971,,
38972,,
38973,,
38974,,
38975,,
38976,,
38977,,
38978,,
38979,,
38980,,
38981,,
38982,,
38983,,
38984,,
38985,,
38986,,
38987,,
38988,,
38989,,
38990,,
38991,,
38992,,
38993,,
38994,,
38995,,
38996,,
38997,,
38998,,
38999,,
39000,,
39001,,
39002,,
39003,,
39004,,
39005,,
39006,,
39007,,
39008,,
39009,,
39010,,
39011,,
39012,,
39013,,
39014,,
39015,,
39016,,
39017,,
39018,,
39019,,
39020,,
39021,,
39022,,
39023,,
39024,,
39025,,
39026,,
39027,,
39028,,
39029,,
39030,,
39031,,
39032,,
39033,,
39034,,
39035,,
39036,,
39037,,
39038,,
39039,,
39040,,
39041,,
39042,,
39043,,
39044,,
39045,,
39046,,
39047,,
39048,,
39049,,
39050,,
39051,,
39052,,
39053,,
39054,,
39055,,
39056,,
39057,,
39058,,
39059,,
39060,,
39061,,
39062,,
39063,,
39064,,
39065,,
39066,,
39067,,
39068,,
39069,,
39070,,
39071,,
39072,,
39073,,
39074,,
39075,,
39076,,
39077,,
39078,,
39079,,
39080,,
39081,,
39082,,
39083,,
39084,,
39085,,
39086,,
39087,,
39088,,
39089,,
39090,,
39091,,
39092,,
39093,,
39094,,
39095,,
39096,,
39097,,
39098,,
39099,,
39100,,
39101,,
39102,,
39103,,
39104,,
39105,,
39106,,
39107,,
39108,,
39109,,
39110,,
39111,,
39112,,
39113,,
39114,,
39115,,
39116,,
39117,,
39118,,
39119,,
39120,,
39121,,
39122,,
39123,,
39124,,
39125,,
39126,,
39127,,
39128,,
39129,,
39130,,
39131,,
39132,,
39133,,
39134,,
39135,,
39136,,
39137,,
39138,,
39139,,
39140,,
39141,,
39142,,
39143,,
39144,,
39145,,
39146,,
39147,,
39148,,
39149,,
39150,,
39151,,
39152,,
39153,,
39154,,
39155,,
39156,,
39157,,
39158,,
39159,,
39160,,
39161,,
39162,,
39163,,
39164,,
39165,,
39166,,
39167,,
39168,,
39169,,
39170,,
39171,,
39172,,
39173,,
39174,,
39175,,
39176,,
39177,,
39178,,
39179,,
39180,,
39181,,
39182,,
39183,,
39184,,
39185,,
39186,,
39187,,
39188,,
39189,,
39190,,
39191,,
39192,,
39193,,
39194,,
39195,,
39196,,
39197,,
39198,,
39199,,
39200,,
39201,,
39202,,
39203,,
39204,,
39205,,
39206,,
39207,,
39208,,
39209,,
39210,,
39211,,
39212,,
39213,,
39214,,
39215,,
39216,,
39217,,
39218,,
39219,,
39220,,
39221,,
39222,,
39223,,
39224,,
39225,,
39226,,
39227,,
39228,,
39229,,
39230,,
39231,,
39232,,
39233,,
39234,,
39235,,
39236,,
39237,,
39238,,
39239,,
39240,,
39241,,
39242,,
39243,,
39244,,
39245,,
39246,,
39247,,
39248,,
39249,,
39250,,
39251,,
39252,,
39253,,
39254,,
39255,,
39256,,
39257,,
39258,,
39259,,
39260,,
39261,,
39262,,
39263,,
39264,,
39265,,
39266,,
39267,,
39268,,
39269,,
39270,,
39271,,
39272,,
39273,,
39274,,
39275,,
39276,,
39277,,
39278,,
39279,,
39280,,
39281,,
39282,,
39283,,
39284,,
39285,,
39286,,
39287,,
39288,,
39289,,
39290,,
39291,,
39292,,
39293,,
39294,,
39295,,
39296,,
39297,,
39298,,
39299,,
39300,,
39301,,
39302,,
39303,,
39304,,
39305,,
39306,,
39307,,
39308,,
39309,,
39310,,
39311,,
39312,,
39313,,
39314,,
39315,,
39316,,
39317,,
39318,,
39319,,
39320,,
39321,,
39322,,
39323,,
39324,,
39325,,
39326,,
39327,,
39328,,
39329,,
39330,,
39331,,
39332,,
39333,,
39334,,
39335,,
39336,,
39337,,
39338,,
39339,,
39340,,
39341,,
39342,,
39343,,
39344,,
39345,,
39346,,
39347,,
39348,,
39349,,
39350,,
39351,,
39352,,
39353,,
39354,,
39355,,
39356,,
39357,,
39358,,
39359,,
39360,,
39361,,
39362,,
39363,,
39364,,
39365,,
39366,,
39367,,
39368,,
39369,,
39370,,
39371,,
39372,,
39373,,
39374,,
39375,,
39376,,
39377,,
39378,,
39379,,
39380,,
39381,,
39382,,
39383,,
39384,,
39385,,
39386,,
39387,,
39388,,
39389,,
39390,,
39391,,
39392,,
39393,,
39394,,
39395,,
39396,,
39397,,
39398,,
39399,,
39400,,
39401,,
39402,,
39403,,
39404,,
39405,,
39406,,
39407,,
39408,,
39409,,
39410,,
39411,,
39412,,
39413,,
39414,,
39415,,
39416,,
39417,,
39418,,
39419,,
39420,,
39421,,
39422,,
39423,,
39424,,
39425,,
39426,,
39427,,
39428,,
39429,,
39430,,
39431,,
39432,,
39433,,
39434,,
39435,,
39436,,
39437,,
39438,,
39439,,
39440,,
39441,,
39442,,
39443,,
39444,,
39445,,
39446,,
39447,,
39448,,
39449,,
39450,,
39451,,
39452,,
39453,,
39454,,
39455,,
39456,,
39457,,
39458,,
39459,,
39460,,
39461,,
39462,,
39463,,
39464,,
39465,,
39466,,
39467,,
39468,,
39469,,
39470,,
39471,,
39472,,
39473,,
39474,,
39475,,
39476,,
39477,,
39478,,
39479,,
39480,,
39481,,
39482,,
39483,,
39484,,
39485,,
39486,,
39487,,
39488,,
39489,,
39490,,
39491,,
39492,,
39493,,
39494,,
39495,,
39496,,
39497,,
39498,,
39499,,
39500,,
39501,,
39502,,
39503,,
39504,,
39505,,
39506,,
39507,,
39508,,
39509,,
39510,,
39511,,
39512,,
39513,,
39514,,
39515,,
39516,,
39517,,
39518,,
39519,,
39520,,
39521,,
39522,,
39523,,
39524,,
39525,,
39526,,
39527,,
39528,,
39529,,
39530,,
39531,,
39532,,
39533,,
39534,,
39535,,
39536,,
39537,,
39538,,
39539,,
39540,,
39541,,
39542,,
39543,,
39544,,
39545,,
39546,,
39547,,
39548,,
39549,,
39550,,
39551,,
39552,,
39553,,
39554,,
39555,,
39556,,
39557,,
39558,,
39559,,
39560,,
39561,,
39562,,
39563,,
39564,,
39565,,
39566,,
39567,,
39568,,
39569,,
39570,,
39571,,
39572,,
39573,,
39574,,
39575,,
39576,,
39577,,
39578,,
39579,,
39580,,
39581,,
39582,,
39583,,
39584,,
39585,,
39586,,
39587,,
39588,,
39589,,
39590,,
39591,,
39592,,
39593,,
39594,,
39595,,
39596,,
39597,,
39598,,
39599,,
39600,,
39601,,
39602,,
39603,,
39604,,
39605,,
39606,,
39607,,
39608,,
39609,,
39610,,
39611,,
39612,,
39613,,
39614,,
39615,,
39616,,
39617,,
39618,,
39619,,
39620,,
39621,,
39622,,
39623,,
39624,,
39625,,
39626,,
39627,,
39628,,
39629,,
39630,,
39631,,
39632,,
39633,,
39634,,
39635,,
39636,,
39637,,
39638,,
39639,,
39640,,
39641,,
39642,,
39643,,
39644,,
39645,,
39646,,
39647,,
39648,,
39649,,
39650,,
39651,,
39652,,
39653,,
39654,,
39655,,
39656,,
39657,,
39658,,
39659,,
39660,,
39661,,
39662,,
39663,,
39664,,
39665,,
39666,,
39667,,
39668,,
39669,,
39670,,
39671,,
39672,,
39673,,
39674,,
39675,,
39676,,
39677,,
39678,,
39679,,
39680,,
39681,,
39682,,
39683,,
39684,,
39685,,
39686,,
39687,,
39688,,
39689,,
39690,,
39691,,
39692,,
39693,,
39694,,
39695,,
39696,,
39697,,
39698,,
39699,,
39700,,
39701,,
39702,,
39703,,
39704,,
39705,,
39706,,
39707,,
39708,,
39709,,
39710,,
39711,,
39712,,
39713,,
39714,,
39715,,
39716,,
39717,,
39718,,
39719,,
39720,,
39721,,
39722,,
39723,,
39724,,
39725,,
39726,,
39727,,
39728,,
39729,,
39730,,
39731,,
39732,,
39733,,
39734,,
39735,,
39736,,
39737,,
39738,,
39739,,
39740,,
39741,,
39742,,
39743,,
39744,,
39745,,
39746,,
39747,,
39748,,
39749,,
39750,,
39751,,
39752,,
39753,,
39754,,
39755,,
39756,,
39757,,
39758,,
39759,,
39760,,
39761,,
39762,,
39763,,
39764,,
39765,,
39766,,
39767,,
39768,,
39769,,
39770,,
39771,,
39772,,
39773,,
39774,,
39775,,
39776,,
39777,,
39778,,
39779,,
39780,,
39781,,
39782,,
39783,,
39784,,
39785,,
39786,,
39787,,
39788,,
39789,,
39790,,
39791,,
39792,,
39793,,
39794,,
39795,,
39796,,
39797,,
39798,,
39799,,
39800,,
39801,,
39802,,
39803,,
39804,,
39805,,
39806,,
39807,,
39808,,
39809,,
39810,,
39811,,
39812,,
39813,,
39814,,
39815,,
39816,,
39817,,
39818,,
39819,,
39820,,
39821,,
39822,,
39823,,
39824,,
39825,,
39826,,
39827,,
39828,,
39829,,
39830,,
39831,,
39832,,
39833,,
39834,,
39835,,
39836,,
39837,,
39838,,
39839,,
39840,,
39841,,
39842,,
39843,,
39844,,
39845,,
39846,,
39847,,
39848,,
39849,,
39850,,
39851,,
39852,,
39853,,
39854,,
39855,,
39856,,
39857,,
39858,,
39859,,
39860,,
39861,,
39862,,
39863,,
39864,,
39865,,
39866,,
39867,,
39868,,
39869,,
39870,,
39871,,
39872,,
39873,,
39874,,
39875,,
39876,,
39877,,
39878,,
39879,,
39880,,
39881,,
39882,,
39883,,
39884,,
39885,,
39886,,
39887,,
39888,,
39889,,
39890,,
39891,,
39892,,
39893,,
39894,,
39895,,
39896,,
39897,,
39898,,
39899,,
39900,,
39901,,
39902,,
39903,,
39904,,
39905,,
39906,,
39907,,
39908,,
39909,,
39910,,
39911,,
39912,,
39913,,
39914,,
39915,,
39916,,
39917,,
39918,,
39919,,
39920,,
39921,,
39922,,
39923,,
39924,,
39925,,
39926,,
39927,,
39928,,
39929,,
39930,,
39931,,
39932,,
39933,,
39934,,
39935,,
39936,,
39937,,
39938,,
39939,,
39940,,
39941,,
39942,,
39943,,
39944,,
39945,,
39946,,
39947,,
39948,,
39949,,
39950,,
39951,,
39952,,
39953,,
39954,,
39955,,
39956,,
39957,,
39958,,
39959,,
39960,,
39961,,
39962,,
39963,,
39964,,
39965,,
39966,,
39967,,
39968,,
39969,,
39970,,
39971,,
39972,,
39973,,
39974,,
39975,,
39976,,
39977,,
39978,,
39979,,
39980,,
39981,,
39982,,
39983,,
39984,,
39985,,
39986,,
39987,,
39988,,
39989,,
39990,,
39991,,
39992,,
39993,,
39994,,
39995,,
39996,,
39997,,
39998,,
39999,,
40000,,
40001,,
40002,,
40003,,
40004,,
40005,,
40006,,
40007,,
40008,,
40009,,
40010,,
40011,,
40012,,
40013,,
40014,,
40015,,
40016,,
40017,,
40018,,
40019,,
40020,,
40021,,
40022,,
40023,,
40024,,
40025,,
40026,,
40027,,
40028,,
40029,,
40030,,
40031,,
40032,,
40033,,
40034,,
40035,,
40036,,
40037,,
40038,,
40039,,
40040,,
40041,,
40042,,
40043,,
40044,,
40045,,
40046,,
40047,,
40048,,
40049,,
40050,,
40051,,
40052,,
40053,,
40054,,
40055,,
40056,,
40057,,
40058,,
40059,,
40060,,
40061,,
40062,,
40063,,
40064,,
40065,,
40066,,
40067,,
40068,,
40069,,
40070,,
40071,,
40072,,
40073,,
40074,,
40075,,
40076,,
40077,,
40078,,
40079,,
40080,,
40081,,
40082,,
40083,,
40084,,
40085,,
40086,,
40087,,
40088,,
40089,,
40090,,
40091,,
40092,,
40093,,
40094,,
40095,,
40096,,
40097,,
40098,,
40099,,
40100,,
40101,,
40102,,
40103,,
40104,,
40105,,
40106,,
40107,,
40108,,
40109,,
40110,,
40111,,
40112,,
40113,,
40114,,
40115,,
40116,,
40117,,
40118,,
40119,,
40120,,
40121,,
40122,,
40123,,
40124,,
40125,,
40126,,
40127,,
40128,,
40129,,
40130,,
40131,,
40132,,
40133,,
40134,,
40135,,
40136,,
40137,,
40138,,
40139,,
40140,,
40141,,
40142,,
40143,,
40144,,
40145,,
40146,,
40147,,
40148,,
40149,,
40150,,
40151,,
40152,,
40153,,
40154,,
40155,,
40156,,
40157,,
40158,,
40159,,
40160,,
40161,,
40162,,
40163,,
40164,,
40165,,
40166,,
40167,,
40168,,
40169,,
40170,,
40171,,
40172,,
40173,,
40174,,
40175,,
40176,,
40177,,
40178,,
40179,,
40180,,
40181,,
40182,,
40183,,
40184,,
40185,,
40186,,
40187,,
40188,,
40189,,
40190,,
40191,,
40192,,
40193,,
40194,,
40195,,
40196,,
40197,,
40198,,
40199,,
40200,,
40201,,
40202,,
40203,,
40204,,
40205,,
40206,,
40207,,
40208,,
40209,,
40210,,
40211,,
40212,,
40213,,
40214,,
40215,,
40216,,
40217,,
40218,,
40219,,
40220,,
40221,,
40222,,
40223,,
40224,,
40225,,
40226,,
40227,,
40228,,
40229,,
40230,,
40231,,
40232,,
40233,,
40234,,
40235,,
40236,,
40237,,
40238,,
40239,,
40240,,
40241,,
40242,,
40243,,
40244,,
40245,,
40246,,
40247,,
40248,,
40249,,
40250,,
40251,,
40252,,
40253,,
40254,,
40255,,
40256,,
40257,,
40258,,
40259,,
40260,,
40261,,
40262,,
40263,,
40264,,
40265,,
40266,,
40267,,
40268,,
40269,,
40270,,
40271,,
40272,,
40273,,
40274,,
40275,,
40276,,
40277,,
40278,,
40279,,
40280,,
40281,,
40282,,
40283,,
40284,,
40285,,
40286,,
40287,,
40288,,
40289,,
40290,,
40291,,
40292,,
40293,,
40294,,
40295,,
40296,,
40297,,
40298,,
40299,,
40300,,
40301,,
40302,,
40303,,
40304,,
40305,,
40306,,
40307,,
40308,,
40309,,
40310,,
40311,,
40312,,
40313,,
40314,,
40315,,
40316,,
40317,,
40318,,
40319,,
40320,,
40321,,
40322,,
40323,,
40324,,
40325,,
40326,,
40327,,
40328,,
40329,,
40330,,
40331,,
40332,,
40333,,
40334,,
40335,,
40336,,
40337,,
40338,,
40339,,
40340,,
40341,,
40342,,
40343,,
40344,,
40345,,
40346,,
40347,,
40348,,
40349,,
40350,,
40351,,
40352,,
40353,,
40354,,
40355,,
40356,,
40357,,
40358,,
40359,,
40360,,
40361,,
40362,,
40363,,
40364,,
40365,,
40366,,
40367,,
40368,,
40369,,
40370,,
40371,,
40372,,
40373,,
40374,,
40375,,
40376,,
40377,,
40378,,
40379,,
40380,,
40381,,
40382,,
40383,,
40384,,
40385,,
40386,,
40387,,
40388,,
40389,,
40390,,
40391,,
40392,,
40393,,
40394,,
40395,,
40396,,
40397,,
40398,,
40399,,
40400,,
40401,,
40402,,
40403,,
40404,,
40405,,
40406,,
40407,,
40408,,
40409,,
40410,,
40411,,
40412,,
40413,,
40414,,
40415,,
40416,,
40417,,
40418,,
40419,,
40420,,
40421,,
40422,,
40423,,
40424,,
40425,,
40426,,
40427,,
40428,,
40429,,
40430,,
40431,,
40432,,
40433,,
40434,,
40435,,
40436,,
40437,,
40438,,
40439,,
40440,,
40441,,
40442,,
40443,,
40444,,
40445,,
40446,,
40447,,
40448,,
40449,,
40450,,
40451,,
40452,,
40453,,
40454,,
40455,,
40456,,
40457,,
40458,,
40459,,
40460,,
40461,,
40462,,
40463,,
40464,,
40465,,
40466,,
40467,,
40468,,
40469,,
40470,,
40471,,
40472,,
40473,,
40474,,
40475,,
40476,,
40477,,
40478,,
40479,,
40480,,
40481,,
40482,,
40483,,
40484,,
40485,,
40486,,
40487,,
40488,,
40489,,
40490,,
40491,,
40492,,
40493,,
40494,,
40495,,
40496,,
40497,,
40498,,
40499,,
40500,,
40501,,
40502,,
40503,,
40504,,
40505,,
40506,,
40507,,
40508,,
40509,,
40510,,
40511,,
40512,,
40513,,
40514,,
40515,,
40516,,
40517,,
40518,,
40519,,
40520,,
40521,,
40522,,
40523,,
40524,,
40525,,
40526,,
40527,,
40528,,
40529,,
40530,,
40531,,
40532,,
40533,,
40534,,
40535,,
40536,,
40537,,
40538,,
40539,,
40540,,
40541,,
40542,,
40543,,
40544,,
40545,,
40546,,
40547,,
40548,,
40549,,
40550,,
40551,,
40552,,
40553,,
40554,,
40555,,
40556,,
40557,,
40558,,
40559,,
40560,,
40561,,
40562,,
40563,,
40564,,
40565,,
40566,,
40567,,
40568,,
40569,,
40570,,
40571,,
40572,,
40573,,
40574,,
40575,,
40576,,
40577,,
40578,,
40579,,
40580,,
40581,,
40582,,
40583,,
40584,,
40585,,
40586,,
40587,,
40588,,
40589,,
40590,,
40591,,
40592,,
40593,,
40594,,
40595,,
40596,,
40597,,
40598,,
40599,,
40600,,
40601,,
40602,,
40603,,
40604,,
40605,,
40606,,
40607,,
40608,,
40609,,
40610,,
40611,,
40612,,
40613,,
40614,,
40615,,
40616,,
40617,,
40618,,
40619,,
40620,,
40621,,
40622,,
40623,,
40624,,
40625,,
40626,,
40627,,
40628,,
40629,,
40630,,
40631,,
40632,,
40633,,
40634,,
40635,,
40636,,
40637,,
40638,,
40639,,
40640,,
40641,,
40642,,
40643,,
40644,,
40645,,
40646,,
40647,,
40648,,
40649,,
40650,,
40651,,
40652,,
40653,,
40654,,
40655,,
40656,,
40657,,
40658,,
40659,,
40660,,
40661,,
40662,,
40663,,
40664,,
40665,,
40666,,
40667,,
40668,,
40669,,
40670,,
40671,,
40672,,
40673,,
40674,,
40675,,
40676,,
40677,,
40678,,
40679,,
40680,,
40681,,
40682,,
40683,,
40684,,
40685,,
40686,,
40687,,
40688,,
40689,,
40690,,
40691,,
40692,,
40693,,
40694,,
40695,,
40696,,
40697,,
40698,,
40699,,
40700,,
40701,,
40702,,
40703,,
40704,,
40705,,
40706,,
40707,,
40708,,
40709,,
40710,,
40711,,
40712,,
40713,,
40714,,
40715,,
40716,,
40717,,
40718,,
40719,,
40720,,
40721,,
40722,,
40723,,
40724,,
40725,,
40726,,
40727,,
40728,,
40729,,
40730,,
40731,,
40732,,
40733,,
40734,,
40735,,
40736,,
40737,,
40738,,
40739,,
40740,,
40741,,
40742,,
40743,,
40744,,
40745,,
40746,,
40747,,
40748,,
40749,,
40750,,
40751,,
40752,,
40753,,
40754,,
40755,,
40756,,
40757,,
40758,,
40759,,
40760,,
40761,,
40762,,
40763,,
40764,,
40765,,
40766,,
40767,,
40768,,
40769,,
40770,,
40771,,
40772,,
40773,,
40774,,
40775,,
40776,,
40777,,
40778,,
40779,,
40780,,
40781,,
40782,,
40783,,
40784,,
40785,,
40786,,
40787,,
40788,,
40789,,
40790,,
40791,,
40792,,
40793,,
40794,,
40795,,
40796,,
40797,,
40798,,
40799,,
40800,,
40801,,
40802,,
40803,,
40804,,
40805,,
40806,,
40807,,
40808,,
40809,,
40810,,
40811,,
40812,,
40813,,
40814,,
40815,,
40816,,
40817,,
40818,,
40819,,
40820,,
40821,,
40822,,
40823,,
40824,,
40825,,
40826,,
40827,,
40828,,
40829,,
40830,,
40831,,
40832,,
40833,,
40834,,
40835,,
40836,,
40837,,
40838,,
40839,,
40840,,
40841,,
40842,,
40843,,
40844,,
40845,,
40846,,
40847,,
40848,,
40849,,
40850,,
40851,,
40852,,
40853,,
40854,,
40855,,
40856,,
40857,,
40858,,
40859,,
40860,,
40861,,
40862,,
40863,,
40864,,
40865,,
40866,,
40867,,
40868,,
40869,,
40870,,
40871,,
40872,,
40873,,
40874,,
40875,,
40876,,
40877,,
40878,,
40879,,
40880,,
40881,,
40882,,
40883,,
40884,,
40885,,
40886,,
40887,,
40888,,
40889,,
40890,,
40891,,
40892,,
40893,,
40894,,
40895,,
40896,,
40897,,
40898,,
40899,,
40900,,
40901,,
40902,,
40903,,
40904,,
40905,,
40906,,
40907,,
40908,,
40909,,
40910,,
40911,,
40912,,
40913,,
40914,,
40915,,
40916,,
40917,,
40918,,
40919,,
40920,,
40921,,
40922,,
40923,,
40924,,
40925,,
40926,,
40927,,
40928,,
40929,,
40930,,
40931,,
40932,,
40933,,
40934,,
40935,,
40936,,
40937,,
40938,,
40939,,
40940,,
40941,,
40942,,
40943,,
40944,,
40945,,
40946,,
40947,,
40948,,
40949,,
40950,,
40951,,
40952,,
40953,,
40954,,
40955,,
40956,,
40957,,
40958,,
40959,,
40960,,
40961,,
40962,,
40963,,
40964,,
40965,,
40966,,
40967,,
40968,,
40969,,
40970,,
40971,,
40972,,
40973,,
40974,,
40975,,
40976,,
40977,,
40978,,
40979,,
40980,,
40981,,
40982,,
40983,,
40984,,
40985,,
40986,,
40987,,
40988,,
40989,,
40990,,
40991,,
40992,,
40993,,
40994,,
40995,,
40996,,
40997,,
40998,,
40999,,
41000,,
41001,,
41002,,
41003,,
41004,,
41005,,
41006,,
41007,,
41008,,
41009,,
41010,,
41011,,
41012,,
41013,,
41014,,
41015,,
41016,,
41017,,
41018,,
41019,,
41020,,
41021,,
41022,,
41023,,
41024,,
41025,,
41026,,
41027,,
41028,,
41029,,
41030,,
41031,,
41032,,
41033,,
41034,,
41035,,
41036,,
41037,,
41038,,
41039,,
41040,,
41041,,
41042,,
41043,,
41044,,
41045,,
41046,,
41047,,
41048,,
41049,,
41050,,
41051,,
41052,,
41053,,
41054,,
41055,,
41056,,
41057,,
41058,,
41059,,
41060,,
41061,,
41062,,
41063,,
41064,,
41065,,
41066,,
41067,,
41068,,
41069,,
41070,,
41071,,
41072,,
41073,,
41074,,
41075,,
41076,,
41077,,
41078,,
41079,,
41080,,
41081,,
41082,,
41083,,
41084,,
41085,,
41086,,
41087,,
41088,,
41089,,
41090,,
41091,,
41092,,
41093,,
41094,,
41095,,
41096,,
41097,,
41098,,
41099,,
41100,,
41101,,
41102,,
41103,,
41104,,
41105,,
41106,,
41107,,
41108,,
41109,,
41110,,
41111,,
41112,,
41113,,
41114,,
41115,,
41116,,
41117,,
41118,,
41119,,
41120,,
41121,,
41122,,
41123,,
41124,,
41125,,
41126,,
41127,,
41128,,
41129,,
41130,,
41131,,
41132,,
41133,,
41134,,
41135,,
41136,,
41137,,
41138,,
41139,,
41140,,
41141,,
41142,,
41143,,
41144,,
41145,,
41146,,
41147,,
41148,,
41149,,
41150,,
41151,,
41152,,
41153,,
41154,,
41155,,
41156,,
41157,,
41158,,
41159,,
41160,,
41161,,
41162,,
41163,,
41164,,
41165,,
41166,,
41167,,
41168,,
41169,,
41170,,
41171,,
41172,,
41173,,
41174,,
41175,,
41176,,
41177,,
41178,,
41179,,
41180,,
41181,,
41182,,
41183,,
41184,,
41185,,
41186,,
41187,,
41188,,
41189,,
41190,,
41191,,
41192,,
41193,,
41194,,
41195,,
41196,,
41197,,
41198,,
41199,,
41200,,
41201,,
41202,,
41203,,
41204,,
41205,,
41206,,
41207,,
41208,,
41209,,
41210,,
41211,,
41212,,
41213,,
41214,,
41215,,
41216,,
41217,,
41218,,
41219,,
41220,,
41221,,
41222,,
41223,,
41224,,
41225,,
41226,,
41227,,
41228,,
41229,,
41230,,
41231,,
41232,,
41233,,
41234,,
41235,,
41236,,
41237,,
41238,,
41239,,
41240,,
41241,,
41242,,
41243,,
41244,,
41245,,
41246,,
41247,,
41248,,
41249,,
41250,,
41251,,
41252,,
41253,,
41254,,
41255,,
41256,,
41257,,
41258,,
41259,,
41260,,
41261,,
41262,,
41263,,
41264,,
41265,,
41266,,
41267,,
41268,,
41269,,
41270,,
41271,,
41272,,
41273,,
41274,,
41275,,
41276,,
41277,,
41278,,
41279,,
41280,,
41281,,
41282,,
41283,,
41284,,
41285,,
41286,,
41287,,
41288,,
41289,,
41290,,
41291,,
41292,,
41293,,
41294,,
41295,,
41296,,
41297,,
41298,,
41299,,
41300,,
41301,,
41302,,
41303,,
41304,,
41305,,
41306,,
41307,,
41308,,
41309,,
41310,,
41311,,
41312,,
41313,,
41314,,
41315,,
41316,,
41317,,
41318,,
41319,,
41320,,
41321,,
41322,,
41323,,
41324,,
41325,,
41326,,
41327,,
41328,,
41329,,
41330,,
41331,,
41332,,
41333,,
41334,,
41335,,
41336,,
41337,,
41338,,
41339,,
41340,,
41341,,
41342,,
41343,,
41344,,
41345,,
41346,,
41347,,
41348,,
41349,,
41350,,
41351,,
41352,,
41353,,
41354,,
41355,,
41356,,
41357,,
41358,,
41359,,
41360,,
41361,,
41362,,
41363,,
41364,,
41365,,
41366,,
41367,,
41368,,
41369,,
41370,,
41371,,
41372,,
41373,,
41374,,
41375,,
41376,,
41377,,
41378,,
41379,,
41380,,
41381,,
41382,,
41383,,
41384,,
41385,,
41386,,
41387,,
41388,,
41389,,
41390,,
41391,,
41392,,
41393,,
41394,,
41395,,
41396,,
41397,,
41398,,
41399,,
41400,,
41401,,
41402,,
41403,,
41404,,
41405,,
41406,,
41407,,
41408,,
41409,,
41410,,
41411,,
41412,,
41413,,
41414,,
41415,,
41416,,
41417,,
41418,,
41419,,
41420,,
41421,,
41422,,
41423,,
41424,,
41425,,
41426,,
41427,,
41428,,
41429,,
41430,,
41431,,
41432,,
41433,,
41434,,
41435,,
41436,,
41437,,
41438,,
41439,,
41440,,
41441,,
41442,,
41443,,
41444,,
41445,,
41446,,
41447,,
41448,,
41449,,
41450,,
41451,,
41452,,
41453,,
41454,,
41455,,
41456,,
41457,,
41458,,
41459,,
41460,,
41461,,
41462,,
41463,,
41464,,
41465,,
41466,,
41467,,
41468,,
41469,,
41470,,
41471,,
41472,,
41473,,
41474,,
41475,,
41476,,
41477,,
41478,,
41479,,
41480,,
41481,,
41482,,
41483,,
41484,,
41485,,
41486,,
41487,,
41488,,
41489,,
41490,,
41491,,
41492,,
41493,,
41494,,
41495,,
41496,,
41497,,
41498,,
41499,,
41500,,
41501,,
41502,,
41503,,
41504,,
41505,,
41506,,
41507,,
41508,,
41509,,
41510,,
41511,,
41512,,
41513,,
41514,,
41515,,
41516,,
41517,,
41518,,
41519,,
41520,,
41521,,
41522,,
41523,,
41524,,
41525,,
41526,,
41527,,
41528,,
41529,,
41530,,
41531,,
41532,,
41533,,
41534,,
41535,,
41536,,
41537,,
41538,,
41539,,
41540,,
41541,,
41542,,
41543,,
41544,,
41545,,
41546,,
41547,,
41548,,
41549,,
41550,,
41551,,
41552,,
41553,,
41554,,
41555,,
41556,,
41557,,
41558,,
41559,,
41560,,
41561,,
41562,,
41563,,
41564,,
41565,,
41566,,
41567,,
41568,,
41569,,
41570,,
41571,,
41572,,
41573,,
41574,,
41575,,
41576,,
41577,,
41578,,
41579,,
41580,,
41581,,
41582,,
41583,,
41584,,
41585,,
41586,,
41587,,
41588,,
41589,,
41590,,
41591,,
41592,,
41593,,
41594,,
41595,,
41596,,
41597,,
41598,,
41599,,
41600,,
41601,,
41602,,
41603,,
41604,,
41605,,
41606,,
41607,,
41608,,
41609,,
41610,,
41611,,
41612,,
41613,,
41614,,
41615,,
41616,,
41617,,
41618,,
41619,,
41620,,
41621,,
41622,,
41623,,
41624,,
41625,,
41626,,
41627,,
41628,,
41629,,
41630,,
41631,,
41632,,
41633,,
41634,,
41635,,
41636,,
41637,,
41638,,
41639,,
41640,,
41641,,
41642,,
41643,,
41644,,
41645,,
41646,,
41647,,
41648,,
41649,,
41650,,
41651,,
41652,,
41653,,
41654,,
41655,,
41656,,
41657,,
41658,,
41659,,
41660,,
41661,,
41662,,
41663,,
41664,,
41665,,
41666,,
41667,,
41668,,
41669,,
41670,,
41671,,
41672,,
41673,,
41674,,
41675,,
41676,,
41677,,
41678,,
41679,,
41680,,
41681,,
41682,,
41683,,
41684,,
41685,,
41686,,
41687,,
41688,,
41689,,
41690,,
41691,,
41692,,
41693,,
41694,,
41695,,
41696,,
41697,,
41698,,
41699,,
41700,,
41701,,
41702,,
41703,,
41704,,
41705,,
41706,,
41707,,
41708,,
41709,,
41710,,
41711,,
41712,,
41713,,
41714,,
41715,,
41716,,
41717,,
41718,,
41719,,
41720,,
41721,,
41722,,
41723,,
41724,,
41725,,
41726,,
41727,,
41728,,
41729,,
41730,,
41731,,
41732,,
41733,,
41734,,
41735,,
41736,,
41737,,
41738,,
41739,,
41740,,
41741,,
41742,,
41743,,
41744,,
41745,,
41746,,
41747,,
41748,,
41749,,
41750,,
41751,,
41752,,
41753,,
41754,,
41755,,
41756,,
41757,,
41758,,
41759,,
41760,,
41761,,
41762,,
41763,,
41764,,
41765,,
41766,,
41767,,
41768,,
41769,,
41770,,
41771,,
41772,,
41773,,
41774,,
41775,,
41776,,
41777,,
41778,,
41779,,
41780,,
41781,,
41782,,
41783,,
41784,,
41785,,
41786,,
41787,,
41788,,
41789,,
41790,,
41791,,
41792,,
41793,,
41794,,
41795,,
41796,,
41797,,
41798,,
41799,,
41800,,
41801,,
41802,,
41803,,
41804,,
41805,,
41806,,
41807,,
41808,,
41809,,
41810,,
41811,,
41812,,
41813,,
41814,,
41815,,
41816,,
41817,,
41818,,
41819,,
41820,,
41821,,
41822,,
41823,,
41824,,
41825,,
41826,,
41827,,
41828,,
41829,,
41830,,
41831,,
41832,,
41833,,
41834,,
41835,,
41836,,
41837,,
41838,,
41839,,
41840,,
41841,,
41842,,
41843,,
41844,,
41845,,
41846,,
41847,,
41848,,
41849,,
41850,,
41851,,
41852,,
41853,,
41854,,
41855,,
41856,,
41857,,
41858,,
41859,,
41860,,
41861,,
41862,,
41863,,
41864,,
41865,,
41866,,
41867,,
41868,,
41869,,
41870,,
41871,,
41872,,
41873,,
41874,,
41875,,
41876,,
41877,,
41878,,
41879,,
41880,,
41881,,
41882,,
41883,,
41884,,
41885,,
41886,,
41887,,
41888,,
41889,,
41890,,
41891,,
41892,,
41893,,
41894,,
41895,,
41896,,
41897,,
41898,,
41899,,
41900,,
41901,,
41902,,
41903,,
41904,,
41905,,
41906,,
41907,,
41908,,
41909,,
41910,,
41911,,
41912,,
41913,,
41914,,
41915,,
41916,,
41917,,
41918,,
41919,,
41920,,
41921,,
41922,,
41923,,
41924,,
41925,,
41926,,
41927,,
41928,,
41929,,
41930,,
41931,,
41932,,
41933,,
41934,,
41935,,
41936,,
41937,,
41938,,
41939,,
41940,,
41941,,
41942,,
41943,,
41944,,
41945,,
41946,,
41947,,
41948,,
41949,,
41950,,
41951,,
41952,,
41953,,
41954,,
41955,,
41956,,
41957,,
41958,,
41959,,
41960,,
41961,,
41962,,
41963,,
41964,,
41965,,
41966,,
41967,,
41968,,
41969,,
41970,,
41971,,
41972,,
41973,,
41974,,
41975,,
41976,,
41977,,
41978,,
41979,,
41980,,
41981,,
41982,,
41983,,
41984,,
41985,,
41986,,
41987,,
41988,,
41989,,
41990,,
41991,,
41992,,
41993,,
41994,,
41995,,
41996,,
41997,,
41998,,
41999,,
42000,,
42001,,
42002,,
42003,,
42004,,
42005,,
42006,,
42007,,
42008,,
42009,,
42010,,
42011,,
42012,,
42013,,
42014,,
42015,,
42016,,
42017,,
42018,,
42019,,
42020,,
42021,,
42022,,
42023,,
42024,,
42025,,
42026,,
42027,,
42028,,
42029,,
42030,,
42031,,
42032,,
42033,,
42034,,
42035,,
42036,,
42037,,
42038,,
42039,,
42040,,
42041,,
42042,,
42043,,
42044,,
42045,,
42046,,
42047,,
42048,,
42049,,
42050,,
42051,,
42052,,
42053,,
42054,,
42055,,
42056,,
42057,,
42058,,
42059,,
42060,,
42061,,
42062,,
42063,,
42064,,
42065,,
42066,,
42067,,
42068,,
42069,,
42070,,
42071,,
42072,,
42073,,
42074,,
42075,,
42076,,
42077,,
42078,,
42079,,
42080,,
42081,,
42082,,
42083,,
42084,,
42085,,
42086,,
42087,,
42088,,
42089,,
42090,,
42091,,
42092,,
42093,,
42094,,
42095,,
42096,,
42097,,
42098,,
42099,,
42100,,
42101,,
42102,,
42103,,
42104,,
42105,,
42106,,
42107,,
42108,,
42109,,
42110,,
42111,,
42112,,
42113,,
42114,,
42115,,
42116,,
42117,,
42118,,
42119,,
42120,,
42121,,
42122,,
42123,,
42124,,
42125,,
42126,,
42127,,
42128,,
42129,,
42130,,
42131,,
42132,,
42133,,
42134,,
42135,,
42136,,
42137,,
42138,,
42139,,
42140,,
42141,,
42142,,
42143,,
42144,,
42145,,
42146,,
42147,,
42148,,
42149,,
42150,,
42151,,
42152,,
42153,,
42154,,
42155,,
42156,,
42157,,
42158,,
42159,,
42160,,
42161,,
42162,,
42163,,
42164,,
42165,,
42166,,
42167,,
42168,,
42169,,
42170,,
42171,,
42172,,
42173,,
42174,,
42175,,
42176,,
42177,,
42178,,
42179,,
42180,,
42181,,
42182,,
42183,,
42184,,
42185,,
42186,,
42187,,
42188,,
42189,,
42190,,
42191,,
42192,,
42193,,
42194,,
42195,,
42196,,
42197,,
42198,,
42199,,
42200,,
42201,,
42202,,
42203,,
42204,,
42205,,
42206,,
42207,,
42208,,
42209,,
42210,,
42211,,
42212,,
42213,,
42214,,
42215,,
42216,,
42217,,
42218,,
42219,,
42220,,
42221,,
42222,,
42223,,
42224,,
42225,,
42226,,
42227,,
42228,,
42229,,
42230,,
42231,,
42232,,
42233,,
42234,,
42235,,
42236,,
42237,,
42238,,
42239,,
42240,,
42241,,
42242,,
42243,,
42244,,
42245,,
42246,,
42247,,
42248,,
42249,,
42250,,
42251,,
42252,,
42253,,
42254,,
42255,,
42256,,
42257,,
42258,,
42259,,
42260,,
42261,,
42262,,
42263,,
42264,,
42265,,
42266,,
42267,,
42268,,
42269,,
42270,,
42271,,
42272,,
42273,,
42274,,
42275,,
42276,,
42277,,
42278,,
42279,,
42280,,
42281,,
42282,,
42283,,
42284,,
42285,,
42286,,
42287,,
42288,,
42289,,
42290,,
42291,,
42292,,
42293,,
42294,,
42295,,
42296,,
42297,,
42298,,
42299,,
42300,,
42301,,
42302,,
42303,,
42304,,
42305,,
42306,,
42307,,
42308,,
42309,,
42310,,
42311,,
42312,,
42313,,
42314,,
42315,,
42316,,
42317,,
42318,,
42319,,
42320,,
42321,,
42322,,
42323,,
42324,,
42325,,
42326,,
42327,,
42328,,
42329,,
42330,,
42331,,
42332,,
42333,,
42334,,
42335,,
42336,,
42337,,
42338,,
42339,,
42340,,
42341,,
42342,,
42343,,
42344,,
42345,,
42346,,
42347,,
42348,,
42349,,
42350,,
42351,,
42352,,
42353,,
42354,,
42355,,
42356,,
42357,,
42358,,
42359,,
42360,,
42361,,
42362,,
42363,,
42364,,
42365,,
42366,,
42367,,
42368,,
42369,,
42370,,
42371,,
42372,,
42373,,
42374,,
42375,,
42376,,
42377,,
42378,,
42379,,
42380,,
42381,,
42382,,
42383,,
42384,,
42385,,
42386,,
42387,,
42388,,
42389,,
42390,,
42391,,
42392,,
42393,,
42394,,
42395,,
42396,,
42397,,
42398,,
42399,,
42400,,
42401,,
42402,,
42403,,
42404,,
42405,,
42406,,
42407,,
42408,,
42409,,
42410,,
42411,,
42412,,
42413,,
42414,,
42415,,
42416,,
42417,,
42418,,
42419,,
42420,,
42421,,
42422,,
42423,,
42424,,
42425,,
42426,,
42427,,
42428,,
42429,,
42430,,
42431,,
42432,,
42433,,
42434,,
42435,,
42436,,
42437,,
42438,,
42439,,
42440,,
42441,,
42442,,
42443,,
42444,,
42445,,
42446,,
42447,,
42448,,
42449,,
42450,,
42451,,
42452,,
42453,,
42454,,
42455,,
42456,,
42457,,
42458,,
42459,,
42460,,
42461,,
42462,,
42463,,
42464,,
42465,,
42466,,
42467,,
42468,,
42469,,
42470,,
42471,,
42472,,
42473,,
42474,,
42475,,
42476,,
42477,,
42478,,
42479,,
42480,,
42481,,
42482,,
42483,,
42484,,
42485,,
42486,,
42487,,
42488,,
42489,,
42490,,
42491,,
42492,,
42493,,
42494,,
42495,,
42496,,
42497,,
42498,,
42499,,
42500,,
42501,,
42502,,
42503,,
42504,,
42505,,
42506,,
42507,,
42508,,
42509,,
42510,,
42511,,
42512,,
42513,,
42514,,
42515,,
42516,,
42517,,
42518,,
42519,,
42520,,
42521,,
42522,,
42523,,
42524,,
42525,,
42526,,
42527,,
42528,,
42529,,
42530,,
42531,,
42532,,
42533,,
42534,,
42535,,
42536,,
42537,,
42538,,
42539,,
42540,,
42541,,
42542,,
42543,,
42544,,
42545,,
42546,,
42547,,
42548,,
42549,,
42550,,
42551,,
42552,,
42553,,
42554,,
42555,,
42556,,
42557,,
42558,,
42559,,
42560,,
42561,,
42562,,
42563,,
42564,,
42565,,
42566,,
42567,,
42568,,
42569,,
42570,,
42571,,
42572,,
42573,,
42574,,
42575,,
42576,,
42577,,
42578,,
42579,,
42580,,
42581,,
42582,,
42583,,
42584,,
42585,,
42586,,
42587,,
42588,,
42589,,
42590,,
42591,,
42592,,
42593,,
42594,,
42595,,
42596,,
42597,,
42598,,
42599,,
42600,,
42601,,
42602,,
42603,,
42604,,
42605,,
42606,,
42607,,
42608,,
42609,,
42610,,
42611,,
42612,,
42613,,
42614,,
42615,,
42616,,
42617,,
42618,,
42619,,
42620,,
42621,,
42622,,
42623,,
42624,,
42625,,
42626,,
42627,,
42628,,
42629,,
42630,,
42631,,
42632,,
42633,,
42634,,
42635,,
42636,,
42637,,
42638,,
42639,,
42640,,
42641,,
42642,,
42643,,
42644,,
42645,,
42646,,
42647,,
42648,,
42649,,
42650,,
42651,,
42652,,
42653,,
42654,,
42655,,
42656,,
42657,,
42658,,
42659,,
42660,,
42661,,
42662,,
42663,,
42664,,
42665,,
42666,,
42667,,
42668,,
42669,,
42670,,
42671,,
42672,,
42673,,
42674,,
42675,,
42676,,
42677,,
42678,,
42679,,
42680,,
42681,,
42682,,
42683,,
42684,,
42685,,
42686,,
42687,,
42688,,
42689,,
42690,,
42691,,
42692,,
42693,,
42694,,
42695,,
42696,,
42697,,
42698,,
42699,,
42700,,
42701,,
42702,,
42703,,
42704,,
42705,,
42706,,
42707,,
42708,,
42709,,
42710,,
42711,,
42712,,
42713,,
42714,,
42715,,
42716,,
42717,,
42718,,
42719,,
42720,,
42721,,
42722,,
42723,,
42724,,
42725,,
42726,,
42727,,
42728,,
42729,,
42730,,
42731,,
42732,,
42733,,
42734,,
42735,,
42736,,
42737,,
42738,,
42739,,
42740,,
42741,,
42742,,
42743,,
42744,,
42745,,
42746,,
42747,,
42748,,
42749,,
42750,,
42751,,
42752,,
42753,,
42754,,
42755,,
42756,,
42757,,
42758,,
42759,,
42760,,
42761,,
42762,,
42763,,
42764,,
42765,,
42766,,
42767,,
42768,,
42769,,
42770,,
42771,,
42772,,
42773,,
42774,,
42775,,
42776,,
42777,,
42778,,
42779,,
42780,,
42781,,
42782,,
42783,,
42784,,
42785,,
42786,,
42787,,
42788,,
42789,,
42790,,
42791,,
42792,,
42793,,
42794,,
42795,,
42796,,
42797,,
42798,,
42799,,
42800,,
42801,,
42802,,
42803,,
42804,,
42805,,
42806,,
42807,,
42808,,
42809,,
42810,,
42811,,
42812,,
42813,,
42814,,
42815,,
42816,,
42817,,
42818,,
42819,,
42820,,
42821,,
42822,,
42823,,
42824,,
42825,,
42826,,
42827,,
42828,,
42829,,
42830,,
42831,,
42832,,
42833,,
42834,,
42835,,
42836,,
42837,,
42838,,
42839,,
42840,,
42841,,
42842,,
42843,,
42844,,
42845,,
42846,,
42847,,
42848,,
42849,,
42850,,
42851,,
42852,,
42853,,
42854,,
42855,,
42856,,
42857,,
42858,,
42859,,
42860,,
42861,,
42862,,
42863,,
42864,,
42865,,
42866,,
42867,,
42868,,
42869,,
42870,,
42871,,
42872,,
42873,,
42874,,
42875,,
42876,,
42877,,
42878,,
42879,,
42880,,
42881,,
42882,,
42883,,
42884,,
42885,,
42886,,
42887,,
42888,,
42889,,
42890,,
42891,,
42892,,
42893,,
42894,,
42895,,
42896,,
42897,,
42898,,
42899,,
42900,,
42901,,
42902,,
42903,,
42904,,
42905,,
42906,,
42907,,
42908,,
42909,,
42910,,
42911,,
42912,,
42913,,
42914,,
42915,,
42916,,
42917,,
42918,,
42919,,
42920,,
42921,,
42922,,
42923,,
42924,,
42925,,
42926,,
42927,,
42928,,
42929,,
42930,,
42931,,
42932,,
42933,,
42934,,
42935,,
42936,,
42937,,
42938,,
42939,,
42940,,
42941,,
42942,,
42943,,
42944,,
42945,,
42946,,
42947,,
42948,,
42949,,
42950,,
42951,,
42952,,
42953,,
42954,,
42955,,
42956,,
42957,,
42958,,
42959,,
42960,,
42961,,
42962,,
42963,,
42964,,
42965,,
42966,,
42967,,
42968,,
42969,,
42970,,
42971,,
42972,,
42973,,
42974,,
42975,,
42976,,
42977,,
42978,,
42979,,
42980,,
42981,,
42982,,
42983,,
42984,,
42985,,
42986,,
42987,,
42988,,
42989,,
42990,,
42991,,
42992,,
42993,,
42994,,
42995,,
42996,,
42997,,
42998,,
42999,,
43000,,
43001,,
43002,,
43003,,
43004,,
43005,,
43006,,
43007,,
43008,,
43009,,
43010,,
43011,,
43012,,
43013,,
43014,,
43015,,
43016,,
43017,,
43018,,
43019,,
43020,,
43021,,
43022,,
43023,,
43024,,
43025,,
43026,,
43027,,
43028,,
43029,,
43030,,
43031,,
43032,,
43033,,
43034,,
43035,,
43036,,
43037,,
43038,,
43039,,
43040,,
43041,,
43042,,
43043,,
43044,,
43045,,
43046,,
43047,,
43048,,
43049,,
43050,,
43051,,
43052,,
43053,,
43054,,
43055,,
43056,,
43057,,
43058,,
43059,,
43060,,
43061,,
43062,,
43063,,
43064,,
43065,,
43066,,
43067,,
43068,,
43069,,
43070,,
43071,,
43072,,
43073,,
43074,,
43075,,
43076,,
43077,,
43078,,
43079,,
43080,,
43081,,
43082,,
43083,,
43084,,
43085,,
43086,,
43087,,
43088,,
43089,,
43090,,
43091,,
43092,,
43093,,
43094,,
43095,,
43096,,
43097,,
43098,,
43099,,
43100,,
43101,,
43102,,
43103,,
43104,,
43105,,
43106,,
43107,,
43108,,
43109,,
43110,,
43111,,
43112,,
43113,,
43114,,
43115,,
43116,,
43117,,
43118,,
43119,,
43120,,
43121,,
43122,,
43123,,
43124,,
43125,,
43126,,
43127,,
43128,,
43129,,
43130,,
43131,,
43132,,
43133,,
43134,,
43135,,
43136,,
43137,,
43138,,
43139,,
43140,,
43141,,
43142,,
43143,,
43144,,
43145,,
43146,,
43147,,
43148,,
43149,,
43150,,
43151,,
43152,,
43153,,
43154,,
43155,,
43156,,
43157,,
43158,,
43159,,
43160,,
43161,,
43162,,
43163,,
43164,,
43165,,
43166,,
43167,,
43168,,
43169,,
43170,,
43171,,
43172,,
43173,,
43174,,
43175,,
43176,,
43177,,
43178,,
43179,,
43180,,
43181,,
43182,,
43183,,
43184,,
43185,,
43186,,
43187,,
43188,,
43189,,
43190,,
43191,,
43192,,
43193,,
43194,,
43195,,
43196,,
43197,,
43198,,
43199,,
43200,,
43201,,
43202,,
43203,,
43204,,
43205,,
43206,,
43207,,
43208,,
43209,,
43210,,
43211,,
43212,,
43213,,
43214,,
43215,,
43216,,
43217,,
43218,,
43219,,
43220,,
43221,,
43222,,
43223,,
43224,,
43225,,
43226,,
43227,,
43228,,
43229,,
43230,,
43231,,
43232,,
43233,,
43234,,
43235,,
43236,,
43237,,
43238,,
43239,,
43240,,
43241,,
43242,,
43243,,
43244,,
43245,,
43246,,
43247,,
43248,,
43249,,
43250,,
43251,,
43252,,
43253,,
43254,,
43255,,
43256,,
43257,,
43258,,
43259,,
43260,,
43261,,
43262,,
43263,,
43264,,
43265,,
43266,,
43267,,
43268,,
43269,,
43270,,
43271,,
43272,,
43273,,
43274,,
43275,,
43276,,
43277,,
43278,,
43279,,
43280,,
43281,,
43282,,
43283,,
43284,,
43285,,
43286,,
43287,,
43288,,
43289,,
43290,,
43291,,
43292,,
43293,,
43294,,
43295,,
43296,,
43297,,
43298,,
43299,,
43300,,
43301,,
43302,,
43303,,
43304,,
43305,,
43306,,
43307,,
43308,,
43309,,
43310,,
43311,,
43312,,
43313,,
43314,,
43315,,
43316,,
43317,,
43318,,
43319,,
43320,,
43321,,
43322,,
43323,,
43324,,
43325,,
43326,,
43327,,
43328,,
43329,,
43330,,
43331,,
43332,,
43333,,
43334,,
43335,,
43336,,
43337,,
43338,,
43339,,
43340,,
43341,,
43342,,
43343,,
43344,,
43345,,
43346,,
